1	S	NN	O	s	_	0	SENT_1	[p1l21t108r44b145],
2	3	CD	NUMBER	3	num	1	SENT_1	[p1l51t108r134b145],
3	+	CC	O	+	_	0	SENT_1	[p1l51t108r134b145],
4	E	NN	O	e	conj_+	1	SENT_1	[p1l143t108r163b145],
5	A	DT	O	a	det	6	SENT_1	[p1l306t108r334b145],
6	DI3	NN	O	di3	dep	1	SENT_1	[p1l343t108r399b145],
7	+	CC	O	+	_	0	SENT_1	[p1l343t108r399b145],
8	nature	NN	O	nature	nn	10	SENT_1	[p1l1797t124r1888b145],
9	publishing	NN	O	publishing	nn	10	SENT_1	[p1l1897t121r2046b152],
10	group	NN	O	group	conj_+	6	SENT_1	[p1l2055t128r2139b152],

1	Novel	JJ	O	novel	amod	3	SENT_2	[p1l27t261r262b337],
2	Therapeutic	JJ	O	therapeutic	amod	3	SENT_2	[p1l282t261r798b356],
3	Approaches	NNS	O	approach	_	0	SENT_2	[p1l821t261r1334b356],
4	for	IN	O	for	_	0	SENT_2	[p1l1357t260r1474b337],
5	Hepatitis	NNP	O	Hepatitis	nn	6	SENT_2	[p1l1501t265r1876b356],
6	C	NNP	O	C	prep_for	3	SENT_2	[p1l1901t264r1955b337],

1	IS	VBZ	O	be	_	0	SENT_3	[p1l20t411r60b453],
2	Au1	NN	O	au1	nsubj	1	SENT_3	[p1l71t404r146b446],
3	and	CC	O	and	_	0	SENT_3	[p1l159t409r235b446],
4	PI	NN	O	pi	nn	5	SENT_3	[p1l245t412r290b453],
5	Pockrosm	NN	O	pockrosm	nsubj	1	SENT_3	[p1l301t404r509b446],

1	Chronic	JJ	O	chronic	amod	4	SENT_4	[p1l20t528r156b559],
2	hepatitis	NN	O	hepatitis	nn	4	SENT_4	[p1l166t528r319b566],
3	C	NN	O	c	nn	4	SENT_4	[p1l328t529r350b559],
4	virus	NN	O	virus	nsubj	9	SENT_4	[p1l359t529r444b559],
5	(	CD	NUMBER	(	num	8	SENT_4	[p1l454t529r553b563],
6	HCV	NN	O	hcv	nn	8	SENT_4	[p1l454t529r553b563],
7	)	NN	O	)	nn	8	SENT_4	[p1l454t529r553b563],
8	infection	NN	O	infection	dep	4	SENT_4	[p1l564t528r719b559],
9	afflicts	VBZ	O	afflict	_	0	SENT_4	[p1l729t528r845b559],
10	a	DT	O	a	det	14	SENT_4	[p1l854t537r872b559],
11	reported	VBN	O	report	amod	14	SENT_4	[p1l883t528r1037b567],
12	170	CD	NUMBER	170	num	14	SENT_4	[p1l1049t530r1111b559],
13	million	CD	NUMBER	million	num	14	SENT_4	[p1l1121t528r1240b559],
14	people	NNS	O	people	dobj	9	SENT_4	[p1l1252t528r1373b567],
15	worldwide	JJ	O	worldwide	advmod	9	SENT_4	[p1l1381t528r1569b559],
16	and	CC	O	and	_	0	SENT_4	[p1l1578t528r1643b559],
17	is	VBZ	O	be	auxpass	19	SENT_4	[p1l1655t529r1679b559],
18	often	RB	O	often	advmod	19	SENT_4	[p1l1688t528r1780b559],
19	complicated	VBN	O	complicate	conj_and	9	SENT_4	[p1l1791t528r2007b566],
20	by	IN	O	by	_	0	SENT_4	[p1l2019t528r2061b567],
21	cirrhosis	NN	O	cirrhosis	agent	19	SENT_4	[p1l20t581r168b612],
22	and	CC	O	and	_	0	SENT_4	[p1l177t581r242b612],
23	hepatocellular	JJ	O	hepatocellular	amod	24	SENT_4	[p1l254t581r508b620],
24	carcinoma	NN	O	carcinoma	agent	19	SENT_4	[p1l516t582r709b612],
25	.	.	O	.	_	0	SENT_4	[p1l516t582r709b612],

1	Morbidity	NN	O	morbidity	nsubjpass	5	SENT_5	[p1l719t581r894b621],
2	and	CC	O	and	_	0	SENT_5	[p1l902t581r967b612],
3	mortality	NN	O	mortality	nsubjpass	5	SENT_5	[p1l978t581r1141b621],
4	are	VBP	O	be	auxpass	5	SENT_5	[p1l1149t590r1204b612],
5	decreased	VBN	O	decrease	_	0	SENT_5	[p1l1213t581r1392b612],
6	with	IN	O	with	_	0	SENT_5	[p1l1401t581r1478b612],
7	the	DT	O	the	det	9	SENT_5	[p1l1487t581r1545b612],
8	successful	JJ	O	successful	amod	9	SENT_5	[p1l1555t581r1730b612],
9	treatment	NN	O	treatment	prep_with	5	SENT_5	[p1l1740t586r1918b612],
10	of	IN	O	of	_	0	SENT_5	[p1l1927t581r1963b612],
11	chronic	JJ	O	chronic	amod	13	SENT_5	[p1l1970t581r2100b612],
12	HCV	NN	O	hcv	nn	13	SENT_5	[p1l22t637r97b666],
13	infection	NN	O	infection	prep_of	9	SENT_5	[p1l105t635r342b666],
14	.	.	O	.	_	0	SENT_5	[p1l105t635r342b666],

1	The	DT	O	the	det	3	SENT_6	[p1l105t635r342b666],
2	current	JJ	DATE	current	amod	3	SENT_6	[p1l351t640r479b666],
3	standard	NN	O	standard	_	0	SENT_6	[p1l488t636r644b666],
4	of	IN	O	of	_	0	SENT_6	[p1l654t635r690b666],
5	care	NN	O	care	prep_of	3	SENT_6	[p1l697t645r770b666],
6	in	IN	O	in	dep	3	SENT_6	[p1l779t636r809b666],
7	the	DT	O	the	det	8	SENT_6	[p1l818t636r876b666],
8	treatment	NN	O	treatment	pobj	6	SENT_6	[p1l884t640r1063b666],
9	for	IN	O	for	_	0	SENT_6	[p1l1070t635r1120b666],
10	genotype	NN	O	genotype	prep_for	8	SENT_6	[p1l1129t640r1299b675],
11	1	CD	NUMBER	1	num	13	SENT_6	[p1l1311t638r1322b666],
12	chronic	JJ	O	chronic	amod	13	SENT_6	[p1l1337t636r1467b666],
13	HCV	NN	O	hcv	nsubjpass	15	SENT_6	[p1l1477t637r1552b666],
14	is	VBZ	O	be	auxpass	15	SENT_6	[p1l1561t636r1585b666],
15	pegylated	VBN	O	pegylate	rcmod	10	SENT_6	[p1l1595t636r1771b675],
16	interferon	NN	O	interferon	nn	18	SENT_6	[p1l1782t635r1958b666],
17	(	CD	NUMBER	(	num	18	SENT_6	[p1l1969t635r2138b671],
18	IFN	NN	ORGANIZATION	ifn	dobj	15	SENT_6	[p1l1969t635r2138b671],
19	)	SYM	O	)	dep	21	SENT_6	[p1l1969t635r2138b671],
20	-	:	O	-	_	0	SENT_6	[p1l1969t635r2138b671],
21	alfa	NN	O	alfa	dep	18	SENT_6	[p1l1969t635r2138b671],
22	,	,	O	,	_	0	SENT_6	[p1l1969t635r2138b671],
23	termed	VBN	O	term	partmod	21	SENT_6	[p1l20t690r147b721],
24	PEG	NN	O	peg	dobj	23	SENT_6	[p1l159t691r237b725],
25	,	,	O	,	_	0	SENT_6	[p1l159t691r237b725],
26	and	CC	O	and	_	0	SENT_6	[p1l246t690r311b721],
27	ribavirin	NNP	O	ribavirin	dobj	23	SENT_6	[p1l322t690r467b721],
28	(	CD	NUMBER	(	num	30	SENT_6	[p1l479t690r573b725],
29	RBV	NN	O	rbv	nn	30	SENT_6	[p1l479t690r573b725],
30	)	NN	O	)	dep	27	SENT_6	[p1l479t690r573b725],
31	in	IN	O	in	_	0	SENT_6	[p1l584t691r613b720],
32	conjunction	NN	O	conjunction	prep_in	23	SENT_6	[p1l623t691r834b729],
33	with	IN	O	with	_	0	SENT_6	[p1l844t690r920b721],
34	a	DT	O	a	det	36	SENT_6	[p1l930t699r948b721],
35	protease	NN	O	protease	nn	36	SENT_6	[p1l959t694r1112b728],
36	inhibitor	NN	O	inhibitor	prep_with	32	SENT_6	[p1l1122t690r1281b725],
37	,	,	O	,	_	0	SENT_6	[p1l1122t690r1281b725],
38	either	CC	O	either	prep	23	SENT_6	[p1l1290t690r1394b721],
39	telaprevir	NN	O	telaprevir	dep	38	SENT_6	[p1l1402t690r1574b729],
40	or	CC	O	or	_	0	SENT_6	[p1l1582t699r1618b721],
41	boceprevir	NN	O	boceprevir	conj_or	39	SENT_6	[p1l1628t690r1824b729],
42	,	,	O	,	_	0	SENT_6	[p1l1628t690r1824b729],
43	which	WDT	O	which	nsubj	44	SENT_6	[p1l1832t690r1937b721],
44	results	VBZ	O	result	rcmod	39	SENT_6	[p1l1948t690r2063b721],
45	in	IN	O	in	_	0	SENT_6	[p1l21t744r51b773],
46	67-75	CD	PERCENT	67-75	num	47	SENT_6	[p1l61t745r203b774],
47	%	NN	PERCENT	%	prep_in	44	SENT_6	[p1l61t745r203b774],
48	sustained	JJ	O	sustained	amod	51	SENT_6	[p1l212t743r381b774],
49	viral	JJ	O	viral	amod	51	SENT_6	[p1l390t743r465b774],
50	response	NN	O	response	nn	51	SENT_6	[p1l476t752r635b782],
51	rates	NNS	O	rate	dep	47	SENT_6	[p1l645t748r738b774],
52	.	.	O	.	_	0	SENT_6	[p1l645t748r738b774],

1	Increased	VBN	O	increase	amod	2	SENT_7	[p1l749t743r916b774],
2	understanding	NN	O	understanding	nsubj	24	SENT_7	[p1l927t743r1188b782],
3	of	IN	O	of	_	0	SENT_7	[p1l1198t743r1234b774],
4	the	DT	O	the	det	5	SENT_7	[p1l1240t743r1298b774],
5	HCV	NNP	O	HCV	prep_of	2	SENT_7	[p1l1308t744r1383b774],
6	has	VBZ	O	have	aux	7	SENT_7	[p1l1392t743r1450b774],
7	allowed	VBN	O	allow	_	0	SENT_7	[p1l1459t743r1597b774],
8	further	RB	O	further	advmod	9	SENT_7	[p1l1606t743r1731b774],
9	development	NN	O	development	iobj	7	SENT_7	[p1l1740t743r1977b782],
10	of	IN	O	of	_	0	SENT_7	[p1l1985t743r2022b774],
11	new	JJ	O	new	amod	15	SENT_7	[p1l2030t752r2103b774],
12	direct-acting	JJ	O	direct-acting	amod	15	SENT_7	[p1l20t798r246b836],
13	antiviral	JJ	O	antiviral	amod	15	SENT_7	[p1l256t798r398b828],
14	(	NN	O	(	nn	15	SENT_7	[p1l410t798r510b833],
15	DAA	NN	O	daa	prep_of	9	SENT_7	[p1l410t798r510b833],
16	)	CD	NUMBER	)	num	17	SENT_7	[p1l410t798r510b833],
17	agents	NNS	O	agent	dobj	7	SENT_7	[p1l520t802r638b836],
18	against	IN	O	against	_	0	SENT_7	[p1l647t798r777b836],
19	the	DT	O	the	det	20	SENT_7	[p1l785t798r842b828],
20	HCV	NN	ORGANIZATION	hcv	prep_against	17	SENT_7	[p1l853t799r928b828],
21	and	CC	O	and	_	0	SENT_7	[p1l935t798r1001b828],
22	has	VBZ	O	have	aux	24	SENT_7	[p1l1012t798r1070b828],
23	also	RB	O	also	advmod	24	SENT_7	[p1l1079t798r1149b828],
24	allowed	VBN	O	allow	conj_and	7	SENT_7	[p1l1158t798r1295b828],
25	the	DT	O	the	det	26	SENT_7	[p1l1304t798r1362b828],
26	development	NN	O	development	dobj	24	SENT_7	[p1l1371t798r1608b836],
27	of	IN	O	of	_	0	SENT_7	[p1l1617t797r1654b828],
28	IFN-free	JJ	O	ifn-free	amod	31	SENT_7	[p1l1662t797r1800b828],
29	oral	JJ	O	oral	amod	31	SENT_7	[p1l1809t798r1875b828],
30	treatment	NN	O	treatment	nn	31	SENT_7	[p1l1884t802r2062b828],
31	regimens	NNS	O	regimen	prep_of	26	SENT_7	[p1l21t852r194b890],
32	.	.	O	.	_	0	SENT_7	[p1l21t852r194b890],

1	We	PRP	O	we	nsubj	2	SENT_8	[p1l201t853r255b882],
2	anticipate	VBP	O	anticipate	_	0	SENT_8	[p1l264t852r440b889],
3	the	DT	O	the	det	4	SENT_8	[p1l448t851r506b882],
4	approval	NN	O	approval	iobj	2	SENT_8	[p1l515t851r670b890],
5	in	IN	O	in	_	0	SENT_8	[p1l682t852r711b881],
6	late	JJ	DATE	late	amod	7	SENT_8	[p1l723t851r786b882],
7	2013	CD	DATE	2013	prep_in	4	SENT_8	[p1l795t853r880b882],
8	of	IN	O	of	_	0	SENT_8	[p1l890t851r926b882],
9	the	DT	O	the	det	14	SENT_8	[p1l932t851r990b882],
10	first	JJ	ORDINAL	first	amod	14	SENT_8	[p1l998t851r1067b882],
11	nucleotide	NN	O	nucleotide	nn	14	SENT_8	[p1l1077t851r1264b882],
12	polymerase	NN	O	polymerase	nn	14	SENT_8	[p1l1274t851r1480b890],
13	inhibitor	NN	O	inhibitor	nn	14	SENT_8	[p1l1490t851r1642b882],
14	regimen	NN	O	regimen	prep_of	4	SENT_8	[p1l1651t852r1796b890],
15	with	IN	O	with	_	0	SENT_8	[p1l1806t851r1882b882],
16	RBV	NN	O	rbv	prep_with	14	SENT_8	[p1l1894t853r1963b881],
17	alone	RB	O	alone	advmod	16	SENT_8	[p1l1971t851r2068b882],
18	for	IN	O	for	_	0	SENT_8	[p1l19t904r69b935],
19	genotypes	NNS	O	genotype	prep_for	16	SENT_8	[p1l78t909r265b944],
20	2/3	CD	NUMBER	2/3	dobj	2	SENT_8	[p1l274t905r329b936],
21	and	CC	O	and	_	0	SENT_8	[p1l339t904r404b935],
22	in	IN	O	in	dobj	2	SENT_8	[p1l415t905r445b935],
23	combination	NN	O	combination	pobj	22	SENT_8	[p1l455t904r679b935],
24	with	IN	O	with	_	0	SENT_8	[p1l688t904r765b935],
25	a	DT	O	a	det	27	SENT_8	[p1l775t913r793b935],
26	12-week	JJ	DURATION	12-week	amod	27	SENT_8	[p1l805t904r953b935],
27	regimen	NN	O	regimen	prep_with	23	SENT_8	[p1l962t905r1107b944],
28	of	IN	O	of	_	0	SENT_8	[p1l1117t904r1153b935],
29	PEG+RBV	NN	O	peg+rbv	prep_of	27	SENT_8	[p1l1162t906r1327b935],
30	for	IN	O	for	mark	31	SENT_8	[p1l1334t904r1384b935],
31	genotypes	NNS	O	genotype	dep	27	SENT_8	[p1l1392t909r1580b944],
32	1	CD	NUMBER	1	num	31	SENT_8	[p1l1592t907r1618b940],
33	,	,	O	,	_	0	SENT_8	[p1l1592t907r1618b940],
34	4	CD	NUMBER	4	num	31	SENT_8	[p1l1627t907r1657b940],
35	,	,	O	,	_	0	SENT_8	[p1l1627t907r1657b940],
36	5	CD	NUMBER	5	num	31	SENT_8	[p1l1666t907r1695b940],
37	,	,	O	,	_	0	SENT_8	[p1l1666t907r1695b940],
38	and	CC	NUMBER	and	_	0	SENT_8	[p1l1704t904r1769b935],
39	6	CD	NUMBER	6	conj_and	31	SENT_8	[p1l1780t907r1809b935],
40	.	.	O	.	_	0	SENT_8	[p1l1780t907r1809b935],

1	Most	JJS	O	most	nsubjpass	9	SENT_9	[p1l1819t906r1905b935],
2	of	IN	O	of	_	0	SENT_9	[p1l1914t904r1951b935],
3	the	DT	O	the	det	7	SENT_9	[p1l1956t904r2014b935],
4	promising	JJ	O	promising	amod	7	SENT_9	[p1l10t977r380b1055],
5	new	JJ	O	new	amod	7	SENT_9	[p1l404t994r556b1038],
6	DAA	NNP	O	DAA	nn	7	SENT_9	[p1l577t978r736b1038],
7	regimens	NNS	O	regimen	prep_of	1	SENT_9	[p1l757t977r1097b1055],
8	are	VBP	O	be	auxpass	9	SENT_9	[p1l1115t994r1229b1038],
9	discussed	VBN	O	discuss	_	0	SENT_9	[p1l1247t975r1601b1038],
10	herein	RB	O	herein	advmod	9	SENT_9	[p1l1625t975r1876b1038],
11	.	.	O	.	_	0	SENT_9	[p1l1625t975r1876b1038],

1	An	DT	O	a	det	5	SENT_10	[p1l7t1215r110b1273],
2	estimated	VBN	O	estimate	amod	5	SENT_10	[p1l132t1211r461b1274],
3	3.2-5	CD	NUMBER	3.2-5	number	4	SENT_10	[p1l482t1218r664b1274],
4	million	CD	NUMBER	million	num	5	SENT_10	[p1l686t1211r934b1274],
5	people	NNS	O	people	nsubj	17	SENT_10	[p1l954t1211r1180b1294],
6	in	IN	O	in	_	0	SENT_10	[p1l1201t1217r1268b1273],
7	the	DT	O	the	det	9	SENT_10	[p1l1287t1211r1393b1274],
8	United	NNP	LOCATION	United	nn	9	SENT_10	[p1l1414t1211r1649b1274],
9	States	NNPS	LOCATION	States	prep_in	5	SENT_10	[p1l1670t1215r1861b1274],
10	and	CC	O	and	_	0	SENT_10	[p1l1883t1211r2009b1274],
11	170	CD	NUMBER	170	number	12	SENT_10	[p1l2035t1218r2148b1274],
12	million	CD	NUMBER	million	num	13	SENT_10	[p1l7t1314r253b1377],
13	people	NNS	O	people	nsubj	17	SENT_10	[p1l272t1314r497b1397],
14	worldwide	JJ	O	worldwide	dep	13	SENT_10	[p1l515t1314r874b1377],
15	are	VBP	O	be	aux	17	SENT_10	[p1l895t1337r994b1377],
16	currently	RB	DATE	currently	advmod	17	SENT_10	[p1l1015t1314r1328b1398],
17	living	VBG	O	live	_	0	SENT_10	[p1l1343t1314r1535b1398],
18	with	IN	O	with	_	0	SENT_10	[p1l1551t1314r1703b1377],
19	chronic	JJ	O	chronic	amod	26	SENT_10	[p1l1723t1314r1979b1377],
20	hepatitis	NN	O	hepatitis	nn	26	SENT_10	[p1l1999t1314r2149b1397, p1l8t1423r166b1480],
21	C	NN	O	c	nn	26	SENT_10	[p1l187t1420r238b1480],
22	virus	NN	O	virus	nn	26	SENT_10	[p1l256t1423r424b1480],
23	(	CD	NUMBER	(	num	26	SENT_10	[p1l448t1417r675b1494],
24	HCV	NN	O	hcv	nn	26	SENT_10	[p1l448t1417r675b1494],
25	)	NN	O	)	nn	26	SENT_10	[p1l448t1417r675b1494],
26	infection	NN	O	infection	prep_with	17	SENT_10	[p1l699t1408r1043b1480],
27	}	CD	NUMBER	}	nsubj	38	SENT_10	[p1l699t1408r1043b1480],
28	Among	IN	O	among	_	0	SENT_10	[p1l1065t1421r1319b1501],
29	those	DT	O	those	prep_among	27	SENT_10	[p1l1336t1416r1515b1480],
30	with	IN	O	with	_	0	SENT_10	[p1l1533t1416r1682b1480],
31	chronic	JJ	O	chronic	amod	33	SENT_10	[p1l1703t1416r1956b1480],
32	HCV	NN	O	hcv	nn	33	SENT_10	[p1l1976t1420r2152b1480],
33	infection	NN	O	infection	prep_with	29	SENT_10	[p1l8t1520r333b1592],
34	,	,	O	,	_	0	SENT_10	[p1l8t1520r333b1592],
35	15-40	CD	PERCENT	15-40	num	36	SENT_10	[p1l364t1526r629b1585],
36	%	NN	PERCENT	%	appos	33	SENT_10	[p1l364t1526r629b1585],
37	will	MD	O	will	aux	38	SENT_10	[p1l652t1520r778b1583],
38	develop	VB	O	develop	rcmod	26	SENT_10	[p1l801t1520r1066b1603],
39	cirrhosis	NN	O	cirrhosis	dobj	38	SENT_10	[p1l1090t1520r1387b1583],
40	and	CC	O	and	_	0	SENT_10	[p1l1411t1520r1564b1586],
41	/	:	O	/	punct	42	SENT_10	[p1l1411t1520r1564b1586],
42	or	CC	O	or	dep	39	SENT_10	[p1l1570t1543r1642b1583],
43	hepatocellular	JJ	O	hepatocellular	dep	42	SENT_10	[p1l1662t1520r2152b1603],
44	carcinoma	NN	O	carcinoma	conj_and	39	SENT_10	[p1l8t1629r399b1686],
45	.	.	O	.	_	0	SENT_10	[p1l8t1629r399b1686],

1	Mortality	NN	O	mortality	nsubj	13	SENT_11	[p1l427t1623r767b1707],
2	from	IN	O	from	_	0	SENT_11	[p1l788t1623r962b1686],
3	these	DT	O	these	det	4	SENT_11	[p1l986t1623r1169b1686],
4	complications	NNS	O	complication	prep_from	1	SENT_11	[p1l1195t1623r1693b1706],
5	has	VBZ	O	have	aux	6	SENT_11	[p1l1718t1623r1834b1686],
6	doubled	VBN	O	double	_	0	SENT_11	[p1l1861t1623r2151b1686],
7	from	IN	O	from	_	0	SENT_11	[p1l7t1726r180b1789],
8	1999	CD	DATE	1999	num	10	SENT_11	[p1l210t1733r369b1789],
9	to	TO	DATE	to	dep	10	SENT_11	[p1l393t1738r460b1789],
10	2007	CD	DATE	2007	prep_from	6	SENT_11	[p1l485t1733r671b1798],
11	,	,	O	,	_	0	SENT_11	[p1l485t1733r671b1798],
12	and	CC	O	and	_	0	SENT_11	[p1l697t1726r826b1789],
13	continued	VBD	O	continue	conj_and	6	SENT_11	[p1l850t1726r1206b1789],
14	increase	NN	O	increase	nsubjpass	16	SENT_11	[p1l1229t1732r1515b1789],
15	is	VBZ	O	be	auxpass	16	SENT_11	[p1l1539t1732r1591b1789],
16	expected	VBN	O	expect	ccomp	13	SENT_11	[p1l1615t1726r1928b1809],
17	in	IN	O	in	_	0	SENT_11	[p1l1951t1732r2019b1788],
18	the	DT	DURATION	the	det	21	SENT_11	[p1l2041t1726r2151b1789],
19	next	JJ	DURATION	next	amod	21	SENT_11	[p1l7t1841r156b1892],
20	two	CD	DURATION	two	num	21	SENT_11	[p1l177t1841r303b1892],
21	decades	NNS	DURATION	decade	prep_in	16	SENT_11	[p1l328t1829r612b1892],
22	.	.	O	.	_	0	SENT_11	[p1l328t1829r612b1892],

1	Hepatitis	NNP	O	Hepatitis	nn	2	SENT_12	[p1l639t1834r949b1912],
2	C	NNP	O	C	nsubj	7	SENT_12	[p1l973t1833r1026b1892],
3	is	VBZ	O	be	cop	7	SENT_12	[p1l1049t1835r1099b1892],
4	also	RB	O	also	advmod	7	SENT_12	[p1l1123t1829r1254b1892],
5	the	DT	O	the	det	7	SENT_12	[p1l1278t1829r1384b1892],
6	leading	VBG	O	lead	amod	7	SENT_12	[p1l1406t1829r1659b1913],
7	indication	NN	O	indication	_	0	SENT_12	[p1l1680t1829r2031b1892],
8	for	IN	O	for	_	0	SENT_12	[p1l2053t1829r2151b1892],
9	liver	NN	O	liver	nn	10	SENT_12	[p1l6t1932r158b1996],
10	transplantation	NN	O	transplantation	prep_for	7	SENT_12	[p1l178t1932r704b2016],
11	in	IN	O	in	_	0	SENT_12	[p1l726t1939r792b1995],
12	the	DT	O	the	det	15	SENT_12	[p1l813t1932r920b1996],
13	United	NNP	LOCATION	United	nn	15	SENT_12	[p1l942t1932r1177b1996],
14	States	NNPS	LOCATION	States	nn	15	SENT_12	[p1l1199t1924r1488b1996],
15	.2	NN	NUMBER	.2	prep_in	10	SENT_12	[p1l1199t1924r1488b1996],
16	’	CD	NUMBER	’	number	17	SENT_12	[p1l1199t1924r1488b1996],
17	3	CD	NUMBER	3	num	15	SENT_12	[p1l1199t1924r1488b1996],

1	Genetic	JJ	O	genetic	amod	2	SENT_13	[p1l82t2040r348b2099],
2	analysis	NN	O	analysis	nsubj	6	SENT_13	[p1l369t2036r635b2120],
3	of	IN	O	of	_	0	SENT_13	[p1l657t2036r731b2099],
4	HCV	NNP	O	HCV	prep_of	2	SENT_13	[p1l742t2040r923b2099],
5	has	VBZ	O	have	aux	6	SENT_13	[p1l941t2036r1054b2099],
6	identiﬁed	VBN	O	identiﬁed	_	0	SENT_13	[p1l1075t2036r1403b2099],
7	at	IN	O	at	quantmod	9	SENT_13	[p1l1424t2048r1483b2099],
8	least	JJS	O	least	mwe	7	SENT_13	[p1l1502t2036r1655b2099],
9	six	CD	NUMBER	six	num	10	SENT_13	[p1l1676t2042r1769b2099],
10	genotypes	NNS	O	genotype	dobj	6	SENT_13	[p1l1787t2048r2150b2120],
11	,	,	O	,	_	0	SENT_13	[p1l1787t2048r2150b2120],
12	which	WDT	O	which	nsubj	13	SENT_13	[p1l6t2139r221b2202],
13	vary	VBP	O	vary	rcmod	10	SENT_13	[p1l242t2162r400b2223],
14	by	IN	O	by	_	0	SENT_13	[p1l418t2139r504b2223],
15	30-35	CD	PERCENT	30-35	num	16	SENT_13	[p1l526t2145r803b2204],
16	%	NN	PERCENT	%	prep_by	13	SENT_13	[p1l526t2145r803b2204],
17	in	IN	O	in	_	0	SENT_13	[p1l829t2145r897b2201],
18	their	PRP$	O	they	poss	20	SENT_13	[p1l919t2139r1087b2202],
19	nucleotide	NN	O	nucleotide	nn	20	SENT_13	[p1l1110t2139r1479b2202],
20	sequences	NNS	O	sequence	prep_in	16	SENT_13	[p1l1504t2162r1874b2222],
21	.	.	O	.	_	0	SENT_13	[p1l1504t2162r1874b2222],

1	Within	IN	O	within	_	0	SENT_14	[p1l1900t2139r2151b2202],
2	each	DT	O	each	det	3	SENT_14	[p1l8t2243r168b2306],
3	genotype	NN	O	genotype	prep_within	6	SENT_14	[p1l193t2255r538b2327],
4	,	,	O	,	_	0	SENT_14	[p1l193t2255r538b2327],
5	there	EX	O	there	expl	6	SENT_14	[p1l564t2243r746b2306],
6	are	VBP	O	be	_	0	SENT_14	[p1l773t2266r877b2306],
7	more	RBR	O	more	advmod	10	SENT_14	[p1l903t2266r1088b2306],
8	closely	RB	O	closely	advmod	9	SENT_14	[p1l1114t2243r1356b2327],
9	related	JJ	O	related	amod	10	SENT_14	[p1l1379t2243r1621b2306],
10	subgenotypes	NNS	O	subgenotype	nsubj	6	SENT_14	[p1l1647t2243r2150b2327],
11	,	,	O	,	_	0	SENT_14	[p1l1647t2243r2150b2327],
12	such	JJ	O	such	_	0	SENT_14	[p1l9t2346r169b2409],
13	as	IN	O	as	_	0	SENT_14	[p1l194t2369r260b2409],
14	1a	NN	O	1a	prep_such_as	10	SENT_14	[p1l293t2353r366b2409],
15	and	CC	O	and	_	0	SENT_14	[p1l390t2346r520b2409],
16	1b	NN	O	1b	prep_such_as	10	SENT_14	[p1l551t2346r645b2418],
17	,	,	O	,	_	0	SENT_14	[p1l551t2346r645b2418],
18	which	WDT	O	which	nsubj	19	SENT_14	[p1l669t2346r886b2409],
19	have	VBP	O	have	rcmod	14	SENT_14	[p1l910t2346r1071b2409],
20	an	DT	O	a	det	24	SENT_14	[p1l1097t2369r1179b2409],
21	~	NN	O	~	nn	24	SENT_14	[p1l1207t2351r1403b2411],
22	20	CD	PERCENT	20	num	24	SENT_14	[p1l1207t2351r1403b2411],
23	%	NN	PERCENT	%	nn	24	SENT_14	[p1l1207t2351r1403b2411],
24	difference	NN	O	difference	dobj	19	SENT_14	[p1l1431t2346r1780b2409],
25	in	IN	O	in	_	0	SENT_14	[p1l1806t2352r1874b2408],
26	genetic	JJ	O	genetic	amod	27	SENT_14	[p1l1899t2352r2152b2430],
27	sequence	NN	O	sequence	prep_in	24	SENT_14	[p1l9t2472r351b2532],
28	.	.	O	.	_	0	SENT_14	[p1l9t2472r351b2532],

1	The	DT	O	the	det	2	SENT_15	[p1l380t2449r508b2512],
2	genotypes	NNS	O	genotype	nsubj	4	SENT_15	[p1l535t2461r894b2533],
3	typically	RB	O	typically	advmod	4	SENT_15	[p1l919t2449r1226b2533],
4	vary	VBP	O	vary	_	0	SENT_15	[p1l1246t2472r1406b2533],
5	geographically	RB	O	geographically	advmod	4	SENT_15	[p1l1429t2449r1964b2533],
6	,	,	O	,	_	0	SENT_15	[p1l1429t2449r1964b2533],
7	with	IN	O	with	_	0	SENT_15	[p1l1990t2449r2150b2512],
8	~	NN	O	~	prep_with	4	SENT_15	[p1l10t2557r198b2616],
9	70	CD	PERCENT	70	number	10	SENT_15	[p1l10t2557r198b2616],
10	%	NN	PERCENT	%	amod	8	SENT_15	[p1l10t2557r198b2616],
11	of	IN	O	of	_	0	SENT_15	[p1l220t2552r293b2615],
12	Americans	NNPS	MISC	Americans	prep_of	8	SENT_15	[p1l303t2556r669b2615],
13	being	VBG	O	be	auxpass	14	SENT_15	[p1l687t2552r877b2636],
14	infected	VBN	O	infect	partmod	12	SENT_15	[p1l895t2552r1166b2615],
15	with	IN	O	with	_	0	SENT_15	[p1l1183t2552r1334b2615],
16	genotype	NN	O	genotype	prep_with	14	SENT_15	[p1l1354t2564r1661b2636],
17	1	CD	NUMBER	1	num	16	SENT_15	[p1l1688t2559r1735b2615],
18	.	.	O	.	_	0	SENT_15	[p1l1688t2559r1735b2615],

1	Cumulative	JJ	O	cumulative	amod	2	SENT_16	[p1l1759t2552r2150b2615],
2	studies	NNS	O	study	nsubj	9	SENT_16	[p1l8t2655r244b2718],
3	in	IN	O	in	_	0	SENT_16	[p1l265t2661r332b2717],
4	the	DT	DURATION	the	det	7	SENT_16	[p1l352t2655r458b2718],
5	past	JJ	DURATION	past	amod	7	SENT_16	[p1l478t2667r618b2738],
6	two	CD	DURATION	two	num	7	SENT_16	[p1l636t2667r762b2718],
7	decades	NNS	DURATION	decade	prep_in	2	SENT_16	[p1l785t2655r1052b2718],
8	have	VBP	O	have	aux	9	SENT_16	[p1l1072t2655r1228b2718],
9	shown	VBN	O	show	_	0	SENT_16	[p1l1250t2655r1473b2718],
10	that	IN	O	that	complm	13	SENT_16	[p1l1492t2655r1626b2718],
11	different	JJ	O	different	amod	12	SENT_16	[p1l1647t2655r1937b2718],
12	genotypes	NNS	O	genotype	nsubj	13	SENT_16	[p1l1957t2678r2149b2739, p1l7t2770r179b2842],
13	respond	VBP	O	respond	ccomp	9	SENT_16	[p1l200t2758r470b2841],
14	differently	RB	O	differently	advmod	13	SENT_16	[p1l489t2758r833b2842],
15	to	TO	O	to	_	0	SENT_16	[p1l848t2770r913b2821],
16	interferon	NN	O	interferon	nn	18	SENT_16	[p1l934t2758r1267b2821],
17	(	CD	NUMBER	(	num	18	SENT_16	[p1l1290t2758r1700b2835],
18	IFN	NN	ORGANIZATION	ifn	prep_to	14	SENT_16	[p1l1290t2758r1700b2835],
19	)	SYM	O	)	dep	21	SENT_16	[p1l1290t2758r1700b2835],
20	-	:	O	-	_	0	SENT_16	[p1l1290t2758r1700b2835],
21	based	VBN	O	base	ccomp	13	SENT_16	[p1l1290t2758r1700b2835],
22	therapy	NN	O	therapy	dobj	21	SENT_16	[p1l1718t2758r1981b2842],
23	,	,	O	,	_	0	SENT_16	[p1l1718t2758r1981b2842],
24	with	IN	O	with	_	0	SENT_16	[p1l2000t2758r2149b2821],
25	genotypes	NNS	O	genotype	prep_with	21	SENT_16	[p1l7t2873r356b2945],
26	2	CD	NUMBER	2	num	25	SENT_16	[p1l380t2868r416b2923],
27	and	CC	O	and	_	0	SENT_16	[p1l442t2861r570b2924],
28	3	CD	NUMBER	3	conj_and	25	SENT_16	[p1l593t2868r627b2924],
29	being	VBG	O	be	auxpass	33	SENT_16	[p1l651t2861r845b2945],
30	the	DT	O	the	dep	31	SENT_16	[p1l865t2861r973b2924],
31	most	RBS	O	most	advmod	33	SENT_16	[p1l997t2873r1169b2924],
32	easily	RB	O	easily	advmod	33	SENT_16	[p1l1191t2861r1385b2945],
33	cured	VBN	O	cure	partmod	25	SENT_16	[p1l1405t2861r1601b2924],
34	and	CC	O	and	_	0	SENT_16	[p1l1624t2861r1752b2924],
35	genotype	NN	O	genotype	prep_with	21	SENT_16	[p1l1774t2873r2091b2945],
36	1	CD	NUMBER	1	num	35	SENT_16	[p1l2121t2868r2146b2923],
37	having	VBG	O	have	partmod	35	SENT_16	[p1l7t2964r236b3048],
38	the	DT	O	the	det	41	SENT_16	[p1l254t2964r359b3027],
39	lowest	JJS	O	lowest	amod	41	SENT_16	[p1l378t2964r593b3027],
40	cure	NN	O	cure	nn	41	SENT_16	[p1l612t2987r757b3027],
41	rates	NNS	O	rate	dobj	37	SENT_16	[p1l778t2976r934b3027],
42	with	IN	O	with	_	0	SENT_16	[p1l953t2964r1104b3027],
43	IFN-based	JJ	MISC	ifn-based	amod	44	SENT_16	[p1l1125t2964r1486b3027],
44	regimens	NNS	O	regimen	prep_with	41	SENT_16	[p1l1506t2970r1832b3048],
45	.	.	O	.	_	0	SENT_16	[p1l1506t2970r1832b3048],

1	With	IN	O	with	_	0	SENT_17	[p1l1855t2964r2026b3027],
2	the	DT	O	the	det	3	SENT_17	[p1l2045t2964r2151b3027],
3	approval	NN	O	approval	prep_with	33	SENT_17	[p1l8t3067r299b3150],
4	of	IN	O	of	_	0	SENT_17	[p1l319t3067r392b3130],
5	NS3	NN	O	ns3	prep_of	3	SENT_17	[p1l401t3071r570b3133],
6	/	:	O	/	punct	10	SENT_17	[p1l401t3071r570b3133],
7	4	CD	NUMBER	4	num	9	SENT_17	[p1l574t3074r612b3129],
8	protease	NN	O	protease	nn	9	SENT_17	[p1l631t3079r912b3150],
9	inhibitors	NNS	O	inhibitor	nsubj	10	SENT_17	[p1l932t3067r1259b3130],
10	(	VBP	O	(	dep	3	SENT_17	[p1l1283t3068r1437b3143],
11	PIS	NN	O	pi	nn	12	SENT_17	[p1l1283t3068r1437b3143],
12	)	NN	O	)	dobj	10	SENT_17	[p1l1283t3068r1437b3143],
13	used	VBN	O	use	partmod	12	SENT_17	[p1l1461t3067r1617b3130],
14	in	IN	O	in	_	0	SENT_17	[p1l1636t3073r1702b3129],
15	combination	NN	O	combination	prep_in	13	SENT_17	[p1l1722t3067r2151b3130],
16	with	IN	O	with	prep	13	SENT_17	[p1l6t3170r156b3233],
17	pegylated	VBN	O	pegylate	partmod	3	SENT_17	[p1l175t3170r501b3254],
18	IFN-alfa	NN	O	ifn-alfa	nn	21	SENT_17	[p1l521t3170r807b3233],
19	(	NN	O	(	nn	21	SENT_17	[p1l830t3171r1034b3246],
20	PEG	NN	O	peg	nn	21	SENT_17	[p1l830t3171r1034b3246],
21	)	NN	O	)	dobj	17	SENT_17	[p1l830t3171r1034b3246],
22	and	CC	O	and	_	0	SENT_17	[p1l1059t3170r1184b3233],
23	ribavirin	NNP	O	ribavirin	nn	25	SENT_17	[p1l1203t3170r1497b3233],
24	(	CD	NUMBER	(	num	25	SENT_17	[p1l1520t3171r1715b3246],
25	RBV	NN	O	rbv	conj_and	21	SENT_17	[p1l1520t3171r1715b3246],
26	;	:	O	;	_	0	SENT_17	[p1l1520t3171r1715b3246],
27	PEG+RBV	NN	O	peg+rbv	nn	28	SENT_17	[p1l1738t3171r2149b3247],
28	)	NN	O	)	dep	21	SENT_17	[p1l1738t3171r2149b3247],
29	,	,	O	,	_	0	SENT_17	[p1l1738t3171r2149b3247],
30	genotype	NN	O	genotype	nn	31	SENT_17	[p1l7t3285r314b3357],
31	1b	NN	O	1b	nsubj	44	SENT_17	[p1l341t3273r413b3336],
32	was	VBD	O	be	auxpass	33	SENT_17	[p1l433t3296r557b3336],
33	found	VBN	O	find	_	0	SENT_17	[p1l577t3273r778b3336],
34	to	TO	O	to	aux	35	SENT_17	[p1l795t3285r860b3336],
35	have	VB	O	have	xcomp	33	SENT_17	[p1l880t3273r1033b3336],
36	a	DT	O	a	det	38	SENT_17	[p1l1054t3296r1088b3336],
37	higher	JJR	O	higher	amod	38	SENT_17	[p1l1106t3273r1326b3357],
38	barrier	NN	O	barrier	dobj	35	SENT_17	[p1l1342t3273r1576b3336],
39	to	TO	O	to	_	0	SENT_17	[p1l1594t3285r1659b3336],
40	resistance	NN	O	resistance	prep_to	35	SENT_17	[p1l1680t3279r2008b3336],
41	and	CC	O	and	_	0	SENT_17	[p1l2029t3273r2153b3336],
42	thus	RB	O	thus	advmod	33	SENT_17	[p1l7t3377r155b3440],
43	was	VBD	O	be	cop	44	SENT_17	[p1l178t3400r306b3440],
44	easier	JJR	O	easier	conj_and	33	SENT_17	[p1l332t3383r532b3440],
45	to	TO	O	to	aux	46	SENT_17	[p1l553t3389r620b3440],
46	cure	VB	O	cure	xcomp	44	SENT_17	[p1l646t3400r796b3440],
47	than	IN	O	than	_	0	SENT_17	[p1l818t3377r976b3440],
48	genotype	NN	O	genotype	nn	49	SENT_17	[p1l1000t3389r1319b3461],
49	la.	NN	O	la.	prep_than	46	SENT_17	[p1l1350t3384r1438b3440],
50	.	.	O	.	_	0	SENT_17	[p1l1350t3384r1438b3440],

1	The	DT	O	the	det	2	SENT_18	[p1l1464t3377r1592b3440],
2	genotypes	NNS	O	genotype	nsubjpass	6	SENT_18	[p1l1616t3389r1967b3461],
3	have	VBP	O	have	aux	6	SENT_18	[p1l1990t3377r2150b3440],
4	not	RB	O	not	neg	6	SENT_18	[p1l7t3492r122b3543],
5	been	VBN	O	be	auxpass	6	SENT_18	[p1l142t3480r308b3543],
6	shown	VBN	O	show	_	0	SENT_18	[p1l332t3480r555b3543],
7	to	TO	O	to	aux	8	SENT_18	[p1l577t3492r644b3543],
8	differ	VB	O	differ	xcomp	6	SENT_18	[p1l669t3480r852b3543],
9	in	IN	O	in	_	0	SENT_18	[p1l874t3486r942b3542],
10	their	PRP$	O	they	poss	11	SENT_18	[p1l963t3480r1128b3543],
11	progression	NN	O	progression	prep_in	8	SENT_18	[p1l1149t3486r1554b3564],
12	to	TO	O	to	_	0	SENT_18	[p1l1576t3492r1643b3543],
13	cirrhosis	NN	O	cirrhosis	prep_to	8	SENT_18	[p1l1667t3480r1966b3543],
14	or	CC	O	or	_	0	SENT_18	[p1l1990t3503r2062b3543],
15	in	IN	O	in	_	0	SENT_18	[p1l2084t3486r2151b3542],
16	the	DT	O	the	det	17	SENT_18	[p1l7t3583r113b3647],
17	development	NN	O	development	prep_in	8	SENT_18	[p1l136t3583r581b3667],
18	of	IN	O	of	_	0	SENT_18	[p1l603t3583r677b3647],
19	liver	NN	O	liver	nn	20	SENT_18	[p1l687t3583r839b3647],
20	cancer	NN	O	cancer	prep_of	17	SENT_18	[p1l860t3575r1129b3647],
21	.4	CD	NUMBER	.4	num	20	SENT_18	[p1l860t3575r1129b3647],

1	The	DT	O	the	det	2	SENT_19	[p1l81t3687r206b3750],
2	rate	NN	O	rate	nsubjpass	9	SENT_19	[p1l227t3699r354b3750],
3	of	IN	O	of	_	0	SENT_19	[p1l375t3687r449b3750],
4	cure	NN	O	cure	prep_of	2	SENT_19	[p1l460t3710r606b3750],
5	of	IN	O	of	_	0	SENT_19	[p1l628t3687r702b3750],
6	HCV	NN	O	hcv	prep_of	4	SENT_19	[p1l713t3691r893b3750],
7	was	VBD	O	be	auxpass	9	SENT_19	[p1l911t3710r1036b3750],
8	later	RB	O	later	advmod	9	SENT_19	[p1l1056t3687r1208b3750],
9	found	VBN	O	find	_	0	SENT_19	[p1l1227t3687r1431b3750],
10	to	TO	O	to	aux	12	SENT_19	[p1l1449t3699r1515b3750],
11	be	VB	O	be	auxpass	12	SENT_19	[p1l1535t3687r1614b3750],
12	inﬂuenced	VBN	O	inﬂuenced	xcomp	9	SENT_19	[p1l1635t3687r1997b3750],
13	by	IN	O	by	_	0	SENT_19	[p1l2014t3687r2098b3771],
14	a	DT	O	a	det	16	SENT_19	[p1l2116t3710r2150b3750],
15	genetic	JJ	O	genetic	amod	16	SENT_19	[p2l7t22r254b100],
16	polymorphism	NN	O	polymorphism	agent	12	SENT_19	[p2l276t16r794b100],
17	near	IN	O	near	_	0	SENT_19	[p2l817t39r970b79],
18	the	DT	O	the	det	20	SENT_19	[p2l991t16r1099b79],
19	interleukin	NN	O	interleukin	nn	20	SENT_19	[p2l1122t16r1506b79],
20	28B	NN	O	28b	prep_near	16	SENT_19	[p2l1529t21r1659b79],
21	(	CD	NUMBER	(	num	24	SENT_19	[p2l1687t16r1947b93],
22	IL28B	NN	O	il28b	nn	24	SENT_19	[p2l1687t16r1947b93],
23	)	NN	O	)	nn	24	SENT_19	[p2l1687t16r1947b93],
24	gene	NN	O	gene	dep	20	SENT_19	[p2l1973t39r2148b100],
25	.	.	O	.	_	0	SENT_19	[p2l1973t39r2148b100],

1	Three	CD	NUMBER	three	num	2	SENT_20	[p2l7t119r207b182],
2	polymorphisms	NNS	O	polymorphism	nsubj	3	SENT_20	[p2l231t119r793b203],
3	exist	VBP	O	exist	_	0	SENT_20	[p2l819t125r997b182],
4	:	:	O	:	_	0	SENT_20	[p2l819t125r997b182],
5	CC	NN	O	cc	dobj	3	SENT_20	[p2l1028t123r1154b191],
6	,	,	O	,	_	0	SENT_20	[p2l1028t123r1154b191],
7	TT	NN	O	tt	dobj	3	SENT_20	[p2l1186t122r1304b191],
8	,	,	O	,	_	0	SENT_20	[p2l1186t122r1304b191],
9	and	CC	O	and	_	0	SENT_20	[p2l1332t119r1462b182],
10	CT	NN	O	ct	dobj	3	SENT_20	[p2l1489t122r1610b182],
11	.	.	O	.	_	0	SENT_20	[p2l1489t122r1610b182],

1	Those	DT	O	those	det	2	SENT_21	[p2l1638t119r1846b182],
2	patients	NNS	O	patient	nsubjpass	8	SENT_21	[p2l1870t125r2150b202],
3	with	IN	O	with	_	0	SENT_21	[p2l6t222r159b285],
4	the	DT	O	the	det	6	SENT_21	[p2l180t222r287b285],
5	CC	NN	O	cc	nn	6	SENT_21	[p2l313t226r420b285],
6	genotype	NN	O	genotype	prep_with	2	SENT_21	[p2l439t234r751b306],
7	were	VBD	O	be	auxpass	8	SENT_21	[p2l772t245r933b285],
8	found	VBN	O	find	_	0	SENT_21	[p2l956t222r1160b285],
9	to	TO	O	to	aux	10	SENT_21	[p2l1181t234r1247b285],
10	have	VB	O	have	xcomp	8	SENT_21	[p2l1269t222r1425b285],
11	the	DT	O	the	det	14	SENT_21	[p2l1447t222r1554b285],
12	greatest	JJS	O	greatest	amod	14	SENT_21	[p2l1576t234r1840b306],
13	immune	JJ	O	immune	amod	14	SENT_21	[p2l1861t228r2151b285],
14	response	NN	O	response	dobj	10	SENT_21	[p2l9t347r331b408],
15	and	CC	O	and	_	0	SENT_21	[p2l365t325r499b388],
16	most	RBS	O	most	advmod	17	SENT_21	[p2l530t337r711b388],
17	favorable	JJ	O	favorable	amod	18	SENT_21	[p2l742t325r1079b388],
18	response	NN	O	response	dobj	10	SENT_21	[p2l1112t347r1435b408],
19	to	TO	O	to	_	0	SENT_21	[p2l1467t337r1537b388],
20	HCV	NN	O	hcv	nn	21	SENT_21	[p2l1571t329r1759b388],
21	treatment	NN	O	treatment	prep_to	10	SENT_21	[p2l1790t337r2153b388],
22	with	IN	O	with	_	0	SENT_21	[p2l7t428r167b491],
23	PEG+RBV	NN	O	peg+rbv	prep_with	10	SENT_21	[p2l195t432r584b491],
24	.	.	O	.	_	0	SENT_21	[p2l195t432r584b491],

1	TT	NN	O	tt	nn	3	SENT_22	[p2l621t431r727b490],
2	genotype	NN	O	genotype	nn	3	SENT_22	[p2l748t440r1076b512],
3	patients	NNS	O	patient	nsubj	4	SENT_22	[p2l1103t434r1386b511],
4	had	VBD	O	have	_	0	SENT_22	[p2l1413t428r1547b491],
5	the	DT	O	the	det	8	SENT_22	[p2l1572t428r1684b491],
6	least	JJS	O	least	dep	7	SENT_22	[p2l1710t428r1872b491],
7	favorable	JJ	O	favorable	amod	8	SENT_22	[p2l1898t428r2150b491, p2l6t531r110b594],
8	response	NN	O	response	dobj	4	SENT_22	[p2l136t553r466b614],
9	,	,	O	,	_	0	SENT_22	[p2l136t553r466b614],
10	and	CC	O	and	_	0	SENT_22	[p2l494t531r624b594],
11	CT	NNP	O	CT	nn	13	SENT_22	[p2l652t534r762b594],
12	genotype	NN	O	genotype	nn	13	SENT_22	[p2l780t543r1104b615],
13	patients	NNS	O	patient	nsubj	14	SENT_22	[p2l1129t537r1409b614],
14	had	VBD	O	have	conj_and	4	SENT_22	[p2l1434t531r1567b594],
15	an	DT	O	a	det	17	SENT_22	[p2l1591t554r1674b594],
16	intermediate	JJ	O	intermediate	amod	17	SENT_22	[p2l1699t531r2153b594],
17	response	NN	O	response	dobj	14	SENT_22	[p2l9t627r359b718],
18	.5	CD	NUMBER	.5	num	17	SENT_22	[p2l9t627r359b718],

1	Until	IN	O	until	_	0	SENT_23	[p2l82t737r258b801],
2	2011	CD	DATE	2011	prep_until	15	SENT_23	[p2l281t744r463b809],
3	,	,	O	,	_	0	SENT_23	[p2l281t744r463b809],
4	the	DT	O	the	det	5	SENT_23	[p2l486t737r594b801],
5	standard	NN	O	standard	nsubj	15	SENT_23	[p2l618t737r919b801],
6	of	IN	O	of	_	0	SENT_23	[p2l942t737r1016b801],
7	care	NN	O	care	prep_of	5	SENT_23	[p2l1031t760r1169b801],
8	for	IN	O	for	_	0	SENT_23	[p2l1192t737r1290b801],
9	the	DT	O	the	det	10	SENT_23	[p2l1311t737r1418b801],
10	treatment	NN	O	treatment	prep_for	7	SENT_23	[p2l1440t749r1780b801],
11	of	IN	O	of	_	0	SENT_23	[p2l1802t737r1877b801],
12	chronic	JJ	O	chronic	amod	13	SENT_23	[p2l1890t737r2152b801],
13	HCV	NN	O	hcv	prep_of	10	SENT_23	[p2l9t845r187b904],
14	was	VBD	O	be	cop	15	SENT_23	[p2l205t864r330b904],
15	PEG+RBV	NNP	O	PEG+RBV	_	0	SENT_23	[p2l352t845r717b904],
16	for	IN	O	for	_	0	SENT_23	[p2l736t841r833b904],
17	24-48	CD	NUMBER	24-48	num	18	SENT_23	[p2l852t848r1055b904],
18	weeks	NNS	NUMBER	week	prep_for	15	SENT_23	[p2l1076t841r1296b913],
19	,	,	O	,	_	0	SENT_23	[p2l1076t841r1296b913],
20	depending	VBG	O	depend	_	0	SENT_23	[p2l1319t841r1680b925],
21	on	IN	O	on	prepc_depending_on	15	SENT_23	[p2l1700t864r1785b904],
22	HCV	NNP	O	HCV	nn	23	SENT_23	[p2l1806t845r1984b904],
23	genotype	NN	O	genotype	pobj	15	SENT_23	[p2l2003t864r2149b925, p2l9t956r213b1028],
24	.	.	O	.	_	0	SENT_23	[p2l2003t864r2149b925, p2l9t956r213b1028],

1	PEG	NN	O	peg	nsubj	4	SENT_24	[p2l239t948r394b1007],
2	and	CC	O	and	_	0	SENT_24	[p2l416t944r543b1007],
3	RBV	NN	O	rbv	conj_and	1	SENT_24	[p2l564t949r725b1007],
4	represent	VBP	O	represent	_	0	SENT_24	[p2l746t956r1065b1027],
5	nonspeciﬁc	JJ	O	nonspeciﬁc	amod	6	SENT_24	[p2l1085t944r1477b1027],
6	antivirals	NNS	O	antiviral	dobj	4	SENT_24	[p2l1500t944r1833b1016],
7	,	,	O	,	_	0	SENT_24	[p2l1500t944r1833b1016],
8	of	IN	O	of	_	0	SENT_24	[p2l1858t944r1931b1007],
9	which	WDT	O	which	rel	19	SENT_24	[p2l1942t944r2152b1007],
10	the	DT	O	the	det	11	SENT_24	[p2l7t1047r114b1110],
11	mechanisms	NNS	O	mechanism	nsubjpass	19	SENT_24	[p2l136t1047r565b1110],
12	of	IN	O	of	_	0	SENT_24	[p2l588t1047r662b1110],
13	action	NN	O	action	prep_of	11	SENT_24	[p2l676t1053r887b1110],
14	in	IN	O	in	_	0	SENT_24	[p2l910t1053r977b1109],
15	treating	VBG	O	treat	prepc_in	13	SENT_24	[p2l998t1053r1267b1131],
16	HCV	NN	O	hcv	dobj	15	SENT_24	[p2l1288t1051r1468b1110],
17	were	VBD	O	be	auxpass	19	SENT_24	[p2l1488t1070r1650b1110],
18	poorly	RB	O	poorly	advmod	19	SENT_24	[p2l1671t1047r1900b1131],
19	understood	VBN	O	understand	rcmod	6	SENT_24	[p2l1918t1047r2149b1110, p2l9t1150r209b1213],
20	.	.	O	.	_	0	SENT_24	[p2l1918t1047r2149b1110, p2l9t1150r209b1213],

1	Response	NN	O	response	nsubjpass	5	SENT_25	[p2l232t1155r548b1233],
2	to	TO	O	to	_	0	SENT_25	[p2l567t1162r632b1213],
3	therapy	NN	O	therapy	prep_to	1	SENT_25	[p2l652t1150r909b1234],
4	is	VBZ	O	be	auxpass	5	SENT_25	[p2l925t1156r974b1213],
5	gauged	VBN	O	gauge	_	0	SENT_25	[p2l994t1150r1232b1234],
6	by	IN	O	by	_	0	SENT_25	[p2l1249t1150r1331b1234],
7	rapid	JJ	O	rapid	amod	10	SENT_25	[p2l1348t1150r1523b1233],
8	Virologic	JJ	ORGANIZATION	virologic	amod	10	SENT_25	[p2l1539t1150r1836b1234],
9	response	NN	O	response	nn	10	SENT_25	[p2l1856t1172r2150b1233],
10	(	NN	O	(	agent	5	SENT_25	[p2l12t1253r250b1330],
11	RVR	NN	O	rvr	tmod	10	SENT_25	[p2l12t1253r250b1330],
12	)	CD	NUMBER	)	num	11	SENT_25	[p2l12t1253r250b1330],
13	,	,	O	,	_	0	SENT_25	[p2l12t1253r250b1330],
14	which	WDT	O	which	nsubjpass	16	SENT_25	[p2l273t1253r486b1317],
15	is	VBZ	O	be	auxpass	16	SENT_25	[p2l510t1259r560b1316],
16	deﬁned	VBN	O	deﬁned	rcmod	11	SENT_25	[p2l585t1253r845b1316],
17	as	IN	O	as	_	0	SENT_25	[p2l867t1276r932b1316],
18	an	DT	O	a	det	22	SENT_25	[p2l957t1276r1038b1316],
19	undetectable	JJ	O	undetectable	amod	22	SENT_25	[p2l1061t1253r1507b1316],
20	serum	NN	O	serum	nn	22	SENT_25	[p2l1531t1276r1749b1317],
21	HCV	NN	O	hcv	nn	22	SENT_25	[p2l1773t1257r1955b1317],
22	RNA	NN	O	rna	prep_as	16	SENT_25	[p2l1979t1257r2152b1316],
23	4	CD	DURATION	4	num	24	SENT_25	[p2l8t1363r47b1419],
24	weeks	NNS	NUMBER	week	tmod	22	SENT_25	[p2l69t1356r280b1420],
25	into	IN	O	into	_	0	SENT_25	[p2l305t1362r442b1420],
26	treatment	NN	O	treatment	prep_into	16	SENT_25	[p2l467t1368r830b1420],
27	.	.	O	.	_	0	SENT_25	[p2l467t1368r830b1420],

1	When	WRB	O	when	advmod	6	SENT_26	[p2l856t1356r1073b1420],
2	the	DT	O	the	det	4	SENT_26	[p2l1096t1356r1205b1420],
3	HCV	NN	O	hcv	nn	4	SENT_26	[p2l1230t1360r1415b1420],
4	RNA	NN	O	rna	nsubj	6	SENT_26	[p2l1439t1360r1614b1420],
5	remains	VBZ	O	remain	cop	6	SENT_26	[p2l1638t1362r1920b1420],
6	undetectable	JJ	O	undetectable	_	0	SENT_26	[p2l1944t1356r2150b1420, p2l7t1460r285b1523],

1	from	IN	O	from	_	0	SENT_27	[p2l313t1460r488b1523],
2	4	CD	DURATION	4	num	3	SENT_27	[p2l515t1467r554b1522],
3	weeks	NNS	NUMBER	week	prep_from	12	SENT_27	[p2l580t1460r794b1523],
4	to	TO	O	to	_	0	SENT_27	[p2l821t1472r890b1523],
5	12	CD	DURATION	12	num	6	SENT_27	[p2l926t1467r999b1522],
6	weeks	NNS	NUMBER	week	prep_to	12	SENT_27	[p2l1027t1460r1240b1523],
7	of	IN	O	of	_	0	SENT_27	[p2l1269t1460r1346b1523],
8	therapy	NN	O	therapy	prep_of	6	SENT_27	[p2l1363t1460r1648b1544],
9	,	,	O	,	_	0	SENT_27	[p2l1363t1460r1648b1544],
10	it	PRP	O	it	nsubjpass	12	SENT_27	[p2l1678t1466r1726b1523],
11	is	VBZ	O	be	auxpass	12	SENT_27	[p2l1752t1466r1804b1523],
12	called	VBN	O	call	_	0	SENT_27	[p2l1833t1460r2043b1523],
13	an	DT	O	a	det	18	SENT_27	[p2l2070t1483r2153b1523],
14	extended	JJ	O	extended	amod	18	SENT_27	[p2l9t1563r327b1626],
15	RVR	NNP	O	RVR	nn	18	SENT_27	[p2l350t1568r515b1626],
16	(	CD	NUMBER	(	num	18	SENT_27	[p2l539t1563r814b1640],
17	eRVR	NN	O	ervr	nn	18	SENT_27	[p2l539t1563r814b1640],
18	)	NN	O	)	dobj	12	SENT_27	[p2l539t1563r814b1640],
19	.	.	O	.	_	0	SENT_27	[p2l539t1563r814b1640],

1	Cure	NN	O	cure	nsubjpass	3	SENT_28	[p2l841t1567r1009b1626],
2	is	VBZ	O	be	auxpass	3	SENT_28	[p2l1032t1569r1083b1626],
3	deﬁned	VBN	O	deﬁned	_	0	SENT_28	[p2l1108t1563r1368b1626],
4	by	IN	O	by	_	0	SENT_28	[p2l1387t1563r1473b1647],
5	sustained	JJ	O	sustained	amod	7	SENT_28	[p2l1493t1563r1821b1626],
6	virologic	JJ	O	virologic	amod	7	SENT_28	[p2l1840t1563r2150b1647],
7	response	NN	O	response	agent	3	SENT_28	[p2l9t1688r309b1749],
8	(	CD	NUMBER	(	num	10	SENT_28	[p2l334t1666r561b1743],
9	SVR	NN	ORGANIZATION	svr	nn	10	SENT_28	[p2l334t1666r561b1743],
10	)	NN	O	)	nsubj	24	SENT_28	[p2l334t1666r561b1743],
11	,	,	O	,	_	0	SENT_28	[p2l334t1666r561b1743],
12	a	DT	O	a	det	19	SENT_28	[p2l585t1689r620b1729],
13	persistently	RB	O	persistently	advmod	14	SENT_28	[p2l639t1666r1038b1750],
14	negative	JJ	O	negative	amod	19	SENT_28	[p2l1056t1672r1339b1750],
15	HCV	NN	O	hcv	nn	19	SENT_28	[p2l1361t1670r1542b1729],
16	RNA	NN	O	rna	nn	19	SENT_28	[p2l1563t1670r1734b1729],
17	12	CD	NUMBER	12	number	18	SENT_28	[p2l1762t1673r1833b1728],
18	(	CD	NUMBER	(	num	19	SENT_28	[p2l1860t1666r2148b1743],
19	SVR12	NN	O	svr12	appos	10	SENT_28	[p2l1860t1666r2148b1743],
20	)	CD	NUMBER	)	nn	23	SENT_28	[p2l1860t1666r2148b1743],
21	or	CC	O	or	_	0	SENT_28	[p2l9t1792r81b1832],
22	24	CD	DURATION	24	nn	23	SENT_28	[p2l101t1776r180b1831],
23	weeks	NNS	NUMBER	week	dep	19	SENT_28	[p2l199t1769r404b1832],
24	(	VBP	O	(	rcmod	7	SENT_28	[p2l430t1770r717b1845],
25	SVR24	NN	O	svr24	nn	26	SENT_28	[p2l430t1770r717b1845],
26	)	NN	O	)	dobj	24	SENT_28	[p2l430t1770r717b1845],
27	after	IN	O	after	_	0	SENT_28	[p2l743t1769r896b1832],
28	the	DT	O	the	det	29	SENT_28	[p2l915t1769r1022b1832],
29	completion	NN	O	completion	prep_after	24	SENT_28	[p2l1044t1769r1433b1852],
30	of	IN	O	of	_	0	SENT_28	[p2l1455t1769r1529b1832],
31	therapy	NN	O	therapy	prep_of	29	SENT_28	[p2l1539t1769r1809b1853],
32	.	.	O	.	_	0	SENT_28	[p2l1539t1769r1809b1853],

1	Virologic	JJ	O	virologic	amod	2	SENT_29	[p2l1832t1769r2152b1853],
2	relapse	NN	O	relapse	nsubj	5	SENT_29	[p2l9t1872r240b1955],
3	is	VBZ	O	be	cop	5	SENT_29	[p2l260t1878r309b1935],
4	the	DT	O	the	det	5	SENT_29	[p2l328t1872r433b1935],
5	recurrence	NN	O	recurrence	_	0	SENT_29	[p2l453t1895r814b1935],
6	of	IN	O	of	_	0	SENT_29	[p2l834t1872r907b1935],
7	quantiﬁable	JJ	O	quantiﬁable	amod	8	SENT_29	[p2l918t1872r1313b1955],
8	levels	NNS	O	level	prep_of	5	SENT_29	[p2l1332t1872r1514b1935],
9	of	IN	O	of	_	0	SENT_29	[p2l1535t1872r1607b1935],
10	HCV	NN	O	hcv	nn	11	SENT_29	[p2l1618t1876r1795b1935],
11	RNA	NN	O	rna	prep_of	8	SENT_29	[p2l1815t1876r1982b1935],
12	after	IN	O	after	_	0	SENT_29	[p2l2003t1872r2152b1935],
13	the	DT	O	the	det	14	SENT_29	[p2l7t1975r114b2039],
14	completion	NN	O	completion	prep_after	11	SENT_29	[p2l136t1975r526b2059],
15	of	IN	O	of	_	0	SENT_29	[p2l548t1975r622b2039],
16	treatment	NN	O	treatment	prep_of	14	SENT_29	[p2l633t1967r1020b2039],
17	.6	CD	NUMBER	.6	num	16	SENT_29	[p2l633t1967r1020b2039],

1	In	IN	O	in	_	0	SENT_30	[p2l83t2084r153b2141],
2	patients	NNS	O	patient	prep_in	16	SENT_30	[p2l173t2085r441b2162],
3	with	IN	O	with	_	0	SENT_30	[p2l460t2079r613b2142],
4	genotype	NN	O	genotype	nn	6	SENT_30	[p2l633t2091r944b2163],
5	1	CD	NUMBER	1	num	6	SENT_30	[p2l972t2086r996b2141],
6	infection	NN	O	infection	prep_with	2	SENT_30	[p2l1023t2079r1328b2142],
7	treated	VBN	O	treat	partmod	6	SENT_30	[p2l1348t2079r1585b2142],
8	with	IN	O	with	_	0	SENT_30	[p2l1603t2079r1755b2142],
9	PEG+RBV	NN	O	peg+rbv	prep_with	7	SENT_30	[p2l1777t2083r2150b2151],
10	,	,	O	,	_	0	SENT_30	[p2l1777t2083r2150b2151],
11	SVR	NN	ORGANIZATION	svr	nn	12	SENT_30	[p2l9t2186r167b2245],
12	rates	NNS	O	rate	nsubj	16	SENT_30	[p2l189t2194r353b2245],
13	were	VBD	O	be	cop	16	SENT_30	[p2l376t2205r542b2245],
14	~	CD	NUMBER	~	number	15	SENT_30	[p2l569t2187r918b2246],
15	40	CD	NUMBER	40	num	16	SENT_30	[p2l569t2187r918b2246],
16	—	NN	O	—	_	0	SENT_30	[p2l569t2187r918b2246],
17	50	CD	PERCENT	50	number	18	SENT_30	[p2l569t2187r918b2246],
18	%	NN	PERCENT	%	amod	16	SENT_30	[p2l569t2187r918b2246],
19	.	.	O	.	_	0	SENT_30	[p2l569t2187r918b2246],

1	PEG	NN	O	peg	nsubjpass	4	SENT_31	[p2l946t2186r1105b2245],
2	is	VBZ	O	be	auxpass	4	SENT_31	[p2l1130t2188r1182b2245],
3	commonly	RB	O	commonly	advmod	4	SENT_31	[p2l1208t2182r1592b2266],
4	associated	VBN	O	associate	_	0	SENT_31	[p2l1613t2182r1974b2245],
5	with	IN	O	with	_	0	SENT_31	[p2l1996t2182r2153b2245],
6	inﬂuenza-like	JJ	O	inﬂuenza-like	amod	7	SENT_31	[p2l9t2285r508b2348],
7	symptoms	NNS	O	symptom	prep_with	4	SENT_31	[p2l538t2297r928b2369],
8	,	,	O	,	_	0	SENT_31	[p2l538t2297r928b2369],
9	thrombocytopenia	NN	O	thrombocytopenia	appos	7	SENT_31	[p2l958t2285r1658b2369],
10	,	,	O	,	_	0	SENT_31	[p2l958t2285r1658b2369],
11	neutropenia	NN	O	neutropenia	conj_and	9	SENT_31	[p2l1688t2291r2151b2368],
12	,	,	O	,	_	0	SENT_31	[p2l1688t2291r2151b2368],
13	fatigue	NN	O	fatigue	conj_and	9	SENT_31	[p2l8t2388r250b2472],
14	,	,	O	,	_	0	SENT_31	[p2l8t2388r250b2472],
15	and	CC	O	and	_	0	SENT_31	[p2l272t2388r395b2451],
16	depression	NN	O	depression	appos	7	SENT_31	[p2l414t2388r786b2471],
17	.	.	O	.	_	0	SENT_31	[p2l414t2388r786b2471],

1	These	DT	O	these	det	3	SENT_32	[p2l809t2388r999b2451],
2	adverse	JJ	O	adverse	amod	3	SENT_32	[p2l1019t2388r1267b2451],
3	events	NNS	O	event	nsubj	4	SENT_32	[p2l1287t2400r1494b2451],
4	(	VBP	O	(	_	0	SENT_32	[p2l1517t2388r1702b2465],
5	AEs	NNS	O	ae	dobj	4	SENT_32	[p2l1517t2388r1702b2465],
6	)	RB	O	)	advmod	8	SENT_32	[p2l1517t2388r1702b2465],
7	often	RB	O	often	advmod	8	SENT_32	[p2l1726t2388r1895b2451],
8	limited	JJ	O	limited	amod	10	SENT_32	[p2l1913t2388r2151b2451],
9	effective	JJ	O	effective	amod	10	SENT_32	[p2l9t2491r290b2555],
10	treatment	NN	O	treatment	dep	5	SENT_32	[p2l311t2503r664b2564],
11	,	,	O	,	_	0	SENT_32	[p2l311t2503r664b2564],
12	resulting	VBG	O	result	partmod	5	SENT_32	[p2l688t2491r990b2576],
13	in	IN	O	in	_	0	SENT_32	[p2l1010t2498r1077b2554],
14	early	JJ	O	early	amod	15	SENT_32	[p2l1099t2491r1266b2576],
15	termination	NN	O	termination	prep_in	12	SENT_32	[p2l1283t2498r1694b2555],
16	of	IN	O	of	_	0	SENT_32	[p2l1716t2491r1791b2555],
17	therapy	NN	O	therapy	prep_of	15	SENT_32	[p2l1802t2484r2106b2576],
18	.7	CD	NUMBER	.7	num	17	SENT_32	[p2l1802t2484r2106b2576],
19	A	DT	O	a	det	21	SENT_32	[p2l81t2599r140b2657],
20	greater	JJR	O	greater	amod	21	SENT_32	[p2l164t2607r407b2679],
21	understanding	NN	O	understanding	nsubj	26	SENT_32	[p2l431t2595r947b2679],
22	of	IN	O	of	_	0	SENT_32	[p2l971t2595r1046b2658],
23	the	DT	O	the	det	24	SENT_32	[p2l1060t2595r1169b2658],
24	HCV	NNP	O	HCV	prep_of	21	SENT_32	[p2l1195t2599r1379b2658],
25	has	VBZ	O	have	aux	26	SENT_32	[p2l1402t2595r1517b2658],
26	enabled	VBN	O	enable	rcmod	17	SENT_32	[p2l1542t2595r1815b2658],
27	efforts	NNS	O	effort	dobj	26	SENT_32	[p2l1839t2595r2058b2658],
28	to	TO	O	to	aux	29	SENT_32	[p2l2083t2607r2150b2658],
29	improve	VB	O	improve	xcomp	26	SENT_32	[p2l9t2704r298b2781],
30	efficacy	NN	O	efficacy	dobj	29	SENT_32	[p2l323t2698r587b2782],
31	and	CC	O	and	_	0	SENT_32	[p2l609t2698r738b2761],
32	tolerability	NN	O	tolerability	conj_and	30	SENT_32	[p2l761t2698r1146b2782],
33	of	IN	O	of	_	0	SENT_32	[p2l1167t2698r1243b2761],
34	HCV	NN	O	hcv	nn	35	SENT_32	[p2l1259t2702r1443b2761],
35	treatment	NN	O	treatment	prep_of	30	SENT_32	[p2l1466t2710r1826b2761],
36	.	.	O	.	_	0	SENT_32	[p2l1466t2710r1826b2761],

1	Multiple	JJ	O	multiple	amod	3	SENT_33	[p2l1854t2698r2151b2781],
2	direct-acting	JJ	O	direct-acting	amod	3	SENT_33	[p2l9t2801r456b2885],
3	antivirals	NNS	O	antiviral	nsubj	4	SENT_33	[p2l478t2801r796b2864],
4	(	VBP	O	(	_	0	SENT_33	[p2l823t2801r1598b2877],
5	DAAs	NNS	O	daa	dobj	4	SENT_33	[p2l823t2801r1598b2877],
6	)	CD	NUMBER	)	tmod	4	SENT_33	[p2l823t2801r1598b2877],
7	.	.	O	.	_	0	SENT_33	[p2l823t2801r1598b2877],

1	—	NN	O	—	_	0	SENT_34	[p2l823t2801r1598b2877],
2	.	.	O	.	_	0	SENT_34	[p2l823t2801r1598b2877],

1	medications	NNS	O	medication	nsubj	13	SENT_35	[p2l823t2801r1598b2877],
2	targeted	VBN	O	target	partmod	1	SENT_35	[p2l1621t2801r1904b2885],
3	at	IN	O	at	_	0	SENT_35	[p2l1926t2813r1987b2864],
4	speciﬁc	NN	O	speciﬁc	nn	5	SENT_35	[p2l2009t2823r2148b2884, p2l9t2904r151b2967],
5	processes	NNS	O	process	prep_at	2	SENT_35	[p2l175t2926r506b2987],
6	within	IN	O	within	_	0	SENT_35	[p2l530t2904r759b2967],
7	the	DT	O	the	det	10	SENT_35	[p2l784t2904r893b2967],
8	HCV	NNP	O	HCV	nn	10	SENT_35	[p2l919t2908r1103b2967],
9	life	NN	O	life	nn	10	SENT_35	[p2l1126t2904r1233b2967],
10	cycle	NN	O	cycle	prep_within	2	SENT_35	[p2l1259t2904r1676b2988],
11	—	CD	NUMBER	—	dep	10	SENT_35	[p2l1259t2904r1676b2988],
12	have	VBP	O	have	aux	13	SENT_35	[p2l1259t2904r1676b2988],
13	been	VBN	O	be	_	0	SENT_35	[p2l1699t2904r1868b2967],
14	and	CC	O	and	_	0	SENT_35	[p2l1893t2904r2023b2967],
15	are	VBP	O	be	aux	17	SENT_35	[p2l2048t2927r2150b2967],
16	being	VBG	O	be	auxpass	17	SENT_35	[p2l6t3007r204b3091],
17	developed	VBN	O	develop	conj_and	13	SENT_35	[p2l230t3007r592b3090],
18	(	CD	NUMBER	(	num	21	SENT_35	[p2l621t3008r889b3090],
19	Figure	NN	O	figure	nn	21	SENT_35	[p2l621t3008r889b3090],
20	1	CD	NUMBER	1	num	21	SENT_35	[p2l920t3008r1003b3084],
21	)	NN	O	)	nsubjpass	17	SENT_35	[p2l920t3008r1003b3084],
22	.	.	O	.	_	0	SENT_35	[p2l920t3008r1003b3084],

1	DAAs	NNS	O	daa	nsubj	3	SENT_36	[p2l1034t3011r1246b3070],
2	are	VBP	O	be	cop	3	SENT_36	[p2l1274t3030r1377b3070],
3	molecules	NNS	O	molecule	_	0	SENT_36	[p2l1404t3007r1759b3070],
4	that	WDT	O	that	nsubj	5	SENT_36	[p2l1785t3007r1924b3070],
5	target	VBP	O	target	rcmod	3	SENT_36	[p2l1949t3019r2153b3091],
6	speciﬁc	NN	O	speciﬁc	nn	8	SENT_36	[p2l9t3110r257b3193],
7	nonstructural	JJ	O	nonstructural	amod	8	SENT_36	[p2l278t3110r741b3173],
8	proteins	NNS	O	protein	dobj	5	SENT_36	[p2l759t3116r1034b3193],
9	within	IN	O	within	_	0	SENT_36	[p2l1053t3110r1273b3173],
10	the	DT	O	the	det	11	SENT_36	[p2l1292t3110r1398b3173],
11	HCV	NN	MISC	hcv	prep_within	5	SENT_36	[p2l1419t3114r1602b3182],
12	,	,	O	,	_	0	SENT_36	[p2l1419t3114r1602b3182],
13	which	WDT	O	which	nsubj	14	SENT_36	[p2l1622t3110r1829b3173],
14	results	VBZ	O	result	rcmod	11	SENT_36	[p2l1850t3110r2065b3173],
15	in	IN	O	in	prep	14	SENT_36	[p2l2086t3116r2152b3172],

1	‘	NN	O	‘	nn	3	SENT_37	[p2l21t3278r134b3305],
2	Division	NN	O	division	nn	3	SENT_37	[p2l21t3278r134b3305],
3	ofGastroenterology/Hepatology	NN	O	ofgastroenterology/hepatology	nsubj	20	SENT_37	[p2l142t3281r568b3311],
4	,	,	O	,	_	0	SENT_37	[p2l142t3281r568b3311],
5	Department	NNP	ORGANIZATION	Department	appos	3	SENT_37	[p2l577t3283r734b3311],
6	of	IN	ORGANIZATION	of	_	0	SENT_37	[p2l741t3281r767b3305],
7	Medicine	NNP	ORGANIZATION	Medicine	prep_of	5	SENT_37	[p2l773t3281r897b3308],
8	,	,	O	,	_	0	SENT_37	[p2l773t3281r897b3308],
9	Scripps	NNP	ORGANIZATION	Scripps	nn	10	SENT_37	[p2l904t3282r997b3311],
10	Clinic	NNP	ORGANIZATION	Clinic	appos	7	SENT_37	[p2l1004t3281r1080b3308],
11	,	,	O	,	_	0	SENT_37	[p2l1004t3281r1080b3308],
12	La	NNP	LOCATION	La	nn	13	SENT_37	[p2l1089t3283r1115b3305],
13	Jolla	NNP	LOCATION	Jolla	appos	7	SENT_37	[p2l1122t3281r1186b3308],
14	,	,	O	,	_	0	SENT_37	[p2l1122t3281r1186b3308],
15	California	NNP	LOCATION	California	appos	7	SENT_37	[p2l1193t3281r1321b3308],
16	,	,	O	,	_	0	SENT_37	[p2l1193t3281r1321b3308],
17	USA	NNP	LOCATION	USA	appos	15	SENT_37	[p2l1329t3282r1388b3308],
18	;	:	O	;	_	0	SENT_37	[p2l1329t3282r1388b3308],
19	2ScrippsTrans	NNS	O	2scrippstran	dep	7	SENT_37	[p2l1395t3278r1669b3311],
20	|	VBP	O	|	_	0	SENT_37	[p2l1395t3278r1669b3311],
21	ationa	NN	O	ationa	nn	24	SENT_37	[p2l1395t3278r1669b3311],
22	|	CD	ORGANIZATION	|	num	24	SENT_37	[p2l1395t3278r1669b3311],
23	Science	NNP	ORGANIZATION	Science	nn	24	SENT_37	[p2l1677t3282r1775b3305],
24	Institute	NNP	ORGANIZATION	Institute	dobj	20	SENT_37	[p2l1783t3283r1894b3308],
25	,	,	O	,	_	0	SENT_37	[p2l1783t3283r1894b3308],
26	La	NNP	LOCATION	La	nn	27	SENT_37	[p2l1903t3283r1929b3305],
27	Jolla	NNP	LOCATION	Jolla	appos	24	SENT_37	[p2l1936t3281r2000b3308],
28	,	,	O	,	_	0	SENT_37	[p2l1936t3281r2000b3308],
29	California	NNP	LOCATION	California	appos	24	SENT_37	[p2l2007t3281r2135b3308],
30	,	,	O	,	_	0	SENT_37	[p2l2007t3281r2135b3308],
31	USA	NNP	LOCATION	USA	appos	24	SENT_37	[p2l21t3320r79b3342],
32	.	.	O	.	_	0	SENT_37	[p2l21t3320r79b3342],

1	Correspondence	NN	O	correspondence	_	0	SENT_38	[p2l87t3319r307b3348],
2	:	:	O	:	_	0	SENT_38	[p2l87t3319r307b3348],
3	PJ	NNP	PERSON	PJ	nn	4	SENT_38	[p2l315t3320r337b3342],
4	Pockros	NNP	PERSON	Pockros	dep	1	SENT_38	[p2l346t3319r445b3342],
5	(	NN	O	(	nn	6	SENT_38	[p2l453t3319r883b3348],
6	pockros	NNS	O	pockro	dep	4	SENT_38	[p2l453t3319r883b3348],
7	.	.	O	.	_	0	SENT_38	[p2l453t3319r883b3348],

1	pau	NN	O	pau	dep	13	SENT_39	[p2l453t3319r883b3348],
2	|	SYM	O	|	dep	13	SENT_39	[p2l453t3319r883b3348],
3	@scrippshea	FW	O	@scrippshea	nn	6	SENT_39	[p2l453t3319r883b3348],
4	|	FW	O	|	nn	6	SENT_39	[p2l453t3319r883b3348],
5	th.org	FW	O	th.org	nn	6	SENT_39	[p2l453t3319r883b3348],
6	)	FW	O	)	nsubj	13	SENT_39	[p2l453t3319r883b3348],
7	Received	VBN	O	receive	partmod	6	SENT_39	[p2l21t3362r130b3385],
8	3	CD	DATE	3	num	9	SENT_39	[p2l139t3364r151b3385],
9	September	NNP	DATE	September	dep	7	SENT_39	[p2l159t3362r297b3391],
10	201	CD	NUMBER	201	number	11	SENT_39	[p2l304t3364r342b3385],
11	3	CD	NUMBER	3	dep	9	SENT_39	[p2l350t3364r368b3389],
12	;	:	O	;	_	0	SENT_39	[p2l350t3364r368b3389],
13	accepted	VBN	O	accept	_	0	SENT_39	[p2l375t3362r488b3391],
14	27	CD	DATE	27	num	15	SENT_39	[p2l497t3364r525b3385],
15	September	NNP	DATE	September	dobj	13	SENT_39	[p2l533t3362r671b3391],
16	201	CD	NUMBER	201	num	15	SENT_39	[p2l678t3364r716b3385],
17	3	CD	NUMBER	3	dep	15	SENT_39	[p2l723t3364r742b3389],
18	;	:	O	;	_	0	SENT_39	[p2l723t3364r742b3389],
19	advance	NN	O	advance	dep	15	SENT_39	[p2l749t3362r852b3385],
20	online	NN	O	online	prep	19	SENT_39	[p2l860t3362r936b3385],
21	publication	NN	O	publication	dep	20	SENT_39	[p2l945t3362r1083b3391],
22	27	CD	DATE	27	num	21	SENT_39	[p2l1091t3364r1120b3385],
23	November	NNP	DATE	November	tmod	19	SENT_39	[p2l1129t3362r1259b3385],
24	201	CD	NUMBER	201	num	23	SENT_39	[p2l1266t3364r1304b3385],
25	3	CD	NUMBER	3	dep	15	SENT_39	[p2l1312t3364r1330b3385],
26	.	.	O	.	_	0	SENT_39	[p2l1312t3364r1330b3385],

1	doi	FW	O	doi	nn	2	SENT_40	[p2l1337t3362r1391b3385],
2	:1	FW	O	:1	dep	8	SENT_40	[p2l1337t3362r1391b3385],
3	0.1	CD	NUMBER	0.1	num	4	SENT_40	[p2l1398t3364r1427b3385],
4	O38/c	NN	O	o38/c	dep	2	SENT_40	[p2l1434t3362r1582b3391],
5	|	CD	NUMBER	|	num	6	SENT_40	[p2l1434t3362r1582b3391],
6	pt	NN	O	pt	dep	8	SENT_40	[p2l1434t3362r1582b3391],
7	.201	CD	NUMBER	.201	num	8	SENT_40	[p2l1434t3362r1582b3391],
8	3.206	CD	NUMBER	3.206	dep	12	SENT_40	[p2l1590t3364r1654b3385],
9	78	CD	NUMBER	78	num	10	SENT_40	[p2l20t3407r51b3428],
10	VOLUME	NN	O	volume	dep	8	SENT_40	[p2l1367t3407r1475b3428],
11	95	CD	NUMBER	95	num	12	SENT_40	[p2l1483t3407r1510b3428],
12	NUMBER	NN	O	number	dep	18	SENT_40	[p2l1520t3407r1628b3428],
13	1	CD	NUMBER	1	number	14	SENT_40	[p2l1638t3408r1645b3428],
14	|	CD	NUMBER	|	dep	12	SENT_40	[p2l1659t3405r1661b3435],
15	JANUARY	NNP	DATE	JANUARY	dep	14	SENT_40	[p2l1670t3407r1788b3428],
16	2014	CD	DATE	2014	num	15	SENT_40	[p2l1796t3407r1854b3428],
17	|	CD	NUMBER	|	num	18	SENT_40	[p2l1863t3405r1865b3435],
18	www.nature.com/cpt	NN	O	www.nature.com/cpt	_	0	SENT_40	[p2l1874t3407r2139b3433],

1	Nucleocapsid	NNP	MISC	Nucleocapsid	nn	2	SENT_41	[p3l457t68r629b95],
2	Envelope	NNP	MISC	Envelope	_	0	SENT_41	[p3l458t108r575b136],

1	Receptor	NN	O	receptor	nsubj	2	SENT_42	[p3l708t158r824b185],
2	binding	NN	O	binding	_	0	SENT_42	[p3l834t158r925b185],
3	Transport	NN	O	transport	dobj	2	SENT_42	[p3l1472t164r1594b191],
4	,	,	O	,	_	0	SENT_42	[p3l1812t180r1813b184],
5	'	''	O	'	_	0	SENT_42	[p3l621t190r624b191],
6	y	NN	O	y	nsubj	14	SENT_42	[p3l649t221r651b223],
7	and	CC	O	and	_	0	SENT_42	[p3l707t193r753b214],
8	endocytosis	NN	O	endocytosis	nsubj	14	SENT_42	[p3l763t193r916b220],
9	and	CC	O	and	_	0	SENT_42	[p3l1458t199r1504b221],
10	reiease	NN	O	reiease	nn	12	SENT_42	[p3l1516t199r1608b221],
11	‘	NN	O	‘	nn	12	SENT_42	[p3l1616t186r1666b235],
12	C	NN	O	c	nsubj	14	SENT_42	[p3l1616t186r1666b235],
13	s	VBZ	O	s	cop	14	SENT_42	[p3l1729t200r1731b213],
14	g	NN	O	g	rcmod	3	SENT_42	[p3l1799t220r1807b223],

1	I	PRP	O	I	nsubj	2	SENT_43	[p3l1611t236r1639b268, p3l1580t256r1652b319],
2	\	VBP	O	\	_	0	SENT_43	[p3l1611t236r1639b268, p3l1580t256r1652b319],
3	;	:	O	;	_	0	SENT_43	[p3l1611t236r1639b268, p3l1580t256r1652b319],

1	Protease	NN	O	protease	nn	2	SENT_44	[p3l257t324r377b345],
2	inhibitors	NNS	O	inhibitor	_	0	SENT_44	[p3l257t358r387b380],
3	Telaprevir	NNP	O	Telaprevir	nn	4	SENT_44	[p3l255t389r381b417],
4	Boceprevir	NNP	O	Boceprevir	dep	2	SENT_44	[p3l257t424r394b452],
5	Asunaprevir	NNP	O	Asunaprevir	nn	7	SENT_44	[p3l255t459r410b487],
6	Simeprevir	NNP	O	Simeprevir	nn	7	SENT_44	[p3l256t494r394b522],
7	Faldaprevir	NNP	O	Faldaprevir	dep	2	SENT_44	[p3l257t529r399b557],

1	I	PRP	O	I	nsubj	2	SENT_45	[p3l1536t465r1538b467],
2	NS5B	VBP	O	ns5b	_	0	SENT_45	[p3l1562t480r1636b503],
3	polymerase	NN	O	polymerase	nn	4	SENT_45	[p3l1647t481r1807b508],
4	inhibitors	NNS	O	inhibitor	dobj	2	SENT_45	[p3l1562t516r1691b538],
5	Sofosbuvir	NNP	O	Sofosbuvir	dep	4	SENT_45	[p3l1561t551r1700b578],
6	,	,	O	,	_	0	SENT_45	[p3l1561t551r1700b578],
7	mericitabine	NN	O	mericitabine	appos	4	SENT_45	[p3l1712t552r1868b574],
8	3	CD	NUMBER	3	amod	7	SENT_45	[p3l1881t555r1882b582],
9	"	''	O	"	punct	4	SENT_45	[p3l924t641r930b647],

1	,	,	O	,	_	0	SENT_46	[p3l944t654r945b658],
2	Daclatasvir	NNP	PERSON	Daclatasvir	nn	3	SENT_46	[p3l983t637r1126b659],
3	Ledipasvir	NNP	PERSON	Ledipasvir	_	0	SENT_46	[p3l983t672r1114b699],

1	Deleobuvir	NNP	PERSON	Deleobuvir	_	0	SENT_47	[p3l1035t776r1176b801],
2	,	,	O	,	_	0	SENT_47	[p3l1035t776r1176b801],
3	filibuvir	JJ	O	filibuvir	amod	5	SENT_47	[p3l1187t775r1277b797],
4	E	NN	O	e	nn	5	SENT_47	[p3l964t832r965b843],
5	VX-222	NN	O	vx-222	appos	1	SENT_47	[p3l1033t811r1136b836],
6	,	,	O	,	_	0	SENT_47	[p3l1033t811r1136b836],
7	setrobuvir	NN	O	setrobuvir	appos	1	SENT_47	[p3l1147t811r1274b832],

1	:	:	O	:	_	0	SENT_48	[p3l801t840r886b879],
2	u	FW	O	u	nn	3	SENT_48	[p3l801t840r886b879],
3	“	FW	O	“	dep	4	SENT_48	[p3l801t840r886b879],
4	n	NN	O	n	_	0	SENT_48	[p3l801t840r886b879],
5	:	:	O	:	_	0	SENT_48	[p3l801t840r886b879],
6	nmu	NN	O	nmu	dep	4	SENT_48	[p3l801t840r886b879],
7	:	:	O	:	_	0	SENT_48	[p3l801t840r886b879],
8	In	IN	O	in	dep	10	SENT_48	[p3l896t871r906b879],
9	liiji	NNS	O	liijus	pobj	8	SENT_48	[p3l916t863r942b883],
10	"	``	O	"	dep	4	SENT_48	[p3l964t848r974b871],
11	:	:	O	:	_	0	SENT_48	[p3l964t848r974b871],
12	Tegobuvir	NN	O	tegobuvir	dep	10	SENT_48	[p3l1033t846r1159b873],

1	Illustrated	NNP	O	Illustrated	_	0	SENT_49	[p3l1922t828r1944b951],
2	by	IN	O	by	dep	1	SENT_49	[p3l1922t789r1950b817],
3	Zina	NNP	PERSON	Zina	nn	4	SENT_49	[p3l1922t724r1944b780],
4	Deretsky	NNP	PERSON	Deretsky	pobj	2	SENT_49	[p3l1922t601r1950b714],

1	Figure	NNP	O	Figure	nn	3	SENT_50	[p3l21t988r112b1018],
2	1	CD	NUMBER	1	num	3	SENT_50	[p3l121t989r131b1011],
3	Mechanisms	NNS	O	mechanism	_	0	SENT_50	[p3l160t987r327b1011],
4	of	IN	O	of	_	0	SENT_50	[p3l335t987r363b1011],
5	action	NN	O	action	prep_of	3	SENT_50	[p3l369t989r451b1011],
6	for	IN	O	for	_	0	SENT_50	[p3l459t987r496b1011],
7	direct	JJ	O	direct	amod	8	SENT_50	[p3l504t987r674b1018],
8	—	NN	O	—	prep_for	5	SENT_50	[p3l504t987r674b1018],
9	acting	VBG	O	act	partmod	3	SENT_50	[p3l504t987r674b1018],
10	antivirals	NNS	O	antiviral	dobj	9	SENT_50	[p3l683t987r803b1011],
11	currently	RB	DATE	currently	advmod	9	SENT_50	[p3l811t987r931b1018],
12	in	IN	O	in	_	0	SENT_50	[p3l940t988r961b1011],
13	development	NN	O	development	prep_in	9	SENT_50	[p3l971t987r1158b1017],
14	.	.	O	.	_	0	SENT_50	[p3l971t987r1158b1017],

1	NNPI	NNP	O	NNPI	_	0	SENT_51	[p3l1167t988r1238b1015],
2	,	,	O	,	_	0	SENT_51	[p3l1167t988r1238b1015],
3	nonnucleoside	JJ	O	nonnucleoside	amod	5	SENT_51	[p3l1248t987r1446b1011],
4	polymerase	NN	O	polymerase	nn	5	SENT_51	[p3l1455t987r1610b1018],
5	inhibitor	NN	O	inhibitor	appos	1	SENT_51	[p3l1619t987r1738b1011],
6	.	.	O	.	_	0	SENT_51	[p3l1619t987r1738b1011],

1	disruption	NN	O	disruption	_	0	SENT_52	[p3l8t1174r353b1257],
2	of	IN	O	of	_	0	SENT_52	[p3l372t1174r444b1237],
3	viral	JJ	O	viral	amod	4	SENT_52	[p3l450t1174r599b1237],
4	replication	NN	O	replication	prep_of	1	SENT_52	[p3l617t1174r969b1257],
5	and	CC	O	and	_	0	SENT_52	[p3l988t1174r1110b1237],
6	infection	NN	O	infection	prep_of	1	SENT_52	[p3l1128t1174r1438b1237],
7	.	.	O	.	_	0	SENT_52	[p3l1128t1174r1438b1237],

1	There	EX	O	there	expl	2	SENT_53	[p3l1459t1174r1646b1237],
2	are	VBP	O	be	_	0	SENT_53	[p3l1665t1197r1762b1237],
3	four	CD	NUMBER	four	num	4	SENT_53	[p3l1781t1174r1919b1237],
4	classes	NNS	O	class	nsubj	2	SENT_53	[p3l1937t1174r2151b1237],
5	of	IN	O	of	_	0	SENT_53	[p3l8t1277r81b1340],
6	DAAS	NNP	O	DAAS	prep_of	4	SENT_53	[p3l90t1281r311b1349],
7	,	,	O	,	_	0	SENT_53	[p3l90t1281r311b1349],
8	which	WDT	O	which	nsubjpass	10	SENT_53	[p3l330t1277r535b1340],
9	are	VBP	O	be	auxpass	10	SENT_53	[p3l555t1300r653b1340],
10	deﬁned	VBN	O	deﬁned	rcmod	6	SENT_53	[p3l673t1277r923b1340],
11	by	IN	O	by	_	0	SENT_53	[p3l939t1277r1022b1361],
12	their	PRP$	O	they	poss	13	SENT_53	[p3l1036t1277r1196b1340],
13	mechanism	NN	O	mechanism	agent	10	SENT_53	[p3l1213t1277r1602b1340],
14	of	IN	O	of	_	0	SENT_53	[p3l1621t1277r1694b1340],
15	action	NN	O	action	prep_of	13	SENT_53	[p3l1704t1283r1910b1340],
16	and	CC	O	and	_	0	SENT_53	[p3l1930t1277r2054b1340],
17	by	IN	O	by	_	0	SENT_53	[p3l2070t1277r2153b1361],
18	their	PRP$	O	they	poss	20	SENT_53	[p3l7t1380r167b1443],
19	therapeutic	JJ	O	therapeutic	amod	20	SENT_53	[p3l185t1380r567b1463],
20	target	NN	O	target	agent	10	SENT_53	[p3l586t1392r794b1464],
21	.	.	O	.	_	0	SENT_53	[p3l586t1392r794b1464],

1	The	DT	O	the	det	3	SENT_54	[p3l817t1380r941b1443],
2	four	CD	NUMBER	four	num	3	SENT_54	[p3l961t1380r1103b1443],
3	classes	NNS	O	class	nsubj	5	SENT_54	[p3l1123t1380r1341b1443],
4	are	VBP	O	be	cop	5	SENT_54	[p3l1363t1403r1461b1443],
5	PIS	NNP	O	PIS	_	0	SENT_54	[p3l1483t1385r1583b1443],
6	(	CD	NUMBER	(	num	7	SENT_54	[p3l1608t1381r1802b1457],
7	NS3	NN	O	ns3	dep	5	SENT_54	[p3l1608t1381r1802b1457],
8	/	:	O	/	punct	7	SENT_54	[p3l1608t1381r1802b1457],
9	4A	NN	O	4a	nn	10	SENT_54	[p3l1805t1384r1903b1442],
10	inhibitors	NNS	O	inhibitor	nsubj	17	SENT_54	[p3l1923t1380r2148b1443, p3l7t1484r178b1559],
11	)	NN	O	)	nn	16	SENT_54	[p3l1923t1380r2148b1443, p3l7t1484r178b1559],
12	,	,	O	,	_	0	SENT_54	[p3l1923t1380r2148b1443, p3l7t1484r178b1559],
13	NS5B	NN	O	ns5b	dep	16	SENT_54	[p3l197t1487r386b1546],
14	nucleoside	NN	O	nucleoside	nn	16	SENT_54	[p3l407t1483r760b1546],
15	polymerase	NN	O	polymerase	nn	16	SENT_54	[p3l778t1483r1161b1567],
16	inhibitors	NNS	O	inhibitor	dep	10	SENT_54	[p3l1180t1483r1502b1546],
17	(	VBP	O	(	dep	7	SENT_54	[p3l1525t1484r1760b1559],
18	NPIs	NNS	O	npi	dobj	17	SENT_54	[p3l1525t1484r1760b1559],
19	)	CD	NUMBER	)	num	18	SENT_54	[p3l1525t1484r1760b1559],
20	,	,	O	,	_	0	SENT_54	[p3l1525t1484r1760b1559],
21	NS5B	NN	O	ns5b	appos	18	SENT_54	[p3l1780t1487r1969b1546],
22	nonnucleoside	JJ	O	nonnucleoside	amod	24	SENT_54	[p3l1988t1506r2146b1546, p3l7t1585r357b1649],
23	polymerase	NN	O	polymerase	nn	24	SENT_54	[p3l375t1585r754b1670],
24	inhibitors	NNS	O	inhibitor	nsubj	25	SENT_54	[p3l773t1585r1092b1649],
25	(	VBP	O	(	rcmod	21	SENT_54	[p3l1114t1586r1409b1662],
26	NNPIS	NNS	O	nnpi	dobj	25	SENT_54	[p3l1114t1586r1409b1662],
27	)	CD	NUMBER	)	dep	26	SENT_54	[p3l1114t1586r1409b1662],
28	,	,	O	,	_	0	SENT_54	[p3l1114t1586r1409b1662],
29	and	CC	O	and	_	0	SENT_54	[p3l1430t1585r1552b1649],
30	NS5A	NN	O	ns5a	nn	31	SENT_54	[p3l1569t1589r1767b1649],
31	inhibitors	NNS	O	inhibitor	dobj	25	SENT_54	[p3l1785t1577r2150b1649],
32	.8	CD	NUMBER	.8	dep	31	SENT_54	[p3l1785t1577r2150b1649],

1	PROTEASE	NN	O	protease	nn	2	SENT_55	[p3l11t1801r383b1857],
2	INHIBITORS	NNS	O	inhibitor	_	0	SENT_55	[p3l405t1801r823b1857],

1	Pls	NNS	O	pl	nsubj	3	SENT_56	[p3l8t1902r106b1960],
2	are	VBP	O	be	cop	3	SENT_56	[p3l125t1920r220b1960],
3	inhibitors	NNS	O	inhibitor	_	0	SENT_56	[p3l238t1897r552b1960],
4	of	IN	O	of	_	0	SENT_56	[p3l570t1897r641b1960],
5	the	DT	O	the	det	7	SENT_56	[p3l648t1897r750b1960],
6	NS3	NN	O	ns3	nn	7	SENT_56	[p3l766t1901r902b1960],
7	protease	NN	O	protease	prep_of	3	SENT_56	[p3l921t1909r1207b1980],
8	,	,	O	,	_	0	SENT_56	[p3l921t1909r1207b1980],
9	which	WDT	O	which	nsubj	12	SENT_56	[p3l1225t1897r1425b1960],
10	is	VBZ	O	be	cop	12	SENT_56	[p3l1442t1903r1490b1960],
11	an	DT	O	a	det	12	SENT_56	[p3l1509t1920r1586b1960],
12	enzyme	NN	O	enzyme	rcmod	7	SENT_56	[p3l1604t1919r1855b1981],
13	involved	VBN	O	involve	partmod	12	SENT_56	[p3l1873t1897r2150b1960],
14	in	IN	O	in	_	0	SENT_56	[p3l8t2006r74b2062],
15	posttranslational	JJ	O	posttranslational	amod	16	SENT_56	[p3l94t2000r668b2083],
16	processing	NN	O	processing	prep_in	13	SENT_56	[p3l687t2006r1052b2084],
17	and	CC	O	and	_	0	SENT_56	[p3l1072t2000r1199b2063],
18	replication	NN	O	replication	prep_in	13	SENT_56	[p3l1219t2000r1583b2083],
19	of	IN	O	of	_	0	SENT_56	[p3l1605t2000r1679b2063],
20	the	DT	O	the	det	21	SENT_56	[p3l1689t2000r1796b2063],
21	HCV	NN	O	hcv	prep_of	16	SENT_56	[p3l1818t2004r2002b2063],
22	.	.	O	.	_	0	SENT_56	[p3l1818t2004r2002b2063],

1	The	DT	O	the	det	3	SENT_57	[p3l2026t2000r2152b2063],
2	NS3	NN	O	ns3	nn	3	SENT_57	[p3l7t2107r145b2166],
3	protease	NN	O	protease	nsubj	4	SENT_57	[p3l165t2115r443b2186],
4	has	VBZ	O	have	_	0	SENT_57	[p3l461t2103r570b2166],
5	a	DT	O	a	det	7	SENT_57	[p3l590t2126r625b2166],
6	binding	NN	O	binding	nn	7	SENT_57	[p3l640t2103r902b2187],
7	site	NN	O	site	dobj	4	SENT_57	[p3l919t2109r1044b2175],
8	,	,	O	,	_	0	SENT_57	[p3l919t2109r1044b2175],
9	an	DT	O	a	det	14	SENT_57	[p3l1065t2126r1144b2166],
10	NS2/NS3	NN	O	ns2/ns3	nn	14	SENT_57	[p3l1161t2107r1471b2169],
11	proteinase	NN	O	proteinase	nn	14	SENT_57	[p3l1491t2109r1835b2186],
12	substrate	NN	O	substrate	nn	14	SENT_57	[p3l1855t2103r2151b2166],
13	recognition	NN	O	recognition	nn	14	SENT_57	[p3l8t2212r394b2290],
14	site	NN	O	site	dobj	4	SENT_57	[p3l415t2212r540b2278],
15	,	,	O	,	_	0	SENT_57	[p3l415t2212r540b2278],
16	a	DT	O	a	det	19	SENT_57	[p3l563t2229r598b2269],
17	helicase	NN	O	helicase	nn	19	SENT_57	[p3l616t2206r877b2269],
18	RNA-binding	JJ	O	rna-binding	amod	19	SENT_57	[p3l899t2206r1357b2290],
19	site	NN	O	site	conj_and	7	SENT_57	[p3l1377t2212r1502b2278],
20	,	,	O	,	_	0	SENT_57	[p3l1377t2212r1502b2278],
21	and	CC	O	and	_	0	SENT_57	[p3l1525t2206r1649b2269],
22	a	DT	O	a	det	24	SENT_57	[p3l1669t2229r1704b2269],
23	zinc-binding	JJ	O	zinc-binding	amod	24	SENT_57	[p3l1723t2206r2153b2290],
24	site	NN	O	site	conj_and	7	SENT_57	[p3l9t2315r134b2372],
25	.	.	O	.	_	0	SENT_57	[p3l9t2315r134b2372],

1	NS3	NN	O	ns3	nsubj	2	SENT_58	[p3l157t2313r298b2372],
2	forms	VBZ	O	form	_	0	SENT_58	[p3l322t2309r519b2372],
3	a	DT	O	a	det	5	SENT_58	[p3l541t2332r576b2372],
4	heterodimeric	JJ	O	heterodimeric	amod	5	SENT_58	[p3l594t2309r1076b2372],
5	complex	NN	O	complex	dobj	2	SENT_58	[p3l1098t2309r1387b2392],
6	with	IN	O	with	_	0	SENT_58	[p3l1404t2309r1555b2372],
7	NS4A	NN	O	ns4a	prep_with	2	SENT_58	[p3l1575t2313r1796b2381],
8	,	,	O	,	_	0	SENT_58	[p3l1575t2313r1796b2381],
9	which	WDT	O	which	nsubj	13	SENT_58	[p3l1817t2309r2025b2372],
10	is	VBZ	O	be	cop	13	SENT_58	[p3l2046t2315r2096b2372],
11	a	DT	O	a	det	13	SENT_58	[p3l2118t2332r2153b2372],
12	membrane	NN	O	membrane	nn	13	SENT_58	[p3l7t2412r381b2475],
13	protein	NN	O	protein	rcmod	7	SENT_58	[p3l403t2418r653b2495],
14	and	CC	O	and	_	0	SENT_58	[p3l677t2412r805b2475],
15	acts	VBZ	O	act	conj_and	2	SENT_58	[p3l828t2424r956b2475],
16	as	IN	O	as	_	0	SENT_58	[p3l981t2435r1045b2475],
17	a	DT	O	a	det	18	SENT_58	[p3l1069t2435r1104b2475],
18	cofactor	NN	O	cofactor	prep_as	15	SENT_58	[p3l1127t2412r1417b2475],
19	.	.	O	.	_	0	SENT_58	[p3l1127t2412r1417b2475],

1	PIS	NN	O	pi	nsubj	2	SENT_59	[p3l1443t2417r1547b2475],
2	disrupt	VB	O	disrupt	_	0	SENT_59	[p3l1571t2412r1818b2495],
3	the	DT	O	the	det	4	SENT_59	[p3l1839t2412r1946b2475],
4	HCV	NN	O	hcv	dobj	2	SENT_59	[p3l1970t2416r2152b2475],
5	by	IN	O	by	_	0	SENT_59	[p3l6t2515r90b2599],
6	blocking	VBG	O	block	prepc_by	2	SENT_59	[p3l105t2515r402b2599],
7	the	DT	O	the	det	10	SENT_59	[p3l420t2515r526b2578],
8	NS3	NN	O	ns3	nn	10	SENT_59	[p3l546t2519r687b2578],
9	catalytic	JJ	O	catalytic	amod	10	SENT_59	[p3l712t2515r990b2599],
10	site	NN	O	site	dobj	6	SENT_59	[p3l1011t2521r1121b2578],
11	or	CC	O	or	_	0	SENT_59	[p3l1143t2538r1215b2578],
12	by	IN	O	by	_	0	SENT_59	[p3l1232t2515r1317b2599],
13	blocking	VBG	O	block	prepc_by	2	SENT_59	[p3l1332t2515r1629b2599],
14	the	DT	O	the	det	16	SENT_59	[p3l1647t2515r1753b2578],
15	NS3/NS4A	NN	O	ns3/ns4a	nn	16	SENT_59	[p3l1773t2519r2151b2581],
16	interaction	NN	O	interaction	dobj	13	SENT_59	[p3l8t2610r442b2682],
17	.9	CD	NUMBER	.9	num	16	SENT_59	[p3l8t2610r442b2682],
18	The	DT	O	the	det	20	SENT_59	[p3l468t2618r596b2682],
19	NS3/NS4A	NN	O	ns3/ns4a	nn	20	SENT_59	[p3l620t2622r1008b2685],
20	protease	NN	O	protease	nsubj	21	SENT_59	[p3l1031t2631r1323b2702],
21	blocks	VBZ	O	block	dep	13	SENT_59	[p3l1346t2618r1569b2682],
22	Toll	NN	O	toll	dobj	21	SENT_59	[p3l1595t2618r1754b2685],
23	/	:	O	/	punct	25	SENT_59	[p3l1595t2618r1754b2685],
24	IL-1	NN	O	il-1	nn	25	SENT_59	[p3l1760t2624r1900b2681],
25	receptor	NN	O	receptor	dep	22	SENT_59	[p3l1932t2641r2147b2702, p3l7t2734r106b2785],
26	(	NN	O	(	nn	27	SENT_59	[p3l130t2722r1033b2806],
27	TIR	NN	O	tir	dep	25	SENT_59	[p3l130t2722r1033b2806],
28	)	SYM	O	)	dep	22	SENT_59	[p3l130t2722r1033b2806],
29	-	:	O	-	_	0	SENT_59	[p3l130t2722r1033b2806],
30	domain	NN	O	domain	nn	31	SENT_59	[p3l130t2722r1033b2806],
31	—	NN	O	—	nsubj	32	SENT_59	[p3l130t2722r1033b2806],
32	containing	VBG	O	contain	parataxis	2	SENT_59	[p3l130t2722r1033b2806],
33	adaptor	NN	O	adaptor	dobj	32	SENT_59	[p3l1053t2722r1315b2805],
34	inducing	VBG	O	induce	xcomp	32	SENT_59	[p3l1335t2722r1641b2806],
35	IFN	NN	O	ifn	nn	36	SENT_59	[p3l1661t2727r1797b2785],
36	[	NN	O	[	dobj	34	SENT_59	[p3l1822t2722r1858b2806],
37	3	CD	NUMBER	3	number	38	SENT_59	[p3l1822t2722r1858b2806],
38	(	CD	NUMBER	(	num	40	SENT_59	[p3l1884t2723r2147b2799, p3l7t2825r311b2888],
39	TRIP	NN	O	trip	nn	40	SENT_59	[p3l1884t2723r2147b2799, p3l7t2825r311b2888],
40	)	NN	O	)	nsubj	41	SENT_59	[p3l1884t2723r2147b2799, p3l7t2825r311b2888],
41	mediated	VBD	O	mediate	rcmod	36	SENT_59	[p3l1884t2723r2147b2799, p3l7t2825r311b2888],
42	Toll	NN	O	toll	dobj	41	SENT_59	[p3l327t2825r594b2888],
43	—	CD	NUMBER	—	num	42	SENT_59	[p3l327t2825r594b2888],
44	like	IN	O	like	_	0	SENT_59	[p3l327t2825r594b2888],
45	receptor	NN	O	receptor	nn	46	SENT_59	[p3l612t2837r881b2908],
46	signaling	NN	O	signaling	prep_like	42	SENT_59	[p3l898t2825r1191b2909],
47	and	CC	O	and	_	0	SENT_59	[p3l1207t2825r1328b2888],
48	Cardif	NNP	O	Cardif	conj_and	46	SENT_59	[p3l1346t2825r1885b2888],
49	—	CD	NUMBER	—	num	48	SENT_59	[p3l1346t2825r1885b2888],
50	mediated	JJ	O	mediated	amod	55	SENT_59	[p3l1346t2825r1885b2888],
51	retinoic	JJ	O	retinoic	amod	55	SENT_59	[p3l1902t2831r2150b2888],
52	acid	NN	O	acid	nn	55	SENT_59	[p3l8t2928r488b2991],
53	—	NN	O	—	nn	55	SENT_59	[p3l8t2928r488b2991],
54	inducible	JJ	O	inducible	amod	55	SENT_59	[p3l8t2928r488b2991],
55	gene	NN	O	gene	dep	36	SENT_59	[p3l506t2951r655b3012],
56	1	CD	NUMBER	1	number	57	SENT_59	[p3l680t2935r704b2990],
57	(	CD	NUMBER	(	num	55	SENT_59	[p3l731t2929r983b3005],
58	RIG-1	NN	O	rig-1	nn	60	SENT_59	[p3l731t2929r983b3005],
59	)	NN	O	)	nn	60	SENT_59	[p3l731t2929r983b3005],
60	signaling	NN	O	signaling	dep	36	SENT_59	[p3l1006t2928r1315b3012],
61	,	,	O	,	_	0	SENT_59	[p3l1006t2928r1315b3012],
62	which	WDT	O	which	nsubj	63	SENT_59	[p3l1332t2928r1533b2991],
63	results	VBZ	O	result	rcmod	60	SENT_59	[p3l1551t2928r1759b2991],
64	in	IN	O	in	_	0	SENT_59	[p3l1777t2934r1841b2990],
65	impaired	JJ	O	impaired	amod	66	SENT_59	[p3l1858t2928r2153b3011],
66	induction	NN	O	induction	prep_in	63	SENT_59	[p3l8t3031r332b3094],
67	of	IN	O	of	prep	66	SENT_59	[p3l352t3031r425b3094],
68	IF	IN	O	if	pcomp	67	SENT_59	[p3l435t3036r503b3093],
69	Ns	NN	O	n	pobj	68	SENT_59	[p3l507t3036r613b3103],
70	,	,	O	,	_	0	SENT_59	[p3l507t3036r613b3103],
71	thereby	RB	O	thereby	advmod	72	SENT_59	[p3l633t3031r886b3115],
72	blocking	VBG	O	block	partmod	36	SENT_59	[p3l899t3031r1191b3115],
73	Viral	JJ	O	viral	amod	74	SENT_59	[p3l1205t3031r1356b3094],
74	elimination	NN	O	elimination	dobj	72	SENT_59	[p3l1375t3031r1773b3094],
75	.	.	O	.	_	0	SENT_59	[p3l1375t3031r1773b3094],

1	In	IN	O	in	_	0	SENT_60	[p3l82t3139r153b3196],
2	May	NNP	DATE	May	prep_in	14	SENT_60	[p3l176t3139r328b3218],
3	2011	CD	DATE	2011	num	2	SENT_60	[p3l347t3141r528b3206],
4	,	,	O	,	_	0	SENT_60	[p3l347t3141r528b3206],
5	the	DT	O	the	det	7	SENT_60	[p3l552t3134r658b3197],
6	ﬁrst	JJ	O	ﬁrst	amod	7	SENT_60	[p3l681t3134r815b3197],
7	DAAS	NNP	O	DAAS	nsubjpass	14	SENT_60	[p3l836t3138r1061b3206],
8	,	,	O	,	_	0	SENT_60	[p3l836t3138r1061b3206],
9	telaprevir	NN	O	telaprevir	appos	7	SENT_60	[p3l1085t3134r1414b3217],
10	and	CC	O	and	_	0	SENT_60	[p3l1436t3134r1563b3197],
11	boceprevir	NN	O	boceprevir	appos	7	SENT_60	[p3l1583t3134r1966b3217],
12	,	,	O	,	_	0	SENT_60	[p3l1583t3134r1966b3217],
13	were	VBD	O	be	auxpass	14	SENT_60	[p3l1989t3157r2150b3197],
14	approved	VBN	O	approve	_	0	SENT_60	[p3l8t3237r327b3320],
15	by	IN	O	by	_	0	SENT_60	[p3l346t3237r431b3321],
16	the	DT	O	the	det	18	SENT_60	[p3l449t3237r555b3300],
17	US	NNP	ORGANIZATION	US	nn	18	SENT_60	[p3l579t3241r678b3300],
18	Food	NNP	ORGANIZATION	Food	agent	14	SENT_60	[p3l704t3237r880b3300],
19	and	CC	ORGANIZATION	and	_	0	SENT_60	[p3l903t3237r1029b3300],
20	Drug	NNP	ORGANIZATION	Drug	nn	24	SENT_60	[p3l1051t3242r1232b3321],
21	Administration	NNP	ORGANIZATION	Administration	nn	24	SENT_60	[p3l1253t3237r1786b3300],
22	(	CD	NUMBER	(	num	24	SENT_60	[p3l1812t3238r2027b3314],
23	FDA	NNP	ORGANIZATION	FDA	nn	24	SENT_60	[p3l1812t3238r2027b3314],
24	)	NN	O	)	conj_and	18	SENT_60	[p3l1812t3238r2027b3314],
25	for	IN	O	for	_	0	SENT_60	[p3l2054t3237r2152b3300],
26	the	DT	O	the	det	27	SENT_60	[p3l7t3340r111b3403],
27	treatment	NN	O	treatment	prep_for	18	SENT_60	[p3l131t3351r461b3403],
28	of	IN	O	of	_	0	SENT_60	[p3l481t3339r554b3403],
29	HCV	NN	O	hcv	nn	30	SENT_60	[p3l565t3331r882b3403],
30	.1	NN	NUMBER	.1	prep_of	27	SENT_60	[p3l565t3331r882b3403],
31	°	CD	NUMBER	°	number	32	SENT_60	[p3l565t3331r882b3403],
32	’11	CD	NUMBER	’11	dobj	14	SENT_60	[p3l565t3331r882b3403],
33	Both	DT	O	both	det	34	SENT_60	[p3l907t3339r1069b3403],
34	compounds	NNS	O	compound	nsubj	39	SENT_60	[p3l1089t3339r1487b3423],
35	are	VBP	O	be	cop	39	SENT_60	[p3l1509t3362r1607b3403],
36	ﬁrst	JJ	O	ﬁrst	amod	39	SENT_60	[p3l1627t3339r1784b3403],
37	—	NN	O	—	nn	39	SENT_60	[p3l1627t3339r1784b3403],
38	generation	NN	O	generation	nn	39	SENT_60	[p3l1791t3346r2151b3424],
39	PIS	NN	O	pi	rcmod	32	SENT_60	[p3l8t3448r114b3506],
40	that	WDT	O	that	nsubjpass	42	SENT_60	[p3l139t3443r277b3506],
41	were	VBD	O	be	auxpass	42	SENT_60	[p3l299t3466r466b3506],
42	approved	VBN	O	approve	rcmod	39	SENT_60	[p3l491t3443r821b3526],
43	for	IN	O	for	_	0	SENT_60	[p3l844t3443r945b3506],
44	use	NN	O	use	prep_for	42	SENT_60	[p3l968t3466r1083b3506],
45	in	IN	O	in	_	0	SENT_60	[p3l1109t3449r1177b3505],
46	conjunction	NN	O	conjunction	prep_in	44	SENT_60	[p3l1203t3449r1631b3527],
47	with	IN	O	with	_	0	SENT_60	[p3l1654t3443r1813b3506],
48	PEG	NN	O	peg	prep_with	42	SENT_60	[p3l1838t3447r1997b3506],
49	and	CC	O	and	_	0	SENT_60	[p3l2023t3443r2153b3506],
50	RBV	NN	O	rbv	prep_with	42	SENT_60	[p3l8t3551r172b3609],
51	in	IN	O	in	_	0	SENT_60	[p3l195t3552r264b3608],
52	HCV	NNP	O	HCV	nn	53	SENT_60	[p3l288t3550r472b3609],
53	genotype	NN	O	genotype	prep_in	42	SENT_60	[p3l495t3558r817b3630],
54	1	CD	NUMBER	1	num	57	SENT_60	[p3l847t3546r1214b3609],
55	—	RB	O	—	advmod	56	SENT_60	[p3l847t3546r1214b3609],
56	infected	JJ	O	infected	amod	57	SENT_60	[p3l847t3546r1214b3609],
57	individuals	NNS	O	individual	dep	42	SENT_60	[p3l1237t3546r1646b3609],
58	.	.	O	.	_	0	SENT_60	[p3l1237t3546r1646b3609],

1	This	DT	O	this	nsubj	11	SENT_61	[p3l1673t3546r1820b3609],
2	included	VBD	O	include	_	0	SENT_61	[p3l1844t3546r2152b3609],
3	compensated	VBN	O	compensate	dep	2	SENT_61	[p3l8t3649r459b3732],
4	cirrhotics	NNS	O	cirrhotic	dobj	3	SENT_61	[p3l480t3649r805b3712],
5	who	WP	O	who	nsubj	8	SENT_61	[p3l825t3649r971b3712],
6	were	VBD	O	be	cop	8	SENT_61	[p3l991t3672r1152b3712],
7	treatment	NN	O	treatment	npadvmod	8	SENT_61	[p3l1171t3661r1506b3712],
8	naive	JJ	O	naive	rcmod	4	SENT_61	[p3l1526t3655r1704b3712],
9	or	CC	O	or	_	0	SENT_61	[p3l1726t3672r1797b3712],
10	had	VBD	O	have	aux	11	SENT_61	[p3l1816t3649r1943b3712],
11	failed	VBN	O	fail	conj_or	2	SENT_61	[p3l1963t3649r2151b3712],
12	previous	JJ	O	previous	amod	13	SENT_61	[p4l6t23r295b100],
13	therapy	NN	O	therapy	dobj	11	SENT_61	[p4l315t17r579b101],
14	.	.	O	.	_	0	SENT_61	[p4l315t17r579b101],

1	Telaprevir	NNP	O	Telaprevir	nsubj	4	SENT_62	[p4l602t17r942b100],
2	and	CC	O	and	_	0	SENT_62	[p4l962t17r1086b80],
3	boceprevir	NN	O	boceprevir	conj_and	1	SENT_62	[p4l1103t17r1468b100],
4	increased	VBD	O	increase	_	0	SENT_62	[p4l1487t17r1806b80],
5	SVR	NN	ORGANIZATION	svr	nn	6	SENT_62	[p4l1826t21r1978b80],
6	rates	NNS	O	rate	dobj	4	SENT_62	[p4l1995t29r2150b80],
7	to	TO	O	to	_	0	SENT_62	[p4l7t132r74b183],
8	75	CD	NUMBER	75	num	11	SENT_62	[p4l100t128r177b183],
9	and	CC	O	and	_	0	SENT_62	[p4l204t120r332b183],
10	67	CD	PERCENT	67	num	11	SENT_62	[p4l356t125r521b192],
11	%	NN	PERCENT	%	prep_to	4	SENT_62	[p4l356t125r521b192],
12	,	,	O	,	_	0	SENT_62	[p4l356t125r521b192],
13	respectively	RB	O	respectively	advmod	4	SENT_62	[p4l546t120r969b204],
14	.	.	O	.	_	0	SENT_62	[p4l546t120r969b204],

1	The	DT	O	the	det	2	SENT_63	[p4l995t120r1123b183],
2	difﬁculties	NNS	O	difﬁculties	nsubj	8	SENT_63	[p4l1147t120r1511b183],
3	encountered	VBN	O	encounter	partmod	2	SENT_63	[p4l1536t120r1974b183],
4	with	IN	O	with	_	0	SENT_63	[p4l1995t120r2151b183],
5	the	DT	O	the	det	7	SENT_63	[p4l7t223r113b286],
6	ﬁrst-generation	NN	O	ﬁrst-generation	nn	7	SENT_63	[p4l134t223r666b307],
7	Pls	NNS	O	pl	prep_with	3	SENT_63	[p4l687t228r790b286],
8	include	VBP	O	include	_	0	SENT_63	[p4l811t223r1063b286],
9	cumbersome	JJ	O	cumbersome	amod	10	SENT_63	[p4l1084t223r1529b286],
10	use	NN	O	use	dobj	8	SENT_63	[p4l1550t246r1678b286],
11	:	:	O	:	_	0	SENT_63	[p4l1550t246r1678b286],
12	each	DT	O	each	nsubj	13	SENT_63	[p4l1702t223r1855b286],
13	requires	VBZ	O	require	parataxis	8	SENT_63	[p4l1876t229r2151b306],
14	multiple	JJ	O	multiple	amod	15	SENT_63	[p4l7t326r291b409],
15	pills	NNS	O	pill	nsubjpass	18	SENT_63	[p4l311t326r450b409],
16	to	TO	O	to	aux	18	SENT_63	[p4l470t338r536b389],
17	be	VB	O	be	auxpass	18	SENT_63	[p4l556t326r635b389],
18	taken	VBN	O	take	xcomp	13	SENT_63	[p4l655t326r843b389],
19	three	CD	NUMBER	three	number	20	SENT_63	[p4l862t326r1036b389],
20	times	NNS	O	time	dobj	18	SENT_63	[p4l1056t332r1241b389],
21	a	DT	DURATION	a	det	22	SENT_63	[p4l1262t349r1297b389],
22	day	NN	DURATION	day	dep	20	SENT_63	[p4l1317t326r1446b410],
23	,	,	O	,	_	0	SENT_63	[p4l1317t326r1446b410],
24	and	CC	O	and	_	0	SENT_63	[p4l1468t326r1594b389],
25	telaprevir	NN	O	telaprevir	nsubj	26	SENT_63	[p4l1613t326r1939b409],
26	needs	VBZ	O	need	parataxis	8	SENT_63	[p4l1958t326r2151b389],
27	to	TO	O	to	aux	29	SENT_63	[p4l7t441r73b492],
28	be	VB	O	be	auxpass	29	SENT_63	[p4l93t429r172b492],
29	administered	VBN	O	administer	xcomp	26	SENT_63	[p4l194t429r648b492],
30	with	IN	O	with	_	0	SENT_63	[p4l666t429r820b492],
31	at	IN	O	at	quantmod	33	SENT_63	[p4l841t441r900b492],
32	least	JJS	O	least	mwe	31	SENT_63	[p4l919t429r1073b492],
33	20	CD	NUMBER	20	num	34	SENT_63	[p4l1092t436r1171b492],
34	g	NN	O	g	prep_with	29	SENT_63	[p4l1186t452r1225b513],
35	of	IN	O	of	_	0	SENT_63	[p4l1244t429r1319b492],
36	fat	NN	O	fat	prep_of	34	SENT_63	[p4l1330t429r1431b492],
37	.	.	O	.	_	0	SENT_63	[p4l1330t429r1431b492],

1	In	IN	O	in	_	0	SENT_64	[p4l1456t434r1527b491],
2	clinical	JJ	O	clinical	amod	3	SENT_64	[p4l1549t429r1794b492],
3	trials	NNS	O	trial	prep_in	39	SENT_64	[p4l1814t429r2004b501],
4	,	,	O	,	_	0	SENT_64	[p4l1814t429r2004b501],
5	1012	CD	PERCENT	1012	num	6	SENT_64	[p4l2034t436r2149b492, p4l14t537r151b596],
6	%	NN	PERCENT	%	nsubj	39	SENT_64	[p4l2034t436r2149b492, p4l14t537r151b596],
7	of	IN	O	of	_	0	SENT_64	[p4l176t532r250b595],
8	patients	NNS	O	patient	prep_of	6	SENT_64	[p4l262t538r533b615],
9	discontinued	VBN	O	discontinue	amod	10	SENT_64	[p4l557t532r1006b595],
10	therapy	NN	O	therapy	nsubj	18	SENT_64	[p4l1027t532r1291b616],
11	due	JJ	O	due	_	0	SENT_64	[p4l1311t532r1434b595],
12	to	TO	O	to	_	0	SENT_64	[p4l1456t544r1522b595],
13	AEs	NNS	O	ae	prep_due_to	10	SENT_64	[p4l1545t536r1702b604],
14	,	,	O	,	_	0	SENT_64	[p4l1545t536r1702b604],
15	and	CC	O	and	_	0	SENT_64	[p4l1727t532r1854b595],
16	36-45	CD	PERCENT	36-45	num	17	SENT_64	[p4l1877t538r2148b597],
17	%	NN	PERCENT	%	prep_due_to	10	SENT_64	[p4l1877t538r2148b597],
18	developed	VBD	O	develop	rcmod	8	SENT_64	[p4l8t634r351b718],
19	signiﬁcant	JJ	O	signiﬁcant	amod	21	SENT_64	[p4l370t634r718b719],
20	anemia	NN	O	anemia	nn	21	SENT_64	[p4l737t641r982b698],
21	(	NN	O	(	dep	25	SENT_64	[p4l1004t635r1153b711],
22	<	JJR	O	<	dep	21	SENT_64	[p4l1004t635r1153b711],
23	10	CD	NUMBER	10	num	24	SENT_64	[p4l1004t635r1153b711],
24	g/dl	NN	O	g/dl	dep	25	SENT_64	[p4l1169t626r1549b719],
25	)	CD	NUMBER	)	dep	18	SENT_64	[p4l1169t626r1549b719],
26	.6	CD	NUMBER	.6	num	27	SENT_64	[p4l1169t626r1549b719],
27	’	NN	O	’	dep	25	SENT_64	[p4l1169t626r1549b719],
28	12	CD	NUMBER	12	number	29	SENT_64	[p4l1169t626r1549b719],
29	'14	CD	NUMBER	'14	num	30	SENT_64	[p4l1169t626r1549b719],
30	One	CD	NUMBER	one	dobj	18	SENT_64	[p4l1569t638r1710b698],
31	of	IN	O	of	_	0	SENT_64	[p4l1731t634r1803b698],
32	the	DT	O	the	det	34	SENT_64	[p4l1812t634r1917b698],
33	significant	JJ	O	significant	amod	34	SENT_64	[p4l1937t634r2148b719, p4l8t744r174b801],
34	AEs	NNS	O	ae	prep_of	30	SENT_64	[p4l192t742r330b801],
35	of	IN	O	of	_	0	SENT_64	[p4l351t738r425b801],
36	telaprevir	NN	O	telaprevir	prep_of	34	SENT_64	[p4l435t738r762b821],
37	is	VBZ	O	be	cop	39	SENT_64	[p4l781t744r831b801],
38	a	DT	O	a	det	39	SENT_64	[p4l853t761r888b801],
39	rash	NN	O	rash	_	0	SENT_64	[p4l907t738r1050b801],
40	occurring	VBG	O	occur	partmod	39	SENT_64	[p4l1071t744r1408b822],
41	in	IN	O	in	_	0	SENT_64	[p4l1427t744r1494b800],
42	up	RB	O	up	quantmod	44	SENT_64	[p4l1514t760r1599b821],
43	to	TO	O	to	dep	44	SENT_64	[p4l1620t750r1685b801],
44	56	CD	PERCENT	56	num	45	SENT_64	[p4l1709t743r1850b803],
45	%	NN	PERCENT	%	prep_in	40	SENT_64	[p4l1709t743r1850b803],
46	of	IN	O	of	_	0	SENT_64	[p4l1873t738r1947b801],
47	cases	NNS	O	case	prep_of	45	SENT_64	[p4l1958t761r2146b801],
48	.	.	O	.	_	0	SENT_64	[p4l1958t761r2146b801],

1	Most	JJS	O	most	nsubj	5	SENT_65	[p4l7t845r182b904],
2	of	IN	O	of	_	0	SENT_65	[p4l202t840r276b904],
3	these	DT	O	these	prep_of	1	SENT_65	[p4l286t840r462b904],
4	are	VBP	O	be	cop	5	SENT_65	[p4l484t863r584b904],
5	mild	JJ	O	mild	_	0	SENT_65	[p4l605t840r782b912],
6	;	:	O	;	_	0	SENT_65	[p4l605t840r782b912],
7	however	RB	O	however	advmod	38	SENT_65	[p4l804t840r1106b912],
8	,	,	O	,	_	0	SENT_65	[p4l804t840r1106b912],
9	fatal	JJ	O	fatal	amod	14	SENT_65	[p4l1129t840r1276b904],
10	and	CC	O	and	_	0	SENT_65	[p4l1296t840r1423b904],
11	nonfatal	JJ	O	nonfatal	conj_and	9	SENT_65	[p4l1442t840r1727b904],
12	serious	JJ	O	serious	amod	14	SENT_65	[p4l1748t846r1989b904],
13	skin	NN	O	skin	nn	14	SENT_65	[p4l2011t840r2151b904],
14	reactions	NNS	O	reaction	nsubjpass	38	SENT_65	[p4l8t950r336b1016],
15	,	,	O	,	_	0	SENT_65	[p4l8t950r336b1016],
16	including	VBG	O	include	_	0	SENT_65	[p4l358t944r684b1028],
17	Stevens	NNP	PERSON	Stevens	prep_including	14	SENT_65	[p4l704t944r1287b1020],
18	—	CD	NUMBER	—	number	19	SENT_65	[p4l704t944r1287b1020],
19	]	CD	NUMBER	]	num	21	SENT_65	[p4l704t944r1287b1020],
20	ohnson	NN	O	ohnson	nn	21	SENT_65	[p4l704t944r1287b1020],
21	syndrome	NN	O	syndrome	dep	17	SENT_65	[p4l1308t944r1666b1028],
22	,	,	O	,	_	0	SENT_65	[p4l1308t944r1666b1028],
23	drug	NN	O	drug	nn	24	SENT_65	[p4l1689t944r1851b1028],
24	reaction	NN	O	reaction	prep_including	14	SENT_65	[p4l1870t950r2149b1007],
25	with	IN	O	with	_	0	SENT_65	[p4l7t1047r159b1110],
26	eosinophilia	NN	O	eosinophilia	nn	29	SENT_65	[p4l180t1047r600b1130],
27	and	CC	O	and	_	0	SENT_65	[p4l621t1047r746b1110],
28	systemic	JJ	O	systemic	nn	29	SENT_65	[p4l767t1053r1058b1131],
29	symptoms	NNS	O	symptom	prep_with	24	SENT_65	[p4l1079t1059r1448b1131],
30	,	,	O	,	_	0	SENT_65	[p4l1079t1059r1448b1131],
31	and	CC	O	and	_	0	SENT_65	[p4l1471t1047r1597b1110],
32	toxic	JJ	O	toxic	amod	34	SENT_65	[p4l1615t1053r1782b1110],
33	epidermal	JJ	O	epidermal	amod	34	SENT_65	[p4l1802t1047r2148b1130],
34	necrolysis	NN	O	necrolysis	prep_including	14	SENT_65	[p4l8t1150r358b1234],
35	,	,	O	,	_	0	SENT_65	[p4l8t1150r358b1234],
36	have	VBP	O	have	aux	38	SENT_65	[p4l379t1150r532b1213],
37	been	VBN	O	be	auxpass	38	SENT_65	[p4l550t1150r711b1213],
38	reported	VBN	O	report	parataxis	5	SENT_65	[p4l732t1150r1022b1233],
39	in	IN	O	in	_	0	SENT_65	[p4l1041t1156r1106b1212],
40	patients	NNS	O	patient	prep_in	38	SENT_65	[p4l1125t1156r1390b1233],
41	treated	VBN	O	treat	partmod	40	SENT_65	[p4l1409t1150r1643b1213],
42	with	IN	O	with	_	0	SENT_65	[p4l1660t1150r1810b1213],
43	telaprevir	NN	O	telaprevir	nn	45	SENT_65	[p4l1829t1150r2150b1233],
44	combination	NN	O	combination	nn	45	SENT_65	[p4l9t1252r445b1316],
45	treatment	NN	O	treatment	prep_with	41	SENT_65	[p4l466t1244r882b1316],
46	.	.	O	.	_	0	SENT_65	[p4l466t1244r882b1316],

1	”	NN	O	”	_	0	SENT_66	[p4l466t1244r882b1316],

1	The	DT	O	the	det	3	SENT_67	[p4l82t1356r210b1419],
2	ﬁrst-generation	JJ	O	ﬁrst-generation	amod	3	SENT_67	[p4l233t1356r779b1440],
3	PIs	NNS	O	pi	nsubjpass	7	SENT_67	[p4l804t1361r908b1419],
4	have	VBP	O	have	aux	7	SENT_67	[p4l932t1356r1091b1419],
5	also	RB	O	also	advmod	7	SENT_67	[p4l1116t1356r1250b1419],
6	been	VBN	O	be	auxpass	7	SENT_67	[p4l1273t1356r1441b1419],
7	found	VBN	O	find	_	0	SENT_67	[p4l1464t1356r1673b1419],
8	to	TO	O	to	aux	9	SENT_67	[p4l1695t1368r1762b1419],
9	have	VB	O	have	xcomp	7	SENT_67	[p4l1786t1356r1945b1419],
10	a	DT	O	a	det	12	SENT_67	[p4l1970t1379r2005b1419],
11	low	JJ	O	low	amod	12	SENT_67	[p4l2026t1356r2153b1419],
12	barrier	NN	O	barrier	dobj	9	SENT_67	[p4l6t1459r244b1522],
13	to	TO	O	to	_	0	SENT_67	[p4l263t1471r329b1522],
14	resistance	NN	O	resistance	prep_to	9	SENT_67	[p4l351t1465r701b1522],
15	.	.	O	.	_	0	SENT_67	[p4l351t1465r701b1522],

1	The	DT	O	the	det	2	SENT_68	[p4l726t1459r851b1522],
2	HCV	NNP	O	HCV	nsubj	3	SENT_68	[p4l872t1463r1052b1522],
3	has	VBZ	O	have	_	0	SENT_68	[p4l1071t1459r1183b1522],
4	preexisting	VBG	O	preexist	amod	7	SENT_68	[p4l1203t1465r1584b1543],
5	amino	NN	O	amino	nn	7	SENT_68	[p4l1604t1465r1820b1522],
6	acid	NN	O	acid	nn	7	SENT_68	[p4l1843t1459r1983b1522],
7	substitutions	NNS	O	substitution	dobj	3	SENT_68	[p4l2003t1459r2147b1522, p4l9t1568r345b1634],
8	,	,	O	,	_	0	SENT_68	[p4l2003t1459r2147b1522, p4l9t1568r345b1634],
9	which	WDT	O	which	nsubjpass	12	SENT_68	[p4l366t1562r576b1625],
10	are	VBP	O	be	auxpass	12	SENT_68	[p4l597t1585r697b1625],
11	usually	RB	O	usually	advmod	12	SENT_68	[p4l718t1562r963b1646],
12	found	VBN	O	find	rcmod	7	SENT_68	[p4l980t1562r1184b1625],
13	at	IN	O	at	_	0	SENT_68	[p4l1204t1574r1264b1625],
14	low	JJ	O	low	amod	15	SENT_68	[p4l1282t1562r1406b1625],
15	levels	NNS	O	level	prep_at	12	SENT_68	[p4l1423t1562r1627b1634],
16	;	:	O	;	_	0	SENT_68	[p4l1423t1562r1627b1634],
17	however	RB	O	however	advmod	24	SENT_68	[p4l1648t1562r1951b1634],
18	,	,	O	,	_	0	SENT_68	[p4l1648t1562r1951b1634],
19	these	DT	O	these	det	21	SENT_68	[p4l1973t1562r2149b1625],
20	resistant	JJ	O	resistant	amod	21	SENT_68	[p4l9t1671r301b1728],
21	strains	NNS	O	strain	nsubjpass	24	SENT_68	[p4l323t1671r551b1728],
22	may	MD	O	may	aux	24	SENT_68	[p4l574t1688r723b1749],
23	be	VB	O	be	auxpass	24	SENT_68	[p4l741t1665r821b1728],
24	selected	VBN	O	select	parataxis	3	SENT_68	[p4l845t1665r1120b1728],
25	within	IN	O	within	_	0	SENT_68	[p4l1141t1665r1368b1728],
26	a	DT	O	a	det	28	SENT_68	[p4l1391t1688r1426b1728],
27	short	JJ	O	short	amod	28	SENT_68	[p4l1450t1665r1628b1728],
28	period	NN	O	period	prep_within	24	SENT_68	[p4l1649t1665r1881b1748],
29	of	IN	O	of	_	0	SENT_68	[p4l1903t1665r1978b1728],
30	time	NN	O	time	prep_of	28	SENT_68	[p4l1991t1671r2147b1728],
31	once	RB	DATE	once	advmod	34	SENT_68	[p4l9t1790r170b1831],
32	HCV	NN	O	hcv	nn	33	SENT_68	[p4l194t1771r375b1831],
33	treatment	NN	O	treatment	nsubj	34	SENT_68	[p4l397t1779r737b1831],
34	begins	VBZ	O	begin	ccomp	24	SENT_68	[p4l757t1759r1065b1852],
35	.	.	O	.	_	0	SENT_68	[p4l757t1759r1065b1852],

1	”	NNP	O	”	nn	2	SENT_69	[p4l757t1759r1065b1852],
2	Administration	NNP	O	Administration	nsubj	10	SENT_69	[p4l1088t1767r1626b1831],
3	of	IN	O	of	_	0	SENT_69	[p4l1650t1767r1725b1831],
4	the	DT	O	the	det	5	SENT_69	[p4l1737t1767r1845b1831],
5	Pls	NNS	O	pl	prep_of	2	SENT_69	[p4l1869t1773r1972b1831],
6	with	IN	O	with	_	0	SENT_69	[p4l1995t1767r2149b1831],
7	PEG	NN	O	peg	prep_with	5	SENT_69	[p4l9t1875r169b1934],
8	and	CC	O	and	_	0	SENT_69	[p4l197t1871r329b1934],
9	RBV	NN	O	rbv	prep_with	5	SENT_69	[p4l355t1876r521b1934],
10	reduces	VBZ	O	reduce	_	0	SENT_69	[p4l548t1871r819b1934],
11	the	DT	O	the	det	12	SENT_69	[p4l846t1871r957b1934],
12	frequency	NN	O	frequency	dobj	10	SENT_69	[p4l984t1871r1346b1955],
13	with	IN	O	with	_	0	SENT_69	[p4l1368t1871r1527b1934],
14	which	WDT	O	which	rel	16	SENT_69	[p4l1553t1871r1771b1934],
15	resistance	NN	O	resistance	nsubj	16	SENT_69	[p4l1798t1877r2150b1934],
16	develops	VBZ	O	develop	rcmod	12	SENT_69	[p4l9t1974r334b2057],
17	,	,	O	,	_	0	SENT_69	[p4l9t1974r334b2057],
18	as	IN	O	as	_	0	SENT_69	[p4l361t1997r426b2037],
19	compared	VBN	O	compare	prepc_as	10	SENT_69	[p4l452t1974r804b2057],
20	with	IN	O	with	pcomp	19	SENT_69	[p4l825t1974r983b2037],
21	the	DT	O	the	det	22	SENT_69	[p4l1006t1974r1116b2037],
22	administration	NN	O	administration	pobj	20	SENT_69	[p4l1141t1974r1667b2037],
23	of	IN	O	of	_	0	SENT_69	[p4l1692t1974r1768b2037],
24	a	DT	O	a	det	25	SENT_69	[p4l1783t1997r1818b2037],
25	PI	NN	O	pi	prep_of	22	SENT_69	[p4l1842t1979r1916b2036],
26	alone	RB	O	alone	advmod	20	SENT_69	[p4l1942t1974r2147b2037],
27	.	.	O	.	_	0	SENT_69	[p4l1942t1974r2147b2037],

1	In	IN	O	in	_	0	SENT_70	[p4l9t2082r82b2139],
2	addition	NN	O	addition	_	0	SENT_70	[p4l108t2077r405b2140],
3	to	TO	O	to	_	0	SENT_70	[p4l428t2089r496b2140],
4	the	DT	O	the	det	5	SENT_70	[p4l521t2077r630b2140],
5	problems	NNS	O	problem	prep_in_addition_to	22	SENT_70	[p4l654t2077r984b2160],
6	with	IN	O	with	_	0	SENT_70	[p4l1007t2077r1165b2140],
7	side	JJ	O	side	amod	8	SENT_70	[p4l1191t2077r1327b2140],
8	effects	NNS	O	effect	prep_with	5	SENT_70	[p4l1353t2077r1572b2140],
9	and	CC	O	and	_	0	SENT_70	[p4l1598t2077r1728b2140],
10	viral	JJ	O	viral	amod	11	SENT_70	[p4l1748t2077r1910b2140],
11	resistance	NN	O	resistance	prep_with	5	SENT_70	[p4l1933t2083r2145b2140, p4l9t2203r181b2252],
12	,	,	O	,	_	0	SENT_70	[p4l1933t2083r2145b2140, p4l9t2203r181b2252],
13	the	DT	O	the	det	14	SENT_70	[p4l205t2180r312b2243],
14	use	NN	O	use	nsubj	22	SENT_70	[p4l335t2203r447b2243],
15	of	IN	O	of	_	0	SENT_70	[p4l471t2180r546b2243],
16	ﬁrst-generation	NN	O	ﬁrst-generation	nn	17	SENT_70	[p4l558t2180r1096b2264],
17	PIs	NNS	O	pi	prep_of	14	SENT_70	[p4l1120t2185r1223b2243],
18	has	VBZ	O	have	aux	22	SENT_70	[p4l1246t2180r1358b2243],
19	also	RB	O	also	advmod	22	SENT_70	[p4l1383t2180r1515b2243],
20	been	VBN	O	be	cop	22	SENT_70	[p4l1537t2180r1703b2243],
21	signiﬁcantly	RB	O	signiﬁcantly	advmod	22	SENT_70	[p4l1727t2180r2150b2264],
22	restricted	JJ	O	restricted	_	0	SENT_70	[p4l9t2283r330b2346],
23	due	JJ	O	due	_	0	SENT_70	[p4l349t2283r471b2346],
24	to	TO	O	to	_	0	SENT_70	[p4l491t2295r556b2346],
25	a	DT	O	a	det	27	SENT_70	[p4l578t2306r612b2346],
26	large	JJ	O	large	amod	27	SENT_70	[p4l630t2283r793b2367],
27	number	NN	O	number	prep_due_to	22	SENT_70	[p4l813t2283r1084b2346],
28	of	IN	O	of	_	0	SENT_70	[p4l1103t2283r1176b2346],
29	drug	NN	O	drug	nn	32	SENT_70	[p4l1188t2283r1556b2367],
30	—	CD	NUMBER	—	num	32	SENT_70	[p4l1188t2283r1556b2367],
31	drug	NN	O	drug	nn	32	SENT_70	[p4l1188t2283r1556b2367],
32	interactions	NNS	O	interaction	prep_of	27	SENT_70	[p4l1575t2289r1976b2346],
33	with	IN	O	with	_	0	SENT_70	[p4l1996t2283r2147b2346],
34	compounds	NNS	O	compound	prep_with	22	SENT_70	[p4l9t2386r424b2469],
35	that	WDT	O	that	nsubjpass	38	SENT_70	[p4l448t2386r586b2449],
36	are	VBP	O	be	auxpass	38	SENT_70	[p4l610t2409r713b2449],
37	commonly	RB	O	commonly	advmod	38	SENT_70	[p4l738t2386r1121b2470],
38	used	VBN	O	use	rcmod	34	SENT_70	[p4l1142t2386r1305b2449],
39	for	IN	O	for	_	0	SENT_70	[p4l1328t2386r1428b2449],
40	human	JJ	O	human	amod	43	SENT_70	[p4l1450t2386r1700b2449],
41	immunodeﬁciency	NN	O	immunodeﬁciency	nn	43	SENT_70	[p4l1724t2386r2144b2449, p4l8t2490r278b2574],
42	virus	NN	O	virus	nn	43	SENT_70	[p4l295t2496r469b2553],
43	infection	NN	O	infection	prep_for	38	SENT_70	[p4l493t2490r820b2562],
44	,	,	O	,	_	0	SENT_70	[p4l493t2490r820b2562],
45	immunosuppression	NN	O	immunosuppression	conj_and	43	SENT_70	[p4l845t2496r1576b2573],
46	,	,	O	,	_	0	SENT_70	[p4l845t2496r1576b2573],
47	hyperlipidemia	NN	O	hyperlipidemia	conj_and	43	SENT_70	[p4l1599t2490r2145b2574],
48	,	,	O	,	_	0	SENT_70	[p4l1599t2490r2145b2574],
49	and	CC	O	and	_	0	SENT_70	[p4l9t2592r135b2656],
50	pulmonary	JJ	O	pulmonary	amod	51	SENT_70	[p4l155t2592r541b2677],
51	hypertension	NN	O	hypertension	prep_for	38	SENT_70	[p4l558t2592r1027b2677],
52	.	.	O	.	_	0	SENT_70	[p4l558t2592r1027b2677],

1	“	NN	O	“	nn	2	SENT_71	[p4l1039t2584r1166b2633],
2	ml	NN	O	ml	_	0	SENT_71	[p4l1039t2584r1166b2633],

1	Second	LS	ORDINAL	second	advmod	19	SENT_72	[p4l83t2696r352b2759],
2	-	:	O	-	_	0	SENT_72	[p4l83t2696r352b2759],
3	generation	NN	O	generation	nn	4	SENT_72	[p4l359t2702r718b2780],
4	PIs	NNS	O	pi	nsubj	19	SENT_72	[p4l738t2701r838b2759],
5	currently	RB	DATE	currently	advmod	19	SENT_72	[p4l860t2696r1170b2780],
6	in	IN	O	in	_	0	SENT_72	[p4l1186t2702r1251b2758],
7	development	NN	O	development	prep_in	19	SENT_72	[p4l1272t2696r1708b2779],
8	are	VBP	O	be	auxpass	10	SENT_72	[p4l1727t2719r1826b2759],
9	generally	RB	O	generally	advmod	10	SENT_72	[p4l1846t2696r2153b2780],
10	thought	VBN	O	think	rcmod	7	SENT_72	[p4l7t2799r275b2883],
11	to	TO	O	to	aux	12	SENT_72	[p4l293t2811r358b2862],
12	have	VB	O	have	xcomp	10	SENT_72	[p4l378t2799r531b2862],
13	fewer	JJR	O	fewer	amod	14	SENT_72	[p4l551t2799r735b2862],
14	drug	NN	O	drug	dobj	12	SENT_72	[p4l755t2799r1122b2883],
15	—	CD	NUMBER	—	num	17	SENT_72	[p4l755t2799r1122b2883],
16	drug	NN	O	drug	nn	17	SENT_72	[p4l755t2799r1122b2883],
17	interactions	NNS	O	interaction	dep	14	SENT_72	[p4l1140t2805r1557b2871],
18	,	,	O	,	_	0	SENT_72	[p4l1140t2805r1557b2871],
19	improved	VBD	O	improve	_	0	SENT_72	[p4l1579t2799r1904b2882],
20	dosing	NN	O	dosing	nn	21	SENT_72	[p4l1923t2799r2149b2883],
21	schedules	NNS	O	schedule	dobj	19	SENT_72	[p4l9t2902r362b2974],
22	,	,	O	,	_	0	SENT_72	[p4l9t2902r362b2974],
23	and	CC	O	and	_	0	SENT_72	[p4l388t2902r516b2965],
24	less	RBR	O	less	advmod	25	SENT_72	[p4l537t2902r658b2965],
25	frequent	JJ	O	frequent	amod	30	SENT_72	[p4l682t2902r978b2985],
26	and	CC	O	and	_	0	SENT_72	[p4l1001t2902r1129b2965],
27	less	RBR	O	less	advmod	28	SENT_72	[p4l1150t2902r1271b2965],
28	severe	JJ	O	severe	conj_and	25	SENT_72	[p4l1296t2925r1508b2965],
29	side	JJ	O	side	amod	30	SENT_72	[p4l1533t2902r1668b2965],
30	effects	NNS	O	effect	dobj	19	SENT_72	[p4l1692t2902r1925b2965],
31	.	.	O	.	_	0	SENT_72	[p4l1692t2902r1925b2965],

1	Many	JJ	O	many	_	0	SENT_73	[p4l1952t2907r2153b2986],
2	of	IN	O	of	_	0	SENT_73	[p4l9t3005r83b3068],
3	the	DT	O	the	det	4	SENT_73	[p4l93t3005r199b3068],
4	second	JJ	ORDINAL	second	prep_of	1	SENT_73	[p4l221t3005r486b3068],
5	-	:	O	-	_	0	SENT_73	[p4l221t3005r486b3068],
6	generation	NN	O	generation	nn	7	SENT_73	[p4l493t3011r859b3089],
7	PIs	NNS	O	pi	nsubj	10	SENT_73	[p4l880t3010r982b3068],
8	are	VBP	O	be	cop	10	SENT_73	[p4l1004t3028r1105b3068],
9	macrocyclic	JJ	O	macrocyclic	amod	10	SENT_73	[p4l1125t3005r1538b3089],
10	molecules	NNS	O	molecule	dep	1	SENT_73	[p4l1558t3005r1920b3077],
11	,	,	O	,	_	0	SENT_73	[p4l1558t3005r1920b3077],
12	which	WDT	O	which	nsubjpass	15	SENT_73	[p4l1941t3005r2150b3068],
13	have	VBP	O	have	aux	15	SENT_73	[p4l7t3109r165b3172],
14	been	VBN	O	be	auxpass	15	SENT_73	[p4l187t3109r353b3172],
15	shown	VBN	O	show	rcmod	10	SENT_73	[p4l377t3109r602b3172],
16	to	TO	O	to	aux	20	SENT_73	[p4l625t3121r692b3172],
17	be	VB	O	be	cop	20	SENT_73	[p4l714t3109r795b3172],
18	generally	RB	O	generally	advmod	20	SENT_73	[p4l818t3109r1137b3193],
19	more	RBR	O	more	advmod	20	SENT_73	[p4l1156t3132r1337b3172],
20	potent	JJ	O	potent	xcomp	15	SENT_73	[p4l1359t3121r1585b3192],
21	and	CC	O	and	_	0	SENT_73	[p4l1608t3109r1753b3181],
22	,	,	O	,	_	0	SENT_73	[p4l1608t3109r1753b3181],
23	depending	VBG	O	depend	xcomp	15	SENT_73	[p4l1778t3109r2149b3193],
24	on	IN	O	on	pcomp	23	SENT_73	[p4l9t3235r95b3275],
25	the	DT	O	the	det	26	SENT_73	[p4l114t3212r221b3275],
26	location	NN	O	location	pobj	24	SENT_73	[p4l240t3212r518b3275],
27	of	IN	O	of	_	0	SENT_73	[p4l540t3212r614b3275],
28	the	DT	O	the	det	29	SENT_73	[p4l623t3212r730b3275],
29	macrocycle	NN	O	macrocycle	prep_of	26	SENT_73	[p4l751t3212r1157b3296],
30	,	,	O	,	_	0	SENT_73	[p4l751t3212r1157b3296],
31	able	JJ	O	able	amod	37	SENT_73	[p4l1180t3212r1315b3275],
32	to	TO	O	to	aux	33	SENT_73	[p4l1335t3224r1400b3275],
33	retain	VB	O	retain	xcomp	31	SENT_73	[p4l1423t3218r1621b3275],
34	activity	NN	O	activity	dobj	33	SENT_73	[p4l1642t3218r1895b3296],
35	against	IN	O	against	_	0	SENT_73	[p4l1913t3218r2152b3296],
36	resistant	JJ	O	resistant	prep_against	33	SENT_73	[p4l9t3321r296b3378],
37	variants	NNS	O	variant	appos	29	SENT_73	[p4l315t3321r605b3378],
38	.	.	O	.	_	0	SENT_73	[p4l315t3321r605b3378],

1	Common	JJ	O	common	amod	2	SENT_74	[p4l632t3319r961b3378],
2	wild-type	JJ	O	wild-type	nsubj	10	SENT_74	[p4l982t3315r1311b3399],
3	and	CC	O	and	_	0	SENT_74	[p4l1335t3315r1461b3378],
4	drug-resistant	JJ	O	drug-resistant	amod	5	SENT_74	[p4l1484t3315r1967b3399],
5	variants	NNS	O	variant	nsubj	10	SENT_74	[p4l1986t3321r2146b3378, p4l9t3430r147b3481],
6	of	IN	O	of	_	0	SENT_74	[p4l171t3418r246b3481],
7	the	DT	O	the	det	9	SENT_74	[p4l259t3418r366b3481],
8	NS3	NN	O	ns3	nn	9	SENT_74	[p4l389t3422r532b3481],
9	protein	NN	O	protein	prep_of	2	SENT_74	[p4l557t3424r809b3501],
10	include	VBP	O	include	_	0	SENT_74	[p4l833t3418r1088b3481],
11	Q80K	NN	O	q80k	dobj	10	SENT_74	[p4l1113t3422r1335b3494],
12	,	,	O	,	_	0	SENT_74	[p4l1113t3422r1335b3494],
13	R155K	NN	O	r155k	dobj	10	SENT_74	[p4l1360t3423r1614b3490],
14	,	,	O	,	_	0	SENT_74	[p4l1360t3423r1614b3490],
15	V36M/R155K	NN	O	v36m/r155k	dobj	10	SENT_74	[p4l1638t3422r2147b3490],
16	,	,	O	,	_	0	SENT_74	[p4l1638t3422r2147b3490],
17	A156T	NN	O	a156t	dobj	10	SENT_74	[p4l8t3523r263b3593],
18	,	,	O	,	_	0	SENT_74	[p4l8t3523r263b3593],
19	and	CC	O	and	_	0	SENT_74	[p4l294t3520r426b3584],
20	D168A	NN	O	d168a	dobj	10	SENT_74	[p4l453t3512r796b3584],
21	.17	CD	NUMBER	.17	nsubj	27	SENT_74	[p4l453t3512r796b3584],
22	The	DT	O	the	det	24	SENT_74	[p4l823t3520r952b3584],
23	second-generation	JJ	O	second-generation	amod	24	SENT_74	[p4l982t3520r1654b3605],
24	PIs	NNS	O	pi	dep	21	SENT_74	[p4l1683t3525r1790b3584],
25	have	VBP	O	have	aux	27	SENT_74	[p4l1818t3521r1980b3584],
26	also	RB	O	also	advmod	27	SENT_74	[p4l2009t3521r2147b3584],
27	shown	VBN	O	show	rcmod	11	SENT_74	[p4l9t3624r231b3687],
28	increased	VBN	O	increase	amod	29	SENT_74	[p4l251t3624r575b3687],
29	efﬁcacy	NN	O	efﬁcacy	dobj	27	SENT_74	[p4l596t3624r852b3708],
30	against	IN	O	against	_	0	SENT_74	[p4l869t3630r1108b3708],
31	genotype	NN	O	genotype	prep_against	29	SENT_74	[p4l1127t3636r1438b3708],
32	1	CD	NUMBER	1	num	31	SENT_74	[p4l1466t3631r1514b3696],
33	;	:	O	;	_	0	SENT_74	[p4l1466t3631r1514b3696],
34	however	RB	O	however	advmod	39	SENT_74	[p4l1536t3624r1837b3696],
35	,	,	O	,	_	0	SENT_74	[p4l1536t3624r1837b3696],
36	they	PRP	O	they	nsubj	39	SENT_74	[p4l1858t3624r2009b3708],
37	still	RB	O	still	advmod	39	SENT_74	[p4l2026t3624r2148b3687],
38	have	VBP	O	have	aux	39	SENT_74	[p4l7t3726r163b3790],
39	limited	VBN	O	limit	parataxis	10	SENT_74	[p4l184t3726r429b3790],
40	eﬂicacy	NN	O	eﬂicacy	nsubj	44	SENT_74	[p4l450t3726r708b3811],
41	against	IN	O	against	_	0	SENT_74	[p4l727t3733r967b3811],
42	other	JJ	O	other	amod	43	SENT_74	[p4l988t3726r1169b3790],
43	genotypes	NNS	O	genotype	prep_against	40	SENT_74	[p4l1190t3739r1534b3811],
44	(	VBP	O	(	ccomp	39	SENT_74	[p4l1560t3727r1688b3803],
45	see	VB	O	see	xcomp	44	SENT_74	[p4l1560t3727r1688b3803],
46	Table	NNP	O	Table	dobj	45	SENT_74	[p4l1710t3727r1903b3790],
47	1	CD	NUMBER	1	num	46	SENT_74	[p4l1929t3718r2074b3804],
48	)	CD	NUMBER	)	num	49	SENT_74	[p4l1929t3718r2074b3804],
49	.18	CD	NUMBER	.18	dep	46	SENT_74	[p4l1929t3718r2074b3804],

1	ASUNAPREVIR	NN	O	asunaprevir	_	0	SENT_75	[p5l8t127r530b182],

1	Asunaprevir	NNP	O	Asunaprevir	nn	3	SENT_76	[p5l7t226r427b305],
2	(	CD	NUMBER	(	num	3	SENT_76	[p5l449t223r637b298],
3	BMS	NNP	O	BMS	nsubj	10	SENT_76	[p5l449t223r637b298],
4	650032	CD	NUMBER	650032	num	5	SENT_76	[p5l659t222r926b299],
5	)	CD	NUMBER	)	nsubj	10	SENT_76	[p5l659t222r926b299],
6	is	VBZ	O	be	cop	10	SENT_76	[p5l950t228r999b285],
7	a	DT	O	a	det	10	SENT_76	[p5l1021t245r1055b285],
8	macrocyclic	JJ	O	macrocyclic	amod	10	SENT_76	[p5l1073t222r1480b306],
9	NS3	NN	O	ns3	nn	10	SENT_76	[p5l1499t226r1638b285],
10	PI	NN	O	pi	_	0	SENT_76	[p5l1662t227r1732b284],
11	currently	RB	DATE	currently	advmod	10	SENT_76	[p5l1754t222r2066b306],
12	in	IN	O	in	_	0	SENT_76	[p5l2083t228r2148b284],
13	phase	NN	O	phase	nn	15	SENT_76	[p5l7t325r200b408],
14	II	CD	NUMBER	ii	num	15	SENT_76	[p5l221t330r274b387],
15	studies	NNS	O	study	prep_in	10	SENT_76	[p5l296t325r546b388],
16	.	.	O	.	_	0	SENT_76	[p5l296t325r546b388],

1	It	PRP	O	it	nsubj	2	SENT_77	[p5l570t330r618b388],
2	has	VBZ	O	have	_	0	SENT_77	[p5l636t325r747b388],
3	in	FW	O	in	nn	4	SENT_77	[p5l770t331r831b388],
4	vitro	FW	O	vitro	advmod	2	SENT_77	[p5l854t331r1005b388],
5	activity	NN	O	activity	dobj	2	SENT_77	[p5l1027t331r1277b409],
6	against	IN	O	against	_	0	SENT_77	[p5l1295t331r1532b409],
7	HCV	NN	O	hcv	nn	8	SENT_77	[p5l1552t329r1730b388],
8	genotypes	NNS	O	genotype	prep_against	5	SENT_77	[p5l1749t337r2090b409],
9	1	CD	NUMBER	1	num	8	SENT_77	[p5l2117t332r2142b387],
10	and	CC	O	and	_	0	SENT_77	[p5l9t428r133b491],
11	4	CD	NUMBER	4	num	8	SENT_77	[p5l151t435r206b491],
12	.	.	O	.	_	0	SENT_77	[p5l151t435r206b491],

1	When	WRB	O	when	advmod	25	SENT_78	[p5l227t428r435b491],
2	dosed	VBN	O	dose	ccomp	25	SENT_78	[p5l455t428r654b491],
3	at	IN	O	at	_	0	SENT_78	[p5l674t440r732b491],
4	600	CD	NUMBER	600	num	5	SENT_78	[p5l752t434r869b491],
5	mg	NN	O	mg	prep_at	2	SENT_78	[p5l884t451r991b512],
6	twice	RB	O	twice	advmod	8	SENT_78	[p5l1009t434r1186b491],
7	a	DT	DURATION	a	det	8	SENT_78	[p5l1206t451r1240b491],
8	day	NN	DURATION	day	tmod	2	SENT_78	[p5l1260t428r1379b512],
9	and	CC	O	and	_	0	SENT_78	[p5l1397t428r1521b491],
10	given	VBN	O	give	conj_and	2	SENT_78	[p5l1540t434r1720b512],
11	in	IN	O	in	_	0	SENT_78	[p5l1740t434r1806b490],
12	combination	NN	O	combination	prep_in	10	SENT_78	[p5l1826t428r2145b491, p5l7t537r143b594],
13	with	IN	O	with	_	0	SENT_78	[p5l162t531r313b594],
14	PEG	NN	O	peg	prep_with	10	SENT_78	[p5l334t535r487b594],
15	and	CC	O	and	_	0	SENT_78	[p5l508t531r632b594],
16	RBV	NN	O	rbv	conj_and	14	SENT_78	[p5l653t536r811b594],
17	to	TO	O	to	_	0	SENT_78	[p5l829t543r895b594],
18	treatment-naive	JJ	O	treatment-naive	amod	19	SENT_78	[p5l915t537r1457b594],
19	genotype	NN	O	genotype	prep_to	10	SENT_78	[p5l1477t543r1786b615],
20	1	CD	NUMBER	1	num	21	SENT_78	[p5l1813t538r1837b593],
21	patients	NNS	O	patient	dep	19	SENT_78	[p5l1863t537r2147b614],
22	,	,	O	,	_	0	SENT_78	[p5l1863t537r2147b614],
23	eRVR	NN	O	ervr	nsubjpass	25	SENT_78	[p5l9t639r215b697],
24	was	VBD	O	be	auxpass	25	SENT_78	[p5l236t657r367b697],
25	achieved	VBN	O	achieve	_	0	SENT_78	[p5l394t634r706b697],
26	in	IN	O	in	_	0	SENT_78	[p5l732t640r800b696],
27	75	CD	PERCENT	75	num	28	SENT_78	[p5l828t639r974b698],
28	%	NN	PERCENT	%	prep_in	25	SENT_78	[p5l828t639r974b698],
29	of	IN	O	of	_	0	SENT_78	[p5l1002t634r1079b697],
30	patients	NNS	O	patient	prep_of	28	SENT_78	[p5l1093t640r1375b717],
31	VS.	NNP	O	VS.	nn	33	SENT_78	[p5l1399t657r1490b697],
32	o	NN	PERCENT	o	nn	33	SENT_78	[p5l1519t639r1623b698],
33	%	NN	PERCENT	%	dobj	25	SENT_78	[p5l1519t639r1623b698],
34	of	IN	O	of	_	0	SENT_78	[p5l1651t634r1728b697],
35	those	DT	O	those	det	37	SENT_78	[p5l1743t634r1933b697],
36	given	VBN	O	give	amod	37	SENT_78	[p5l1959t640r2150b718],
37	PEG+RBV	NN	O	peg+rbv	prep_of	33	SENT_78	[p5l9t741r379b800],
38	alone	RB	O	alone	advmod	37	SENT_78	[p5l402t737r603b809],
39	,	,	O	,	_	0	SENT_78	[p5l402t737r603b809],
40	and	CC	O	and	_	0	SENT_78	[p5l628t737r755b800],
41	SVR	NN	ORGANIZATION	svr	nsubjpass	43	SENT_78	[p5l778t741r931b800],
42	was	VBD	O	be	auxpass	43	SENT_78	[p5l949t760r1076b800],
43	achieved	VBN	O	achieve	conj_and	25	SENT_78	[p5l1100t737r1401b800],
44	in	IN	O	in	_	0	SENT_78	[p5l1423t743r1489b799],
45	83	CD	PERCENT	83	num	46	SENT_78	[p5l1513t742r1655b802],
46	%	NN	PERCENT	%	prep_in	43	SENT_78	[p5l1513t742r1655b802],
47	of	IN	O	of	_	0	SENT_78	[p5l1680t737r1754b800],
48	patients	NNS	O	patient	prep_of	46	SENT_78	[p5l1766t743r2036b820],
49	vs.	IN	O	vs.	amod	48	SENT_78	[p5l2057t760r2145b800],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_79	[p5l20t885r139b906],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_79	[p5l148t885r373b906],
3	&	CC	O	&	_	0	SENT_79	[p5l380t885r600b906],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_79	[p5l380t885r600b906],
5	|	CD	NUMBER	|	num	6	SENT_79	[p5l380t885r600b906],
6	CS	NNP	O	CS	conj_and	2	SENT_79	[p5l380t885r600b906],
7	|	NNP	O	|	nn	8	SENT_79	[p5l610t883r612b913],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_79	[p5l620t885r728b906],
9	95	CD	NUMBER	95	num	10	SENT_79	[p5l736t885r763b906],
10	NUMBER	NN	O	number	dep	12	SENT_79	[p5l773t885r881b906],
11	1	CD	NUMBER	1	num	12	SENT_79	[p5l891t886r898b906],
12	|	CD	NUMBER	|	dep	15	SENT_79	[p5l912t883r914b913],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_79	[p5l923t885r1041b906],
14	2014	CD	DATE	2014	num	15	SENT_79	[p5l1049t885r1107b906],
15	79	CD	DATE	79	_	0	SENT_79	[p5l2109t885r2139b906],

1	Table	NNP	O	Table	_	0	SENT_80	[p5l19t1180r106b1207],
2	1	CD	NUMBER	1	num	3	SENT_80	[p5l115t1183r127b1207],
3	Comparison	NN	O	comparison	dep	1	SENT_80	[p5l157t1181r350b1214],
4	of	IN	O	of	_	0	SENT_80	[p5l359t1180r392b1207],
5	DAAs	NNP	O	DAAs	prep_of	3	SENT_80	[p5l399t1182r484b1207],
6	in	IN	O	in	_	0	SENT_80	[p5l493t1181r520b1207],
7	development	NN	O	development	prep_in	5	SENT_80	[p5l529t1180r743b1214],
8	for	IN	O	for	_	0	SENT_80	[p5l750t1180r796b1207],
9	the	DT	O	the	det	10	SENT_80	[p5l802t1180r855b1207],
10	treatment	NN	O	treatment	prep_for	7	SENT_80	[p5l862t1184r1024b1207],
11	of	IN	O	of	_	0	SENT_80	[p5l1031t1180r1064b1207],
12	chronic	JJ	O	chronic	amod	15	SENT_80	[p5l1070t1180r1188b1207],
13	hepatitis	NN	O	hepatitis	nn	15	SENT_80	[p5l1197t1180r1337b1214],
14	C	NN	O	c	nn	15	SENT_80	[p5l1345t1181r1364b1207],
15	virus	NN	O	virus	prep_of	10	SENT_80	[p5l1371t1181r1450b1207],

1	Study	NNP	O	Study	nn	4	SENT_81	[p5l400t1241r483b1272],
2	Genotype	NNP	O	Genotype	nn	4	SENT_81	[p5l909t1242r1050b1272],
3	Previous	JJ	O	previous	amod	4	SENT_81	[p5l1100t1241r1221b1265],
4	Percentage	NN	O	percentage	_	0	SENT_81	[p5l1494t1242r1653b1272],
5	achieving	VBG	O	achieve	partmod	4	SENT_81	[p5l1661t1241r1798b1272],

1	Class	NNP	O	Class	nn	2	SENT_82	[p5l269t1280r340b1304],
2	phase	NN	O	phase	_	0	SENT_82	[p5l400t1280r483b1310],
3	Proposed	VBN	O	propose	partmod	2	SENT_82	[p5l519t1280r652b1310],
4	therapy	NN	O	therapy	dobj	3	SENT_82	[p5l660t1280r772b1311],
5	studied	VBN	O	study	partmod	4	SENT_82	[p5l926t1280r1032b1304],
6	treatment	NN	O	treatment	dep	15	SENT_82	[p5l1087t1283r1231b1304],
7	End	NN	O	end	nn	8	SENT_82	[p5l1279t1280r1331b1304],
8	point	NN	O	point	dep	6	SENT_82	[p5l1340t1280r1415b1310],
9	end	NN	O	end	nn	12	SENT_82	[p5l1493t1280r1546b1304],
10	point	NN	O	point	nn	12	SENT_82	[p5l1555t1280r1630b1310],
11	Adverse	JJ	O	adverse	amod	12	SENT_82	[p5l1831t1280r1946b1304],
12	events	NNS	O	event	dep	15	SENT_82	[p5l1953t1283r2047b1304],
13	Asunaprevir	JJ	O	asunaprevir	amod	15	SENT_82	[p5l20t1339r186b1369],
14	NS3	NN	O	ns3	nn	15	SENT_82	[p5l239t1339r290b1363],
15	Pl	NN	O	pl	dep	27	SENT_82	[p5l300t1339r321b1362],
16	ll	NN	O	ll	nn	17	SENT_82	[p5l429t1339r441b1362],
17	TRIPLE	NN	O	triple	dep	15	SENT_82	[p5l517t1340r615b1363],
18	:	:	O	:	_	0	SENT_82	[p5l517t1340r615b1363],
19	600	CD	NUMBER	600	num	22	SENT_82	[p5l623t1341r672b1363],
20	mg	NN	O	mg	nn	22	SENT_82	[p5l679t1346r722b1370],
21	b.i.d.	NN	O	b.i.d.	nn	22	SENT_82	[p5l732t1339r794b1363],
22	x	NN	O	x	dep	17	SENT_82	[p5l802t1345r819b1363],
23	1	CD	NUMBER	1	num	26	SENT_82	[p5l974t1340r982b1362],
24	Naive	JJ	O	naive	amod	26	SENT_82	[p5l1119t1339r1194b1362],
25	RVR	NN	O	rvr	nn	26	SENT_82	[p5l1279t1339r1330b1362],
26	at4weeks	NNS	O	at4week	dep	22	SENT_82	[p5l1336t1338r1470b1362],
27	eRVR	NN	O	ervr	dep	2	SENT_82	[p5l1493t1339r1563b1362],
28	in	IN	O	in	_	0	SENT_82	[p5l1571t1339r1594b1362],
29	75	CD	PERCENT	75	num	30	SENT_82	[p5l1603t1340r1668b1366],
30	%	NN	PERCENT	%	prep_in	27	SENT_82	[p5l1603t1340r1668b1366],
31	,	,	O	,	_	0	SENT_82	[p5l1603t1340r1668b1366],
32	SVR	NN	ORGANIZATION	svr	appos	30	SENT_82	[p5l1676t1339r1727b1362],
33	in	IN	O	in	_	0	SENT_82	[p5l1735t1339r1757b1362],
34	Hepatotoxicity	NN	LOCATION	hepatotoxicity	prep_in	32	SENT_82	[p5l1832t1339r2034b1369],

1	12	CD	DURATION	12	num	2	SENT_83	[p5l520t1380r550b1403],
2	weeks	NNS	DURATION	week	_	0	SENT_83	[p5l557t1378r642b1403],
3	plus	CC	O	plus	prep	2	SENT_83	[p5l651t1378r706b1409],
4	PEG+RBV	NN	O	peg+rbv	dep	3	SENT_83	[p5l715t1379r843b1403],
5	and	CC	O	and	_	0	SENT_83	[p5l1278t1377r1327b1402],
6	12	CD	DURATION	12	num	7	SENT_83	[p5l1337t1379r1365b1402],
7	weeks	NNS	NUMBER	week	dep	3	SENT_83	[p5l1372t1377r1454b1402],
8	83	CD	PERCENT	83	num	9	SENT_83	[p5l1493t1379r1552b1402],
9	%	NN	PERCENT	%	dep	2	SENT_83	[p5l1493t1379r1552b1402],
10	for	IN	O	for	_	0	SENT_83	[p5l517t1418r555b1443],
11	24-48	CD	NUMBER	24-48	num	13	SENT_83	[p5l562t1420r645b1443],
12	weeks	NNS	NUMBER	week	nn	13	SENT_83	[p5l652t1418r737b1443],
13	SVR	NN	O	svr	prep_for	9	SENT_83	[p5l1278t1418r1328b1442],

1	Simeprevir	NNP	MISC	Simeprevir	nn	5	SENT_84	[p5l20t1478r169b1508],
2	NS3/4A	NNP	MISC	NS3/4A	nn	5	SENT_84	[p5l239t1478r341b1502],
3	PI	NN	MISC	pi	nn	5	SENT_84	[p5l349t1478r370b1501],
4	Ill	NNP	MISC	Ill	nn	5	SENT_84	[p5l425t1478r445b1501],
5	TRIPLE	NNP	O	TRIPLE	_	0	SENT_84	[p5l517t1479r615b1502],
6	:	:	O	:	_	0	SENT_84	[p5l517t1479r615b1502],
7	150	CD	NUMBER	150	num	10	SENT_84	[p5l625t1479r672b1502],
8	mg	NN	O	mg	nn	10	SENT_84	[p5l679t1485r722b1509],
9	daily	JJ	SET	daily	amod	10	SENT_84	[p5l731t1478r795b1509],
10	x	NN	O	x	dep	13	SENT_84	[p5l803t1484r820b1502],
11	1	CD	NUMBER	1	num	13	SENT_84	[p5l974t1479r982b1501],
12	Naive	JJ	O	naive	amod	13	SENT_84	[p5l1120t1478r1194b1501],
13	SVR12	NN	O	svr12	dep	5	SENT_84	[p5l1278t1478r1363b1501],
14	81	CD	PERCENT	81	num	15	SENT_84	[p5l1493t1478r1552b1501],
15	%	NN	PERCENT	%	tmod	13	SENT_84	[p5l1493t1478r1552b1501],
16	Overall	JJ	O	overall	advmod	15	SENT_84	[p5l1559t1477r1662b1505],
17	,	,	O	,	_	0	SENT_84	[p5l1559t1477r1662b1505],
18	65	CD	PERCENT	65	num	19	SENT_84	[p5l1670t1478r1729b1501],
19	%	NN	PERCENT	%	appos	13	SENT_84	[p5l1670t1478r1729b1501],
20	in	IN	O	in	_	0	SENT_84	[p5l1737t1478r1759b1501],
21	Fatigue	NNP	O	Fatigue	prep_in	19	SENT_84	[p5l1832t1478r1938b1508],
22	,	,	O	,	_	0	SENT_84	[p5l1832t1478r1938b1508],
23	headache	NN	O	headache	appos	21	SENT_84	[p5l1947t1477r2087b1505],
24	,	,	O	,	_	0	SENT_84	[p5l1947t1477r2087b1505],

1	12	CD	DURATION	12	num	2	SENT_85	[p5l521t1518r550b1541],
2	weeks	NNS	DURATION	week	_	0	SENT_85	[p5l558t1517r642b1542],
3	plus	CC	O	plus	prep	2	SENT_85	[p5l651t1517r706b1548],
4	PEG+RBV	NN	O	peg+rbv	nn	6	SENT_85	[p5l715t1518r843b1541],
5	cirrhotics	NNS	O	cirrhotic	nn	6	SENT_85	[p5l1493t1516r1619b1541],
6	pruritus	NN	O	pruritus	dep	3	SENT_85	[p5l1832t1517r1945b1547],
7	,	,	O	,	_	0	SENT_85	[p5l1832t1517r1945b1547],

1	Ill	NNP	O	Ill	nn	2	SENT_86	[p5l425t1577r445b1600],
2	TRIPLE	NNP	O	TRIPLE	_	0	SENT_86	[p5l517t1577r615b1601],
3	:	:	O	:	_	0	SENT_86	[p5l517t1577r615b1601],
4	150	CD	NUMBER	150	num	7	SENT_86	[p5l625t1578r672b1601],
5	mg	NN	O	mg	nn	7	SENT_86	[p5l679t1584r722b1608],
6	daily	JJ	SET	daily	amod	7	SENT_86	[p5l731t1576r796b1608],
7	X	NN	O	x	dep	9	SENT_86	[p5l803t1583r820b1600],
8	1	CD	NUMBER	1	num	9	SENT_86	[p5l974t1578r982b1600],
9	Relapse	NN	O	relapse	dep	2	SENT_86	[p5l1119t1576r1224b1607],
10	SVR12	NN	O	svr12	prep	9	SENT_86	[p5l1278t1576r1363b1600],
11	79	CD	PERCENT	79	num	12	SENT_86	[p5l1494t1577r1552b1600],
12	%	NN	PERCENT	%	dep	10	SENT_86	[p5l1494t1577r1552b1600],
13	Overall	JJ	O	overall	dep	9	SENT_86	[p5l1559t1576r1662b1604],
14	,	,	O	,	_	0	SENT_86	[p5l1559t1576r1662b1604],
15	70	CD	PERCENT	70	num	16	SENT_86	[p5l1671t1577r1729b1600],
16	%	NN	PERCENT	%	appos	13	SENT_86	[p5l1671t1577r1729b1600],
17	:	:	O	:	_	0	SENT_86	[p5l1831t1556r2101b1620],
18	z3	NN	O	z3	dep	16	SENT_86	[p5l1831t1556r2101b1620],
19	‘	CD	NUMBER	‘	dep	18	SENT_86	[p5l1831t1556r2101b1620],
20	:	:	O	:	_	0	SENT_86	[p5l1831t1556r2101b1620],
21	;	:	O	;	_	0	SENT_86	[p5l1831t1556r2101b1620],
22	'	''	O	'	_	0	SENT_86	[p5l1831t1556r2101b1620],
23	:	:	O	:	_	0	SENT_86	[p5l1831t1556r2101b1620],
24	;	:	O	;	_	0	SENT_86	[p5l1831t1556r2101b1620],
25	:	:	O	:	_	0	SENT_86	[p5l1831t1556r2101b1620],
26	"	``	O	"	punct	28	SENT_86	[p5l1831t1556r2101b1620],
27	”	NN	O	”	nn	28	SENT_86	[p5l1831t1556r2101b1620],
28	b	NN	O	b	dep	13	SENT_86	[p5l1831t1556r2101b1620],
29	'	''	O	'	_	0	SENT_86	[p5l1831t1556r2101b1620],
30	“	CD	NUMBER	“	dep	28	SENT_86	[p5l1831t1556r2101b1620],
31	em	NN	O	em	dep	28	SENT_86	[p5l1831t1556r2101b1620],
32	'	''	O	'	_	0	SENT_86	[p5l1831t1556r2101b1620],
33	a	DT	O	a	dep	31	SENT_86	[p5l1831t1556r2101b1620],
34	'	''	O	'	_	0	SENT_86	[p5l1831t1556r2101b1620],

1	12	CD	DURATION	12	num	2	SENT_87	[p5l520t1618r550b1641],
2	weeks	NNS	DURATION	week	_	0	SENT_87	[p5l557t1616r642b1641],
3	+	CC	O	+	_	0	SENT_87	[p5l650t1622r668b1641],
4	PEG+RBV	NN	O	peg+rbv	nn	5	SENT_87	[p5l677t1617r805b1641],
5	genotype	NN	O	genotype	conj_+	2	SENT_87	[p5l1493t1619r1626b1647],
6	1	CD	NUMBER	1	num	7	SENT_87	[p5l1636t1617r1643b1640],
7	a	DT	O	a	dep	2	SENT_87	[p5l1651t1623r1672b1644],
8	,	,	O	,	_	0	SENT_87	[p5l1651t1623r1672b1644],
9	and	CC	O	and	_	0	SENT_87	[p5l1679t1615r1730b1640],
10	86	CD	PERCENT	86	num	11	SENT_87	[p5l1738t1617r1797b1640],
11	%	NN	PERCENT	%	dep	2	SENT_87	[p5l1738t1617r1797b1640],

1	genotype	NN	O	genotype	_	0	SENT_88	[p5l1493t1659r1626b1687],
2	1	CD	NUMBER	1	num	3	SENT_88	[p5l1636t1657r1643b1680],
3	b	NN	O	b	dep	1	SENT_88	[p5l1652t1655r1667b1680],

1	Faldaprevir	NNP	MISC	Faldaprevir	nn	5	SENT_89	[p5l21t1732r173b1763],
2	N53/4A	NNP	MISC	N53/4A	nn	5	SENT_89	[p5l239t1733r341b1757],
3	PI	NN	MISC	pi	nn	5	SENT_89	[p5l349t1733r370b1756],
4	Ill	NNP	MISC	Ill	nn	5	SENT_89	[p5l425t1733r445b1756],
5	TRIPLE	NNP	O	TRIPLE	_	0	SENT_89	[p5l517t1734r615b1757],
6	:	:	O	:	_	0	SENT_89	[p5l517t1734r615b1757],
7	120	CD	NUMBER	120	num	8	SENT_89	[p5l625t1734r672b1757],
8	mg	NN	O	mg	nsubj	10	SENT_89	[p5l679t1740r722b1764],
9	a	DT	DURATION	a	det	10	SENT_89	[p5l730t1740r744b1757],
10	day	NN	DURATION	day	dep	5	SENT_89	[p5l752t1733r801b1764],
11	1	CD	NUMBER	1	num	13	SENT_89	[p5l974t1734r982b1756],
12	Naive	JJ	O	naive	amod	13	SENT_89	[p5l1119t1733r1194b1756],
13	SVR12	NN	O	svr12	dobj	10	SENT_89	[p5l1278t1733r1363b1756],
14	79	CD	PERCENT	79	number	15	SENT_89	[p5l1494t1733r1552b1756],
15	%	NN	PERCENT	%	amod	13	SENT_89	[p5l1494t1733r1552b1756],
16	at	IN	O	at	_	0	SENT_89	[p5l1559t1736r1585b1756],
17	120-mg	JJ	O	120-mg	amod	18	SENT_89	[p5l1594t1734r1697b1763],
18	dose	NN	O	dose	prep_at	10	SENT_89	[p5l1706t1732r1777b1760],
19	,	,	O	,	_	0	SENT_89	[p5l1706t1732r1777b1760],
20	Rash	NNP	O	Rash	appos	18	SENT_89	[p5l1832t1732r1902b1760],
21	,	,	O	,	_	0	SENT_89	[p5l1832t1732r1902b1760],
22	photosensitivity	NN	O	photosensitivity	appos	20	SENT_89	[p5l1911t1732r2137b1763],
23	,	,	O	,	_	0	SENT_89	[p5l1911t1732r2137b1763],

1	vs.	CC	O	vs.	_	0	SENT_90	[p5l518t1779r552b1796],
2	240	CD	NUMBER	240	num	3	SENT_90	[p5l560t1773r609b1796],
3	mg	NN	O	mg	dep	1	SENT_90	[p5l616t1779r658b1803],
4	a	DT	DURATION	a	det	5	SENT_90	[p5l667t1779r680b1796],
5	day	NN	DURATION	day	tmod	3	SENT_90	[p5l689t1772r738b1803],
6	vs.	FW	O	vs.	prep	3	SENT_90	[p5l744t1779r778b1796],
7	80	CD	PERCENT	80	num	8	SENT_90	[p5l1493t1772r1552b1795],
8	%	NN	PERCENT	%	pobj	6	SENT_90	[p5l1493t1772r1552b1795],
9	at	IN	O	at	_	0	SENT_90	[p5l1559t1775r1585b1795],
10	240-mg	JJ	O	240-mg	amod	14	SENT_90	[p5l1592t1773r1697b1802],
11	dose	NN	O	dose	nn	14	SENT_90	[p5l1706t1771r1771b1795],
12	unconjugated	JJ	O	unconjugated	amod	14	SENT_90	[p5l1832t1771r2024b1802],
13	placebo	NN	O	placebo	nn	14	SENT_90	[p5l519t1811r628b1842],
14	X	NN	O	x	prep_at	8	SENT_90	[p5l636t1817r653b1835],
15	12	CD	DURATION	12	num	16	SENT_90	[p5l663t1813r692b1835],
16	weeks	NNS	NUMBER	week	tmod	3	SENT_90	[p5l700t1811r785b1836],
17	plus	CC	O	plus	prep	3	SENT_90	[p5l794t1811r849b1842],
18	hyperbilirubinemia	NN	O	hyperbilirubinemia	dep	17	SENT_90	[p5l1832t1810r2102b1842],
19	,	,	O	,	_	0	SENT_90	[p5l1832t1810r2102b1842],
20	PEG+RBV	NN	O	peg+rbv	nn	22	SENT_90	[p5l519t1851r731b1876],
21	for24	NN	O	for24	nn	22	SENT_90	[p5l519t1851r731b1876],
22	weeks	NNS	DURATION	week	dep	1	SENT_90	[p5l738t1851r822b1876],
23	and	CC	O	and	_	0	SENT_90	[p5l1831t1850r1881b1875],
24	anemia	NN	O	anemia	dep	1	SENT_90	[p5l1890t1851r1990b1875],

1	MK	NN	O	mk	dep	7	SENT_91	[p5l21t1917r141b1941],
2	—	CD	NUMBER	—	num	1	SENT_91	[p5l21t1917r141b1941],
3	5172	CD	NUMBER	5172	num	4	SENT_91	[p5l21t1917r141b1941],
4	NS3/4A	NN	O	ns3/4a	dep	1	SENT_91	[p5l239t1917r341b1942],
5	PI	NN	O	pi	dep	7	SENT_91	[p5l349t1917r370b1940],
6	II	CD	NUMBER	ii	num	5	SENT_91	[p5l429t1917r441b1940],
7	100	CD	NUMBER	100	dep	10	SENT_91	[p5l520t1918r567b1941],
8	vs.	IN	O	vs.	_	0	SENT_91	[p5l574t1923r609b1941],
9	200	CD	NUMBER	200	prep_vs.	7	SENT_91	[p5l616t1918r665b1941],
10	vs.	CC	O	vs.	dep	17	SENT_91	[p5l673t1923r707b1941],
11	400	CD	NUMBER	400	dep	10	SENT_91	[p5l714t1918r764b1941],
12	vs.	CC	O	vs.	prep	11	SENT_91	[p5l771t1923r805b1941],
13	1	CD	NUMBER	1	num	15	SENT_91	[p5l974t1918r982b1940],
14	Naive	JJ	O	naive	amod	15	SENT_91	[p5l1119t1917r1194b1941],
15	SVR24	NN	O	svr24	dep	12	SENT_91	[p5l1278t1917r1364b1941],
16	86	CD	PERCENT	86	num	17	SENT_91	[p5l1493t1919r1552b1942],
17	%	NN	PERCENT	%	dep	56	SENT_91	[p5l1493t1919r1552b1942],
18	at	IN	O	at	_	0	SENT_91	[p5l1559t1921r1585b1941],
19	100	CD	NUMBER	100	num	20	SENT_91	[p5l1594t1919r1641b1941],
20	mg	NN	O	mg	prep_at	17	SENT_91	[p5l1648t1924r1698b1948],
21	,	,	O	,	_	0	SENT_91	[p5l1648t1924r1698b1948],
22	92	CD	PERCENT	92	num	23	SENT_91	[p5l1706t1919r1765b1942],
23	%	NN	PERCENT	%	dep	30	SENT_91	[p5l1706t1919r1765b1942],
24	at	IN	O	at	_	0	SENT_91	[p5l1772t1921r1798b1941],
25	Hyperbilirubinemia	NN	O	hyperbilirubinemia	prep_at	23	SENT_91	[p5l1832t1916r2098b1947],
26	800	CD	NUMBER	800	num	27	SENT_91	[p5l518t1957r567b1980],
27	mg	NN	O	mg	dep	30	SENT_91	[p5l575t1963r617b1986],
28	a	DT	DURATION	a	det	30	SENT_91	[p5l626t1963r639b1980],
29	day	NN	DURATION	day	nn	30	SENT_91	[p5l647t1955r697b1987],
30	x	NN	O	x	dep	56	SENT_91	[p5l704t1962r721b1979],
31	12	CD	DURATION	12	num	32	SENT_91	[p5l731t1957r761b1979],
32	weeks	NNS	NUMBER	week	dep	30	SENT_91	[p5l768t1955r853b1980],
33	200	CD	NUMBER	200	num	34	SENT_91	[p5l1493t1958r1542b1981],
34	mg	NN	O	mg	dep	32	SENT_91	[p5l1550t1963r1599b1987],
35	,	,	O	,	_	0	SENT_91	[p5l1550t1963r1599b1987],
36	91	CD	PERCENT	91	num	37	SENT_91	[p5l1607t1958r1666b1981],
37	%	NN	PERCENT	%	npadvmod	53	SENT_91	[p5l1607t1958r1666b1981],
38	at	IN	O	at	_	0	SENT_91	[p5l1673t1960r1699b1981],
39	400	CD	NUMBER	400	num	40	SENT_91	[p5l1705t1958r1755b1981],
40	mg	NN	O	mg	prep_at	37	SENT_91	[p5l1762t1963r1812b1987],
41	,	,	O	,	_	0	SENT_91	[p5l1762t1963r1812b1987],
42	and	CC	O	and	_	0	SENT_91	[p5l1831t1955r1881b1980],
43	elevated	JJ	O	elevated	amod	44	SENT_91	[p5l1890t1955r2006b1980],
44	levels	NNS	O	level	conj_and	37	SENT_91	[p5l2016t1955r2091b1980],
45	of	IN	O	of	_	0	SENT_91	[p5l2099t1955r2127b1980],
46	plus	CC	O	plus	_	0	SENT_91	[p5l519t1994r574b2025],
47	PEG+RBV	NN	O	peg+rbv	nn	48	SENT_91	[p5l583t1995r736b2019],
48	x	NN	O	x	prep_of	44	SENT_91	[p5l583t1995r736b2019],
49	24-48	CD	NUMBER	24-48	dep	48	SENT_91	[p5l744t1996r827b2019],
50	and	CC	O	and	_	0	SENT_91	[p5l1493t1995r1543b2019],
51	87	CD	PERCENT	87	num	52	SENT_91	[p5l1552t1996r1611b2020],
52	%	NN	PERCENT	%	conj_and	48	SENT_91	[p5l1552t1996r1611b2020],
53	at	IN	O	at	advmod	32	SENT_91	[p5l1618t1999r1644b2019],
54	800	CD	NUMBER	800	num	56	SENT_91	[p5l1651t1996r1700b2019],
55	mg	NN	O	mg	nn	56	SENT_91	[p5l1709t2002r1751b2026],
56	transaminases	NNS	O	transaminase	_	0	SENT_91	[p5l1830t1995r2028b2019],
57	seen	VBN	O	see	partmod	56	SENT_91	[p5l2036t2001r2097b2019],
58	at	IN	O	at	_	0	SENT_91	[p5l2106t1998r2132b2019],
59	weeks	NNS	DURATION	week	prep_at	57	SENT_91	[p5l518t2033r602b2057],
60	higher	JJR	O	higher	amod	61	SENT_91	[p5l1832t2033r1921b2064],
61	doses	NNS	O	dose	dep	59	SENT_91	[p5l1928t2033r2006b2057],

1	No	DT	O	no	det	2	SENT_92	[p5l1494t2078r1531b2102],
2	effect	NN	O	effect	_	0	SENT_92	[p5l1539t2077r1616b2102],
3	of	IN	O	of	_	0	SENT_92	[p5l1623t2077r1652b2102],
4	IL28B	NN	O	il28b	prep_of	2	SENT_92	[p5l1657t2078r1728b2102],
5	on	IN	O	on	_	0	SENT_92	[p5l1735t2085r1769b2102],
6	Rash	NNP	O	Rash	prep_on	2	SENT_92	[p5l1832t2077r1894b2102],
7	and	CC	O	and	_	0	SENT_92	[p5l1903t2077r1953b2102],
8	anemia	NN	O	anemia	nn	9	SENT_92	[p5l1962t2078r2062b2102],
9	SVR	NN	O	svr	prep_on	2	SENT_92	[p5l1493t2118r1544b2142],

1	Daclatasvir	NNP	O	Daclatasvir	nn	2	SENT_93	[p5l21t2182r171b2207],
2	NSSA	NNP	ORGANIZATION	NSSA	_	0	SENT_93	[p5l239t2183r312b2207],
3	Ila	NN	O	ilum	dep	2	SENT_93	[p5l421t2183r449b2207],
4	3	CD	NUMBER	3	num	3	SENT_93	[p5l518t2185r532b2207],
5	vs.	CC	O	vs.	prep	3	SENT_93	[p5l540t2190r574b2207],
6	10	CD	NUMBER	10	dep	5	SENT_93	[p5l585t2185r614b2207],
7	vs.	CC	O	vs.	prep	6	SENT_93	[p5l621t2190r655b2207],
8	60	CD	NUMBER	60	num	9	SENT_93	[p5l663t2185r695b2207],
9	mg	NN	O	mg	dep	7	SENT_93	[p5l703t2190r745b2214],
10	a	DT	DURATION	a	det	11	SENT_93	[p5l754t2190r767b2207],
11	day	NN	DURATION	day	dep	9	SENT_93	[p5l775t2183r824b2214],
12	1	CD	NUMBER	1	num	14	SENT_93	[p5l974t2184r982b2206],
13	Naive	JJ	O	naive	amod	14	SENT_93	[p5l1119t2183r1194b2207],
14	RVR	NN	O	rvr	dep	9	SENT_93	[p5l1279t2183r1331b2206],
15	at	IN	O	at	_	0	SENT_93	[p5l1339t2186r1364b2207],
16	4	CD	NUMBER	4	prep_at	14	SENT_93	[p5l1371t2184r1387b2206],
17	and	CC	O	and	_	0	SENT_93	[p5l1394t2182r1444b2207],
18	42	CD	PERCENT	42	num	19	SENT_93	[p5l1492t2184r1552b2207],
19	%	NN	PERCENT	%	npadvmod	14	SENT_93	[p5l1492t2184r1552b2207],
20	at	IN	O	at	_	0	SENT_93	[p5l1559t2187r1585b2207],
21	3	CD	NUMBER	3	num	22	SENT_93	[p5l1592t2185r1606b2207],
22	mg	NN	O	mg	conj_and	16	SENT_93	[p5l1614t2190r1664b2214],
23	,	,	O	,	_	0	SENT_93	[p5l1614t2190r1664b2214],
24	83	CD	PERCENT	83	num	25	SENT_93	[p5l1672t2184r1730b2207],
25	%	NN	PERCENT	%	conj_and	16	SENT_93	[p5l1672t2184r1730b2207],
26	at	IN	O	at	_	0	SENT_93	[p5l1738t2187r1763b2207],
27	Diarrhea	NNP	O	Diarrhea	prep_at	25	SENT_93	[p5l1832t2182r1947b2206],
28	and	CC	O	and	_	0	SENT_93	[p5l1956t2182r2006b2206],
29	plus	CC	O	plus	cc	30	SENT_93	[p5l519t2222r574b2253],
30	PEG+RBV	NN	O	peg+rbv	conj_and	22	SENT_93	[p5l583t2223r776b2246],
31	>	JJR	O	>	npadvmod	32	SENT_93	[p5l583t2223r776b2246],
32	<	JJR	O	<	amod	30	SENT_93	[p5l583t2223r776b2246],
33	48	CD	DURATION	48	num	34	SENT_93	[p5l583t2223r776b2246],
34	weeks	NNS	NUMBER	week	tmod	32	SENT_93	[p5l783t2222r868b2246],
35	12weeks	CD	NUMBER	12weeks	num	36	SENT_93	[p5l1280t2221r1402b2246],
36	10mg	CD	NUMBER	10mg	dep	14	SENT_93	[p5l1496t2222r1640b2253],
37	,	,	O	,	_	0	SENT_93	[p5l1496t2222r1640b2253],
38	and	CC	O	and	_	0	SENT_93	[p5l1496t2222r1640b2253],
39	75	CD	PERCENT	75	num	40	SENT_93	[p5l1650t2224r1708b2247],
40	%	NN	PERCENT	%	conj_and	9	SENT_93	[p5l1650t2224r1708b2247],
41	at	IN	O	at	_	0	SENT_93	[p5l1715t2226r1741b2246],
42	headache	NN	O	headache	prep_at	40	SENT_93	[p5l1832t2221r1965b2246],

1	60	CD	NUMBER	60	num	2	SENT_94	[p5l1493t2263r1525b2285],
2	mg	NN	O	mg	_	0	SENT_94	[p5l1534t2268r1576b2292],

1	Sofosbuvir	NNP	O	Sofosbuvir	nn	3	SENT_95	[p5l21t2324r167b2349],
2	NPI	NNP	O	NPI	nn	3	SENT_95	[p5l239t2325r282b2349],
3	III	NNP	O	III	dep	20	SENT_95	[p5l425t2326r445b2349],
4	400	CD	NUMBER	400	num	5	SENT_95	[p5l517t2327r567b2350],
5	mg	NN	O	mg	npadvmod	6	SENT_95	[p5l575t2333r617b2357],
6	daily	JJ	SET	daily	amod	3	SENT_95	[p5l626t2325r691b2357],
7	plus	CC	O	plus	prep	3	SENT_95	[p5l699t2325r754b2356],
8	1	CD	NUMBER	1	dep	7	SENT_95	[p5l900t2326r920b2353],
9	,	,	O	,	_	0	SENT_95	[p5l900t2326r920b2353],
10	4	CD	NUMBER	4	dep	7	SENT_95	[p5l927t2326r949b2353],
11	,	,	O	,	_	0	SENT_95	[p5l927t2326r949b2353],
12	5	CD	NUMBER	5	dep	7	SENT_95	[p5l957t2326r979b2353],
13	,	,	O	,	_	0	SENT_95	[p5l957t2326r979b2353],
14	and	CC	NUMBER	and	_	0	SENT_95	[p5l987t2324r1037b2349],
15	6	CD	NUMBER	6	num	17	SENT_95	[p5l1046t2326r1061b2349],
16	Naive	JJ	O	naive	amod	17	SENT_95	[p5l1119t2325r1194b2349],
17	SVR12	NN	O	svr12	dep	7	SENT_95	[p5l1278t2325r1363b2349],
18	89	CD	PERCENT	89	num	19	SENT_95	[p5l1493t2326r1552b2349],
19	%	NN	PERCENT	%	dep	20	SENT_95	[p5l1493t2326r1552b2349],
20	Genotype	NN	O	genotype	dep	56	SENT_95	[p5l1559t2325r1695b2356],
21	1	CD	NUMBER	1	num	20	SENT_95	[p5l1705t2326r1725b2353],
22	,	,	O	,	_	0	SENT_95	[p5l1705t2326r1725b2353],
23	96	CD	PERCENT	96	num	25	SENT_95	[p5l1733t2326r1791b2349],
24	%	NN	PERCENT	%	nn	25	SENT_95	[p5l1733t2326r1791b2349],
25	Fatigue	NN	O	fatigue	appos	20	SENT_95	[p5l1832t2326r1939b2356],
26	,	,	O	,	_	0	SENT_95	[p5l1832t2326r1939b2356],
27	headache	NN	O	headache	appos	20	SENT_95	[p5l1947t2324r2087b2353],
28	,	,	O	,	_	0	SENT_95	[p5l1947t2324r2087b2353],
29	PEG+RBV	NN	O	peg+rbv	nn	30	SENT_95	[p5l519t2366r648b2389],
30	genotype	NN	O	genotype	appos	20	SENT_95	[p5l1493t2368r1626b2395],
31	4	CD	NUMBER	4	dep	30	SENT_95	[p5l1633t2366r1655b2392],
32	,	,	O	,	_	0	SENT_95	[p5l1633t2366r1655b2392],
33	and	CC	PERCENT	and	_	0	SENT_95	[p5l1663t2364r1713b2388],
34	100	CD	PERCENT	100	number	35	SENT_95	[p5l1725t2365r1798b2388],
35	%	NN	PERCENT	%	amod	36	SENT_95	[p5l1725t2365r1798b2388],
36	nausea	NN	O	nausea	conj_and	30	SENT_95	[p5l1832t2371r1935b2392],
37	,	,	O	,	_	0	SENT_95	[p5l1832t2371r1935b2392],
38	and	CC	O	and	_	0	SENT_95	[p5l1942t2364r1993b2388],
39	insomnia	NN	O	insomnia	nn	40	SENT_95	[p5l2002t2365r2126b2388],
40	genotypes	NNS	O	genotype	conj_and	30	SENT_95	[p5l1493t2407r1639b2435],
41	5	CD	NUMBER	5	number	44	SENT_95	[p5l1647t2405r1661b2428],
42	and	CC	O	and	_	0	SENT_95	[p5l1669t2403r1720b2428],
43	6	CD	NUMBER	6	num	45	SENT_95	[p5l1729t2405r1744b2428],
44	400	CD	NUMBER	400	num	45	SENT_95	[p5l517t2449r567b2472],
45	mg	NN	O	mg	npadvmod	46	SENT_95	[p5l575t2454r617b2479],
46	daily	JJ	SET	daily	amod	40	SENT_95	[p5l626t2447r691b2479],
47	+	CC	O	+	_	0	SENT_95	[p5l698t2453r715b2472],
48	RBV	NN	O	rbv	nn	49	SENT_95	[p5l724t2448r777b2472],
49	X	NN	O	x	conj_and	36	SENT_95	[p5l784t2454r801b2471],
50	2	CD	NUMBER	2	dep	49	SENT_95	[p5l957t2448r979b2475],
51	,	,	O	,	_	0	SENT_95	[p5l957t2448r979b2475],
52	3	CD	NUMBER	3	num	54	SENT_95	[p5l987t2448r1001b2471],
53	Naive	JJ	O	naive	amod	54	SENT_95	[p5l1119t2447r1194b2471],
54	SVR12	NN	O	svr12	appos	20	SENT_95	[p5l1278t2447r1363b2471],
55	67	CD	PERCENT	67	num	56	SENT_95	[p5l1493t2448r1552b2471],
56	%	NN	PERCENT	%	dep	66	SENT_95	[p5l1493t2448r1552b2471],
57	with	IN	O	with	_	0	SENT_95	[p5l1559t2446r1618b2471],
58	sofosbuvir	NN	O	sofosbuvir	prep_with	56	SENT_95	[p5l1627t2446r1774b2475],
59	,	,	O	,	_	0	SENT_95	[p5l1627t2446r1774b2475],
60	12	CD	DURATION	12	num	61	SENT_95	[p5l520t2488r550b2511],
61	weeks	NNS	NUMBER	week	appos	58	SENT_95	[p5l558t2487r642b2511],
62	vs.	CC	O	vs.	prep	61	SENT_95	[p5l649t2494r684b2511],
63	PEG+RBV	NN	O	peg+rbv	nn	64	SENT_95	[p5l693t2488r821b2511],
64	X	NN	O	x	dep	62	SENT_95	[p5l828t2493r845b2511],
65	67	CD	PERCENT	67	num	66	SENT_95	[p5l1493t2487r1552b2510],
66	%	NN	PERCENT	%	_	0	SENT_95	[p5l1493t2487r1552b2510],
67	with	IN	O	with	_	0	SENT_95	[p5l1559t2486r1618b2510],
68	PEG+RBV	NN	O	peg+rbv	prep_with	66	SENT_95	[p5l1628t2487r1756b2510],
69	24	CD	DURATION	24	num	70	SENT_95	[p5l518t2527r551b2550],
70	weeks	NNS	NUMBER	week	tmod	68	SENT_95	[p5l558t2526r642b2550],

1	Mericitabine	NNP	O	Mericitabine	nn	3	SENT_96	[p5l21t2583r192b2608],
2	NPI	NNP	O	NPI	nn	3	SENT_96	[p5l239t2584r282b2607],
3	II	NNP	O	II	_	0	SENT_96	[p5l429t2584r441b2607],
4	1,000	CD	NUMBER	1,000	num	5	SENT_96	[p5l521t2586r591b2612],
5	mg	NN	O	mg	dep	3	SENT_96	[p5l599t2591r641b2615],
6	daily	JJ	SET	daily	amod	7	SENT_96	[p5l650t2584r715b2615],
7	x	NN	O	x	dep	5	SENT_96	[p5l722t2590r739b2608],
8	1	CD	NUMBER	1	num	7	SENT_96	[p5l959t2585r979b2611],
9	,	,	O	,	_	0	SENT_96	[p5l959t2585r979b2611],
10	4	CD	NUMBER	4	num	12	SENT_96	[p5l986t2585r1002b2607],
11	Naive	JJ	O	naive	amod	12	SENT_96	[p5l1119t2584r1194b2608],
12	SVR12	NN	O	svr12	appos	7	SENT_96	[p5l1278t2584r1363b2608],
13	56.8	CD	PERCENT	56.8	num	14	SENT_96	[p5l1493t2585r1576b2608],
14	%	NN	PERCENT	%	dep	12	SENT_96	[p5l1493t2585r1576b2608],
15	vs.	CC	O	vs.	_	0	SENT_96	[p5l1583t2590r1617b2608],
16	36.5	CD	PERCENT	36.5	num	17	SENT_96	[p5l1625t2585r1714b2611],
17	%	NN	PERCENT	%	conj_vs.	12	SENT_96	[p5l1625t2585r1714b2611],
18	,	,	O	,	_	0	SENT_96	[p5l1625t2585r1714b2611],
19	Fatigue	NNP	O	Fatigue	appos	17	SENT_96	[p5l1832t2584r1939b2614],
20	,	,	O	,	_	0	SENT_96	[p5l1832t2584r1939b2614],
21	headache	NN	O	headache	appos	17	SENT_96	[p5l1947t2583r2087b2611],
22	,	,	O	,	_	0	SENT_96	[p5l1947t2583r2087b2611],

1	24	CD	DURATION	24	num	2	SENT_97	[p5l518t2625r551b2648],
2	weeks	NNS	DURATION	week	dep	8	SENT_97	[p5l557t2623r642b2648],
3	plus	CC	O	plus	prep	2	SENT_97	[p5l651t2623r706b2654],
4	PEG+RBV	NN	O	peg+rbv	dep	3	SENT_97	[p5l715t2624r843b2648],
5	>	JJR	O	>	amod	4	SENT_97	[p5l850t2629r867b2647],
6	<	JJR	O	<	amod	7	SENT_97	[p5l850t2629r867b2647],
7	mericitabine	NN	O	mericitabine	dep	8	SENT_97	[p5l1494t2622r1666b2647],
8	vs.	NN	O	v.	dep	13	SENT_97	[p5l1673t2629r1707b2647],
9	and	CC	O	and	_	0	SENT_97	[p5l1831t2622r1881b2647],
10	nausea	NN	O	nausea	conj_and	8	SENT_97	[p5l1891t2629r1986b2647],
11	24-48	CD	NUMBER	24-48	num	12	SENT_97	[p5l518t2664r601b2687],
12	weeks	NNS	NUMBER	week	dep	8	SENT_97	[p5l608t2663r693b2687],
13	placebo	NN	O	placebo	_	0	SENT_97	[p5l1494t2662r1603b2693],

1	Deleobuvir	NNP	MISC	Deleobuvir	nn	3	SENT_98	[p5l21t2738r173b2762],
2	NNPI	NNP	MISC	NNPI	nn	3	SENT_98	[p5l239t2739r304b2762],
3	II	NNP	MISC	II	_	0	SENT_98	[p5l429t2739r441b2762],
4	600	CD	NUMBER	600	num	6	SENT_98	[p5l518t2740r567b2763],
5	mg	NN	O	mg	nn	6	SENT_98	[p5l575t2746r617b2770],
6	3x	NN	O	3x	dep	3	SENT_98	[p5l626t2740r660b2763],
7	a	DT	DURATION	a	det	8	SENT_98	[p5l668t2746r681b2763],
8	day	NN	DURATION	day	dep	6	SENT_98	[p5l690t2739r739b2770],
9	plus	CC	O	plus	_	0	SENT_98	[p5l747t2739r802b2769],
10	1	CD	NUMBER	1	num	12	SENT_98	[p5l974t2740r982b2762],
11	Naive	JJ	O	naive	amod	12	SENT_98	[p5l1119t2739r1194b2762],
12	RVR	NN	O	rvr	dep	3	SENT_98	[p5l1279t2739r1331b2762],
13	58	CD	PERCENT	58	number	14	SENT_98	[p5l1499t2739r1557b2762],
14	%	NN	PERCENT	%	amod	16	SENT_98	[p5l1499t2739r1557b2762],
15	GI	NN	O	gi	nn	16	SENT_98	[p5l1831t2739r1857b2762],
16	events	NNS	O	event	dep	12	SENT_98	[p5l1866t2742r1962b2766],
17	,	,	O	,	_	0	SENT_98	[p5l1866t2742r1962b2766],
18	rash	NN	O	rash	appos	16	SENT_98	[p5l1971t2738r2033b2766],
19	,	,	O	,	_	0	SENT_98	[p5l1971t2738r2033b2766],
20	and	CC	O	and	_	0	SENT_98	[p5l2041t2738r2091b2762],
21	PEG+RBV	NN	O	peg+rbv	conj_and	6	SENT_98	[p5l519t2779r712b2802],
22	x28	CD	NUMBER	x28	num	23	SENT_98	[p5l519t2779r712b2802],
23	days	NNS	NUMBER	day	tmod	21	SENT_98	[p5l719t2778r781b2809],
24	hyperbilirubinemia	NN	O	hyperbilirubinemia	dep	3	SENT_98	[p5l1832t2777r2094b2808],

1	VX	NN	O	vx	nn	2	SENT_99	[p5l19t2854r116b2877],
2	—	NN	O	—	_	0	SENT_99	[p5l19t2854r116b2877],
3	222	CD	NUMBER	222	num	4	SENT_99	[p5l19t2854r116b2877],
4	NNPI	NN	O	nnpus	dep	12	SENT_99	[p5l239t2854r304b2877],
5	II	CD	NUMBER	ii	num	6	SENT_99	[p5l429t2854r441b2877],
6	100	CD	NUMBER	100	dep	4	SENT_99	[p5l521t2856r567b2878],
7	or400	NN	O	or400	nn	8	SENT_99	[p5l575t2856r659b2878],
8	mg	NN	O	mg	dep	12	SENT_99	[p5l666t2861r709b2885],
9	daily	RB	SET	daily	advmod	12	SENT_99	[p5l717t2854r782b2885],
10	1	CD	NUMBER	1	num	12	SENT_99	[p5l974t2855r982b2877],
11	Naive	JJ	O	naive	amod	12	SENT_99	[p5l1119t2854r1194b2877],
12	RVR	NN	O	rvr	dep	45	SENT_99	[p5l1279t2854r1331b2877],
13	at	IN	O	at	_	0	SENT_99	[p5l1339t2857r1364b2877],
14	12	CD	PERCENT	12	number	15	SENT_99	[p5l1374t2855r1403b2877],
15	85	CD	PERCENT	85	num	16	SENT_99	[p5l1493t2855r1552b2878],
16	%	NN	PERCENT	%	prep_at	12	SENT_99	[p5l1493t2855r1552b2878],
17	on	IN	O	on	_	0	SENT_99	[p5l1559t2861r1593b2878],
18	100	CD	NUMBER	100	num	21	SENT_99	[p5l1604t2856r1651b2878],
19	mg	NN	O	mg	nn	21	SENT_99	[p5l1658t2861r1701b2885],
20	QUAD	NNP	MISC	QUAD	nn	21	SENT_99	[p5l1709t2855r1793b2881],
21	Fatigue	NNP	MISC	Fatigue	prep_on	16	SENT_99	[p5l1832t2854r1932b2884],
22	and	CC	O	and	_	0	SENT_99	[p5l1940t2853r1990b2877],
23	GI	NNP	O	GI	nn	24	SENT_99	[p5l1999t2854r2025b2877],
24	upset	NN	O	upset	conj_and	12	SENT_99	[p5l2035t2857r2111b2884],
25	plus	CC	O	plus	prep	24	SENT_99	[p5l519t2893r574b2924],
26	DUAL	NN	O	dual	dep	25	SENT_99	[p5l583t2894r666b2917],
27	:	:	O	:	_	0	SENT_99	[p5l583t2894r666b2917],
28	telaprevir	NN	O	telaprevir	dep	24	SENT_99	[p5l673t2893r805b2924],
29	vs.	CC	O	vs.	prep	28	SENT_99	[p5l811t2900r845b2917],
30	weeks	NNS	DURATION	week	nn	31	SENT_99	[p5l1278t2892r1362b2917],
31	therapy	NN	O	therapy	dep	29	SENT_99	[p5l1492t2893r1604b2924],
32	,	,	O	,	_	0	SENT_99	[p5l1492t2893r1604b2924],
33	90	CD	PERCENT	90	num	34	SENT_99	[p5l1612t2894r1671b2917],
34	%	NN	PERCENT	%	appos	31	SENT_99	[p5l1612t2894r1671b2917],
35	on	IN	O	on	_	0	SENT_99	[p5l1678t2900r1712b2917],
36	TRIPLE	NNP	O	TRIPLE	prep_on	34	SENT_99	[p5l517t2933r615b2957],
37	:	:	O	:	_	0	SENT_99	[p5l517t2933r615b2957],
38	telaprevir	NN	O	telaprevir	dep	24	SENT_99	[p5l622t2932r754b2963],
39	plus	CC	O	plus	prep	38	SENT_99	[p5l762t2932r817b2963],
40	RBV	NN	O	rbv	nn	43	SENT_99	[p5l826t2933r879b2957],
41	400	CD	NUMBER	400	num	43	SENT_99	[p5l1492t2934r1542b2957],
42	mg	NN	O	mg	nn	43	SENT_99	[p5l1550t2939r1592b2964],
43	QUAD	NN	O	quad	dep	39	SENT_99	[p5l1601t2933r1685b2960],
44	therapy	NN	O	therapy	nn	45	SENT_99	[p5l1692t2932r1799b2964],
45	QUAD	NN	O	quad	dep	2	SENT_99	[p5l518t2977r609b3004],
46	:	:	O	:	_	0	SENT_99	[p5l518t2977r609b3004],
47	telaprevir	NN	O	telaprevir	dep	2	SENT_99	[p5l616t2976r748b3007],
48	plus	CC	O	plus	prep	47	SENT_99	[p5l756t2976r811b3007],
49	RBV	NN	O	rbv	dep	48	SENT_99	[p5l820t2977r873b3001],
50	plus	CC	O	plus	prep	49	SENT_99	[p5l519t3015r574b3046],
51	IFN	NN	O	ifn	dep	50	SENT_99	[p5l583t3016r625b3039],

1	Setrobuvir	NNP	O	Setrobuvir	nn	3	SENT_100	[p5l20t3091r164b3115],
2	NNPI	NNP	O	NNPI	nn	3	SENT_100	[p5l239t3092r304b3115],
3	II	NNP	O	II	dep	14	SENT_100	[p5l429t3092r441b3115],
4	200	CD	NUMBER	200	num	8	SENT_100	[p5l518t3093r567b3116],
5	or	CC	O	or	_	0	SENT_100	[p5l575t3099r603b3116],
6	400	CD	NUMBER	400	num	8	SENT_100	[p5l609t3093r659b3116],
7	mg	NN	O	mg	nn	8	SENT_100	[p5l666t3099r709b3123],
8	2x	NN	O	2x	dep	3	SENT_100	[p5l718t3093r752b3116],
9	a	DT	DURATION	a	det	10	SENT_100	[p5l760t3099r773b3116],
10	day	NN	DURATION	day	dep	8	SENT_100	[p5l782t3092r831b3123],
11	1	CD	NUMBER	1	dep	14	SENT_100	[p5l974t3093r982b3115],
12	Naive	JJ	O	naive	amod	14	SENT_100	[p5l1119t3092r1194b3115],
13	SVR12	NN	O	svr12	nn	14	SENT_100	[p5l1278t3092r1363b3115],
14	SVR	NN	ORGANIZATION	svr	_	0	SENT_100	[p5l1493t3092r1544b3115],
15	equal	JJ	O	equal	amod	14	SENT_100	[p5l1552t3091r1626b3121],
16	between	IN	O	between	_	0	SENT_100	[p5l1636t3091r1755b3115],
17	Rash	NNP	O	Rash	nn	20	SENT_100	[p5l1832t3091r1894b3115],
18	plus	CC	O	plus	_	0	SENT_100	[p5l519t3131r574b3161],
19	PEG+RBV	NNP	O	PEG+RBV	nn	20	SENT_100	[p5l583t3132r712b3155],
20	PEG+RBV	NNP	O	PEG+RBV	prep_between	15	SENT_100	[p5l1494t3131r1622b3154],
21	and	CC	O	and	_	0	SENT_100	[p5l1629t3130r1679b3154],
22	therapy	NN	O	therapy	conj_and	14	SENT_100	[p5l1687t3130r1794b3161],
23	with	IN	O	with	_	0	SENT_100	[p5l1493t3169r1552b3193],
24	setrobuvir	NN	O	setrobuvir	prep_with	22	SENT_100	[p5l1561t3169r1701b3193],

1	Tegobuvir	NNP	O	Tegobuvir	nn	6	SENT_101	[p5l19t3245r159b3277],
2	NNPI	NNP	O	NNPI	nn	6	SENT_101	[p5l239t3246r304b3270],
3	II	NNP	O	II	nn	6	SENT_101	[p5l429t3246r441b3270],
4	40	CD	NUMBER	40	num	6	SENT_101	[p5l517t3248r550b3271],
5	mg	NN	O	mg	nn	6	SENT_101	[p5l557t3253r600b3278],
6	2x	NN	O	2x	_	0	SENT_101	[p5l609t3248r643b3271],
7	a	DT	DURATION	a	det	8	SENT_101	[p5l651t3253r664b3271],
8	day	NN	DURATION	day	dep	6	SENT_101	[p5l673t3246r722b3278],
9	plus	CC	O	plus	prep	6	SENT_101	[p5l730t3246r785b3277],
10	DUAL	NN	O	dual	dep	9	SENT_101	[p5l794t3247r876b3271],
11	:	:	O	:	_	0	SENT_101	[p5l794t3247r876b3271],
12	1	CD	NUMBER	1	num	14	SENT_101	[p5l974t3247r982b3270],
13	Naive	JJ	O	naive	amod	14	SENT_101	[p5l1119t3246r1194b3270],
14	RVR	NN	O	rvr	dep	6	SENT_101	[p5l1279t3246r1331b3270],
15	at	IN	O	at	_	0	SENT_101	[p5l1339t3249r1364b3270],
16	28	CD	DURATION	28	num	17	SENT_101	[p5l1372t3247r1403b3270],
17	days	NNS	NUMBER	day	prep_at	14	SENT_101	[p5l1411t3245r1472b3277],
18	7	CD	PERCENT	7	number	19	SENT_101	[p5l1494t3247r1535b3270],
19	%	NN	PERCENT	%	amod	17	SENT_101	[p5l1494t3247r1535b3270],
20	on	IN	O	on	dep	6	SENT_101	[p5l1542t3252r1576b3270],
21	DUAL	JJ	O	dual	amod	22	SENT_101	[p5l1586t3246r1662b3270],
22	therapy	NN	O	therapy	pobj	20	SENT_101	[p5l1668t3245r1780b3277],
23	,	,	O	,	_	0	SENT_101	[p5l1668t3245r1780b3277],
24	Transient	JJ	O	transient	amod	25	SENT_101	[p5l1830t3246r1957b3270],
25	elevations	NNS	O	elevation	appos	22	SENT_101	[p5l1964t3245r2104b3270],
26	in	IN	O	in	dep	6	SENT_101	[p5l2112t3246r2135b3270],

1	GS-9256	NN	O	gs-9256	dep	6	SENT_102	[p5l518t3286r633b3310],
2	38	CD	PERCENT	38	num	3	SENT_102	[p5l1493t3286r1552b3309],
3	%	NN	PERCENT	%	dep	1	SENT_102	[p5l1493t3286r1552b3309],
4	onTR	NN	O	ontr	dep	6	SENT_102	[p5l1559t3285r1691b3309],
5	|	CD	NUMBER	|	num	4	SENT_102	[p5l1559t3285r1691b3309],
6	PLE	NN	O	ple	dep	12	SENT_102	[p5l1559t3285r1691b3309],
7	therapy	NN	O	therapy	dep	6	SENT_102	[p5l1698t3284r1809b3316],
8	,	,	O	,	_	0	SENT_102	[p5l1698t3284r1809b3316],
9	bilirubin	NN	O	bilirubin	nn	10	SENT_102	[p5l1832t3284r1945b3309],
10	TRIPLE	NNP	O	TRIPLE	appos	7	SENT_102	[p5l517t3344r615b3368],
11	:	:	O	:	_	0	SENT_102	[p5l517t3344r615b3368],
12	GS-9256	NN	O	gs-9256	_	0	SENT_102	[p5l623t3344r805b3369],
13	/	:	O	/	punct	12	SENT_102	[p5l623t3344r805b3369],
14	RBV	NN	O	rbv	dep	12	SENT_102	[p5l623t3344r805b3369],
15	100	CD	PERCENT	100	num	16	SENT_102	[p5l1495t3325r1569b3349],
16	%	NN	PERCENT	%	dep	14	SENT_102	[p5l1495t3325r1569b3349],
17	°	CD	NUMBER	°	number	18	SENT_102	[p5l1576t3331r1610b3348],
18	“	CD	NUMBER	“	num	19	SENT_102	[p5l1576t3331r1610b3348],
19	QUAD	NN	O	quad	dep	16	SENT_102	[p5l1619t3325r1703b3351],

1	therapy	NN	O	therapy	_	0	SENT_103	[p5l1492t3364r1599b3395],

1	QUAD	NNP	O	QUAD	_	0	SENT_104	[p5l518t3395r609b3422],
2	:	:	O	:	_	0	SENT_104	[p5l518t3395r609b3422],
3	GS-9256	NN	O	gs-9256	dep	1	SENT_104	[p5l617t3395r874b3420],
4	/	:	O	/	punct	5	SENT_104	[p5l617t3395r874b3420],
5	PEG+RBV	NN	O	peg+rbv	dep	3	SENT_104	[p5l617t3395r874b3420],

1	DAA	NNP	O	DAA	nsubj	10	SENT_105	[p5l21t3483r79b3507],
2	,	,	O	,	_	0	SENT_105	[p5l21t3483r79b3507],
3	direct	JJ	O	direct	amod	4	SENT_105	[p5l86t3482r239b3509],
4	—	NN	O	—	appos	1	SENT_105	[p5l86t3482r239b3509],
5	acting	VBG	O	act	partmod	4	SENT_105	[p5l86t3482r239b3509],
6	antiviral	JJ	O	antiviral	dobj	5	SENT_105	[p5l246t3482r348b3507],
7	;	:	O	;	_	0	SENT_105	[p5l246t3482r348b3507],
8	eRVR	NN	O	ervr	dep	6	SENT_105	[p5l355t3483r422b3507],
9	,	,	O	,	_	0	SENT_105	[p5l355t3483r422b3507],
10	extended	VBD	O	extend	_	0	SENT_105	[p5l429t3482r542b3503],
11	rapid	JJ	O	rapid	amod	13	SENT_105	[p5l551t3482r610b3509],
12	virologic	JJ	O	virologic	amod	13	SENT_105	[p5l618t3482r722b3509],
13	response	NN	O	response	dobj	10	SENT_105	[p5l729t3488r843b3509],
14	;	:	O	;	_	0	SENT_105	[p5l729t3488r843b3509],
15	GI	NNP	O	GI	dep	13	SENT_105	[p5l849t3483r879b3507],
16	,	,	O	,	_	0	SENT_105	[p5l849t3483r879b3507],
17	gastrointestinal	JJ	O	gastrointestinal	appos	15	SENT_105	[p5l886t3482r1080b3509],
18	;	:	O	;	_	0	SENT_105	[p5l886t3482r1080b3509],
19	NPI	NNP	ORGANIZATION	NPI	dep	15	SENT_105	[p5l1087t3483r1132b3507],
20	,	,	O	,	_	0	SENT_105	[p5l1087t3483r1132b3507],
21	nucleoside	JJ	O	nucleoside	amod	23	SENT_105	[p5l1140t3482r1269b3503],
22	polymerase	NN	O	polymerase	nn	23	SENT_105	[p5l1277t3482r1416b3509],
23	inhibitor	NN	O	inhibitor	appos	19	SENT_105	[p5l1424t3482r1532b3507],
24	;	:	O	;	_	0	SENT_105	[p5l1424t3482r1532b3507],
25	NNPI	NNP	O	NNPI	dep	15	SENT_105	[p5l1540t3483r1604b3507],
26	,	,	O	,	_	0	SENT_105	[p5l1540t3483r1604b3507],
27	nonnucleoside	JJ	O	nonnucleoside	amod	29	SENT_105	[p5l1611t3482r1789b3503],
28	polymerase	NN	O	polymerase	nn	29	SENT_105	[p5l1797t3482r1936b3509],
29	inhibitor	NN	O	inhibitor	appos	25	SENT_105	[p5l1944t3482r2052b3507],
30	;	:	O	;	_	0	SENT_105	[p5l1944t3482r2052b3507],
31	PEG	NNP	O	PEG	nsubj	59	SENT_105	[p5l21t3517r73b3541],
32	,	,	O	,	_	0	SENT_105	[p5l21t3517r73b3541],
33	pegylated	VBN	O	pegylate	partmod	31	SENT_105	[p5l81t3516r200b3544],
34	interferon-alfa	NN	O	interferon-alfa	dep	33	SENT_105	[p5l208t3516r386b3541],
35	;	:	O	;	_	0	SENT_105	[p5l208t3516r386b3541],
36	Pl	NN	O	pl	dep	34	SENT_105	[p5l393t3517r419b3541],
37	,	,	O	,	_	0	SENT_105	[p5l393t3517r419b3541],
38	protease	NN	O	protease	nn	39	SENT_105	[p5l427t3520r530b3544],
39	inhibitor	NN	O	inhibitor	appos	36	SENT_105	[p5l538t3516r646b3541],
40	;	:	O	;	_	0	SENT_105	[p5l538t3516r646b3541],
41	QUAD	NNP	O	QUAD	dep	36	SENT_105	[p5l653t3517r731b3541],
42	,	,	O	,	_	0	SENT_105	[p5l653t3517r731b3541],
43	quadruple	NN	O	quadruple	appos	41	SENT_105	[p5l738t3516r869b3544],
44	;	:	O	;	_	0	SENT_105	[p5l738t3516r869b3544],
45	RB	NN	O	rb	dep	43	SENT_105	[p5l877t3517r926b3541],
46	\	CD	NUMBER	\	num	45	SENT_105	[p5l877t3517r926b3541],
47	/	:	O	/	punct	45	SENT_105	[p5l877t3517r926b3541],
48	,	,	O	,	_	0	SENT_105	[p5l877t3517r926b3541],
49	ribavirin	NNP	O	ribavirin	appos	43	SENT_105	[p5l934t3516r1038b3541],
50	;	:	O	;	_	0	SENT_105	[p5l934t3516r1038b3541],
51	RVR	NNP	O	RVR	dep	36	SENT_105	[p5l1045t3517r1097b3541],
52	,	,	O	,	_	0	SENT_105	[p5l1045t3517r1097b3541],
53	rapid	JJ	O	rapid	amod	55	SENT_105	[p5l1104t3516r1164b3544],
54	virologic	JJ	O	virologic	amod	55	SENT_105	[p5l1171t3516r1275b3544],
55	response	NN	O	response	appos	51	SENT_105	[p5l1283t3523r1396b3544],
56	;	:	O	;	_	0	SENT_105	[p5l1283t3523r1396b3544],
57	SVR	NNP	ORGANIZATION	SVR	dep	34	SENT_105	[p5l1403t3517r1454b3541],
58	,	,	O	,	_	0	SENT_105	[p5l1403t3517r1454b3541],
59	sustained	VBD	O	sustain	parataxis	10	SENT_105	[p5l1460t3516r1575b3538],
60	virologic	JJ	O	virologic	amod	61	SENT_105	[p5l1582t3516r1686b3544],
61	response	NN	O	response	dobj	59	SENT_105	[p5l1693t3523r1806b3544],
62	.	.	O	.	_	0	SENT_105	[p5l1693t3523r1806b3544],

1	46	CD	PERCENT	46	num	2	SENT_106	[p6l20t51r89b79],
2	%	NN	PERCENT	%	npadvmod	51	SENT_106	[p6l20t51r89b79],
3	in	IN	O	in	_	0	SENT_106	[p6l100t51r132b78],
4	the	DT	O	the	det	6	SENT_106	[p6l142t48r194b79],
5	PEG+RBV	NN	O	peg+rbv	nn	6	SENT_106	[p6l205t50r382b79],
6	arm	NN	O	arm	prep_in	51	SENT_106	[p6l393t44r498b79],
7	.19	CD	NUMBER	.19	npadvmod	8	SENT_106	[p6l393t44r498b79],
8	Unfortunately	RB	O	unfortunately	advmod	6	SENT_106	[p6l508t48r746b89],
9	,	,	O	,	_	0	SENT_106	[p6l508t48r746b89],
10	the	DT	O	the	det	11	SENT_106	[p6l757t48r808b79],
11	drug	NN	O	drug	nsubjpass	14	SENT_106	[p6l819t48r897b89],
12	has	VBZ	O	have	aux	14	SENT_106	[p6l906t48r960b79],
13	been	VBN	O	be	auxpass	14	SENT_106	[p6l970t48r1049b79],
14	associated	VBN	O	associate	dep	51	SENT_106	[p6l21t98r193b129],
15	with	IN	O	with	_	0	SENT_106	[p6l203t98r279b129],
16	hepatotoxicity	NN	O	hepatotoxicity	prep_with	14	SENT_106	[p6l289t98r533b139],
17	at	IN	O	at	_	0	SENT_106	[p6l543t104r572b129],
18	the	DT	O	the	det	22	SENT_106	[p6l583t98r635b129],
19	600	CD	NUMBER	600	number	20	SENT_106	[p6l647t101r777b139],
20	—	CD	NUMBER	—	num	22	SENT_106	[p6l647t101r777b139],
21	mg	NN	O	mg	nn	22	SENT_106	[p6l647t101r777b139],
22	dosage	NN	O	dosage	prep_at	14	SENT_106	[p6l788t98r902b139],
23	and	CC	O	and	_	0	SENT_106	[p6l914t98r977b129],
24	will	MD	O	will	aux	27	SENT_106	[p6l987t98r1049b129],
25	probably	RB	O	probably	advmod	27	SENT_106	[p6l20t148r168b189],
26	be	VB	O	be	auxpass	27	SENT_106	[p6l176t148r215b179],
27	restricted	VBN	O	restrict	conj_and	14	SENT_106	[p6l226t148r384b179],
28	to	TO	O	to	_	0	SENT_106	[p6l394t154r426b179],
29	the	DT	O	the	det	32	SENT_106	[p6l437t148r489b179],
30	lower	JJR	O	lower	amod	32	SENT_106	[p6l499t148r592b179],
31	dose	NN	O	dose	nn	32	SENT_106	[p6l602t148r677b179],
32	ranges	NNS	O	range	prep_to	27	SENT_106	[p6l688t159r795b189],
33	of	IN	O	of	_	0	SENT_106	[p6l806t148r842b179],
34	100-200	CD	NUMBER	100-200	num	35	SENT_106	[p6l852t151r989b179],
35	mg	NN	O	mg	prep_of	32	SENT_106	[p6l997t159r1050b189],
36	per	IN	O	per	_	0	SENT_106	[p6l20t209r74b239],
37	day	NN	DURATION	day	prep_per	35	SENT_106	[p6l84t198r146b239],
38	,	,	O	,	_	0	SENT_106	[p6l84t198r146b239],
39	unless	IN	O	unless	mark	43	SENT_106	[p6l156t198r257b229],
40	they	PRP	O	they	nsubjpass	43	SENT_106	[p6l267t198r339b239],
41	too	RB	O	too	advmod	43	SENT_106	[p6l347t204r400b229],
42	are	VBP	O	be	auxpass	43	SENT_106	[p6l410t209r459b229],
43	found	VBN	O	find	advcl	51	SENT_106	[p6l468t198r566b229],
44	to	TO	O	to	aux	46	SENT_106	[p6l575t204r606b229],
45	be	VB	O	be	cop	46	SENT_106	[p6l616t198r654b229],
46	hepatotoXic	JJ	O	hepatotoxic	xcomp	43	SENT_106	[p6l663t194r895b239],
47	.19	CD	NUMBER	.19	tmod	46	SENT_106	[p6l663t194r895b239],
48	The	DT	O	the	det	50	SENT_106	[p6l905t198r965b229],
49	dose	NN	O	dose	nn	50	SENT_106	[p6l975t198r1049b229],
50	limitation	NN	O	limitation	nsubj	51	SENT_106	[p6l19t248r181b279],
51	restricts	VBZ	O	restrict	_	0	SENT_106	[p6l191t251r321b279],
52	the	DT	O	the	det	54	SENT_106	[p6l331t248r381b279],
53	potential	JJ	O	potential	amod	54	SENT_106	[p6l390t248r536b289],
54	use	NN	O	use	dobj	51	SENT_106	[p6l545t259r599b279],
55	of	IN	O	of	_	0	SENT_106	[p6l609t248r644b279],
56	asunaprevir	NN	O	asunaprevir	prep_of	54	SENT_106	[p6l649t251r842b289],
57	in	IN	O	in	_	0	SENT_106	[p6l851t251r883b278],
58	combination	NN	O	combination	prep_in	56	SENT_106	[p6l892t248r1047b279, p6l20t301r87b329],
59	with	IN	O	with	_	0	SENT_106	[p6l97t298r171b329],
60	PEG	NN	O	peg	prep_with	51	SENT_106	[p6l183t300r258b329],
61	and	CC	O	and	_	0	SENT_106	[p6l269t298r331b329],
62	RBV	NN	O	rbv	conj_and	60	SENT_106	[p6l342t300r425b333],
63	;	:	O	;	_	0	SENT_106	[p6l342t300r425b333],
64	however	RB	O	however	advmod	69	SENT_106	[p6l436t298r583b333],
65	,	,	O	,	_	0	SENT_106	[p6l436t298r583b333],
66	its	PRP$	O	its	poss	67	SENT_106	[p6l595t301r632b329],
67	efficacy	NN	O	efficacy	nsubj	69	SENT_106	[p6l644t298r769b339],
68	has	VBZ	O	have	aux	69	SENT_106	[p6l778t298r833b329],
69	led	VBN	O	lead	parataxis	51	SENT_106	[p6l843t298r894b329],
70	to	TO	O	to	_	0	SENT_106	[p6l904t304r936b329],
71	its	PRP$	O	its	poss	72	SENT_106	[p6l947t301r984b329],
72	use	NN	O	use	prep_to	69	SENT_106	[p6l996t309r1050b329],
73	in	IN	O	in	_	0	SENT_106	[p6l20t351r52b378],
74	multiple	JJ	O	multiple	amod	75	SENT_106	[p6l62t348r200b389],
75	IFN	NN	O	ifn	prep_in	69	SENT_106	[p6l211t348r354b379],
76	—	CD	NUMBER	—	num	79	SENT_106	[p6l211t348r354b379],
77	free	JJ	O	free	amod	79	SENT_106	[p6l211t348r354b379],
78	DAA	NN	O	daa	nn	79	SENT_106	[p6l364t350r449b379],
79	regimens	NNS	O	regimen	dep	75	SENT_106	[p6l459t351r618b389],
80	.	.	O	.	_	0	SENT_106	[p6l459t351r618b389],

1	SIMEPREVIR	NNP	PERSON	SIMEPREVIR	nn	5	SENT_107	[p6l1111t52r1321b79],
2	Simeprevir	NNP	PERSON	Simeprevir	nn	5	SENT_107	[p6l1111t100r1291b139],
3	(	NN	O	(	nn	5	SENT_107	[p6l1303t98r1476b135],
4	TMC435	NN	O	tmc435	nn	5	SENT_107	[p6l1303t98r1476b135],
5	)	NN	O	)	nsubj	9	SENT_107	[p6l1303t98r1476b135],
6	is	VBZ	O	be	cop	9	SENT_107	[p6l1488t101r1512b129],
7	an	DT	O	a	det	9	SENT_107	[p6l1523t109r1561b129],
8	NS3/4A	NN	O	ns3/4a	nn	9	SENT_107	[p6l1570t100r1703b130],
9	PI	NN	O	pi	_	0	SENT_107	[p6l1713t100r1756b129],
10	.	.	O	.	_	0	SENT_107	[p6l1713t100r1756b129],

1	Along	IN	O	along	_	0	SENT_108	[p6l1767t98r1869b139],
2	with	IN	O	with	prepc_along_with	10	SENT_108	[p6l1877t98r1951b129],
3	sofosbuvir	NN	O	sofosbuvir	pobj	10	SENT_108	[p6l1961t98r2138b133],
4	,	,	O	,	_	0	SENT_108	[p6l1961t98r2138b133],
5	it	PRP	O	it	nsubj	10	SENT_108	[p6l1110t151r1132b179],
6	is	VBZ	O	be	cop	10	SENT_108	[p6l1142t151r1166b179],
7	the	DT	O	the	det	10	SENT_108	[p6l1176t148r1227b179],
8	only	RB	O	only	advmod	9	SENT_108	[p6l1238t148r1311b189],
9	other	JJ	O	other	amod	10	SENT_108	[p6l1319t148r1407b179],
10	DAA	NNP	O	DAA	_	0	SENT_108	[p6l1417t150r1502b178],
11	that	WDT	O	that	nsubj	19	SENT_108	[p6l1511t148r1576b179],
12	has	VBZ	O	have	aux	13	SENT_108	[p6l1585t148r1639b179],
13	completed	VBN	O	complete	rcmod	10	SENT_108	[p6l1649t148r1822b189],
14	phase	NN	O	phase	dobj	13	SENT_108	[p6l1831t148r1925b189],
15	III	CD	NUMBER	iii	num	16	SENT_108	[p6l1935t150r1975b178],
16	trials	NNS	O	trial	dep	14	SENT_108	[p6l1986t148r2068b179],
17	and	CC	O	and	_	0	SENT_108	[p6l2079t148r2140b179],
18	is	VBZ	O	be	aux	19	SENT_108	[p6l1110t201r1134b229],
19	awaiting	VBG	O	await	conj_and	13	SENT_108	[p6l1144t201r1283b239],
20	FDA	NNP	ORGANIZATION	FDA	nn	21	SENT_108	[p6l1292t200r1370b228],
21	approval	NN	O	approval	dobj	19	SENT_108	[p6l1379t198r1521b239],
22	for	IN	O	for	_	0	SENT_108	[p6l1530t198r1576b229],
23	the	DT	O	the	det	24	SENT_108	[p6l1585t198r1636b229],
24	treatment	NN	O	treatment	prep_for	19	SENT_108	[p6l1646t204r1806b229],
25	of	IN	O	of	_	0	SENT_108	[p6l1815t198r1851b229],
26	HCV	NN	O	hcv	prep_of	24	SENT_108	[p6l1856t200r1944b229],
27	.	.	O	.	_	0	SENT_108	[p6l1856t200r1944b229],

1	In	IN	O	in	_	0	SENT_109	[p6l1955t201r1989b228],
2	a	DT	O	a	det	3	SENT_109	[p6l1999t209r2016b229],
3	phase	NN	O	phase	prep_in	5	SENT_109	[p6l2025t198r2118b239],
4	I	PRP	O	I	nsubj	5	SENT_109	[p6l2128t201r2139b228],
5	study	VBP	O	study	ccomp	11	SENT_109	[p6l1111t248r1205b289],
6	,	,	O	,	_	0	SENT_109	[p6l1111t248r1205b289],
7	once-a	JJ	O	once-a	amod	10	SENT_109	[p6l1217t248r1403b289],
8	—	NN	O	—	nn	10	SENT_109	[p6l1217t248r1403b289],
9	day	NN	DURATION	day	nn	10	SENT_109	[p6l1217t248r1403b289],
10	dosing	NN	O	dosing	nsubj	11	SENT_109	[p6l1413t248r1524b289],
11	achieved	VBD	O	achieve	_	0	SENT_109	[p6l1534t248r1680b279],
12	maximal	JJ	O	maximal	amod	14	SENT_109	[p6l1690t248r1836b279],
13	median	JJ	O	median	amod	14	SENT_109	[p6l1846t248r1971b279],
14	decreases	NNS	O	decrease	nsubj	23	SENT_109	[p6l1983t248r2138b279],
15	in	IN	O	in	_	0	SENT_109	[p6l1110t301r1143b328],
16	HCV	NN	O	hcv	nn	17	SENT_109	[p6l1154t300r1241b329],
17	RNA	NN	O	rna	prep_in	14	SENT_109	[p6l1252t300r1336b329],
18	of	IN	O	of	_	0	SENT_109	[p6l1347t298r1383b329],
19	3.9	CD	NUMBER	3.9	num	22	SENT_109	[p6l1390t298r1529b339],
20	log10	JJ	O	log10	amod	22	SENT_109	[p6l1390t298r1529b339],
21	international	JJ	O	international	amod	22	SENT_109	[p6l1541t298r1758b329],
22	units	NNS	O	unit	prep_of	17	SENT_109	[p6l1768t301r1851b329],
23	(	VBP	O	(	ccomp	11	SENT_109	[p6l1864t298r1949b335],
24	IU	NN	O	iu	dobj	23	SENT_109	[p6l1864t298r1949b335],
25	)	CD	NUMBER	)	num	24	SENT_109	[p6l1864t298r1949b335],
26	/	:	O	/	punct	27	SENT_109	[p6l1864t298r1949b335],
27	ml	NN	O	ml	dep	24	SENT_109	[p6l1951t298r1995b329],
28	and	CC	O	and	_	0	SENT_109	[p6l2006t298r2068b329],
29	was	VBD	O	be	auxpass	31	SENT_109	[p6l2077t309r2139b329],
30	well	RB	O	well	advmod	31	SENT_109	[p6l1109t348r1176b379],
31	tolerated	VBN	O	tolerate	ccomp	11	SENT_109	[p6l1185t344r1370b379],
32	.	.	O	.	_	0	SENT_109	[p6l1185t344r1370b379],

1	”	NN	O	”	_	0	SENT_110	[p6l1185t344r1370b379],

1	VOLUME	NN	O	volume	nn	3	SENT_111	[p6l1367t454r1475b475],
2	95	CD	NUMBER	95	num	3	SENT_111	[p6l1483t454r1510b475],
3	NUMBER	NN	O	number	_	0	SENT_111	[p6l1520t454r1628b475],
4	1	CD	NUMBER	1	number	5	SENT_111	[p6l1638t455r1645b475],
5	|	CD	NUMBER	|	dep	3	SENT_111	[p6l1659t452r1661b482],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_111	[p6l1670t454r1788b475],
7	2014	CD	DATE	2014	num	6	SENT_111	[p6l1796t454r1854b475],
8	|	CD	NUMBER	|	num	9	SENT_111	[p6l1863t452r1865b482],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_111	[p6l1874t454r2139b480],

1	A	DT	O	a	det	4	SENT_112	[p6l81t834r138b892],
2	phase	NN	O	phase	nn	4	SENT_112	[p6l156t830r348b913],
3	II	CD	NUMBER	ii	num	4	SENT_112	[p6l369t835r422b892],
4	study	NN	O	study	nsubj	15	SENT_112	[p6l444t830r627b914],
5	of	IN	O	of	_	0	SENT_112	[p6l644t830r717b893],
6	simeprevir	NN	O	simeprevir	prep_of	4	SENT_112	[p6l729t836r1091b913],
7	in	IN	O	in	_	0	SENT_112	[p6l1110t836r1175b892],
8	the	DT	O	the	det	9	SENT_112	[p6l1194t830r1299b893],
9	treatment	NN	O	treatment	prep_in	6	SENT_112	[p6l1318t842r1650b893],
10	of	IN	O	of	_	0	SENT_112	[p6l1669t830r1742b893],
11	HCV	NNP	O	HCV	nn	12	SENT_112	[p6l1753t834r1930b893],
12	genotype	NN	O	genotype	prep_of	9	SENT_112	[p6l1950t853r2139b914, p6l8t945r158b1017],
13	1	CD	NUMBER	1	num	14	SENT_112	[p6l189t940r214b995],
14	patients	NNS	O	patient	dep	4	SENT_112	[p6l243t939r520b1016],
15	demonstrated	VBD	O	demonstrate	_	0	SENT_112	[p6l545t933r1033b996],
16	low	JJ	O	low	amod	17	SENT_112	[p6l1055t933r1183b996],
17	rates	NNS	O	rate	dobj	15	SENT_112	[p6l1204t945r1366b996],
18	of	IN	O	of	_	0	SENT_112	[p6l1392t933r1467b996],
19	viral	JJ	O	viral	amod	20	SENT_112	[p6l1478t933r1639b996],
20	breakthrough	NN	O	breakthrough	prep_of	17	SENT_112	[p6l1659t933r2143b1017],
21	while	IN	O	while	prep	15	SENT_112	[p6l7t1036r195b1099],
22	on	IN	O	on	pcomp	21	SENT_112	[p6l218t1059r305b1099],
23	treatment	NN	O	treatment	pobj	22	SENT_112	[p6l327t1048r684b1108],
24	,	,	O	,	_	0	SENT_112	[p6l327t1048r684b1108],
25	and	CC	O	and	_	0	SENT_112	[p6l710t1036r837b1099],
26	eﬂicacy	NN	O	eﬂicacy	nsubjpass	28	SENT_112	[p6l859t1036r1120b1120],
27	was	VBD	O	be	auxpass	28	SENT_112	[p6l1137t1059r1264b1099],
28	improved	VBN	O	improve	conj_and	15	SENT_112	[p6l1288t1036r1621b1119],
29	with	IN	O	with	_	0	SENT_112	[p6l1641t1036r1796b1099],
30	the	DT	O	the	det	31	SENT_112	[p6l1818t1036r1925b1099],
31	coadministration	NN	O	coadministration	prep_with	28	SENT_112	[p6l1949t1036r2139b1099, p6l8t1145r455b1202],
32	of	IN	O	of	_	0	SENT_112	[p6l483t1139r559b1202],
33	PEG+RBV	NN	O	peg+rbv	prep_of	31	SENT_112	[p6l577t1131r1028b1202],
34	.	.	O	.	_	0	SENT_112	[p6l577t1131r1028b1202],

1	”	NN	O	”	nsubj	42	SENT_113	[p6l577t1131r1028b1202],
2	When	WRB	O	when	advmod	13	SENT_113	[p6l1058t1139r1276b1202],
3	given	VBN	O	give	prep	13	SENT_113	[p6l1302t1145r1493b1223],
4	alone	RB	O	alone	dep	3	SENT_113	[p6l1521t1139r1729b1211],
5	,	,	O	,	_	0	SENT_113	[p6l1521t1139r1729b1211],
6	simeprevir	NN	O	simeprevir	nn	7	SENT_113	[p6l1759t1145r2142b1222],
7	(	NN	O	(	appos	4	SENT_113	[p6l12t1243r163b1318],
8	100	CD	NUMBER	100	num	9	SENT_113	[p6l12t1243r163b1318],
9	mg	NN	O	mg	dep	7	SENT_113	[p6l181t1265r292b1326],
10	a	DT	DURATION	a	det	11	SENT_113	[p6l317t1265r352b1305],
11	day	NN	DURATION	day	dep	9	SENT_113	[p6l377t1242r525b1326],
12	)	CD	NUMBER	)	nsubj	13	SENT_113	[p6l377t1242r525b1326],
13	had	VBD	O	have	dep	1	SENT_113	[p6l554t1242r686b1305],
14	SVR24	NN	O	svr24	nn	15	SENT_113	[p6l712t1246r953b1305],
15	rates	NNS	O	rate	dobj	13	SENT_113	[p6l978t1254r1142b1305],
16	of	IN	O	of	_	0	SENT_113	[p6l1169t1242r1245b1305],
17	61-67	CD	PERCENT	61-67	num	18	SENT_113	[p6l1262t1247r1562b1314],
18	%	NN	PERCENT	%	prep_of	15	SENT_113	[p6l1262t1247r1562b1314],
19	,	,	O	,	_	0	SENT_113	[p6l1262t1247r1562b1314],
20	and	CC	O	and	_	0	SENT_113	[p6l1590t1242r1720b1305],
21	at	IN	O	at	advmod	25	SENT_113	[p6l1745t1254r1806b1305],
22	150	CD	NUMBER	150	num	23	SENT_113	[p6l1838t1249r1954b1305],
23	mg	NN	O	mg	pobj	21	SENT_113	[p6l1972t1265r2084b1326],
24	a	DT	DURATION	a	det	25	SENT_113	[p6l2108t1265r2143b1305],
25	day	NN	DURATION	day	tmod	28	SENT_113	[p6l9t1345r137b1429],
26	,	,	O	,	_	0	SENT_113	[p6l9t1345r137b1429],
27	it	PRP	O	it	nsubj	28	SENT_113	[p6l158t1351r203b1408],
28	had	VBD	O	have	dep	1	SENT_113	[p6l221t1345r347b1408],
29	SVR	NN	O	svr	nn	30	SENT_113	[p6l367t1349r519b1408],
30	rates	NNS	O	rate	dobj	28	SENT_113	[p6l536t1357r692b1408],
31	of	IN	O	of	_	0	SENT_113	[p6l713t1345r786b1408],
32	67-80	CD	PERCENT	67-80	num	33	SENT_113	[p6l797t1350r1083b1417],
33	%	NN	PERCENT	%	prep_of	30	SENT_113	[p6l797t1350r1083b1417],
34	,	,	O	,	_	0	SENT_113	[p6l797t1350r1083b1417],
35	as	IN	O	as	_	0	SENT_113	[p6l1105t1368r1168b1408],
36	compared	VBN	O	compare	prepc_as	28	SENT_113	[p6l1190t1345r1527b1428],
37	with	IN	O	with	pcomp	36	SENT_113	[p6l1544t1345r1695b1408],
38	23	CD	PERCENT	23	num	39	SENT_113	[p6l1715t1350r1856b1410],
39	%	NN	PERCENT	%	pobj	37	SENT_113	[p6l1715t1350r1856b1410],
40	in	IN	O	in	_	0	SENT_113	[p6l1878t1351r1943b1407],
41	those	DT	O	those	prep_in	39	SENT_113	[p6l1962t1345r2143b1408],
42	treated	VBN	O	treat	_	0	SENT_113	[p6l8t1447r246b1510],
43	with	IN	O	with	_	0	SENT_113	[p6l266t1447r419b1510],
44	PEG+RBV	NN	O	peg+rbv	prep_with	42	SENT_113	[p6l442t1451r811b1511],
45	alone	RB	O	alone	advmod	42	SENT_113	[p6l833t1439r1098b1510],
46	.	.	O	.	_	0	SENT_113	[p6l833t1439r1098b1510],

1	”	NN	O	”	nsubj	19	SENT_114	[p6l833t1439r1098b1510],
2	When	WRB	O	when	advmod	3	SENT_114	[p6l1119t1447r1330b1510],
3	administered	VBN	O	administer	dep	1	SENT_114	[p6l1354t1447r1806b1510],
4	as	IN	O	as	_	0	SENT_114	[p6l1828t1470r1892b1510],
5	part	NN	O	part	prep_as	3	SENT_114	[p6l1914t1459r2055b1530],
6	of	IN	O	of	_	0	SENT_114	[p6l2077t1447r2151b1510],
7	a	DT	O	a	det	9	SENT_114	[p6l9t1573r44b1613],
8	triple	JJ	O	triple	amod	9	SENT_114	[p6l65t1550r248b1633],
9	therapy	NN	O	therapy	prep_of	5	SENT_114	[p6l270t1550r534b1634],
10	in	IN	O	in	_	0	SENT_114	[p6l553t1556r620b1612],
11	a	DT	O	a	det	13	SENT_114	[p6l644t1573r679b1613],
12	dose-response	JJ	O	dose-response	amod	13	SENT_114	[p6l701t1550r1208b1633],
13	manner	NN	O	manner	prep_in	9	SENT_114	[p6l1231t1573r1513b1622],
14	,	,	O	,	_	0	SENT_114	[p6l1231t1573r1513b1622],
15	SVR24	NN	O	svr24	nn	16	SENT_114	[p6l1538t1554r1774b1613],
16	rates	NNS	O	rate	appos	13	SENT_114	[p6l1797t1562r1956b1613],
17	were	VBD	O	be	cop	19	SENT_114	[p6l1978t1573r2140b1613],
18	65	CD	PERCENT	65	num	19	SENT_114	[p6l9t1659r151b1717],
19	%	NN	PERCENT	%	_	0	SENT_114	[p6l9t1659r151b1717],
20	in	IN	O	in	_	0	SENT_114	[p6l175t1659r241b1715],
21	the	DT	O	the	det	23	SENT_114	[p6l263t1653r369b1716],
22	PEG+RBV	NN	O	peg+rbv	nn	23	SENT_114	[p6l392t1657r761b1716],
23	group	NN	O	group	prep_in	19	SENT_114	[p6l782t1675r998b1737],
24	,	,	O	,	_	0	SENT_114	[p6l782t1675r998b1737],
25	75-82	CD	PERCENT	75-82	num	26	SENT_114	[p6l1024t1658r1293b1718],
26	%	NN	PERCENT	%	conj_and	19	SENT_114	[p6l1024t1658r1293b1718],
27	in	IN	O	in	_	0	SENT_114	[p6l1317t1659r1383b1715],
28	the	DT	O	the	det	30	SENT_114	[p6l1404t1653r1511b1716],
29	75-mg	JJ	O	75-mg	amod	30	SENT_114	[p6l1535t1661r1755b1737],
30	simeprevir	NN	O	simeprevir	prep_in	26	SENT_114	[p6l1776t1659r2143b1736],
31	plus	CC	O	plus	prep	30	SENT_114	[p6l7t1756r148b1839],
32	PEG+RBV	NN	O	peg+rbv	nn	33	SENT_114	[p6l173t1760r546b1819],
33	group	NN	O	group	dep	31	SENT_114	[p6l569t1778r788b1840],
34	,	,	O	,	_	0	SENT_114	[p6l569t1778r788b1840],
35	and	CC	O	and	_	0	SENT_114	[p6l814t1756r941b1819],
36	81-86	CD	PERCENT	81-86	num	37	SENT_114	[p6l965t1761r1237b1821],
37	%	NN	PERCENT	%	conj_and	19	SENT_114	[p6l965t1761r1237b1821],
38	in	IN	O	in	_	0	SENT_114	[p6l1262t1762r1329b1818],
39	the	DT	O	the	det	41	SENT_114	[p6l1351t1756r1459b1819],
40	150-mg	JJ	O	150-mg	amod	41	SENT_114	[p6l1489t1763r1749b1840],
41	simeprevir	NN	O	simeprevir	prep_in	37	SENT_114	[p6l1771t1762r2143b1839],
42	plus	CC	O	plus	prep	41	SENT_114	[p6l7t1859r147b1942],
43	PEG+RBV	NN	O	peg+rbv	nn	44	SENT_114	[p6l170t1863r538b1922],
44	group	NN	O	group	dep	42	SENT_114	[p6l559t1851r841b1943],
45	.	.	O	.	_	0	SENT_114	[p6l559t1851r841b1943],

1	”	NN	O	”	_	0	SENT_115	[p6l559t1851r841b1943],

1	Jacobson	NNP	PERSON	Jacobson	nsubj	4	SENT_116	[p6l82t1962r418b2038],
2	et	FW	O	et	nn	3	SENT_116	[p6l452t1973r516b2025],
3	al.	FW	O	al.	dep	1	SENT_116	[p6l546t1962r629b2025],
4	conducted	VBN	O	conduct	_	0	SENT_116	[p6l666t1962r1058b2025],
5	the	DT	O	the	det	6	SENT_116	[p6l1090t1962r1205b2025],
6	phase	NN	O	phase	dobj	4	SENT_116	[p6l1237t1962r1448b2045],
7	III	CD	NUMBER	iii	dep	6	SENT_116	[p6l1483t1967r1596b2034],
8	,	,	O	,	_	0	SENT_116	[p6l1483t1967r1596b2034],
9	double	JJ	O	double	advmod	6	SENT_116	[p6l1632t1962r2141b2034],
10	—	RB	O	—	advmod	11	SENT_116	[p6l1632t1962r2141b2034],
11	blind	JJ	O	blind	amod	6	SENT_116	[p6l1632t1962r2141b2034],
12	,	,	O	,	_	0	SENT_116	[p6l1632t1962r2141b2034],
13	multicenter	JJ	O	multicenter	amod	6	SENT_116	[p6l8t2065r455b2137],
14	,	,	O	,	_	0	SENT_116	[p6l8t2065r455b2137],
15	placebo-controlled	JJ	O	placebo-controlled	amod	17	SENT_116	[p6l487t2065r1195b2148],
16	QUEST-1	NN	MISC	quest-1	nn	17	SENT_116	[p6l1226t2068r1574b2141],
17	trial	NN	O	trial	appos	6	SENT_116	[p6l1611t2065r1785b2137],
18	,	,	O	,	_	0	SENT_116	[p6l1611t2065r1785b2137],
19	in	IN	O	in	_	0	SENT_116	[p6l1818t2071r1888b2127],
20	which	WDT	O	which	rel	28	SENT_116	[p6l1917t2065r2142b2128],
21	treatment-naive	JJ	O	treatment-naive	amod	26	SENT_116	[p6l8t2174r635b2240],
22	,	,	O	,	_	0	SENT_116	[p6l8t2174r635b2240],
23	genotype	NN	O	genotype	dep	26	SENT_116	[p6l671t2180r1013b2252],
24	1	CD	NUMBER	1	num	26	SENT_116	[p6l1054t2175r1079b2230],
25	HCV	NN	O	hcv	nn	26	SENT_116	[p6l1120t2172r1310b2231],
26	patients	NNS	O	patient	nsubjpass	28	SENT_116	[p6l1342t2174r1641b2251],
27	were	VBD	O	be	auxpass	28	SENT_116	[p6l1674t2191r1847b2231],
28	treated	VBN	O	treat	rcmod	17	SENT_116	[p6l1881t2168r2144b2231],
29	with	IN	O	with	_	0	SENT_116	[p6l7t2271r165b2334],
30	simeprevir	NN	O	simeprevir	nn	31	SENT_116	[p6l191t2277r574b2354],
31	(	NN	O	(	prep_with	28	SENT_116	[p6l602t2272r753b2347],
32	150	CD	NUMBER	150	num	33	SENT_116	[p6l602t2272r753b2347],
33	mg	NN	O	mg	dep	31	SENT_116	[p6l772t2294r883b2355],
34	a	DT	DURATION	a	det	35	SENT_116	[p6l908t2294r942b2334],
35	day	NN	DURATION	day	dep	33	SENT_116	[p6l968t2271r1116b2355],
36	)	CD	NUMBER	)	dep	33	SENT_116	[p6l968t2271r1116b2355],
37	or	CC	O	or	_	0	SENT_116	[p6l1146t2294r1220b2334],
38	placebo	NN	O	placebo	conj_or	31	SENT_116	[p6l1244t2271r1517b2354],
39	for	IN	O	for	_	0	SENT_116	[p6l1544t2271r1645b2334],
40	12	CD	DURATION	12	num	41	SENT_116	[p6l1676t2278r1749b2333],
41	weeks	NNS	NUMBER	week	prep_for	38	SENT_116	[p6l1774t2271r1986b2334],
42	and	CC	O	and	_	0	SENT_116	[p6l2013t2271r2143b2334],
43	PEG+RBV	NN	O	peg+rbv	dobj	4	SENT_116	[p6l9t2378r400b2437],
44	for	IN	O	for	_	0	SENT_116	[p6l429t2374r533b2437],
45	24	CD	NUMBER	24	nn	48	SENT_116	[p6l562t2381r645b2436],
46	or	CC	O	or	_	0	SENT_116	[p6l676t2397r751b2437],
47	48	CD	DURATION	48	nn	48	SENT_116	[p6l779t2381r861b2437],
48	weeks	NNS	NUMBER	week	prep_for	43	SENT_116	[p6l891t2374r1109b2437],
49	in	IN	O	in	_	0	SENT_116	[p6l1140t2380r1210b2436],
50	a	DT	O	a	det	52	SENT_116	[p6l1240t2397r1275b2437],
51	response-guided	JJ	O	response-guided	amod	52	SENT_116	[p6l1305t2374r1919b2458],
52	manner	NN	O	manner	prep_in	48	SENT_116	[p6l1948t2397r2138b2437, p6l8t2500r138b2540],
53	.	.	O	.	_	0	SENT_116	[p6l1948t2397r2138b2437, p6l8t2500r138b2540],

1	Response-guided	JJ	O	response-guided	amod	2	SENT_117	[p6l168t2477r789b2561],
2	treatment	NN	O	treatment	nsubj	3	SENT_117	[p6l813t2489r1166b2540],
3	meant	VBD	O	mean	_	0	SENT_117	[p6l1190t2489r1414b2540],
4	that	IN	O	that	complm	10	SENT_117	[p6l1437t2477r1578b2540],
5	the	DT	O	the	det	6	SENT_117	[p6l1601t2477r1712b2540],
6	duration	NN	O	duration	nsubj	51	SENT_117	[p6l1739t2477r2048b2540],
7	of	IN	O	of	_	0	SENT_117	[p6l2075t2477r2151b2540],
8	treatment	NN	O	treatment	prep_of	6	SENT_117	[p6l8t2592r363b2643],
9	was	VBD	O	be	auxpass	10	SENT_117	[p6l386t2603r518b2643],
10	determined	VBN	O	determine	ccomp	3	SENT_117	[p6l546t2580r967b2643],
11	by	IN	O	by	_	0	SENT_117	[p6l990t2580r1077b2664],
12	HCV	NN	O	hcv	nn	14	SENT_117	[p6l1101t2584r1287b2643],
13	RNA	NN	O	rna	nn	14	SENT_117	[p6l1313t2584r1490b2643],
14	levels	NNS	O	level	dep	15	SENT_117	[p6l1515t2580r1712b2643],
15	<	JJR	O	<	agent	10	SENT_117	[p6l1742t2598r1781b2642],
16	25	CD	NUMBER	25	num	17	SENT_117	[p6l1811t2587r1890b2643],
17	IU	NN	O	iu	dep	15	SENT_117	[p6l1920t2584r2041b2646],
18	/	:	O	/	punct	40	SENT_117	[p6l1920t2584r2041b2646],
19	ml	NN	O	ml	dep	30	SENT_117	[p6l2048t2580r2142b2642],
20	(	CD	NUMBER	(	num	19	SENT_117	[p6l12t2683r251b2759],
21	Roche	NNP	O	Roche	nn	25	SENT_117	[p6l12t2683r251b2759],
22	COBAS	NNP	O	COBAS	nn	25	SENT_117	[p6l274t2687r537b2746],
23	TaqMan	NNP	O	TaqMan	nn	25	SENT_117	[p6l560t2686r842b2766],
24	HCV	NNP	O	HCV	nn	25	SENT_117	[p6l864t2687r1042b2746],
25	Test	NNP	O	Test	npadvmod	30	SENT_117	[p6l1063t2686r1217b2755],
26	,	,	O	,	_	0	SENT_117	[p6l1063t2686r1217b2755],
27	V2	NN	O	v2	appos	25	SENT_117	[p6l1238t2690r1397b2755],
28	.0	CD	NUMBER	.0	num	27	SENT_117	[p6l1238t2690r1397b2755],
29	,	,	O	,	_	0	SENT_117	[p6l1238t2690r1397b2755],
30	for	IN	O	for	dep	40	SENT_117	[p6l1421t2683r1518b2746],
31	use	NN	O	use	pobj	30	SENT_117	[p6l1538t2706r1649b2746],
32	with	IN	O	with	_	0	SENT_117	[p6l1669t2683r1821b2746],
33	the	DT	O	the	det	38	SENT_117	[p6l1842t2683r1948b2746],
34	High	JJ	O	high	amod	38	SENT_117	[p6l1970t2683r2141b2767],
35	Pure	NNP	O	Pure	nn	38	SENT_117	[p6l9t2791r170b2849],
36	System	NNP	O	System	nn	38	SENT_117	[p6l197t2790r442b2870],
37	(	NNP	O	(	nn	38	SENT_117	[p6l470t2786r716b2862],
38	Roche	NNP	ORGANIZATION	Roche	prep_with	31	SENT_117	[p6l470t2786r716b2862],
39	Molecular	JJ	ORGANIZATION	molecular	amod	40	SENT_117	[p6l742t2786r1102b2849],
40	Systems	NNPS	ORGANIZATION	Systems	dep	17	SENT_117	[p6l1126t2790r1423b2870],
41	,	,	O	,	_	0	SENT_117	[p6l1126t2790r1423b2870],
42	Pleasanton	NNP	LOCATION	Pleasanton	appos	40	SENT_117	[p6l1451t2786r1853b2858],
43	,	,	O	,	_	0	SENT_117	[p6l1451t2786r1853b2858],
44	CA	NNP	O	CA	nn	46	SENT_117	[p6l1881t2787r2053b2863],
45	)	NNP	O	)	nn	46	SENT_117	[p6l1881t2787r2053b2863],
46	)	NN	O	)	appos	40	SENT_117	[p6l1881t2787r2053b2863],
47	at	IN	O	at	_	0	SENT_117	[p6l2083t2798r2143b2849],
48	week	NN	DURATION	week	prep_at	10	SENT_117	[p6l7t2888r192b2951],
49	4	CD	NUMBER	4	num	48	SENT_117	[p6l215t2895r254b2950],
50	and	CC	O	and	_	0	SENT_117	[p6l283t2888r415b2951],
51	undetectable	JJ	O	undetectable	conj_and	10	SENT_117	[p6l441t2888r909b2951],
52	at	IN	O	at	_	0	SENT_117	[p6l937t2900r999b2951],
53	week	NN	DURATION	week	prep_at	51	SENT_117	[p6l1024t2888r1209b2951],
54	12	CD	NUMBER	12	num	53	SENT_117	[p6l1240t2895r1334b2951],
55	.	.	O	.	_	0	SENT_117	[p6l1240t2895r1334b2951],

1	Those	DT	O	those	_	0	SENT_118	[p6l1365t2888r1576b2951],
2	who	WP	O	who	nsubj	3	SENT_118	[p6l1602t2888r1755b2951],
3	met	VBD	O	meet	dep	1	SENT_118	[p6l1784t2900r1921b2951],
4	criteria	NNS	O	criterion	dobj	3	SENT_118	[p6l1948t2894r2138b2951, p6l9t2997r102b3054],

1	for	IN	O	for	dep	4	SENT_119	[p6l126t2991r226b3054],
2	eRVR	NN	O	ervr	nsubjpass	4	SENT_119	[p6l250t2996r453b3054],
3	were	VBD	O	be	auxpass	4	SENT_119	[p6l473t3014r638b3054],
4	qualiﬁed	VBN	O	qualiﬁed	_	0	SENT_119	[p6l664t2991r971b3074],
5	to	TO	O	to	aux	6	SENT_119	[p6l994t3003r1061b3054],
6	complete	VB	O	complete	xcomp	4	SENT_119	[p6l1088t2991r1407b3074],
7	therapy	NN	O	therapy	dobj	6	SENT_119	[p6l1431t2991r1701b3075],
8	at	IN	O	at	_	0	SENT_119	[p6l1723t3003r1784b3054],
9	24	CD	DURATION	24	num	10	SENT_119	[p6l1808t2998r1888b3053],
10	weeks	NNS	NUMBER	week	prep_at	6	SENT_119	[p6l1911t2991r2139b3054],
11	.	.	O	.	_	0	SENT_119	[p6l1911t2991r2139b3054],

1	Those	DT	O	those	_	0	SENT_120	[p6l8t3094r219b3157],
2	who	WP	O	who	nsubj	3	SENT_120	[p6l244t3094r397b3157],
3	did	VBD	O	do	rcmod	1	SENT_120	[p6l425t3094r542b3157],
4	not	RB	O	not	neg	3	SENT_120	[p6l568t3106r687b3157],
5	had	VBN	O	have	partmod	1	SENT_120	[p6l712t3094r845b3157],
6	to	TO	O	to	aux	7	SENT_120	[p6l869t3106r938b3157],
7	complete	VB	O	complete	xcomp	5	SENT_120	[p6l967t3094r1295b3177],
8	48	CD	DURATION	48	num	9	SENT_120	[p6l1321t3101r1403b3157],
9	weeks	NNS	NUMBER	week	dobj	7	SENT_120	[p6l1429t3094r1644b3157],
10	of	IN	O	of	_	0	SENT_120	[p6l1672t3094r1749b3157],
11	treatment	NN	O	treatment	prep_of	9	SENT_120	[p6l1765t3106r2139b3157],
12	.	.	O	.	_	0	SENT_120	[p6l1765t3106r2139b3157],

1	RVR	NN	O	rvr	nsubjpass	3	SENT_121	[p6l9t3202r175b3260],
2	was	VBD	O	be	auxpass	3	SENT_121	[p6l196t3220r326b3260],
3	seen	VBN	O	see	_	0	SENT_121	[p6l353t3220r507b3260],
4	in	IN	O	in	_	0	SENT_121	[p6l533t3203r601b3259],
5	80	CD	PERCENT	80	num	6	SENT_121	[p6l628t3202r773b3261],
6	%	NN	PERCENT	%	prep_in	3	SENT_121	[p6l628t3202r773b3261],
7	of	IN	O	of	_	0	SENT_121	[p6l802t3197r877b3260],
8	patients	NNS	O	patient	prep_of	6	SENT_121	[p6l892t3203r1173b3280],
9	treated	VBN	O	treat	partmod	8	SENT_121	[p6l1198t3197r1447b3260],
10	with	IN	O	with	_	0	SENT_121	[p6l1470t3197r1628b3260],
11	simeprevir	NN	O	simeprevir	prep_with	9	SENT_121	[p6l1654t3203r2049b3280],
12	,	,	O	,	_	0	SENT_121	[p6l1654t3203r2049b3280],
13	of	IN	O	of	_	0	SENT_121	[p6l2077t3197r2153b3260],
14	whom	WP	O	whom	rel	17	SENT_121	[p6l7t3300r234b3363],
15	91	CD	PERCENT	91	num	16	SENT_121	[p6l262t3305r410b3365],
16	%	NN	PERCENT	%	nsubj	17	SENT_121	[p6l262t3305r410b3365],
17	achieved	VBD	O	achieve	rcmod	11	SENT_121	[p6l439t3300r758b3363],
18	SVR12	NN	O	svr12	dobj	17	SENT_121	[p6l784t3304r1049b3363],
19	.	.	O	.	_	0	SENT_121	[p6l784t3304r1049b3363],

1	In	IN	O	in	_	0	SENT_122	[p6l1080t3305r1154b3362],
2	the	DT	O	the	det	4	SENT_122	[p6l1180t3300r1292b3363],
3	placebo	NN	O	placebo	nn	4	SENT_122	[p6l1318t3300r1596b3383],
4	arm	NN	O	arm	prep_in	8	SENT_122	[p6l1626t3323r1788b3372],
5	,	,	O	,	_	0	SENT_122	[p6l1626t3323r1788b3372],
6	RVR	NN	O	rvr	nsubjpass	8	SENT_122	[p6l1817t3305r1986b3363],
7	was	VBD	O	be	auxpass	8	SENT_122	[p6l2009t3323r2141b3363],
8	achieved	VBN	O	achieve	_	0	SENT_122	[p6l9t3403r323b3466],
9	in	IN	O	in	_	0	SENT_122	[p6l348t3409r417b3465],
10	12	CD	PERCENT	12	num	11	SENT_122	[p6l450t3408r590b3468],
11	%	NN	PERCENT	%	prep_in	8	SENT_122	[p6l450t3408r590b3468],
12	of	IN	O	of	_	0	SENT_122	[p6l619t3403r695b3466],
13	patients	NNS	O	patient	prep_of	11	SENT_122	[p6l710t3409r1012b3486],
14	.	.	O	.	_	0	SENT_122	[p6l710t3409r1012b3486],

1	SVR12	NN	O	svr12	nsubjpass	3	SENT_123	[p6l1042t3407r1283b3466],
2	was	VBD	O	be	auxpass	3	SENT_123	[p6l1309t3426r1439b3466],
3	achieved	VBN	O	achieve	_	0	SENT_123	[p6l1467t3403r1781b3466],
4	in	IN	O	in	_	0	SENT_123	[p6l1806t3409r1874b3465],
5	80	CD	PERCENT	80	num	6	SENT_123	[p6l1902t3408r2047b3468],
6	%	NN	PERCENT	%	prep_in	3	SENT_123	[p6l1902t3408r2047b3468],
7	of	IN	O	of	_	0	SENT_123	[p6l2076t3403r2152b3466],
8	patients	NNS	O	patient	prep_of	6	SENT_123	[p6l7t3512r297b3589],
9	receiving	VBG	O	receive	partmod	8	SENT_123	[p6l327t3512r664b3590],
10	simeprevir	NN	O	simeprevir	dobj	9	SENT_123	[p6l692t3512r1086b3589],
11	and	CC	O	and	_	0	SENT_123	[p6l1115t3506r1248b3569],
12	50	CD	PERCENT	50	num	13	SENT_123	[p6l1278t3511r1426b3570],
13	%	NN	PERCENT	%	prep_in	3	SENT_123	[p6l1278t3511r1426b3570],
14	of	IN	O	of	_	0	SENT_123	[p6l1457t3506r1535b3569],
15	those	DT	O	those	det	17	SENT_123	[p6l1553t3506r1748b3569],
16	given	VBN	O	give	amod	17	SENT_123	[p6l1778t3512r1973b3590],
17	placebo	NN	O	placebo	prep_of	13	SENT_123	[p6l2001t3506r2140b3589, p6l9t3609r189b3672],
18	.	.	O	.	_	0	SENT_123	[p6l2001t3506r2140b3589, p6l9t3609r189b3672],

1	Virologic	JJ	O	virologic	amod	2	SENT_124	[p6l217t3609r551b3693],
2	relapse	NN	O	relapse	nsubjpass	4	SENT_124	[p6l577t3609r825b3692],
3	was	VBD	O	be	auxpass	4	SENT_124	[p6l850t3632r980b3672],
4	seen	VBN	O	see	_	0	SENT_124	[p6l1007t3632r1163b3672],
5	in	IN	O	in	_	0	SENT_124	[p6l1189t3615r1257b3671],
6	9	CD	PERCENT	9	num	7	SENT_124	[p6l1284t3614r1387b3674],
7	%	NN	PERCENT	%	prep_in	4	SENT_124	[p6l1284t3614r1387b3674],
8	of	IN	O	of	_	0	SENT_124	[p6l1416t3609r1492b3672],
9	patients	NNS	O	patient	prep_of	7	SENT_124	[p6l1507t3615r1790b3692],
10	receiving	VBG	O	receive	partmod	9	SENT_124	[p6l1817t3615r2145b3693],
11	simeprevir	NN	O	simeprevir	dobj	10	SENT_124	[p6l9t3717r382b3794],
12	and	CC	O	and	_	0	SENT_124	[p6l404t3711r531b3774],
13	21	CD	PERCENT	21	number	14	SENT_124	[p6l553t3717r696b3776],
14	%	NN	PERCENT	%	amod	16	SENT_124	[p6l553t3717r696b3776],
15	given	VBN	O	give	amod	16	SENT_124	[p6l720t3717r906b3795],
16	placebo	NN	O	placebo	prep_in	4	SENT_124	[p6l927t3703r1276b3794],
17	.	.	O	.	_	0	SENT_124	[p6l927t3703r1276b3794],

1	“	NN	O	“	nn	2	SENT_125	[p6l927t3703r1276b3794],
2	A	NN	O	a	nsubj	3	SENT_125	[p6l1297t3715r1353b3773],
3	prespeciﬁed	VBD	O	prespeciﬁed	_	0	SENT_125	[p6l1374t3711r1794b3794],
4	subgroup	NN	O	subgroup	nn	5	SENT_125	[p6l1817t3711r2141b3795],
5	analysis	NN	O	analysis	nsubj	12	SENT_125	[p7l9t16r283b100],
6	comparing	VBG	O	compare	partmod	5	SENT_125	[p7l310t22r692b100],
7	simeprevir	NN	O	simeprevir	dobj	6	SENT_125	[p7l717t22r1096b99],
8	with	IN	O	with	_	0	SENT_125	[p7l1118t16r1275b79],
9	the	DT	O	the	det	11	SENT_125	[p7l1299t16r1408b79],
10	control	NN	O	control	nn	11	SENT_125	[p7l1434t16r1687b79],
11	arm	NN	O	arm	prep_with	6	SENT_125	[p7l1712t39r1850b79],
12	showed	VBD	O	show	ccomp	3	SENT_125	[p7l1877t16r2141b79],
13	superiority	NN	O	superiority	nsubj	17	SENT_125	[p7l10t125r418b203],
14	in	IN	O	in	_	0	SENT_125	[p7l444t125r514b181],
15	all	DT	O	all	det	16	SENT_125	[p7l544t119r629b182],
16	subgroups	NNS	O	subgroup	prep_in	13	SENT_125	[p7l659t119r1037b203],
17	(	VBP	O	(	ccomp	12	SENT_125	[p7l1070t119r1397b195],
18	baseline	NN	O	baseline	nn	20	SENT_125	[p7l1070t119r1397b195],
19	HCV	NN	O	hcv	nn	20	SENT_125	[p7l1427t123r1615b182],
20	RNA	NN	O	rna	nsubj	31	SENT_125	[p7l1644t123r1843b191],
21	,	,	O	,	_	0	SENT_125	[p7l1644t123r1843b191],
22	gender	NN	O	gender	nsubj	31	SENT_125	[p7l1874t119r2140b203],
23	,	,	O	,	_	0	SENT_125	[p7l1874t119r2140b203],
24	genotype	NN	O	genotype	conj_and	20	SENT_125	[p7l8t234r348b306],
25	,	,	O	,	_	0	SENT_125	[p7l8t234r348b306],
26	IL28B	NN	O	il28b	nn	27	SENT_125	[p7l372t227r582b285],
27	allele	NN	O	allele	conj_and	20	SENT_125	[p7l607t222r805b294],
28	,	,	O	,	_	0	SENT_125	[p7l607t222r805b294],
29	and	CC	O	and	_	0	SENT_125	[p7l832t222r961b285],
30	METAVIR	NN	O	metavir	conj_and	20	SENT_125	[p7l983t225r1358b285],
31	score	VBP	NUMBER	score	ccomp	17	SENT_125	[p7l1380t223r1609b299],
32	)	NN	O	)	dobj	31	SENT_125	[p7l1380t223r1609b299],
33	.	.	O	.	_	0	SENT_125	[p7l1380t223r1609b299],

1	The	DT	O	the	det	3	SENT_126	[p7l82t325r204b388],
2	QUEST-2	NN	MISC	quest-2	nn	3	SENT_126	[p7l225t328r548b401],
3	trial	NN	O	trial	nsubj	6	SENT_126	[p7l568t325r705b388],
4	was	VBD	O	be	cop	6	SENT_126	[p7l722t348r845b388],
5	a	DT	O	a	det	6	SENT_126	[p7l866t348r900b388],
6	phase	NN	O	phase	_	0	SENT_126	[p7l917t325r1107b408],
7	III	CD	NUMBER	iii	num	6	SENT_126	[p7l1128t330r1227b397],
8	,	,	O	,	_	0	SENT_126	[p7l1128t330r1227b397],
9	randomized	VBN	O	randomize	partmod	6	SENT_126	[p7l1248t325r1669b397],
10	,	,	O	,	_	0	SENT_126	[p7l1248t325r1669b397],
11	double-blind	JJ	O	double-blind	amod	14	SENT_126	[p7l1691t325r2140b397],
12	,	,	O	,	_	0	SENT_126	[p7l1691t325r2140b397],
13	placebo-controlled	JJ	O	placebo-controlled	amod	14	SENT_126	[p7l7t428r660b511],
14	study	NN	O	study	appos	6	SENT_126	[p7l683t428r870b512],
15	that	WDT	O	that	nsubj	16	SENT_126	[p7l888t428r1022b491],
16	evaluated	VBD	O	evaluate	rcmod	14	SENT_126	[p7l1045t428r1370b491],
17	the	DT	O	the	det	18	SENT_126	[p7l1391t428r1498b491],
18	efﬁcacy	NN	O	efﬁcacy	dobj	16	SENT_126	[p7l1521t428r1780b512],
19	and	CC	O	and	_	0	SENT_126	[p7l1799t428r1926b491],
20	safety	NN	O	safety	conj_and	18	SENT_126	[p7l1949t428r2146b512],
21	of	IN	O	of	_	0	SENT_126	[p7l9t531r83b594],
22	simeprevir	NN	O	simeprevir	nn	23	SENT_126	[p7l95t537r461b614],
23	(	NN	O	(	prep_of	18	SENT_126	[p7l485t532r630b607],
24	150	CD	NUMBER	150	num	25	SENT_126	[p7l485t532r630b607],
25	mg	NN	O	mg	dep	23	SENT_126	[p7l646t554r755b615],
26	a	DT	DURATION	a	det	27	SENT_126	[p7l774t554r809b594],
27	day	NN	DURATION	day	dep	25	SENT_126	[p7l829t531r972b615],
28	)	CD	NUMBER	)	dep	25	SENT_126	[p7l829t531r972b615],
29	or	CC	O	or	_	0	SENT_126	[p7l998t554r1069b594],
30	placebo	NN	O	placebo	prep_of	18	SENT_126	[p7l1088t531r1350b614],
31	for	IN	O	for	_	0	SENT_126	[p7l1372t531r1469b594],
32	12	CD	DURATION	12	num	33	SENT_126	[p7l1496t538r1566b593],
33	weeks	NNS	NUMBER	week	prep_for	30	SENT_126	[p7l1587t531r1791b594],
34	in	IN	O	in	_	0	SENT_126	[p7l1813t537r1879b593],
35	combination	NN	O	combination	prep_in	33	SENT_126	[p7l1901t531r2139b594, p7l8t639r231b697],
36	With	IN	O	with	_	0	SENT_126	[p7l252t633r407b697],
37	PEG+RBV	NN	O	peg+rbv	prep_with	16	SENT_126	[p7l431t637r804b697],
38	for	IN	O	for	_	0	SENT_126	[p7l826t633r925b697],
39	24	CD	NUMBER	24	nn	42	SENT_126	[p7l947t640r1027b696],
40	or	CC	O	or	_	0	SENT_126	[p7l1051t656r1123b697],
41	48	CD	DURATION	48	conj_or	39	SENT_126	[p7l1144t640r1223b697],
42	weeks	NNS	NUMBER	week	prep_for	16	SENT_126	[p7l1246t633r1453b697],
43	in	IN	O	in	_	0	SENT_126	[p7l1477t639r1544b696],
44	treatment-naive	JJ	O	treatment-naive	prep_in	42	SENT_126	[p7l1566t639r2140b705],
45	,	,	O	,	_	0	SENT_126	[p7l1566t639r2140b705],
46	genotype	NN	O	genotype	appos	6	SENT_126	[p7l8t749r320b821],
47	1	CD	NUMBER	1	num	49	SENT_126	[p7l349t744r373b799],
48	HCV	NN	O	hcv	nn	49	SENT_126	[p7l402t741r581b800],
49	patients	NNS	O	patient	dep	46	SENT_126	[p7l601t743r887b820],
50	.	.	O	.	_	0	SENT_126	[p7l601t743r887b820],

1	In	IN	O	in	_	0	SENT_127	[p7l913t742r984b799],
2	the	DT	O	the	det	4	SENT_127	[p7l1004t737r1110b800],
3	simeprevir	JJ	O	simeprevir	amod	4	SENT_127	[p7l1133t743r1500b820],
4	group	NN	O	group	prep_in	10	SENT_127	[p7l1520t759r1736b821],
5	,	,	O	,	_	0	SENT_127	[p7l1520t759r1736b821],
6	duration	NN	O	duration	nsubj	10	SENT_127	[p7l1761t737r2055b800],
7	of	IN	O	of	_	0	SENT_127	[p7l2077t737r2151b800],
8	treatment	NN	O	treatment	prep_of	6	SENT_127	[p7l8t852r352b903],
9	was	VBD	O	be	cop	10	SENT_127	[p7l372t863r501b903],
10	response	NN	O	response	_	0	SENT_127	[p7l525t862r832b923],
11	guided	VBN	O	guide	partmod	10	SENT_127	[p7l856t840r1112b924],
12	.	.	O	.	_	0	SENT_127	[p7l856t840r1112b924],

1	SVR12	NN	O	svr12	nsubj	4	SENT_128	[p7l1140t844r1378b903],
2	was	VBD	O	be	cop	4	SENT_128	[p7l1401t863r1530b903],
3	81	CD	PERCENT	81	num	4	SENT_128	[p7l1556t846r1699b904],
4	%	NN	PERCENT	%	_	0	SENT_128	[p7l1556t846r1699b904],
5	in	IN	O	in	_	0	SENT_128	[p7l1725t846r1793b902],
6	the	DT	O	the	det	8	SENT_128	[p7l1816t840r1924b903],
7	simeprevir	NN	O	simeprevir	nn	8	SENT_128	[p7l1950t846r2139b903, p7l7t949r212b1026],
8	arm	NN	O	arm	prep_in	4	SENT_128	[p7l232t966r366b1006],
9	and	CC	O	and	_	0	SENT_128	[p7l387t943r512b1006],
10	50	CD	PERCENT	50	num	11	SENT_128	[p7l533t948r673b1008],
11	%	NN	PERCENT	%	conj_and	4	SENT_128	[p7l533t948r673b1008],
12	in	IN	O	in	_	0	SENT_128	[p7l695t949r761b1005],
13	the	DT	O	the	det	15	SENT_128	[p7l780t943r885b1006],
14	placebo	NN	O	placebo	nn	15	SENT_128	[p7l905t943r1164b1026],
15	arm	NN	O	arm	prep_in	11	SENT_128	[p7l1187t966r1337b1006],
16	.	.	O	.	_	0	SENT_128	[p7l1187t966r1337b1006],

1	Among	IN	O	among	_	0	SENT_129	[p7l1360t947r1616b1027],
2	cirrhotics	NNS	O	cirrhotic	prep_among	6	SENT_129	[p7l1635t943r1976b1015],
3	,	,	O	,	_	0	SENT_129	[p7l1635t943r1976b1015],
4	65	CD	PERCENT	65	num	5	SENT_129	[p7l1999t948r2140b1008],
5	%	NN	PERCENT	%	nsubj	6	SENT_129	[p7l1999t948r2140b1008],
6	achieved	VBD	O	achieve	_	0	SENT_129	[p7l9t1046r304b1109],
7	SVR12	NN	O	svr12	dobj	6	SENT_129	[p7l324t1050r553b1109],
8	with	IN	O	with	_	0	SENT_129	[p7l573t1046r724b1109],
9	simeprevir	NN	O	simeprevir	prep_with	6	SENT_129	[p7l745t1052r1106b1129],
10	as	IN	O	as	prep	6	SENT_129	[p7l1126t1069r1189b1109],
11	compared	VBN	O	compare	_	0	SENT_129	[p7l1210t1046r1548b1129],
12	with	IN	O	with	prepc_compared_with	6	SENT_129	[p7l1565t1046r1716b1109],
13	40	CD	PERCENT	40	num	14	SENT_129	[p7l1735t1051r1876b1111],
14	%	NN	PERCENT	%	pobj	6	SENT_129	[p7l1735t1051r1876b1111],
15	achieving	VBG	O	achieve	partmod	14	SENT_129	[p7l1899t1046r2139b1109, p7l9t1154r116b1232],
16	SVR12	NN	O	svr12	dobj	15	SENT_129	[p7l137t1152r369b1211],
17	with	IN	O	with	_	0	SENT_129	[p7l390t1148r543b1211],
18	placebo	NN	O	placebo	prep_with	15	SENT_129	[p7l563t1140r907b1231],
19	.25	CD	NUMBER	.25	num	18	SENT_129	[p7l563t1140r907b1231],

1	The	DT	O	the	det	3	SENT_130	[p7l82t1251r207b1314],
2	PROMISE	NN	O	promise	nn	3	SENT_130	[p7l229t1255r584b1314],
3	trial	NN	O	trial	nsubj	4	SENT_130	[p7l605t1251r745b1314],
4	evaluated	VBD	O	evaluate	_	0	SENT_130	[p7l767t1251r1091b1314],
5	simeprevir	NN	O	simeprevir	dobj	4	SENT_130	[p7l1112t1257r1478b1334],
6	in	IN	O	in	_	0	SENT_130	[p7l1499t1257r1565b1313],
7	treatmentexperienced	JJ	O	treatmentexperienced	amod	11	SENT_130	[p7l1586t1263r2139b1334, p7l9t1354r260b1417],
8	genotype	NN	O	genotype	nn	11	SENT_130	[p7l278t1366r585b1438],
9	1	CD	NUMBER	1	num	11	SENT_130	[p7l611t1361r635b1416],
10	HCV	NN	ORGANIZATION	hcv	nn	11	SENT_130	[p7l662t1358r839b1417],
11	patients	NNS	O	patient	prep_in	5	SENT_130	[p7l857t1360r1121b1437],
12	who	WP	O	who	nsubj	14	SENT_130	[p7l1140t1354r1284b1417],
13	had	VBD	O	have	aux	14	SENT_130	[p7l1304t1354r1430b1417],
14	relapsed	VBN	O	relapse	rcmod	5	SENT_130	[p7l1449t1354r1727b1437],
15	after	IN	O	after	_	0	SENT_130	[p7l1746t1354r1896b1417],
16	at	IN	DURATION	at	quantmod	18	SENT_130	[p7l1915t1366r1974b1417],
17	least	JJS	DURATION	least	mwe	16	SENT_130	[p7l1991t1354r2141b1417],
18	24	CD	DURATION	24	num	19	SENT_130	[p7l9t1464r87b1519],
19	weeks	NNS	NUMBER	week	prep_after	14	SENT_130	[p7l106t1457r309b1520],
20	of	IN	O	of	_	0	SENT_130	[p7l330t1457r403b1520],
21	an	DT	O	a	det	23	SENT_130	[p7l415t1480r494b1520],
22	IFN-based	JJ	MISC	ifn-based	amod	23	SENT_130	[p7l516t1457r877b1520],
23	therapy	NN	O	therapy	prep_of	19	SENT_130	[p7l895t1457r1163b1541],
24	.	.	O	.	_	0	SENT_130	[p7l895t1457r1163b1541],

1	It	PRP	O	it	nsubj	9	SENT_131	[p7l1187t1462r1236b1520],
2	was	VBD	O	be	cop	9	SENT_131	[p7l1253t1480r1378b1520],
3	an	DT	O	a	det	9	SENT_131	[p7l1400t1480r1479b1520],
4	international	JJ	O	international	amod	9	SENT_131	[p7l1500t1457r1958b1529],
5	,	,	O	,	_	0	SENT_131	[p7l1500t1457r1958b1529],
6	double-blind	JJ	O	double-blind	amod	9	SENT_131	[p7l1981t1457r2137b1520, p7l7t1560r327b1632],
7	,	,	O	,	_	0	SENT_131	[p7l1981t1457r2137b1520, p7l7t1560r327b1632],
8	placebo	NN	O	placebo	dep	9	SENT_131	[p7l347t1560r995b1643],
9	—	NN	O	—	_	0	SENT_131	[p7l347t1560r995b1643],
10	controlled	VBN	O	control	partmod	9	SENT_131	[p7l347t1560r995b1643],
11	,	,	O	,	_	0	SENT_131	[p7l347t1560r995b1643],
12	phase	NN	O	phase	nn	14	SENT_131	[p7l1015t1560r1205b1643],
13	III	CD	NUMBER	iii	num	14	SENT_131	[p7l1226t1565r1306b1622],
14	trial	NN	O	trial	appos	9	SENT_131	[p7l1326t1560r1463b1623],
15	that	WDT	O	that	nsubj	16	SENT_131	[p7l1481t1560r1611b1623],
16	treated	VBD	O	treat	rcmod	14	SENT_131	[p7l1629t1560r1861b1623],
17	patients	NNS	O	patient	dobj	16	SENT_131	[p7l1878t1566r2140b1643],
18	with	IN	O	with	_	0	SENT_131	[p7l7t1663r164b1726],
19	simeprevir	NN	O	simeprevir	prep_with	16	SENT_131	[p7l190t1669r570b1746],
20	or	CC	O	or	_	0	SENT_131	[p7l595t1686r668b1726],
21	placebo	NN	O	placebo	conj_or	19	SENT_131	[p7l691t1663r963b1746],
22	for	IN	O	for	_	0	SENT_131	[p7l989t1663r1090b1726],
23	12	CD	DURATION	12	num	24	SENT_131	[p7l1120t1670r1193b1725],
24	weeks	NNS	NUMBER	week	prep_for	16	SENT_131	[p7l1218t1663r1447b1726],
25	.	.	O	.	_	0	SENT_131	[p7l1218t1663r1447b1726],

1	Simeprevir	FW	O	simeprevir	nn	2	SENT_132	[p7l1476t1663r2144b1746],
2	—	FW	O	—	nsubj	5	SENT_132	[p7l1476t1663r2144b1746],
3	treated	VBN	O	treat	partmod	2	SENT_132	[p7l1476t1663r2144b1746],
4	patients	NNS	O	patient	dobj	3	SENT_132	[p7l7t1772r280b1849],
5	received	VBD	O	receive	_	0	SENT_132	[p7l304t1766r591b1829],
6	PEG+RBV	NN	O	peg+rbv	dobj	5	SENT_132	[p7l614t1770r988b1829],
7	for	IN	O	for	_	0	SENT_132	[p7l1010t1766r1108b1829],
8	24	CD	NUMBER	24	num	11	SENT_132	[p7l1131t1773r1211b1828],
9	or	CC	O	or	_	0	SENT_132	[p7l1234t1789r1307b1829],
10	48	CD	DURATION	48	num	11	SENT_132	[p7l1328t1773r1407b1829],
11	weeks	NNS	NUMBER	week	prep_for	5	SENT_132	[p7l1430t1766r1637b1829],
12	depending	VBG	O	depend	_	0	SENT_132	[p7l1661t1766r2032b1850],
13	on	IN	O	on	prepc_depending_on	5	SENT_132	[p7l2054t1789r2141b1829],
14	treatment	NN	O	treatment	nn	15	SENT_132	[p7l8t1881r343b1932],
15	response	NN	O	response	pobj	5	SENT_132	[p7l362t1891r678b1952],
16	.	.	O	.	_	0	SENT_132	[p7l362t1891r678b1952],

1	All	PDT	O	all	predet	2	SENT_133	[p7l701t1869r802b1931],
2	those	DT	O	those	nsubjpass	6	SENT_133	[p7l821t1869r1004b1932],
3	given	VBN	O	give	partmod	2	SENT_133	[p7l1025t1875r1208b1953],
4	placebo	NN	O	placebo	dobj	3	SENT_133	[p7l1227t1869r1489b1952],
5	were	VBD	O	be	auxpass	6	SENT_133	[p7l1509t1892r1670b1932],
6	treated	VBN	O	treat	_	0	SENT_133	[p7l1689t1869r1927b1932],
7	for	IN	O	for	_	0	SENT_133	[p7l1947t1869r2044b1932],
8	48	CD	DURATION	48	num	9	SENT_133	[p7l2063t1876r2141b1932],
9	weeks	NNS	NUMBER	week	prep_for	6	SENT_133	[p7l7t1972r225b2035],
10	.	.	O	.	_	0	SENT_133	[p7l7t1972r225b2035],

1	SVR12	NN	O	svr12	nsubjpass	3	SENT_134	[p7l249t1976r479b2035],
2	was	VBD	O	be	auxpass	3	SENT_134	[p7l498t1995r623b2035],
3	attained	VBN	O	attain	_	0	SENT_134	[p7l644t1972r916b2035],
4	in	IN	O	in	_	0	SENT_134	[p7l936t1978r1001b2034],
5	79	CD	PERCENT	79	num	6	SENT_134	[p7l1023t1978r1162b2036],
6	%	NN	PERCENT	%	prep_in	3	SENT_134	[p7l1023t1978r1162b2036],
7	of	IN	O	of	_	0	SENT_134	[p7l1185t1972r1258b2035],
8	the	DT	O	the	det	10	SENT_134	[p7l1267t1972r1372b2035],
9	simeprevir	NN	O	simeprevir	nn	10	SENT_134	[p7l1394t1978r1755b2055],
10	cohort	NN	O	cohort	prep_of	6	SENT_134	[p7l1775t1972r1997b2035],
11	and	CC	O	and	_	0	SENT_134	[p7l2017t1972r2142b2035],
12	in	IN	O	in	_	0	SENT_134	[p7l9t2081r75b2137],
13	37	CD	PERCENT	37	num	14	SENT_134	[p7l96t2080r236b2139],
14	%	NN	PERCENT	%	conj_and	6	SENT_134	[p7l96t2080r236b2139],
15	of	IN	O	of	_	0	SENT_134	[p7l260t2075r333b2138],
16	the	DT	O	the	det	18	SENT_134	[p7l343t2075r448b2138],
17	placebo	NN	O	placebo	nn	18	SENT_134	[p7l467t2075r728b2158],
18	cohort	NN	O	cohort	prep_of	14	SENT_134	[p7l750t2075r989b2138],
19	.	.	O	.	_	0	SENT_134	[p7l750t2075r989b2138],

1	Ninety-three	CD	PERCENT	ninety-three	num	2	SENT_135	[p7l1012t2075r1450b2159],
2	percent	NN	PERCENT	percent	nsubj	7	SENT_135	[p7l1469t2087r1725b2158],
3	of	IN	O	of	_	0	SENT_135	[p7l1745t2075r1818b2138],
4	the	DT	O	the	det	6	SENT_135	[p7l1828t2075r1933b2138],
5	simeprevir	NN	O	simeprevir	nn	6	SENT_135	[p7l1955t2081r2139b2138, p7l7t2184r218b2261],
6	cohort	NN	O	cohort	prep_of	2	SENT_135	[p7l241t2178r471b2241],
7	qualiﬁed	VBN	O	qualiﬁed	_	0	SENT_135	[p7l493t2178r798b2261],
8	for	IN	O	for	_	0	SENT_135	[p7l821t2178r920b2241],
9	stoppage	NN	O	stoppage	prep_for	7	SENT_135	[p7l943t2190r1248b2262],
10	of	IN	O	of	_	0	SENT_135	[p7l1273t2178r1348b2241],
11	treatment	NN	O	treatment	prep_of	9	SENT_135	[p7l1361t2190r1703b2241],
12	at	IN	O	at	_	0	SENT_135	[p7l1726t2190r1786b2241],
13	24	CD	DURATION	24	num	14	SENT_135	[p7l1809t2185r1889b2240],
14	weeks	NNS	NUMBER	week	prep_at	7	SENT_135	[p7l1911t2178r2137b2241],
15	.	.	O	.	_	0	SENT_135	[p7l1911t2178r2137b2241],

1	Among	IN	O	among	_	0	SENT_136	[p7l8t2285r265b2365],
2	genotype	NN	O	genotype	nn	4	SENT_136	[p7l284t2293r594b2365],
3	1a	NN	O	1a	nn	4	SENT_136	[p7l621t2288r691b2344],
4	patients	NNS	O	patient	prep_among	8	SENT_136	[p7l709t2287r995b2364],
5	,	,	O	,	_	0	SENT_136	[p7l709t2287r995b2364],
6	SVR	NN	ORGANIZATION	svr	nsubjpass	8	SENT_136	[p7l1018t2285r1171b2344],
7	was	VBD	O	be	auxpass	8	SENT_136	[p7l1187t2304r1312b2344],
8	attained	VBN	O	attain	_	0	SENT_136	[p7l1334t2281r1607b2344],
9	in	IN	O	in	prep	8	SENT_136	[p7l1627t2287r1693b2343],
10	70	CD	PERCENT	70	num	11	SENT_136	[p7l1715t2286r1855b2345],
11	%	NN	PERCENT	%	npadvmod	12	SENT_136	[p7l1715t2286r1855b2345],
12	as	IN	O	as	pcomp	9	SENT_136	[p7l1878t2304r1942b2344],
13	compared	VBN	O	compare	_	0	SENT_136	[p7l1964t2304r2139b2344, p7l7t2383r202b2466],
14	with	IN	O	with	prepc_compared_with	8	SENT_136	[p7l221t2383r373b2446],
15	86	CD	PERCENT	86	num	16	SENT_136	[p7l396t2389r537b2448],
16	%	NN	PERCENT	%	pobj	8	SENT_136	[p7l396t2389r537b2448],
17	among	IN	O	among	_	0	SENT_136	[p7l561t2406r796b2467],
18	genotype	NN	O	genotype	nn	20	SENT_136	[p7l816t2395r1127b2467],
19	1b	NN	O	1b	nn	20	SENT_136	[p7l1156t2383r1229b2446],
20	patients	NNS	O	patient	prep_among	16	SENT_136	[p7l1251t2375r1602b2466],
21	.26	CD	NUMBER	.26	tmod	16	SENT_136	[p7l1251t2375r1602b2466],

1	Common	JJ	O	common	amod	2	SENT_137	[p7l83t2490r409b2549],
2	AEs	NNS	O	ae	nsubj	3	SENT_137	[p7l430t2490r566b2549],
3	include	VBP	O	include	_	0	SENT_137	[p7l589t2486r837b2549],
4	fatigue	NN	O	fatigue	dobj	3	SENT_137	[p7l859t2486r1104b2570],
5	,	,	O	,	_	0	SENT_137	[p7l859t2486r1104b2570],
6	headache	NN	O	headache	dobj	3	SENT_137	[p7l1127t2486r1461b2558],
7	,	,	O	,	_	0	SENT_137	[p7l1127t2486r1461b2558],
8	pruritus	NN	O	pruritus	dobj	3	SENT_137	[p7l1483t2492r1776b2569],
9	,	,	O	,	_	0	SENT_137	[p7l1483t2492r1776b2569],
10	inﬂuenzalike	JJ	O	inﬂuenzalike	amod	11	SENT_137	[p7l1799t2486r2139b2549, p7l7t2589r135b2652],
11	illness	NN	O	illness	dobj	3	SENT_137	[p7l165t2589r408b2661],
12	,	,	O	,	_	0	SENT_137	[p7l165t2589r408b2661],
13	and	CC	O	and	_	0	SENT_137	[p7l440t2589r571b2652],
14	indirect	JJ	O	indirect	amod	15	SENT_137	[p7l600t2589r882b2652],
15	hyperbilirubinemia	NN	O	hyperbilirubinemia	conj_and	4	SENT_137	[p7l910t2589r1633b2673],
16	.	.	O	.	_	0	SENT_137	[p7l910t2589r1633b2673],

1	As	IN	O	as	mark	28	SENT_138	[p7l1665t2593r1754b2652],
2	compared	VBN	O	compare	_	0	SENT_138	[p7l1785t2589r2143b2672],
3	with	IN	O	with	prepc_compared_with	28	SENT_138	[p7l7t2692r160b2755],
4	patients	NNS	O	patient	pobj	28	SENT_138	[p7l181t2698r450b2775],
5	receiving	VBG	O	receive	partmod	4	SENT_138	[p7l473t2698r785b2776],
6	PEG	NN	O	peg	dobj	5	SENT_138	[p7l806t2696r961b2755],
7	and	CC	O	and	_	0	SENT_138	[p7l984t2692r1111b2755],
8	RBV	NN	O	rbv	dobj	5	SENT_138	[p7l1133t2697r1293b2755],
9	alone	RB	O	alone	advmod	5	SENT_138	[p7l1315t2692r1515b2764],
10	,	,	O	,	_	0	SENT_138	[p7l1315t2692r1515b2764],
11	the	DT	O	the	det	13	SENT_138	[p7l1538t2692r1644b2755],
12	only	JJ	O	only	amod	13	SENT_138	[p7l1668t2692r1818b2776],
13	AE	NN	O	ae	nsubj	28	SENT_138	[p7l1836t2696r1942b2754],
14	more	RBR	O	more	advmod	15	SENT_138	[p7l1964t2715r2142b2755],
15	commonly	RB	O	commonly	advmod	16	SENT_138	[p7l10t2819r400b2903],
16	encountered	VBN	O	encounter	partmod	13	SENT_138	[p7l427t2819r879b2882],
17	in	IN	O	in	_	0	SENT_138	[p7l908t2825r978b2881],
18	patients	NNS	O	patient	prep_in	16	SENT_138	[p7l1006t2825r1292b2902],
19	receiving	VBG	O	receive	xcomp	16	SENT_138	[p7l1323t2825r1654b2903],
20	therapy	NN	O	therapy	dobj	19	SENT_138	[p7l1681t2819r1958b2903],
21	with	IN	O	with	_	0	SENT_138	[p7l1983t2819r2143b2882],
22	simeprevir	NN	O	simeprevir	prep_with	19	SENT_138	[p7l10t2928r395b3005],
23	,	,	O	,	_	0	SENT_138	[p7l10t2928r395b3005],
24	PEG	NN	O	peg	prep_with	19	SENT_138	[p7l421t2926r578b2985],
25	and	CC	O	and	_	0	SENT_138	[p7l603t2922r731b2985],
26	RBV	NN	O	rbv	prep_with	19	SENT_138	[p7l754t2927r916b2985],
27	was	VBD	O	be	cop	28	SENT_138	[p7l937t2945r1066b2985],
28	rash	JJ	O	rash	advcl	33	SENT_138	[p7l1090t2922r1254b2994],
29	,	,	O	,	_	0	SENT_138	[p7l1090t2922r1254b2994],
30	which	WDT	O	which	nsubj	33	SENT_138	[p7l1277t2922r1490b2985],
31	was	VBD	O	be	cop	33	SENT_138	[p7l1511t2945r1640b2985],
32	typically	RB	O	typically	advmod	33	SENT_138	[p7l1662t2922r1961b3006],
33	mild	JJ	O	mild	_	0	SENT_138	[p7l1980t2922r2143b2985],
34	to	TO	O	to	_	0	SENT_138	[p7l8t3036r74b3088],
35	moderate	JJ	O	moderate	amod	36	SENT_138	[p7l95t3016r498b3088],
36	.26	CD	NUMBER	.26	prep_to	33	SENT_138	[p7l95t3016r498b3088],

1	The	DT	O	the	det	4	SENT_139	[p7l83t3128r205b3191],
2	improved	VBN	O	improve	amod	4	SENT_139	[p7l225t3128r546b3211],
3	AE	NN	O	ae	nn	4	SENT_139	[p7l564t3132r667b3190],
4	proﬁle	NN	O	proﬁle	nsubj	23	SENT_139	[p7l686t3128r900b3211],
5	in	IN	O	in	_	0	SENT_139	[p7l920t3134r985b3190],
6	relation	NN	O	relation	prep_in	4	SENT_139	[p7l1005t3128r1260b3191],
7	to	TO	O	to	aux	8	SENT_139	[p7l1278t3140r1342b3191],
8	ﬁrst	VB	O	ﬁrst	infmod	6	SENT_139	[p7l1363t3128r1518b3191],
9	-	:	O	-	_	0	SENT_139	[p7l1363t3128r1518b3191],
10	generation	NN	O	generation	nn	11	SENT_139	[p7l1525t3134r1880b3212],
11	PIs	NNS	O	pi	nsubj	17	SENT_139	[p7l1900t3133r2000b3191],
12	and	CC	O	and	_	0	SENT_139	[p7l2021t3128r2144b3191],
13	the	DT	O	the	det	16	SENT_139	[p7l8t3231r114b3294],
14	high	JJ	O	high	amod	16	SENT_139	[p7l135t3231r288b3315],
15	SVR	NN	ORGANIZATION	svr	nn	16	SENT_139	[p7l310t3235r463b3294],
16	rates	NNS	O	rate	conj_and	11	SENT_139	[p7l482t3243r640b3294],
17	reported	VBN	O	report	parataxis	8	SENT_139	[p7l662t3231r957b3314],
18	in	IN	O	in	_	0	SENT_139	[p7l977t3237r1043b3293],
19	treatment-naive	JJ	O	treatment-naive	amod	22	SENT_139	[p7l1063t3237r1611b3294],
20	and	CC	O	and	_	0	SENT_139	[p7l1633t3231r1759b3294],
21	treatmentexperienced	JJ	O	treatmentexperienced	amod	22	SENT_139	[p7l1778t3243r2140b3294, p7l10t3335r438b3418],
22	patients	NNS	O	patient	prep_in	17	SENT_139	[p7l460t3341r737b3418],
23	makes	VBZ	O	make	_	0	SENT_139	[p7l762t3335r983b3398],
24	simeprevir	NN	O	simeprevir	nsubjpass	33	SENT_139	[p7l1008t3341r1386b3418],
25	one	CD	NUMBER	one	num	24	SENT_139	[p7l1409t3358r1534b3398],
26	of	IN	O	of	_	0	SENT_139	[p7l1560t3335r1635b3398],
27	the	DT	O	the	det	29	SENT_139	[p7l1648t3335r1757b3398],
28	promising	JJ	O	promising	amod	29	SENT_139	[p7l1781t3341r2144b3419],
29	DAAs	NNS	O	daa	prep_of	24	SENT_139	[p7l10t3442r213b3501],
30	soon	RB	O	soon	advmod	29	SENT_139	[p7l235t3461r396b3501],
31	to	TO	O	to	aux	33	SENT_139	[p7l415t3450r480b3501],
32	be	VB	O	be	auxpass	33	SENT_139	[p7l499t3438r578b3501],
33	approved	VBN	O	approve	xcomp	23	SENT_139	[p7l599t3438r913b3521],
34	by	IN	O	by	_	0	SENT_139	[p7l930t3438r1014b3522],
35	the	DT	O	the	det	36	SENT_139	[p7l1029t3438r1134b3501],
36	FDA	NNP	ORGANIZATION	FDA	agent	33	SENT_139	[p7l1155t3442r1315b3500],
37	for	IN	O	for	_	0	SENT_139	[p7l1335t3438r1431b3501],
38	treatment	NN	O	treatment	prep_for	33	SENT_139	[p7l1449t3450r1782b3501],
39	of	IN	O	of	_	0	SENT_139	[p7l1801t3438r1874b3501],
40	chronic	JJ	O	chronic	amod	41	SENT_139	[p7l1885t3438r2142b3501],
41	HCV	NN	O	hcv	prep_of	38	SENT_139	[p7l10t3545r189b3604],
42	in	IN	O	in	_	0	SENT_139	[p7l210t3547r277b3603],
43	conjunction	NN	O	conjunction	prep_in	41	SENT_139	[p7l299t3547r711b3625],
44	with	IN	O	with	_	0	SENT_139	[p7l731t3541r883b3604],
45	PEG+RBV	NN	O	peg+rbv	prep_with	33	SENT_139	[p7l906t3545r1277b3604],
46	.	.	O	.	_	0	SENT_139	[p7l906t3545r1277b3604],

1	FALDAPREVIR	NN	O	faldaprevir	_	0	SENT_140	[p7l13t3756r509b3810],

1	Faldaprevir	NNP	O	Faldaprevir	nn	3	SENT_141	[p8l10t36r389b119],
2	(	CD	NUMBER	(	num	3	SENT_141	[p8l410t36r509b113],
3	BI	NN	O	bus	nsubj	17	SENT_141	[p8l410t36r509b113],
4	201335	CD	NUMBER	201335	num	5	SENT_141	[p8l529t37r792b112],
5	)	NN	O	)	dep	3	SENT_141	[p8l529t37r792b112],
6	is	VBZ	O	be	cop	17	SENT_141	[p8l816t42r864b99],
7	a	DT	O	a	det	17	SENT_141	[p8l885t59r919b99],
8	selective	JJ	O	selective	amod	17	SENT_141	[p8l938t36r1231b108],
9	,	,	O	,	_	0	SENT_141	[p8l938t36r1231b108],
10	once	RB	DATE	once	dep	11	SENT_141	[p8l1252t36r1610b120],
11	—	CD	NUMBER	—	dep	17	SENT_141	[p8l1252t36r1610b120],
12	daily	RB	SET	daily	advmod	11	SENT_141	[p8l1252t36r1610b120],
13	,	,	O	,	_	0	SENT_141	[p8l1252t36r1610b120],
14	NS3	NN	O	ns3	appos	11	SENT_141	[p8l1630t40r1796b102],
15	/	:	O	/	punct	11	SENT_141	[p8l1630t40r1796b102],
16	4A	NN	O	4a	nn	17	SENT_141	[p8l1800t40r1896b98],
17	inhibitor	NN	O	inhibitor	_	0	SENT_141	[p8l1915t36r2138b99, p8l8t151r111b202],
18	currently	RB	DATE	currently	advmod	17	SENT_141	[p8l135t139r462b223],
19	in	IN	O	in	_	0	SENT_141	[p8l483t145r551b201],
20	phase	NN	O	phase	nn	22	SENT_141	[p8l575t139r775b222],
21	III	CD	NUMBER	iii	num	22	SENT_141	[p8l801t144r886b201],
22	trials	NNS	O	trial	prep_in	17	SENT_141	[p8l912t139r1107b202],
23	.	.	O	.	_	0	SENT_141	[p8l912t139r1107b202],

1	In	IN	O	in	_	0	SENT_142	[p8l1136t144r1208b201],
2	phase	NN	O	phase	prep_in	7	SENT_142	[p8l1232t139r1433b222],
3	I	PRP	O	I	dep	4	SENT_142	[p8l1458t144r1482b201],
4	trials	NNS	O	trial	dep	7	SENT_142	[p8l1507t139r1685b202],
5	it	PRP	O	it	nsubjpass	7	SENT_142	[p8l1710t145r1757b202],
6	was	VBD	O	be	auxpass	7	SENT_142	[p8l1779t162r1908b202],
7	found	VBN	O	find	_	0	SENT_142	[p8l1934t139r2144b202],
8	to	TO	O	to	aux	10	SENT_142	[p8l8t254r76b305],
9	be	VB	O	be	cop	10	SENT_142	[p8l98t242r180b305],
10	potent	JJ	O	potent	xcomp	7	SENT_142	[p8l203t254r448b325],
11	,	,	O	,	_	0	SENT_142	[p8l203t254r448b325],
12	with	IN	O	with	_	0	SENT_142	[p8l472t242r629b305],
13	a	DT	O	a	det	16	SENT_142	[p8l653t265r688b305],
14	viral	JJ	O	viral	amod	16	SENT_142	[p8l708t242r868b305],
15	load	NN	O	load	nn	16	SENT_142	[p8l889t242r1042b305],
16	reduction	NN	O	reduction	prep_with	10	SENT_142	[p8l1064t242r1406b305],
17	of	IN	O	of	_	0	SENT_142	[p8l1430t242r1505b305],
18	4.2	CD	NUMBER	4.2	num	19	SENT_142	[p8l1518t242r1814b326],
19	log10	NN	O	log10	prep_of	16	SENT_142	[p8l1518t242r1814b326],
20	at	IN	O	at	_	0	SENT_142	[p8l1841t254r1901b305],
21	a	DT	O	a	det	22	SENT_142	[p8l1925t265r1959b305],
22	dose	NN	O	dose	prep_at	19	SENT_142	[p8l1983t242r2141b305],
23	of	IN	O	of	_	0	SENT_142	[p8l10t345r85b408],
24	240	CD	NUMBER	240	num	25	SENT_142	[p8l99t352r222b408],
25	mg	NN	O	mg	prep_of	22	SENT_142	[p8l239t368r350b429],
26	a	DT	DURATION	a	det	27	SENT_142	[p8l373t368r408b408],
27	day	NN	DURATION	day	dep	25	SENT_142	[p8l431t345r562b429],
28	.	.	O	.	_	0	SENT_142	[p8l431t345r562b429],

1	Viral	JJ	O	viral	amod	2	SENT_143	[p8l588t345r763b408],
2	breakthroughs	NNS	O	breakthrough	nsubj	3	SENT_143	[p8l783t345r1297b429],
3	occurred	VBD	O	occur	dep	31	SENT_143	[p8l1322t345r1638b408],
4	in	IN	O	in	_	0	SENT_143	[p8l1661t351r1729b407],
5	patients	NNS	O	patient	prep_in	3	SENT_143	[p8l1752t351r2028b428],
6	on	IN	O	on	_	0	SENT_143	[p8l2053t368r2141b408],
7	faldaprevir	NN	O	faldaprevir	nn	8	SENT_143	[p8l9t448r382b531],
8	monotherapy	NN	O	monotherapy	prep_on	3	SENT_143	[p8l403t448r868b532],
9	due	JJ	O	due	_	0	SENT_143	[p8l888t448r1010b511],
10	to	TO	O	to	_	0	SENT_143	[p8l1031t460r1097b511],
11	the	DT	O	the	det	12	SENT_143	[p8l1120t448r1226b511],
12	NS3	NN	O	ns3	prep_due_to	8	SENT_143	[p8l1248t452r1419b514],
13	/	:	O	/	punct	31	SENT_143	[p8l1248t452r1419b514],
14	4A	NN	O	4a	nn	15	SENT_143	[p8l1423t452r1522b510],
15	mutations	NNS	O	mutation	dep	21	SENT_143	[p8l1543t454r1887b511],
16	R155K	NN	O	r155k	dep	15	SENT_143	[p8l1911t453r2144b511],
17	and	CC	O	and	_	0	SENT_143	[p8l10t550r139b614],
18	D168V	NN	O	d168v	conj_and	16	SENT_143	[p8l161t542r482b614],
19	.27	CD	NUMBER	.27	dep	21	SENT_143	[p8l161t542r482b614],
20	The	DT	O	the	det	21	SENT_143	[p8l505t550r632b614],
21	addition	NN	O	addition	dep	31	SENT_143	[p8l656t550r949b614],
22	of	IN	O	of	_	0	SENT_143	[p8l973t550r1048b614],
23	PEG	NN	O	peg	prep_of	21	SENT_143	[p8l1063t554r1220b614],
24	and	CC	O	and	_	0	SENT_143	[p8l1244t550r1372b614],
25	RBV	NN	O	rbv	prep_of	21	SENT_143	[p8l1395t556r1557b614],
26	to	TO	O	to	_	0	SENT_143	[p8l1580t562r1646b614],
27	the	DT	O	the	det	29	SENT_143	[p8l1670t550r1778b614],
28	treatment	NN	O	treatment	nn	29	SENT_143	[p8l1801t562r2143b614],
29	regimen	NN	O	regimen	prep_to	23	SENT_143	[p8l10t660r300b738],
30	greatly	RB	O	greatly	advmod	31	SENT_143	[p8l324t654r564b738],
31	decreased	VBD	O	decrease	_	0	SENT_143	[p8l585t654r932b717],
32	viral	JJ	O	viral	amod	33	SENT_143	[p8l952t654r1112b717],
33	breakthrough	NN	O	breakthrough	dobj	31	SENT_143	[p8l1134t654r1635b738],
34	.	.	O	.	_	0	SENT_143	[p8l1134t654r1635b738],

1	Faldaprevir	NNP	O	Faldaprevir	nsubjpass	4	SENT_144	[p8l1663t654r2066b737],
2	is	VBZ	O	be	auxpass	4	SENT_144	[p8l2089t660r2140b717],
3	well	RB	O	well	advmod	4	SENT_144	[p8l8t757r146b820],
4	tolerated	VBN	O	tolerate	_	0	SENT_144	[p8l167t757r489b829],
5	,	,	O	,	_	0	SENT_144	[p8l167t757r489b829],
6	with	IN	O	with	_	0	SENT_144	[p8l512t757r665b820],
7	mild	JJ	O	mild	amod	8	SENT_144	[p8l688t757r848b820],
8	rash	NN	O	rash	prep_with	4	SENT_144	[p8l870t757r1014b820],
9	and	CC	O	and	_	0	SENT_144	[p8l1038t757r1164b820],
10	photosensitivity	NN	O	photosensitivity	prep_with	4	SENT_144	[p8l1185t757r1741b841],
11	being	VBG	O	be	auxpass	12	SENT_144	[p8l1758t757r1951b841],
12	seen	VBN	O	see	partmod	8	SENT_144	[p8l1973t780r2141b829],
13	,	,	O	,	_	0	SENT_144	[p8l1973t780r2141b829],
14	as	RB	O	as	_	0	SENT_144	[p8l10t883r76b923],
15	well	RB	O	well	_	0	SENT_144	[p8l100t860r242b923],
16	as	IN	O	as	_	0	SENT_144	[p8l267t883r333b923],
17	a	DT	O	a	det	20	SENT_144	[p8l359t883r394b923],
18	mild	JJ	O	mild	amod	20	SENT_144	[p8l418t860r582b923],
19	unconjugated	JJ	O	unconjugated	amod	20	SENT_144	[p8l606t860r1090b944],
20	hyperbilirubinemia	NN	O	hyperbilirubinemia	conj_and	8	SENT_144	[p8l1113t860r1823b944],
21	,	,	O	,	_	0	SENT_144	[p8l1113t860r1823b944],
22	which	WDT	O	which	nsubj	24	SENT_144	[p8l1848t860r2064b923],
23	is	VBZ	O	be	cop	24	SENT_144	[p8l2089t866r2140b923],
24	dose	NN	O	dose	rcmod	20	SENT_144	[p8l10t962r164b1025],
25	dependent	JJ	O	dependent	amod	24	SENT_144	[p8l186t954r629b1045],
26	.28	CD	NUMBER	.28	tmod	25	SENT_144	[p8l186t954r629b1045],

1	In	IN	O	in	_	0	SENT_145	[p8l84t1070r156b1127],
2	studies	NNS	O	study	prep_in	23	SENT_145	[p8l184t1065r430b1128],
3	of	IN	O	of	_	0	SENT_145	[p8l458t1065r534b1128],
4	treatment	NN	O	treatment	prep_of	2	SENT_145	[p8l550t1071r1123b1128],
5	—	CD	NUMBER	—	npadvmod	6	SENT_145	[p8l550t1071r1123b1128],
6	naive	JJ	O	naive	amod	4	SENT_145	[p8l550t1071r1123b1128],
7	and	CC	O	and	_	0	SENT_145	[p8l1151t1065r1281b1128],
8	previous	JJ	O	previous	amod	10	SENT_145	[p8l1306t1071r1612b1148],
9	nonresponder	JJ	O	nonresponder	amod	10	SENT_145	[p8l1640t1065r2145b1148],
10	genotype	NN	O	genotype	conj_and	2	SENT_145	[p8l9t1180r331b1252],
11	1	CD	NUMBER	1	num	12	SENT_145	[p8l363t1175r388b1230],
12	noncirrhotics	NNS	O	noncirrhotic	dep	10	SENT_145	[p8l419t1168r919b1240],
13	,	,	O	,	_	0	SENT_145	[p8l419t1168r919b1240],
14	the	DT	O	the	det	15	SENT_145	[p8l944t1168r1054b1231],
15	efﬁcacy	NN	O	efﬁcacy	nsubjpass	23	SENT_145	[p8l1079t1168r1345b1252],
16	of	IN	O	of	_	0	SENT_145	[p8l1366t1168r1442b1231],
17	faldaprevir	NN	O	faldaprevir	prep_of	15	SENT_145	[p8l1457t1168r1844b1251],
18	in	IN	O	in	_	0	SENT_145	[p8l1868t1174r1936b1230],
19	combination	NN	O	combination	prep_in	17	SENT_145	[p8l1961t1191r2140b1231, p8l7t1271r302b1334],
20	with	IN	O	with	_	0	SENT_145	[p8l324t1271r480b1334],
21	PEG+RBV	NN	O	peg+rbv	prep_with	19	SENT_145	[p8l504t1275r881b1334],
22	was	VBD	O	be	auxpass	23	SENT_145	[p8l902t1294r1031b1334],
23	assessed	VBN	O	assess	_	0	SENT_145	[p8l1056t1271r1359b1334],
24	.	.	O	.	_	0	SENT_145	[p8l1056t1271r1359b1334],

1	Four	CD	NUMBER	four	num	3	SENT_146	[p8l1387t1276r1552b1334],
2	study	NN	O	study	nn	3	SENT_146	[p8l1575t1271r1766b1355],
3	arms	NNS	O	arm	nsubjpass	5	SENT_146	[p8l1787t1294r1957b1334],
4	were	VBD	O	be	auxpass	5	SENT_146	[p8l1979t1294r2144b1334],
5	designed	VBN	O	design	_	0	SENT_146	[p8l10t1374r340b1458],
6	:	:	O	:	_	0	SENT_146	[p8l10t1374r340b1458],
7	a	DT	O	a	det	9	SENT_146	[p8l368t1397r403b1437],
8	placebo	NN	O	placebo	nn	9	SENT_146	[p8l424t1374r695b1457],
9	arm	NN	O	arm	nsubj	10	SENT_146	[p8l721t1397r860b1437],
10	treated	VBN	O	treat	parataxis	5	SENT_146	[p8l883t1374r1128b1437],
11	with	IN	O	with	_	0	SENT_146	[p8l1149t1374r1306b1437],
12	PEG+RBV	NN	O	peg+rbv	prep_with	10	SENT_146	[p8l1331t1378r1715b1446],
13	,	,	O	,	_	0	SENT_146	[p8l1331t1378r1715b1446],
14	and	CC	O	and	_	0	SENT_146	[p8l1742t1374r1871b1437],
15	the	DT	O	the	det	17	SENT_146	[p8l1893t1374r2002b1437],
16	faldaprevir	NN	O	faldaprevir	nn	17	SENT_146	[p8l2026t1374r2139b1437, p8l10t1477r297b1560],
17	arms	NNS	O	arm	conj_and	12	SENT_146	[p8l317t1500r483b1540],
18	at	IN	O	at	_	0	SENT_146	[p8l506t1489r565b1540],
19	doses	NNS	O	dose	prep_at	17	SENT_146	[p8l586t1477r771b1540],
20	of	IN	O	of	_	0	SENT_146	[p8l794t1477r867b1540],
21	120	CD	NUMBER	120	num	22	SENT_146	[p8l885t1484r998b1540],
22	mg	NN	O	mg	dep	32	SENT_146	[p8l1014t1500r1122b1561],
23	a	DT	DURATION	a	det	24	SENT_146	[p8l1142t1500r1177b1540],
24	day	NN	DURATION	day	dep	22	SENT_146	[p8l1197t1477r1319b1561],
25	with	IN	O	with	_	0	SENT_146	[p8l1334t1477r1487b1540],
26	a	DT	O	a	det	29	SENT_146	[p8l1508t1500r1543b1540],
27	3-day	JJ	DURATION	3-day	amod	29	SENT_146	[p8l1564t1477r1756b1561],
28	PEG+RBV	NN	O	peg+rbv	nn	29	SENT_146	[p8l1775t1481r2143b1540],
29	lead-in	NN	O	lead-in	prep_with	22	SENT_146	[p8l8t1580r251b1643],
30	(	CD	NUMBER	(	num	32	SENT_146	[p8l277t1580r424b1657],
31	LI	NNP	O	LI	nn	32	SENT_146	[p8l277t1580r424b1657],
32	)	NNP	O	)	prep_of	19	SENT_146	[p8l277t1580r424b1657],
33	,	,	O	,	_	0	SENT_146	[p8l277t1580r424b1657],
34	240	CD	NUMBER	240	num	35	SENT_146	[p8l449t1587r569b1643],
35	mg	NN	O	mg	prep_at	17	SENT_146	[p8l585t1603r694b1664],
36	a	DT	DURATION	a	det	37	SENT_146	[p8l716t1603r750b1643],
37	day	NN	DURATION	day	dep	35	SENT_146	[p8l773t1580r895b1664],
38	with	IN	O	with	_	0	SENT_146	[p8l912t1580r1066b1643],
39	a	DT	O	a	det	40	SENT_146	[p8l1089t1603r1124b1643],
40	L1	NN	O	l1	prep_with	35	SENT_146	[p8l1146t1585r1236b1652],
41	,	,	O	,	_	0	SENT_146	[p8l1146t1585r1236b1652],
42	or	CC	O	or	_	0	SENT_146	[p8l1261t1603r1333b1643],
43	240	CD	NUMBER	240	num	44	SENT_146	[p8l1355t1587r1475b1643],
44	mg	NN	O	mg	prep_at	17	SENT_146	[p8l1490t1603r1600b1664],
45	a	DT	DURATION	a	det	46	SENT_146	[p8l1622t1603r1656b1643],
46	day	NN	DURATION	day	dep	44	SENT_146	[p8l1678t1580r1800b1664],
47	without	IN	O	without	_	0	SENT_146	[p8l1818t1580r2087b1643],
48	a	DT	O	a	det	49	SENT_146	[p8l2109t1603r2144b1643],
49	LI	NNP	O	LI	prep_without	10	SENT_146	[p8l10t1688r99b1755],
50	,	,	O	,	_	0	SENT_146	[p8l10t1688r99b1755],
51	followed	VBN	O	follow	_	0	SENT_146	[p8l122t1683r416b1746],
52	by	IN	O	by	prepc_followed_by	10	SENT_146	[p8l434t1683r517b1767],
53	an	DT	O	a	det	56	SENT_146	[p8l536t1706r615b1746],
54	additional	JJ	O	additional	amod	56	SENT_146	[p8l637t1683r985b1746],
55	24	CD	DURATION	24	num	56	SENT_146	[p8l1005t1690r1084b1745],
56	weeks	NNS	NUMBER	week	pobj	10	SENT_146	[p8l1103t1683r1307b1746],
57	of	IN	O	of	_	0	SENT_146	[p8l1329t1683r1403b1746],
58	PEG+RBV	NN	O	peg+rbv	prep_of	56	SENT_146	[p8l1415t1687r1787b1746],
59	.	.	O	.	_	0	SENT_146	[p8l1415t1687r1787b1746],

1	SVR	NN	ORGANIZATION	svr	nn	2	SENT_147	[p8l1813t1687r1966b1746],
2	rates	NNS	O	rate	nsubj	8	SENT_147	[p8l1984t1695r2142b1746],
3	in	IN	O	in	_	0	SENT_147	[p8l10t1792r77b1848],
4	treatment-naive	JJ	O	treatment-naive	amod	5	SENT_147	[p8l99t1792r658b1849],
5	patients	NNS	O	patient	prep_in	2	SENT_147	[p8l680t1792r954b1869],
6	were	VBD	O	be	cop	8	SENT_147	[p8l976t1809r1140b1849],
7	56	CD	PERCENT	56	num	8	SENT_147	[p8l1165t1791r1308b1850],
8	%	NN	PERCENT	%	_	0	SENT_147	[p8l1165t1791r1308b1850],
9	with	IN	O	with	_	0	SENT_147	[p8l1332t1786r1487b1849],
10	placebo	NN	O	placebo	prep_with	8	SENT_147	[p8l1509t1786r1794b1869],
11	,	,	O	,	_	0	SENT_147	[p8l1509t1786r1794b1869],
12	72	CD	PERCENT	72	num	13	SENT_147	[p8l1820t1791r1964b1851],
13	%	NN	PERCENT	%	conj_and	8	SENT_147	[p8l1820t1791r1964b1851],
14	with	IN	O	with	_	0	SENT_147	[p8l1987t1786r2143b1849],
15	120	CD	NUMBER	120	num	17	SENT_147	[p8l16t1896r129b1952],
16	mg	NN	O	mg	nn	17	SENT_147	[p8l145t1912r255b1973],
17	faldaprevir	NN	O	faldaprevir	prep_with	13	SENT_147	[p8l275t1889r663b1972],
18	,	,	O	,	_	0	SENT_147	[p8l275t1889r663b1972],
19	72	CD	PERCENT	72	num	20	SENT_147	[p8l689t1895r831b1953],
20	%	NN	PERCENT	%	conj_and	8	SENT_147	[p8l689t1895r831b1953],
21	with	IN	O	with	_	0	SENT_147	[p8l854t1889r1008b1952],
22	240	CD	NUMBER	240	num	24	SENT_147	[p8l1030t1896r1150b1952],
23	mg	NN	O	mg	nn	24	SENT_147	[p8l1166t1912r1276b1973],
24	faldaprevir	NN	O	faldaprevir	prep_with	20	SENT_147	[p8l1297t1889r1672b1972],
25	and	CC	O	and	_	0	SENT_147	[p8l1695t1889r1822b1952],
26	a	DT	O	a	det	27	SENT_147	[p8l1845t1912r1879b1952],
27	LI	NNP	O	LI	conj_and	24	SENT_147	[p8l1901t1894r1992b1961],
28	,	,	O	,	_	0	SENT_147	[p8l1901t1894r1992b1961],
29	and	CC	O	and	_	0	SENT_147	[p8l2017t1889r2144b1952],
30	84	CD	PERCENT	84	num	31	SENT_147	[p8l11t1998r154b2056],
31	%	NN	PERCENT	%	conj_and	8	SENT_147	[p8l11t1998r154b2056],
32	with	IN	O	with	_	0	SENT_147	[p8l178t1992r333b2055],
33	240	CD	NUMBER	240	num	35	SENT_147	[p8l356t1999r478b2055],
34	mg	NN	O	mg	nn	35	SENT_147	[p8l494t2015r605b2076],
35	faldaprevir	NN	O	faldaprevir	prep_with	31	SENT_147	[p8l626t1992r1007b2075],
36	without	IN	O	without	_	0	SENT_147	[p8l1028t1992r1301b2055],
37	a	DT	O	a	det	38	SENT_147	[p8l1324t2015r1358b2055],
38	LI	NNP	O	LI	prep_without	8	SENT_147	[p8l1381t1997r1471b2055],
39	.	.	O	.	_	0	SENT_147	[p8l1381t1997r1471b2055],

1	In	IN	O	in	_	0	SENT_148	[p8l1498t1997r1570b2054],
2	previous	JJ	O	previous	amod	4	SENT_148	[p8l1593t1998r1892b2075],
3	partial	JJ	O	partial	amod	4	SENT_148	[p8l1914t1992r2143b2075],
4	responders	NNS	O	responder	prep_in	9	SENT_148	[p8l10t2095r416b2178],
5	,	,	O	,	_	0	SENT_148	[p8l10t2095r416b2178],
6	SVR	NN	ORGANIZATION	svr	nn	7	SENT_148	[p8l443t2099r600b2158],
7	rates	NNS	O	rate	nsubj	9	SENT_148	[p8l622t2107r784b2158],
8	were	VBD	O	be	cop	9	SENT_148	[p8l807t2118r972b2158],
9	32	CD	NUMBER	32	_	0	SENT_148	[p8l998t2102r1097b2167],
10	,	,	O	,	_	0	SENT_148	[p8l998t2102r1097b2167],
11	50	CD	NUMBER	50	conj_and	9	SENT_148	[p8l1124t2102r1222b2167],
12	,	,	O	,	_	0	SENT_148	[p8l1124t2102r1222b2167],
13	and	CC	PERCENT	and	_	0	SENT_148	[p8l1249t2095r1378b2158],
14	42	CD	PERCENT	42	num	15	SENT_148	[p8l1400t2100r1547b2160],
15	%	NN	PERCENT	%	conj_and	9	SENT_148	[p8l1400t2100r1547b2160],
16	in	IN	O	in	_	0	SENT_148	[p8l1573t2101r1642b2157],
17	the	DT	O	the	det	19	SENT_148	[p8l1665t2095r1774b2158],
18	treatment	NN	O	treatment	nn	19	SENT_148	[p8l1797t2107r2143b2158],
19	arms	NNS	O	arm	prep_in	15	SENT_148	[p8l10t2221r193b2270],
20	,	,	O	,	_	0	SENT_148	[p8l10t2221r193b2270],
21	and	CC	O	and	_	0	SENT_148	[p8l215t2198r340b2261],
22	in	IN	O	in	_	0	SENT_148	[p8l359t2204r425b2260],
23	previous	JJ	O	previous	amod	24	SENT_148	[p8l444t2204r734b2281],
24	nonresponders	NNS	O	nonresponder	prep_in	29	SENT_148	[p8l754t2198r1280b2281],
25	,	,	O	,	_	0	SENT_148	[p8l754t2198r1280b2281],
26	the	DT	O	the	det	27	SENT_148	[p8l1301t2198r1406b2261],
27	rates	NNS	O	rate	nsubj	29	SENT_148	[p8l1427t2210r1583b2261],
28	were	VBD	O	be	cop	29	SENT_148	[p8l1601t2221r1760b2261],
29	21	CD	NUMBER	21	conj_and	9	SENT_148	[p8l1781t2205r1877b2270],
30	,	,	O	,	_	0	SENT_148	[p8l1781t2205r1877b2270],
31	35	CD	NUMBER	35	conj_and	9	SENT_148	[p8l1900t2205r1995b2270],
32	,	,	O	,	_	0	SENT_148	[p8l1900t2205r1995b2270],
33	and	CC	PERCENT	and	_	0	SENT_148	[p8l2017t2198r2142b2261],
34	29	CD	PERCENT	29	num	35	SENT_148	[p8l9t2305r171b2364],
35	%	NN	PERCENT	%	conj_and	29	SENT_148	[p8l9t2305r171b2364],
36	.	.	O	.	_	0	SENT_148	[p8l9t2305r171b2364],

1	Discontinuation	NN	O	discontinuation	nsubj	8	SENT_149	[p8l197t2305r758b2363],
2	due	JJ	O	due	_	0	SENT_149	[p8l781t2300r904b2363],
3	to	TO	O	to	_	0	SENT_149	[p8l926t2312r992b2363],
4	the	DT	O	the	det	5	SENT_149	[p8l1015t2300r1122b2363],
5	incidence	NN	O	incidence	prep_due_to	1	SENT_149	[p8l1145t2300r1475b2363],
6	of	IN	O	of	_	0	SENT_149	[p8l1499t2300r1573b2363],
7	AEs	NNS	O	ae	prep_of	5	SENT_149	[p8l1585t2304r1722b2363],
8	occurred	VBD	O	occur	_	0	SENT_149	[p8l1746t2300r2055b2363],
9	in	IN	O	in	prep	8	SENT_149	[p8l2077t2306r2144b2362],

1	4	CD	PERCENT	4	num	2	SENT_150	[p8l9t2409r242b2467],
2	—	CD	PERCENT	—	_	0	SENT_150	[p8l9t2409r242b2467],
3	23	CD	PERCENT	23	number	4	SENT_150	[p8l9t2409r242b2467],
4	%	NN	PERCENT	%	amod	2	SENT_150	[p8l9t2409r242b2467],
5	of	IN	O	of	_	0	SENT_150	[p8l268t2403r343b2466],
6	patients	NNS	O	patient	prep_of	2	SENT_150	[p8l355t2409r630b2486],
7	within	IN	O	within	dep	2	SENT_150	[p8l652t2403r879b2466],
8	each	DT	O	each	det	9	SENT_150	[p8l903t2403r1059b2466],
9	group	NN	O	group	pobj	7	SENT_150	[p8l1082t2425r1303b2487],
10	,	,	O	,	_	0	SENT_150	[p8l1082t2425r1303b2487],
11	with	IN	O	with	_	0	SENT_150	[p8l1326t2403r1481b2466],
12	the	DT	O	the	det	15	SENT_150	[p8l1504t2403r1612b2466],
13	most	RBS	O	most	advmod	15	SENT_150	[p8l1635t2415r1808b2466],
14	common	JJ	O	common	amod	15	SENT_150	[p8l1830t2426r2142b2466],
15	AEs	NNS	O	ae	nsubj	18	SENT_150	[p8l8t2509r145b2568],
16	being	VBG	O	be	cop	18	SENT_150	[p8l166t2505r357b2589],
17	gastrointestinal	JJ	O	gastrointestinal	amod	18	SENT_150	[p8l377t2505r904b2589],
18	disorders	NNS	O	disorder	prepc_with	9	SENT_150	[p8l925t2505r1259b2577],
19	,	,	O	,	_	0	SENT_150	[p8l925t2505r1259b2577],
20	jaundice	NN	O	jaundice	conj_and	18	SENT_150	[p8l1277t2505r1589b2589],
21	,	,	O	,	_	0	SENT_150	[p8l1277t2505r1589b2589],
22	and	CC	O	and	_	0	SENT_150	[p8l1613t2505r1739b2568],
23	rash	NN	O	rash	prepc_with	9	SENT_150	[p8l1760t2497r2062b2568],
24	.29	CD	NUMBER	.29	number	25	SENT_150	[p8l1760t2497r2062b2568],
25	’30	CD	NUMBER	’30	dep	23	SENT_150	[p8l1760t2497r2062b2568],

1	In	IN	O	in	_	0	SENT_151	[p8l83t2613r158b2670],
2	a	DT	O	a	det	3	SENT_151	[p8l188t2631r223b2671],
3	phase	NN	O	phase	prep_in	28	SENT_151	[p8l250t2608r458b2691],
4	III	CD	NUMBER	iii	num	3	SENT_151	[p8l489t2613r599b2680],
5	,	,	O	,	_	0	SENT_151	[p8l489t2613r599b2680],
6	randomized	VBN	O	randomize	partmod	3	SENT_151	[p8l631t2608r1095b2680],
7	,	,	O	,	_	0	SENT_151	[p8l631t2608r1095b2680],
8	double-blind	JJ	O	double-blind	amod	11	SENT_151	[p8l1126t2608r1625b2680],
9	,	,	O	,	_	0	SENT_151	[p8l1126t2608r1625b2680],
10	placebocontrolled	JJ	O	placebocontrolled	amod	11	SENT_151	[p8l1655t2608r2139b2691, p8l8t2711r242b2774],
11	trial	NN	O	trial	nsubj	28	SENT_151	[p8l263t2711r408b2774],
12	of	IN	O	of	_	0	SENT_151	[p8l432t2711r506b2774],
13	treatment-naive	JJ	O	treatment-naive	amod	15	SENT_151	[p8l519t2717r1083b2774],
14	HCV	NN	O	hcv	nn	15	SENT_151	[p8l1108t2715r1289b2774],
15	genotype	NN	O	genotype	prep_of	11	SENT_151	[p8l1311t2723r1632b2795],
16	1	CD	NUMBER	1	num	17	SENT_151	[p8l1661t2718r1686b2773],
17	patients	NNS	O	patient	dep	15	SENT_151	[p8l1714t2717r2011b2794],
18	,	,	O	,	_	0	SENT_151	[p8l1714t2717r2011b2794],
19	the	DT	O	the	det	20	SENT_151	[p8l2036t2711r2144b2774],
20	addition	NN	O	addition	appos	15	SENT_151	[p8l10t2814r308b2877],
21	of	IN	O	of	_	0	SENT_151	[p8l334t2814r409b2877],
22	faldaprevir	NN	O	faldaprevir	prep_of	20	SENT_151	[p8l425t2814r814b2897],
23	to	TO	O	to	_	0	SENT_151	[p8l837t2826r904b2877],
24	a	DT	O	a	det	25	SENT_151	[p8l932t2837r966b2877],
25	regimen	NN	O	regimen	prep_to	22	SENT_151	[p8l991t2820r1282b2898],
26	of	IN	O	of	_	0	SENT_151	[p8l1309t2814r1384b2877],
27	PEG+RBV	NN	O	peg+rbv	prep_of	25	SENT_151	[p8l1400t2818r1779b2877],
28	improved	VBD	O	improve	_	0	SENT_151	[p8l1804t2814r2144b2897],
29	SVR	NNP	O	SVR	nn	30	SENT_151	[p8l10t2921r170b2980],
30	rates	NNS	O	rate	dobj	28	SENT_151	[p8l195t2929r382b2980],
31	.	.	O	.	_	0	SENT_151	[p8l195t2929r382b2980],

1	Patients	NNS	O	patient	nsubjpass	11	SENT_152	[p8l414t2922r721b2989],
2	,	,	O	,	_	0	SENT_152	[p8l414t2922r721b2989],
3	including	VBG	O	include	_	0	SENT_152	[p8l750t2917r1098b3001],
4	17	CD	PERCENT	17	num	5	SENT_152	[p8l1130t2922r1272b2982],
5	%	NN	PERCENT	%	prep_including	1	SENT_152	[p8l1130t2922r1272b2982],
6	with	IN	O	with	_	0	SENT_152	[p8l1299t2917r1461b2980],
7	advanced	JJ	O	advanced	amod	8	SENT_152	[p8l1488t2917r1831b2980],
8	ﬁbrosis	NN	O	ﬁbrosis	prep_with	5	SENT_152	[p8l1856t2917r2139b2989],
9	,	,	O	,	_	0	SENT_152	[p8l1856t2917r2139b2989],
10	were	VBD	O	be	auxpass	11	SENT_152	[p8l8t3042r179b3082],
11	treated	VBN	O	treat	_	0	SENT_152	[p8l210t3019r470b3082],
12	with	IN	O	with	_	0	SENT_152	[p8l498t3019r662b3082],
13	PEG+RBV	NN	O	peg+rbv	prep_with	11	SENT_152	[p8l695t3023r1087b3082],
14	for	IN	O	for	_	0	SENT_152	[p8l1118t3019r1223b3082],
15	24	CD	DURATION	24	num	16	SENT_152	[p8l1254t3026r1337b3081],
16	weeks	NNS	NUMBER	week	prep_for	13	SENT_152	[p8l1366t3019r1586b3082],
17	and	CC	O	and	cc	11	SENT_152	[p8l1619t3019r1753b3082],
18	then	RB	O	then	advmod	11	SENT_152	[p8l1782t3019r1947b3082],
19	with	IN	O	with	dep	11	SENT_152	[p8l1977t3019r2141b3082],

1	120	CD	NUMBER	120	num	3	SENT_153	[p8l16t3129r134b3185],
2	mg	NN	O	mg	nn	3	SENT_153	[p8l153t3145r265b3206],
3	faldaprevir	NN	O	faldaprevir	_	0	SENT_153	[p8l290t3122r686b3205],
4	a	DT	DURATION	a	det	5	SENT_153	[p8l712t3145r747b3185],
5	day	NN	DURATION	day	dep	3	SENT_153	[p8l773t3122r909b3206],
6	,	,	O	,	_	0	SENT_153	[p8l773t3122r909b3206],
7	240	CD	NUMBER	240	num	9	SENT_153	[p8l937t3129r1061b3185],
8	mg	NN	O	mg	nn	9	SENT_153	[p8l1080t3145r1192b3206],
9	faldaprevir	NN	O	faldaprevir	npadvmod	10	SENT_153	[p8l1217t3122r1613b3205],
10	once	RB	DATE	once	advmod	3	SENT_153	[p8l1639t3145r1805b3185],
11	a	DT	DURATION	a	det	12	SENT_153	[p8l1833t3145r1867b3185],
12	day	NN	DURATION	day	dep	3	SENT_153	[p8l1893t3122r2019b3206],
13	for	IN	O	for	_	0	SENT_153	[p8l2042t3122r2144b3185],
14	12	CD	DURATION	12	num	15	SENT_153	[p8l16t3232r87b3287],
15	weeks	NNS	NUMBER	week	prep_for	12	SENT_153	[p8l109t3225r334b3297],
16	,	,	O	,	_	0	SENT_153	[p8l109t3225r334b3297],
17	or	CC	O	or	_	0	SENT_153	[p8l358t3248r430b3288],
18	placebo	NN	O	placebo	dep	3	SENT_153	[p8l451t3225r716b3308],
19	for	IN	O	for	_	0	SENT_153	[p8l740t3225r838b3288],
20	24	CD	DURATION	24	num	21	SENT_153	[p8l859t3232r938b3287],
21	weeks	NNS	NUMBER	week	prep_for	18	SENT_153	[p8l959t3225r1182b3288],
22	.	.	O	.	_	0	SENT_153	[p8l959t3225r1182b3288],

1	Treatment	NN	O	treatment	nn	2	SENT_154	[p8l1207t3228r1565b3288],
2	duration	NN	O	duration	nsubj	9	SENT_154	[p8l1587t3225r1886b3288],
3	for	IN	O	for	_	0	SENT_154	[p8l1907t3225r2006b3288],
4	faldaprevir	NN	O	faldaprevir	nn	5	SENT_154	[p8l2027t3225r2138b3288, p8l10t3328r715b3412],
5	—	NN	O	—	prep_for	2	SENT_154	[p8l2027t3225r2138b3288, p8l10t3328r715b3412],
6	containing	VBG	O	contain	partmod	5	SENT_154	[p8l2027t3225r2138b3288, p8l10t3328r715b3412],
7	regimens	NNS	O	regimen	dobj	6	SENT_154	[p8l737t3334r1056b3412],
8	was	VBD	O	be	cop	9	SENT_154	[p8l1078t3351r1206b3391],
9	response	NN	O	response	_	0	SENT_154	[p8l1229t3350r1536b3411],
10	guided	VBD	O	guide	rcmod	9	SENT_154	[p8l1559t3328r1817b3412],
11	,	,	O	,	_	0	SENT_154	[p8l1559t3328r1817b3412],
12	enabling	VBG	O	enable	xcomp	10	SENT_154	[p8l1843t3328r2143b3412],
13	those	DT	O	those	dobj	12	SENT_154	[p8l8t3431r203b3494],
14	with	IN	O	with	_	0	SENT_154	[p8l231t3431r393b3494],
15	viral	JJ	O	viral	amod	16	SENT_154	[p8l418t3431r585b3494],
16	loads	NNS	O	load	prep_with	13	SENT_154	[p8l611t3431r802b3494],
17	<	JJR	O	<	dep	16	SENT_154	[p8l834t3438r963b3494],
18	25	CD	NUMBER	25	num	19	SENT_154	[p8l834t3438r963b3494],
19	IU	NN	O	iu	dep	17	SENT_154	[p8l994t3435r1117b3497],
20	/	:	O	/	punct	21	SENT_154	[p8l994t3435r1117b3497],
21	ml	NN	O	ml	dep	12	SENT_154	[p8l1124t3431r1218b3493],
22	(	CD	NUMBER	(	num	21	SENT_154	[p8l1249t3431r1505b3508],
23	Roche	NNP	MISC	Roche	nn	27	SENT_154	[p8l1249t3431r1505b3508],
24	COBAS	NNP	MISC	COBAS	nn	27	SENT_154	[p8l1535t3435r1813b3494],
25	TaqMan	NNP	MISC	TaqMan	nn	27	SENT_154	[p8l1843t3434r2143b3514],
26	HCV	NNP	MISC	HCV	nn	27	SENT_154	[p8l10t3538r195b3598],
27	Test	NNP	MISC	Test	dep	21	SENT_154	[p8l220t3537r381b3606],
28	,	,	O	,	_	0	SENT_154	[p8l220t3537r381b3606],
29	v2	NN	O	v2	nn	31	SENT_154	[p8l406t3535r582b3611],
30	.0	CD	NUMBER	.0	num	31	SENT_154	[p8l406t3535r582b3611],
31	)	NN	O	)	dep	12	SENT_154	[p8l406t3535r582b3611],
32	at	IN	O	at	_	0	SENT_154	[p8l613t3546r674b3597],
33	week	NN	DURATION	week	prep_at	31	SENT_154	[p8l697t3534r880b3597],
34	4	CD	NUMBER	4	num	33	SENT_154	[p8l902t3541r941b3596],
35	and	CC	O	and	_	0	SENT_154	[p8l967t3534r1098b3597],
36	an	DT	O	a	det	39	SENT_154	[p8l1124t3557r1206b3597],
37	undetectable	JJ	O	undetectable	amod	39	SENT_154	[p8l1232t3534r1692b3597],
38	viral	JJ	O	viral	amod	39	SENT_154	[p8l1715t3534r1878b3597],
39	load	NN	O	load	conj_and	21	SENT_154	[p8l1903t3534r2057b3597],
40	at	IN	O	at	_	0	SENT_154	[p8l2083t3546r2144b3597],
41	week	NN	DURATION	week	prep_at	39	SENT_154	[p9l8t20r192b83],
42	8	CD	NUMBER	8	num	41	SENT_154	[p9l216t27r251b83],
43	to	TO	O	to	aux	44	SENT_154	[p9l278t32r346b83],
44	stop	VB	O	stop	xcomp	12	SENT_154	[p9l375t32r522b103],
45	therapy	NN	O	therapy	dobj	44	SENT_154	[p9l548t20r825b104],
46	at	IN	O	at	_	0	SENT_154	[p9l848t32r910b83],
47	24	CD	DURATION	24	num	48	SENT_154	[p9l935t27r1017b82],
48	weeks	NNS	NUMBER	week	prep_at	44	SENT_154	[p9l1042t20r1275b83],
49	.	.	O	.	_	0	SENT_154	[p9l1042t20r1275b83],

1	Eighty-eight	CD	PERCENT	eighty-eight	num	2	SENT_155	[p9l1304t20r1754b104],
2	percent	NN	PERCENT	percent	nsubj	11	SENT_155	[p9l1778t32r2050b103],
3	of	IN	O	of	_	0	SENT_155	[p9l2075t20r2152b83],
4	patients	NNS	O	patient	prep_of	2	SENT_155	[p9l8t129r289b206],
5	treated	VBN	O	treat	partmod	4	SENT_155	[p9l314t123r563b186],
6	with	IN	O	with	_	0	SENT_155	[p9l585t123r743b186],
7	a	DT	O	a	det	9	SENT_155	[p9l769t146r804b186],
8	faldaprevir-containing	JJ	O	faldaprevir-containing	amod	9	SENT_155	[p9l828t123r1636b207],
9	regimen	NN	O	regimen	prep_with	5	SENT_155	[p9l1660t129r1953b207],
10	were	VBD	O	be	cop	11	SENT_155	[p9l1977t146r2142b186],
11	able	JJ	O	able	_	0	SENT_155	[p9l10t226r150b289],
12	to	TO	O	to	aux	13	SENT_155	[p9l175t238r243b289],
13	stop	VB	O	stop	xcomp	11	SENT_155	[p9l271t238r417b309],
14	treatment	NN	O	treatment	dobj	13	SENT_155	[p9l442t238r793b289],
15	at	IN	O	at	_	0	SENT_155	[p9l819t238r880b289],
16	week	NN	DURATION	week	prep_at	13	SENT_155	[p9l903t226r1085b289],
17	24	CD	NUMBER	24	num	16	SENT_155	[p9l1108t233r1207b289],
18	.	.	O	.	_	0	SENT_155	[p9l1108t233r1207b289],

1	The	DT	O	the	det	4	SENT_156	[p9l1236t226r1363b289],
2	primary	JJ	O	primary	amod	4	SENT_156	[p9l1388t232r1683b310],
3	end	NN	O	end	nn	4	SENT_156	[p9l1706t226r1836b289],
4	point	NN	O	point	nsubjpass	8	SENT_156	[p9l1859t232r2050b309],
5	of	IN	O	of	_	0	SENT_156	[p9l2075t226r2151b289],
6	SVR12	NN	O	svr12	prep_of	4	SENT_156	[p9l10t333r244b392],
7	was	VBD	O	be	auxpass	8	SENT_156	[p9l267t352r394b392],
8	obtained	VBN	O	obtain	_	0	SENT_156	[p9l417t329r723b392],
9	in	IN	O	in	_	0	SENT_156	[p9l744t335r811b391],
10	79	CD	PERCENT	79	num	11	SENT_156	[p9l835t334r977b394],
11	%	NN	PERCENT	%	prep_in	8	SENT_156	[p9l835t334r977b394],
12	of	IN	O	of	_	0	SENT_156	[p9l1002t329r1077b392],
13	patients	NNS	O	patient	prep_of	11	SENT_156	[p9l1088t335r1363b412],
14	on	IN	O	on	_	0	SENT_156	[p9l1387t352r1473b392],
15	120	CD	NUMBER	120	num	17	SENT_156	[p9l1502t336r1616b392],
16	mg	NN	O	mg	nn	17	SENT_156	[p9l1633t352r1742b413],
17	faldaprevir	NN	O	faldaprevir	prep_on	13	SENT_156	[p9l1763t329r2144b412],
18	a	DT	DURATION	a	det	19	SENT_156	[p9l10t455r44b495],
19	day	NN	DURATION	day	dep	17	SENT_156	[p9l66t432r188b516],
20	and	CC	O	and	_	0	SENT_156	[p9l208t432r335b495],
21	in	IN	O	in	_	0	SENT_156	[p9l357t438r424b494],
22	80	CD	PERCENT	80	num	23	SENT_156	[p9l448t437r590b497],
23	%	NN	PERCENT	%	conj_and	11	SENT_156	[p9l448t437r590b497],
24	of	IN	O	of	_	0	SENT_156	[p9l615t432r689b495],
25	patients	NNS	O	patient	prep_of	23	SENT_156	[p9l701t438r975b515],
26	on	IN	O	on	_	0	SENT_156	[p9l999t455r1085b495],
27	240	CD	NUMBER	240	num	28	SENT_156	[p9l1108t439r1228b495],
28	mg	NN	O	mg	prep_on	25	SENT_156	[p9l1246t455r1355b516],
29	a	DT	DURATION	a	det	30	SENT_156	[p9l1376t455r1411b495],
30	day	NN	DURATION	day	dep	28	SENT_156	[p9l1433t432r1562b516],
31	.	.	O	.	_	0	SENT_156	[p9l1433t432r1562b516],

1	Among	IN	O	among	_	0	SENT_157	[p9l1587t436r1848b516],
2	patients	NNS	O	patient	prep_among	18	SENT_157	[p9l1868t438r2142b515],
3	with	IN	O	with	_	0	SENT_157	[p9l7t535r161b598],
4	the	DT	O	the	det	7	SENT_157	[p9l183t535r289b598],
5	IL28B	NN	O	il28b	nn	7	SENT_157	[p9l311t540r517b598],
6	CC	NN	O	cc	nn	7	SENT_157	[p9l543t539r650b598],
7	genotype	NN	O	genotype	prep_with	2	SENT_157	[p9l668t547r1002b619],
8	,	,	O	,	_	0	SENT_157	[p9l668t547r1002b619],
9	SVR	NN	ORGANIZATION	svr	nn	10	SENT_157	[p9l1027t539r1181b598],
10	rates	NNS	O	rate	nsubj	18	SENT_157	[p9l1200t547r1360b598],
11	on	IN	O	on	_	0	SENT_157	[p9l1384t558r1470b598],
12	triple	JJ	O	triple	amod	13	SENT_157	[p9l1491t535r1676b618],
13	therapy	NN	O	therapy	prep_on	10	SENT_157	[p9l1697t535r1962b619],
14	were	VBD	O	be	cop	18	SENT_157	[p9l1980t558r2141b598],
15	90	CD	NUMBER	90	num	18	SENT_157	[p9l10t645r88b701],
16	and	CC	O	and	_	0	SENT_157	[p9l112t638r239b701],
17	95	CD	PERCENT	95	num	18	SENT_157	[p9l262t644r404b702],
18	%	NN	PERCENT	%	_	0	SENT_157	[p9l262t644r404b702],
19	on	IN	O	on	_	0	SENT_157	[p9l430t661r516b701],
20	120	CD	NUMBER	120	num	24	SENT_157	[p9l545t645r659b701],
21	and	CC	O	and	_	0	SENT_157	[p9l684t638r811b701],
22	240	CD	NUMBER	240	num	24	SENT_157	[p9l833t645r953b701],
23	mg	NN	O	mg	nn	24	SENT_157	[p9l971t661r1080b722],
24	faldaprevir	NN	O	faldaprevir	prep_on	18	SENT_157	[p9l1101t638r1495b721],
25	,	,	O	,	_	0	SENT_157	[p9l1101t638r1495b721],
26	respectively	RB	O	respectively	advmod	18	SENT_157	[p9l1520t638r1942b722],
27	.	.	O	.	_	0	SENT_157	[p9l1520t638r1942b722],

1	In	IN	O	in	_	0	SENT_158	[p9l1968t643r2039b700],
2	all	DT	O	all	det	4	SENT_158	[p9l2063t638r2143b701],
3	three	CD	NUMBER	three	num	4	SENT_158	[p9l8t741r183b804],
4	arms	NNS	O	arm	prep_in	19	SENT_158	[p9l207t764r373b804],
5	of	IN	O	of	_	0	SENT_158	[p9l396t741r469b804],
6	the	DT	O	the	det	7	SENT_158	[p9l481t741r588b804],
7	study	NN	O	study	prep_of	4	SENT_158	[p9l611t741r806b825],
8	,	,	O	,	_	0	SENT_158	[p9l611t741r806b825],
9	discontinuation	NN	O	discontinuation	nn	10	SENT_158	[p9l831t741r1374b804],
10	rates	NNS	O	rate	nsubj	13	SENT_158	[p9l1396t753r1555b804],
11	were	VBD	O	be	cop	13	SENT_158	[p9l1576t764r1736b804],
12	4	CD	PERCENT	4	number	13	SENT_158	[p9l1758t746r1966b813],
13	—	CD	PERCENT	—	dep	19	SENT_158	[p9l1758t746r1966b813],
14	5	CD	PERCENT	5	number	15	SENT_158	[p9l1758t746r1966b813],
15	%	NN	PERCENT	%	amod	13	SENT_158	[p9l1758t746r1966b813],
16	,	,	O	,	_	0	SENT_158	[p9l1758t746r1966b813],
17	serious	JJ	O	serious	amod	18	SENT_158	[p9l1991t747r2140b804, p9l10t866r128b907],
18	AEs	NNS	O	ae	nsubj	19	SENT_158	[p9l153t847r293b907],
19	occurred	VBD	O	occur	_	0	SENT_158	[p9l319t843r636b907],
20	6	CD	PERCENT	6	num	21	SENT_158	[p9l661t849r852b908],
21	—	NN	PERCENT	—	dobj	19	SENT_158	[p9l661t849r852b908],
22	7	CD	PERCENT	7	number	23	SENT_158	[p9l661t849r852b908],
23	%	NN	PERCENT	%	amod	21	SENT_158	[p9l661t849r852b908],
24	of	IN	O	of	_	0	SENT_158	[p9l880t843r955b907],
25	the	DT	O	the	det	26	SENT_158	[p9l969t843r1078b907],
26	time	NN	O	time	prep_of	21	SENT_158	[p9l1103t849r1280b915],
27	,	,	O	,	_	0	SENT_158	[p9l1103t849r1280b915],
28	and	CC	O	and	_	0	SENT_158	[p9l1308t843r1436b907],
29	anemia	NN	O	anemia	nsubjpass	31	SENT_158	[p9l1461t849r1718b907],
30	was	VBD	O	be	auxpass	31	SENT_158	[p9l1740t866r1868b907],
31	seen	VBN	O	see	conj_and	19	SENT_158	[p9l1895t866r2048b907],
32	in	IN	O	in	_	0	SENT_158	[p9l2073t849r2141b906],
33	2	CD	PERCENT	2	number	34	SENT_158	[p9l9t953r199b1012],
34	—	CD	PERCENT	—	prep_in	31	SENT_158	[p9l9t953r199b1012],
35	3	CD	PERCENT	3	num	36	SENT_158	[p9l9t953r199b1012],
36	%	NN	PERCENT	%	dobj	31	SENT_158	[p9l9t953r199b1012],
37	of	IN	O	of	_	0	SENT_158	[p9l225t947r299b1010],
38	patients	NNS	O	patient	prep_of	36	SENT_158	[p9l312t953r606b1030],
39	.	.	O	.	_	0	SENT_158	[p9l312t953r606b1030],

1	Grade	NNP	O	Grade	nsubjpass	5	SENT_159	[p9l633t947r845b1010],
2	3	CD	NUMBER	3	num	3	SENT_159	[p9l870t954r903b1010],
3	rash	NN	O	rash	dep	1	SENT_159	[p9l929t947r1075b1010],
4	was	VBD	O	be	auxpass	5	SENT_159	[p9l1096t970r1224b1010],
5	seen	VBN	O	see	_	0	SENT_159	[p9l1248t970r1400b1010],
6	in	IN	O	in	_	0	SENT_159	[p9l1423t953r1490b1009],
7	<	JJR	O	<	prep_in	5	SENT_159	[p9l1516t953r1663b1011],
8	1	CD	PERCENT	1	number	9	SENT_159	[p9l1516t953r1663b1011],
9	%	NN	PERCENT	%	amod	7	SENT_159	[p9l1516t953r1663b1011],
10	of	IN	O	of	_	0	SENT_159	[p9l1689t947r1763b1010],
11	patients	NNS	O	patient	prep_of	7	SENT_159	[p9l1776t953r2052b1030],
12	in	IN	O	in	_	0	SENT_159	[p9l2075t953r2143b1009],
13	each	DT	O	each	det	14	SENT_159	[p9l10t1050r166b1113],
14	arm	NN	O	arm	prep_in	11	SENT_159	[p9l189t1073r344b1113],
15	.	.	O	.	_	0	SENT_159	[p9l189t1073r344b1113],

1	Results	NNS	O	result	nsubj	2	SENT_160	[p9l371t1050r619b1113],
2	indicated	VBD	O	indicate	_	0	SENT_160	[p9l642t1050r967b1113],
3	that	IN	O	that	complm	5	SENT_160	[p9l989t1050r1125b1113],
4	there	EX	O	there	expl	5	SENT_160	[p9l1146t1050r1324b1113],
5	was	VBD	O	be	ccomp	2	SENT_160	[p9l1345t1073r1472b1113],
6	no	DT	O	no	det	8	SENT_160	[p9l1496t1073r1582b1113],
7	clear	JJ	O	clear	amod	8	SENT_160	[p9l1607t1050r1772b1113],
8	advantage	NN	O	advantage	nsubj	5	SENT_160	[p9l1794t1050r2144b1134],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_161	[p9l22t1199r141b1220],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_161	[p9l150t1199r375b1220],
3	&	CC	O	&	_	0	SENT_161	[p9l382t1199r602b1220],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_161	[p9l382t1199r602b1220],
5	|	CD	NUMBER	|	num	6	SENT_161	[p9l382t1199r602b1220],
6	CS	NNP	O	CS	conj_and	2	SENT_161	[p9l382t1199r602b1220],
7	|	NNP	O	|	nn	8	SENT_161	[p9l612t1197r614b1227],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_161	[p9l622t1199r730b1220],
9	95	CD	NUMBER	95	num	10	SENT_161	[p9l738t1199r765b1220],
10	NUMBER	NN	O	number	dep	12	SENT_161	[p9l775t1199r883b1220],
11	1	CD	NUMBER	1	num	12	SENT_161	[p9l893t1200r900b1220],
12	|	CD	NUMBER	|	dep	15	SENT_161	[p9l914t1197r916b1227],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_161	[p9l925t1199r1043b1220],
14	2014	CD	DATE	2014	num	15	SENT_161	[p9l1051t1199r1109b1220],
15	81	CD	DATE	81	_	0	SENT_161	[p9l2110t1199r2137b1220],

1	to	TO	O	to	dep	18	SENT_162	[p9l9t1587r76b1638],
2	triple	JJ	O	triple	amod	3	SENT_162	[p9l101t1575r291b1658],
3	therapy	NN	O	therapy	pobj	1	SENT_162	[p9l315t1575r587b1659],
4	with	IN	O	with	_	0	SENT_162	[p9l607t1575r764b1638],
5	240	CD	NUMBER	240	num	7	SENT_162	[p9l790t1582r912b1638],
6	mg	NN	O	mg	nn	7	SENT_162	[p9l931t1598r1041b1659],
7	faldaprevir	NN	O	faldaprevir	prep_with	3	SENT_162	[p9l1064t1575r1453b1658],
8	a	DT	DURATION	a	det	9	SENT_162	[p9l1478t1598r1513b1638],
9	day	NN	DURATION	day	dep	7	SENT_162	[p9l1538t1575r1662b1659],
10	in	IN	O	in	_	0	SENT_162	[p9l1684t1581r1752b1637],
11	relation	NN	O	relation	prep_in	1	SENT_162	[p9l1778t1575r2050b1638],
12	to	TO	O	to	_	0	SENT_162	[p9l2074t1587r2142b1638],
13	120	CD	NUMBER	120	num	15	SENT_162	[p9l16t1680r132b1736],
14	mg	NN	O	mg	nn	15	SENT_162	[p9l150t1696r259b1757],
15	faldaprevir	NN	O	faldaprevir	prep_to	1	SENT_162	[p9l282t1673r668b1756],
16	a	DT	DURATION	a	det	17	SENT_162	[p9l692t1696r726b1736],
17	day	NN	DURATION	day	dep	15	SENT_162	[p9l750t1665r945b1757],
18	.31	CD	NUMBER	.31	_	0	SENT_162	[p9l750t1665r945b1757],

1	MK-51	NN	O	mk-51	nsubj	10	SENT_163	[p9l12t1888r226b1943],
2	72	CD	NUMBER	72	num	3	SENT_163	[p9l243t1889r323b1942],
3	MK	NN	O	mk	dep	1	SENT_163	[p9l9t1988r208b2046],
4	—	CD	NUMBER	—	number	5	SENT_163	[p9l9t1988r208b2046],
5	5	CD	NUMBER	5	dep	1	SENT_163	[p9l9t1988r208b2046],
6	172	CD	NUMBER	172	dep	5	SENT_163	[p9l221t1990r332b2046],
7	is	VBZ	O	be	cop	10	SENT_163	[p9l354t1989r403b2046],
8	a	DT	O	a	det	10	SENT_163	[p9l425t2006r459b2046],
9	macrocyclic	JJ	O	macrocyclic	amod	10	SENT_163	[p9l477t1983r884b2067],
10	NS3	NN	O	ns3	_	0	SENT_163	[p9l903t1987r1072b2049],
11	/	:	O	/	punct	13	SENT_163	[p9l903t1987r1072b2049],
12	4A	NN	O	4a	nn	13	SENT_163	[p9l1076t1987r1173b2045],
13	P1	NN	O	p1	dep	10	SENT_163	[p9l1194t1988r1265b2045],
14	with	IN	O	with	_	0	SENT_163	[p9l1284t1983r1435b2046],
15	broad	JJ	O	broad	amod	16	SENT_163	[p9l1453t1983r1652b2046],
16	activity	NN	O	activity	prep_with	13	SENT_163	[p9l1672t1989r1920b2067],
17	across	IN	O	across	_	0	SENT_163	[p9l1937t2006r2142b2046],
18	multiple	JJ	O	multiple	amod	20	SENT_163	[p9l9t2086r286b2169],
19	HCV	NN	O	hcv	nn	20	SENT_163	[p9l306t2090r482b2149],
20	genotypes	NNS	O	genotype	prep_across	16	SENT_163	[p9l500t2098r834b2170],
21	and	CC	O	and	_	0	SENT_163	[p9l855t2086r978b2149],
22	clinically	RB	O	clinically	advmod	23	SENT_163	[p9l997t2086r1297b2170],
23	important	JJ	O	important	amod	25	SENT_163	[p9l1313t2092r1651b2169],
24	resistance	NN	O	resistance	nn	25	SENT_163	[p9l1670t2092r1994b2149],
25	variants	NNS	O	variant	conj_and	10	SENT_163	[p9l2011t2109r2140b2149, p9l10t2195r188b2261],
26	;	:	O	;	_	0	SENT_163	[p9l2011t2109r2140b2149, p9l10t2195r188b2261],
27	it	PRP	O	it	nsubj	28	SENT_163	[p9l211t2195r256b2252],
28	is	VBZ	O	be	parataxis	10	SENT_163	[p9l276t2195r326b2252],
29	currently	RB	DATE	currently	advmod	28	SENT_163	[p9l349t2189r664b2273],
30	in	IN	O	in	_	0	SENT_163	[p9l682t2195r748b2251],
31	phase	NN	O	phase	nn	33	SENT_163	[p9l768t2189r962b2272],
32	II	CD	NUMBER	ii	num	33	SENT_163	[p9l984t2194r1037b2251],
33	trials	NNS	O	trial	prep_in	28	SENT_163	[p9l1058t2189r1247b2252],
34	.	.	O	.	_	0	SENT_163	[p9l1058t2189r1247b2252],

1	Mutations	NNS	O	mutation	nsubj	10	SENT_164	[p9l1271t2194r1619b2252],
2	within	IN	O	within	_	0	SENT_164	[p9l1640t2189r1862b2252],
3	R155	NN	O	r155	prep_within	1	SENT_164	[p9l1884t2194r2055b2252],
4	of	IN	O	of	_	0	SENT_164	[p9l2079t2189r2153b2252],
5	NS3	NN	O	ns3	nn	6	SENT_164	[p9l9t2296r153b2355],
6	protease	NN	O	protease	prep_of	3	SENT_164	[p9l179t2304r474b2375],
7	are	VBP	O	be	cop	10	SENT_164	[p9l499t2315r602b2355],
8	relatively	RB	O	relatively	advmod	9	SENT_164	[p9l627t2292r949b2376],
9	common	JJ	O	common	amod	10	SENT_164	[p9l971t2315r1286b2355],
10	variants	NNS	O	variant	_	0	SENT_164	[p9l1308t2298r1589b2355],
11	that	WDT	O	that	nsubj	13	SENT_164	[p9l1613t2292r1751b2355],
12	can	MD	O	can	aux	13	SENT_164	[p9l1775t2315r1895b2355],
13	confer	VB	O	confer	rcmod	10	SENT_164	[p9l1920t2292r2144b2355],
14	viral	JJ	O	viral	amod	15	SENT_164	[p9l7t2395r163b2458],
15	resistance	NN	O	resistance	dobj	13	SENT_164	[p9l185t2401r521b2458],
16	against	IN	O	against	_	0	SENT_164	[p9l545t2401r786b2479],
17	the	DT	O	the	det	18	SENT_164	[p9l806t2395r913b2458],
18	majority	NN	O	majority	prep_against	13	SENT_164	[p9l936t2401r1231b2479],
19	of	IN	O	of	_	0	SENT_164	[p9l1251t2395r1325b2458],
20	PIS	NN	O	pi	prep_of	18	SENT_164	[p9l1339t2400r1461b2467],
21	;	:	O	;	_	0	SENT_164	[p9l1339t2400r1461b2467],
22	however	RB	O	however	advmod	20	SENT_164	[p9l1484t2395r1788b2467],
23	,	,	O	,	_	0	SENT_164	[p9l1484t2395r1788b2467],
24	MK	NN	O	mk	appos	20	SENT_164	[p9l1813t2400r2141b2458],
25	—	CD	NUMBER	—	num	29	SENT_164	[p9l1813t2400r2141b2458],
26	5172	CD	NUMBER	5172	num	27	SENT_164	[p9l1813t2400r2141b2458],
27	shows	NNS	O	show	npadvmod	28	SENT_164	[p9l10t2498r218b2561],
28	potent	JJ	O	potent	amod	29	SENT_164	[p9l240t2510r465b2581],
29	activity	NN	O	activity	dep	24	SENT_164	[p9l487t2504r742b2582],
30	against	IN	O	against	_	0	SENT_164	[p9l763t2504r1004b2582],
31	viruses	NNS	O	virus	prep_against	13	SENT_164	[p9l1023t2504r1267b2561],
32	harboring	VBG	O	harbor	partmod	31	SENT_164	[p9l1289t2498r1638b2582],
33	the	DT	O	the	det	34	SENT_164	[p9l1658t2498r1765b2561],
34	variants	NNS	O	variant	dobj	32	SENT_164	[p9l1786t2490r2142b2561],
35	.	.	O	.	_	0	SENT_164	[p9l1786t2490r2142b2561],

1	”	NN	O	”	nsubj	31	SENT_165	[p9l1786t2490r2142b2561],
2	When	WRB	O	when	advmod	3	SENT_165	[p9l8t2601r217b2664],
3	given	VBN	O	give	dep	1	SENT_165	[p9l237t2607r418b2685],
4	at	IN	O	at	_	0	SENT_165	[p9l439t2613r498b2664],
5	a	DT	O	a	det	6	SENT_165	[p9l518t2624r552b2664],
6	dose	NN	O	dose	prep_at	3	SENT_165	[p9l572t2601r724b2664],
7	of	IN	O	of	_	0	SENT_165	[p9l746t2601r819b2664],
8	400	CD	NUMBER	400	num	9	SENT_165	[p9l828t2608r947b2664],
9	mg	NN	O	mg	prep_of	6	SENT_165	[p9l963t2624r1070b2685],
10	a	DT	DURATION	a	det	11	SENT_165	[p9l1090t2624r1124b2664],
11	day	NN	DURATION	day	dep	9	SENT_165	[p9l1143t2601r1264b2685],
12	for	IN	O	for	_	0	SENT_165	[p9l1280t2601r1377b2664],
13	7	CD	DURATION	7	num	14	SENT_165	[p9l1397t2609r1433b2664],
14	days	NNS	NUMBER	day	prep_for	3	SENT_165	[p9l1454t2601r1601b2685],
15	to	TO	O	to	_	0	SENT_165	[p9l1621t2613r1686b2664],
16	patients	NNS	O	patient	prep_to	3	SENT_165	[p9l1706t2607r1973b2684],
17	with	IN	O	with	_	0	SENT_165	[p9l1992t2601r2144b2664],
18	genotypes	NNS	O	genotype	prep_with	16	SENT_165	[p9l9t2716r343b2788],
19	1	CD	NUMBER	1	num	18	SENT_165	[p9l370t2711r394b2766],
20	and	CC	O	and	_	0	SENT_165	[p9l420t2704r543b2767],
21	3	CD	NUMBER	3	conj_and	18	SENT_165	[p9l563t2711r616b2776],
22	,	,	O	,	_	0	SENT_165	[p9l563t2711r616b2776],
23	mean	VB	O	mean	dep	3	SENT_165	[p9l636t2727r821b2767],
24	maximal	JJ	O	maximal	amod	25	SENT_165	[p9l840t2704r1132b2767],
25	reductions	NNS	O	reduction	dobj	23	SENT_165	[p9l1151t2704r1504b2767],
26	in	IN	O	in	_	0	SENT_165	[p9l1524t2710r1588b2766],
27	HCV	NN	O	hcv	nn	28	SENT_165	[p9l1609t2708r1784b2767],
28	RNA	NN	O	rna	prep_in	23	SENT_165	[p9l1803t2708r1970b2767],
29	were	VBD	O	be	cop	31	SENT_165	[p9l1987t2727r2144b2767],
30	5.4	CD	NUMBER	5.4	num	31	SENT_165	[p9l11t2806r296b2890],
31	log10	NN	O	log10	_	0	SENT_165	[p9l11t2806r296b2890],
32	and	CC	O	and	_	0	SENT_165	[p9l320t2806r446b2869],
33	3.98	CD	NUMBER	3.98	num	34	SENT_165	[p9l468t2806r814b2890],
34	log10	NN	O	log10	conj_and	31	SENT_165	[p9l468t2806r814b2890],
35	,	,	O	,	_	0	SENT_165	[p9l468t2806r814b2890],
36	respectively	RB	O	respectively	advmod	37	SENT_165	[p9l837t2798r1319b2890],
37	.33	CD	NUMBER	.33	rcmod	34	SENT_165	[p9l837t2798r1319b2890],

1	In	IN	O	in	_	0	SENT_166	[p9l84t2914r156b2971],
2	a	DT	O	a	det	3	SENT_166	[p9l180t2932r215b2972],
3	phase	NN	O	phase	prep_in	18	SENT_166	[p9l236t2909r435b2992],
4	II	CD	NUMBER	ii	num	3	SENT_166	[p9l460t2914r534b2981],
5	,	,	O	,	_	0	SENT_166	[p9l460t2914r534b2981],
6	dose-escalating	JJ	O	dose-escalating	amod	7	SENT_166	[p9l560t2909r1100b2993],
7	study	NN	O	study	nsubjpass	18	SENT_166	[p9l1123t2909r1313b2993],
8	of	IN	O	of	_	0	SENT_166	[p9l1334t2909r1409b2972],
9	previously	RB	DATE	previously	advmod	10	SENT_166	[p9l1422t2909r1789b2993],
10	untreated	JJ	O	untreated	amod	12	SENT_166	[p9l1809t2909r2145b2972],
11	HCV	NN	O	hcv	nn	12	SENT_166	[p9l10t3016r195b3075],
12	genotype	NN	O	genotype	prep_of	7	SENT_166	[p9l222t3024r547b3096],
13	1	CD	NUMBER	1	num	14	SENT_166	[p9l582t3019r607b3074],
14	patients	NNS	O	patient	tmod	12	SENT_166	[p9l639t3018r942b3095],
15	,	,	O	,	_	0	SENT_166	[p9l639t3018r942b3095],
16	MK-5172	NN	O	mk-5172	appos	14	SENT_166	[p9l971t3017r1310b3075],
17	was	VBD	O	be	auxpass	18	SENT_166	[p9l1338t3035r1468b3075],
18	shown	VBN	O	show	_	0	SENT_166	[p9l1497t3012r1728b3075],
19	to	TO	O	to	aux	20	SENT_166	[p9l1754t3024r1822b3075],
20	increase	VB	O	increase	xcomp	18	SENT_166	[p9l1851t3018r2142b3075],
21	SVR	NNP	ORGANIZATION	SVR	nn	22	SENT_166	[p9l11t3119r164b3178],
22	rates	NNS	O	rate	dobj	20	SENT_166	[p9l182t3127r340b3178],
23	as	IN	O	as	prep	20	SENT_166	[p9l362t3138r426b3178],
24	compared	VBN	O	compare	_	0	SENT_166	[p9l449t3115r791b3198],
25	with	IN	O	with	prepc_compared_with	20	SENT_166	[p9l808t3115r961b3178],
26	PEG+RBV	NN	O	peg+rbv	pobj	20	SENT_166	[p9l983t3119r1355b3178],
27	.	.	O	.	_	0	SENT_166	[p9l983t3119r1355b3178],

1	The	DT	O	the	det	2	SENT_167	[p9l1379t3115r1504b3178],
2	study	NN	O	study	nsubj	3	SENT_167	[p9l1526t3115r1712b3199],
3	randomized	VBD	O	randomize	_	0	SENT_167	[p9l1730t3115r2144b3178],
4	patients	NNS	O	patient	dobj	3	SENT_167	[p9l8t3224r273b3301],
5	to	TO	O	to	aux	6	SENT_167	[p9l293t3230r358b3281],
6	receive	VB	O	receive	xcomp	3	SENT_167	[p9l379t3224r611b3281],
7	MK-5172	NN	O	mk-5172	dobj	6	SENT_167	[p9l631t3223r953b3281],
8	at	IN	O	at	_	0	SENT_167	[p9l976t3230r1034b3281],
9	doses	NNS	O	dose	prep_at	6	SENT_167	[p9l1054t3218r1236b3281],
10	of	IN	O	of	_	0	SENT_167	[p9l1257t3218r1330b3281],
11	100	CD	NUMBER	100	prep_of	9	SENT_167	[p9l1347t3225r1477b3290],
12	,	,	O	,	_	0	SENT_167	[p9l1347t3225r1477b3290],
13	200	CD	NUMBER	200	prep_at	6	SENT_167	[p9l1499t3225r1636b3290],
14	,	,	O	,	_	0	SENT_167	[p9l1499t3225r1636b3290],
15	400	CD	NUMBER	400	num	13	SENT_167	[p9l1656t3225r1794b3290],
16	,	,	O	,	_	0	SENT_167	[p9l1656t3225r1794b3290],
17	or	CC	O	or	_	0	SENT_167	[p9l1816t3241r1887b3281],
18	800	CD	NUMBER	800	prep_at	6	SENT_167	[p9l1907t3225r2023b3281],
19	mg	NN	O	mg	npadvmod	22	SENT_167	[p9l2038t3241r2145b3302],
20	a	DT	DURATION	a	det	21	SENT_167	[p9l10t3344r44b3384],
21	day	NN	DURATION	day	dep	19	SENT_167	[p9l64t3321r183b3405],
22	along	IN	O	along	advmod	13	SENT_167	[p9l201t3321r386b3405],
23	with	IN	O	with	_	0	SENT_167	[p9l402t3321r553b3384],
24	PEG+RBV	NN	O	peg+rbv	prep_with	6	SENT_167	[p9l574t3325r938b3384],
25	for	IN	O	for	_	0	SENT_167	[p9l957t3321r1053b3384],
26	12	CD	DURATION	12	num	27	SENT_167	[p9l1079t3328r1149b3383],
27	weeks	NNS	NUMBER	week	prep_for	24	SENT_167	[p9l1169t3321r1389b3393],
28	,	,	O	,	_	0	SENT_167	[p9l1169t3321r1389b3393],
29	followed	VBN	O	follow	partmod	27	SENT_167	[p9l1410t3321r1700b3384],
30	by	IN	O	by	_	0	SENT_167	[p9l1717t3321r1800b3405],
31	responseguided	VBN	O	responseguide	agent	29	SENT_167	[p9l1817t3343r2140b3404, p9l9t3424r238b3508],
32	PEG+RBV	NN	O	peg+rbv	nn	33	SENT_167	[p9l258t3428r617b3487],
33	treatment	NN	O	treatment	dobj	31	SENT_167	[p9l635t3436r961b3487],
34	for	IN	O	for	_	0	SENT_167	[p9l979t3424r1074b3487],
35	a	DT	O	a	det	36	SENT_167	[p9l1093t3447r1127b3487],
36	total	NN	O	total	prep_for	33	SENT_167	[p9l1144t3424r1294b3487],
37	of	IN	O	of	_	0	SENT_167	[p9l1313t3424r1385b3487],
38	24-48	CD	NUMBER	24-48	num	39	SENT_167	[p9l1395t3431r1595b3487],
39	weeks	NNS	NUMBER	week	prep_of	36	SENT_167	[p9l1615t3424r1830b3487],
40	.	.	O	.	_	0	SENT_167	[p9l1615t3424r1830b3487],

1	The	DT	O	the	det	3	SENT_168	[p9l1852t3424r1975b3487],
2	control	NN	O	control	nn	3	SENT_168	[p9l1995t3447r2141b3487, p9l9t3527r130b3590],
3	group	NN	O	group	nsubjpass	5	SENT_168	[p9l151t3549r351b3611],
4	was	VBD	O	be	auxpass	5	SENT_168	[p9l374t3550r500b3590],
5	treated	VBN	O	treat	_	0	SENT_168	[p9l522t3527r760b3590],
6	with	IN	O	with	_	0	SENT_168	[p9l780t3527r933b3590],
7	boceprevir	NN	O	boceprevir	prep_with	5	SENT_168	[p9l953t3527r1324b3610],
8	plus	CC	O	plus	prep	7	SENT_168	[p9l1344t3527r1484b3610],
9	PEG+RBV	NN	O	peg+rbv	dep	8	SENT_168	[p9l1508t3531r1881b3590],
10	.	.	O	.	_	0	SENT_168	[p9l1508t3531r1881b3590],

1	SVR24	NN	O	svr24	nn	2	SENT_169	[p9l1907t3531r2141b3590],
2	rates	NNS	O	rate	nsubj	4	SENT_169	[p9l10t3641r168b3693],
3	were	VBD	O	be	cop	4	SENT_169	[p9l188t3652r349b3693],
4	86	CD	NUMBER	86	_	0	SENT_169	[p9l373t3635r468b3701],
5	,	,	O	,	_	0	SENT_169	[p9l373t3635r468b3701],
6	92	CD	NUMBER	92	conj_and	4	SENT_169	[p9l493t3636r589b3701],
7	,	,	O	,	_	0	SENT_169	[p9l493t3636r589b3701],
8	91	CD	NUMBER	91	conj_and	4	SENT_169	[p9l614t3636r710b3701],
9	,	,	O	,	_	0	SENT_169	[p9l614t3636r710b3701],
10	and	CC	PERCENT	and	_	0	SENT_169	[p9l735t3629r861b3693],
11	87	CD	PERCENT	87	num	12	SENT_169	[p9l883t3635r1024b3694],
12	%	NN	PERCENT	%	conj_and	4	SENT_169	[p9l883t3635r1024b3694],
13	in	IN	O	in	_	0	SENT_169	[p9l1049t3635r1115b3692],
14	the	DT	O	the	det	15	SENT_169	[p9l1136t3629r1242b3693],
15	100	CD	NUMBER	100	prep_in	12	SENT_169	[p9l1271t3636r1434b3701],
16	-	:	O	-	_	0	SENT_169	[p9l1271t3636r1434b3701],
17	,	,	O	,	_	0	SENT_169	[p9l1271t3636r1434b3701],
18	200	CD	NUMBER	200	dep	12	SENT_169	[p9l1458t3636r1627b3701],
19	-	:	O	-	_	0	SENT_169	[p9l1458t3636r1627b3701],
20	,	,	O	,	_	0	SENT_169	[p9l1458t3636r1627b3701],
21	400	CD	NUMBER	400	dep	18	SENT_169	[p9l1650t3636r1820b3701],
22	-	:	O	-	_	0	SENT_169	[p9l1650t3636r1820b3701],
23	,	,	O	,	_	0	SENT_169	[p9l1650t3636r1820b3701],
24	and	CC	O	and	_	0	SENT_169	[p9l1845t3629r1971b3693],
25	800mg	NN	O	800mg	conj_and	12	SENT_169	[p9l1993t3636r2140b3693, p10l9t46r116b107],

1	cohorts	NNS	O	cohort	_	0	SENT_170	[p10l134t23r401b95],
2	,	,	O	,	_	0	SENT_170	[p10l134t23r401b95],
3	respectively	RB	O	respectively	advmod	1	SENT_170	[p10l422t23r823b107],
4	.	.	O	.	_	0	SENT_170	[p10l422t23r823b107],

1	Serum	NN	O	serum	nn	3	SENT_171	[p10l847t27r1065b86],
2	drug	NN	O	drug	nn	3	SENT_171	[p10l1086t23r1244b107],
3	levels	NNS	O	level	nsubj	12	SENT_171	[p10l1260t23r1441b86],
4	of	IN	O	of	_	0	SENT_171	[p10l1462t23r1534b86],
5	those	DT	O	those	prep_of	3	SENT_171	[p10l1543t23r1721b86],
6	who	WP	O	who	nsubj	9	SENT_171	[p10l1739t23r1883b86],
7	did	VBD	O	do	aux	9	SENT_171	[p10l1904t23r2013b86],
8	not	RB	O	not	neg	9	SENT_171	[p10l2031t35r2143b86],
9	achieve	VB	O	achieve	rcmod	5	SENT_171	[p10l10t126r259b189],
10	SVR	NN	ORGANIZATION	svr	dobj	9	SENT_171	[p10l281t130r432b189],
11	were	VBD	O	be	cop	12	SENT_171	[p10l448t149r607b189],
12	low	JJ	O	low	_	0	SENT_171	[p10l626t126r757b198],
13	,	,	O	,	_	0	SENT_171	[p10l626t126r757b198],
14	suggesting	VBG	O	suggest	xcomp	12	SENT_171	[p10l780t132r1135b210],
15	noncompliance	NN	O	noncompliance	dobj	14	SENT_171	[p10l1154t126r1677b209],
16	with	IN	O	with	_	0	SENT_171	[p10l1695t126r1846b189],
17	medication	NN	O	medication	nn	18	SENT_171	[p10l1866t126r2138b189, p10l9t235r146b292],
18	regimen	NN	O	regimen	prep_with	14	SENT_171	[p10l166t235r448b313],
19	as	IN	O	as	_	0	SENT_171	[p10l469t252r533b292],
20	a	DT	O	a	det	22	SENT_171	[p10l555t252r590b292],
21	possible	JJ	O	possible	amod	22	SENT_171	[p10l608t229r882b312],
22	cause	NN	O	cause	prep_as	14	SENT_171	[p10l904t252r1086b292],
23	of	IN	O	of	_	0	SENT_171	[p10l1108t229r1182b292],
24	persistent	JJ	O	persistent	amod	25	SENT_171	[p10l1191t235r1524b312],
25	infection	NN	O	infection	prep_of	22	SENT_171	[p10l1543t229r1865b292],
26	.	.	O	.	_	0	SENT_171	[p10l1543t229r1865b292],

1	Among	IN	O	among	_	0	SENT_172	[p10l1888t233r2146b313],
2	those	DT	O	those	det	3	SENT_172	[p10l9t332r193b395],
3	patients	NNS	O	patient	prep_among	15	SENT_172	[p10l215t338r486b415],
4	who	WP	O	who	nsubj	5	SENT_172	[p10l507t332r655b395],
5	received	VBD	O	receive	rcmod	3	SENT_172	[p10l679t332r964b395],
6	100	CD	NUMBER	100	num	7	SENT_172	[p10l993t339r1106b395],
7	mg	NN	O	mg	dobj	5	SENT_172	[p10l1123t355r1233b416],
8	a	DT	DURATION	a	det	9	SENT_172	[p10l1254t355r1289b395],
9	day	NN	DURATION	day	dep	7	SENT_172	[p10l1311t332r1441b416],
10	,	,	O	,	_	0	SENT_172	[p10l1311t332r1441b416],
11	91	CD	PERCENT	91	num	12	SENT_172	[p10l1467t338r1609b397],
12	%	NN	PERCENT	%	nsubj	15	SENT_172	[p10l1467t338r1609b397],
13	of	IN	O	of	_	0	SENT_172	[p10l1635t332r1709b395],
14	patients	NNS	O	patient	prep_of	12	SENT_172	[p10l1721t338r1992b415],
15	had	VBD	O	have	_	0	SENT_172	[p10l2015t332r2143b395],
16	undetectable	JJ	O	undetectable	amod	17	SENT_172	[p10l9t435r437b498],
17	RNA	NN	O	rna	dobj	15	SENT_172	[p10l458t439r625b498],
18	at	IN	O	at	_	0	SENT_172	[p10l645t447r703b498],
19	week	NN	DURATION	week	prep_at	17	SENT_172	[p10l719t435r892b498],
20	4	CD	NUMBER	4	num	19	SENT_172	[p10l908t442r963b507],
21	,	,	O	,	_	0	SENT_172	[p10l908t442r963b507],
22	making	VBG	O	make	partmod	15	SENT_172	[p10l984t435r1239b519],
23	them	PRP	O	they	nsubj	24	SENT_172	[p10l1256t435r1430b498],
24	eligible	JJ	O	eligible	xcomp	22	SENT_172	[p10l1450t435r1687b519],
25	for	IN	O	for	_	0	SENT_172	[p10l1707t435r1802b498],
26	responseguided	JJ	O	responseguided	amod	27	SENT_172	[p10l1821t457r2141b518, p10l10t538r259b622],
27	therapy	NN	O	therapy	prep_for	24	SENT_172	[p10l288t538r575b622],
28	.	.	O	.	_	0	SENT_172	[p10l288t538r575b622],

1	Ninety	CD	PERCENT	ninety	num	2	SENT_173	[p10l609t543r859b622],
2	percent	NN	PERCENT	percent	nsubj	6	SENT_173	[p10l885t550r1159b621],
3	of	IN	O	of	_	0	SENT_173	[p10l1190t538r1267b601],
4	these	DT	O	these	det	5	SENT_173	[p10l1286t538r1473b601],
5	patients	NNS	O	patient	prep_of	2	SENT_173	[p10l1503t544r1791b621],
6	achieved	VBD	O	achieve	_	0	SENT_173	[p10l1823t538r2142b601],
7	SVR24	NN	O	svr24	dobj	6	SENT_173	[p10l11t645r264b704],
8	.	.	O	.	_	0	SENT_173	[p10l11t645r264b704],

1	IL28B	NN	O	il28b	nn	2	SENT_174	[p10l289t646r496b704],
2	genotype	NN	O	genotype	nsubj	5	SENT_174	[p10l520t653r836b725],
3	did	VBD	O	do	aux	5	SENT_174	[p10l860t641r972b704],
4	not	RB	O	not	neg	5	SENT_174	[p10l994t653r1109b704],
5	appear	VB	O	appear	_	0	SENT_174	[p10l1132t663r1365b724],
6	to	TO	O	to	aux	7	SENT_174	[p10l1386t653r1452b704],
7	affect	VB	O	affect	xcomp	5	SENT_174	[p10l1478t641r1662b704],
8	SVR24	NN	O	svr24	dobj	7	SENT_174	[p10l1685t645r1940b713],
9	;	:	O	;	_	0	SENT_174	[p10l1685t645r1940b713],
10	however	RB	O	however	advmod	15	SENT_174	[p10l1964t641r2139b704, p10l10t767r164b816],
11	,	,	O	,	_	0	SENT_174	[p10l1964t641r2139b704, p10l10t767r164b816],
12	genotype	NN	O	genotype	nn	14	SENT_174	[p10l187t756r498b828],
13	1a	NN	O	1a	nn	14	SENT_174	[p10l526t751r596b807],
14	patients	NNS	O	patient	nsubj	15	SENT_174	[p10l616t750r884b827],
15	had	VBD	O	have	parataxis	5	SENT_174	[p10l906t744r1033b807],
16	lower	JJR	O	lower	amod	17	SENT_174	[p10l1052t744r1243b807],
17	SVRs	NNS	O	svr	dobj	15	SENT_174	[p10l1264t748r1445b807],
18	of	IN	O	of	_	0	SENT_174	[p10l1468t744r1542b807],
19	81-90	CD	PERCENT	81-90	num	20	SENT_174	[p10l1555t749r1844b816],
20	%	NN	PERCENT	%	prep_of	17	SENT_174	[p10l1555t749r1844b816],
21	,	,	O	,	_	0	SENT_174	[p10l1555t749r1844b816],
22	whereas	IN	O	whereas	mark	28	SENT_174	[p10l1865t744r2142b807],
23	those	DT	O	those	nsubj	28	SENT_174	[p10l9t847r191b910],
24	with	IN	O	with	_	0	SENT_174	[p10l211t847r364b910],
25	genotype	NN	O	genotype	nn	27	SENT_174	[p10l385t859r697b931],
26	1b	NN	O	1b	nn	27	SENT_174	[p10l725t847r798b910],
27	infection	NN	O	infection	prep_with	23	SENT_174	[p10l822t847r1127b910],
28	had	VBD	O	have	advcl	15	SENT_174	[p10l1147t847r1275b910],
29	92	CD	PERCENT	92	num	30	SENT_174	[p10l1296t853r1607b912],
30	—	NN	PERCENT	—	amod	33	SENT_174	[p10l1296t853r1607b912],
31	100	CD	PERCENT	100	num	32	SENT_174	[p10l1296t853r1607b912],
32	%	NN	PERCENT	%	dep	30	SENT_174	[p10l1296t853r1607b912],
33	SVRs	NNS	O	svr	dobj	28	SENT_174	[p10l1632t851r1831b910],
34	.	.	O	.	_	0	SENT_174	[p10l1632t851r1831b910],

1	The	DT	O	the	det	2	SENT_175	[p10l83t950r221b1013],
2	rate	NN	O	rate	nsubj	8	SENT_175	[p10l251t962r386b1013],
3	of	IN	O	of	_	0	SENT_175	[p10l416t950r493b1013],
4	serious	JJ	O	serious	amod	5	SENT_175	[p10l514t956r769b1013],
5	AEs	NNS	O	ae	prep_of	2	SENT_175	[p10l799t954r942b1013],
6	was	VBD	O	be	cop	8	SENT_175	[p10l971t973r1103b1013],
7	9	CD	PERCENT	9	num	8	SENT_175	[p10l1134t955r1238b1015],
8	%	NN	PERCENT	%	_	0	SENT_175	[p10l1134t955r1238b1015],
9	across	IN	O	across	_	0	SENT_175	[p10l1271t973r1491b1013],
10	all	DT	O	all	det	11	SENT_175	[p10l1522t950r1605b1013],
11	patients	NNS	O	patient	prep_across	8	SENT_175	[p10l1633t956r1920b1033],
12	given	VBN	O	give	partmod	11	SENT_175	[p10l1950t956r2144b1034],
13	MK	NNP	O	MK	iobj	12	SENT_175	[p10l9t1058r352b1116],
14	—	CD	NUMBER	—	num	13	SENT_175	[p10l9t1058r352b1116],
15	5172	CD	NUMBER	5172	num	18	SENT_175	[p10l9t1058r352b1116],
16	and	CC	O	and	_	0	SENT_175	[p10l384t1053r516b1116],
17	8	CD	PERCENT	8	num	18	SENT_175	[p10l546t1058r649b1118],
18	%	NN	PERCENT	%	dobj	12	SENT_175	[p10l546t1058r649b1118],
19	in	IN	O	in	_	0	SENT_175	[p10l681t1059r750b1115],
20	the	DT	O	the	det	22	SENT_175	[p10l779t1053r890b1116],
21	control	NN	O	control	nn	22	SENT_175	[p10l921t1053r1180b1116],
22	arm	NN	O	arm	prep_in	18	SENT_175	[p10l1210t1076r1372b1125],
23	;	:	O	;	_	0	SENT_175	[p10l1210t1076r1372b1125],
24	however	RB	O	however	advmod	36	SENT_175	[p10l1402t1053r1722b1125],
25	,	,	O	,	_	0	SENT_175	[p10l1402t1053r1722b1125],
26	only	RB	O	only	quantmod	27	SENT_175	[p10l1754t1053r1913b1137],
27	7	CD	PERCENT	7	num	28	SENT_175	[p10l1940t1059r2043b1117],
28	%	NN	PERCENT	%	nsubj	36	SENT_175	[p10l1940t1059r2043b1117],
29	of	IN	O	of	_	0	SENT_175	[p10l2075t1053r2152b1116],
30	those	DT	O	those	prep_of	28	SENT_175	[p10l9t1156r195b1219],
31	treated	VBN	O	treat	partmod	30	SENT_175	[p10l218t1156r461b1219],
32	with	IN	O	with	_	0	SENT_175	[p10l482t1156r638b1219],
33	MK	NN	O	mk	prep_with	31	SENT_175	[p10l661t1161r994b1219],
34	—	CD	NUMBER	—	number	35	SENT_175	[p10l661t1161r994b1219],
35	5172	CD	NUMBER	5172	num	33	SENT_175	[p10l661t1161r994b1219],
36	stopped	VBD	O	stop	parataxis	8	SENT_175	[p10l1020t1156r1296b1239],
37	treatment	NN	O	treatment	dobj	36	SENT_175	[p10l1317t1168r1677b1228],
38	,	,	O	,	_	0	SENT_175	[p10l1317t1168r1677b1228],
39	as	IN	O	as	_	0	SENT_175	[p10l1704t1179r1769b1219],
40	compared	VBN	O	compare	prepc_as	36	SENT_175	[p10l1793t1156r2143b1239],
41	with	IN	O	with	pcomp	40	SENT_175	[p10l8t1259r167b1322],
42	14	CD	PERCENT	14	num	43	SENT_175	[p10l202t1264r342b1324],
43	%	NN	PERCENT	%	pobj	41	SENT_175	[p10l202t1264r342b1324],
44	of	IN	O	of	_	0	SENT_175	[p10l373t1259r449b1322],
45	those	DT	O	those	prep_of	43	SENT_175	[p10l466t1259r657b1322],
46	in	IN	O	in	_	0	SENT_175	[p10l685t1265r754b1321],
47	the	DT	O	the	det	49	SENT_175	[p10l780t1259r891b1322],
48	boceprevir	NN	O	boceprevir	nn	49	SENT_175	[p10l917t1259r1306b1342],
49	arm	NN	O	arm	prep_in	45	SENT_175	[p10l1333t1282r1492b1322],
50	.	.	O	.	_	0	SENT_175	[p10l1333t1282r1492b1322],

1	Rash	NNP	O	Rash	nsubj	8	SENT_176	[p10l1524t1259r1696b1322],
2	and	CC	O	and	_	0	SENT_176	[p10l1725t1259r1856b1322],
3	anemia	NN	O	anemia	conj_and	1	SENT_176	[p10l1883t1265r2144b1322],
4	were	VBD	O	be	cop	8	SENT_176	[p10l8t1385r174b1425],
5	two	CD	NUMBER	two	num	8	SENT_176	[p10l199t1374r328b1425],
6	relatively	RB	O	relatively	advmod	7	SENT_176	[p10l355t1362r679b1446],
7	common	JJ	O	common	amod	8	SENT_176	[p10l702t1385r1018b1425],
8	AEs	NNS	O	ae	_	0	SENT_176	[p10l1043t1366r1184b1425],
9	seen	VBN	O	see	partmod	8	SENT_176	[p10l1212t1385r1366b1425],
10	across	IN	O	across	_	0	SENT_176	[p10l1392t1385r1607b1425],
11	all	DT	O	all	det	12	SENT_176	[p10l1634t1362r1716b1425],
12	groups	NNS	O	group	prep_across	9	SENT_176	[p10l1741t1384r2002b1446],
13	,	,	O	,	_	0	SENT_176	[p10l1741t1384r2002b1446],
14	but	CC	O	but	_	0	SENT_176	[p10l2027t1362r2144b1425],
15	these	DT	O	these	nsubjpass	17	SENT_176	[p10l9t1465r187b1528],
16	were	VBD	O	be	auxpass	17	SENT_176	[p10l209t1488r372b1528],
17	seen	VBN	O	see	conj_but	8	SENT_176	[p10l397t1488r548b1528],
18	with	IN	O	with	_	0	SENT_176	[p10l569t1465r724b1528],
19	higher	JJR	O	higher	amod	20	SENT_176	[p10l747t1465r974b1549],
20	frequency	NN	O	frequency	prep_with	17	SENT_176	[p10l996t1465r1347b1549],
21	in	IN	O	in	_	0	SENT_176	[p10l1367t1471r1434b1527],
22	the	DT	O	the	det	24	SENT_176	[p10l1456t1465r1564b1528],
23	boceprevir	NN	O	boceprevir	nn	24	SENT_176	[p10l1586t1465r1963b1548],
24	arm	NN	O	arm	prep_in	20	SENT_176	[p10l1986t1488r2141b1528],
25	.	.	O	.	_	0	SENT_176	[p10l1986t1488r2141b1528],

1	Hyperbilirubinemia	NN	O	hyperbilirubinemia	nn	4	SENT_177	[p10l10t1568r701b1652],
2	and	CC	O	and	_	0	SENT_177	[p10l723t1568r850b1631],
3	elevated	JJ	O	elevated	nn	4	SENT_177	[p10l872t1568r1151b1631],
4	levels	NNS	O	level	nsubjpass	8	SENT_177	[p10l1172t1568r1358b1631],
5	of	IN	O	of	_	0	SENT_177	[p10l1382t1568r1456b1631],
6	transaminases	NNS	O	transaminase	prep_of	4	SENT_177	[p10l1469t1574r1959b1631],
7	were	VBD	O	be	auxpass	8	SENT_177	[p10l1981t1591r2143b1631],
8	noted	VBN	O	note	_	0	SENT_177	[p10l9t1670r205b1733],
9	at	IN	O	at	_	0	SENT_177	[p10l227t1682r286b1733],
10	higher	JJR	O	higher	amod	11	SENT_177	[p10l305t1670r528b1754],
11	doses	NNS	O	dose	prep_at	8	SENT_177	[p10l549t1670r735b1733],
12	of	IN	O	of	_	0	SENT_177	[p10l757t1670r831b1733],
13	MK	NN	O	mk	prep_of	11	SENT_177	[p10l842t1662r1253b1733],
14	—	CD	NUMBER	—	number	15	SENT_177	[p10l842t1662r1253b1733],
15	5172.34	CD	NUMBER	5172.34	num	13	SENT_177	[p10l842t1662r1253b1733],

1	NS5A	NN	O	ns5a	nn	2	SENT_178	[p10l13t1885r201b1940],
2	INHIBITORS	NNS	O	inhibitor	_	0	SENT_178	[p10l222t1884r638b1940],
3	The	DT	O	the	det	5	SENT_178	[p10l9t1980r134b2043],
4	NS5A	NN	O	ns5a	nn	5	SENT_178	[p10l155t1984r359b2043],
5	enzyme	NN	O	enzyme	nsubj	6	SENT_178	[p10l380t2002r643b2064],
6	plays	VBZ	O	play	rcmod	2	SENT_178	[p10l663t1980r834b2064],
7	a	DT	O	a	det	8	SENT_178	[p10l857t2003r892b2043],
8	role	NN	O	role	dobj	6	SENT_178	[p10l912t1980r1041b2043],
9	in	IN	O	in	_	0	SENT_178	[p10l1063t1986r1129b2042],
10	both	CC	O	both	preconj	12	SENT_178	[p10l1148t1980r1307b2043],
11	viral	JJ	O	viral	amod	12	SENT_178	[p10l1326t1980r1481b2043],
12	replication	NN	O	replication	prep_in	8	SENT_178	[p10l1503t1980r1869b2063],
13	and	CC	O	and	_	0	SENT_178	[p10l1891t1980r2017b2043],
14	the	DT	O	the	det	15	SENT_178	[p10l2037t1980r2143b2043],
15	assembly	NN	O	assembly	conj_and	12	SENT_178	[p10l10t2082r321b2166],
16	of	IN	O	of	_	0	SENT_178	[p10l340t2082r413b2145],
17	the	DT	O	the	det	18	SENT_178	[p10l423t2082r530b2145],
18	HCV	NN	O	hcv	prep_of	2	SENT_178	[p10l551t2074r877b2145],
19	.35	CD	NUMBER	.35	num	20	SENT_178	[p10l551t2074r877b2145],
20	>	JJR	O	>	nsubj	33	SENT_178	[p10l551t2074r877b2145],
21	36	CD	NUMBER	36	num	23	SENT_178	[p10l551t2074r877b2145],
22	NS5A	NN	O	ns5a	nn	23	SENT_178	[p10l897t2086r1101b2145],
23	inhibitors	NNS	O	inhibitor	dep	20	SENT_178	[p10l1121t2082r1453b2145],
24	have	VBP	O	have	aux	26	SENT_178	[p10l1474t2082r1629b2145],
25	been	VBN	O	be	auxpass	26	SENT_178	[p10l1649t2082r1812b2145],
26	shown	VBN	O	show	rcmod	18	SENT_178	[p10l1835t2082r2056b2145],
27	to	TO	O	to	aux	29	SENT_178	[p10l2076t2094r2142b2145],
28	signiﬁcantly	RB	O	signiﬁcantly	advmod	29	SENT_178	[p10l10t2185r435b2269],
29	reduce	VB	O	reduce	xcomp	26	SENT_178	[p10l455t2185r685b2248],
30	HCV	NN	O	hcv	nn	31	SENT_178	[p10l709t2189r890b2248],
31	RNA	NN	O	rna	dobj	29	SENT_178	[p10l914t2189r1086b2248],
32	and	CC	O	and	_	0	SENT_178	[p10l1110t2185r1237b2248],
33	enhance	VBP	O	enhance	rcmod	18	SENT_178	[p10l1260t2185r1546b2248],
34	SVR	NN	ORGANIZATION	svr	dobj	33	SENT_178	[p10l1571t2189r1726b2248],
35	when	WRB	O	when	advmod	36	SENT_178	[p10l1744t2185r1934b2248],
36	given	VBN	O	give	advcl	33	SENT_178	[p10l1957t2191r2143b2269],
37	in	IN	O	in	_	0	SENT_178	[p10l10t2293r76b2349],
38	conjunction	NN	O	conjunction	prep_in	36	SENT_178	[p10l98t2293r510b2371],
39	with	IN	O	with	_	0	SENT_178	[p10l530t2287r683b2350],
40	PEG+RBV	NN	O	peg+rbv	prep_with	36	SENT_178	[p10l705t2279r1142b2350],
41	.37	CD	NUMBER	.37	num	40	SENT_178	[p10l705t2279r1142b2350],

1	These	DT	O	these	det	2	SENT_179	[p10l83t2390r272b2453],
2	drugs	NNS	O	drug	nsubj	14	SENT_179	[p10l293t2390r498b2474],
3	,	,	O	,	_	0	SENT_179	[p10l293t2390r498b2474],
4	as	IN	O	as	_	0	SENT_179	[p10l519t2413r582b2453],
5	a	DT	O	a	det	6	SENT_179	[p10l603t2413r637b2453],
6	class	NN	O	class	prep_as	11	SENT_179	[p10l656t2390r823b2462],
7	,	,	O	,	_	0	SENT_179	[p10l656t2390r823b2462],
8	are	VBP	O	be	cop	11	SENT_179	[p10l845t2413r943b2453],
9	generally	RB	O	generally	advmod	11	SENT_179	[p10l963t2390r1268b2474],
10	quite	RB	O	quite	advmod	11	SENT_179	[p10l1284t2396r1449b2473],
11	potent	JJ	O	potent	dep	31	SENT_179	[p10l1468t2402r1684b2473],
12	and	CC	O	and	_	0	SENT_179	[p10l1703t2390r1827b2453],
13	are	VBP	O	be	cop	14	SENT_179	[p10l1846t2413r1943b2453],
14	effective	JJ	O	effective	dep	31	SENT_179	[p10l1964t2390r2140b2453, p10l9t2499r127b2556],
15	across	IN	O	across	_	0	SENT_179	[p10l148t2516r350b2556],
16	all	DT	O	all	det	17	SENT_179	[p10l371t2493r447b2556],
17	genotypes	NNS	O	genotype	prep_across	14	SENT_179	[p10l466t2505r818b2577],
18	,	,	O	,	_	0	SENT_179	[p10l466t2505r818b2577],
19	but	CC	O	but	_	0	SENT_179	[p10l837t2493r947b2556],
20	they	PRP	O	they	nsubj	21	SENT_179	[p10l965t2493r1111b2577],
21	have	VBP	O	have	conj_but	11	SENT_179	[p10l1127t2493r1278b2556],
22	a	DT	O	a	det	24	SENT_179	[p10l1299t2516r1332b2556],
23	low	JJ	O	low	amod	24	SENT_179	[p10l1349t2493r1471b2556],
24	barrier	NN	O	barrier	dobj	21	SENT_179	[p10l1485t2493r1717b2556],
25	to	TO	O	to	_	0	SENT_179	[p10l1734t2505r1798b2556],
26	resistance	NN	O	resistance	nn	30	SENT_179	[p10l1819t2499r2144b2556],
27	and	CC	O	and	_	0	SENT_179	[p10l10t2596r137b2659],
28	variable	JJ	O	variable	nn	30	SENT_179	[p10l154t2596r425b2659],
29	toxicity	NN	O	toxicity	nn	30	SENT_179	[p10l445t2602r704b2680],
30	proﬁles	NNS	O	proﬁles	prep_to	21	SENT_179	[p10l720t2596r972b2679],
31	(	VBP	O	(	_	0	SENT_179	[p10l998t2597r1127b2672],
32	see	VB	O	see	xcomp	31	SENT_179	[p10l998t2597r1127b2672],
33	Table	NNP	O	Table	dobj	32	SENT_179	[p10l1148t2597r1340b2659],
34	1	CD	NUMBER	1	num	33	SENT_179	[p10l1366t2597r1446b2673],
35	)	CD	NUMBER	)	nsubj	31	SENT_179	[p10l1366t2597r1446b2673],
36	.	.	O	.	_	0	SENT_179	[p10l1366t2597r1446b2673],

1	DACLATASVIR	NNP	PERSON	DACLATASVIR	nn	6	SENT_180	[p10l13t2811r508b2866],
2	Daclatasvir	NNP	PERSON	Daclatasvir	nn	6	SENT_180	[p10l10t2906r398b2969],
3	(	CD	NUMBER	(	num	6	SENT_180	[p10l423t2907r688b2983],
4	BMS-7	NN	O	bms-7	nn	6	SENT_180	[p10l423t2907r688b2983],
5	90052	CD	NUMBER	90052	num	6	SENT_180	[p10l693t2907r924b2983],
6	)	NN	O	)	nsubj	11	SENT_180	[p10l693t2907r924b2983],
7	was	VBD	O	be	cop	11	SENT_180	[p10l948t2929r1075b2969],
8	the	DT	O	the	det	11	SENT_180	[p10l1098t2906r1205b2969],
9	ﬁrst	NN	O	ﬁrst	nn	11	SENT_180	[p10l1228t2906r1362b2969],
10	NS5A	NN	O	ns5a	nn	11	SENT_180	[p10l1383t2910r1588b2970],
11	inhibitor	NN	O	inhibitor	_	0	SENT_180	[p10l1610t2906r1915b2969],
12	investigated	VBN	O	investigate	partmod	11	SENT_180	[p10l1937t2912r2139b2969, p10l9t3009r254b3093],
13	in	IN	O	in	_	0	SENT_180	[p10l282t3015r350b3071],
14	clinical	JJ	O	clinical	amod	15	SENT_180	[p10l379t3009r638b3072],
15	trials	NNS	O	trial	prep_in	12	SENT_180	[p10l664t3009r864b3072],
16	.	.	O	.	_	0	SENT_180	[p10l664t3009r864b3072],

1	In	FW	O	in	nn	2	SENT_181	[p10l894t3014r964b3072],
2	vitro	FW	O	vitro	nsubj	5	SENT_181	[p10l996t3015r1177b3081],
3	,	,	O	,	_	0	SENT_181	[p10l996t3015r1177b3081],
4	daclatasvir	NN	O	daclatasvir	appos	2	SENT_181	[p10l1208t3009r1595b3072],
5	exhibited	VBD	O	exhibit	_	0	SENT_181	[p10l1622t3009r1956b3072],
6	high	JJ	O	high	amod	8	SENT_181	[p10l1982t3009r2143b3093],
7	antiviral	JJ	O	antiviral	amod	8	SENT_181	[p10l10t3112r303b3175],
8	activity	NN	O	activity	dobj	5	SENT_181	[p10l327t3118r588b3196],
9	against	IN	O	against	_	0	SENT_181	[p10l609t3118r855b3196],
10	all	DT	O	all	det	12	SENT_181	[p10l879t3112r960b3175],
11	HCV	NN	O	hcv	nn	12	SENT_181	[p10l984t3116r1167b3175],
12	genotypes	NNS	O	genotype	prep_against	5	SENT_181	[p10l1191t3124r1562b3196],
13	.	.	O	.	_	0	SENT_181	[p10l1191t3124r1562b3196],

1	In	IN	O	in	_	0	SENT_182	[p10l1590t3117r1663b3174],
2	phase	NN	O	phase	nn	4	SENT_182	[p10l1685t3112r1886b3195],
3	I	NN	O	i	nn	4	SENT_182	[p10l1910t3117r1934b3174],
4	studies	NNS	O	study	prep_in	7	SENT_182	[p10l1961t3112r2140b3175, p10l10t3221r120b3287],
5	,	,	O	,	_	0	SENT_182	[p10l1961t3112r2140b3175, p10l10t3221r120b3287],
6	monotherapy	NN	O	monotherapy	nsubj	7	SENT_182	[p10l149t3215r633b3299],
7	resulted	VBD	O	result	_	0	SENT_182	[p10l656t3215r941b3278],
8	in	IN	O	in	_	0	SENT_182	[p10l967t3221r1035b3277],
9	a	DT	O	a	det	12	SENT_182	[p10l1062t3238r1098b3278],
10	sharp	JJ	O	sharp	amod	12	SENT_182	[p10l1124t3215r1319b3298],
11	initial	JJ	O	initial	amod	12	SENT_182	[p10l1346t3215r1556b3278],
12	decline	NN	O	decline	prep_in	7	SENT_182	[p10l1583t3215r1837b3278],
13	in	IN	O	in	_	0	SENT_182	[p10l1864t3221r1932b3277],
14	HCV	NN	O	hcv	nn	15	SENT_182	[p10l1960t3219r2145b3278],
15	RNA	NN	O	rna	prep_in	7	SENT_182	[p10l10t3322r203b3390],
16	;	:	O	;	_	0	SENT_182	[p10l10t3322r203b3390],
17	however	RB	O	however	advmod	21	SENT_182	[p10l227t3318r537b3390],
18	,	,	O	,	_	0	SENT_182	[p10l227t3318r537b3390],
19	it	PRP	O	it	nsubjpass	21	SENT_182	[p10l563t3324r610b3381],
20	was	VBD	O	be	auxpass	21	SENT_182	[p10l630t3341r759b3381],
21	found	VBN	O	find	parataxis	7	SENT_182	[p10l783t3318r992b3381],
22	to	TO	O	to	aux	23	SENT_182	[p10l1014t3330r1081b3381],
23	have	VB	O	have	xcomp	21	SENT_182	[p10l1105t3318r1264b3381],
24	low	JJ	O	low	amod	25	SENT_182	[p10l1287t3318r1414b3381],
25	resistance	NN	O	resistance	nsubj	29	SENT_182	[p10l1435t3324r1778b3381],
26	to	TO	O	to	_	0	SENT_182	[p10l1800t3330r1868b3381],
27	genetic	JJ	O	genetic	amod	28	SENT_182	[p10l1893t3324r2143b3402],
28	variants	NNS	O	variant	prep_to	25	SENT_182	[p10l7t3412r373b3484],
29	.37	CD	NUMBER	.37	xcomp	23	SENT_182	[p10l7t3412r373b3484],
30	The	DT	O	the	det	34	SENT_182	[p10l397t3420r525b3484],
31	most	RBS	O	most	advmod	33	SENT_182	[p10l549t3432r723b3484],
32	common	JJ	O	common	amod	33	SENT_182	[p10l747t3443r1062b3484],
33	resistant	JJ	O	resistant	amod	34	SENT_182	[p10l1086t3427r1382b3484],
34	variants	NNS	O	variant	nsubjpass	36	SENT_182	[p10l1402t3427r1682b3484],
35	were	VBD	O	be	auxpass	36	SENT_182	[p10l1705t3443r1870b3484],
36	seen	VBN	O	see	rcmod	29	SENT_182	[p10l1896t3443r2048b3484],
37	in	IN	O	in	_	0	SENT_182	[p10l2073t3427r2141b3483],
38	genotype	NN	O	genotype	nn	40	SENT_182	[p10l9t3536r315b3608],
39	1a	NN	O	1a	nn	40	SENT_182	[p10l342t3531r410b3587],
40	patients	NNS	O	patient	prep_in	36	SENT_182	[p10l428t3530r709b3607],
41	,	,	O	,	_	0	SENT_182	[p10l428t3530r709b3607],
42	and	CC	O	and	_	0	SENT_182	[p10l732t3524r855b3587],
43	few	JJ	O	few	nsubjpass	45	SENT_182	[p10l874t3524r992b3587],
44	were	VBD	O	be	auxpass	45	SENT_182	[p10l1007t3547r1165b3587],
45	seen	VBN	O	see	parataxis	7	SENT_182	[p10l1186t3547r1332b3587],
46	in	IN	O	in	_	0	SENT_182	[p10l1352t3530r1417b3586],
47	genotype	NN	O	genotype	nn	49	SENT_182	[p10l1436t3536r1742b3608],
48	1b	NN	O	1b	nn	49	SENT_182	[p10l1768t3524r1841b3587],
49	patients	NNS	O	patient	prep_in	45	SENT_182	[p10l1861t3530r2141b3607],
50	.	.	O	.	_	0	SENT_182	[p10l1861t3530r2141b3607],

1	No	DT	O	no	det	4	SENT_183	[p11l9t31r113b89],
2	cross	NN	O	cross	nn	4	SENT_183	[p11l139t32r694b89],
3	—	NN	O	—	nn	4	SENT_183	[p11l139t32r694b89],
4	resistance	NN	O	resistance	nsubjpass	12	SENT_183	[p11l139t32r694b89],
5	between	IN	O	between	_	0	SENT_183	[p11l716t26r1010b89],
6	daclatasvir	NN	O	daclatasvir	nn	9	SENT_183	[p11l1035t26r1413b89],
7	and	CC	O	and	_	0	SENT_183	[p11l1436t26r1566b89],
8	other	JJ	O	other	nn	9	SENT_183	[p11l1589t26r1776b89],
9	DAAs	NNS	O	daa	prep_between	4	SENT_183	[p11l1799t30r2010b89],
10	has	VBZ	O	have	aux	12	SENT_183	[p11l2033t26r2148b89],
11	been	VBN	O	be	auxpass	12	SENT_183	[p11l7t129r172b192],
12	reported	VBN	O	report	_	0	SENT_183	[p11l194t129r507b212],
13	,	,	O	,	_	0	SENT_183	[p11l194t129r507b212],
14	making	VBG	O	make	xcomp	12	SENT_183	[p11l531t129r792b213],
15	it	PRP	O	it	nsubj	16	SENT_183	[p11l813t135r859b192],
16	desirable	JJ	O	desirable	xcomp	14	SENT_183	[p11l881t129r1185b192],
17	for	IN	O	for	_	0	SENT_183	[p11l1208t129r1305b192],
18	use	NN	O	use	prep_for	16	SENT_183	[p11l1327t152r1438b192],
19	in	IN	O	in	_	0	SENT_183	[p11l1461t135r1527b191],
20	an	DT	O	a	det	25	SENT_183	[p11l1551t152r1630b192],
21	IFN	NN	O	ifn	npadvmod	23	SENT_183	[p11l1654t129r1951b192],
22	—	CD	NUMBER	—	num	21	SENT_183	[p11l1654t129r1951b192],
23	free	JJ	O	free	amod	25	SENT_183	[p11l1654t129r1951b192],
24	DAA	NN	O	daa	nn	25	SENT_183	[p11l1974t133r2150b191],
25	regimen	NN	O	regimen	prep_in	18	SENT_183	[p11l10t223r373b316],
26	.	.	O	.	_	0	SENT_183	[p11l10t223r373b316],

1	”	NN	O	”	_	0	SENT_184	[p11l10t223r373b316],

1	Daclatasvir	NNP	O	Daclatasvir	nsubjpass	3	SENT_185	[p11l83t335r474b398],
2	was	VBD	O	be	auxpass	3	SENT_185	[p11l494t358r621b398],
3	studied	VBN	O	study	_	0	SENT_185	[p11l646t335r900b398],
4	in	IN	O	in	_	0	SENT_185	[p11l921t341r989b397],
5	conjunction	NN	O	conjunction	prep_in	3	SENT_185	[p11l1013t341r1430b419],
6	with	IN	O	with	_	0	SENT_185	[p11l1451t335r1606b398],
7	PEG+RBV	NN	O	peg+rbv	prep_with	3	SENT_185	[p11l1630t339r2003b398],
8	in	IN	O	in	_	0	SENT_185	[p11l2025t341r2093b397],
9	a	DT	O	a	det	14	SENT_185	[p11l2116t358r2151b398],
10	double-blind	JJ	O	double-blind	amod	14	SENT_185	[p11l10t438r463b510],
11	,	,	O	,	_	0	SENT_185	[p11l10t438r463b510],
12	phase	NN	O	phase	dep	14	SENT_185	[p11l483t438r675b521],
13	Ila	NN	O	ilum	nn	14	SENT_185	[p11l696t443r785b501],
14	study	NN	O	study	prep_in	7	SENT_185	[p11l805t438r988b522],
15	of	IN	O	of	_	0	SENT_185	[p11l1005t438r1078b501],
16	treatment-naive	JJ	O	treatment-naive	amod	18	SENT_185	[p11l1087t444r1626b501],
17	HCV	NN	O	hcv	nn	18	SENT_185	[p11l1647t442r1824b501],
18	genotype	NN	O	genotype	prep_of	14	SENT_185	[p11l1843t450r2150b522],
19	1	CD	NUMBER	1	tmod	7	SENT_185	[p11l16t548r65b613],
20	,	,	O	,	_	0	SENT_185	[p11l16t548r65b613],
21	noncirrhotic	JJ	O	noncirrhotic	amod	22	SENT_185	[p11l88t541r522b604],
22	patients	NNS	O	patient	appos	19	SENT_185	[p11l543t547r830b624],
23	.	.	O	.	_	0	SENT_185	[p11l543t547r830b624],

1	Forty	CD	NUMBER	forty	number	2	SENT_186	[p11l856t541r1242b625],
2	—	CD	NUMBER	—	_	0	SENT_186	[p11l856t541r1242b625],
3	eight	CD	NUMBER	eight	num	4	SENT_186	[p11l856t541r1242b625],
4	patients	NNS	O	patient	dep	2	SENT_186	[p11l1261t547r1531b624],
5	were	VBD	O	be	auxpass	6	SENT_186	[p11l1552t564r1713b604],
6	randomized	VBN	O	randomize	rcmod	2	SENT_186	[p11l1735t541r2151b604],
7	to	TO	O	to	_	0	SENT_186	[p11l8t656r74b707],
8	PEG+RBV	NN	O	peg+rbv	prep_to	6	SENT_186	[p11l97t648r466b707],
9	and	CC	O	and	_	0	SENT_186	[p11l487t644r613b707],
10	placebo	NN	O	placebo	prep_to	6	SENT_186	[p11l632t644r895b727],
11	or	CC	O	or	_	0	SENT_186	[p11l917t667r989b707],
12	daclatasvir	NN	O	daclatasvir	nn	13	SENT_186	[p11l1009t644r1376b707],
13	(	NN	O	(	prep_to	6	SENT_186	[p11l1400t645r1481b720],
14	3	CD	NUMBER	3	dep	13	SENT_186	[p11l1400t645r1481b720],
15	,	,	O	,	_	0	SENT_186	[p11l1400t645r1481b720],
16	10	CD	NUMBER	10	prep_to	6	SENT_186	[p11l1511t651r1601b716],
17	,	,	O	,	_	0	SENT_186	[p11l1511t651r1601b716],
18	or	CC	O	or	_	0	SENT_186	[p11l1624t667r1696b707],
19	60	CD	NUMBER	60	num	20	SENT_186	[p11l1716t650r1793b707],
20	mg	NN	O	mg	npadvmod	21	SENT_186	[p11l1808t667r1917b728],
21	once	RB	DATE	once	advmod	8	SENT_186	[p11l1936t667r2095b707],
22	a	DT	DURATION	a	det	23	SENT_186	[p11l2117t667r2151b707],
23	day	NN	DURATION	day	pobj	21	SENT_186	[p11l10t747r149b831],
24	)	CD	NUMBER	)	conj_or	8	SENT_186	[p11l10t747r149b831],
25	for	IN	O	for	_	0	SENT_186	[p11l172t747r267b810],
26	48	CD	DURATION	48	num	27	SENT_186	[p11l285t754r361b810],
27	weeks	NNS	NUMBER	week	prep_for	6	SENT_186	[p11l380t747r596b810],
28	.	.	O	.	_	0	SENT_186	[p11l380t747r596b810],

1	The	DT	O	the	det	4	SENT_187	[p11l618t747r741b810],
2	primary	JJ	O	primary	amod	4	SENT_187	[p11l759t753r1034b831],
3	end	NN	O	end	nn	4	SENT_187	[p11l1051t747r1174b810],
4	point	NN	O	point	nsubj	8	SENT_187	[p11l1191t753r1369b830],
5	was	VBD	O	be	cop	8	SENT_187	[p11l1385t770r1508b810],
6	undetectable	JJ	O	undetectable	amod	8	SENT_187	[p11l1528t747r1953b810],
7	HCV	NN	O	hcv	nn	8	SENT_187	[p11l1974t751r2149b810],
8	RNA	NN	O	rna	_	0	SENT_187	[p11l10t853r181b912],
9	at	IN	O	at	_	0	SENT_187	[p11l202t861r262b912],
10	weeks	NNS	DURATION	week	prep_at	8	SENT_187	[p11l280t849r485b912],
11	4	CD	NUMBER	4	num	10	SENT_187	[p11l506t856r545b911],
12	and	CC	O	and	_	0	SENT_187	[p11l568t849r694b912],
13	12	CD	NUMBER	12	conj_and	10	SENT_187	[p11l721t856r792b911],
14	of	IN	O	of	_	0	SENT_187	[p11l816t849r890b912],
15	treatment	NN	O	treatment	prep_of	10	SENT_187	[p11l901t861r1253b912],
16	.	.	O	.	_	0	SENT_187	[p11l901t861r1253b912],

1	Fifteen	CD	NUMBER	fifteen	num	2	SENT_188	[p11l84t952r342b1015],
2	patients	NNS	O	patient	_	0	SENT_188	[p11l375t958r669b1035],
3	discontinued	VBN	O	discontinue	partmod	2	SENT_188	[p11l704t952r1191b1015],
4	therapy	NN	O	therapy	dobj	3	SENT_188	[p11l1223t952r1506b1036],
5	early	RB	O	early	advmod	3	SENT_188	[p11l1537t952r1729b1036],
6	,	,	O	,	_	0	SENT_188	[p11l1537t952r1729b1036],
7	with	IN	O	with	_	0	SENT_188	[p11l1763t952r1927b1015],
8	similar	JJ	O	similar	amod	9	SENT_188	[p11l1961t958r2148b1015, p11l8t1055r101b1118],
9	occurrence	NN	O	occurrence	prep_with	3	SENT_188	[p11l124t1078r518b1118],
10	among	IN	O	among	_	0	SENT_188	[p11l544t1078r785b1139],
11	all	DT	O	all	det	13	SENT_188	[p11l809t1055r890b1118],
12	study	NN	O	study	nn	13	SENT_188	[p11l915t1055r1107b1139],
13	arms	NNS	O	arm	prep_among	9	SENT_188	[p11l1128t1078r1318b1118],
14	.	.	O	.	_	0	SENT_188	[p11l1128t1078r1318b1118],

1	The	DT	O	the	det	4	SENT_189	[p11l1346t1055r1474b1118],
2	primary	JJ	O	primary	amod	4	SENT_189	[p11l1497t1061r1789b1139],
3	end	NN	O	end	nn	4	SENT_189	[p11l1811t1055r1940b1118],
4	point	NN	O	point	nsubjpass	8	SENT_189	[p11l1963t1061r2151b1138],
5	of	IN	O	of	_	0	SENT_189	[p11l10t1158r86b1221],
6	eRVR	NN	O	ervr	prep_of	4	SENT_189	[p11l103t1163r309b1221],
7	was	VBD	O	be	auxpass	8	SENT_189	[p11l330t1181r461b1221],
8	obtained	VBN	O	obtain	ccomp	63	SENT_189	[p11l488t1158r802b1221],
9	in	IN	O	in	_	0	SENT_189	[p11l827t1164r896b1220],
10	42	CD	NUMBER	42	prep_in	8	SENT_189	[p11l921t1165r1023b1230],
11	,	,	O	,	_	0	SENT_189	[p11l921t1165r1023b1230],
12	83	CD	NUMBER	83	conj_and	10	SENT_189	[p11l1052t1165r1152b1230],
13	,	,	O	,	_	0	SENT_189	[p11l1052t1165r1152b1230],
14	75	CD	NUMBER	75	conj_and	10	SENT_189	[p11l1181t1166r1280b1230],
15	,	,	O	,	_	0	SENT_189	[p11l1181t1166r1280b1230],
16	and	CC	PERCENT	and	_	0	SENT_189	[p11l1309t1158r1440b1221],
17	8	CD	PERCENT	8	num	18	SENT_189	[p11l1466t1164r1569b1222],
18	%	NN	PERCENT	%	conj_and	10	SENT_189	[p11l1466t1164r1569b1222],
19	of	IN	O	of	_	0	SENT_189	[p11l1598t1158r1674b1221],
20	patients	NNS	O	patient	prep_of	18	SENT_189	[p11l1689t1164r1971b1241],
21	who	WP	O	who	nsubj	22	SENT_189	[p11l1996t1158r2147b1221],
22	received	VBD	O	receive	rcmod	20	SENT_189	[p11l9t1260r286b1324],
23	3	CD	NUMBER	3	dobj	22	SENT_189	[p11l306t1267r359b1333],
24	,	,	O	,	_	0	SENT_189	[p11l306t1267r359b1333],
25	10	CD	NUMBER	10	num	23	SENT_189	[p11l387t1267r476b1333],
26	,	,	O	,	_	0	SENT_189	[p11l387t1267r476b1333],
27	and	CC	NUMBER	and	_	0	SENT_189	[p11l498t1260r621b1324],
28	60	CD	NUMBER	60	conj_and	23	SENT_189	[p11l640t1267r717b1324],
29	mg	NN	O	mg	nn	30	SENT_189	[p11l731t1283r838b1345],
30	daclatasvir	NN	O	daclatasvir	dep	23	SENT_189	[p11l857t1260r1226b1333],
31	,	,	O	,	_	0	SENT_189	[p11l857t1260r1226b1333],
32	and	CC	O	and	_	0	SENT_189	[p11l1248t1260r1372b1324],
33	placebo	NN	O	placebo	conj_and	23	SENT_189	[p11l1389t1260r1662b1344],
34	,	,	O	,	_	0	SENT_189	[p11l1389t1260r1662b1344],
35	respectively	RB	O	respectively	advmod	33	SENT_189	[p11l1684t1252r2149b1345],
36	.38	CD	NUMBER	.38	nsubj	43	SENT_189	[p11l1684t1252r2149b1345],
37	In	IN	O	in	_	0	SENT_189	[p11l84t1369r159b1426],
38	genotype	NN	O	genotype	prep_in	36	SENT_189	[p11l194t1376r532b1448],
39	1	CD	NUMBER	1	num	38	SENT_189	[p11l574t1371r599b1426],
40	and	CC	O	and	_	0	SENT_189	[p11l641t1364r776b1427],
41	4	CD	NUMBER	4	num	42	SENT_189	[p11l809t1371r848b1426],
42	patients	NNS	O	patient	conj_and	38	SENT_189	[p11l882t1370r1177b1447],
43	treated	VBN	O	treat	rcmod	18	SENT_189	[p11l1211t1364r1472b1427],
44	with	IN	O	with	_	0	SENT_189	[p11l1504t1364r1668b1427],
45	20	CD	NUMBER	20	prep_with	43	SENT_189	[p11l1703t1371r1786b1427],
46	or	CC	O	or	_	0	SENT_189	[p11l1823t1387r1899b1427],
47	60	CD	NUMBER	60	prep_with	43	SENT_189	[p11l1933t1370r2015b1427],
48	mg	NN	O	mg	nn	49	SENT_189	[p11l2037t1387r2152b1448],
49	daclatasvir	NN	O	daclatasvir	npadvmod	52	SENT_189	[p11l10t1467r368b1530],
50	a	DT	DURATION	a	det	51	SENT_189	[p11l387t1490r421b1530],
51	day	NN	DURATION	day	dep	49	SENT_189	[p11l440t1467r558b1551],
52	along	IN	O	along	advmod	45	SENT_189	[p11l575t1467r758b1551],
53	with	IN	O	with	_	0	SENT_189	[p11l775t1467r924b1530],
54	PEG+RBV	NN	O	peg+rbv	prep_with	43	SENT_189	[p11l944t1471r1305b1530],
55	for	IN	O	for	_	0	SENT_189	[p11l1324t1467r1419b1530],
56	24	CD	NUMBER	24	num	59	SENT_189	[p11l1438t1474r1515b1529],
57	or	CC	O	or	_	0	SENT_189	[p11l1535t1490r1606b1530],
58	28	CD	DURATION	28	num	59	SENT_189	[p11l1624t1474r1700b1530],
59	weeks	NNS	NUMBER	week	prep_for	43	SENT_189	[p11l1719t1467r1937b1539],
60	,	,	O	,	_	0	SENT_189	[p11l1719t1467r1937b1539],
61	eRVR	NN	O	ervr	nsubjpass	63	SENT_189	[p11l1958t1472r2153b1530],
62	was	VBD	O	be	auxpass	63	SENT_189	[p11l8t1593r133b1633],
63	achieved	VBN	O	achieve	_	0	SENT_189	[p11l155t1570r454b1633],
64	in	IN	O	in	_	0	SENT_189	[p11l473t1576r540b1632],
65	54	CD	PERCENT	54	num	66	SENT_189	[p11l562t1576r702b1635],
66	%	NN	PERCENT	%	prep_in	63	SENT_189	[p11l562t1576r702b1635],
67	of	IN	O	of	_	0	SENT_189	[p11l726t1570r799b1633],
68	patients	NNS	O	patient	prep_of	66	SENT_189	[p11l809t1576r1077b1653],
69	as	IN	O	as	_	0	SENT_189	[p11l1099t1593r1163b1633],
70	compared	VBN	O	compare	prepc_as	63	SENT_189	[p11l1185t1570r1526b1653],
71	with	IN	O	with	pcomp	70	SENT_189	[p11l1544t1570r1696b1633],
72	13	CD	PERCENT	13	num	73	SENT_189	[p11l1723t1575r1859b1635],
73	%	NN	PERCENT	%	pobj	71	SENT_189	[p11l1723t1575r1859b1635],
74	of	IN	O	of	_	0	SENT_189	[p11l1882t1570r1955b1633],
75	those	DT	O	those	prep_of	73	SENT_189	[p11l1965t1570r2148b1633],
76	in	IN	O	in	_	0	SENT_189	[p11l9t1679r74b1735],
77	the	DT	O	the	det	79	SENT_189	[p11l92t1673r196b1736],
78	placebo	NN	O	placebo	nn	79	SENT_189	[p11l215t1673r470b1756],
79	group	NN	O	group	prep_in	75	SENT_189	[p11l491t1695r701b1757],
80	.	.	O	.	_	0	SENT_189	[p11l491t1695r701b1757],

1	The	DT	O	the	det	2	SENT_190	[p11l723t1673r845b1736],
2	rates	NNS	O	rate	nsubj	8	SENT_190	[p11l865t1685r1019b1736],
3	of	IN	O	of	_	0	SENT_190	[p11l1040t1673r1112b1736],
4	AEs	NNS	O	ae	prep_of	2	SENT_190	[p11l1121t1677r1255b1736],
5	and	CC	O	and	_	0	SENT_190	[p11l1276t1673r1399b1736],
6	discontinuations	NNS	O	discontinuation	conj_and	4	SENT_190	[p11l1418t1673r1972b1736],
7	were	VBD	O	be	cop	8	SENT_190	[p11l1991t1696r2148b1736],
8	comparable	JJ	O	comparable	_	0	SENT_190	[p11l10t1776r409b1860],
9	between	IN	O	between	_	0	SENT_190	[p11l429t1776r716b1840],
10	the	DT	O	the	det	14	SENT_190	[p11l736t1776r843b1840],
11	treatment	NN	O	treatment	nn	14	SENT_190	[p11l864t1788r1200b1840],
12	and	CC	O	and	_	0	SENT_190	[p11l1221t1776r1348b1840],
13	placebo	NN	O	placebo	conj_and	11	SENT_190	[p11l1367t1776r1631b1860],
14	arms	NNS	O	arm	prep_between	8	SENT_190	[p11l1654t1768r1903b1840],
15	.	.	O	.	_	0	SENT_190	[p11l1654t1768r1903b1840],

1	”	NN	O	”	_	0	SENT_191	[p11l1654t1768r1903b1840],

1	LEDIPASVIR	NNP	PERSON	LEDIPASVIR	nn	2	SENT_192	[p11l13t1993r435b2048],
2	Ledipasvir	NNP	PERSON	Ledipasvir	nsubj	6	SENT_192	[p11l10t2088r371b2171],
3	(	CD	NUMBER	(	num	5	SENT_192	[p11l396t2089r745b2165],
4	GS-5885	NN	O	gs-5885	nn	5	SENT_192	[p11l396t2089r745b2165],
5	)	NN	O	)	dep	2	SENT_192	[p11l396t2089r745b2165],
6	is	VBZ	O	be	_	0	SENT_192	[p11l772t2094r822b2151],
7	currently	RB	DATE	currently	advmod	6	SENT_192	[p11l845t2088r1163b2172],
8	in	IN	O	in	_	0	SENT_192	[p11l1182t2094r1248b2150],
9	phase	NN	O	phase	prep_in	6	SENT_192	[p11l1270t2088r1465b2171],
10	III	CD	NUMBER	iii	num	12	SENT_192	[p11l1489t2093r1572b2150],
11	clinical	JJ	O	clinical	amod	12	SENT_192	[p11l1596t2088r1842b2151],
12	trials	NNS	O	trial	dep	9	SENT_192	[p11l1863t2088r2052b2151],
13	.	.	O	.	_	0	SENT_192	[p11l1863t2088r2052b2151],

1	In	IN	O	in	_	0	SENT_193	[p11l2078t2093r2149b2150],
2	a	DT	O	a	det	3	SENT_193	[p11l10t2214r45b2254],
3	phase	NN	O	phase	prep_in	41	SENT_193	[p11l62t2191r256b2274],
4	I	PRP	O	I	dep	3	SENT_193	[p11l278t2196r301b2253],
5	trial	NN	O	trial	dobj	4	SENT_193	[p11l322t2191r462b2254],
6	of	IN	O	of	_	0	SENT_193	[p11l483t2191r556b2254],
7	HCV	NNP	O	HCV	nn	8	SENT_193	[p11l568t2195r747b2254],
8	genotype	NN	O	genotype	prep_of	5	SENT_193	[p11l766t2203r1077b2275],
9	1	CD	NUMBER	1	num	10	SENT_193	[p11l1105t2198r1129b2253],
10	patients	NNS	O	patient	dep	4	SENT_193	[p11l1155t2197r1423b2274],
11	given	VBN	O	give	partmod	10	SENT_193	[p11l1444t2197r1627b2275],
12	3	CD	DURATION	3	num	13	SENT_193	[p11l1648t2198r1681b2254],
13	days	NNS	NUMBER	day	dobj	11	SENT_193	[p11l1706t2191r1854b2275],
14	of	IN	O	of	_	0	SENT_193	[p11l1875t2191r1949b2254],
15	oncedaily	JJ	O	oncedaily	amod	16	SENT_193	[p11l1960t2214r2146b2254, p11l10t2294r181b2378],
16	placebo	NN	O	placebo	prep_of	13	SENT_193	[p11l200t2294r469b2377],
17	or	CC	O	or	_	0	SENT_193	[p11l495t2317r568b2357],
18	1	CD	NUMBER	1	conj_or	13	SENT_193	[p11l598t2301r647b2366],
19	,	,	O	,	_	0	SENT_193	[p11l598t2301r647b2366],
20	3	CD	NUMBER	3	conj_or	18	SENT_193	[p11l674t2301r730b2366],
21	,	,	O	,	_	0	SENT_193	[p11l674t2301r730b2366],
22	10	CD	NUMBER	10	conj_or	13	SENT_193	[p11l762t2301r855b2366],
23	,	,	O	,	_	0	SENT_193	[p11l762t2301r855b2366],
24	30	CD	NUMBER	30	conj_or	13	SENT_193	[p11l882t2301r980b2366],
25	,	,	O	,	_	0	SENT_193	[p11l882t2301r980b2366],
26	or	CC	O	or	_	0	SENT_193	[p11l1005t2317r1079b2357],
27	90	CD	NUMBER	90	num	29	SENT_193	[p11l1102t2301r1181b2357],
28	mg	NN	O	mg	nn	29	SENT_193	[p11l1197t2317r1308b2378],
29	ledipasvir	NN	O	ledipasvir	conj_or	13	SENT_193	[p11l1329t2294r1686b2377],
30	,	,	O	,	_	0	SENT_193	[p11l1329t2294r1686b2377],
31	the	DT	O	the	det	34	SENT_193	[p11l1710t2294r1819b2357],
32	maximal	JJ	O	maximal	amod	34	SENT_193	[p11l1843t2294r2151b2357],
33	median	JJ	O	median	amod	34	SENT_193	[p11l9t2397r275b2460],
34	reduction	NN	O	reduction	nsubj	41	SENT_193	[p11l299t2397r642b2460],
35	in	IN	O	in	_	0	SENT_193	[p11l666t2403r734b2459],
36	HCV	NN	O	hcv	nn	37	SENT_193	[p11l759t2401r944b2460],
37	RNA	NN	O	rna	prep_in	34	SENT_193	[p11l968t2401r1143b2460],
38	was	VBD	O	be	cop	41	SENT_193	[p11l1165t2420r1294b2460],
39	3.3	CD	NUMBER	3.3	num	41	SENT_193	[p11l1321t2397r1615b2481],
40	log1O	NN	O	log1o	nn	41	SENT_193	[p11l1321t2397r1615b2481],
41	IU/ml	NN	O	iu/ml	_	0	SENT_193	[p11l1642t2397r1877b2469],
42	,	,	O	,	_	0	SENT_193	[p11l1642t2397r1877b2469],
43	seen	VBN	O	see	partmod	41	SENT_193	[p11l1903t2420r2057b2460],
44	in	IN	O	in	_	0	SENT_193	[p11l2081t2403r2150b2459],
45	those	DT	O	those	prep_in	43	SENT_193	[p11l8t2500r199b2563],
46	treated	VBN	O	treat	partmod	45	SENT_193	[p11l223t2500r471b2563],
47	with	IN	O	with	_	0	SENT_193	[p11l494t2500r653b2563],
48	30	CD	NUMBER	30	num	49	SENT_193	[p11l680t2507r758b2563],
49	mg	NN	O	mg	prep_with	46	SENT_193	[p11l776t2523r887b2584],
50	of	IN	O	of	_	0	SENT_193	[p11l912t2500r988b2563],
51	ledipasvir	NN	O	ledipasvir	prep_of	49	SENT_193	[p11l1003t2500r1353b2583],
52	a	DT	DURATION	a	det	53	SENT_193	[p11l1379t2523r1414b2563],
53	day	NN	DURATION	day	dep	51	SENT_193	[p11l1439t2500r1572b2584],
54	.	.	O	.	_	0	SENT_193	[p11l1439t2500r1572b2584],

1	No	DT	O	no	det	3	SENT_194	[p11l1600t2505r1705b2563],
2	serious	JJ	O	serious	amod	3	SENT_194	[p11l1733t2506r1983b2563],
3	AEs	NNS	O	ae	nsubjpass	5	SENT_194	[p11l2008t2504r2150b2563],
4	were	VBD	O	be	auxpass	5	SENT_194	[p11l8t2626r167b2666],
5	reported	VBN	O	report	_	0	SENT_194	[p11l188t2603r495b2686],
6	.	.	O	.	_	0	SENT_194	[p11l188t2603r495b2686],

1	Headache	NN	O	headache	nsubj	12	SENT_195	[p11l519t2603r871b2675],
2	,	,	O	,	_	0	SENT_195	[p11l519t2603r871b2675],
3	rash	NN	O	rash	conj_and	1	SENT_195	[p11l893t2603r1053b2675],
4	,	,	O	,	_	0	SENT_195	[p11l893t2603r1053b2675],
5	and	CC	O	and	_	0	SENT_195	[p11l1075t2603r1201b2666],
6	frequent	JJ	O	frequent	amod	7	SENT_195	[p11l1220t2603r1507b2686],
7	urination	NN	O	urination	conj_and	1	SENT_195	[p11l1526t2609r1845b2666],
8	were	VBD	O	be	cop	12	SENT_195	[p11l1863t2626r2023b2666],
9	the	DT	O	the	det	12	SENT_195	[p11l2042t2603r2148b2666],
10	most	RBS	O	most	advmod	12	SENT_195	[p11l9t2717r176b2769],
11	commonly	RB	O	commonly	advmod	12	SENT_195	[p11l195t2705r562b2790],
12	reported	VBN	O	report	ccomp	59	SENT_195	[p11l578t2705r869b2789],
13	mild	JJ	O	mild	amod	12	SENT_195	[p11l887t2705r1044b2769],
14	to	TO	O	to	_	0	SENT_195	[p11l1062t2717r1127b2769],
15	moderate	JJ	O	moderate	amod	16	SENT_195	[p11l1148t2705r1468b2769],
16	AEs	NNS	O	ae	prep_to	12	SENT_195	[p11l1487t2697r1703b2769],
17	.4	CD	NUMBER	.4	number	18	SENT_195	[p11l1487t2697r1703b2769],
18	°	CD	NUMBER	°	dep	16	SENT_195	[p11l1487t2697r1703b2769],
19	Although	IN	O	although	mark	25	SENT_195	[p11l1722t2705r2044b2790],
20	no	DT	O	no	det	22	SENT_195	[p11l2064t2728r2149b2769],
21	published	VBN	O	publish	amod	22	SENT_195	[p11l8t2809r350b2892],
22	data	NNS	O	datum	nsubj	25	SENT_195	[p11l373t2809r519b2872],
23	are	VBP	O	be	cop	25	SENT_195	[p11l542t2832r643b2872],
24	yet	RB	O	yet	advmod	25	SENT_195	[p11l664t2821r768b2893],
25	available	JJ	O	available	advcl	30	SENT_195	[p11l790t2809r1089b2872],
26	on	IN	O	on	_	0	SENT_195	[p11l1113t2832r1200b2872],
27	results	NNS	O	result	prep_on	25	SENT_195	[p11l1224t2809r1466b2881],
28	,	,	O	,	_	0	SENT_195	[p11l1224t2809r1466b2881],
29	there	EX	O	there	expl	30	SENT_195	[p11l1490t2809r1667b2872],
30	are	VBP	O	be	rcmod	16	SENT_195	[p11l1691t2832r1792b2872],
31	a	DT	O	a	det	32	SENT_195	[p11l1817t2832r1852b2872],
32	number	NN	O	number	dep	30	SENT_195	[p11l1874t2809r2150b2872],
33	of	IN	O	of	_	0	SENT_195	[p11l10t2912r86b2975],
34	phase	NN	O	phase	nn	36	SENT_195	[p11l101t2912r303b2995],
35	III	CD	NUMBER	iii	num	36	SENT_195	[p11l329t2917r415b2974],
36	studies	NNS	O	study	prep_of	32	SENT_195	[p11l443t2912r688b2975],
37	currently	RB	DATE	currently	advmod	32	SENT_195	[p11l715t2912r1044b2996],
38	under	IN	O	under	_	0	SENT_195	[p11l1066t2912r1278b2975],
39	way	NN	O	way	prep_under	32	SENT_195	[p11l1301t2935r1443b2996],
40	or	CC	O	or	_	0	SENT_195	[p11l1465t2935r1539b2975],
41	completed	VBN	O	complete	dep	30	SENT_195	[p11l1564t2912r1936b2995],
42	using	VBG	O	use	xcomp	41	SENT_195	[p11l1960t2918r2153b2996],
43	the	DT	O	the	det	44	SENT_195	[p11l8t3015r115b3078],
44	combination	NN	O	combination	dobj	42	SENT_195	[p11l137t3015r573b3078],
45	of	IN	O	of	_	0	SENT_195	[p11l594t3015r668b3078],
46	sofosbuvir	NN	O	sofosbuvir	prep_of	44	SENT_195	[p11l681t3015r1038b3078],
47	and	CC	O	and	_	0	SENT_195	[p11l1059t3015r1185b3078],
48	ledipasvir	NN	O	ledipasvir	conj_and	46	SENT_195	[p11l1204t3015r1541b3098],
49	in	IN	O	in	_	0	SENT_195	[p11l1561t3021r1628b3077],
50	multiple	JJ	O	multiple	amod	51	SENT_195	[p11l1648t3015r1934b3098],
51	genotype	NN	O	genotype	prep_in	42	SENT_195	[p11l1955t3038r2147b3099, p11l8t3130r172b3202],
52	,	,	O	,	_	0	SENT_195	[p11l1955t3038r2147b3099, p11l8t3130r172b3202],
53	treatment-naive	JJ	O	treatment-naive	conj_and	51	SENT_195	[p11l194t3124r743b3181],
54	and	CC	O	and	_	0	SENT_195	[p11l765t3118r892b3181],
55	treatment	NN	O	treatment	nn	57	SENT_195	[p11l911t3118r1516b3190],
56	—	CD	NUMBER	—	num	57	SENT_195	[p11l911t3118r1516b3190],
57	failure	NN	O	failure	conj_and	51	SENT_195	[p11l911t3118r1516b3190],
58	,	,	O	,	_	0	SENT_195	[p11l911t3118r1516b3190],
59	advanced	VBD	O	advance	_	0	SENT_195	[p11l1539t3118r1863b3181],
60	ﬁbrosis	NN	O	ﬁbrosis	dobj	59	SENT_195	[p11l1883t3118r2148b3190],
61	,	,	O	,	_	0	SENT_195	[p11l1883t3118r2148b3190],
62	decompensated	VBN	O	decompensate	partmod	60	SENT_195	[p11l10t3221r550b3304],
63	liver	NN	O	liver	nn	64	SENT_195	[p11l571t3221r724b3284],
64	disease	NN	O	disease	nsubj	59	SENT_195	[p11l747t3221r1008b3293],
65	,	,	O	,	_	0	SENT_195	[p11l747t3221r1008b3293],
66	human	JJ	O	human	amod	68	SENT_195	[p11l1031t3221r1276b3284],
67	immunodeﬁciency	NN	O	immunodeﬁciency	nn	68	SENT_195	[p11l1300t3221r1957b3305],
68	virus	NN	O	virus	appos	64	SENT_195	[p11l1973t3227r2147b3284],
69	coinfected	VBN	O	coinfect	partmod	68	SENT_195	[p11l10t3324r382b3396],
70	,	,	O	,	_	0	SENT_195	[p11l10t3324r382b3396],
71	and	CC	O	and	_	0	SENT_195	[p11l406t3324r532b3387],
72	posttransplant	JJ	O	posttransplant	amod	74	SENT_195	[p11l552t3324r1048b3407],
73	patient	NN	O	patient	nn	74	SENT_195	[p11l1068t3330r1307b3407],
74	populations	NNS	O	population	appos	64	SENT_195	[p11l1327t3324r1752b3407],
75	.	.	O	.	_	0	SENT_195	[p11l1327t3324r1752b3407],

1	RNA-DEPENDENT	JJ	O	rna-dependent	amod	4	SENT_196	[p11l13t3539r638b3593],
2	RNA	NN	O	rna	nn	4	SENT_196	[p11l658t3539r808b3593],
3	POLYMERASE	NN	O	polymerase	nn	4	SENT_196	[p11l829t3538r1310b3594],
4	INHIBITORS	NNS	O	inhibitor	nsubj	5	SENT_196	[p11l1332t3538r1749b3594],
5	(	VBP	O	(	_	0	SENT_196	[p11l1771t3535r2006b3599],
6	NS5B	NN	O	ns5b	nn	7	SENT_196	[p11l1771t3535r2006b3599],
7	)	NN	O	)	dobj	5	SENT_196	[p11l1771t3535r2006b3599],

1	NS5B	NN	O	ns5b	nsubj	6	SENT_197	[p12l8t28r201b87],
2	is	VBZ	O	be	cop	6	SENT_197	[p12l223t30r272b87],
3	an	DT	O	a	det	6	SENT_197	[p12l294t47r374b87],
4	RNA-dependent	JJ	O	rna-dependent	amod	6	SENT_197	[p12l395t24r958b107],
5	RNA	NN	O	rna	nn	6	SENT_197	[p12l977t28r1147b87],
6	polymerase	NN	O	polymerase	_	0	SENT_197	[p12l1166t24r1558b108],
7	involved	VBN	O	involve	partmod	6	SENT_197	[p12l1579t24r1870b87],
8	in	IN	O	in	_	0	SENT_197	[p12l1889t30r1956b86],
9	posttranslational	JJ	O	posttranslational	amod	10	SENT_197	[p12l1975t36r2147b107, p12l8t127r443b190],
10	processing	NN	O	processing	prep_in	7	SENT_197	[p12l465t133r834b211],
11	that	WDT	O	that	nsubj	13	SENT_197	[p12l854t127r989b190],
12	is	VBZ	O	be	cop	13	SENT_197	[p12l1011t133r1062b190],
13	necessary	JJ	O	necessary	rcmod	10	SENT_197	[p12l1085t150r1421b211],
14	for	IN	O	for	_	0	SENT_197	[p12l1440t127r1538b190],
15	replication	NN	O	replication	prep_for	13	SENT_197	[p12l1560t127r1931b210],
16	of	IN	O	of	_	0	SENT_197	[p12l1954t127r2029b190],
17	the	DT	O	the	det	18	SENT_197	[p12l2041t127r2148b190],
18	HCV	NN	O	hcv	prep_of	15	SENT_197	[p12l10t234r190b293],
19	.	.	O	.	_	0	SENT_197	[p12l10t234r190b293],

1	The	DT	O	the	det	2	SENT_198	[p12l214t230r337b293],
2	enzyme	NN	O	enzyme	nsubj	3	SENT_198	[p12l358t252r617b314],
3	has	VBZ	O	have	_	0	SENT_198	[p12l636t230r747b293],
4	a	DT	O	a	det	6	SENT_198	[p12l768t253r802b293],
5	catalytic	JJ	O	catalytic	amod	6	SENT_198	[p12l821t230r1098b314],
6	site	NN	O	site	dobj	3	SENT_198	[p12l1119t236r1229b293],
7	for	IN	O	for	_	0	SENT_198	[p12l1249t230r1345b293],
8	nucleoside	NN	O	nucleoside	nn	9	SENT_198	[p12l1363t230r1722b293],
9	binding	NN	O	binding	prep_for	6	SENT_198	[p12l1740t230r2005b314],
10	and	CC	O	and	_	0	SENT_198	[p12l2024t230r2149b293],
11	at	IN	O	at	quantmod	13	SENT_198	[p12l10t345r69b396],
12	least	JJS	O	least	mwe	11	SENT_198	[p12l86t333r237b396],
13	four	CD	NUMBER	four	num	15	SENT_198	[p12l255t333r396b396],
14	other	JJ	O	other	amod	15	SENT_198	[p12l416t333r594b396],
15	sites	NNS	O	site	conj_and	6	SENT_198	[p12l614t339r755b396],
16	at	IN	O	at	_	0	SENT_198	[p12l776t345r834b396],
17	which	WDT	O	which	rel	22	SENT_198	[p12l851t333r1058b396],
18	a	DT	O	a	det	20	SENT_198	[p12l1078t356r1112b396],
19	nonnucleoside	JJ	O	nonnucleoside	amod	20	SENT_198	[p12l1131t333r1625b396],
20	compound	NN	O	compound	nsubj	22	SENT_198	[p12l1645t333r2014b416],
21	can	MD	O	can	aux	22	SENT_198	[p12l2033t356r2148b396],
22	bind	VB	O	bind	rcmod	15	SENT_198	[p12l7t436r168b499],
23	and	CC	O	and	_	0	SENT_198	[p12l192t436r320b499],
24	cause	VB	O	cause	rcmod	15	SENT_198	[p12l344t459r531b499],
25	allosteric	JJ	O	allosteric	amod	26	SENT_198	[p12l556t436r872b499],
26	alteration	NN	O	alteration	dobj	22	SENT_198	[p12l896t436r1247b499],
27	.	.	O	.	_	0	SENT_198	[p12l896t436r1247b499],

1	The	DT	O	the	det	3	SENT_199	[p12l1274t436r1401b499],
2	enzymes	NNS	O	enzyme	nn	3	SENT_199	[p12l1425t436r1732b520],
3	structure	NN	O	structure	nsubjpass	6	SENT_199	[p12l1757t448r2073b499],
4	is	VBZ	O	be	auxpass	6	SENT_199	[p12l2097t442r2148b499],
5	highly	RB	O	highly	advmod	6	SENT_199	[p12l8t539r222b623],
6	conserved	VBN	O	conserve	_	0	SENT_199	[p12l239t539r579b602],
7	across	IN	O	across	_	0	SENT_199	[p12l599t562r801b602],
8	all	DT	O	all	det	10	SENT_199	[p12l822t539r899b602],
9	HCV	NN	O	hcv	nn	10	SENT_199	[p12l919t543r1095b602],
10	genotypes	NNS	O	genotype	prep_across	6	SENT_199	[p12l1114t551r1467b623],
11	,	,	O	,	_	0	SENT_199	[p12l1114t551r1467b623],
12	giving	VBG	O	give	xcomp	6	SENT_199	[p12l1488t545r1695b623],
13	NS5B	NN	O	ns5b	nn	14	SENT_199	[p12l1713t543r1902b602],
14	inhibitors	NNS	O	inhibitor	iobj	12	SENT_199	[p12l1923t539r2147b602, p12l8t654r137b706],
15	eﬂicacy	NN	O	eﬂicacy	dobj	12	SENT_199	[p12l160t642r418b727],
16	against	IN	O	against	_	0	SENT_199	[p12l437t649r676b727],
17	all	DT	O	all	det	19	SENT_199	[p12l698t642r777b706],
18	six	CD	NUMBER	six	num	19	SENT_199	[p12l798t649r891b706],
19	genotypes	NNS	O	genotype	prep_against	15	SENT_199	[p12l911t634r1306b727],
20	.9	CD	NUMBER	.9	dep	19	SENT_199	[p12l911t634r1306b727],

1	There	EX	O	there	expl	2	SENT_200	[p12l83t746r281b809],
2	are	VBP	O	be	dep	9	SENT_200	[p12l305t769r408b809],
3	two	CD	NUMBER	two	num	4	SENT_200	[p12l431t758r559b809],
4	classes	NNS	O	class	nsubj	2	SENT_200	[p12l585t746r815b809],
5	of	IN	O	of	_	0	SENT_200	[p12l840t746r915b809],
6	polymerase	NN	O	polymerase	nn	7	SENT_200	[p12l928t746r1333b830],
7	inhibitors	NNS	O	inhibitor	prep_of	4	SENT_200	[p12l1357t746r1718b809],
8	:	:	O	:	_	0	SENT_200	[p12l1357t746r1718b809],
9	nucleoside	NN	O	nucleoside	_	0	SENT_200	[p12l1745t746r2148b812],
10	/	:	O	/	punct	9	SENT_200	[p12l1745t746r2148b812],
11	nucleotide	NN	O	nucleotide	nn	12	SENT_200	[p12l9t849r388b912],
12	analogues	NNS	O	analogue	nsubj	13	SENT_200	[p12l418t849r775b933],
13	(	VBP	O	(	dep	9	SENT_200	[p12l808t849r1040b926],
14	NPIs	NNS	O	npi	nsubj	19	SENT_200	[p12l808t849r1040b926],
15	)	CD	NUMBER	)	num	14	SENT_200	[p12l808t849r1040b926],
16	and	CC	O	and	_	0	SENT_200	[p12l1073t849r1205b912],
17	nonnucleoside	JJ	O	nonnucleoside	amod	18	SENT_200	[p12l1232t849r1762b912],
18	analogues	NNS	O	analogue	nsubj	19	SENT_200	[p12l1792t849r2149b933],
19	(	VBN	O	(	dep	13	SENT_200	[p12l13t952r324b1029],
20	NNPIs	NNS	O	nnpi	dobj	19	SENT_200	[p12l13t952r324b1029],
21	)	CD	NUMBER	)	tmod	19	SENT_200	[p12l13t952r324b1029],
22	.	.	O	.	_	0	SENT_200	[p12l13t952r324b1029],

1	The	DT	O	the	det	2	SENT_201	[p12l350t952r477b1015],
2	NPIs	NNS	MISC	npi	nsubj	3	SENT_201	[p12l500t957r671b1015],
3	target	VBP	O	target	_	0	SENT_201	[p12l694t964r894b1036],
4	the	DT	O	the	det	6	SENT_201	[p12l915t952r1024b1015],
5	catalytic	JJ	O	catalytic	amod	6	SENT_201	[p12l1048t952r1336b1036],
6	site	NN	O	site	dobj	3	SENT_201	[p12l1359t958r1473b1015],
7	of	IN	O	of	_	0	SENT_201	[p12l1497t952r1572b1015],
8	NS5B	NN	O	ns5b	prep_of	6	SENT_201	[p12l1585t956r1781b1015],
9	and	CC	O	and	_	0	SENT_201	[p12l1807t952r1935b1015],
10	result	NN	O	result	conj_and	8	SENT_201	[p12l1958t952r2151b1015],
11	in	IN	O	in	_	0	SENT_201	[p12l9t1060r76b1116],
12	chain	NN	O	chain	nn	13	SENT_201	[p12l98t1054r284b1117],
13	termination	NN	O	termination	prep_in	3	SENT_201	[p12l304t1060r732b1117],
14	.	.	O	.	_	0	SENT_201	[p12l304t1060r732b1117],

1	NNPIs	NNS	O	nnpi	nsubj	2	SENT_202	[p12l756t1059r989b1117],
2	act	VBP	O	act	_	0	SENT_202	[p12l1012t1066r1110b1117],
3	as	IN	O	as	_	0	SENT_202	[p12l1131t1077r1195b1117],
4	allosteric	JJ	O	allosteric	amod	5	SENT_202	[p12l1219t1054r1528b1117],
5	inhibitors	NNS	O	inhibitor	prep_as	2	SENT_202	[p12l1549t1054r1900b1117],
6	.	.	O	.	_	0	SENT_202	[p12l1549t1054r1900b1117],

1	NUCLEOTISIIDE	NNP	O	NUCLEOTISIIDE	nn	3	SENT_203	[p12l13t1265r571b1329],
2	POLYMERASE	NNP	O	POLYMERASE	nn	3	SENT_203	[p12l593t1268r1074b1324],
3	INHIBITORS	NNPS	O	INHIBITORS	nsubjpass	7	SENT_203	[p12l1096t1268r1513b1324],
4	Nucleotide	NN	O	nucleotide	nn	5	SENT_203	[p12l9t1364r394b1427],
5	inhibitors	NNS	O	inhibitor	dep	3	SENT_203	[p12l419t1364r761b1427],
6	are	VBP	O	be	auxpass	7	SENT_203	[p12l787t1387r890b1427],
7	activated	VBN	O	activate	_	0	SENT_203	[p12l915t1364r1230b1427],
8	through	IN	O	through	_	0	SENT_203	[p12l1252t1364r1538b1448],
9	phosphorylation	NN	O	phosphorylation	prep_through	7	SENT_203	[p12l1560t1364r2148b1448],
10	within	IN	O	within	_	0	SENT_203	[p12l8t1467r232b1530],
11	the	DT	O	the	det	12	SENT_203	[p12l254t1467r361b1530],
12	hepatocyte	NN	O	hepatocyte	prep_within	9	SENT_203	[p12l383t1467r759b1551],
13	to	TO	O	to	_	0	SENT_203	[p12l781t1479r847b1530],
14	nucleoside	JJ	O	nucleoside	amod	15	SENT_203	[p12l871t1467r1238b1530],
15	triphosphate	NN	O	triphosphate	prep_to	7	SENT_203	[p12l1260t1467r1715b1550],
16	,	,	O	,	_	0	SENT_203	[p12l1260t1467r1715b1550],
17	which	WDT	O	which	nsubj	18	SENT_203	[p12l1738t1467r1949b1530],
18	competes	VBZ	O	compete	rcmod	15	SENT_203	[p12l1973t1490r2148b1530, p12l8t1582r186b1653],
19	with	IN	O	with	_	0	SENT_203	[p12l209t1570r366b1633],
20	nucleotides	NNS	O	nucleotide	prep_with	18	SENT_203	[p12l389t1570r809b1642],
21	,	,	O	,	_	0	SENT_203	[p12l389t1570r809b1642],
22	resulting	VBG	O	result	xcomp	18	SENT_203	[p12l835t1570r1144b1654],
23	in	IN	O	in	_	0	SENT_203	[p12l1166t1576r1234b1632],
24	chain	NN	O	chain	nn	25	SENT_203	[p12l1258t1570r1448b1633],
25	termination	NN	O	termination	prep_in	22	SENT_203	[p12l1471t1576r1892b1633],
26	during	IN	O	during	_	0	SENT_203	[p12l1917t1570r2153b1654],
27	RNA	NN	MISC	rna	nn	28	SENT_203	[p12l10t1677r179b1736],
28	replication	NN	O	replication	prep_during	22	SENT_203	[p12l199t1673r563b1756],
29	of	IN	O	of	_	0	SENT_203	[p12l583t1673r656b1736],
30	the	DT	O	the	det	32	SENT_203	[p12l666t1673r772b1736],
31	viral	JJ	O	viral	amod	32	SENT_203	[p12l789t1673r943b1736],
32	genome	NN	O	genome	prep_of	28	SENT_203	[p12l963t1696r1246b1757],
33	.	.	O	.	_	0	SENT_203	[p12l963t1696r1246b1757],

1	As	IN	O	as	_	0	SENT_204	[p12l1269t1677r1355b1736],
2	a	DT	O	a	det	3	SENT_204	[p12l1376t1696r1411b1736],
3	class	NN	O	class	prep_as	6	SENT_204	[p12l1430t1673r1601b1745],
4	,	,	O	,	_	0	SENT_204	[p12l1430t1673r1601b1745],
5	they	PRP	O	they	nsubjpass	35	SENT_204	[p12l1622t1673r1771b1757],
6	have	VBP	O	have	_	0	SENT_204	[p12l1787t1673r1941b1736],
7	moderate	JJ	O	moderate	amod	9	SENT_204	[p12l1961t1673r2145b1736, p12l10t1789r175b1840],
8	to	TO	O	to	dep	9	SENT_204	[p12l197t1789r263b1840],
9	high	JJ	O	high	amod	10	SENT_204	[p12l287t1777r442b1861],
10	efﬁcacy	NN	O	efﬁcacy	dobj	6	SENT_204	[p12l466t1777r725b1861],
11	across	IN	O	across	_	0	SENT_204	[p12l745t1800r955b1840],
12	all	DT	O	all	det	14	SENT_204	[p12l979t1777r1059b1840],
13	six	CD	NUMBER	six	num	14	SENT_204	[p12l1082t1783r1176b1840],
14	genotypes	NNS	O	genotype	prep_across	10	SENT_204	[p12l1197t1789r1562b1861],
15	,	,	O	,	_	0	SENT_204	[p12l1197t1789r1562b1861],
16	have	VBP	O	have	conj_and	6	SENT_204	[p12l1586t1777r1743b1840],
17	a	DT	O	a	det	20	SENT_204	[p12l1767t1800r1801b1840],
18	very	RB	O	very	advmod	19	SENT_204	[p12l1820t1800r1975b1861],
19	high	JJ	O	high	amod	20	SENT_204	[p12l1993t1777r2149b1861],
20	barrier	NN	O	barrier	dobj	16	SENT_204	[p12l7t1880r250b1943],
21	to	TO	O	to	_	0	SENT_204	[p12l271t1892r339b1943],
22	resistance	NN	O	resistance	prep_to	20	SENT_204	[p12l364t1886r723b1952],
23	,	,	O	,	_	0	SENT_204	[p12l364t1886r723b1952],
24	are	VBP	O	be	cop	26	SENT_204	[p12l749t1903r851b1943],
25	equally	RB	O	equally	advmod	26	SENT_204	[p12l875t1880r1127b1964],
26	effective	JJ	O	effective	conj_and	6	SENT_204	[p12l1148t1880r1433b1943],
27	in	IN	O	in	_	0	SENT_204	[p12l1457t1886r1525b1942],
28	genotypes	NNS	O	genotype	nn	29	SENT_204	[p12l1548t1892r1898b1964],
29	1a	NN	O	1a	prep_in	26	SENT_204	[p12l1929t1887r2000b1943],
30	and	CC	O	and	_	0	SENT_204	[p12l2023t1880r2152b1943],
31	1b	NN	O	1b	prep_in	26	SENT_204	[p12l16t1983r107b2055],
32	,	,	O	,	_	0	SENT_204	[p12l16t1983r107b2055],
33	and	CC	O	and	_	0	SENT_204	[p12l133t1983r260b2046],
34	are	VBP	O	be	auxpass	35	SENT_204	[p12l283t2006r384b2046],
35	taken	VBN	O	take	conj_and	6	SENT_204	[p12l406t1983r597b2046],
36	once	RB	DATE	once	advmod	35	SENT_204	[p12l620t2006r780b2046],
37	daily	RB	SET	daily	advmod	35	SENT_204	[p12l805t1983r980b2067],
38	.	.	O	.	_	0	SENT_204	[p12l805t1983r980b2067],

1	However	RB	O	however	advmod	8	SENT_205	[p12l1007t1988r1329b2055],
2	,	,	O	,	_	0	SENT_205	[p12l1007t1988r1329b2055],
3	the	DT	O	the	det	5	SENT_205	[p12l1353t1983r1460b2046],
4	drug	NN	O	drug	nn	5	SENT_205	[p12l1484t1983r1648b2067],
5	class	NN	O	class	nsubjpass	8	SENT_205	[p12l1669t1983r1825b2046],
6	has	VBZ	O	have	aux	8	SENT_205	[p12l1848t1983r1961b2046],
7	been	VBN	O	be	auxpass	8	SENT_205	[p12l1982t1983r2148b2046],
8	plagued	VBN	O	plague	dep	12	SENT_205	[p12l8t2085r281b2170],
9	with	IN	O	with	_	0	SENT_205	[p12l299t2085r452b2149],
10	toxicity	NN	O	toxicity	nn	11	SENT_205	[p12l473t2092r732b2170],
11	problems	NNS	O	problem	prep_with	8	SENT_205	[p12l749t2085r1069b2169],
12	(	VBP	O	(	_	0	SENT_205	[p12l1095t2086r1223b2163],
13	see	VB	O	see	xcomp	12	SENT_205	[p12l1095t2086r1223b2163],
14	Table	NNP	O	Table	dobj	13	SENT_205	[p12l1245t2086r1438b2149],
15	1	CD	NUMBER	1	num	14	SENT_205	[p12l1464t2077r1606b2163],
16	)	CD	NUMBER	)	nsubj	12	SENT_205	[p12l1464t2077r1606b2163],
17	.	.	O	.	_	0	SENT_205	[p12l1464t2077r1606b2163],

1	“	NN	O	“	_	0	SENT_206	[p12l1464t2077r1606b2163],

1	VOLUME	NN	O	volume	nn	3	SENT_207	[p12l544t2305r768b2347],
2	95	CD	NUMBER	95	num	3	SENT_207	[p12l785t2306r841b2347],
3	NUMBER	NN	O	number	_	0	SENT_207	[p12l863t2305r1087b2347],
4	1	CD	NUMBER	1	number	5	SENT_207	[p12l1108t2307r1121b2347],
5	|	CD	NUMBER	|	dep	3	SENT_207	[p12l1151t2301r1156b2362],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_207	[p12l1174t2305r1419b2347],
7	2014	CD	DATE	2014	num	6	SENT_207	[p12l1435t2306r1557b2347],
8	|	CD	NUMBER	|	num	9	SENT_207	[p12l1575t2301r1580b2362],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_207	[p12l1599t2305r2150b2358],

1	SOFOSBUVIR	NNP	O	SOFOSBUVIR	nn	4	SENT_208	[p12l10t2710r479b2766],
2	Sofosbuvir	NNP	O	Sofosbuvir	nn	4	SENT_208	[p12l9t2806r366b2869],
3	(	NN	O	(	nn	4	SENT_208	[p12l388t2807r580b2882],
4	GS-7	NN	O	gs-7	nsubjpass	26	SENT_208	[p12l388t2807r580b2882],
5	97	CD	NUMBER	97	number	6	SENT_208	[p12l585t2813r661b2869],
6	7	CD	NUMBER	7	num	7	SENT_208	[p12l667t2807r727b2883],
7	)	NN	O	)	nsubj	14	SENT_208	[p12l667t2807r727b2883],
8	is	VBZ	O	be	cop	14	SENT_208	[p12l751t2812r799b2869],
9	an	DT	O	a	det	14	SENT_208	[p12l821t2829r899b2869],
10	orally	RB	O	orally	advmod	13	SENT_208	[p12l919t2806r1110b2890],
11	bioavailable	JJ	O	bioavailable	amod	13	SENT_208	[p12l1124t2806r1537b2878],
12	,	,	O	,	_	0	SENT_208	[p12l1124t2806r1537b2878],
13	direct-acting	JJ	O	direct-acting	amod	14	SENT_208	[p12l1559t2806r1988b2890],
14	NPI	NNP	ORGANIZATION	NPI	rcmod	4	SENT_208	[p12l2005t2811r2140b2869],
15	currently	RB	DATE	currently	advmod	14	SENT_208	[p12l9t2908r320b2992],
16	pending	VBG	O	pend	_	0	SENT_208	[p12l335t2908r616b2992],
17	FDA	NNP	ORGANIZATION	FDA	nn	18	SENT_208	[p12l635t2912r795b2970],
18	approval	NN	O	approval	prep_pending	14	SENT_208	[p12l815t2908r1105b2991],
19	at	IN	O	at	_	0	SENT_208	[p12l1125t2920r1184b2971],
20	the	DT	O	the	det	21	SENT_208	[p12l1202t2908r1306b2971],
21	end	NN	O	end	prep_at	18	SENT_208	[p12l1327t2908r1451b2971],
22	of	IN	O	of	_	0	SENT_208	[p12l1471t2908r1544b2971],
23	2013.39	CD	NUMBER	2013.39	prep_of	21	SENT_208	[p12l1555t2900r1793b2971],
24	It	PRP	O	it	nsubjpass	26	SENT_208	[p12l1815t2913r1863b2971],
25	is	VBZ	O	be	auxpass	26	SENT_208	[p12l1882t2914r1931b2971],
26	phosphorylated	VBN	O	phosphorylate	ccomp	38	SENT_208	[p12l1950t2908r2139b2991, p12l7t3011r390b3095],
27	within	IN	O	within	_	0	SENT_208	[p12l411t3011r639b3074],
28	the	DT	O	the	det	29	SENT_208	[p12l662t3011r770b3074],
29	liver	NN	O	liver	prep_within	26	SENT_208	[p12l793t3011r948b3074],
30	to	TO	O	to	_	0	SENT_208	[p12l969t3023r1037b3074],
31	a	DT	O	a	det	33	SENT_208	[p12l1062t3034r1097b3074],
32	nucleotide	NN	O	nucleotide	nn	33	SENT_208	[p12l1119t3011r1486b3074],
33	triphosphate	NN	O	triphosphate	prep_to	26	SENT_208	[p12l1509t3011r1970b3094],
34	,	,	O	,	_	0	SENT_208	[p12l1509t3011r1970b3094],
35	This	DT	O	this	det	36	SENT_208	[p12l1997t3011r2143b3074],
36	molecule	NN	O	molecule	nsubj	38	SENT_208	[p12l8t3114r311b3177],
37	actively	RB	O	actively	advmod	38	SENT_208	[p12l332t3114r585b3198],
38	competes	VBZ	O	compete	_	0	SENT_208	[p12l601t3126r914b3197],
39	with	IN	O	with	_	0	SENT_208	[p12l933t3114r1081b3177],
40	naturally	RB	O	naturally	advmod	41	SENT_208	[p12l1101t3114r1401b3198],
41	occurring	VBG	O	occur	prepc_with	38	SENT_208	[p12l1417t3120r1745b3198],
42	nucleotides	NNS	O	nucleotide	dobj	41	SENT_208	[p12l1763t3114r2142b3177],
43	at	IN	O	at	_	0	SENT_208	[p12l9t3229r67b3280],
44	the	DT	O	the	det	61	SENT_208	[p12l84t3217r188b3280],
45	highly	RB	O	highly	amod	61	SENT_208	[p12l206t3217r420b3301],
46	conserved	VBN	O	conserve	dep	45	SENT_208	[p12l436t3217r775b3280],
47	active	JJ	O	active	amod	48	SENT_208	[p12l795t3223r985b3280],
48	site	NN	O	site	dobj	46	SENT_208	[p12l1005t3223r1113b3280],
49	of	IN	O	of	_	0	SENT_208	[p12l1134t3217r1206b3280],
50	the	DT	O	the	det	53	SENT_208	[p12l1215t3217r1319b3280],
51	HCV	NN	O	hcv	nn	53	SENT_208	[p12l1339t3221r1514b3280],
52	NS5B	NN	O	ns5b	nn	53	SENT_208	[p12l1532t3221r1721b3280],
53	polymerase	NN	O	polymerase	prep_of	48	SENT_208	[p12l1740t3217r2141b3301],
54	,	,	O	,	_	0	SENT_208	[p12l1740t3217r2141b3301],
55	resulting	VBG	O	result	partmod	46	SENT_208	[p12l9t3319r309b3403],
56	in	IN	O	in	_	0	SENT_208	[p12l329t3325r396b3381],
57	early	JJ	O	early	amod	58	SENT_208	[p12l418t3319r584b3403],
58	RNA	NN	O	rna	prep_in	55	SENT_208	[p12l602t3323r772b3382],
59	chain	NN	O	chain	nn	61	SENT_208	[p12l794t3319r979b3382],
60	termination	NN	O	termination	nn	61	SENT_208	[p12l1000t3311r1567b3382],
61	.42	NN	NUMBER	.42	prep_at	41	SENT_208	[p12l1000t3311r1567b3382],
62	=	JJ	O	=	amod	61	SENT_208	[p12l1000t3311r1567b3382],
63	43	CD	NUMBER	43	tmod	62	SENT_208	[p12l1000t3311r1567b3382],

1	In	IN	O	in	_	0	SENT_209	[p12l83t3427r153b3484],
2	a	DT	O	a	det	3	SENT_209	[p12l176t3445r210b3485],
3	phase	NN	O	phase	prep_in	15	SENT_209	[p12l230t3422r424b3505],
4	I	PRP	O	I	dep	5	SENT_209	[p12l446t3427r470b3484],
5	trial	NN	O	trial	dep	3	SENT_209	[p12l492t3422r649b3494],
6	,	,	O	,	_	0	SENT_209	[p12l492t3422r649b3494],
7	monotherapy	NN	O	monotherapy	appos	3	SENT_209	[p12l672t3422r1137b3506],
8	with	IN	O	with	_	0	SENT_209	[p12l1153t3422r1306b3485],
9	400	CD	NUMBER	400	num	11	SENT_209	[p12l1327t3429r1446b3485],
10	mg	NN	O	mg	nn	11	SENT_209	[p12l1462t3445r1571b3506],
11	sofosbuvir	NN	O	sofosbuvir	prep_with	7	SENT_209	[p12l1592t3422r1948b3485],
12	a	DT	DURATION	a	det	13	SENT_209	[p12l1969t3445r2004b3485],
13	day	NN	DURATION	day	dep	11	SENT_209	[p12l2024t3422r2146b3506],
14	was	VBD	O	be	auxpass	15	SENT_209	[p12l7t3548r137b3588],
15	found	VBN	O	find	dep	31	SENT_209	[p12l163t3525r374b3588],
16	to	TO	O	to	aux	17	SENT_209	[p12l398t3537r466b3588],
17	result	VB	O	result	xcomp	15	SENT_209	[p12l494t3525r691b3588],
18	in	IN	O	in	_	0	SENT_209	[p12l717t3531r785b3587],
19	a	DT	O	a	det	22	SENT_209	[p12l812t3548r847b3588],
20	3.9	CD	NUMBER	3.9	num	22	SENT_209	[p12l873t3525r1170b3609],
21	log1O	NN	O	log1o	nn	22	SENT_209	[p12l873t3525r1170b3609],
22	decline	NN	O	decline	prep_in	17	SENT_209	[p12l1199t3525r1451b3588],
23	in	IN	O	in	_	0	SENT_209	[p12l1478t3531r1546b3587],
24	HCV	NN	O	hcv	nn	25	SENT_209	[p12l1573t3529r1757b3588],
25	RNA	NN	O	rna	prep_in	22	SENT_209	[p12l1784t3529r1959b3588],
26	after	IN	O	after	_	0	SENT_209	[p12l1985t3525r2143b3588],
27	3	CD	DURATION	3	num	28	SENT_209	[p12l10t3634r43b3690],
28	days	NNS	NUMBER	day	prep_after	17	SENT_209	[p12l70t3619r305b3711],
29	/	:	O	/	punct	31	SENT_209	[p12l70t3619r305b3711],
30	*	CD	NUMBER	*	num	31	SENT_209	[p12l70t3619r305b3711],
31	4	CD	NUMBER	4	_	0	SENT_209	[p12l70t3619r305b3711],
32	No	DT	O	no	det	36	SENT_209	[p12l326t3632r429b3690],
33	dosage	NN	O	dosage	nn	36	SENT_209	[p12l454t3627r687b3711],
34	or	CC	O	or	_	0	SENT_209	[p12l712t3650r784b3690],
35	interval	NN	O	interval	conj_or	33	SENT_209	[p12l806t3627r1072b3690],
36	modiﬁcations	NNS	O	modiﬁcations	nsubj	38	SENT_209	[p12l1094t3627r1570b3690],
37	are	VBP	O	be	cop	38	SENT_209	[p12l1595t3650r1696b3690],
38	necessary	JJ	O	necessary	rcmod	31	SENT_209	[p12l1719t3650r2055b3711],
39	in	IN	O	in	_	0	SENT_209	[p12l2075t3633r2142b3689],
40	those	DT	O	those	prep_in	38	SENT_209	[p12l8t3729r189b3792],
41	with	IN	O	with	_	0	SENT_209	[p12l208t3729r359b3792],
42	cirrhosis	NN	O	cirrhosis	prep_with	40	SENT_209	[p12l380t3729r691b3801],
43	,	,	O	,	_	0	SENT_209	[p12l380t3729r691b3801],
44	including	VBG	O	include	_	0	SENT_209	[p12l713t3729r1037b3813],
45	Child	NNP	O	Child	prep_including	40	SENT_209	[p12l1056t3729r1470b3813],
46	.	.	O	.	_	0	SENT_209	[p12l1056t3729r1470b3813],

1	—	NN	O	—	_	0	SENT_210	[p12l1056t3729r1470b3813],
2	.	.	O	.	_	0	SENT_210	[p12l1056t3729r1470b3813],

1	Pugh	NNP	PERSON	Pugh	_	0	SENT_211	[p12l1056t3729r1470b3813],
2	class	NN	O	class	nn	4	SENT_211	[p12l1491t3729r1643b3792],
3	C	NN	O	c	nn	4	SENT_211	[p12l1665t3733r1717b3792],
4	cirrhotics	NNS	O	cirrhotic	dep	1	SENT_211	[p12l1738t3721r2141b3792],
5	.45	CD	NUMBER	.45	dep	1	SENT_211	[p12l1738t3721r2141b3792],

1	Sofosbuvir	NNP	O	Sofosbuvir	poss	3	SENT_212	[p13l83t16r513b79],
2	’s	POS	O	’s	_	0	SENT_212	[p13l83t16r513b79],
3	activity	NN	O	activity	nsubj	9	SENT_212	[p13l544t22r811b100],
4	against	IN	O	against	_	0	SENT_212	[p13l837t22r1089b100],
5	the	DT	O	the	prep_against	3	SENT_212	[p13l1116t16r1227b79],
6	conserved	VBN	O	conserve	partmod	5	SENT_212	[p13l1256t16r1624b79],
7	NSSB	NN	ORGANIZATION	nssb	nn	8	SENT_212	[p13l1651t20r1852b79],
8	protein	NN	O	protein	dobj	6	SENT_212	[p13l1881t22r2143b99],
9	resulted	VBD	O	result	_	0	SENT_212	[p13l9t118r280b181],
10	in	IN	O	in	_	0	SENT_212	[p13l301t124r368b180],
11	similar	JJ	O	similar	prep_in	9	SENT_212	[p13l391t118r628b181],
12	in	FW	O	in	nn	13	SENT_212	[p13l652t124r712b181],
13	vitro	FW	O	vitro	advmod	14	SENT_212	[p13l737t124r889b181],
14	activity	NN	O	activity	rcmod	11	SENT_212	[p13l913t124r1165b202],
15	across	IN	O	across	_	0	SENT_212	[p13l1185t141r1391b181],
16	all	DT	O	all	det	18	SENT_212	[p13l1415t118r1494b181],
17	HCV	NN	O	hcv	nn	18	SENT_212	[p13l1516t122r1695b181],
18	genotypes	NNS	O	genotype	prep_across	14	SENT_212	[p13l1716t110r2141b202],
19	.	.	O	.	_	0	SENT_212	[p13l1716t110r2141b202],

1	“	NN	O	“	_	0	SENT_213	[p13l1716t110r2141b202],
2	This	DT	O	this	nsubjpass	5	SENT_213	[p13l8t221r151b284],
3	was	VBD	O	be	auxpass	5	SENT_213	[p13l171t244r296b284],
4	also	RB	O	also	advmod	5	SENT_213	[p13l318t221r449b284],
5	seen	VBN	O	see	rcmod	1	SENT_213	[p13l471t244r620b284],
6	in	IN	O	in	_	0	SENT_213	[p13l640t227r707b283],
7	phase	NN	O	phase	nn	9	SENT_213	[p13l726t221r921b304],
8	II	CD	NUMBER	ii	num	9	SENT_213	[p13l942t226r995b283],
9	studies	NNS	O	study	prep_in	5	SENT_213	[p13l1018t221r1271b293],
10	,	,	O	,	_	0	SENT_213	[p13l1018t221r1271b293],
11	with	IN	O	with	_	0	SENT_213	[p13l1291t221r1444b284],
12	SVR	NN	ORGANIZATION	svr	prep_with	5	SENT_213	[p13l1465t225r1618b284],
13	being	VBG	O	be	auxpass	14	SENT_213	[p13l1634t221r1825b305],
14	achieved	VBN	O	achieve	partmod	12	SENT_213	[p13l1845t221r2144b284],
15	in	IN	O	in	_	0	SENT_213	[p13l9t330r73b386],
16	>	JJR	PERCENT	>	prep_in	14	SENT_213	[p13l95t329r278b388],
17	87	CD	PERCENT	87	number	18	SENT_213	[p13l95t329r278b388],
18	%	NN	PERCENT	%	amod	16	SENT_213	[p13l95t329r278b388],
19	of	IN	O	of	_	0	SENT_213	[p13l299t324r371b387],
20	patients	NNS	O	patient	prep_of	1	SENT_213	[p13l380t330r641b407],
21	in	IN	O	in	mark	85	SENT_213	[p13l661t330r726b386],
22	genotypes	NNS	O	genotype	dep	45	SENT_213	[p13l745t336r1077b408],
23	1	CD	NUMBER	1	num	22	SENT_213	[p13l1104t331r1151b396],
24	,	,	O	,	_	0	SENT_213	[p13l1104t331r1151b396],
25	2	CD	NUMBER	2	num	22	SENT_213	[p13l1172t331r1226b396],
26	,	,	O	,	_	0	SENT_213	[p13l1172t331r1226b396],
27	3	CD	NUMBER	3	num	22	SENT_213	[p13l1249t331r1301b396],
28	,	,	O	,	_	0	SENT_213	[p13l1249t331r1301b396],
29	4	CD	NUMBER	4	num	22	SENT_213	[p13l1321t331r1376b396],
30	,	,	O	,	_	0	SENT_213	[p13l1321t331r1376b396],
31	and	CC	NUMBER	and	_	0	SENT_213	[p13l1398t324r1521b387],
32	6	CD	NUMBER	6	conj_and	22	SENT_213	[p13l1540t330r1575b387],
33	when	WRB	O	when	advmod	45	SENT_213	[p13l1593t324r1776b387],
34	sofosbuvir	JJ	O	sofosbuvir	amod	35	SENT_213	[p13l1796t324r2141b387],
35	(	NN	O	(	nsubjpass	45	SENT_213	[p13l12t427r158b504],
36	400	CD	NUMBER	400	num	37	SENT_213	[p13l12t427r158b504],
37	mg	NN	O	mg	dep	35	SENT_213	[p13l174t450r282b511],
38	a	DT	DURATION	a	det	39	SENT_213	[p13l304t450r339b490],
39	day	NN	DURATION	day	dep	37	SENT_213	[p13l360t427r482b511],
40	for	IN	O	for	_	0	SENT_213	[p13l500t427r598b490],
41	12	CD	DURATION	12	num	43	SENT_213	[p13l626t434r697b489],
42	weeks	NNS	NUMBER	week	nn	43	SENT_213	[p13l719t427r950b504],
43	)	NN	O	)	prep_for	35	SENT_213	[p13l719t427r950b504],
44	was	VBD	O	be	auxpass	45	SENT_213	[p13l975t450r1101b490],
45	administered	VBN	O	administer	csubj	85	SENT_213	[p13l1125t427r1577b490],
46	with	IN	O	with	_	0	SENT_213	[p13l1596t427r1749b490],
47	PEG+RBV	NN	O	peg+rbv	prep_with	45	SENT_213	[p13l1772t431r2142b490],
48	in	IN	O	in	_	0	SENT_213	[p13l9t535r77b591],
49	a	DT	O	a	det	51	SENT_213	[p13l101t552r137b592],
50	response-guided	JJ	O	response-guided	amod	51	SENT_213	[p13l159t529r746b613],
51	fashion	NN	O	fashion	prep_in	47	SENT_213	[p13l769t529r1027b592],
52	for	IN	O	for	_	0	SENT_213	[p13l1051t529r1151b592],
53	up	RB	DURATION	up	advmod	59	SENT_213	[p13l1173t551r1261b612],
54	to	TO	DURATION	to	_	0	SENT_213	[p13l1285t541r1352b592],
55	36	CD	DURATION	36	num	56	SENT_213	[p13l1379t535r1458b592],
56	weeks	NNS	NUMBER	week	prep_to	53	SENT_213	[p13l1481t521r1856b592],
57	.46	CD	NUMBER	.46	number	58	SENT_213	[p13l1481t521r1856b592],
58	*	CD	NUMBER	*	num	56	SENT_213	[p13l1481t521r1856b592],
59	47	CD	NUMBER	47	prep_for	51	SENT_213	[p13l1481t521r1856b592],
60	Among	IN	O	among	_	0	SENT_213	[p13l1878t533r2144b613],
61	treatment-naive	JJ	O	treatment-naive	amod	65	SENT_213	[p13l8t638r622b704],
62	,	,	O	,	_	0	SENT_213	[p13l8t638r622b704],
63	noncirrhotic	JJ	O	noncirrhotic	amod	65	SENT_213	[p13l657t632r1127b695],
64	HCV	NN	O	hcv	nn	65	SENT_213	[p13l1161t636r1349b695],
65	genotype	NN	O	genotype	prep_among	45	SENT_213	[p13l1382t644r1717b716],
66	1	CD	NUMBER	1	num	69	SENT_213	[p13l1758t632r2143b695],
67	—	RB	O	—	advmod	68	SENT_213	[p13l1758t632r2143b695],
68	infected	JJ	O	infected	amod	69	SENT_213	[p13l1758t632r2143b695],
69	patients	NNS	O	patient	dep	65	SENT_213	[p13l7t741r297b818],
70	,	,	O	,	_	0	SENT_213	[p13l7t741r297b818],
71	the	DT	O	the	det	72	SENT_213	[p13l321t735r428b798],
72	regimen	NN	O	regimen	appos	65	SENT_213	[p13l452t741r735b819],
73	of	IN	O	of	_	0	SENT_213	[p13l759t735r833b798],
74	400	CD	NUMBER	400	number	75	SENT_213	[p13l846t742r1112b819],
75	—	CD	NUMBER	—	num	77	SENT_213	[p13l846t742r1112b819],
76	mg	NN	O	mg	nn	77	SENT_213	[p13l846t742r1112b819],
77	sofosbuvir	NN	O	sofosbuvir	prep_of	72	SENT_213	[p13l1134t735r1493b798],
78	a	DT	DURATION	a	det	79	SENT_213	[p13l1515t758r1550b798],
79	day	NN	DURATION	day	dep	77	SENT_213	[p13l1573t735r1695b819],
80	for	IN	O	for	_	0	SENT_213	[p13l1714t735r1812b798],
81	12	CD	DURATION	12	num	82	SENT_213	[p13l1840t742r1911b797],
82	weeks	NNS	NUMBER	week	prep_for	45	SENT_213	[p13l1934t735r2140b798],
83	with	IN	O	with	_	0	SENT_213	[p13l7t837r165b901],
84	PEG+RBV	NN	O	peg+rbv	prep_with	82	SENT_213	[p13l191t841r571b901],
85	resulted	VBD	O	result	dep	20	SENT_213	[p13l597t837r879b901],
86	in	IN	O	in	_	0	SENT_213	[p13l904t843r972b900],
87	a	DT	O	a	det	90	SENT_213	[p13l998t860r1033b901],
88	91	CD	PERCENT	91	number	89	SENT_213	[p13l1059t842r1205b902],
89	%	NN	PERCENT	%	amod	90	SENT_213	[p13l1059t842r1205b902],
90	SVR	NN	O	svr	prep_in	85	SENT_213	[p13l1233t841r1409b909],
91	,	,	O	,	_	0	SENT_213	[p13l1233t841r1409b909],
92	with	IN	O	with	_	0	SENT_213	[p13l1434t837r1592b901],
93	no	DT	O	no	det	95	SENT_213	[p13l1617t860r1706b901],
94	viral	JJ	O	viral	amod	95	SENT_213	[p13l1730t837r1891b901],
95	breakthrough	NN	O	breakthrough	prep_with	85	SENT_213	[p13l1914t837r2140b901, p13l8t941r287b1025],

1	seen	VBN	O	see	_	0	SENT_214	[p13l310t964r460b1004],
2	during	IN	O	during	_	0	SENT_214	[p13l484t941r715b1025],
3	treatment	NN	O	treatment	prep_during	1	SENT_214	[p13l735t953r1088b1004],
4	.	.	O	.	_	0	SENT_214	[p13l735t953r1088b1004],

1	In	IN	O	in	_	0	SENT_215	[p13l1115t946r1186b1003],
2	addition	NN	O	addition	prep_in	8	SENT_215	[p13l1210t941r1517b1013],
3	,	,	O	,	_	0	SENT_215	[p13l1210t941r1517b1013],
4	the	DT	O	the	det	5	SENT_215	[p13l1540t941r1647b1004],
5	IL28B	NN	O	il28b	nsubj	8	SENT_215	[p13l1669t946r1874b1004],
6	genetic	JJ	O	genetic	amod	7	SENT_215	[p13l1898t947r2142b1025],
7	polymorphisms	NNS	O	polymorphism	dep	5	SENT_215	[p13l7t1045r545b1129],
8	appeared	VBD	O	appear	_	0	SENT_215	[p13l567t1045r876b1128],
9	to	TO	O	to	aux	10	SENT_215	[p13l894t1057r960b1108],
10	have	VB	O	have	xcomp	8	SENT_215	[p13l980t1045r1135b1108],
11	no	DT	O	no	det	12	SENT_215	[p13l1155t1068r1241b1108],
12	effect	NN	O	effect	dobj	10	SENT_215	[p13l1263t1045r1443b1108],
13	on	IN	O	on	_	0	SENT_215	[p13l1463t1068r1549b1108],
14	viral	JJ	O	viral	amod	15	SENT_215	[p13l1566t1045r1720b1108],
15	clearance	NN	O	clearance	prep_on	12	SENT_215	[p13l1740t1045r2056b1108],
16	as	IN	O	as	mark	26	SENT_215	[p13l2077t1068r2141b1108],
17	100	CD	PERCENT	100	num	18	SENT_215	[p13l15t1153r192b1212],
18	%	NN	PERCENT	%	nsubj	26	SENT_215	[p13l15t1153r192b1212],
19	of	IN	O	of	_	0	SENT_215	[p13l216t1147r290b1210],
20	the	DT	O	the	det	21	SENT_215	[p13l301t1147r407b1210],
21	patients	NNS	O	patient	prep_of	18	SENT_215	[p13l428t1153r697b1230],
22	with	IN	O	with	_	0	SENT_215	[p13l717t1147r870b1210],
23	the	DT	O	the	det	25	SENT_215	[p13l890t1147r996b1210],
24	TT	NN	O	tt	nn	25	SENT_215	[p13l1024t1150r1126b1209],
25	allele	NN	O	allele	prep_with	21	SENT_215	[p13l1143t1147r1315b1210],
26	had	VBD	O	have	advcl	10	SENT_215	[p13l1336t1147r1464b1210],
27	viral	JJ	O	viral	amod	28	SENT_215	[p13l1481t1147r1636b1210],
28	clearance	NN	O	clearance	dobj	26	SENT_215	[p13l1658t1139r2134b1210],
29	.18	CD	NUMBER	.18	number	30	SENT_215	[p13l1658t1139r2134b1210],
30	’47	CD	NUMBER	’47	num	32	SENT_215	[p13l1658t1139r2134b1210],
31	The	DT	O	the	det	32	SENT_215	[p13l82t1250r207b1313],
32	utility	NN	O	utility	nsubjpass	36	SENT_215	[p13l230t1250r436b1334],
33	of	IN	O	of	_	0	SENT_215	[p13l456t1250r530b1313],
34	sofosbuvir	NN	O	sofosbuvir	prep_of	32	SENT_215	[p13l544t1250r902b1313],
35	was	VBD	O	be	auxpass	36	SENT_215	[p13l922t1273r1048b1313],
36	studied	VBN	O	study	rcmod	28	SENT_215	[p13l1073t1250r1325b1313],
37	in	IN	O	in	_	0	SENT_215	[p13l1346t1256r1413b1312],
38	previously	RB	DATE	previously	advmod	39	SENT_215	[p13l1435t1250r1794b1334],
39	untreated	JJ	O	untreated	amod	40	SENT_215	[p13l1814t1250r2144b1313],
40	genotype	NN	O	genotype	prep_in	36	SENT_215	[p13l8t1365r312b1437],
41	2	CD	NUMBER	2	num	44	SENT_215	[p13l332t1360r367b1415],
42	and	CC	O	and	_	0	SENT_215	[p13l389t1353r512b1416],
43	3	CD	NUMBER	3	conj_and	41	SENT_215	[p13l532t1360r565b1416],
44	patients	NNS	O	patient	dep	40	SENT_215	[p13l586t1359r864b1436],
45	.	.	O	.	_	0	SENT_215	[p13l586t1359r864b1436],

1	Patients	NNS	O	patient	nsubjpass	3	SENT_216	[p13l887t1358r1149b1416],
2	were	VBD	O	be	auxpass	3	SENT_216	[p13l1167t1376r1324b1416],
3	given	VBN	O	give	conj_or	3	SENT_216	[p13l1343t1359r1522b1437],
4	400	CD	NUMBER	400	num	6	SENT_216	[p13l1540t1360r1658b1416],
5	mg	NN	O	mg	nn	6	SENT_216	[p13l1672t1376r1778b1437],
6	sofosbuvir	NN	O	sofosbuvir	dobj	3	SENT_216	[p13l1797t1353r2143b1416],
7	a	DT	DURATION	a	det	8	SENT_216	[p13l9t1479r43b1519],
8	day	NN	DURATION	day	dep	6	SENT_216	[p13l63t1456r183b1540],
9	with	IN	O	with	_	0	SENT_216	[p13l197t1456r348b1519],
10	or	CC	O	or	_	0	SENT_216	[p13l369t1479r440b1519],
11	without	IN	O	without	_	0	SENT_216	[p13l457t1456r721b1519],
12	weight-based	JJ	O	weight-based	amod	13	SENT_216	[p13l738t1456r1190b1540],
13	RBV	NN	O	rbv	prep_without	3	SENT_216	[p13l1210t1461r1367b1519],
14	for	IN	O	for	_	0	SENT_216	[p13l1387t1456r1483b1519],
15	12	CD	DURATION	12	num	16	SENT_216	[p13l1508t1463r1578b1518],
16	weeks	NNS	NUMBER	week	prep_for	3	SENT_216	[p13l1598t1456r1800b1519],
17	and	CC	O	and	_	0	SENT_216	[p13l1821t1456r1946b1519],
18	varying	VBG	O	vary	amod	19	SENT_216	[p13l1962t1479r2138b1540, p13l9t1565r115b1643],
19	durations	NNS	O	duration	prep_for	3	SENT_216	[p13l134t1559r453b1622],
20	of	IN	O	of	_	0	SENT_216	[p13l475t1559r547b1622],
21	IFN	NN	O	ifn	nn	22	SENT_216	[p13l558t1564r691b1622],
22	therapy	NN	O	therapy	prep_of	19	SENT_216	[p13l710t1559r975b1643],
23	.	.	O	.	_	0	SENT_216	[p13l710t1559r975b1643],

1	Results	NNS	O	result	nsubj	2	SENT_217	[p13l998t1559r1237b1622],
2	found	VBD	O	find	_	0	SENT_217	[p13l1257t1559r1458b1622],
3	that	IN	O	that	complm	5	SENT_217	[p13l1476t1559r1607b1622],
4	patients	NNS	O	patient	nsubj	5	SENT_217	[p13l1624t1565r1889b1642],
5	treated	VBN	O	treat	ccomp	2	SENT_217	[p13l1909t1559r2143b1622],
6	with	IN	O	with	_	0	SENT_217	[p13l7t1662r163b1725],
7	sofosbuvir	NN	O	sofosbuvir	prep_with	5	SENT_217	[p13l187t1662r553b1725],
8	and	CC	O	and	_	0	SENT_217	[p13l576t1662r705b1725],
9	RBV	NN	O	rbv	conj_and	7	SENT_217	[p13l728t1667r891b1725],
10	alone	RB	O	alone	advmod	5	SENT_217	[p13l915t1662r1121b1734],
11	;	:	O	;	_	0	SENT_217	[p13l915t1662r1121b1734],
12	those	DT	O	those	nsubj	13	SENT_217	[p13l1145t1662r1332b1725],
13	given	VBN	O	give	conj_and	2	SENT_217	[p13l1356t1668r1544b1746],
14	sofosbuvir	NN	O	sofosbuvir	dobj	13	SENT_217	[p13l1568t1662r1946b1734],
15	,	,	O	,	_	0	SENT_217	[p13l1568t1662r1946b1734],
16	RBV	NN	O	rbv	conj_and	14	SENT_217	[p13l1971t1667r2140b1734],
17	,	,	O	,	_	0	SENT_217	[p13l1971t1667r2140b1734],
18	and	CC	O	and	_	0	SENT_217	[p13l9t1764r135b1828],
19	IFN	NN	ORGANIZATION	ifn	conj_and	14	SENT_217	[p13l155t1769r289b1827],
20	for	IN	O	for	_	0	SENT_217	[p13l309t1764r406b1828],
21	4	CD	NUMBER	4	prep_for	13	SENT_217	[p13l425t1771r481b1836],
22	,	,	O	,	_	0	SENT_217	[p13l425t1771r481b1836],
23	8	CD	NUMBER	8	conj_or	21	SENT_217	[p13l504t1771r558b1836],
24	,	,	O	,	_	0	SENT_217	[p13l504t1771r558b1836],
25	or	CC	O	or	_	0	SENT_217	[p13l581t1787r652b1828],
26	12	CD	DURATION	12	num	27	SENT_217	[p13l678t1771r748b1827],
27	weeks	NNS	NUMBER	week	conj_or	21	SENT_217	[p13l769t1764r990b1836],
28	;	:	O	;	_	0	SENT_217	[p13l769t1764r990b1836],
29	and	CC	O	and	_	0	SENT_217	[p13l1013t1764r1139b1828],
30	those	DT	O	those	nsubj	41	SENT_217	[p13l1157t1764r1339b1828],
31	treated	VBN	O	treat	partmod	30	SENT_217	[p13l1359t1764r1595b1828],
32	with	IN	O	with	_	0	SENT_217	[p13l1613t1764r1765b1828],
33	sofosbuvir	NN	O	sofosbuvir	prep_with	31	SENT_217	[p13l1786t1764r2141b1828],
34	plus	CC	O	plus	prep	33	SENT_217	[p13l7t1868r143b1951],
35	PEG+RBV	NN	O	peg+rbv	dep	34	SENT_217	[p13l163t1872r522b1931],
36	for	IN	O	for	_	0	SENT_217	[p13l541t1868r635b1931],
37	8	CD	DURATION	8	num	38	SENT_217	[p13l655t1875r688b1931],
38	weeks	NNS	NUMBER	week	prep_for	31	SENT_217	[p13l708t1868r906b1931],
39	in	IN	O	in	_	0	SENT_217	[p13l926t1874r991b1930],
40	total	NN	O	total	prep_in	38	SENT_217	[p13l1009t1868r1158b1931],
41	had	VBD	O	have	conj_and	2	SENT_217	[p13l1176t1868r1300b1931],
42	100	CD	PERCENT	100	number	43	SENT_217	[p13l1325t1873r1498b1933],
43	%	NN	PERCENT	%	amod	44	SENT_217	[p13l1325t1873r1498b1933],
44	SVR24	NN	O	svr24	dobj	41	SENT_217	[p13l1520t1872r1763b1931],
45	.	.	O	.	_	0	SENT_217	[p13l1520t1872r1763b1931],

1	Sofosbuvir	JJ	O	sofosbuvir	amod	2	SENT_218	[p13l1786t1868r2141b1931],
2	monotherapy	NN	O	monotherapy	dep	3	SENT_218	[p13l8t1970r473b2054],
3	achieved	VBD	O	achieve	_	0	SENT_218	[p13l491t1970r791b2033],
4	an	DT	O	a	det	5	SENT_218	[p13l812t1993r892b2033],
5	SVR24	NN	O	svr24	dobj	3	SENT_218	[p13l914t1974r1148b2033],
6	in	IN	O	in	_	0	SENT_218	[p13l1169t1976r1236b2032],
7	60	CD	PERCENT	60	num	8	SENT_218	[p13l1258t1975r1399b2035],
8	%	NN	PERCENT	%	prep_in	3	SENT_218	[p13l1258t1975r1399b2035],
9	of	IN	O	of	_	0	SENT_218	[p13l1424t1970r1497b2033],
10	patients	NNS	O	patient	prep_of	8	SENT_218	[p13l1508t1962r1859b2053],
11	.48	CD	NUMBER	.48	nsubj	3	SENT_218	[p13l1508t1962r1859b2053],

1	Two	CD	NUMBER	two	num	2	SENT_219	[p13l82t2076r232b2136],
2	phase	NN	O	phase	tmod	8	SENT_219	[p13l261t2073r464b2156],
3	III	CD	NUMBER	iii	dep	2	SENT_219	[p13l494t2078r602b2145],
4	,	,	O	,	_	0	SENT_219	[p13l494t2078r602b2145],
5	multicenter	JJ	O	multicenter	amod	6	SENT_219	[p13l632t2073r1051b2136],
6	trials	NNS	O	trial	nsubj	8	SENT_219	[p13l1077t2073r1258b2136],
7	further	RB	O	further	advmod	8	SENT_219	[p13l1287t2073r1544b2136],
8	investigated	VBD	O	investigate	_	0	SENT_219	[p13l1572t2073r2003b2157],
9	the	DT	O	the	det	10	SENT_219	[p13l2030t2073r2141b2136],
10	eﬂicacy	NN	O	eﬂicacy	nsubjpass	33	SENT_219	[p13l9t2175r271b2259],
11	of	IN	O	of	_	0	SENT_219	[p13l291t2175r366b2238],
12	sofosbuvir	JJ	O	sofosbuvir	amod	13	SENT_219	[p13l380t2167r820b2238],
13	.47	CD	NUMBER	.47	prep_of	10	SENT_219	[p13l380t2167r820b2238],
14	In	IN	O	in	_	0	SENT_219	[p13l844t2180r916b2237],
15	the	DT	O	the	det	17	SENT_219	[p13l938t2175r1046b2238],
16	NEUTRINO	NN	O	neutrino	nn	17	SENT_219	[p13l1069t2178r1513b2238],
17	trial	NN	O	trial	prep_in	33	SENT_219	[p13l1537t2175r1698b2247],
18	,	,	O	,	_	0	SENT_219	[p13l1537t2175r1698b2247],
19	327	CD	NUMBER	327	num	20	SENT_219	[p13l1724t2182r1845b2238],
20	patients	NNS	O	patient	appos	17	SENT_219	[p13l1868t2181r2142b2258],
21	with	IN	O	with	_	0	SENT_219	[p13l7t2278r158b2341],
22	HCV	NN	O	hcv	nn	23	SENT_219	[p13l178t2282r356b2341],
23	genotype	NN	O	genotype	prep_with	20	SENT_219	[p13l375t2290r683b2362],
24	1	CD	NUMBER	1	num	23	SENT_219	[p13l710t2285r759b2350],
25	,	,	O	,	_	0	SENT_219	[p13l710t2285r759b2350],
26	4	CD	NUMBER	4	appos	17	SENT_219	[p13l779t2285r835b2350],
27	,	,	O	,	_	0	SENT_219	[p13l779t2285r835b2350],
28	5	CD	NUMBER	5	num	26	SENT_219	[p13l859t2286r912b2350],
29	,	,	O	,	_	0	SENT_219	[p13l859t2286r912b2350],
30	or	CC	O	or	_	0	SENT_219	[p13l934t2301r1005b2341],
31	6	CD	NUMBER	6	appos	17	SENT_219	[p13l1025t2284r1061b2341],
32	were	VBD	O	be	auxpass	33	SENT_219	[p13l1080t2301r1239b2341],
33	treated	VBN	O	treat	ccomp	8	SENT_219	[p13l1258t2278r1493b2341],
34	with	IN	O	with	_	0	SENT_219	[p13l1510t2278r1661b2341],
35	400	CD	NUMBER	400	num	37	SENT_219	[p13l1680t2285r1799b2341],
36	mg	NN	O	mg	nn	37	SENT_219	[p13l1815t2301r1923b2362],
37	sofosbuvir	NN	O	sofosbuvir	prep_with	33	SENT_219	[p13l1942t2278r2139b2341, p13l7t2381r191b2444],
38	a	DT	DURATION	a	det	39	SENT_219	[p13l213t2404r248b2444],
39	day	NN	DURATION	day	dep	37	SENT_219	[p13l270t2381r391b2465],
40	with	IN	O	with	_	0	SENT_219	[p13l409t2381r562b2444],
41	PEG+RBV	NN	O	peg+rbv	prep_with	33	SENT_219	[p13l586t2385r960b2444],
42	.	.	O	.	_	0	SENT_219	[p13l586t2385r960b2444],

1	The	DT	O	the	det	3	SENT_220	[p13l986t2381r1111b2444],
2	FISSION	NNP	O	FISSION	nn	3	SENT_220	[p13l1135t2385r1444b2444],
3	trial	NN	O	trial	nsubj	13	SENT_220	[p13l1466t2381r1625b2453],
4	,	,	O	,	_	0	SENT_220	[p13l1466t2381r1625b2453],
5	a	DT	O	a	appos	3	SENT_220	[p13l1650t2404r1685b2444],
6	randomized	VBN	O	randomize	partmod	5	SENT_220	[p13l1707t2381r2140b2453],
7	,	,	O	,	_	0	SENT_220	[p13l1707t2381r2140b2453],
8	open-label	JJ	O	open-label	amod	11	SENT_220	[p13l9t2484r386b2567],
9	,	,	O	,	_	0	SENT_220	[p13l9t2484r386b2567],
10	noninferiority	JJ	O	noninferiority	amod	11	SENT_220	[p13l408t2484r894b2568],
11	study	NN	O	study	appos	3	SENT_220	[p13l912t2484r1105b2568],
12	,	,	O	,	_	0	SENT_220	[p13l912t2484r1105b2568],
13	enrolled	VBN	O	enrol	_	0	SENT_220	[p13l1128t2484r1408b2547],
14	HCV	NNP	O	HCV	nn	15	SENT_220	[p13l1428t2488r1607b2547],
15	genotype	NN	O	genotype	dobj	13	SENT_220	[p13l1626t2496r1936b2568],
16	2	CD	NUMBER	2	num	15	SENT_220	[p13l1957t2491r1993b2546],
17	and	CC	O	and	_	0	SENT_220	[p13l2016t2484r2141b2547],
18	3	CD	NUMBER	3	num	19	SENT_220	[p13l10t2594r43b2650],
19	patients	NNS	O	patient	dobj	13	SENT_220	[p13l68t2593r342b2670],
20	who	WP	O	who	nsubjpass	22	SENT_220	[p13l363t2587r512b2650],
21	were	VBD	O	be	auxpass	22	SENT_220	[p13l534t2610r697b2650],
22	treated	VBN	O	treat	rcmod	19	SENT_220	[p13l719t2587r961b2650],
23	with	IN	O	with	_	0	SENT_220	[p13l981t2587r1136b2650],
24	400	CD	NUMBER	400	num	26	SENT_220	[p13l1159t2594r1280b2650],
25	mg	NN	O	mg	nn	26	SENT_220	[p13l1298t2610r1408b2671],
26	sofosbuvir	NN	O	sofosbuvir	prep_with	22	SENT_220	[p13l1430t2587r1791b2650],
27	a	DT	DURATION	a	det	28	SENT_220	[p13l1814t2610r1849b2650],
28	day	NN	DURATION	day	dep	26	SENT_220	[p13l1872t2587r1994b2671],
29	and	CC	O	and	_	0	SENT_220	[p13l2015t2587r2142b2650],
30	weight-based	JJ	O	weight-based	amod	31	SENT_220	[p13l7t2690r450b2774],
31	RBV	NN	O	rbv	prep_with	22	SENT_220	[p13l469t2695r624b2753],
32	for	IN	O	for	_	0	SENT_220	[p13l643t2690r738b2753],
33	12	CD	DURATION	12	num	34	SENT_220	[p13l763t2697r831b2752],
34	weeks	NNS	NUMBER	week	prep_for	31	SENT_220	[p13l851t2690r1048b2753],
35	or	CC	O	or	_	0	SENT_220	[p13l1069t2713r1139b2753],
36	PEG+RBV	NN	O	peg+rbv	prep_for	31	SENT_220	[p13l1158t2694r1517b2753],
37	for	IN	O	for	_	0	SENT_220	[p13l1535t2690r1630b2753],
38	24	CD	DURATION	24	num	39	SENT_220	[p13l1648t2697r1725b2752],
39	weeks	NNS	NUMBER	week	prep_for	22	SENT_220	[p13l1743t2690r1957b2753],
40	.	.	O	.	_	0	SENT_220	[p13l1743t2690r1957b2753],

1	Both	DT	O	both	det	2	SENT_221	[p13l1980t2690r2140b2753],
2	studies	NNS	O	study	nsubj	3	SENT_221	[p13l9t2793r244b2856],
3	had	VBD	O	have	_	0	SENT_221	[p13l265t2793r393b2856],
4	the	DT	O	the	det	7	SENT_221	[p13l412t2793r518b2856],
5	primary	JJ	O	primary	amod	7	SENT_221	[p13l539t2799r821b2877],
6	end	NN	O	end	nn	7	SENT_221	[p13l840t2793r966b2856],
7	point	NN	O	point	dobj	3	SENT_221	[p13l985t2799r1168b2876],
8	of	IN	O	of	_	0	SENT_221	[p13l1189t2793r1263b2856],
9	SVR12	NN	O	svr12	prep_of	7	SENT_221	[p13l1275t2797r1525b2856],
10	.	.	O	.	_	0	SENT_221	[p13l1275t2797r1525b2856],

1	In	IN	O	in	_	0	SENT_222	[p13l83t2900r154b2958],
2	both	DT	O	both	preconj	4	SENT_222	[p13l174t2895r334b2959],
3	the	DT	O	the	det	4	SENT_222	[p13l356t2895r463b2959],
4	NEUTRINO	NNP	O	NEUTRINO	prep_in	10	SENT_222	[p13l485t2898r924b2959],
5	and	CC	O	and	_	0	SENT_222	[p13l949t2895r1075b2959],
6	FISSION	NNP	O	FISSION	nn	7	SENT_222	[p13l1098t2899r1407b2959],
7	studies	NNS	O	study	prep_in	10	SENT_222	[p13l1431t2895r1686b2967],
8	,	,	O	,	_	0	SENT_222	[p13l1431t2895r1686b2967],
9	there	EX	O	there	expl	10	SENT_222	[p13l1709t2895r1884b2959],
10	was	VBD	O	be	_	0	SENT_222	[p13l1905t2918r2031b2959],
11	no	DT	O	no	det	12	SENT_222	[p13l2055t2918r2141b2959],
12	inﬂuence	NN	O	inﬂuence	nsubj	10	SENT_222	[p13l9t2999r321b3062],
13	of	IN	O	of	_	0	SENT_222	[p13l342t2999r416b3062],
14	HCV	NNP	O	HCV	nn	15	SENT_222	[p13l427t3003r605b3062],
15	genotype	NN	O	genotype	prep_of	12	SENT_222	[p13l625t3011r953b3083],
16	,	,	O	,	_	0	SENT_222	[p13l625t3011r953b3083],
17	ethnicity	NN	O	ethnicity	prep_of	12	SENT_222	[p13l975t2999r1286b3083],
18	,	,	O	,	_	0	SENT_222	[p13l975t2999r1286b3083],
19	IL28B	NN	O	il28b	nn	20	SENT_222	[p13l1306t3004r1510b3062],
20	genotype	NN	O	genotype	prep_of	12	SENT_222	[p13l1531t3011r1858b3083],
21	,	,	O	,	_	0	SENT_222	[p13l1531t3011r1858b3083],
22	or	CC	O	or	_	0	SENT_222	[p13l1880t3022r1952b3062],
23	presence	NN	O	presence	conj_or	15	SENT_222	[p13l1970t3021r2138b3082, p13l9t3125r160b3165],
24	of	IN	O	of	_	0	SENT_222	[p13l181t3102r254b3165],
25	cirrhosis	NN	O	cirrhosis	prep_of	23	SENT_222	[p13l265t3102r558b3165],
26	on	IN	O	on	_	0	SENT_222	[p13l579t3125r664b3165],
27	the	DT	O	the	det	28	SENT_222	[p13l684t3102r789b3165],
28	magnitude	NN	O	magnitude	prep_on	10	SENT_222	[p13l809t3102r1174b3186],
29	of	IN	O	of	_	0	SENT_222	[p13l1195t3102r1268b3165],
30	HCV	NN	O	hcv	nn	32	SENT_222	[p13l1280t3106r1458b3165],
31	RNA	NN	O	rna	nn	32	SENT_222	[p13l1478t3106r1647b3165],
32	decline	NN	O	decline	prep_of	28	SENT_222	[p13l1667t3102r1924b3165],
33	.	.	O	.	_	0	SENT_222	[p13l1667t3102r1924b3165],

1	In	IN	O	in	_	0	SENT_223	[p13l1948t3107r2018b3164],
2	the	DT	O	the	det	4	SENT_223	[p13l2037t3102r2143b3165],
3	NEUTRINO	NNP	O	NEUTRINO	nn	4	SENT_223	[p13l8t3208r455b3268],
4	study	NN	O	study	prep_in	10	SENT_223	[p13l482t3205r681b3289],
5	,	,	O	,	_	0	SENT_223	[p13l482t3205r681b3289],
6	90	CD	PERCENT	90	num	7	SENT_223	[p13l707t3211r852b3269],
7	%	NN	PERCENT	%	nsubj	10	SENT_223	[p13l707t3211r852b3269],
8	of	IN	O	of	_	0	SENT_223	[p13l879t3205r954b3268],
9	patients	NNS	O	patient	prep_of	7	SENT_223	[p13l967t3211r1244b3288],
10	achieved	VBD	O	achieve	_	0	SENT_223	[p13l1269t3205r1576b3268],
11	SVR12	NN	O	svr12	dobj	10	SENT_223	[p13l1600t3209r1856b3268],
12	.	.	O	.	_	0	SENT_223	[p13l1600t3209r1856b3268],

1	Eightynine	NN	PERCENT	eightynine	nn	2	SENT_224	[p13l1883t3205r2138b3289, p13l8t3314r163b3371],
2	percent	NN	PERCENT	percent	nsubj	25	SENT_224	[p13l186t3320r452b3391],
3	of	IN	O	of	_	0	SENT_224	[p13l476t3308r552b3371],
4	HCV	NNP	O	HCV	nn	5	SENT_224	[p13l567t3312r751b3371],
5	genotype	NN	O	genotype	prep_of	2	SENT_224	[p13l775t3320r1096b3392],
6	1	CD	NUMBER	1	num	7	SENT_224	[p13l1128t3315r1153b3370],
7	patients	NNS	O	patient	dep	5	SENT_224	[p13l1182t3314r1480b3391],
8	,	,	O	,	_	0	SENT_224	[p13l1182t3314r1480b3391],
9	along	IN	O	along	_	0	SENT_224	[p13l1507t3308r1700b3392],
10	with	IN	O	with	_	0	SENT_224	[p13l1721t3308r1878b3371],
11	92	CD	PERCENT	92	num	12	SENT_224	[p13l1903t3313r2049b3372],
12	%	NN	PERCENT	%	prep_along_with	5	SENT_224	[p13l1903t3313r2049b3372],
13	of	IN	O	of	_	0	SENT_224	[p13l2076t3308r2151b3371],
14	genotype	NN	O	genotype	nn	16	SENT_224	[p13l8t3423r316b3495],
15	1a	NN	O	1a	nn	16	SENT_224	[p13l344t3418r413b3474],
16	patients	NNS	O	patient	prep_of	12	SENT_224	[p13l431t3417r697b3494],
17	and	CC	O	and	_	0	SENT_224	[p13l718t3411r843b3474],
18	82	CD	PERCENT	82	num	19	SENT_224	[p13l863t3416r1003b3476],
19	%	NN	PERCENT	%	conj_and	5	SENT_224	[p13l863t3416r1003b3476],
20	of	IN	O	of	_	0	SENT_224	[p13l1026t3411r1099b3474],
21	genotype	NN	O	genotype	nn	23	SENT_224	[p13l1110t3423r1418b3495],
22	1b	NN	O	1b	nn	23	SENT_224	[p13l1445t3411r1518b3474],
23	patients	NNS	O	patient	prep_of	19	SENT_224	[p13l1538t3417r1822b3494],
24	,	,	O	,	_	0	SENT_224	[p13l1538t3417r1822b3494],
25	achieved	VBD	O	achieve	_	0	SENT_224	[p13l1845t3411r2141b3474],
26	SVR	NNP	O	SVR	dobj	25	SENT_224	[p13l10t3518r180b3577],
27	.	.	O	.	_	0	SENT_224	[p13l10t3518r180b3577],

1	Among	IN	O	among	_	0	SENT_225	[p13l205t3518r467b3598],
2	the	DT	O	the	det	4	SENT_225	[p13l487t3514r595b3577],
3	28	CD	NUMBER	28	num	4	SENT_225	[p13l618t3521r696b3577],
4	genotype	NN	O	genotype	prep_among	25	SENT_225	[p13l721t3526r1036b3598],
5	4	CD	NUMBER	4	num	6	SENT_225	[p13l1059t3521r1098b3576],
6	patients	NNS	O	patient	dep	4	SENT_225	[p13l1119t3520r1411b3597],
7	,	,	O	,	_	0	SENT_225	[p13l1119t3520r1411b3597],
8	96	CD	PERCENT	96	num	9	SENT_225	[p13l1437t3519r1580b3579],
9	%	NN	PERCENT	%	prep_among	25	SENT_225	[p13l1437t3519r1580b3579],
10	had	VBD	O	have	rcmod	9	SENT_225	[p13l1604t3514r1733b3577],
11	SVR12	NN	O	svr12	dobj	10	SENT_225	[p13l1756t3518r2010b3586],
12	;	:	O	;	_	0	SENT_225	[p13l1756t3518r2010b3586],
13	the	DT	O	the	det	15	SENT_225	[p13l2034t3514r2142b3577],
14	single	JJ	O	single	amod	15	SENT_225	[p13l9t3617r204b3701],
15	genotype	NN	O	genotype	prep_among	25	SENT_225	[p13l224t3629r533b3701],
16	5	CD	NUMBER	5	num	17	SENT_225	[p13l555t3625r589b3680],
17	patient	NN	O	patient	dep	15	SENT_225	[p13l610t3623r847b3700],
18	and	CC	O	and	_	0	SENT_225	[p13l867t3617r992b3680],
19	the	DT	O	the	det	21	SENT_225	[p13l1010t3617r1116b3680],
20	six	CD	NUMBER	six	num	21	SENT_225	[p13l1137t3623r1229b3680],
21	genotype	NN	O	genotype	conj_and	4	SENT_225	[p13l1247t3629r1556b3701],
22	6	CD	NUMBER	6	num	23	SENT_225	[p13l1577t3623r1613b3680],
23	patients	NNS	O	patient	dep	21	SENT_225	[p13l1633t3623r1899b3700],
24	all	DT	O	all	nsubj	25	SENT_225	[p13l1922t3617r1999b3680],
25	had	VBD	O	have	_	0	SENT_225	[p13l2018t3617r2144b3680],
26	SVR12	NN	O	svr12	dobj	25	SENT_225	[p13l10t3724r267b3783],
27	.	.	O	.	_	0	SENT_225	[p13l10t3724r267b3783],

1	A	DT	O	a	det	4	SENT_226	[p13l294t3724r352b3782],
2	non-CC	JJ	O	non-cc	amod	4	SENT_226	[p13l376t3724r662b3783],
3	IL28B	NN	O	il28b	nn	4	SENT_226	[p13l682t3725r892b3783],
4	genotype	NN	O	genotype	nsubj	12	SENT_226	[p13l917t3732r1239b3804],
5	as	RB	O	as	_	0	SENT_226	[p13l1264t3743r1330b3783],
6	well	RB	O	well	_	0	SENT_226	[p13l1353t3720r1495b3783],
7	as	IN	O	as	_	0	SENT_226	[p13l1519t3743r1585b3783],
8	the	DT	O	the	det	9	SENT_226	[p13l1610t3720r1719b3783],
9	presence	NN	O	presence	conj_and	4	SENT_226	[p13l1742t3742r2050b3803],
10	of	IN	O	of	_	0	SENT_226	[p13l2075t3720r2151b3783],
11	cirrhosis	NN	O	cirrhosis	prep_of	9	SENT_226	[p14l9t16r304b79],
12	decreased	VBD	O	decrease	_	0	SENT_226	[p14l328t16r664b79],
13	response	NN	O	response	dobj	12	SENT_226	[p14l686t38r1002b99],
14	.	.	O	.	_	0	SENT_226	[p14l686t38r1002b99],

1	In	IN	O	in	_	0	SENT_227	[p14l1028t21r1099b78],
2	the	DT	O	the	det	4	SENT_227	[p14l1120t16r1226b79],
3	FISSION	NNP	O	FISSION	nn	4	SENT_227	[p14l1250t20r1557b79],
4	trial	NN	O	trial	prep_in	24	SENT_227	[p14l1579t16r1736b88],
5	,	,	O	,	_	0	SENT_227	[p14l1579t16r1736b88],
6	SVR12	NN	O	svr12	nsubj	24	SENT_227	[p14l1762t20r1993b79],
7	was	VBD	O	be	cop	24	SENT_227	[p14l2015t39r2141b79],
8	67	CD	PERCENT	67	num	9	SENT_227	[p14l9t125r148b183],
9	%	NN	PERCENT	%	attr	24	SENT_227	[p14l9t125r148b183],
10	in	IN	O	in	_	0	SENT_227	[p14l170t125r234b181],
11	the	DT	O	the	det	12	SENT_227	[p14l253t119r357b182],
12	sofosbuvir	NN	O	sofosbuvir	prep_in	24	SENT_227	[p14l377t119r724b182],
13	plus	CC	O	plus	prep	12	SENT_227	[p14l742t119r878b202],
14	RBV	NN	O	rbv	nn	15	SENT_227	[p14l898t124r1055b182],
15	group	NN	O	group	dep	13	SENT_227	[p14l1074t141r1269b203],
16	and	CC	O	and	_	0	SENT_227	[p14l1290t119r1414b182],
17	in	IN	O	in	_	0	SENT_227	[p14l1432t125r1497b181],
18	the	DT	O	the	det	19	SENT_227	[p14l1516t119r1619b182],
19	sofosbuvir	NN	O	sofosbuvir	conj_and	12	SENT_227	[p14l1640t119r1987b182],
20	plus	CC	O	plus	prep	19	SENT_227	[p14l2005t119r2141b202],
21	PEG+RBV	NN	O	peg+rbv	nn	22	SENT_227	[p14l9t226r373b285],
22	group	NN	O	group	dep	20	SENT_227	[p14l392t244r606b306],
23	,	,	O	,	_	0	SENT_227	[p14l392t244r606b306],
24	showing	VBG	O	show	_	0	SENT_227	[p14l629t222r911b306],
25	noninferiority	NN	O	noninferiority	dobj	24	SENT_227	[p14l929t222r1411b306],
26	of	IN	O	of	_	0	SENT_227	[p14l1428t222r1501b285],
27	the	DT	O	the	det	28	SENT_227	[p14l1510t222r1615b285],
28	sofosbuvir	NN	O	sofosbuvir	prep_of	25	SENT_227	[p14l1637t222r1987b285],
29	plus	CC	O	plus	prep	28	SENT_227	[p14l2005t222r2143b305],
30	RBV	NN	O	rbv	nn	31	SENT_227	[p14l9t330r169b388],
31	regimen	NNS	O	regimen	dep	29	SENT_227	[p14l189t331r488b409],
32	.	.	O	.	_	0	SENT_227	[p14l189t331r488b409],

1	On	IN	O	on	_	0	SENT_228	[p14l513t329r620b388],
2	further	JJ	O	further	amod	3	SENT_228	[p14l640t325r884b388],
3	analysis	NN	O	analysis	prep_on	13	SENT_228	[p14l905t325r1188b409],
4	,	,	O	,	_	0	SENT_228	[p14l905t325r1188b409],
5	genotype	NN	O	genotype	nsubjpass	13	SENT_228	[p14l1211t337r1522b409],
6	2	CD	NUMBER	2	num	5	SENT_228	[p14l1543t332r1579b387],
7	and	CC	O	and	_	0	SENT_228	[p14l1603t325r1728b388],
8	the	DT	O	the	det	9	SENT_228	[p14l1748t325r1854b388],
9	absence	NN	O	absence	nsubjpass	13	SENT_228	[p14l1876t325r2142b388],
10	of	IN	O	of	_	0	SENT_228	[p14l9t428r85b491],
11	cirrhosis	NN	O	cirrhosis	prep_of	9	SENT_228	[p14l100t428r405b491],
12	were	VBD	O	be	auxpass	13	SENT_228	[p14l428t451r594b491],
13	associated	VBN	O	associate	_	0	SENT_228	[p14l619t428r978b491],
14	with	IN	O	with	_	0	SENT_228	[p14l999t428r1157b491],
15	signiﬁcantly	RB	O	signiﬁcantly	advmod	16	SENT_228	[p14l1182t428r1614b512],
16	higher	JJR	O	higher	amod	17	SENT_228	[p14l1634t428r1864b512],
17	rates	NNS	O	rate	prep_with	13	SENT_228	[p14l1888t440r2051b491],
18	of	IN	O	of	_	0	SENT_228	[p14l2076t428r2152b491],
19	SVR	NN	O	svr	prep_of	17	SENT_228	[p14l9t534r180b594],
20	.	.	O	.	_	0	SENT_228	[p14l9t534r180b594],

1	Treatment	NN	O	treatment	nn	2	SENT_229	[p14l207t533r566b594],
2	discontinuations	NNS	O	discontinuation	nsubj	8	SENT_229	[p14l589t530r1170b594],
3	due	JJ	O	due	_	0	SENT_229	[p14l1195t530r1319b594],
4	to	TO	O	to	_	0	SENT_229	[p14l1341t542r1408b594],
5	AEs	NNS	O	ae	prep_due_to	2	SENT_229	[p14l1432t534r1571b594],
6	were	VBD	O	be	cop	8	SENT_229	[p14l1593t553r1756b594],
7	1	CD	NUMBER	1	num	8	SENT_229	[p14l1787t535r1990b602],
8	—	NN	O	—	_	0	SENT_229	[p14l1787t535r1990b602],
9	2	CD	PERCENT	2	number	10	SENT_229	[p14l1787t535r1990b602],
10	%	NN	PERCENT	%	amod	8	SENT_229	[p14l1787t535r1990b602],
11	,	,	O	,	_	0	SENT_229	[p14l1787t535r1990b602],
12	and	CC	O	and	_	0	SENT_229	[p14l2016t530r2144b594],
13	most	JJS	O	most	amod	14	SENT_229	[p14l8t646r174b697],
14	AEs	NNS	O	ae	nsubj	16	SENT_229	[p14l191t638r326b697],
15	were	VBD	O	be	cop	16	SENT_229	[p14l344t657r502b697],
16	mild	JJ	O	mild	conj_and	8	SENT_229	[p14l521t634r693b706],
17	,	,	O	,	_	0	SENT_229	[p14l521t634r693b706],
18	with	IN	O	with	_	0	SENT_229	[p14l712t634r861b697],
19	fatigue	NN	O	fatigue	prep_with	16	SENT_229	[p14l881t634r1123b718],
20	,	,	O	,	_	0	SENT_229	[p14l881t634r1123b718],
21	headache	NN	O	headache	conj_and	19	SENT_229	[p14l1143t634r1473b706],
22	,	,	O	,	_	0	SENT_229	[p14l1143t634r1473b706],
23	nausea	NN	O	nausea	conj_and	19	SENT_229	[p14l1494t657r1739b706],
24	,	,	O	,	_	0	SENT_229	[p14l1494t657r1739b706],
25	and	CC	O	and	_	0	SENT_229	[p14l1761t634r1884b697],
26	insomnia	NN	O	insomnia	conj_and	19	SENT_229	[p14l1903t640r2137b697, p14l8t742r114b799],
27	being	VBG	O	be	_	0	SENT_229	[p14l133t736r324b820],
28	the	DT	O	the	det	30	SENT_229	[p14l343t736r449b799],
29	most	RBS	O	most	advmod	30	SENT_229	[p14l470t748r640b799],
30	common	JJ	O	common	prep_being	19	SENT_229	[p14l661t728r1049b799],
31	.49	CD	NUMBER	.49	num	30	SENT_229	[p14l661t728r1049b799],

1	Sofosbuvir	NNP	O	Sofosbuvir	nsubjpass	4	SENT_230	[p14l83t839r442b902],
2	is	VBZ	O	be	auxpass	4	SENT_230	[p14l461t845r511b902],
3	well	RB	O	well	advmod	4	SENT_230	[p14l529t839r665b902],
4	tolerated	VBN	O	tolerate	_	0	SENT_230	[p14l683t839r994b902],
5	.	.	O	.	_	0	SENT_230	[p14l683t839r994b902],

1	The	DT	O	the	det	4	SENT_231	[p14l1018t839r1142b902],
2	most	RBS	O	most	advmod	4	SENT_231	[p14l1163t851r1330b902],
3	frequent	JJ	O	frequent	amod	4	SENT_231	[p14l1349t839r1634b922],
4	AEs	NNS	O	ae	nsubj	9	SENT_231	[p14l1652t843r1788b902],
5	associated	VBN	O	associate	partmod	4	SENT_231	[p14l1810t839r2150b902],
6	with	IN	O	with	_	0	SENT_231	[p14l7t942r159b1005],
7	sofosbuvir	JJ	O	sofosbuvir	amod	8	SENT_231	[p14l181t942r536b1005],
8	treatment	NN	O	treatment	prep_with	5	SENT_231	[p14l555t954r889b1005],
9	include	VBP	O	include	_	0	SENT_231	[p14l909t942r1159b1005],
10	fatigue	NN	O	fatigue	nsubj	18	SENT_231	[p14l1181t942r1427b1026],
11	,	,	O	,	_	0	SENT_231	[p14l1181t942r1427b1026],
12	headache	NN	O	headache	appos	10	SENT_231	[p14l1450t942r1786b1014],
13	,	,	O	,	_	0	SENT_231	[p14l1450t942r1786b1014],
14	insomnia	NN	O	insomnia	appos	10	SENT_231	[p14l1810t948r2147b1014],
15	,	,	O	,	_	0	SENT_231	[p14l1810t948r2147b1014],
16	nausea	NN	O	nausea	appos	10	SENT_231	[p14l8t1068r254b1117],
17	,	,	O	,	_	0	SENT_231	[p14l8t1068r254b1117],
18	decreased	VBD	O	decrease	ccomp	9	SENT_231	[p14l275t1045r606b1108],
19	appetite	NN	O	appetite	dobj	18	SENT_231	[p14l625t1051r906b1128],
20	,	,	O	,	_	0	SENT_231	[p14l625t1051r906b1128],
21	dizziness	NN	O	dizziness	conj_and	19	SENT_231	[p14l928t1045r1245b1117],
22	,	,	O	,	_	0	SENT_231	[p14l928t1045r1245b1117],
23	inﬂuenza	NN	O	inﬂuenza	conj_and	19	SENT_231	[p14l1266t1045r1727b1108],
24	—	CD	NUMBER	—	num	23	SENT_231	[p14l1266t1045r1727b1108],
25	like	IN	O	like	_	0	SENT_231	[p14l1266t1045r1727b1108],
26	illness	NN	O	illness	prep_like	23	SENT_231	[p14l1746t1045r1969b1117],
27	,	,	O	,	_	0	SENT_231	[p14l1746t1045r1969b1117],
28	rash	NN	O	rash	conj_and	19	SENT_231	[p14l1990t1045r2148b1117],
29	,	,	O	,	_	0	SENT_231	[p14l1990t1045r2148b1117],
30	anemia	NN	O	anemia	conj_and	19	SENT_231	[p14l9t1154r259b1211],
31	(	CD	NUMBER	(	num	33	SENT_231	[p14l283t1148r564b1232],
32	average	JJ	O	average	amod	33	SENT_231	[p14l283t1148r564b1232],
33	decrease	NN	O	decrease	dep	30	SENT_231	[p14l586t1147r876b1211],
34	of	IN	O	of	_	0	SENT_231	[p14l898t1147r973b1211],
35	0.54	CD	NUMBER	0.54	num	37	SENT_231	[p14l985t1154r1125b1211],
36	g/dl	NN	O	g/dl	nn	37	SENT_231	[p14l1138t1147r1319b1232],
37	)	NN	O	)	prep_of	33	SENT_231	[p14l1138t1147r1319b1232],
38	,	,	O	,	_	0	SENT_231	[p14l1138t1147r1319b1232],
39	and	CC	O	and	_	0	SENT_231	[p14l1343t1147r1470b1211],
40	lymphopenia	NN	O	lymphopenia	conj_and	19	SENT_231	[p14l1489t1139r2023b1232],
41	.5	CD	NUMBER	.5	number	42	SENT_231	[p14l1489t1139r2023b1232],
42	°	CD	NUMBER	°	num	44	SENT_231	[p14l1489t1139r2023b1232],
43	An	DT	O	a	det	44	SENT_231	[p14l2044t1151r2149b1210],
44	analysis	NN	O	analysis	nsubj	56	SENT_231	[p14l9t1251r277b1335],
45	of	IN	O	of	_	0	SENT_231	[p14l300t1251r375b1314],
46	patients	NNS	O	patient	prep_of	44	SENT_231	[p14l387t1257r658b1334],
47	who	WP	O	who	nsubj	48	SENT_231	[p14l680t1251r829b1314],
48	experienced	VBD	O	experience	rcmod	46	SENT_231	[p14l853t1251r1273b1334],
49	Zgrade	NNP	O	Zgrade	dobj	48	SENT_231	[p14l1297t1251r1537b1335],
50	2	CD	NUMBER	2	num	51	SENT_231	[p14l1560t1258r1596b1313],
51	AEs	NNS	O	ae	dep	49	SENT_231	[p14l1619t1255r1759b1314],
52	and	CC	O	and	_	0	SENT_231	[p14l1783t1251r1911b1314],
53	>	JJR	O	>	dobj	48	SENT_231	[p14l1935t1258r2012b1313],
54	1	CD	NUMBER	1	num	55	SENT_231	[p14l1935t1258r2012b1313],
55	AE	NN	O	ae	dep	53	SENT_231	[p14l2040t1255r2148b1313],
56	found	VBD	O	find	rcmod	40	SENT_231	[p14l8t1354r206b1417],
57	that	IN	O	that	complm	60	SENT_231	[p14l221t1354r351b1417],
58	such	JJ	O	such	amod	59	SENT_231	[p14l369t1354r519b1417],
59	AEs	NNS	O	ae	nsubj	60	SENT_231	[p14l536t1358r670b1417],
60	occurred	VBD	O	occur	ccomp	56	SENT_231	[p14l689t1354r986b1417],
61	in	IN	O	in	_	0	SENT_231	[p14l1003t1360r1067b1416],
62	only	RB	O	only	quantmod	63	SENT_231	[p14l1086t1354r1233b1438],
63	10	CD	PERCENT	10	num	64	SENT_231	[p14l1254t1359r1386b1418],
64	%	NN	PERCENT	%	prep_in	60	SENT_231	[p14l1254t1359r1386b1418],
65	of	IN	O	of	_	0	SENT_231	[p14l1407t1354r1479b1417],
66	patients	NNS	O	patient	prep_of	64	SENT_231	[p14l1486t1360r1745b1437],
67	on	IN	O	on	_	0	SENT_231	[p14l1764t1377r1848b1417],
68	sofosbuvir	JJ	O	sofosbuvir	amod	69	SENT_231	[p14l1868t1354r2145b1417, p14l6t1463r98b1520],
69	monotherapy	NN	O	monotherapy	prep_on	60	SENT_231	[p14l114t1457r570b1541],
70	,	,	O	,	_	0	SENT_231	[p14l114t1457r570b1541],
71	7	CD	PERCENT	7	num	72	SENT_231	[p14l592t1463r689b1521],
72	%	NN	PERCENT	%	conj_and	40	SENT_231	[p14l592t1463r689b1521],
73	of	IN	O	of	_	0	SENT_231	[p14l710t1457r781b1520],
74	patients	NNS	O	patient	prep_of	72	SENT_231	[p14l789t1463r1047b1540],
75	treated	VBN	O	treat	partmod	74	SENT_231	[p14l1065t1457r1294b1520],
76	with	IN	O	with	_	0	SENT_231	[p14l1309t1457r1457b1520],
77	sofosbuvir	NN	O	sofosbuvir	prep_with	75	SENT_231	[p14l1476t1457r1818b1520],
78	plus	CC	O	plus	prep	77	SENT_231	[p14l1834t1457r1969b1540],
79	RBV	NN	O	rbv	dep	78	SENT_231	[p14l1988t1462r2148b1529],
80	,	,	O	,	_	0	SENT_231	[p14l1988t1462r2148b1529],
81	and	CC	O	and	_	0	SENT_231	[p14l9t1560r134b1624],
82	23	CD	PERCENT	23	num	83	SENT_231	[p14l153t1566r293b1625],
83	%	NN	PERCENT	%	conj_and	40	SENT_231	[p14l153t1566r293b1625],
84	of	IN	O	of	_	0	SENT_231	[p14l316t1560r389b1624],
85	patients	NNS	O	patient	prep_of	83	SENT_231	[p14l398t1567r662b1644],
86	treated	VBN	O	treat	partmod	85	SENT_231	[p14l682t1560r915b1624],
87	with	IN	O	with	_	0	SENT_231	[p14l932t1560r1083b1624],
88	sofosbuvir	NN	O	sofosbuvir	prep_with	86	SENT_231	[p14l1103t1560r1452b1624],
89	plus	CC	O	plus	prep	88	SENT_231	[p14l1470t1560r1607b1644],
90	PEG+RBV	NN	O	peg+rbv	dep	89	SENT_231	[p14l1629t1552r2056b1624],
91	.	.	O	.	_	0	SENT_231	[p14l1629t1552r2056b1624],

1	“	NN	O	“	_	0	SENT_232	[p14l1629t1552r2056b1624],

1	MERICITABINE	NN	O	mericitabine	nn	2	SENT_233	[p14l11t1777r525b1832],
2	Mericitabine	NN	O	mericitabine	nsubj	8	SENT_233	[p14l8t1872r459b1935],
3	(	CD	NUMBER	(	num	5	SENT_233	[p14l487t1872r826b1949],
4	RG7128	NN	O	rg7128	nn	5	SENT_233	[p14l487t1872r826b1949],
5	)	NN	O	)	dep	2	SENT_233	[p14l487t1872r826b1949],
6	is	VBZ	O	be	cop	8	SENT_233	[p14l855t1878r906b1935],
7	a	DT	O	a	det	8	SENT_233	[p14l932t1895r967b1935],
8	prodrug	NN	O	prodrug	_	0	SENT_233	[p14l989t1872r1282b1956],
9	of	IN	O	of	_	0	SENT_233	[p14l1305t1872r1381b1935],
10	a	DT	O	a	det	13	SENT_233	[p14l1396t1895r1431b1935],
11	cytosine	NN	O	cytosine	nn	13	SENT_233	[p14l1455t1878r1746b1956],
12	nucleoside	NN	O	nucleoside	nn	13	SENT_233	[p14l1770t1872r2146b1935],
13	analogue	NN	O	analogue	prep_of	8	SENT_233	[p14l9t1975r311b2059],
14	that	WDT	O	that	nsubj	19	SENT_233	[p14l330t1975r461b2038],
15	is	VBZ	O	be	cop	19	SENT_233	[p14l480t1981r529b2038],
16	a	DT	O	a	det	19	SENT_233	[p14l551t1998r585b2038],
17	potent	JJ	O	potent	amod	19	SENT_233	[p14l602t1987r837b2058],
18	,	,	O	,	_	0	SENT_233	[p14l602t1987r837b2058],
19	selective	JJ	O	selective	rcmod	8	SENT_233	[p14l860t1975r1157b2047],
20	,	,	O	,	_	0	SENT_233	[p14l860t1975r1157b2047],
21	and	CC	O	and	_	0	SENT_233	[p14l1179t1975r1304b2038],
22	noncytotoxic	JJ	O	noncytotoxic	amod	23	SENT_233	[p14l1323t1981r1764b2059],
23	NPI	NN	O	npus	rcmod	8	SENT_233	[p14l1783t1980r1936b2038],
24	.	.	O	.	_	0	SENT_233	[p14l1783t1980r1936b2038],

1	It	PRP	O	it	nsubjpass	3	SENT_234	[p14l1959t1980r2008b2038],
2	was	VBD	O	be	auxpass	3	SENT_234	[p14l2025t1998r2149b2038],
3	shown	VBN	O	show	_	0	SENT_234	[p14l9t2078r228b2141],
4	in	IN	O	in	_	0	SENT_234	[p14l248t2084r313b2140],
5	clinical	JJ	O	clinical	amod	6	SENT_234	[p14l334t2078r574b2141],
6	trials	NNS	O	trial	prep_in	3	SENT_234	[p14l593t2078r761b2141],
7	to	TO	O	to	aux	9	SENT_234	[p14l781t2090r845b2141],
8	be	VB	O	be	cop	9	SENT_234	[p14l864t2078r942b2141],
9	effective	JJ	O	effective	ccomp	3	SENT_234	[p14l963t2078r1238b2141],
10	against	IN	O	against	_	0	SENT_234	[p14l1259t2084r1495b2162],
11	genotypes	NNS	O	genotype	prep_against	9	SENT_234	[p14l1513t2090r1851b2162],
12	1	CD	NUMBER	1	dep	11	SENT_234	[p14l1878t2085r1926b2150],
13	,	,	O	,	_	0	SENT_234	[p14l1878t2085r1926b2150],
14	2	CD	NUMBER	2	num	12	SENT_234	[p14l1948t2085r2002b2150],
15	,	,	O	,	_	0	SENT_234	[p14l1948t2085r2002b2150],
16	and	CC	NUMBER	and	_	0	SENT_234	[p14l2025t2078r2149b2141],
17	3	CD	NUMBER	3	dep	11	SENT_234	[p14l10t2188r43b2244],
18	and	CC	O	and	_	0	SENT_234	[p14l68t2181r195b2244],
19	to	TO	O	to	aux	20	SENT_234	[p14l214t2193r280b2244],
20	have	VB	O	have	ccomp	3	SENT_234	[p14l302t2181r458b2244],
21	a	DT	O	a	det	23	SENT_234	[p14l480t2204r515b2244],
22	high	JJ	O	high	amod	23	SENT_234	[p14l534t2181r689b2265],
23	barrier	NN	O	barrier	dobj	20	SENT_234	[p14l708t2181r947b2244],
24	to	TO	O	to	_	0	SENT_234	[p14l966t2193r1032b2244],
25	resistance	NN	O	resistance	prep_to	20	SENT_234	[p14l1055t2187r1406b2244],
26	.	.	O	.	_	0	SENT_234	[p14l1055t2187r1406b2244],

1	In	IN	O	in	_	0	SENT_235	[p14l83t2289r156b2346],
2	phase	NN	O	phase	nn	4	SENT_235	[p14l181t2284r383b2367],
3	II	CD	NUMBER	ii	num	4	SENT_235	[p14l410t2289r465b2346],
4	trials	NNS	O	trial	prep_in	20	SENT_235	[p14l492t2284r691b2356],
5	,	,	O	,	_	0	SENT_235	[p14l492t2284r691b2356],
6	mericitabine	NN	O	mericitabine	nsubj	20	SENT_235	[p14l719t2284r1170b2347],
7	plus	CC	O	plus	prep	6	SENT_235	[p14l1195t2284r1341b2367],
8	PEG+RBV	NN	O	peg+rbv	dep	7	SENT_235	[p14l1368t2288r1750b2347],
9	for	IN	O	for	_	0	SENT_235	[p14l1776t2284r1877b2347],
10	8	CD	NUMBER	8	nn	13	SENT_235	[p14l1903t2291r1938b2347],
11	or	CC	O	or	_	0	SENT_235	[p14l1967t2307r2041b2347],
12	12	CD	DURATION	12	conj_or	10	SENT_235	[p14l2073t2291r2146b2346],
13	weeks	NNS	NUMBER	week	prep_for	8	SENT_235	[p14l7t2387r211b2450],
14	in	IN	O	in	_	0	SENT_235	[p14l232t2393r299b2449],
15	genotype	NN	O	genotype	prep_in	13	SENT_235	[p14l319t2399r632b2471],
16	1	CD	NUMBER	1	num	15	SENT_235	[p14l660t2394r684b2449],
17	and	CC	O	and	_	0	SENT_235	[p14l712t2387r838b2450],
18	4	CD	NUMBER	4	num	19	SENT_235	[p14l857t2394r896b2449],
19	patients	NNS	O	patient	prep_in	13	SENT_235	[p14l915t2393r1185b2470],
20	resulted	VBD	O	result	_	0	SENT_235	[p14l1206t2387r1479b2450],
21	in	IN	O	in	_	0	SENT_235	[p14l1499t2393r1565b2449],
22	potent	JJ	O	potent	amod	24	SENT_235	[p14l1585t2399r1808b2470],
23	viral	JJ	O	viral	amod	24	SENT_235	[p14l1824t2387r1980b2450],
24	suppression	NN	O	suppression	prep_in	20	SENT_235	[p14l2001t2409r2146b2470, p14l7t2496r309b2573],
25	.	.	O	.	_	0	SENT_235	[p14l2001t2409r2146b2470, p14l7t2496r309b2573],

1	Resistance	NN	O	resistance	nsubjpass	4	SENT_236	[p14l333t2495r688b2553],
2	was	VBD	O	be	auxpass	4	SENT_236	[p14l707t2513r832b2553],
3	not	RB	O	not	neg	4	SENT_236	[p14l853t2502r967b2553],
4	selected	VBN	O	select	_	0	SENT_236	[p14l987t2490r1272b2562],
5	,	,	O	,	_	0	SENT_236	[p14l987t2490r1272b2562],
6	but	CC	O	but	_	0	SENT_236	[p14l1293t2490r1406b2553],
7	there	EX	O	there	expl	8	SENT_236	[p14l1424t2490r1598b2553],
8	was	VBD	O	be	conj_but	4	SENT_236	[p14l1616t2513r1742b2553],
9	no	DT	O	no	det	10	SENT_236	[p14l1763t2513r1849b2553],
10	increase	NN	O	increase	nsubj	8	SENT_236	[p14l1871t2496r2147b2553],
11	in	IN	O	in	_	0	SENT_236	[p14l8t2599r76b2655],
12	SVR	NNP	ORGANIZATION	SVR	prep_in	10	SENT_236	[p14l100t2597r255b2656],
13	as	IN	O	as	mark	39	SENT_236	[p14l275t2616r340b2656],
14	compared	VBN	O	compare	_	0	SENT_236	[p14l365t2593r710b2676],
15	with	IN	O	with	prepc_compared_with	39	SENT_236	[p14l731t2593r885b2656],
16	that	DT	O	that	pobj	39	SENT_236	[p14l907t2593r1042b2656],
17	seen	VBN	O	see	partmod	16	SENT_236	[p14l1065t2616r1216b2656],
18	with	IN	O	with	_	0	SENT_236	[p14l1237t2593r1391b2656],
19	PEG+RBV	NN	O	peg+rbv	nn	20	SENT_236	[p14l1415t2597r1788b2656],
20	treatment	NN	O	treatment	prep_with	17	SENT_236	[p14l1809t2605r2149b2656],
21	alone	RB	O	alone	advmod	20	SENT_236	[p14l9t2687r280b2759],
22	.52	CD	NUMBER	.52	pobj	21	SENT_236	[p14l9t2687r280b2759],
23	However	RB	O	however	advmod	17	SENT_236	[p14l305t2701r633b2768],
24	,	,	O	,	_	0	SENT_236	[p14l305t2701r633b2768],
25	when	WRB	O	when	advmod	26	SENT_236	[p14l657t2695r850b2759],
26	given	VBN	O	give	advcl	17	SENT_236	[p14l873t2702r1062b2780],
27	as	IN	O	as	_	0	SENT_236	[p14l1086t2718r1152b2759],
28	part	NN	O	part	prep_as	26	SENT_236	[p14l1175t2707r1320b2779],
29	of	IN	O	of	_	0	SENT_236	[p14l1343t2695r1419b2759],
30	a	DT	O	a	det	33	SENT_236	[p14l1433t2718r1469b2759],
31	24-week	JJ	DURATION	24-week	amod	33	SENT_236	[p14l1491t2695r1788b2759],
32	responseguided	JJ	O	responseguided	amod	33	SENT_236	[p14l1808t2718r2145b2779, p14l8t2799r255b2883],
33	combination	NN	O	combination	prep_of	28	SENT_236	[p14l282t2799r737b2862],
34	with	IN	O	with	_	0	SENT_236	[p14l763t2799r923b2862],
35	PEG+RBV	NN	O	peg+rbv	prep_with	33	SENT_236	[p14l950t2803r1341b2871],
36	,	,	O	,	_	0	SENT_236	[p14l950t2803r1341b2871],
37	SVR	NN	ORGANIZATION	svr	nsubjpass	39	SENT_236	[p14l1371t2803r1530b2862],
38	was	VBD	O	be	auxpass	39	SENT_236	[p14l1553t2822r1684b2862],
39	increased	VBN	O	increase	advcl	8	SENT_236	[p14l1712t2799r2053b2862],
40	to	TO	O	to	_	0	SENT_236	[p14l2078t2811r2147b2862],
41	56.8	CD	PERCENT	56.8	num	42	SENT_236	[p14l10t2908r212b2967],
42	%	NN	PERCENT	%	prep_to	39	SENT_236	[p14l10t2908r212b2967],
43	from	IN	O	from	_	0	SENT_236	[p14l237t2902r404b2965],
44	36.5	CD	PERCENT	36.5	num	45	SENT_236	[p14l428t2908r630b2966],
45	%	NN	PERCENT	%	prep_from	39	SENT_236	[p14l428t2908r630b2966],
46	in	IN	O	in	_	0	SENT_236	[p14l655t2908r722b2964],
47	patients	NNS	O	patient	prep_in	45	SENT_236	[p14l742t2908r1012b2985],
48	treated	VBN	O	treat	partmod	47	SENT_236	[p14l1034t2902r1273b2965],
49	with	IN	O	with	_	0	SENT_236	[p14l1292t2902r1445b2965],
50	a	DT	O	a	det	53	SENT_236	[p14l1468t2925r1502b2965],
51	standard	JJ	O	standard	amod	53	SENT_236	[p14l1524t2902r1823b2965],
52	48	CD	DURATION	48	num	53	SENT_236	[p14l1843t2909r1921b2965],
53	weeks	NNS	NUMBER	week	prep_with	48	SENT_236	[p14l1944t2902r2148b2965],
54	of	IN	O	of	_	0	SENT_236	[p14l9t3004r85b3068],
55	PEG+RBV	NN	O	peg+rbv	nn	56	SENT_236	[p14l103t3008r485b3068],
56	treatment	NN	O	treatment	prep_of	53	SENT_236	[p14l509t3016r876b3068],
57	.	.	O	.	_	0	SENT_236	[p14l509t3016r876b3068],

1	The	DT	O	the	det	2	SENT_237	[p14l905t3004r1034b3068],
2	medication	NN	O	medication	nsubjpass	5	SENT_237	[p14l1060t3004r1463b3068],
3	was	VBD	O	be	auxpass	5	SENT_237	[p14l1487t3027r1618b3068],
4	well	RB	O	well	advmod	5	SENT_237	[p14l1643t3004r1786b3068],
5	tolerated	VBN	O	tolerate	_	0	SENT_237	[p14l1811t3004r2145b3076],
6	,	,	O	,	_	0	SENT_237	[p14l1811t3004r2145b3076],
7	with	IN	O	with	_	0	SENT_237	[p14l7t3108r164b3171],
8	a	DT	O	a	det	12	SENT_237	[p14l190t3131r225b3171],
9	similar	JJ	O	similar	amod	12	SENT_237	[p14l249t3108r496b3171],
10	side	NN	O	side	nn	12	SENT_237	[p14l520t3108r657b3171],
11	effect	NN	O	effect	nn	12	SENT_237	[p14l683t3108r871b3171],
12	proﬁle	NN	O	proﬁle	prep_with	5	SENT_237	[p14l893t3108r1122b3191],
13	to	TO	O	to	_	0	SENT_237	[p14l1146t3120r1214b3171],
14	that	DT	O	that	prep_to	12	SENT_237	[p14l1239t3108r1378b3171],
15	of	IN	O	of	_	0	SENT_237	[p14l1402t3108r1478b3171],
16	the	DT	O	the	det	18	SENT_237	[p14l1492t3108r1602b3171],
17	placebo	NN	O	placebo	nn	18	SENT_237	[p14l1625t3108r1897b3191],
18	group	NN	O	group	prep_of	14	SENT_237	[p14l1924t3130r2148b3192],
19	,	,	O	,	_	0	SENT_237	[p14l1924t3130r2148b3192],
20	with	IN	O	with	_	0	SENT_237	[p14l7t3211r162b3274],
21	fatigue	NN	O	fatigue	prep_with	5	SENT_237	[p14l186t3211r440b3295],
22	,	,	O	,	_	0	SENT_237	[p14l186t3211r440b3295],
23	nausea	NN	O	nausea	conj_and	21	SENT_237	[p14l465t3234r722b3283],
24	,	,	O	,	_	0	SENT_237	[p14l465t3234r722b3283],
25	and	CC	O	and	_	0	SENT_237	[p14l748t3211r876b3274],
26	headache	NN	O	headache	conj_and	21	SENT_237	[p14l897t3211r1225b3274],
27	being	VBG	O	be	auxpass	31	SENT_237	[p14l1247t3211r1442b3295],
28	the	DT	O	the	dep	29	SENT_237	[p14l1463t3211r1571b3274],
29	most	RBS	O	most	advmod	31	SENT_237	[p14l1595t3223r1768b3274],
30	frequently	RB	O	frequently	advmod	31	SENT_237	[p14l1790t3211r2152b3295],
31	encountered	VBN	O	encounter	partmod	21	SENT_237	[p14l9t3313r438b3377],
32	AEs	NNS	O	ae	xcomp	31	SENT_237	[p14l457t3305r676b3377],
33	.53	CD	NUMBER	.53	dep	32	SENT_237	[p14l457t3305r676b3377],

1	NNPIS	NNS	O	nnpi	_	0	SENT_238	[p14l12t3529r221b3584],

1	The	DT	O	the	det	3	SENT_239	[p15l8t27r132b90],
2	antiviral	JJ	O	antiviral	amod	3	SENT_239	[p15l153t27r434b90],
3	potency	NN	O	potency	nsubj	9	SENT_239	[p15l452t39r727b111],
4	of	IN	O	of	_	0	SENT_239	[p15l744t27r817b90],
5	NNPIs	NNS	O	nnpi	prep_of	3	SENT_239	[p15l827t32r1057b90],
6	as	IN	O	as	_	0	SENT_239	[p15l1079t50r1142b90],
7	monotherapy	NN	O	monotherapy	prep_as	5	SENT_239	[p15l1163t27r1623b111],
8	is	VBZ	O	be	cop	9	SENT_239	[p15l1640t33r1689b90],
9	less	JJR	O	less	_	0	SENT_239	[p15l1709t27r1826b90],
10	than	IN	O	than	_	0	SENT_239	[p15l1846t27r1999b90],
11	that	DT	O	that	prep_than	9	SENT_239	[p15l2018t27r2150b90],
12	of	IN	O	of	_	0	SENT_239	[p15l9t130r82b193],
13	NS3	NN	O	ns3	nn	14	SENT_239	[p15l92t134r233b193],
14	PIS	NN	O	pi	prep_of	11	SENT_239	[p15l257t135r376b193],
15	.	.	O	.	_	0	SENT_239	[p15l257t135r376b193],

1	The	DT	O	the	det	4	SENT_240	[p15l399t130r524b193],
2	four	CD	NUMBER	four	num	4	SENT_240	[p15l545t130r687b193],
3	allosteric	JJ	O	allosteric	amod	4	SENT_240	[p15l708t130r1015b193],
4	sites	NNS	O	site	nsubj	13	SENT_240	[p15l1036t136r1178b193],
5	that	WDT	O	that	nsubj	6	SENT_240	[p15l1198t130r1332b193],
6	act	VBP	O	act	rcmod	4	SENT_240	[p15l1352t142r1450b193],
7	as	IN	O	as	_	0	SENT_240	[p15l1469t153r1533b193],
8	targets	NNS	O	target	prep_as	6	SENT_240	[p15l1554t142r1779b214],
9	for	IN	O	for	_	0	SENT_240	[p15l1800t130r1897b193],
10	NNPIs	NNS	O	nnpi	prep_for	8	SENT_240	[p15l1916t135r2147b193],
11	are	VBP	O	be	cop	13	SENT_240	[p15l9t256r112b296],
12	thumb	NN	O	thumb	nn	13	SENT_240	[p15l137t233r371b296],
13	domains	NNS	O	domain	_	0	SENT_240	[p15l398t233r701b296],
14	1	CD	NUMBER	1	dep	13	SENT_240	[p15l734t240r759b295],
15	and	CC	O	and	_	0	SENT_240	[p15l791t233r921b296],
16	2	CD	NUMBER	2	dep	13	SENT_240	[p15l945t240r982b295],
17	and	CC	O	and	_	0	SENT_240	[p15l1010t233r1140b296],
18	palm	NN	O	palm	nn	19	SENT_240	[p15l1163t233r1342b316],
19	domains	NNS	O	domain	conj_and	13	SENT_240	[p15l1368t233r1671b296],
20	1	CD	NUMBER	1	dep	19	SENT_240	[p15l1703t240r1729b295],
21	and	CC	O	and	_	0	SENT_240	[p15l1761t233r1891b296],
22	2	CD	NUMBER	2	dep	19	SENT_240	[p15l1915t240r1971b296],
23	.	.	O	.	_	0	SENT_240	[p15l1915t240r1971b296],

1	As	IN	O	as	_	0	SENT_241	[p15l1998t237r2087b296],
2	a	DT	O	a	det	3	SENT_241	[p15l2113t256r2149b296],
3	class	NN	O	class	prep_as	8	SENT_241	[p15l9t336r189b408],
4	,	,	O	,	_	0	SENT_241	[p15l9t336r189b408],
5	NNPIs	NNS	O	nnpi	nsubj	29	SENT_241	[p15l215t341r455b399],
6	are	VBP	O	be	cop	8	SENT_241	[p15l482t359r586b399],
7	less	RBR	O	less	advmod	8	SENT_241	[p15l610t336r733b399],
8	potent	JJ	O	potent	dep	33	SENT_241	[p15l758t348r1006b419],
9	,	,	O	,	_	0	SENT_241	[p15l758t348r1006b419],
10	tend	VB	O	tend	dep	33	SENT_241	[p15l1032t336r1191b399],
11	to	TO	O	to	aux	13	SENT_241	[p15l1214t348r1282b399],
12	be	VB	O	be	cop	13	SENT_241	[p15l1307t336r1389b399],
13	effective	JJ	O	effective	xcomp	10	SENT_241	[p15l1415t336r1705b399],
14	in	IN	O	in	_	0	SENT_241	[p15l1731t342r1800b398],
15	genotype	NN	O	genotype	prep_in	13	SENT_241	[p15l1825t348r2148b420],
16	1	CD	NUMBER	1	num	15	SENT_241	[p15l15t446r40b501],
17	only	RB	O	only	advmod	13	SENT_241	[p15l71t439r234b523],
18	,	,	O	,	_	0	SENT_241	[p15l71t439r234b523],
19	have	VBP	O	have	dep	33	SENT_241	[p15l259t439r418b502],
20	a	DT	O	a	det	24	SENT_241	[p15l443t462r477b502],
21	low	JJ	O	low	amod	23	SENT_241	[p15l499t439r626b502],
22	to	TO	O	to	dep	23	SENT_241	[p15l646t451r713b502],
23	moderate	JJ	O	moderate	amod	24	SENT_241	[p15l738t439r1071b502],
24	barrier	NN	O	barrier	dobj	19	SENT_241	[p15l1093t439r1338b502],
25	to	TO	O	to	_	0	SENT_241	[p15l1359t451r1427b502],
26	resistance	NN	O	resistance	prep_to	24	SENT_241	[p15l1452t445r1813b511],
27	,	,	O	,	_	0	SENT_241	[p15l1452t445r1813b511],
28	and	CC	O	and	_	0	SENT_241	[p15l1840t439r1969b502],
29	have	VBP	O	have	conj_and	8	SENT_241	[p15l1990t439r2150b502],
30	variable	JJ	O	variable	amod	32	SENT_241	[p15l6t542r277b605],
31	toxicity	NN	O	toxicity	nn	32	SENT_241	[p15l298t548r557b626],
32	proﬁles	NNS	O	proﬁles	dobj	29	SENT_241	[p15l574t542r826b625],
33	(	VBP	O	(	_	0	SENT_241	[p15l852t543r981b618],
34	see	VB	O	see	xcomp	33	SENT_241	[p15l852t543r981b618],
35	Table	NNP	O	Table	dobj	34	SENT_241	[p15l1003t543r1195b605],
36	1	CD	NUMBER	1	num	35	SENT_241	[p15l1222t543r1302b618],
37	)	CD	NUMBER	)	nsubj	33	SENT_241	[p15l1222t543r1302b618],
38	.	.	O	.	_	0	SENT_241	[p15l1222t543r1302b618],

1	DELEOBUVIR	NNP	O	DELEOBUVIR	nn	4	SENT_242	[p15l12t757r476b813],
2	Deleobuvir	NNP	O	Deleobuvir	nn	4	SENT_242	[p15l9t853r376b916],
3	(	NN	O	(	nn	4	SENT_242	[p15l396t853r786b930],
4	BI	NN	O	bus	nsubj	12	SENT_242	[p15l396t853r786b930],
5	—	CD	NUMBER	—	num	7	SENT_242	[p15l396t853r786b930],
6	207127	CD	NUMBER	207127	num	7	SENT_242	[p15l396t853r786b930],
7	)	NN	O	)	dep	4	SENT_242	[p15l396t853r786b930],
8	is	VBZ	O	be	cop	12	SENT_242	[p15l808t859r856b916],
9	an	DT	O	a	det	12	SENT_242	[p15l875t876r953b916],
10	orally	RB	O	orally	advmod	11	SENT_242	[p15l971t853r1158b937],
11	bioavailable	JJ	O	bioavailable	amod	12	SENT_242	[p15l1171t853r1558b916],
12	NNPI	NN	O	nnpus	_	0	SENT_242	[p15l1576t858r1771b916],
13	that	WDT	O	that	nsubj	14	SENT_242	[p15l1789t853r1917b916],
14	targets	VBZ	O	target	rcmod	12	SENT_242	[p15l1933t865r2149b937],
15	thumb	NN	O	thumb	nn	16	SENT_242	[p15l7t956r231b1019],
16	domain	NN	O	domain	dobj	14	SENT_242	[p15l253t956r512b1019],
17	1	CD	NUMBER	1	num	16	SENT_242	[p15l538t963r585b1019],
18	.	.	O	.	_	0	SENT_242	[p15l538t963r585b1019],

1	It	PRP	O	it	nsubjpass	11	SENT_243	[p15l608t961r656b1019],
2	is	VBZ	O	be	_	0	SENT_243	[p15l675t962r724b1019],
3	currently	RB	DATE	currently	advmod	2	SENT_243	[p15l744t956r1055b1040],
4	in	IN	O	in	_	0	SENT_243	[p15l1071t962r1136b1018],
5	phase	NN	O	phase	nn	7	SENT_243	[p15l1155t956r1346b1039],
6	11	CD	NUMBER	11	num	7	SENT_243	[p15l1367t961r1419b1018],
7	development	NN	O	development	prep_in	2	SENT_243	[p15l1440t956r1877b1039],
8	and	CC	O	and	_	0	SENT_243	[p15l1896t956r2021b1019],
9	has	VBZ	O	have	aux	11	SENT_243	[p15l2038t956r2148b1019],
10	been	VBN	O	be	auxpass	11	SENT_243	[p15l6t1058r173b1121],
11	studied	VBN	O	study	conj_and	2	SENT_243	[p15l197t1058r452b1121],
12	in	IN	O	in	_	0	SENT_243	[p15l474t1064r542b1120],
13	combination	NN	O	combination	prep_in	11	SENT_243	[p15l565t1058r1007b1121],
14	with	IN	O	with	_	0	SENT_243	[p15l1028t1058r1184b1121],
15	PEG+RBV	NN	O	peg+rbv	prep_with	11	SENT_243	[p15l1207t1062r1583b1121],
16	and	CC	O	and	_	0	SENT_243	[p15l1606t1058r1734b1121],
17	in	IN	O	in	_	0	SENT_243	[p15l1756t1064r1824b1120],
18	IFN-free	JJ	O	ifn-free	amod	19	SENT_243	[p15l1848t1058r2150b1121],
19	regimens	NNS	O	regimen	prep_in	11	SENT_243	[p15l9t1167r328b1245],
20	.	.	O	.	_	0	SENT_243	[p15l9t1167r328b1245],

1	In	IN	O	in	_	0	SENT_244	[p15l349t1166r419b1223],
2	a	DT	O	a	det	4	SENT_244	[p15l438t1184r472b1224],
3	double	JJ	O	double	amod	4	SENT_244	[p15l490t1161r935b1233],
4	—	NN	O	—	prep_in	16	SENT_244	[p15l490t1161r935b1233],
5	blind	JJ	O	blind	amod	4	SENT_244	[p15l490t1161r935b1233],
6	,	,	O	,	_	0	SENT_244	[p15l490t1161r935b1233],
7	phase	NN	O	phase	nn	9	SENT_244	[p15l954t1161r1143b1244],
8	lb	NN	O	lb	nn	9	SENT_244	[p15l1162t1161r1228b1224],
9	study	NN	O	study	nsubjpass	16	SENT_244	[p15l1249t1161r1436b1245],
10	,	,	O	,	_	0	SENT_244	[p15l1249t1161r1436b1245],
11	patients	NNS	O	patient	appos	9	SENT_244	[p15l1455t1167r1715b1244],
12	with	IN	O	with	_	0	SENT_244	[p15l1732t1161r1881b1224],
13	chronic	JJ	O	chronic	amod	14	SENT_244	[p15l1899t1161r2150b1224],
14	HCV	NN	O	hcv	prep_with	11	SENT_244	[p15l9t1268r188b1327],
15	were	VBD	O	be	auxpass	16	SENT_244	[p15l207t1287r367b1327],
16	given	VBN	O	give	_	0	SENT_244	[p15l388t1270r570b1348],
17	5	CD	DURATION	5	num	18	SENT_244	[p15l593t1272r626b1327],
18	days	NNS	NUMBER	day	dobj	16	SENT_244	[p15l651t1264r798b1348],
19	of	IN	O	of	_	0	SENT_244	[p15l820t1264r894b1327],
20	deleobuvir	NN	O	deleobuvir	nn	21	SENT_244	[p15l906t1264r1268b1327],
21	therapy	NN	O	therapy	prep_of	18	SENT_244	[p15l1286t1264r1546b1348],
22	to	TO	O	to	aux	23	SENT_244	[p15l1563t1276r1629b1327],
23	assess	VB	O	assess	xcomp	16	SENT_244	[p15l1651t1287r1845b1327],
24	antiviral	JJ	O	antiviral	amod	25	SENT_244	[p15l1868t1264r2148b1327],
25	activity	NN	O	activity	dobj	23	SENT_244	[p15l9t1373r256b1451],
26	,	,	O	,	_	0	SENT_244	[p15l9t1373r256b1451],
27	Virology	NNP	O	Virology	conj_and	25	SENT_244	[p15l273t1367r556b1451],
28	,	,	O	,	_	0	SENT_244	[p15l273t1367r556b1451],
29	pharmacokinetics	NNS	O	pharmacokinetic	dobj	23	SENT_244	[p15l575t1367r1180b1450],
30	,	,	O	,	_	0	SENT_244	[p15l575t1367r1180b1450],
31	and	CC	O	and	_	0	SENT_244	[p15l1200t1367r1322b1430],
32	safety	NN	O	safety	dobj	23	SENT_244	[p15l1340t1367r1533b1451],
33	.	.	O	.	_	0	SENT_244	[p15l1340t1367r1533b1451],

1	Fifteen	CD	NUMBER	fifteen	num	2	SENT_245	[p15l1555t1367r1781b1430],
2	treatmentnaive	NNS	O	treatmentnaive	nsubjpass	12	SENT_245	[p15l1798t1379r2144b1430, p15l8t1476r188b1533],
3	and	CC	O	and	_	0	SENT_245	[p15l211t1470r339b1533],
4	45	CD	NUMBER	45	num	5	SENT_245	[p15l359t1477r437b1533],
5	treatment	NN	O	treatment	nsubjpass	12	SENT_245	[p15l460t1470r1250b1553],
6	—	CD	NUMBER	—	num	8	SENT_245	[p15l460t1470r1250b1553],
7	eXperienced	JJ	O	experienced	amod	8	SENT_245	[p15l460t1470r1250b1553],
8	patients	NNS	O	patient	dep	5	SENT_245	[p15l1271t1476r1541b1553],
9	without	IN	O	without	_	0	SENT_245	[p15l1562t1470r1832b1533],
10	cirrhosis	NN	O	cirrhosis	prep_without	8	SENT_245	[p15l1853t1470r2149b1533],
11	were	VBD	O	be	auxpass	12	SENT_245	[p15l7t1596r169b1636],
12	randomized	VBN	O	randomize	_	0	SENT_245	[p15l192t1573r613b1636],
13	to	TO	O	to	aux	14	SENT_245	[p15l633t1585r700b1636],
14	receive	VB	O	receive	xcomp	12	SENT_245	[p15l724t1579r962b1636],
15	placebo	NN	O	placebo	dobj	14	SENT_245	[p15l984t1573r1249b1656],
16	or	CC	O	or	_	0	SENT_245	[p15l1274t1596r1347b1636],
17	deleobuvir	NN	O	deleobuvir	dobj	14	SENT_245	[p15l1369t1573r1738b1636],
18	at	IN	O	at	_	0	SENT_245	[p15l1760t1585r1820b1636],
19	100	CD	NUMBER	100	prep_at	14	SENT_245	[p15l1848t1580r1982b1645],
20	,	,	O	,	_	0	SENT_245	[p15l1848t1580r1982b1645],
21	200	CD	NUMBER	200	conj_or	19	SENT_245	[p15l2006t1580r2146b1645],
22	,	,	O	,	_	0	SENT_245	[p15l2006t1580r2146b1645],
23	400	CD	NUMBER	400	conj_or	19	SENT_245	[p15l7t1683r145b1748],
24	,	,	O	,	_	0	SENT_245	[p15l7t1683r145b1748],
25	800	CD	NUMBER	800	conj_or	19	SENT_245	[p15l167t1683r302b1748],
26	,	,	O	,	_	0	SENT_245	[p15l167t1683r302b1748],
27	or	CC	O	or	_	0	SENT_245	[p15l323t1699r394b1739],
28	1,200	CD	NUMBER	1,200	num	29	SENT_245	[p15l419t1683r590b1748],
29	mg	NN	O	mg	conj_or	19	SENT_245	[p15l604t1699r712b1760],
30	every	DT	SET	every	quantmod	31	SENT_245	[p15l730t1699r914b1760],
31	8	CD	SET	8	num	32	SENT_245	[p15l931t1683r965b1739],
32	hours	NNS	NUMBER	hour	tmod	29	SENT_245	[p15l985t1676r1177b1739],
33	for	IN	O	for	_	0	SENT_245	[p15l1197t1676r1292b1739],
34	5	CD	DURATION	5	num	35	SENT_245	[p15l1312t1684r1346b1739],
35	days	NNS	NUMBER	day	prep_for	14	SENT_245	[p15l1368t1676r1530b1760],
36	.	.	O	.	_	0	SENT_245	[p15l1368t1676r1530b1760],

1	Thirteen	CD	NUMBER	thirteen	num	3	SENT_246	[p15l1553t1676r1840b1739],
2	cirrhotic	JJ	O	cirrhotic	amod	3	SENT_246	[p15l1860t1676r2149b1739],
3	patients	NNS	O	patient	nsubjpass	5	SENT_246	[p15l7t1785r271b1862],
4	were	VBD	O	be	auxpass	5	SENT_246	[p15l289t1802r447b1842],
5	given	VBN	O	give	_	0	SENT_246	[p15l467t1785r647b1863],
6	400	CD	NUMBER	400	num	10	SENT_246	[p15l665t1786r784b1842],
7	or	CC	O	or	_	0	SENT_246	[p15l806t1802r877b1842],
8	600	CD	NUMBER	600	num	10	SENT_246	[p15l895t1785r1013b1842],
9	mg	NN	O	mg	nn	10	SENT_246	[p15l1026t1802r1135b1863],
10	deleobuvir	NN	O	deleobuvir	iobj	5	SENT_246	[p15l1153t1779r1511b1842],
11	every	DT	SET	every	quantmod	12	SENT_246	[p15l1530t1802r1714b1863],
12	8	CD	SET	8	num	13	SENT_246	[p15l1731t1786r1765b1842],
13	hours	NNS	NUMBER	hour	dobj	5	SENT_246	[p15l1786t1779r1977b1842],
14	for	IN	O	for	_	0	SENT_246	[p15l1997t1779r2093b1842],
15	5	CD	DURATION	5	num	16	SENT_246	[p15l2113t1787r2147b1842],
16	days	NNS	NUMBER	day	prep_for	5	SENT_246	[p15l9t1882r172b1966],
17	.	.	O	.	_	0	SENT_246	[p15l9t1882r172b1966],

1	After	IN	O	after	_	0	SENT_247	[p15l193t1882r367b1945],
2	completion	NN	O	completion	prep_after	9	SENT_247	[p15l387t1882r768b1965],
3	of	IN	O	of	_	0	SENT_247	[p15l788t1882r861b1945],
4	treatment	NN	O	treatment	prep_of	2	SENT_247	[p15l869t1894r1215b1954],
5	,	,	O	,	_	0	SENT_247	[p15l869t1894r1215b1954],
6	those	DT	O	those	nsubj	9	SENT_247	[p15l1235t1882r1415b1945],
7	without	IN	O	without	_	0	SENT_247	[p15l1433t1882r1697b1945],
8	cirrhosis	NN	O	cirrhosis	prep_without	6	SENT_247	[p15l1716t1882r2004b1945],
9	had	VBD	O	have	_	0	SENT_247	[p15l2024t1882r2150b1945],
10	dose	NN	O	dose	nn	11	SENT_247	[p15l9t1985r536b2068],
11	—	NN	O	—	dobj	9	SENT_247	[p15l9t1985r536b2068],
12	dependent	JJ	O	dependent	amod	16	SENT_247	[p15l9t1985r536b2068],
13	median	NN	O	median	nn	16	SENT_247	[p15l552t1985r798b2048],
14	HCV	NN	O	hcv	nn	16	SENT_247	[p15l817t1989r990b2048],
15	RNA	NN	O	rna	nn	16	SENT_247	[p15l1008t1989r1173b2048],
16	reductions	NNS	O	reduction	nsubj	25	SENT_247	[p15l1190t1985r1535b2048],
17	up	IN	O	up	quantmod	19	SENT_247	[p15l1553t2007r1635b2068],
18	to	TO	O	to	dep	19	SENT_247	[p15l1653t1997r1716b2048],
19	3.8	CD	NUMBER	3.8	num	20	SENT_247	[p15l1737t1985r2009b2069],
20	log10	NN	O	log10	dep	16	SENT_247	[p15l1737t1985r2009b2069],
21	and	CC	O	and	_	0	SENT_247	[p15l2028t1985r2149b2048],
22	those	DT	O	those	nsubj	25	SENT_247	[p15l7t2087r187b2151],
23	with	IN	O	with	_	0	SENT_247	[p15l205t2087r356b2151],
24	cirrhosis	NN	O	cirrhosis	prep_with	22	SENT_247	[p15l376t2087r665b2151],
25	had	VBD	O	have	rcmod	11	SENT_247	[p15l685t2087r811b2151],
26	RNA	NN	MISC	rna	nn	27	SENT_247	[p15l831t2092r1000b2151],
27	reductions	NNS	O	reduction	dobj	25	SENT_247	[p15l1019t2087r1375b2151],
28	of	IN	O	of	_	0	SENT_247	[p15l1396t2087r1469b2151],
29	~	NN	O	~	nn	31	SENT_247	[p15l1482t2079r1892b2172],
30	3.0	CD	NUMBER	3.0	num	31	SENT_247	[p15l1482t2079r1892b2172],
31	log10	NN	O	log10	prep_of	27	SENT_247	[p15l1482t2079r1892b2172],
32	.54	CD	NUMBER	.54	num	31	SENT_247	[p15l1482t2079r1892b2172],

1	In	IN	O	in	_	0	SENT_248	[p15l83t2195r154b2253],
2	combination	NN	O	combination	prep_in	11	SENT_248	[p15l177t2190r616b2254],
3	with	IN	O	with	_	0	SENT_248	[p15l636t2190r790b2254],
4	PEG	NN	O	peg	prep_with	2	SENT_248	[p15l814t2194r969b2254],
5	and	CC	O	and	_	0	SENT_248	[p15l993t2190r1120b2254],
6	RBV	NN	O	rbv	conj_and	4	SENT_248	[p15l1143t2195r1308b2262],
7	,	,	O	,	_	0	SENT_248	[p15l1143t2195r1308b2262],
8	deleobuvir	NN	O	deleobuvir	nsubjpass	11	SENT_248	[p15l1333t2190r1702b2254],
9	was	VBD	O	be	auxpass	11	SENT_248	[p15l1721t2213r1848b2254],
10	well	RB	O	well	advmod	11	SENT_248	[p15l1870t2190r2008b2254],
11	tolerated	VBN	O	tolerate	_	0	SENT_248	[p15l2030t2190r2147b2254, p15l9t2294r227b2357],
12	at	IN	O	at	_	0	SENT_248	[p15l251t2306r312b2357],
13	a	DT	O	a	det	14	SENT_248	[p15l336t2317r371b2357],
14	dose	NN	O	dose	prep_at	11	SENT_248	[p15l395t2294r554b2357],
15	of	IN	O	of	_	0	SENT_248	[p15l580t2294r656b2357],
16	600	CD	NUMBER	600	num	17	SENT_248	[p15l671t2300r794b2357],
17	mg	NN	O	mg	prep_of	14	SENT_248	[p15l811t2317r923b2378],
18	three	CD	NUMBER	three	num	19	SENT_248	[p15l944t2294r1125b2357],
19	times	NNS	O	time	tmod	14	SENT_248	[p15l1149t2300r1341b2357],
20	a	DT	DURATION	a	det	21	SENT_248	[p15l1366t2317r1402b2357],
21	day	NN	DURATION	day	tmod	11	SENT_248	[p15l1426t2294r1551b2378],
22	for	IN	O	for	_	0	SENT_248	[p15l1571t2294r1672b2357],
23	28	CD	DURATION	28	num	24	SENT_248	[p15l1695t2301r1774b2357],
24	days	NNS	NUMBER	day	prep_for	11	SENT_248	[p15l1802t2294r1973b2378],
25	.	.	O	.	_	0	SENT_248	[p15l1802t2294r1973b2378],

1	This	DT	O	this	det	2	SENT_249	[p15l2001t2294r2148b2357],
2	regimen	NN	O	regimen	nsubj	3	SENT_249	[p15l9t2403r294b2481],
3	resulted	VBD	O	result	_	0	SENT_249	[p15l317t2397r593b2460],
4	in	IN	O	in	_	0	SENT_249	[p15l614t2403r681b2459],
5	58	CD	PERCENT	58	number	6	SENT_249	[p15l706t2402r849b2461],
6	%	NN	PERCENT	%	amod	7	SENT_249	[p15l706t2402r849b2461],
7	RVR	NN	O	rvr	prep_in	3	SENT_249	[p15l874t2402r1038b2460],
8	in	IN	O	in	_	0	SENT_249	[p15l1059t2403r1126b2459],
9	treatment-naive	JJ	O	treatment-naive	amod	10	SENT_249	[p15l1148t2403r1703b2460],
10	patients	NNS	O	patient	prep_in	3	SENT_249	[p15l1724t2403r1997b2480],
11	and	CC	O	and	_	0	SENT_249	[p15l2021t2397r2149b2460],
12	no	DT	O	no	det	14	SENT_249	[p15l8t2523r95b2563],
13	viral	JJ	O	viral	amod	14	SENT_249	[p15l116t2500r272b2563],
14	breakthrough	NN	O	breakthrough	prep_in	3	SENT_249	[p15l293t2500r782b2584],
15	.	.	O	.	_	0	SENT_249	[p15l293t2500r782b2584],

1	Treatment	NN	O	treatment	dep	2	SENT_250	[p15l808t2503r1165b2563],
2	was	VBD	O	be	_	0	SENT_250	[p15l1185t2523r1312b2563],
3	relatively	RB	O	relatively	advmod	4	SENT_250	[p15l1335t2500r1649b2584],
4	well	RB	O	well	advmod	2	SENT_250	[p15l1667t2500r1806b2563],
5	tolerated	VBD	O	tolerate	dep	4	SENT_250	[p15l1826t2500r2149b2572],
6	,	,	O	,	_	0	SENT_250	[p15l1826t2500r2149b2572],
7	with	IN	O	with	_	0	SENT_250	[p15l7t2603r160b2666],
8	gastrointestinal	JJ	O	gastrointestinal	amod	9	SENT_250	[p15l180t2603r708b2687],
9	events	NNS	O	event	prep_with	5	SENT_250	[p15l729t2615r941b2666],
10	and	CC	O	and	_	0	SENT_250	[p15l963t2603r1090b2666],
11	rash	NN	O	rash	conj_and	9	SENT_250	[p15l1110t2603r1253b2666],
12	being	VBG	O	be	auxpass	16	SENT_250	[p15l1272t2603r1464b2687],
13	the	DT	O	the	dep	14	SENT_250	[p15l1482t2603r1588b2666],
14	most	RBS	O	most	advmod	16	SENT_250	[p15l1609t2615r1779b2666],
15	frequently	RB	O	frequently	advmod	16	SENT_250	[p15l1798t2603r2153b2687],
16	encountered	VBN	O	encounter	partmod	11	SENT_250	[p15l9t2706r463b2770],
17	AEs	NNS	O	ae	dobj	16	SENT_250	[p15l491t2699r723b2770],
18	.55	CD	NUMBER	.55	num	17	SENT_250	[p15l491t2699r723b2770],
19	The	DT	O	the	det	22	SENT_250	[p15l754t2706r892b2770],
20	most	RBS	O	most	advmod	22	SENT_250	[p15l922t2718r1100b2770],
21	common	JJ	O	common	amod	22	SENT_250	[p15l1130t2729r1452b2770],
22	AE	NN	O	ae	nsubj	24	SENT_250	[p15l1481t2710r1590b2769],
23	is	VBZ	O	be	cop	24	SENT_250	[p15l1620t2713r1673b2770],
24	hyperbilirubinemia	NN	O	hyperbilirubinemia	rcmod	17	SENT_250	[p15l1702t2706r2146b2791, p15l6t2810r318b2882],
25	,	,	O	,	_	0	SENT_250	[p15l1702t2706r2146b2791, p15l6t2810r318b2882],
26	which	WDT	O	which	nsubj	27	SENT_250	[p15l345t2810r564b2873],
27	results	VBZ	O	result	rcmod	24	SENT_250	[p15l590t2810r821b2873],
28	from	IN	O	from	_	0	SENT_250	[p15l849t2810r1023b2873],
29	inhibition	NN	O	inhibition	prep_from	27	SENT_250	[p15l1050t2810r1408b2873],
30	of	IN	O	of	_	0	SENT_250	[p15l1436t2810r1512b2873],
31	hepatic	JJ	O	hepatic	amod	33	SENT_250	[p15l1529t2810r1789b2893],
32	transport	NN	O	transport	nn	33	SENT_250	[p15l1815t2822r2151b2893],
33	enzymes	NNS	O	enzyme	prep_of	29	SENT_250	[p15l9t2905r386b2997],
34	.56	CD	NUMBER	.56	nsubj	2	SENT_250	[p15l9t2905r386b2997],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_251	[p15l21t3062r140b3083],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	_	0	SENT_251	[p15l149t3062r374b3083],
3	&	CC	O	&	_	0	SENT_251	[p15l381t3062r601b3083],
4	THERAPEUTlCS	NNP	O	THERAPEUTlCS	nn	6	SENT_251	[p15l381t3062r601b3083],
5	|	NNP	O	|	nn	6	SENT_251	[p15l611t3060r613b3090],
6	VOLUME	NNP	O	VOLUME	conj_and	2	SENT_251	[p15l621t3062r729b3083],
7	95	CD	NUMBER	95	num	8	SENT_251	[p15l737t3062r764b3083],
8	NUMBER	NN	O	number	dep	2	SENT_251	[p15l774t3062r882b3083],
9	1	CD	NUMBER	1	number	10	SENT_251	[p15l892t3063r899b3083],
10	]	CD	NUMBER	]	num	11	SENT_251	[p15l912t3060r915b3090],
11	JANUARY	NNP	DATE	JANUARY	dep	8	SENT_251	[p15l924t3062r1042b3083],
12	2014	CD	DATE	2014	num	13	SENT_251	[p15l1049t3062r1108b3083],
13	83	CD	DATE	83	dep	2	SENT_251	[p15l2109t3062r2139b3083],

1	VX-222	NN	O	vx-222	_	0	SENT_252	[p15l8t3438r262b3492],

1	VX-222	NN	O	vx-222	nsubj	6	SENT_253	[p16l7t32r278b90],
2	is	VBZ	O	be	cop	6	SENT_253	[p16l302t33r353b90],
3	an	DT	O	a	det	6	SENT_253	[p16l377t50r458b90],
4	orally	RB	O	orally	advmod	5	SENT_253	[p16l481t27r679b111],
5	bioavailable	JJ	O	bioavailable	amod	6	SENT_253	[p16l696t27r1107b90],
6	NNPI	NN	O	nnpus	_	0	SENT_253	[p16l1129t32r1332b90],
7	that	WDT	O	that	nsubj	9	SENT_253	[p16l1356t27r1491b90],
8	also	RB	O	also	advmod	9	SENT_253	[p16l1513t27r1645b90],
9	targets	VBZ	O	target	rcmod	6	SENT_253	[p16l1668t39r1897b111],
10	thumb	NN	O	thumb	nn	11	SENT_253	[p16l1919t27r2148b90],
11	domain	NN	O	domain	dobj	9	SENT_253	[p16l9t130r282b193],
12	2	CD	NUMBER	2	num	11	SENT_253	[p16l308t137r364b193],
13	.	.	O	.	_	0	SENT_253	[p16l308t137r364b193],

1	In	IN	O	in	_	0	SENT_254	[p16l394t135r467b192],
2	phase	NN	O	phase	nn	4	SENT_254	[p16l492t130r695b213],
3	I	NN	O	i	nn	4	SENT_254	[p16l721t135r746b192],
4	studies	NNS	O	study	prep_in	25	SENT_254	[p16l774t130r1018b193],
5	of	IN	O	of	_	0	SENT_254	[p16l1046t130r1122b193],
6	treatment-naive	JJ	O	treatment-naive	amod	9	SENT_254	[p16l1137t136r1710b193],
7	HCV	NN	O	hcv	nn	9	SENT_254	[p16l1737t134r1922b193],
8	genotype	NN	O	genotype	nn	9	SENT_254	[p16l1948t153r2147b214, p16l8t245r154b317],
9	la	NNP	O	la	prep_of	4	SENT_254	[p16l183t240r253b296],
10	and	CC	O	and	_	0	SENT_254	[p16l275t233r401b296],
11	1b	JJ	O	1b	amod	12	SENT_254	[p16l429t233r503b296],
12	patients	NNS	O	patient	conj_and	9	SENT_254	[p16l525t239r813b316],
13	,	,	O	,	_	0	SENT_254	[p16l525t239r813b316],
14	a	DT	O	a	det	15	SENT_254	[p16l838t256r873b296],
15	dose	NN	O	dose	nsubj	25	SENT_254	[p16l894t233r1049b296],
16	of	IN	O	of	_	0	SENT_254	[p16l1072t233r1146b296],
17	750	CD	NUMBER	750	num	18	SENT_254	[p16l1160t240r1278b296],
18	mg	NN	O	mg	prep_of	15	SENT_254	[p16l1294t256r1402b317],
19	twice	RB	O	twice	advmod	21	SENT_254	[p16l1422t239r1602b296],
20	a	DT	DURATION	a	det	21	SENT_254	[p16l1625t256r1659b296],
21	day	NN	DURATION	day	tmod	18	SENT_254	[p16l1681t233r1803b317],
22	for	IN	O	for	_	0	SENT_254	[p16l1821t233r1918b296],
23	3	CD	DURATION	3	num	24	SENT_254	[p16l1941t240r1974b296],
24	days	NNS	NUMBER	day	prep_for	18	SENT_254	[p16l2000t233r2149b317],
25	resulted	VBD	O	result	_	0	SENT_254	[p16l9t336r278b399],
26	in	IN	O	in	_	0	SENT_254	[p16l297t342r363b398],
27	a	DT	O	a	det	30	SENT_254	[p16l384t359r418b399],
28	3.7	CD	NUMBER	3.7	num	30	SENT_254	[p16l439t336r722b420],
29	log10	NN	O	log10	nn	30	SENT_254	[p16l439t336r722b420],
30	decrease	NN	O	decrease	prep_in	25	SENT_254	[p16l744t336r1031b399],
31	in	IN	O	in	_	0	SENT_254	[p16l1051t342r1117b398],
32	median	JJ	O	median	amod	35	SENT_254	[p16l1137t336r1393b399],
33	HCV	NN	O	hcv	nn	35	SENT_254	[p16l1413t340r1592b399],
34	RNA	NN	O	rna	nn	35	SENT_254	[p16l1612t340r1781b399],
35	levels	NNS	O	level	prep_in	25	SENT_254	[p16l1800t336r2000b399],
36	.	.	O	.	_	0	SENT_254	[p16l1800t336r2000b399],

1	The	DT	O	the	det	2	SENT_255	[p16l2023t336r2147b399],
2	compound	NN	O	compound	nsubjpass	5	SENT_255	[p16l9t439r388b523],
3	was	VBD	O	be	auxpass	5	SENT_255	[p16l409t462r537b503],
4	well	RB	O	well	advmod	5	SENT_255	[p16l558t439r699b503],
5	tolerated	VBN	O	tolerate	_	0	SENT_255	[p16l720t439r1045b512],
6	,	,	O	,	_	0	SENT_255	[p16l720t439r1045b512],
7	without	IN	O	without	_	0	SENT_255	[p16l1069t439r1341b503],
8	any	DT	O	any	det	10	SENT_255	[p16l1364t462r1486b524],
9	serious	JJ	O	serious	amod	10	SENT_255	[p16l1507t446r1751b503],
10	AEs	NNS	O	ae	prep_without	5	SENT_255	[p16l1774t432r1999b503],
11	.57	CD	NUMBER	.57	dep	10	SENT_255	[p16l1774t432r1999b503],
12	The	DT	O	the	det	16	SENT_255	[p16l2022t439r2149b503],
13	most	RBS	O	most	advmod	15	SENT_255	[p16l8t555r182b606],
14	commonly	RB	O	commonly	advmod	15	SENT_255	[p16l205t543r585b627],
15	reported	VBN	O	report	amod	16	SENT_255	[p16l605t543r907b626],
16	AEs	NNS	O	ae	nsubj	17	SENT_255	[p16l929t547r1068b606],
17	included	VBD	O	include	rcmod	10	SENT_255	[p16l1093t543r1398b606],
18	fatigue	NN	O	fatigue	dobj	17	SENT_255	[p16l1421t543r1657b627],
19	and	CC	O	and	_	0	SENT_255	[p16l1682t543r1811b606],
20	gastrointestinal	JJ	O	gastrointestinal	amod	21	SENT_255	[p16l1833t549r2145b627, p16l8t646r259b709],
21	upset	NN	O	upset	conj_and	18	SENT_255	[p16l281t658r482b729],
22	.	.	O	.	_	0	SENT_255	[p16l281t658r482b729],

1	In	IN	O	in	_	0	SENT_256	[p16l508t651r580b708],
2	the	DT	O	the	det	4	SENT_256	[p16l602t646r709b709],
3	ZENITH	NNP	ORGANIZATION	ZENITH	nn	4	SENT_256	[p16l733t649r1045b709],
4	study	NN	O	study	prep_in	16	SENT_256	[p16l1070t646r1266b730],
5	,	,	O	,	_	0	SENT_256	[p16l1070t646r1266b730],
6	treatment	NN	O	treatment	nn	7	SENT_256	[p16l1290t652r1861b718],
7	—	NN	O	—	nsubjpass	16	SENT_256	[p16l1290t652r1861b718],
8	naive	JJ	O	naive	amod	7	SENT_256	[p16l1290t652r1861b718],
9	,	,	O	,	_	0	SENT_256	[p16l1290t652r1861b718],
10	chronic	JJ	O	chronic	amod	12	SENT_256	[p16l1887t646r2148b709],
11	HCV	NN	O	hcv	nn	12	SENT_256	[p16l9t753r192b812],
12	genotype	NN	O	genotype	dep	8	SENT_256	[p16l215t761r534b833],
13	1	CD	NUMBER	1	num	14	SENT_256	[p16l565t756r590b811],
14	patients	NNS	O	patient	dep	12	SENT_256	[p16l618t755r894b832],
15	were	VBD	O	be	auxpass	16	SENT_256	[p16l916t772r1081b812],
16	treated	VBN	O	treat	conj_or	16	SENT_256	[p16l1103t749r1347b812],
17	with	IN	O	with	_	0	SENT_256	[p16l1368t749r1524b812],
18	VX-222	NN	O	vx-222	prep_with	16	SENT_256	[p16l1546t754r1820b812],
19	at	IN	O	at	dep	24	SENT_256	[p16l1846t761r1907b812],
20	100	CD	NUMBER	100	num	23	SENT_256	[p16l1936t756r2051b812],
21	or	CC	O	or	_	0	SENT_256	[p16l2076t772r2149b812],
22	400	CD	NUMBER	400	num	23	SENT_256	[p16l8t859r126b915],
23	mg	NN	O	mg	pobj	24	SENT_256	[p16l141t875r248b936],
24	twice	RB	O	twice	advmod	18	SENT_256	[p16l266t858r442b915],
25	a	DT	DURATION	a	det	26	SENT_256	[p16l463t875r497b915],
26	day	NN	DURATION	day	pobj	24	SENT_256	[p16l517t852r636b936],
27	in	IN	O	in	_	0	SENT_256	[p16l652t858r718b914],
28	conjunction	NN	O	conjunction	prep_in	24	SENT_256	[p16l738t858r1143b936],
29	with	IN	O	with	_	0	SENT_256	[p16l1161t852r1312b915],
30	1,125	CD	NUMBER	1,125	num	32	SENT_256	[p16l1338t859r1508b924],
31	mg	NN	O	mg	nn	32	SENT_256	[p16l1524t875r1631b936],
32	telaprevir	NN	O	telaprevir	prep_with	28	SENT_256	[p16l1648t852r1970b935],
33	daily	JJ	SET	daily	advmod	16	SENT_256	[p16l1989t852r2153b936],
34	(	CD	NUMBER	(	num	36	SENT_256	[p16l12t955r309b1032],
35	DUAL	JJ	O	dual	amod	36	SENT_256	[p16l12t955r309b1032],
36	)	NN	O	)	dep	33	SENT_256	[p16l12t955r309b1032],
37	;	:	O	;	_	0	SENT_256	[p16l12t955r309b1032],
38	in	IN	O	in	_	0	SENT_256	[p16l332t961r398b1017],
39	conjunction	NN	O	conjunction	prep_in	16	SENT_256	[p16l420t961r833b1039],
40	with	IN	O	with	_	0	SENT_256	[p16l852t955r1005b1018],
41	telaprevir	NN	O	telaprevir	prep_with	39	SENT_256	[p16l1024t955r1353b1038],
42	and	CC	O	and	_	0	SENT_256	[p16l1373t955r1500b1018],
43	RBV	NN	O	rbv	conj_and	39	SENT_256	[p16l1520t960r1680b1018],
44	(	CD	NUMBER	(	num	43	SENT_256	[p16l1703t956r2055b1032],
45	TRIPLE	NN	O	triple	dep	43	SENT_256	[p16l1703t956r2055b1032],
46	)	CD	NUMBER	)	num	45	SENT_256	[p16l1703t956r2055b1032],
47	;	:	O	;	_	0	SENT_256	[p16l1703t956r2055b1032],
48	or	CC	O	or	_	0	SENT_256	[p16l2078t978r2150b1018],
49	in	IN	O	in	_	0	SENT_256	[p16l9t1064r77b1120],
50	addition	NN	O	addition	prep_in	16	SENT_256	[p16l102t1058r397b1121],
51	to	TO	O	to	_	0	SENT_256	[p16l420t1070r487b1121],
52	telaprevir	NN	O	telaprevir	prep_to	50	SENT_256	[p16l511t1058r860b1141],
53	,	,	O	,	_	0	SENT_256	[p16l511t1058r860b1141],
54	RBV	NN	O	rbv	prep_to	50	SENT_256	[p16l887t1063r1056b1130],
55	,	,	O	,	_	0	SENT_256	[p16l887t1063r1056b1130],
56	and	CC	O	and	_	0	SENT_256	[p16l1082t1058r1212b1121],
57	PEG	NN	O	peg	nn	60	SENT_256	[p16l1235t1062r1393b1121],
58	(	CD	NUMBER	(	num	60	SENT_256	[p16l1421t1059r1742b1134],
59	QUAD	NN	O	quad	nn	60	SENT_256	[p16l1421t1059r1742b1134],
60	)	NN	O	)	conj_and	52	SENT_256	[p16l1421t1059r1742b1134],
61	.	.	O	.	_	0	SENT_256	[p16l1421t1059r1742b1134],

1	The	DT	O	the	det	3	SENT_257	[p16l1769t1058r1897b1121],
2	DUAL	JJ	O	dual	amod	3	SENT_257	[p16l1921t1062r2149b1121],
3	arm	NN	O	arm	nsubjpass	5	SENT_257	[p16l9t1184r151b1224],
4	was	VBD	O	be	auxpass	5	SENT_257	[p16l175t1184r306b1224],
5	terminated	VBN	O	terminate	_	0	SENT_257	[p16l333t1161r730b1224],
6	early	RB	O	early	advmod	5	SENT_257	[p16l757t1161r931b1245],
7	due	JJ	O	due	_	0	SENT_257	[p16l955t1161r1082b1224],
8	to	TO	O	to	_	0	SENT_257	[p16l1108t1173r1176b1224],
9	a	DT	O	a	det	11	SENT_257	[p16l1205t1184r1240b1224],
10	high	JJ	O	high	amod	11	SENT_257	[p16l1265t1161r1426b1245],
11	level	NN	O	level	prep_due_to	5	SENT_257	[p16l1451t1161r1613b1224],
12	of	IN	O	of	_	0	SENT_257	[p16l1640t1161r1717b1224],
13	viral	JJ	O	viral	amod	14	SENT_257	[p16l1731t1161r1894b1224],
14	breakthrough	NN	O	breakthrough	prep_of	11	SENT_257	[p16l1918t1161r2147b1224, p16l8t1264r308b1348],
15	.	.	O	.	_	0	SENT_257	[p16l1918t1161r2147b1224, p16l8t1264r308b1348],

1	In	IN	O	in	_	0	SENT_258	[p16l335t1269r407b1326],
2	the	DT	O	the	det	4	SENT_258	[p16l429t1264r538b1327],
3	TRIPLE	NNP	O	TRIPLE	nn	4	SENT_258	[p16l561t1267r843b1327],
4	arm	NN	O	arm	prep_in	24	SENT_258	[p16l867t1287r1024b1336],
5	,	,	O	,	_	0	SENT_258	[p16l867t1287r1024b1336],
6	57	CD	PERCENT	57	num	7	SENT_258	[p16l1051t1270r1194b1329],
7	%	NN	PERCENT	%	nsubj	24	SENT_258	[p16l1051t1270r1194b1329],
8	treated	VBN	O	treat	partmod	7	SENT_258	[p16l1219t1264r1462b1327],
9	with	IN	O	with	_	0	SENT_258	[p16l1483t1264r1638b1327],
10	VX-222	NN	O	vx-222	prep_with	8	SENT_258	[p16l1661t1269r1934b1327],
11	at	IN	O	at	_	0	SENT_258	[p16l1960t1276r2020b1327],
12	the	DT	O	the	det	14	SENT_258	[p16l2041t1264r2150b1327],
13	higher	JJR	O	higher	amod	14	SENT_258	[p16l8t1367r228b1451],
14	dose	NN	O	dose	prep_at	8	SENT_258	[p16l247t1367r399b1430],
15	and	CC	O	and	_	0	SENT_258	[p16l420t1367r545b1430],
16	38	CD	PERCENT	38	num	17	SENT_258	[p16l565t1373r704b1431],
17	%	NN	PERCENT	%	prep_at	8	SENT_258	[p16l565t1373r704b1431],
18	at	IN	O	at	_	0	SENT_258	[p16l727t1379r785b1430],
19	the	DT	O	the	det	21	SENT_258	[p16l803t1367r908b1430],
20	lower	JJR	O	lower	amod	21	SENT_258	[p16l927t1367r1115b1430],
21	dose	NN	O	dose	prep_at	8	SENT_258	[p16l1134t1367r1286b1430],
22	were	VBD	O	be	cop	24	SENT_258	[p16l1304t1390r1463b1430],
23	HCV	NN	O	hcv	nn	24	SENT_258	[p16l1484t1371r1661b1430],
24	RNA	NN	O	rna	_	0	SENT_258	[p16l1682t1371r1849b1430],
25	negative	JJ	O	negative	amod	24	SENT_258	[p16l1869t1373r2147b1451],
26	at	IN	O	at	_	0	SENT_258	[p16l9t1482r68b1533],
27	week	NN	DURATION	week	prep_at	25	SENT_258	[p16l86t1470r261b1533],
28	2	CD	NUMBER	2	num	27	SENT_258	[p16l278t1477r333b1533],
29	.	.	O	.	_	0	SENT_258	[p16l278t1477r333b1533],

1	However	RB	O	however	advmod	10	SENT_259	[p16l356t1475r674b1542],
2	,	,	O	,	_	0	SENT_259	[p16l356t1475r674b1542],
3	a	DT	O	a	det	5	SENT_259	[p16l697t1493r732b1533],
4	large	JJ	O	large	amod	5	SENT_259	[p16l750t1470r913b1554],
5	number	NN	O	number	nsubj	10	SENT_259	[p16l934t1470r1205b1533],
6	of	IN	O	of	_	0	SENT_259	[p16l1225t1470r1298b1533],
7	genotype	NN	O	genotype	nn	9	SENT_259	[p16l1309t1482r1620b1554],
8	1a	NN	O	1a	nn	9	SENT_259	[p16l1647t1477r1717b1533],
9	patients	NNS	O	patient	prep_of	5	SENT_259	[p16l1735t1476r2003b1553],
10	had	VBD	O	have	_	0	SENT_259	[p16l2023t1470r2150b1533],
11	viral	JJ	O	viral	amod	12	SENT_259	[p16l6t1573r158b1636],
12	breakthrough	NN	O	breakthrough	dobj	10	SENT_259	[p16l175t1573r638b1657],
13	on	IN	O	on	_	0	SENT_259	[p16l658t1596r743b1636],
14	treatment	NN	O	treatment	prep_on	12	SENT_259	[p16l762t1585r1107b1636],
15	.	.	O	.	_	0	SENT_259	[p16l762t1585r1107b1636],

1	On	IN	O	on	_	0	SENT_260	[p16l1131t1577r1237b1636],
2	QUAD	NN	O	quad	nn	3	SENT_260	[p16l1257t1577r1491b1649],
3	therapy	NN	O	therapy	prep_on	21	SENT_260	[p16l1512t1573r1778b1657],
4	,	,	O	,	_	0	SENT_260	[p16l1512t1573r1778b1657],
5	85	CD	PERCENT	85	num	6	SENT_260	[p16l1800t1578r1940b1638],
6	%	NN	PERCENT	%	nsubj	21	SENT_260	[p16l1800t1578r1940b1638],
7	of	IN	O	of	_	0	SENT_260	[p16l1962t1573r2035b1636],
8	the	DT	O	the	det	10	SENT_260	[p16l2044t1573r2149b1636],
9	low-dose	JJ	O	low-dose	amod	10	SENT_260	[p16l7t1676r327b1739],
10	VX-222	NN	O	vx-222	prep_of	6	SENT_260	[p16l349t1681r625b1739],
11	and	CC	O	and	_	0	SENT_260	[p16l651t1676r780b1739],
12	90	CD	PERCENT	90	num	13	SENT_260	[p16l804t1681r949b1740],
13	%	NN	PERCENT	%	prep_of	6	SENT_260	[p16l804t1681r949b1740],
14	of	IN	O	of	_	0	SENT_260	[p16l975t1676r1051b1739],
15	the	DT	O	the	det	18	SENT_260	[p16l1064t1676r1173b1739],
16	high-dose	JJ	O	high-dose	amod	18	SENT_260	[p16l1196t1676r1549b1760],
17	VX-222	NN	MISC	vx-222	nn	18	SENT_260	[p16l1572t1681r1847b1739],
18	patients	NNS	O	patient	prep_of	13	SENT_260	[p16l1871t1682r2148b1759],
19	were	VBD	O	be	cop	21	SENT_260	[p16l7t1801r168b1842],
20	HCV	NN	O	hcv	nn	21	SENT_260	[p16l190t1782r370b1842],
21	RNA	NN	O	rna	_	0	SENT_260	[p16l392t1783r563b1842],
22	negative	JJ	O	negative	amod	21	SENT_260	[p16l583t1785r866b1863],
23	at	IN	O	at	_	0	SENT_260	[p16l889t1790r948b1842],
24	week	NN	DURATION	week	prep_at	22	SENT_260	[p16l967t1778r1144b1842],
25	12.58	CD	NUMBER	12.58	num	24	SENT_260	[p16l1169t1770r1322b1842],

1	SETROBUVIR	NN	O	setrobuvir	_	0	SENT_261	[p16l10t1994r472b2050],

1	Setrobuvir	NNP	O	Setrobuvir	nsubj	6	SENT_262	[p16l10t2090r395b2153],
2	is	VBZ	O	be	cop	6	SENT_262	[p16l424t2096r477b2153],
3	a	DT	O	a	det	6	SENT_262	[p16l509t2113r544b2153],
4	moderately	RB	O	moderately	advmod	5	SENT_262	[p16l573t2090r988b2174],
5	potent	JJ	O	potent	amod	6	SENT_262	[p16l1014t2102r1250b2173],
6	NNPI	NN	O	nnpus	_	0	SENT_262	[p16l1279t2095r1491b2153],
7	that	WDT	O	that	nsubj	8	SENT_262	[p16l1521t2090r1664b2153],
8	targets	VBZ	O	target	rcmod	6	SENT_262	[p16l1692t2102r1935b2174],
9	palm	NN	O	palm	nn	10	SENT_262	[p16l1965t2090r2148b2173],
10	domain	NN	O	domain	dobj	8	SENT_262	[p16l9t2193r275b2256],
11	1	CD	NUMBER	1	num	10	SENT_262	[p16l305t2200r353b2256],
12	.	.	O	.	_	0	SENT_262	[p16l305t2200r353b2256],

1	In	IN	O	in	_	0	SENT_263	[p16l380t2198r452b2255],
2	phase	NN	O	phase	prep_in	8	SENT_263	[p16l474t2193r671b2276],
3	I	PRP	O	I	dep	4	SENT_263	[p16l695t2198r719b2255],
4	trials	NNS	O	trial	dep	2	SENT_263	[p16l742t2193r935b2265],
5	,	,	O	,	_	0	SENT_263	[p16l742t2193r935b2265],
6	it	PRP	O	it	nsubjpass	19	SENT_263	[p16l960t2199r1007b2256],
7	was	VBD	O	be	auxpass	8	SENT_263	[p16l1027t2216r1154b2256],
8	shown	VBN	O	show	_	0	SENT_263	[p16l1179t2193r1404b2256],
9	to	TO	O	to	aux	10	SENT_263	[p16l1426t2205r1493b2256],
10	reduce	VB	O	reduce	xcomp	8	SENT_263	[p16l1517t2193r1748b2256],
11	HCV	NN	O	hcv	nn	12	SENT_263	[p16l1772t2197r1954b2256],
12	RNA	NN	O	rna	dobj	10	SENT_263	[p16l1977t2197r2150b2256],
13	by	IN	O	by	_	0	SENT_263	[p16l7t2295r92b2380],
14	2.9	CD	NUMBER	2.9	num	15	SENT_263	[p16l111t2295r402b2380],
15	log1O	NN	O	log1o	prep_by	10	SENT_263	[p16l111t2295r402b2380],
16	and	CC	O	and	_	0	SENT_263	[p16l427t2295r555b2359],
17	was	VBD	O	be	auxpass	19	SENT_263	[p16l575t2318r702b2359],
18	well	RB	O	well	advmod	19	SENT_263	[p16l725t2295r864b2359],
19	tolerated	VBN	O	tolerate	conj_and	8	SENT_263	[p16l886t2287r1273b2359],
20	.59	CD	NUMBER	.59	dobj	19	SENT_263	[p16l886t2287r1273b2359],
21	It	PRP	O	it	nsubj	22	SENT_263	[p16l1298t2301r1347b2359],
22	is	VBZ	O	be	rcmod	20	SENT_263	[p16l1369t2302r1420b2359],
23	currently	RB	DATE	currently	advmod	22	SENT_263	[p16l1444t2295r1765b2380],
24	in	IN	O	in	_	0	SENT_263	[p16l1784t2302r1852b2358],
25	phase	NN	O	phase	nn	27	SENT_263	[p16l1873t2295r2070b2379],
26	II	CD	NUMBER	ii	num	27	SENT_263	[p16l2095t2300r2148b2358],
27	trials	NNS	O	trial	prep_in	22	SENT_263	[p16l8t2399r195b2462],
28	.	.	O	.	_	0	SENT_263	[p16l8t2399r195b2462],

1	One	CD	NUMBER	one	num	2	SENT_264	[p16l220t2403r363b2462],
2	study	NN	O	study	nsubj	20	SENT_264	[p16l384t2399r570b2483],
3	treated	VBN	O	treat	partmod	2	SENT_264	[p16l586t2399r824b2462],
4	patients	NNS	O	patient	dobj	3	SENT_264	[p16l842t2405r1111b2482],
5	with	IN	O	with	_	0	SENT_264	[p16l1130t2399r1282b2462],
6	200	CD	NUMBER	200	num	10	SENT_264	[p16l1303t2406r1422b2462],
7	or	CC	O	or	_	0	SENT_264	[p16l1444t2422r1516b2462],
8	400	CD	NUMBER	400	num	10	SENT_264	[p16l1534t2406r1654b2462],
9	mg	NN	O	mg	nn	10	SENT_264	[p16l1672t2422r1780b2483],
10	setrobuvir	NN	O	setrobuvir	prep_with	4	SENT_264	[p16l1800t2399r2150b2462],
11	twice	RB	O	twice	advmod	13	SENT_264	[p16l8t2508r193b2565],
12	a	DT	DURATION	a	det	13	SENT_264	[p16l218t2525r253b2565],
13	day	NN	DURATION	day	tmod	3	SENT_264	[p16l277t2502r401b2586],
14	along	IN	O	along	_	0	SENT_264	[p16l423t2502r616b2586],
15	with	IN	O	with	_	0	SENT_264	[p16l636t2502r794b2565],
16	PEG+RBV	NN	O	peg+rbv	prep_along_with	20	SENT_264	[p16l819t2506r1198b2565],
17	for	IN	O	for	_	0	SENT_264	[p16l1222t2502r1322b2565],
18	12	CD	DURATION	12	num	19	SENT_264	[p16l1352t2509r1425b2564],
19	weeks	NNS	NUMBER	week	prep_for	16	SENT_264	[p16l1449t2502r1659b2565],
20	followed	VBN	O	follow	conj_or	20	SENT_264	[p16l1684t2502r1987b2565],
21	by	IN	O	by	_	0	SENT_264	[p16l2008t2502r2094b2586],
22	a	DT	O	a	det	24	SENT_264	[p16l2115t2525r2151b2565],
23	response-guided	JJ	O	response-guided	amod	24	SENT_264	[p16l9t2605r595b2689],
24	therapy	NN	O	therapy	prep_by	20	SENT_264	[p16l617t2605r886b2689],
25	with	IN	O	with	_	0	SENT_264	[p16l904t2605r1061b2668],
26	PEG+RBV	NN	O	peg+rbv	prep_with	24	SENT_264	[p16l1086t2609r1470b2677],
27	,	,	O	,	_	0	SENT_264	[p16l1086t2609r1470b2677],
28	or	CC	O	or	_	0	SENT_264	[p16l1496t2628r1569b2668],
29	with	IN	O	with	_	0	SENT_264	[p16l1590t2605r1747b2668],
30	PEG+RBV	NN	O	peg+rbv	prep_with	20	SENT_264	[p16l1771t2609r2149b2668],
31	alone	RB	O	alone	dep	20	SENT_264	[p16l9t2708r210b2771],
32	.	.	O	.	_	0	SENT_264	[p16l9t2708r210b2771],

1	The	DT	O	the	det	3	SENT_265	[p16l236t2708r363b2771],
2	triple	JJ	O	triple	amod	3	SENT_265	[p16l385t2708r569b2791],
3	therapy	NN	O	therapy	nsubj	4	SENT_265	[p16l591t2708r856b2792],
4	had	VBD	O	have	_	0	SENT_265	[p16l875t2708r1004b2771],
5	a	DT	O	a	det	7	SENT_265	[p16l1026t2731r1061b2771],
6	better	JJR	O	better	amod	7	SENT_265	[p16l1081t2708r1285b2771],
7	RVR	NN	O	rvr	dobj	4	SENT_265	[p16l1307t2713r1471b2771],
8	and	CC	O	and	_	0	SENT_265	[p16l1492t2708r1620b2771],
9	eRVR	NN	O	ervr	dobj	4	SENT_265	[p16l1642t2713r1843b2771],
10	than	IN	O	than	_	0	SENT_265	[p16l1863t2708r2018b2771],
11	the	DT	O	the	det	13	SENT_265	[p16l2040t2708r2148b2771],
12	PEG+RBV	NN	O	peg+rbv	nn	13	SENT_265	[p16l9t2815r384b2874],
13	therapy	NN	O	therapy	prep_than	9	SENT_265	[p16l405t2811r672b2895],
14	alone	RB	O	alone	advmod	4	SENT_265	[p16l692t2811r896b2883],
15	;	:	O	;	_	0	SENT_265	[p16l692t2811r896b2883],
16	however	RB	O	however	advmod	19	SENT_265	[p16l920t2811r1228b2883],
17	,	,	O	,	_	0	SENT_265	[p16l920t2811r1228b2883],
18	there	EX	O	there	expl	19	SENT_265	[p16l1252t2811r1429b2874],
19	was	VBD	O	be	parataxis	4	SENT_265	[p16l1450t2834r1578b2874],
20	no	DT	O	no	det	21	SENT_265	[p16l1602t2834r1689b2874],
21	difference	NN	O	difference	nsubj	19	SENT_265	[p16l1715t2811r2056b2874],
22	in	IN	O	in	_	0	SENT_265	[p16l2080t2817r2148b2873],
23	SVR	NNP	O	SVR	prep_in	21	SENT_265	[p16l10t2918r163b2977],
24	due	JJ	O	due	_	0	SENT_265	[p16l182t2914r304b2977],
25	to	TO	O	to	_	0	SENT_265	[p16l324t2926r390b2977],
26	high	JJ	O	high	amod	27	SENT_265	[p16l411t2914r565b2998],
27	rates	NNS	O	rate	prep_due_to	19	SENT_265	[p16l585t2926r744b2977],
28	of	IN	O	of	_	0	SENT_265	[p16l765t2914r839b2977],
29	relapse	NN	O	relapse	prep_of	27	SENT_265	[p16l851t2914r1103b2997],
30	.	.	O	.	_	0	SENT_265	[p16l851t2914r1103b2997],

1	A	DT	O	a	det	4	SENT_266	[p16l1126t2918r1183b2976],
2	currently	RB	DATE	currently	advmod	4	SENT_266	[p16l1204t2914r1521b2998],
3	ongoing	JJ	O	ongoing	amod	4	SENT_266	[p16l1538t2920r1818b2998],
4	phase	NN	O	phase	nsubj	8	SENT_266	[p16l1836t2914r2031b2997],
5	IIb	NN	O	iib	nn	6	SENT_266	[p16l2052t2914r2150b2977],
6	trial	NN	O	trial	dep	4	SENT_266	[p16l8t3017r155b3080],
7	is	VBZ	O	be	aux	8	SENT_266	[p16l179t3023r231b3080],
8	examining	VBG	O	examine	_	0	SENT_266	[p16l257t3023r635b3101],
9	200	CD	NUMBER	200	num	11	SENT_266	[p16l658t3024r781b3080],
10	mg	NN	O	mg	nn	11	SENT_266	[p16l798t3040r910b3101],
11	setrobuvir	NN	O	setrobuvir	dobj	8	SENT_266	[p16l935t3017r1299b3080],
12	twice	RB	O	twice	advmod	14	SENT_266	[p16l1322t3023r1509b3080],
13	a	DT	DURATION	a	det	14	SENT_266	[p16l1535t3040r1570b3080],
14	day	NN	DURATION	day	tmod	8	SENT_266	[p16l1595t3017r1720b3101],
15	in	IN	O	in	_	0	SENT_266	[p16l1742t3023r1810b3079],
16	conjunction	NN	O	conjunction	prep_in	8	SENT_266	[p16l1836t3023r2147b3101, p16l8t3125r145b3182],
17	with	IN	O	with	_	0	SENT_266	[p16l165t3119r318b3182],
18	PEG+RBV	NN	O	peg+rbv	prep_with	8	SENT_266	[p16l340t3123r709b3182],
19	for	IN	O	for	_	0	SENT_266	[p16l730t3119r827b3182],
20	24	CD	NUMBER	24	nn	23	SENT_266	[p16l847t3126r927b3181],
21	or	CC	O	or	_	0	SENT_266	[p16l948t3142r1020b3182],
22	48	CD	DURATION	48	nn	23	SENT_266	[p16l1040t3126r1118b3182],
23	weeks	NNS	NUMBER	week	prep_for	8	SENT_266	[p16l1139t3119r1344b3182],
24	in	IN	O	in	_	0	SENT_266	[p16l1365t3125r1432b3181],
25	treatment-naive	JJ	O	treatment-naive	amod	28	SENT_266	[p16l1452t3125r2001b3182],
26	and	CC	O	and	_	0	SENT_266	[p16l2024t3119r2150b3182],
27	treatment-experienced	JJ	O	treatment-experienced	conj_and	25	SENT_266	[p16l8t3222r795b3306],
28	patients	NNS	O	patient	prep_in	23	SENT_266	[p16l814t3214r1167b3306],
29	.6	CD	NUMBER	.6	number	30	SENT_266	[p16l814t3214r1167b3306],
30	°	CD	NUMBER	°	num	28	SENT_266	[p16l814t3214r1167b3306],

1	TEGOBUVIR	NN	O	tegobuvir	_	0	SENT_267	[p16l8t3438r435b3494],

1	Tegobuvir	JJ	O	tegobuvir	amod	6	SENT_268	[p17l8t27r379b111],
2	(	NN	O	(	nn	6	SENT_268	[p17l409t28r781b103],
3	GS-9190	NN	O	gs-9190	nn	6	SENT_268	[p17l409t28r781b103],
4	)	CD	NUMBER	)	num	6	SENT_268	[p17l409t28r781b103],
5	targets	NNS	O	target	nn	6	SENT_268	[p17l812t39r1056b111],
6	palm	NN	O	palm	_	0	SENT_268	[p17l1083t27r1268b110],
7	domain	NN	O	domain	dep	6	SENT_268	[p17l1297t27r1575b90],
8	2	CD	NUMBER	2	num	7	SENT_268	[p17l1603t34r1639b89],
9	and	CC	O	and	_	0	SENT_268	[p17l1670t27r1803b90],
10	has	VBZ	O	have	aux	12	SENT_268	[p17l1829t27r1947b90],
11	been	VBN	O	be	auxpass	12	SENT_268	[p17l1974t27r2148b90],
12	shown	VBN	O	show	dep	6	SENT_268	[p17l10t129r243b193],
13	to	TO	O	to	aux	14	SENT_268	[p17l269t141r337b193],
14	decrease	VB	O	decrease	xcomp	12	SENT_268	[p17l366t129r674b193],
15	HCV	NN	O	hcv	nn	16	SENT_268	[p17l701t133r888b193],
16	RNA	NN	O	rna	dobj	14	SENT_268	[p17l914t133r1092b193],
17	by	IN	O	by	_	0	SENT_268	[p17l1116t130r1203b214],
18	1.7	CD	NUMBER	1.7	num	19	SENT_268	[p17l1233t121r1621b214],
19	log10	NN	O	log10	prep_by	14	SENT_268	[p17l1233t121r1621b214],
20	.18	CD	NUMBER	.18	dep	6	SENT_268	[p17l1233t121r1621b214],
21	It	PRP	O	it	nsubj	23	SENT_268	[p17l1648t135r1700b193],
22	was	VBD	O	be	aux	23	SENT_268	[p17l1723t152r1856b193],
23	studied	VBN	O	study	rcmod	20	SENT_268	[p17l1884t129r2150b193],
24	in	IN	O	in	_	0	SENT_268	[p17l9t239r79b295],
25	a	DT	O	a	det	26	SENT_268	[p17l108t256r143b296],
26	phase	NN	O	phase	prep_in	23	SENT_268	[p17l168t233r376b316],
27	II	CD	NUMBER	ii	num	26	SENT_268	[p17l405t238r483b305],
28	,	,	O	,	_	0	SENT_268	[p17l405t238r483b305],
29	randomized	VBN	O	randomize	dep	23	SENT_268	[p17l513t233r975b305],
30	,	,	O	,	_	0	SENT_268	[p17l513t233r975b305],
31	open-label	JJ	O	open-label	amod	32	SENT_268	[p17l1005t233r1395b316],
32	trial	NN	O	trial	dobj	23	SENT_268	[p17l1421t233r1573b296],
33	as	IN	O	as	_	0	SENT_268	[p17l1601t256r1669b296],
34	part	NN	O	part	prep_as	32	SENT_268	[p17l1696t245r1846b316],
35	of	IN	O	of	_	0	SENT_268	[p17l1874t233r1951b296],
36	therapy	NN	O	therapy	prep_of	34	SENT_268	[p17l1969t233r2146b296, p17l9t358r136b420],
37	With	IN	O	with	_	0	SENT_268	[p17l160t336r324b399],
38	GS	NN	O	g	prep_with	36	SENT_268	[p17l355t340r670b399],
39	—	CD	NUMBER	—	num	38	SENT_268	[p17l355t340r670b399],
40	9256	CD	NUMBER	9256	number	41	SENT_268	[p17l355t340r670b399],
41	(	CD	NUMBER	(	num	43	SENT_268	[p17l705t337r1022b413],
42	DUAL	JJ	O	dual	amod	43	SENT_268	[p17l705t337r1022b413],
43	)	NN	O	)	dep	38	SENT_268	[p17l705t337r1022b413],
44	,	,	O	,	_	0	SENT_268	[p17l705t337r1022b413],
45	GS-9256	NN	O	gs-9256	prep_with	36	SENT_268	[p17l1055t340r1370b399],
46	and	CC	O	and	_	0	SENT_268	[p17l1402t336r1536b399],
47	RBV	NN	O	rbv	conj_or	38	SENT_268	[p17l1565t341r1734b399],
48	(	CD	NUMBER	(	num	49	SENT_268	[p17l1767t337r2145b413],
49	TRIPLE	NN	O	triple	dep	45	SENT_268	[p17l1767t337r2145b413],
50	)	CD	NUMBER	)	dep	45	SENT_268	[p17l1767t337r2145b413],
51	,	,	O	,	_	0	SENT_268	[p17l1767t337r2145b413],
52	or	CC	O	or	_	0	SENT_268	[p17l9t462r85b502],
53	GS-9256	NN	MISC	gs-9256	prep_with	36	SENT_268	[p17l116t443r432b502],
54	plus	CC	O	plus	prep	53	SENT_268	[p17l463t439r614b522],
55	PEG+RBV	NN	O	peg+rbv	nn	58	SENT_268	[p17l646t443r1039b502],
56	(	CD	NUMBER	(	num	58	SENT_268	[p17l1072t439r1384b516],
57	QUAD	NN	O	quad	nn	58	SENT_268	[p17l1072t439r1384b516],
58	)	NN	O	)	dep	54	SENT_268	[p17l1072t439r1384b516],
59	in	IN	O	in	_	0	SENT_268	[p17l1419t445r1490b501],
60	HCV	NNP	O	HCV	nn	61	SENT_268	[p17l1521t443r1710b502],
61	genotype	NN	O	genotype	prep_in	58	SENT_268	[p17l1741t451r2078b523],
62	1	CD	NUMBER	1	num	63	SENT_268	[p17l2116t446r2141b501],
63	patients	NNS	O	patient	dep	53	SENT_268	[p17l7t548r307b625],
64	.	.	O	.	_	0	SENT_268	[p17l7t548r307b625],

1	The	DT	O	the	det	4	SENT_269	[p17l336t542r463b605],
2	primary	JJ	O	primary	amod	4	SENT_269	[p17l488t548r781b626],
3	end	NN	O	end	nn	4	SENT_269	[p17l804t542r934b605],
4	point	NN	O	point	nsubj	6	SENT_269	[p17l957t548r1147b625],
5	was	VBD	O	be	cop	6	SENT_269	[p17l1170t565r1299b605],
6	RVR	NNP	MISC	RVR	_	0	SENT_269	[p17l1326t547r1510b614],
7	,	,	O	,	_	0	SENT_269	[p17l1326t547r1510b614],
8	after	IN	O	after	_	0	SENT_269	[p17l1538t542r1696b605],
9	which	WDT	O	which	det	10	SENT_269	[p17l1719t542r1935b605],
10	point	NN	O	point	rel	14	SENT_269	[p17l1959t548r2149b625],
11	all	DT	O	all	det	12	SENT_269	[p17l9t645r92b708],
12	patients	NNS	O	patient	nsubjpass	14	SENT_269	[p17l116t651r398b728],
13	were	VBD	O	be	auxpass	14	SENT_269	[p17l423t668r590b708],
14	treated	VBN	O	treat	rcmod	6	SENT_269	[p17l615t645r865b708],
15	with	IN	O	with	_	0	SENT_269	[p17l888t645r1047b708],
16	PEG+RBV	NN	O	peg+rbv	prep_with	14	SENT_269	[p17l1074t649r1461b708],
17	.	.	O	.	_	0	SENT_269	[p17l1074t649r1461b708],

1	RVR	NN	O	rvr	nsubjpass	3	SENT_270	[p17l1491t650r1658b708],
2	was	VBD	O	be	auxpass	3	SENT_270	[p17l1679t668r1809b708],
3	achieved	VBN	O	achieve	_	0	SENT_270	[p17l1837t645r2150b708],
4	in	IN	O	in	_	0	SENT_270	[p17l9t754r77b810],
5	7	CD	PERCENT	7	num	6	SENT_270	[p17l101t753r202b813],
6	%	NN	PERCENT	%	prep_in	3	SENT_270	[p17l101t753r202b813],
7	of	IN	O	of	_	0	SENT_270	[p17l228t748r303b811],
8	patients	NNS	O	patient	prep_of	6	SENT_270	[p17l316t754r594b831],
9	on	IN	O	on	_	0	SENT_270	[p17l619t771r706b811],
10	DUAL	JJ	O	dual	amod	11	SENT_270	[p17l729t752r956b811],
11	therapy	NN	O	therapy	prep_on	8	SENT_270	[p17l977t748r1257b832],
12	,	,	O	,	_	0	SENT_270	[p17l977t748r1257b832],
13	38	CD	PERCENT	38	num	14	SENT_270	[p17l1283t754r1427b813],
14	%	NN	PERCENT	%	prep_of	6	SENT_270	[p17l1283t754r1427b813],
15	on	IN	O	on	_	0	SENT_270	[p17l1453t771r1540b811],
16	TRIPLE	NN	O	triple	nn	17	SENT_270	[p17l1563t751r1847b811],
17	therapy	NN	O	therapy	prep_on	14	SENT_270	[p17l1869t748r2149b832],
18	,	,	O	,	_	0	SENT_270	[p17l1869t748r2149b832],
19	and	CC	O	and	_	0	SENT_270	[p17l9t850r139b914],
20	100	CD	PERCENT	100	num	21	SENT_270	[p17l171t856r354b915],
21	%	NN	PERCENT	%	prep_of	6	SENT_270	[p17l171t856r354b915],
22	on	IN	O	on	_	0	SENT_270	[p17l382t873r471b914],
23	QUAD	NN	O	quad	nn	24	SENT_270	[p17l498t854r741b927],
24	therapy	NN	O	therapy	prep_on	21	SENT_270	[p17l767t842r1113b935],
25	.	.	O	.	_	0	SENT_270	[p17l767t842r1113b935],

1	“	NN	O	“	dep	26	SENT_271	[p17l767t842r1113b935],
2	In	IN	O	in	dep	1	SENT_271	[p17l1144t856r1216b913],
3	a	DT	O	a	det	4	SENT_271	[p17l1243t873r1277b914],
4	trial	NN	O	trial	pobj	2	SENT_271	[p17l1301t850r1449b914],
5	of	IN	O	of	_	0	SENT_271	[p17l1475t850r1551b914],
6	QUAD	NNP	O	QUAD	nn	7	SENT_271	[p17l1568t854r1811b927],
7	IFN	NN	O	ifn	prep_of	4	SENT_271	[p17l1839t850r2149b914],
8	—	CD	NUMBER	—	num	10	SENT_271	[p17l1839t850r2149b914],
9	free	JJ	O	free	amod	10	SENT_271	[p17l1839t850r2149b914],
10	therapy	NN	O	therapy	dep	7	SENT_271	[p17l8t954r299b1038],
11	,	,	O	,	_	0	SENT_271	[p17l8t954r299b1038],
12	tegobuvir	NN	O	tegobuvir	nsubjpass	14	SENT_271	[p17l328t954r680b1038],
13	was	VBD	O	be	auxpass	14	SENT_271	[p17l706t977r838b1017],
14	combined	VBN	O	combine	parataxis	26	SENT_271	[p17l868t954r1233b1017],
15	with	IN	O	with	_	0	SENT_271	[p17l1257t954r1420b1017],
16	GS	NN	O	g	prep_with	14	SENT_271	[p17l1450t958r1761b1017],
17	—	CD	NUMBER	—	num	16	SENT_271	[p17l1450t958r1761b1017],
18	5885	CD	NUMBER	5885	number	19	SENT_271	[p17l1450t958r1761b1017],
19	(	CD	NUMBER	(	dep	16	SENT_271	[p17l1795t954r1909b1031],
20	an	DT	O	a	det	23	SENT_271	[p17l1795t954r1909b1031],
21	NS5A	NN	O	ns5a	nn	23	SENT_271	[p17l1936t958r2151b1017],
22	inhibitor	NN	O	inhibitor	nn	23	SENT_271	[p17l9t1057r370b1133],
23	)	NN	O	)	dep	19	SENT_271	[p17l9t1057r370b1133],
24	,	,	O	,	_	0	SENT_271	[p17l9t1057r370b1133],
25	GS-9451	NN	O	gs-9451	nsubj	26	SENT_271	[p17l396t1061r691b1120],
26	(	VBD	O	(	_	0	SENT_271	[p17l723t1058r786b1133],
27	a	DT	O	a	det	29	SENT_271	[p17l723t1058r786b1133],
28	PI	NN	O	pi	nn	29	SENT_271	[p17l808t1058r933b1134],
29	)	NN	O	)	dobj	26	SENT_271	[p17l808t1058r933b1134],
30	,	,	O	,	_	0	SENT_271	[p17l808t1058r933b1134],
31	and	CC	O	and	_	0	SENT_271	[p17l958t1057r1086b1120],
32	RBV	NN	O	rbv	dobj	26	SENT_271	[p17l1109t1062r1275b1120],
33	.	.	O	.	_	0	SENT_271	[p17l1109t1062r1275b1120],

1	Interim	JJ	O	interim	amod	2	SENT_272	[p17l1302t1062r1567b1120],
2	analysis	NN	O	analysis	nsubj	3	SENT_272	[p17l1591t1057r1863b1141],
3	showed	VBD	O	show	_	0	SENT_272	[p17l1888t1057r2151b1120],
4	that	IN	O	that	complm	9	SENT_272	[p17l8t1160r148b1223],
5	the	DT	O	the	det	6	SENT_272	[p17l171t1160r282b1223],
6	regimen	NN	O	regimen	nsubjpass	9	SENT_272	[p17l308t1166r603b1244],
7	was	VBD	O	be	auxpass	9	SENT_272	[p17l627t1183r757b1223],
8	well	RB	O	well	advmod	9	SENT_272	[p17l782t1160r926b1223],
9	tolerated	VBN	O	tolerate	ccomp	3	SENT_272	[p17l950t1160r1269b1223],
10	and	CC	O	and	_	0	SENT_272	[p17l1295t1160r1425b1223],
11	that	IN	O	that	complm	16	SENT_272	[p17l1449t1160r1589b1223],
12	the	DT	O	the	det	13	SENT_272	[p17l1613t1160r1723b1223],
13	SVR12	NN	O	svr12	nsubj	16	SENT_272	[p17l1750t1164r1991b1223],
14	was	VBD	O	be	cop	16	SENT_272	[p17l2017t1183r2147b1223],
15	81	CD	PERCENT	81	num	16	SENT_272	[p17l10t1269r158b1328],
16	%	NN	PERCENT	%	ccomp	3	SENT_272	[p17l10t1269r158b1328],
17	in	IN	O	in	_	0	SENT_272	[p17l189t1269r258b1325],
18	noncirrhotic	JJ	O	noncirrhotic	amod	19	SENT_272	[p17l287t1263r751b1326],
19	genotype	NN	O	genotype	prep_in	16	SENT_272	[p17l779t1275r1112b1347],
20	1	CD	NUMBER	1	num	21	SENT_272	[p17l1147t1270r1172b1325],
21	patients	NNS	O	patient	dep	19	SENT_272	[p17l1205t1269r1515b1346],
22	.	.	O	.	_	0	SENT_272	[p17l1205t1269r1515b1346],

1	Virologic	JJ	O	virologic	amod	2	SENT_273	[p17l1544t1263r1887b1347],
2	breakthroughs	NNS	O	breakthrough	nsubj	6	SENT_273	[p17l1912t1263r2145b1326, p17l8t1366r330b1450],
3	and	CC	O	and	_	0	SENT_273	[p17l357t1366r488b1429],
4	relapses	NNS	O	relapse	conj_and	2	SENT_273	[p17l513t1366r794b1449],
5	were	VBD	O	be	cop	6	SENT_273	[p17l819t1389r986b1429],
6	lower	JJR	O	lower	_	0	SENT_273	[p17l1011t1366r1210b1429],
7	in	IN	O	in	_	0	SENT_273	[p17l1235t1372r1303b1428],
8	patients	NNS	O	patient	prep_in	6	SENT_273	[p17l1328t1372r1611b1449],
9	with	IN	O	with	_	0	SENT_273	[p17l1636t1366r1795b1429],
10	genotype	NN	O	genotype	nn	11	SENT_273	[p17l1821t1378r2147b1450],
11	1b	NN	O	1b	prep_with	8	SENT_273	[p17l15t1469r89b1532],
12	as	IN	O	as	_	0	SENT_273	[p17l114t1492r179b1532],
13	opposed	VBN	O	oppose	prep_as	6	SENT_273	[p17l203t1469r497b1552],
14	to	TO	O	to	_	0	SENT_273	[p17l518t1481r584b1532],
15	those	DT	O	those	prep_to	13	SENT_273	[p17l607t1469r793b1532],
16	with	IN	O	with	_	0	SENT_273	[p17l814t1469r969b1532],
17	genotype	NN	O	genotype	nn	18	SENT_273	[p17l992t1481r1309b1553],
18	1a	NN	O	1a	prep_with	15	SENT_273	[p17l1338t1476r1427b1541],
19	,	,	O	,	_	0	SENT_273	[p17l1338t1476r1427b1541],
20	as	RB	O	as	_	0	SENT_273	[p17l1452t1492r1517b1532],
21	well	RB	O	well	_	0	SENT_273	[p17l1538t1469r1679b1532],
22	as	IN	O	as	_	0	SENT_273	[p17l1701t1492r1766b1532],
23	those	DT	O	those	prep_to	13	SENT_273	[p17l1788t1469r1974b1532],
24	with	IN	O	with	_	0	SENT_273	[p17l1995t1469r2150b1532],
25	IL28B	NN	O	il28b	nn	27	SENT_273	[p17l7t1577r217b1635],
26	CC	NN	O	cc	nn	27	SENT_273	[p17l245t1575r354b1635],
27	genotype	NN	O	genotype	prep_with	23	SENT_273	[p17l374t1563r781b1656],
28	.62	CD	NUMBER	.62	dep	23	SENT_273	[p17l374t1563r781b1656],

1	IFN-FREE	NN	O	ifn-free	nn	2	SENT_274	[p17l12t1788r332b1842],
2	REGIMENS	NNS	O	regimen	nsubj	8	SENT_274	[p17l354t1788r728b1843],
3	Many	JJ	O	many	amod	4	SENT_274	[p17l8t1888r211b1967],
4	patients	NNS	O	patient	dep	2	SENT_274	[p17l230t1889r508b1966],
5	are	VBP	O	be	cop	6	SENT_274	[p17l533t1906r636b1946],
6	ineligible	JJ	O	ineligible	_	0	SENT_274	[p17l660t1883r984b1967],
7	or	CC	O	or	_	0	SENT_274	[p17l1009t1906r1082b1946],
8	intolerant	JJ	O	intolerant	conj_or	6	SENT_274	[p17l1105t1883r1451b1946],
9	to	TO	O	to	_	0	SENT_274	[p17l1472t1895r1540b1946],
10	PEG-based	JJ	O	peg-based	amod	11	SENT_274	[p17l1566t1883r1961b1946],
11	regimens	NNS	O	regimen	prep_to	6	SENT_274	[p17l1984t1889r2144b1967, p17l8t2009r192b2049],
12	due	JJ	O	due	_	0	SENT_274	[p17l217t1986r341b2049],
13	to	TO	O	to	_	0	SENT_274	[p17l363t1998r430b2049],
14	possible	JJ	O	possible	amod	15	SENT_274	[p17l453t1986r732b2069],
15	decompensation	NN	O	decompensation	prep_due_to	11	SENT_274	[p17l757t1986r1331b2069],
16	of	IN	O	of	_	0	SENT_274	[p17l1355t1986r1430b2049],
17	cirrhosis	NN	O	cirrhosis	prep_of	11	SENT_274	[p17l1444t1986r1763b2058],
18	,	,	O	,	_	0	SENT_274	[p17l1444t1986r1763b2058],
19	worsening	VBG	O	worsen	appos	11	SENT_274	[p17l1786t1992r2151b2070],
20	of	IN	O	of	_	0	SENT_274	[p17l9t2089r82b2152],
21	cytopenias	NNS	O	cytopenia	prep_of	19	SENT_274	[p17l93t2095r473b2173],
22	,	,	O	,	_	0	SENT_274	[p17l93t2095r473b2173],
23	exacerbation	NN	O	exacerbation	appos	21	SENT_274	[p17l496t2089r929b2152],
24	of	IN	O	of	_	0	SENT_274	[p17l949t2089r1023b2152],
25	underlying	VBG	O	underlie	amod	27	SENT_274	[p17l1033t2089r1406b2173],
26	psychiatric	JJ	O	psychiatric	amod	27	SENT_274	[p17l1424t2089r1794b2173],
27	disorders	NNS	O	disorder	prep_of	23	SENT_274	[p17l1815t2089r2146b2161],
28	,	,	O	,	_	0	SENT_274	[p17l1815t2089r2146b2161],

1	84	CD	NUMBER	84	_	0	SENT_275	[p17l8t2309r73b2351],
2	or	CC	O	or	_	0	SENT_275	[p17l10t2413r84b2453],
3	previous	JJ	O	previous	amod	4	SENT_275	[p17l108t2396r415b2473],
4	intolerance	NN	O	intolerance	conj_or	1	SENT_275	[p17l442t2390r842b2453],
5	to	TO	O	to	_	0	SENT_275	[p17l868t2402r936b2453],
6	the	DT	O	the	det	7	SENT_275	[p17l964t2390r1074b2453],
7	medication	NN	O	medication	prep_to	1	SENT_275	[p17l1101t2390r1522b2453],
8	.	.	O	.	_	0	SENT_275	[p17l1101t2390r1522b2453],

1	The	DT	O	the	det	2	SENT_276	[p17l1552t2390r1680b2453],
2	discovery	NN	O	discovery	nsubj	6	SENT_276	[p17l1708t2390r2053b2474],
3	of	IN	O	of	_	0	SENT_276	[p17l2076t2390r2152b2453],
4	DAAs	NNP	O	DAAs	prep_of	2	SENT_276	[p17l10t2497r221b2556],
5	has	VBZ	O	have	aux	6	SENT_276	[p17l246t2493r362b2556],
6	enabled	VBN	O	enable	_	0	SENT_276	[p17l389t2493r664b2556],
7	research	NN	O	research	dobj	6	SENT_276	[p17l689t2493r984b2556],
8	and	CC	O	and	_	0	SENT_276	[p17l1010t2493r1140b2556],
9	development	NN	O	development	dobj	6	SENT_276	[p17l1165t2493r1625b2576],
10	of	IN	O	of	_	0	SENT_276	[p17l1650t2493r1726b2556],
11	HCV	NN	O	hcv	nn	13	SENT_276	[p17l1742t2497r1927b2556],
12	treatment	NN	O	treatment	nn	13	SENT_276	[p17l1951t2505r2141b2556, p17l9t2608r188b2659],
13	regimens	NNS	O	regimen	prep_of	7	SENT_276	[p17l209t2602r525b2680],
14	that	WDT	O	that	nsubj	17	SENT_276	[p17l548t2596r683b2659],
15	do	VBP	O	do	aux	17	SENT_276	[p17l706t2596r790b2659],
16	not	RB	O	not	neg	17	SENT_276	[p17l814t2608r929b2659],
17	use	VB	O	use	rcmod	7	SENT_276	[p17l951t2619r1063b2659],
18	PEG	NN	O	peg	nn	20	SENT_276	[p17l1087t2600r1243b2659],
19	(	CD	NUMBER	(	num	20	SENT_276	[p17l1269t2597r1490b2672],
20	Table	NNP	O	Table	dobj	17	SENT_276	[p17l1269t2597r1490b2672],
21	2	CD	NUMBER	2	num	22	SENT_276	[p17l1512t2596r1597b2673],
22	)	CD	NUMBER	)	dep	20	SENT_276	[p17l1512t2596r1597b2673],
23	.	.	O	.	_	0	SENT_276	[p17l1512t2596r1597b2673],

1	One	CD	NUMBER	one	nsubj	19	SENT_277	[p17l1625t2600r1769b2659],
2	of	IN	O	of	_	0	SENT_277	[p17l1793t2596r1867b2659],
3	the	DT	O	the	det	5	SENT_277	[p17l1879t2596r1987b2659],
4	ﬁrst	NN	O	ﬁrst	nn	5	SENT_277	[p17l2010t2596r2144b2659],
5	trials	NNS	O	trial	prep_of	1	SENT_277	[p17l8t2699r181b2762],
6	to	TO	O	to	aux	7	SENT_277	[p17l204t2711r271b2762],
7	investigate	VB	O	investigate	infmod	1	SENT_277	[p17l295t2705r661b2783],
8	the	DT	O	the	det	9	SENT_277	[p17l683t2699r791b2762],
9	possibility	NN	O	possibility	dobj	7	SENT_277	[p17l813t2699r1171b2783],
10	of	IN	O	of	_	0	SENT_277	[p17l1191t2699r1266b2762],
11	an	DT	O	a	det	15	SENT_277	[p17l1280t2722r1360b2762],
12	IFN	NN	MISC	ifn	npadvmod	14	SENT_277	[p17l1384t2699r1685b2762],
13	—	CD	NUMBER	—	num	12	SENT_277	[p17l1384t2699r1685b2762],
14	free	JJ	O	free	amod	15	SENT_277	[p17l1384t2699r1685b2762],
15	regimen	NN	O	regimen	prep_of	9	SENT_277	[p17l1708t2705r1993b2783],
16	was	VBD	O	be	cop	19	SENT_277	[p17l2015t2722r2142b2762],
17	the	DT	O	the	det	19	SENT_277	[p17l8t2802r117b2865],
18	INFORM-1	NN	MISC	inform-1	nn	19	SENT_277	[p17l141t2806r545b2865],
19	trial	NN	O	trial	_	0	SENT_277	[p17l574t2802r734b2865],
20	.	.	O	.	_	0	SENT_277	[p17l574t2802r734b2865],

1	Chronic	JJ	O	chronic	amod	3	SENT_278	[p17l762t2802r1048b2865],
2	HCV	NN	O	hcv	nn	3	SENT_278	[p17l1072t2806r1255b2865],
3	genotype	NN	O	genotype	nsubjpass	7	SENT_278	[p17l1278t2814r1597b2886],
4	1	CD	NUMBER	1	num	5	SENT_278	[p17l1627t2809r1652b2864],
5	patients	NNS	O	patient	dep	3	SENT_278	[p17l1681t2808r1956b2885],
6	were	VBD	O	be	auxpass	7	SENT_278	[p17l1979t2825r2143b2865],
7	treated	VBN	O	treat	_	0	SENT_278	[p17l8t2905r240b2968],
8	with	IN	O	with	_	0	SENT_278	[p17l257t2905r406b2968],
9	danoprevir	NN	O	danoprevir	prep_with	7	SENT_278	[p17l426t2905r794b2988],
10	and	CC	O	and	_	0	SENT_278	[p17l813t2905r937b2968],
11	mericitabine	NN	O	mericitabine	conj_and	9	SENT_278	[p17l955t2905r1375b2968],
12	at	IN	O	at	_	0	SENT_278	[p17l1396t2917r1454b2968],
13	varying	VBG	O	vary	amod	14	SENT_278	[p17l1469t2911r1725b2989],
14	doses	NNS	O	dose	prep_at	7	SENT_278	[p17l1744t2905r1924b2968],
15	for	IN	O	for	_	0	SENT_278	[p17l1944t2905r2039b2968],
16	up	RB	DURATION	up	quantmod	18	SENT_278	[p17l2058t2927r2141b2988],
17	to	TO	DURATION	to	dep	18	SENT_278	[p17l8t3020r73b3071],
18	13	CD	DURATION	13	num	19	SENT_278	[p17l101t3015r169b3071],
19	days	NNS	NUMBER	day	prep_for	14	SENT_278	[p17l192t3008r357b3092],
20	,	,	O	,	_	0	SENT_278	[p17l192t3008r357b3092],
21	followed	VBN	O	follow	_	0	SENT_278	[p17l378t3008r667b3071],
22	by	IN	O	by	prepc_followed_by	7	SENT_278	[p17l684t3008r766b3092],
23	a	DT	O	a	det	25	SENT_278	[p17l783t3031r817b3071],
24	48-week	JJ	DURATION	48-week	amod	25	SENT_278	[p17l835t3008r1119b3071],
25	regimen	NN	O	regimen	pobj	7	SENT_278	[p17l1136t3014r1413b3092],
26	of	IN	O	of	_	0	SENT_278	[p17l1434t3008r1506b3071],
27	PEG	NN	O	peg	prep_of	25	SENT_278	[p17l1517t3012r1669b3071],
28	and	CC	O	and	_	0	SENT_278	[p17l1690t3008r1814b3071],
29	RBV	NN	O	rbv	conj_and	27	SENT_278	[p17l1834t3013r1994b3071],
30	.	.	O	.	_	0	SENT_278	[p17l1834t3013r1994b3071],

1	The	DT	O	the	det	3	SENT_279	[p17l2017t3008r2140b3071],
2	median	JJ	O	median	amod	3	SENT_279	[p17l9t3111r265b3174],
3	change	NN	O	change	nsubj	7	SENT_279	[p17l287t3111r523b3195],
4	in	IN	O	in	_	0	SENT_279	[p17l544t3117r610b3173],
5	HCV	NN	O	hcv	nn	6	SENT_279	[p17l631t3115r810b3174],
6	RNA	NN	O	rna	prep_in	3	SENT_279	[p17l830t3115r999b3174],
7	ranged	VBD	O	range	_	0	SENT_279	[p17l1020t3111r1254b3195],
8	from	IN	O	from	_	0	SENT_279	[p17l1273t3111r1440b3174],
9	3.7	CD	NUMBER	3.7	num	10	SENT_279	[p17l1462t3111r1746b3195],
10	log1O	NN	O	log1o	prep_from	7	SENT_279	[p17l1462t3111r1746b3195],
11	to	TO	O	to	_	0	SENT_279	[p17l1767t3123r1832b3174],
12	5.2	CD	NUMBER	5.2	num	14	SENT_279	[p17l1856t3111r2140b3195],
13	log10	CD	NUMBER	log10	num	14	SENT_279	[p17l1856t3111r2140b3195],
14	IU	NN	O	iu	prep_to	7	SENT_279	[p17l10t3218r125b3280],
15	/	:	O	/	punct	16	SENT_279	[p17l10t3218r125b3280],
16	ml	NN	O	ml	dep	14	SENT_279	[p17l130t3214r236b3286],
17	,	,	O	,	_	0	SENT_279	[p17l130t3214r236b3286],
18	and	CC	O	and	_	0	SENT_279	[p17l259t3214r385b3277],
19	the	DT	O	the	det	20	SENT_279	[p17l403t3214r509b3277],
20	regimen	NN	O	regimen	nsubjpass	23	SENT_279	[p17l530t3220r811b3298],
21	was	VBD	O	be	auxpass	23	SENT_279	[p17l829t3237r955b3277],
22	well	RB	O	well	advmod	23	SENT_279	[p17l974t3214r1110b3277],
23	tolerated	VBN	O	tolerate	conj_and	7	SENT_279	[p17l1129t3214r1431b3277],
24	for	IN	O	for	_	0	SENT_279	[p17l1450t3214r1547b3277],
25	the	DT	O	the	det	27	SENT_279	[p17l1565t3214r1671b3277],
26	2-week	JJ	DURATION	2-week	amod	27	SENT_279	[p17l1692t3214r1937b3277],
27	duration	NN	O	duration	prep_for	23	SENT_279	[p17l1955t3214r2137b3277, p17l8t3323r145b3380],
28	of	IN	O	of	_	0	SENT_279	[p17l168t3316r241b3380],
29	the	DT	O	the	det	30	SENT_279	[p17l253t3316r359b3380],
30	trial	NN	O	trial	prep_of	27	SENT_279	[p17l379t3308r599b3380],
31	.63	CD	NUMBER	.63	num	30	SENT_279	[p17l379t3308r599b3380],

1	The	DT	O	the	det	3	SENT_280	[p18l83t27r205b90],
2	SOUND-C1	NN	O	sound-c1	nn	3	SENT_280	[p18l226t31r631b90],
3	trial	NN	O	trial	nsubj	4	SENT_280	[p18l656t27r793b90],
4	used	VBN	O	use	_	0	SENT_280	[p18l811t27r966b90],
5	faldaprevir	NN	O	faldaprevir	dobj	4	SENT_280	[p18l984t27r1348b110],
6	and	CC	O	and	_	0	SENT_280	[p18l1367t27r1491b90],
7	deleobuvir	NN	O	deleobuvir	conj_and	5	SENT_280	[p18l1510t27r1866b90],
8	in	IN	O	in	_	0	SENT_280	[p18l1884t33r1949b89],
9	combination	NN	O	combination	prep_in	4	SENT_280	[p18l1969t50r2139b90, p18l7t130r297b193],
10	with	IN	O	with	_	0	SENT_280	[p18l318t130r471b193],
11	RBV	NN	O	rbv	prep_with	9	SENT_280	[p18l495t135r655b193],
12	as	IN	O	as	_	0	SENT_280	[p18l678t153r742b193],
13	an	DT	O	a	det	17	SENT_280	[p18l767t153r847b193],
14	all	DT	O	all	quantmod	15	SENT_280	[p18l871t130r1117b193],
15	—	CD	NUMBER	—	num	17	SENT_280	[p18l871t130r1117b193],
16	oral	JJ	O	oral	amod	17	SENT_280	[p18l871t130r1117b193],
17	regimen	NNS	O	regimen	prep_as	4	SENT_280	[p18l1139t136r1423b214],
18	for	IN	O	for	_	0	SENT_280	[p18l1446t130r1544b193],
19	HCV	NNP	O	HCV	nn	23	SENT_280	[p18l1566t134r1746b193],
20	genotype	NN	O	genotype	nn	23	SENT_280	[p18l1768t142r2082b214],
21	1	CD	NUMBER	1	num	23	SENT_280	[p18l2112t137r2137b192],
22	treatment-naive	JJ	O	treatment-naive	amod	23	SENT_280	[p18l8t239r539b296],
23	patients	NNS	O	patient	prep_for	17	SENT_280	[p18l557t239r834b316],
24	.	.	O	.	_	0	SENT_280	[p18l557t239r834b316],

1	Thirty-two	CD	NUMBER	thirty-two	num	2	SENT_281	[p18l856t233r1215b317],
2	patients	NNS	O	patient	nsubjpass	4	SENT_281	[p18l1234t239r1495b316],
3	were	VBD	O	be	auxpass	4	SENT_281	[p18l1513t256r1669b296],
4	placed	VBN	O	place	_	0	SENT_281	[p18l1687t233r1903b316],
5	on	IN	O	on	_	0	SENT_281	[p18l1922t256r2006b296],
6	400	CD	NUMBER	400	num	10	SENT_281	[p18l2024t240r2141b296],
7	or	CC	O	or	_	0	SENT_281	[p18l10t359r81b399],
8	600	CD	NUMBER	600	num	10	SENT_281	[p18l100t342r217b399],
9	mg	NN	O	mg	nn	10	SENT_281	[p18l232t359r340b420],
10	deleobuvir	NN	O	deleobuvir	prep_on	4	SENT_281	[p18l358t336r718b399],
11	three	CD	NUMBER	three	num	12	SENT_281	[p18l736t336r908b399],
12	times	NNS	O	time	tmod	10	SENT_281	[p18l927t342r1110b399],
13	a	DT	DURATION	a	det	14	SENT_281	[p18l1132t359r1165b399],
14	day	NN	DURATION	day	tmod	4	SENT_281	[p18l1185t336r1304b420],
15	and	CC	O	and	_	0	SENT_281	[p18l1321t336r1446b399],
16	120	CD	NUMBER	120	num	18	SENT_281	[p18l1472t343r1583b399],
17	mg	NN	O	mg	nn	18	SENT_281	[p18l1597t359r1704b420],
18	faldaprevir	NN	O	faldaprevir	nsubj	36	SENT_281	[p18l1723t336r2090b419],
19	a	DT	DURATION	a	det	20	SENT_281	[p18l2110t359r2144b399],
20	day	NN	DURATION	day	dep	18	SENT_281	[p18l10t439r131b523],
21	along	IN	O	along	_	0	SENT_281	[p18l150t439r338b523],
22	with	IN	O	with	_	0	SENT_281	[p18l356t439r509b502],
23	weight-based	JJ	O	weight-based	amod	24	SENT_281	[p18l529t439r987b523],
24	RBV	NN	O	rbv	prep_along_with	18	SENT_281	[p18l1009t444r1168b502],
25	for	IN	O	for	_	0	SENT_281	[p18l1190t439r1287b502],
26	4	CD	DURATION	4	num	27	SENT_281	[p18l1307t446r1346b501],
27	weeks	NNS	NUMBER	week	prep_for	18	SENT_281	[p18l1366t439r1589b511],
28	,	,	O	,	_	0	SENT_281	[p18l1366t439r1589b511],
29	which	WDT	O	which	nsubjpass	32	SENT_281	[p18l1611t439r1820b502],
30	was	VBD	O	be	auxpass	32	SENT_281	[p18l1841t462r1967b502],
31	then	RB	O	then	advmod	32	SENT_281	[p18l1989t439r2143b502],
32	followed	VBN	O	follow	rcmod	18	SENT_281	[p18l9t542r312b605],
33	by	IN	O	by	_	0	SENT_281	[p18l333t542r420b626],
34	response	NN	O	response	agent	32	SENT_281	[p18l440t564r778b625],
35	-	:	O	-	_	0	SENT_281	[p18l440t564r778b625],
36	guided	VBN	O	guide	conj_and	4	SENT_281	[p18l786t542r1028b626],
37	faldaprevir	NN	O	faldaprevir	dobj	36	SENT_281	[p18l1052t542r1438b625],
38	with	IN	O	with	_	0	SENT_281	[p18l1459t542r1616b605],
39	PEG+RBV	NN	O	peg+rbv	prep_with	36	SENT_281	[p18l1642t546r2020b605],
40	for	IN	O	for	_	0	SENT_281	[p18l2044t542r2144b605],
41	24	CD	NUMBER	24	num	44	SENT_281	[p18l10t651r90b707],
42	or	CC	O	or	_	0	SENT_281	[p18l114t667r186b708],
43	48	CD	DURATION	48	conj_or	41	SENT_281	[p18l208t651r287b708],
44	weeks	NNS	NUMBER	week	prep_for	36	SENT_281	[p18l310t644r536b708],
45	.	.	O	.	_	0	SENT_281	[p18l310t644r536b708],

1	At	IN	O	at	_	0	SENT_282	[p18l561t648r643b708],
2	week	NN	DURATION	week	prep_at	7	SENT_282	[p18l663t644r843b708],
3	4	CD	NUMBER	4	num	2	SENT_282	[p18l862t651r919b716],
4	,	,	O	,	_	0	SENT_282	[p18l862t651r919b716],
5	RVR	NNP	O	RVR	nsubjpass	7	SENT_282	[p18l945t649r1109b708],
6	was	VBD	O	be	auxpass	7	SENT_282	[p18l1128t667r1256b708],
7	achieved	VBN	O	achieve	_	0	SENT_282	[p18l1281t644r1585b708],
8	in	IN	O	in	_	0	SENT_282	[p18l1608t650r1675b707],
9	73	CD	NUMBER	73	prep_in	7	SENT_282	[p18l1700t651r1776b708],
10	and	CC	O	and	_	0	SENT_282	[p18l1803t644r1931b708],
11	100	CD	PERCENT	100	num	12	SENT_282	[p18l1960t649r2141b709],
12	%	NN	PERCENT	%	conj_and	9	SENT_282	[p18l1960t649r2141b709],

1	of	IN	O	of	_	0	SENT_283	[p18l10t748r86b811],
2	patients	NNS	O	patient	pobj	1	SENT_283	[p18l99t754r378b831],
3	on	IN	O	on	_	0	SENT_283	[p18l404t771r492b811],
4	400	CD	NUMBER	400	num	8	SENT_283	[p18l517t755r640b811],
5	and	CC	O	and	_	0	SENT_283	[p18l667t748r797b811],
6	600	CD	NUMBER	600	num	8	SENT_283	[p18l821t754r943b811],
7	mg	NN	O	mg	nn	8	SENT_283	[p18l961t771r1073b832],
8	deleobuvir	NN	O	deleobuvir	prep_on	2	SENT_283	[p18l1096t748r1486b820],
9	,	,	O	,	_	0	SENT_283	[p18l1096t748r1486b820],
10	respectively	RB	O	respectively	advmod	1	SENT_283	[p18l1513t748r1940b832],
11	.	.	O	.	_	0	SENT_283	[p18l1513t748r1940b832],

1	Viral	JJ	O	viral	amod	2	SENT_284	[p18l1967t748r2143b811],
2	breakthrough	NN	O	breakthrough	nsubjpass	4	SENT_284	[p18l7t851r477b935],
3	was	VBD	O	be	auxpass	4	SENT_284	[p18l497t874r623b914],
4	noted	VBN	O	note	_	0	SENT_284	[p18l646t851r842b914],
5	in	IN	O	in	_	0	SENT_284	[p18l864t857r930b913],
6	two	CD	NUMBER	two	num	7	SENT_284	[p18l952t863r1077b914],
7	patients	NNS	O	patient	prep_in	4	SENT_284	[p18l1099t857r1368b934],
8	who	WP	O	who	nsubjpass	11	SENT_284	[p18l1390t851r1536b914],
9	were	VBD	O	be	auxpass	11	SENT_284	[p18l1558t874r1719b914],
10	successfully	RB	O	successfully	advmod	11	SENT_284	[p18l1742t851r2147b935],
11	treated	VBN	O	treat	rcmod	7	SENT_284	[p18l8t953r246b1016],
12	with	IN	O	with	_	0	SENT_284	[p18l265t953r418b1016],
13	the	DT	O	the	det	15	SENT_284	[p18l438t953r544b1016],
14	IFN	NN	O	ifn	nn	15	SENT_284	[p18l567t953r930b1016],
15	—	NN	O	—	prep_with	11	SENT_284	[p18l567t953r930b1016],
16	based	VBN	O	base	partmod	15	SENT_284	[p18l567t953r930b1016],
17	therapy	NN	O	therapy	dobj	16	SENT_284	[p18l950t945r1284b1037],
18	.64	CD	NUMBER	.64	num	17	SENT_284	[p18l950t945r1284b1037],

1	The	DT	O	the	det	2	SENT_285	[p18l83t1056r211b1119],
2	SOUND	NNP	O	SOUND	_	0	SENT_285	[p18l238t1060r673b1119],
3	.	.	O	.	_	0	SENT_285	[p18l238t1060r673b1119],

1	—	NN	O	—	_	0	SENT_286	[p18l238t1060r673b1119],
2	.	.	O	.	_	0	SENT_286	[p18l238t1060r673b1119],

1	C2	NN	O	c2	nn	2	SENT_287	[p18l238t1060r673b1119],
2	trial	NN	O	trial	nsubj	4	SENT_287	[p18l699t1056r847b1119],
3	further	RB	O	further	advmod	4	SENT_287	[p18l872t1056r1127b1119],
4	investigated	VBD	O	investigate	_	0	SENT_287	[p18l1151t1056r1578b1140],
5	the	DT	O	the	det	6	SENT_287	[p18l1602t1056r1713b1119],
6	faldaprevir	NN	O	faldaprevir	dobj	4	SENT_287	[p18l1739t1056r2142b1139],
7	,	,	O	,	_	0	SENT_287	[p18l1739t1056r2142b1139],
8	deleobuvir	NN	O	deleobuvir	dobj	4	SENT_287	[p18l10t1159r405b1231],
9	,	,	O	,	_	0	SENT_287	[p18l10t1159r405b1231],
10	and	CC	O	and	_	0	SENT_287	[p18l435t1159r566b1222],
11	RBV	NN	O	rbv	nn	12	SENT_287	[p18l593t1164r758b1222],
12	regimen	NNS	O	regimen	dobj	4	SENT_287	[p18l784t1165r1079b1243],
13	in	IN	O	in	_	0	SENT_287	[p18l1106t1165r1175b1221],
14	362	CD	NUMBER	362	num	17	SENT_287	[p18l1204t1165r1326b1222],
15	treatment-naive	JJ	O	treatment-naive	amod	17	SENT_287	[p18l1354t1165r1928b1222],
16	HCV	NN	O	hcv	nn	17	SENT_287	[p18l1956t1163r2142b1222],
17	genotype	NN	O	genotype	prep_in	4	SENT_287	[p18l9t1274r320b1346],
18	1	CD	NUMBER	1	num	19	SENT_287	[p18l349t1269r373b1324],
19	patients	NNS	O	patient	dep	17	SENT_287	[p18l400t1268r686b1345],
20	.	.	O	.	_	0	SENT_287	[p18l400t1268r686b1345],

1	Patients	NNS	O	patient	nsubjpass	3	SENT_288	[p18l711t1267r979b1325],
2	were	VBD	O	be	auxpass	3	SENT_288	[p18l999t1285r1159b1325],
3	randomized	VBN	O	randomize	_	0	SENT_288	[p18l1181t1262r1595b1325],
4	into	IN	O	into	_	0	SENT_288	[p18l1616t1268r1749b1325],
5	ﬁve	NN	O	ﬁve	nn	6	SENT_288	[p18l1771t1262r1889b1325],
6	groups	NNS	O	group	prep_into	3	SENT_288	[p18l1910t1284r2142b1346],
7	to	TO	O	to	aux	8	SENT_288	[p18l8t1377r73b1428],
8	receive	VB	O	receive	xcomp	3	SENT_288	[p18l95t1371r328b1428],
9	120	CD	NUMBER	120	num	11	SENT_288	[p18l354t1372r466b1428],
10	mg	NN	O	mg	nn	11	SENT_288	[p18l482t1388r589b1449],
11	faldaprevir	NN	O	faldaprevir	dobj	8	SENT_288	[p18l607t1365r976b1448],
12	a	DT	DURATION	a	det	13	SENT_288	[p18l996t1388r1030b1428],
13	day	NN	DURATION	day	dep	11	SENT_288	[p18l1050t1365r1169b1449],
14	and	CC	O	and	_	0	SENT_288	[p18l1187t1365r1311b1428],
15	600	CD	NUMBER	600	num	17	SENT_288	[p18l1331t1371r1448b1428],
16	mg	NN	O	mg	nn	17	SENT_288	[p18l1464t1388r1572b1449],
17	deleobuvir	NN	O	deleobuvir	conj_and	11	SENT_288	[p18l1591t1365r1951b1428],
18	three	CD	NUMBER	three	num	19	SENT_288	[p18l1969t1365r2142b1428],
19	times	NNS	O	time	tmod	17	SENT_288	[p18l8t1474r197b1531],
20	a	DT	DURATION	a	det	21	SENT_288	[p18l222t1491r257b1531],
21	day	NN	DURATION	day	npadvmod	8	SENT_288	[p18l280t1468r403b1552],
22	along	IN	O	along	_	0	SENT_288	[p18l423t1468r614b1552],
23	with	IN	O	with	_	0	SENT_288	[p18l634t1468r789b1531],
24	RBV	NN	O	rbv	prep_along_with	8	SENT_288	[p18l813t1473r975b1531],
25	for	IN	O	for	_	0	SENT_288	[p18l998t1468r1097b1531],
26	16	CD	NUMBER	16	number	27	SENT_288	[p18l1126t1474r1198b1531],
27	(	CD	NUMBER	(	num	34	SENT_288	[p18l1226t1469r1617b1544],
28	TID16W	NN	O	tid16w	nn	34	SENT_288	[p18l1226t1469r1617b1544],
29	)	NN	O	)	nn	34	SENT_288	[p18l1226t1469r1617b1544],
30	,	,	O	,	_	0	SENT_288	[p18l1226t1469r1617b1544],
31	28	CD	NUMBER	28	number	32	SENT_288	[p18l1643t1475r1721b1531],
32	(	CD	NUMBER	(	num	34	SENT_288	[p18l1750t1469r2141b1545],
33	TID28W	NN	O	tid28w	nn	34	SENT_288	[p18l1750t1469r2141b1545],
34	)	NN	O	)	prep_for	24	SENT_288	[p18l1750t1469r2141b1545],
35	,	,	O	,	_	0	SENT_288	[p18l1750t1469r2141b1545],
36	or	CC	O	or	_	0	SENT_288	[p18l10t1594r82b1634],
37	40	CD	NUMBER	40	number	38	SENT_288	[p18l102t1578r181b1634],
38	(	CD	NUMBER	(	prep_for	24	SENT_288	[p18l208t1572r570b1647],
39	TID40W	NN	O	tid40w	nn	41	SENT_288	[p18l208t1572r570b1647],
40	)	NN	O	)	nn	41	SENT_288	[p18l208t1572r570b1647],
41	weeks	NNS	DURATION	week	dep	38	SENT_288	[p18l595t1571r817b1643],
42	;	:	O	;	_	0	SENT_288	[p18l595t1571r817b1643],
43	120	CD	NUMBER	120	num	45	SENT_288	[p18l848t1578r961b1634],
44	mg	NN	O	mg	nn	45	SENT_288	[p18l976t1594r1085b1655],
45	faldaprevir	NN	O	faldaprevir	dep	38	SENT_288	[p18l1106t1571r1479b1654],
46	a	DT	DURATION	a	det	47	SENT_288	[p18l1501t1594r1535b1634],
47	day	NN	DURATION	day	dep	45	SENT_288	[p18l1558t1571r1687b1655],
48	,	,	O	,	_	0	SENT_288	[p18l1558t1571r1687b1655],
49	600	CD	NUMBER	600	num	51	SENT_288	[p18l1711t1577r1830b1634],
50	mg	NN	O	mg	nn	51	SENT_288	[p18l1846t1594r1954b1655],
51	deleobuvir	NN	O	deleobuvir	npadvmod	52	SENT_288	[p18l1976t1571r2140b1634, p18l10t1674r231b1737],
52	twice	RB	O	twice	advmod	34	SENT_288	[p18l249t1680r427b1737],
53	a	DT	DURATION	a	det	54	SENT_288	[p18l448t1697r482b1737],
54	day	NN	DURATION	day	pobj	52	SENT_288	[p18l502t1674r629b1758],
55	,	,	O	,	_	0	SENT_288	[p18l502t1674r629b1758],
56	and	CC	O	and	_	0	SENT_288	[p18l652t1674r777b1737],
57	RBV	NN	O	rbv	nsubj	84	SENT_288	[p18l797t1679r955b1737],
58	for	IN	O	for	_	0	SENT_288	[p18l974t1674r1070b1737],
59	28	CD	DURATION	28	num	60	SENT_288	[p18l1089t1681r1165b1737],
60	weeks	NNS	NUMBER	week	prep_for	57	SENT_288	[p18l1186t1674r1387b1737],
61	(	VBP	O	(	conj_and	3	SENT_288	[p18l1412t1675r1788b1751],
62	BID28W	NN	O	bid28w	nn	63	SENT_288	[p18l1412t1675r1788b1751],
63	)	NN	O	)	dobj	61	SENT_288	[p18l1412t1675r1788b1751],
64	;	:	O	;	_	0	SENT_288	[p18l1412t1675r1788b1751],
65	or	CC	O	or	_	0	SENT_288	[p18l1811t1697r1882b1737],
66	120	CD	NUMBER	120	num	68	SENT_288	[p18l1908t1681r2019b1737],
67	mg	NN	O	mg	nn	68	SENT_288	[p18l2037t1697r2144b1758],
68	faldaprevir	NN	O	faldaprevir	dobj	61	SENT_288	[p18l9t1777r379b1860],
69	a	DT	DURATION	a	det	70	SENT_288	[p18l399t1800r433b1840],
70	day	NN	DURATION	day	dep	68	SENT_288	[p18l453t1777r573b1861],
71	and	CC	O	and	_	0	SENT_288	[p18l590t1777r715b1840],
72	600	CD	NUMBER	600	num	74	SENT_288	[p18l736t1783r853b1840],
73	mg	NN	O	mg	nn	74	SENT_288	[p18l868t1800r976b1861],
74	deleobuvir	NN	O	deleobuvir	dep	76	SENT_288	[p18l995t1777r1357b1840],
75	three	CD	NUMBER	three	num	76	SENT_288	[p18l1375t1777r1548b1840],
76	times	NNS	O	time	advmod	84	SENT_288	[p18l1567t1783r1751b1840],
77	a	DT	DURATION	a	det	78	SENT_288	[p18l1773t1800r1807b1840],
78	day	NN	DURATION	day	dep	76	SENT_288	[p18l1827t1777r1947b1861],
79	without	IN	O	without	_	0	SENT_288	[p18l1962t1777r2140b1840, p18l10t1892r121b1943],
80	RBV	NN	O	rbv	prep_without	76	SENT_288	[p18l142t1885r301b1943],
81	for	IN	O	for	_	0	SENT_288	[p18l322t1880r419b1943],
82	28	CD	DURATION	28	num	83	SENT_288	[p18l440t1887r517b1943],
83	weeks	NNS	NUMBER	week	prep_for	80	SENT_288	[p18l539t1880r742b1943],
84	(	VBP	O	(	conj_and	3	SENT_288	[p18l768t1880r1318b1957],
85	TID28W	NN	O	tid28w	dobj	84	SENT_288	[p18l768t1880r1318b1957],
86	.	.	O	.	_	0	SENT_288	[p18l768t1880r1318b1957],

1	—	NN	O	—	_	0	SENT_289	[p18l768t1880r1318b1957],
2	.	.	O	.	_	0	SENT_289	[p18l768t1880r1318b1957],

1	NR	NN	MISC	nr	_	0	SENT_290	[p18l768t1880r1318b1957],
2	)	NN	O	)	dep	1	SENT_290	[p18l768t1880r1318b1957],
3	.	.	O	.	_	0	SENT_290	[p18l768t1880r1318b1957],

1	SVR12	NN	O	svr12	nsubjpass	12	SENT_291	[p18l84t1987r339b2055],
2	,	,	O	,	_	0	SENT_291	[p18l84t1987r339b2055],
3	the	DT	O	the	det	6	SENT_291	[p18l363t1983r471b2046],
4	primary	JJ	O	primary	amod	6	SENT_291	[p18l493t1989r780b2067],
5	end	NN	O	end	nn	6	SENT_291	[p18l801t1983r929b2046],
6	point	NN	O	point	appos	1	SENT_291	[p18l950t1989r1135b2066],
7	of	IN	O	of	_	0	SENT_291	[p18l1159t1983r1233b2046],
8	the	DT	O	the	det	9	SENT_291	[p18l1246t1983r1354b2046],
9	study	NN	O	study	prep_of	6	SENT_291	[p18l1378t1983r1576b2067],
10	,	,	O	,	_	0	SENT_291	[p18l1378t1983r1576b2067],
11	was	VBD	O	be	auxpass	12	SENT_291	[p18l1599t2006r1727b2046],
12	met	VBN	O	meet	_	0	SENT_291	[p18l1751t1995r1884b2046],
13	in	IN	O	in	_	0	SENT_291	[p18l1906t1989r1973b2045],
14	59	CD	PERCENT	59	num	15	SENT_291	[p18l1999t1988r2141b2048],
15	%	NN	PERCENT	%	prep_in	12	SENT_291	[p18l1999t1988r2141b2048],
16	of	IN	O	of	_	0	SENT_291	[p18l10t2085r82b2149],
17	TID16W	NN	O	tid16w	prep_of	15	SENT_291	[p18l93t2088r404b2157],
18	,	,	O	,	_	0	SENT_291	[p18l93t2088r404b2157],
19	59	CD	PERCENT	59	num	20	SENT_291	[p18l428t2091r566b2150],
20	%	NN	PERCENT	%	appos	15	SENT_291	[p18l428t2091r566b2150],
21	of	IN	O	of	_	0	SENT_291	[p18l589t2085r662b2149],
22	TID28W	NN	O	tid28w	prep_of	20	SENT_291	[p18l673t2088r983b2157],
23	,	,	O	,	_	0	SENT_291	[p18l673t2088r983b2157],
24	52	CD	PERCENT	52	num	25	SENT_291	[p18l1007t2091r1146b2150],
25	%	NN	PERCENT	%	appos	15	SENT_291	[p18l1007t2091r1146b2150],
26	of	IN	O	of	_	0	SENT_291	[p18l1169t2085r1241b2149],
27	TID40W	NN	O	tid40w	prep_of	25	SENT_291	[p18l1252t2088r1562b2157],
28	,	,	O	,	_	0	SENT_291	[p18l1252t2088r1562b2157],
29	69	CD	PERCENT	69	num	30	SENT_291	[p18l1585t2091r1725b2150],
30	%	NN	PERCENT	%	appos	15	SENT_291	[p18l1585t2091r1725b2150],
31	of	IN	O	of	_	0	SENT_291	[p18l1748t2085r1821b2149],
32	BID28W	NN	O	bid28w	prep_of	30	SENT_291	[p18l1832t2090r2139b2157],
33	,	,	O	,	_	0	SENT_291	[p18l1832t2090r2139b2157],

1	and	CC	O	and	dep	3	SENT_292	[p18l10t2189r136b2252],
2	39	CD	PERCENT	39	num	3	SENT_292	[p18l157t2194r297b2253],
3	%	NN	PERCENT	%	_	0	SENT_292	[p18l157t2194r297b2253],
4	of	IN	O	of	_	0	SENT_292	[p18l321t2189r394b2252],
5	TID28W-NR	NN	O	tid28w-nr	nn	6	SENT_292	[p18l405t2192r859b2252],
6	patients	NNS	O	patient	prep_of	3	SENT_292	[p18l876t2195r1162b2272],
7	.	.	O	.	_	0	SENT_292	[p18l876t2195r1162b2272],

1	Among	IN	O	among	_	0	SENT_293	[p18l1185t2193r1443b2273],
2	the	DT	O	the	det	4	SENT_293	[p18l1461t2189r1567b2252],
3	RBV-containing	JJ	MISC	rbv-containing	amod	4	SENT_293	[p18l1589t2194r2144b2273],
4	regimens	NNS	O	regimen	prep_among	7	SENT_293	[p18l9t2298r335b2376],
5	,	,	O	,	_	0	SENT_293	[p18l9t2298r335b2376],
6	there	EX	O	there	expl	7	SENT_293	[p18l356t2292r527b2355],
7	was	VBD	O	be	_	0	SENT_293	[p18l545t2315r669b2355],
8	no	DT	O	no	det	11	SENT_293	[p18l690t2315r774b2355],
9	statistically	RB	O	statistically	advmod	10	SENT_293	[p18l797t2292r1173b2376],
10	signiﬁcant	JJ	O	signiﬁcant	amod	11	SENT_293	[p18l1191t2292r1539b2376],
11	difference	NN	O	difference	nsubj	7	SENT_293	[p18l1559t2292r1889b2355],
12	in	IN	O	in	_	0	SENT_293	[p18l1910t2298r1975b2354],
13	SVR	NN	ORGANIZATION	svr	prep_in	11	SENT_293	[p18l1996t2296r2147b2355],
14	based	VBN	O	base	partmod	13	SENT_293	[p18l7t2395r201b2458],
15	on	IN	O	on	_	0	SENT_293	[p18l221t2418r305b2458],
16	duration	NN	O	duration	prep_on	14	SENT_293	[p18l326t2395r617b2458],
17	of	IN	O	of	_	0	SENT_293	[p18l638t2395r711b2458],
18	therapy	NN	O	therapy	prep_of	16	SENT_293	[p18l721t2395r979b2479],
19	or	CC	O	or	_	0	SENT_293	[p18l997t2418r1067b2458],
20	on	IN	O	on	_	0	SENT_293	[p18l1087t2418r1171b2458],
21	deleobuvir	JJ	O	deleobuvir	amod	22	SENT_293	[p18l1193t2395r1553b2458],
22	dosage	NN	O	dosage	conj_or	16	SENT_293	[p18l1573t2395r1819b2479],
23	;	:	O	;	_	0	SENT_293	[p18l1573t2395r1819b2479],
24	however	RB	O	however	advmod	34	SENT_293	[p18l1840t2395r2138b2467],
25	,	,	O	,	_	0	SENT_293	[p18l1840t2395r2138b2467],
26	the	DT	O	the	det	27	SENT_293	[p18l8t2498r114b2561],
27	addition	NN	O	addition	nsubj	34	SENT_293	[p18l135t2498r420b2561],
28	of	IN	O	of	_	0	SENT_293	[p18l441t2498r514b2561],
29	RBV	NN	O	rbv	prep_of	27	SENT_293	[p18l526t2503r684b2561],
30	to	TO	O	to	_	0	SENT_293	[p18l703t2510r768b2561],
31	the	DT	O	the	det	32	SENT_293	[p18l789t2498r895b2561],
32	regimen	NN	O	regimen	prep_to	29	SENT_293	[p18l916t2504r1195b2582],
33	signiﬁcantly	RB	O	signiﬁcantly	advmod	34	SENT_293	[p18l1217t2498r1632b2582],
34	increased	VBD	O	increase	parataxis	7	SENT_293	[p18l1649t2498r1972b2561],
35	SVR	NN	O	svr	nn	36	SENT_293	[p18l1992t2502r2144b2561],
36	rates	NNS	O	rate	dobj	34	SENT_293	[p18l10t2613r193b2664],
37	.	.	O	.	_	0	SENT_293	[p18l10t2613r193b2664],

1	In	IN	O	in	_	0	SENT_294	[p18l221t2606r294b2663],
2	genotype	NN	O	genotype	prep_in	9	SENT_294	[p18l319t2613r643b2685],
3	la	DT	O	la	det	4	SENT_294	[p18l675t2608r747b2664],
4	patients	NNS	O	patient	dep	2	SENT_294	[p18l770t2607r1070b2684],
5	,	,	O	,	_	0	SENT_294	[p18l770t2607r1070b2684],
6	SVR	NN	ORGANIZATION	svr	nsubj	9	SENT_294	[p18l1098t2605r1256b2664],
7	was	VBD	O	be	cop	9	SENT_294	[p18l1276t2624r1406b2664],
8	11-47	CD	PERCENT	11-47	num	9	SENT_294	[p18l1439t2606r1733b2673],
9	%	NN	PERCENT	%	_	0	SENT_294	[p18l1439t2606r1733b2673],
10	,	,	O	,	_	0	SENT_294	[p18l1439t2606r1733b2673],
11	whereas	IN	O	whereas	mark	20	SENT_294	[p18l1758t2601r2046b2664],
12	in	IN	O	in	_	0	SENT_294	[p18l2072t2607r2141b2663],
13	genotype	NN	O	genotype	nn	15	SENT_294	[p18l9t2716r324b2788],
14	1b	NN	O	1b	nn	15	SENT_294	[p18l355t2704r428b2767],
15	patients	NNS	O	patient	prep_in	20	SENT_294	[p18l452t2710r743b2787],
16	,	,	O	,	_	0	SENT_294	[p18l452t2710r743b2787],
17	SVR	NN	ORGANIZATION	svr	nsubj	20	SENT_294	[p18l770t2708r924b2767],
18	was	VBD	O	be	cop	20	SENT_294	[p18l943t2727r1070b2767],
19	56-85	CD	PERCENT	56-85	num	20	SENT_294	[p18l1096t2710r1386b2768],
20	%	NN	PERCENT	%	advcl	9	SENT_294	[p18l1096t2710r1386b2768],
21	.	.	O	.	_	0	SENT_294	[p18l1096t2710r1386b2768],

1	Among	IN	O	among	_	0	SENT_295	[p18l1412t2708r1672b2788],
2	patients	NNS	O	patient	prep_among	11	SENT_295	[p18l1693t2710r1965b2787],
3	with	IN	O	with	_	0	SENT_295	[p18l1987t2704r2142b2767],
4	the	DT	O	the	det	7	SENT_295	[p18l8t2807r116b2870],
5	IL28B	NN	O	il28b	nn	7	SENT_295	[p18l138t2812r346b2870],
6	genotype	NN	O	genotype	nn	7	SENT_295	[p18l370t2819r687b2891],
7	CC	NN	O	cc	prep_with	2	SENT_295	[p18l714t2811r837b2879],
8	,	,	O	,	_	0	SENT_295	[p18l714t2811r837b2879],
9	58-84	CD	PERCENT	58-84	num	10	SENT_295	[p18l864t2813r1136b2872],
10	%	NN	PERCENT	%	nsubj	11	SENT_295	[p18l864t2813r1136b2872],
11	achieved	VBD	O	achieve	_	0	SENT_295	[p18l1163t2807r1467b2870],
12	SVR	NNP	ORGANIZATION	SVR	dobj	11	SENT_295	[p18l1491t2811r1663b2879],
13	,	,	O	,	_	0	SENT_295	[p18l1491t2811r1663b2879],
14	whereas	IN	O	whereas	mark	17	SENT_295	[p18l1686t2807r1968b2870],
15	only	RB	O	only	advmod	17	SENT_295	[p18l1993t2807r2146b2891],
16	33-64	CD	PERCENT	33-64	num	17	SENT_295	[p18l11t2915r274b2975],
17	%	NN	PERCENT	%	advcl	11	SENT_295	[p18l11t2915r274b2975],
18	of	IN	O	of	_	0	SENT_295	[p18l297t2910r369b2973],
19	non	JJ	O	non	prep_of	17	SENT_295	[p18l379t2914r652b2973],
20	.	.	O	.	_	0	SENT_295	[p18l379t2914r652b2973],

1	—	NN	O	—	_	0	SENT_296	[p18l379t2914r652b2973],
2	.	.	O	.	_	0	SENT_296	[p18l379t2914r652b2973],

1	CC	NN	O	cc	nn	2	SENT_297	[p18l379t2914r652b2973],
2	patients	NNS	O	patient	nsubj	3	SENT_297	[p18l667t2916r931b2993],
3	achieved	VBD	O	achieve	_	0	SENT_297	[p18l952t2910r1246b2973],
4	SVR	NNP	O	SVR	dobj	3	SENT_297	[p18l1266t2914r1431b2973],
5	.	.	O	.	_	0	SENT_297	[p18l1266t2914r1431b2973],

1	The	DT	O	the	det	5	SENT_298	[p18l1453t2910r1576b2973],
2	most	RBS	O	most	advmod	4	SENT_298	[p18l1596t2922r1762b2973],
3	commonly	RB	O	commonly	advmod	4	SENT_298	[p18l1782t2910r2146b2994],
4	encountered	VBN	O	encounter	amod	5	SENT_298	[p18l10t3013r435b3076],
5	AEs	NNS	O	ae	nsubj	6	SENT_298	[p18l454t3017r590b3076],
6	include	VBP	O	include	_	0	SENT_298	[p18l612t3013r861b3076],
7	rash	NN	O	rash	dobj	6	SENT_298	[p18l882t3013r1043b3085],
8	,	,	O	,	_	0	SENT_298	[p18l882t3013r1043b3085],
9	photosensitivity	NN	O	photosensitivity	dobj	6	SENT_298	[p18l1064t3013r1621b3097],
10	,	,	O	,	_	0	SENT_298	[p18l1064t3013r1621b3097],
11	nausea	NN	O	nausea	dobj	6	SENT_298	[p18l1644t3036r1893b3085],
12	,	,	O	,	_	0	SENT_298	[p18l1644t3036r1893b3085],
13	vomiting	VBG	O	vomit	appos	11	SENT_298	[p18l1913t3019r2140b3076, p18l9t3121r135b3199],
14	,	,	O	,	_	0	SENT_298	[p18l1913t3019r2140b3076, p18l9t3121r135b3199],
15	and	CC	O	and	_	0	SENT_298	[p18l160t3115r287b3178],
16	diarrhea	NN	O	diarrhea	conj_and	7	SENT_298	[p18l309t3107r680b3178],
17	.65	CD	NUMBER	.65	num	16	SENT_298	[p18l309t3107r680b3178],

1	A	DT	O	a	det	2	SENT_299	[p18l82t3221r138b3280],
2	combination	NN	O	combination	nsubj	7	SENT_299	[p18l159t3217r594b3281],
3	of	IN	O	of	_	0	SENT_299	[p18l616t3217r689b3281],
4	a	DT	O	a	det	6	SENT_299	[p18l702t3240r736b3281],
5	ritonavir	NN	O	ritonavir	nn	6	SENT_299	[p18l757t3217r1360b3281],
6	—	NN	O	—	prep_of	2	SENT_299	[p18l757t3217r1360b3281],
7	boosted	VBD	O	boost	_	0	SENT_299	[p18l757t3217r1360b3281],
8	PI	NN	O	pi	dobj	7	SENT_299	[p18l1381t3222r1472b3289],
9	,	,	O	,	_	0	SENT_299	[p18l1381t3222r1472b3289],
10	an	DT	O	a	det	11	SENT_299	[p18l1496t3240r1575b3281],
11	NNPI	NN	MISC	nnpus	conj_and	8	SENT_299	[p18l1596t3222r1816b3289],
12	,	,	O	,	_	0	SENT_299	[p18l1596t3222r1816b3289],
13	and	CC	O	and	_	0	SENT_299	[p18l1840t3217r1965b3281],
14	RBV	NN	O	rbv	dobj	7	SENT_299	[p18l1987t3222r2144b3281],

1	has	VBZ	O	have	aux	4	SENT_300	[p19l8t26r124b89],
2	also	RB	O	also	advmod	4	SENT_300	[p19l151t26r287b89],
3	been	VBN	O	be	auxpass	4	SENT_300	[p19l312t26r482b89],
4	investigated	VBN	O	investigate	_	0	SENT_300	[p19l508t26r936b110],
5	as	IN	O	as	_	0	SENT_300	[p19l961t49r1027b89],
6	a	DT	O	a	det	9	SENT_300	[p19l1055t49r1089b89],
7	possible	JJ	O	possible	amod	9	SENT_300	[p19l1112t26r1400b109],
8	IFN-free	JJ	O	ifn-free	amod	9	SENT_300	[p19l1427t26r1736b89],
9	regimen	NN	O	regimen	prep_as	4	SENT_300	[p19l1763t18r2142b110],
10	.	.	O	.	_	0	SENT_300	[p19l1763t18r2142b110],

1	“	RB	O	“	advmod	2	SENT_301	[p19l1763t18r2142b110],
2	ABT	NNP	O	ABT	nsubjpass	30	SENT_301	[p19l8t132r354b201],
3	—	CD	NUMBER	—	number	4	SENT_301	[p19l8t132r354b201],
4	450	CD	NUMBER	450	dep	2	SENT_301	[p19l8t132r354b201],
5	,	,	O	,	_	0	SENT_301	[p19l8t132r354b201],
6	a	DT	O	a	det	7	SENT_301	[p19l382t152r418b192],
7	PI	NN	O	pi	appos	2	SENT_301	[p19l443t134r539b201],
8	,	,	O	,	_	0	SENT_301	[p19l443t134r539b201],
9	along	IN	O	along	_	0	SENT_301	[p19l568t129r765b213],
10	with	IN	O	with	_	0	SENT_301	[p19l787t129r947b192],
11	low-dose	JJ	O	low-dose	amod	14	SENT_301	[p19l972t129r1299b192],
12	ritonavir	NN	O	ritonavir	nn	14	SENT_301	[p19l1326t135r1644b192],
13	(	NN	O	(	nn	14	SENT_301	[p19l1672t130r2142b206],
14	ABT-450	NN	O	abt-450	prep_along_with	7	SENT_301	[p19l1672t130r2142b206],
15	/	:	O	/	punct	17	SENT_301	[p19l1672t130r2142b206],
16	r	NN	O	r	nn	17	SENT_301	[p19l1672t130r2142b206],
17	)	NN	O	)	dep	2	SENT_301	[p19l1672t130r2142b206],
18	,	,	O	,	_	0	SENT_301	[p19l1672t130r2142b206],
19	ABT	NNP	O	ABT	conj_and	17	SENT_301	[p19l9t235r335b295],
20	—	CD	NUMBER	—	num	19	SENT_301	[p19l9t235r335b295],
21	333	CD	NUMBER	333	number	22	SENT_301	[p19l9t235r335b295],
22	(	CD	NUMBER	(	num	25	SENT_301	[p19l369t233r482b308],
23	an	DT	O	a	det	25	SENT_301	[p19l369t233r482b308],
24	NNPI	NN	MISC	nnpus	nn	25	SENT_301	[p19l510t233r776b308],
25	)	NN	O	)	dep	19	SENT_301	[p19l510t233r776b308],
26	,	,	O	,	_	0	SENT_301	[p19l510t233r776b308],
27	and	CC	O	and	_	0	SENT_301	[p19l807t232r940b295],
28	RBV	NN	O	rbv	conj_and	17	SENT_301	[p19l967t237r1134b295],
29	were	VBD	O	be	auxpass	30	SENT_301	[p19l1160t255r1330b295],
30	given	VBN	O	give	_	0	SENT_301	[p19l1358t238r1553b316],
31	to	TO	O	to	_	0	SENT_301	[p19l1580t244r1649b295],
32	noncirrhotic	JJ	O	noncirrhotic	amod	36	SENT_301	[p19l1679t232r2144b295],
33	HCV	NN	O	hcv	nn	36	SENT_301	[p19l10t339r196b398],
34	genotype	NN	O	genotype	nn	36	SENT_301	[p19l222t347r551b419],
35	1	CD	NUMBER	1	num	36	SENT_301	[p19l584t342r609b397],
36	patients	NNS	O	patient	prep_to	30	SENT_301	[p19l641t341r927b418],
37	in	IN	O	in	_	0	SENT_301	[p19l954t341r1023b397],
38	a	DT	O	a	det	45	SENT_301	[p19l1050t358r1085b398],
39	phase	NN	O	phase	nn	45	SENT_301	[p19l1109t335r1314b418],
40	Ila	NN	O	ilum	nn	45	SENT_301	[p19l1341t340r1456b407],
41	,	,	O	,	_	0	SENT_301	[p19l1341t340r1456b407],
42	open-label	JJ	O	open-label	amod	45	SENT_301	[p19l1485t335r1888b418],
43	,	,	O	,	_	0	SENT_301	[p19l1485t335r1888b418],
44	multicenter	JJ	O	multicenter	amod	45	SENT_301	[p19l1916t335r2139b398, p19l10t450r227b501],
45	study	NN	O	study	prep_in	36	SENT_301	[p19l252t438r451b522],
46	.	.	O	.	_	0	SENT_301	[p19l252t438r451b522],

1	Patients	NNS	O	patient	nsubjpass	3	SENT_302	[p19l480t443r758b501],
2	were	VBD	O	be	auxpass	3	SENT_302	[p19l781t461r946b501],
3	divided	VBN	O	divide	_	0	SENT_302	[p19l972t438r1237b501],
4	into	IN	O	into	_	0	SENT_302	[p19l1261t444r1398b501],
5	three	CD	NUMBER	three	num	6	SENT_302	[p19l1424t438r1604b501],
6	groups	NNS	O	group	prep_into	3	SENT_302	[p19l1629t460r1887b522],
7	.	.	O	.	_	0	SENT_302	[p19l1629t460r1887b522],

1	Group	NNP	O	Group	_	0	SENT_303	[p19l1916t442r2141b521],
2	1	CD	NUMBER	1	num	1	SENT_303	[p19l16t549r40b604],
3	comprised	VBN	O	comprise	partmod	1	SENT_303	[p19l70t542r436b625],
4	treatment	NN	O	treatment	nn	5	SENT_303	[p19l457t548r1015b605],
5	—	NN	O	—	nsubj	6	SENT_303	[p19l457t548r1015b605],
6	naive	JJ	O	naive	xcomp	3	SENT_303	[p19l457t548r1015b605],
7	patients	NNS	O	patient	dep	1	SENT_303	[p19l1037t548r1311b625],
8	who	WP	O	who	nsubjpass	10	SENT_303	[p19l1333t542r1480b605],
9	were	VBD	O	be	auxpass	10	SENT_303	[p19l1503t565r1665b605],
10	given	VBN	O	give	rcmod	7	SENT_303	[p19l1688t548r1874b626],
11	250	CD	NUMBER	250	num	12	SENT_303	[p19l1897t549r2017b605],
12	mg	NN	O	mg	iobj	10	SENT_303	[p19l2036t565r2144b626],
13	ABT	NNP	O	ABT	nn	15	SENT_303	[p19l8t648r327b708],
14	—	CD	NUMBER	—	num	15	SENT_303	[p19l8t648r327b708],
15	45O	NN	O	45o	dobj	10	SENT_303	[p19l8t648r327b708],
16	and	CC	O	and	_	0	SENT_303	[p19l354t645r483b708],
17	100	CD	NUMBER	100	num	19	SENT_303	[p19l515t652r630b708],
18	mg	NN	O	mg	nn	19	SENT_303	[p19l649t668r759b729],
19	ritonavir	NN	O	ritonavir	dobj	10	SENT_303	[p19l783t651r1094b708],
20	a	DT	DURATION	a	det	21	SENT_303	[p19l1119t668r1154b708],
21	day	NN	DURATION	day	dep	19	SENT_303	[p19l1178t645r1312b729],
22	,	,	O	,	_	0	SENT_303	[p19l1178t645r1312b729],
23	400	CD	NUMBER	400	num	25	SENT_303	[p19l1338t652r1462b708],
24	mg	NN	O	mg	nn	25	SENT_303	[p19l1480t668r1590b729],
25	ABT	NNP	O	ABT	conj_and	15	SENT_303	[p19l1613t648r1930b708],
26	—	CD	NUMBER	—	number	27	SENT_303	[p19l1613t648r1930b708],
27	333	CD	NUMBER	333	dep	25	SENT_303	[p19l1613t648r1930b708],
28	twice	RB	O	twice	advmod	30	SENT_303	[p19l1957t651r2143b708],
29	a	DT	DURATION	a	det	30	SENT_303	[p19l10t771r44b811],
30	day	NN	DURATION	day	tmod	25	SENT_303	[p19l66t748r197b832],
31	,	,	O	,	_	0	SENT_303	[p19l66t748r197b832],
32	and	CC	O	and	_	0	SENT_303	[p19l221t748r348b811],
33	weight-based	JJ	O	weight-based	amod	34	SENT_303	[p19l368t748r831b832],
34	RBV	NN	O	rbv	conj_and	15	SENT_303	[p19l853t753r1017b811],
35	.	.	O	.	_	0	SENT_303	[p19l853t753r1017b811],

1	Groups	NNS	O	group	dep	33	SENT_304	[p19l1044t752r1297b831],
2	2	CD	NUMBER	2	num	1	SENT_304	[p19l1320t755r1356b810],
3	and	CC	O	and	_	0	SENT_304	[p19l1381t748r1507b811],
4	3	CD	NUMBER	3	dep	33	SENT_304	[p19l1530t755r1563b811],
5	received	VBD	O	receive	rcmod	1	SENT_304	[p19l1589t748r1875b811],
6	150	CD	NUMBER	150	num	8	SENT_304	[p19l1903t755r2016b811],
7	mg	NN	O	mg	nn	8	SENT_304	[p19l2036t771r2144b832],
8	ABT	NNP	O	ABT	dobj	5	SENT_304	[p19l8t854r321b914],
9	—	CD	NUMBER	—	number	10	SENT_304	[p19l8t854r321b914],
10	450	CD	NUMBER	450	dep	8	SENT_304	[p19l8t854r321b914],
11	and	CC	O	and	_	0	SENT_304	[p19l346t851r473b914],
12	100	CD	NUMBER	100	num	14	SENT_304	[p19l501t858r615b914],
13	mg	NN	O	mg	nn	14	SENT_304	[p19l632t874r741b935],
14	ritonavir	NN	O	ritonavir	dobj	5	SENT_304	[p19l762t857r1068b914],
15	a	DT	DURATION	a	det	16	SENT_304	[p19l1090t874r1124b914],
16	day	NN	DURATION	day	dep	14	SENT_304	[p19l1146t851r1277b935],
17	,	,	O	,	_	0	SENT_304	[p19l1146t851r1277b935],
18	400	CD	NUMBER	400	num	20	SENT_304	[p19l1301t858r1422b914],
19	mg	NN	O	mg	nn	20	SENT_304	[p19l1440t874r1549b935],
20	ABT	NNP	O	ABT	dobj	5	SENT_304	[p19l1568t854r1880b914],
21	—	CD	NUMBER	—	number	22	SENT_304	[p19l1568t854r1880b914],
22	333	CD	NUMBER	333	dep	20	SENT_304	[p19l1568t854r1880b914],
23	twice	RB	O	twice	advmod	25	SENT_304	[p19l1904t857r2086b914],
24	a	DT	DURATION	a	det	25	SENT_304	[p19l2110t874r2144b914],
25	day	NN	DURATION	day	tmod	20	SENT_304	[p19l10t954r143b1038],
26	,	,	O	,	_	0	SENT_304	[p19l10t954r143b1038],
27	and	CC	O	and	_	0	SENT_304	[p19l168t954r296b1017],
28	weight-based	JJ	O	weight-based	amod	29	SENT_304	[p19l317t954r788b1038],
29	RBV	NN	O	rbv	dobj	5	SENT_304	[p19l810t959r978b1026],
30	,	,	O	,	_	0	SENT_304	[p19l810t959r978b1026],
31	the	DT	O	the	det	32	SENT_304	[p19l1002t954r1110b1017],
32	difference	NN	O	difference	nsubj	33	SENT_304	[p19l1135t954r1480b1017],
33	being	VBG	O	be	_	0	SENT_304	[p19l1502t954r1698b1038],
34	that	IN	O	that	complm	37	SENT_304	[p19l1718t954r1856b1017],
35	group	NN	O	group	nsubj	37	SENT_304	[p19l1878t976r2082b1038],
36	2	CD	NUMBER	2	num	35	SENT_304	[p19l2107t961r2143b1016],
37	comprised	VBN	O	comprise	ccomp	33	SENT_304	[p19l10t1058r381b1141],
38	treatment-naive	JJ	O	treatment-naive	amod	39	SENT_304	[p19l404t1064r971b1121],
39	patients	NNS	O	patient	dobj	37	SENT_304	[p19l996t1064r1294b1141],
40	,	,	O	,	_	0	SENT_304	[p19l996t1064r1294b1141],
41	and	CC	O	and	_	0	SENT_304	[p19l1322t1058r1450b1121],
42	group	NN	O	group	nsubj	44	SENT_304	[p19l1475t1080r1680b1142],
43	3	CD	NUMBER	3	num	42	SENT_304	[p19l1708t1065r1742b1121],
44	comprised	VBN	O	comprise	conj_and	33	SENT_304	[p19l1770t1058r2142b1141],
45	previous	JJ	O	previous	amod	46	SENT_304	[p19l8t1167r314b1244],
46	partial	JJ	O	partial	dobj	44	SENT_304	[p19l340t1161r575b1244],
47	or	CC	O	or	_	0	SENT_304	[p19l601t1184r674b1224],
48	null	JJ	O	null	amod	49	SENT_304	[p19l699t1161r838b1224],
49	responders	NNS	O	responder	dobj	44	SENT_304	[p19l863t1161r1256b1244],
50	to	TO	O	to	_	0	SENT_304	[p19l1281t1173r1349b1224],
51	therapy	NN	O	therapy	prep_to	44	SENT_304	[p19l1375t1161r1657b1245],
52	.	.	O	.	_	0	SENT_304	[p19l1375t1161r1657b1245],

1	All	DT	O	all	det	2	SENT_305	[p19l1684t1161r1790b1223],
2	regimens	NNS	O	regimen	nsubjpass	4	SENT_305	[p19l1816t1167r2141b1245],
3	were	VBD	O	be	auxpass	4	SENT_305	[p19l8t1287r175b1327],
4	given	VBN	O	give	_	0	SENT_305	[p19l202t1270r393b1348],
5	for	IN	O	for	_	0	SENT_305	[p19l419t1264r521b1327],
6	12	CD	DURATION	12	num	7	SENT_305	[p19l553t1271r626b1326],
7	weeks	NNS	NUMBER	week	prep_for	4	SENT_305	[p19l652t1264r884b1327],
8	.	.	O	.	_	0	SENT_305	[p19l652t1264r884b1327],

1	The	DT	O	the	det	4	SENT_306	[p19l914t1264r1042b1327],
2	primary	JJ	O	primary	amod	4	SENT_306	[p19l1067t1270r1363b1348],
3	end	NN	O	end	nn	4	SENT_306	[p19l1387t1264r1518b1327],
4	point	NN	O	point	nsubj	6	SENT_306	[p19l1541t1270r1733b1347],
5	was	VBD	O	be	cop	6	SENT_306	[p19l1756t1287r1887b1327],
6	eRVR	NN	O	ervr	_	0	SENT_306	[p19l1914t1269r2139b1336],
7	,	,	O	,	_	0	SENT_306	[p19l1914t1269r2139b1336],
8	and	CC	O	and	_	0	SENT_306	[p19l10t1367r139b1430],
9	the	DT	O	the	det	12	SENT_306	[p19l161t1367r269b1430],
10	secondary	JJ	O	secondary	amod	12	SENT_306	[p19l295t1367r657b1451],
11	end	NN	O	end	nn	12	SENT_306	[p19l679t1367r807b1430],
12	points	NNS	O	point	nsubj	14	SENT_306	[p19l829t1373r1048b1450],
13	were	VBD	O	be	cop	14	SENT_306	[p19l1071t1390r1235b1430],
14	SVR12	NN	O	svr12	conj_and	6	SENT_306	[p19l1260t1371r1497b1430],
15	and	CC	O	and	_	0	SENT_306	[p19l1524t1367r1652b1430],
16	SVR24	NN	O	svr24	conj_and	6	SENT_306	[p19l1677t1371r1933b1430],
17	.	.	O	.	_	0	SENT_306	[p19l1677t1371r1933b1430],

1	VOLUME	NN	O	volume	nn	3	SENT_307	[p19l542t1585r765b1627],
2	95	CD	NUMBER	95	num	3	SENT_307	[p19l783t1586r839b1627],
3	NUMBER	NN	O	number	_	0	SENT_307	[p19l860t1585r1083b1627],
4	1	CD	NUMBER	1	number	5	SENT_307	[p19l1104t1587r1118b1627],
5	|	CD	NUMBER	|	dep	3	SENT_307	[p19l1147t1581r1152b1642],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_307	[p19l1170t1585r1415b1627],
7	2014	CD	DATE	2014	num	6	SENT_307	[p19l1431t1586r1552b1627],
8	|	CD	NUMBER	|	num	9	SENT_307	[p19l1570t1581r1575b1642],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_307	[p19l1593t1585r2143b1638],

1	Table	NNP	O	Table	_	0	SENT_308	[p19l19t1909r106b1936],
2	2	CD	NUMBER	2	num	4	SENT_308	[p19l114t1911r131b1936],
3	Interferon-free	JJ	O	interferon-free	amod	4	SENT_308	[p19l159t1909r397b1936],
4	regimens	NNS	O	regimen	dep	1	SENT_308	[p19l405t1909r554b1943],
5	Trial	NNP	O	Trial	nn	7	SENT_308	[p19l19t1969r79b1993],
6	DAAs	NNP	O	DAAs	nn	7	SENT_308	[p19l272t1970r347b1993],
7	Study	NNP	O	Study	dep	4	SENT_308	[p19l784t1969r866b2000],
8	population	NN	O	population	dep	1	SENT_308	[p19l874t1969r1030b1999],
9	Primary	JJ	O	primary	amod	13	SENT_308	[p19l1233t1969r1344b2000],
10	end	NN	O	end	nn	13	SENT_308	[p19l1350t1969r1403b1993],
11	point	NN	O	point	nn	13	SENT_308	[p19l1412t1969r1487b1999],
12	Conclusion	NN	O	conclusion	nn	13	SENT_308	[p19l1517t1969r1674b1993],
13	SOUND	NN	O	sound	dep	8	SENT_308	[p19l20t2053r166b2076],
14	.	.	O	.	_	0	SENT_308	[p19l20t2053r166b2076],

1	—	NN	O	—	_	0	SENT_309	[p19l20t2053r166b2076],
2	.	.	O	.	_	0	SENT_309	[p19l20t2053r166b2076],

1	C1	NN	O	c1	_	0	SENT_310	[p19l20t2053r166b2076],
2	De	NNP	O	De	nn	4	SENT_310	[p19l272t2053r479b2077],
3	|	CD	NUMBER	|	num	4	SENT_310	[p19l272t2053r479b2077],
4	eobuvir40O	NN	O	eobuvir40o	dep	1	SENT_310	[p19l272t2053r479b2077],
5	or	CC	O	or	_	0	SENT_310	[p19l487t2060r515b2077],
6	600	CD	NUMBER	600	num	7	SENT_310	[p19l522t2055r571b2077],
7	mg	NN	O	mg	dep	1	SENT_310	[p19l579t2060r621b2084],
8	daily	JJ	SET	daily	amod	9	SENT_310	[p19l630t2053r694b2084],
9	Genotype	NN	O	genotype	dep	7	SENT_310	[p19l784t2053r920b2083],
10	1	CD	NUMBER	1	num	9	SENT_310	[p19l930t2054r1095b2080],
11	,	,	O	,	_	0	SENT_310	[p19l930t2054r1095b2080],
12	treatment	NN	O	treatment	nn	14	SENT_310	[p19l930t2054r1095b2080],
13	naive	JJ	O	naive	amod	14	SENT_310	[p19l1103t2053r1174b2076],
14	RVR	NN	O	rvr	dep	1	SENT_310	[p19l1233t2053r1285b2076],
15	at	IN	O	at	_	0	SENT_310	[p19l1293t2056r1318b2076],
16	4	CD	DURATION	4	num	17	SENT_310	[p19l1325t2054r1341b2076],
17	weeks	NNS	NUMBER	week	amod	27	SENT_310	[p19l1348t2052r1432b2076],
18	73	CD	PERCENT	73	num	19	SENT_310	[p19l1518t2054r1576b2077],
19	%	NN	PERCENT	%	dep	17	SENT_310	[p19l1518t2054r1576b2077],
20	of400	NN	O	of400	nn	27	SENT_310	[p19l1584t2052r1667b2077],
21	mg	NN	O	mg	nn	27	SENT_310	[p19l1674t2060r1716b2084],
22	deleobuvir	NN	O	deleobuvir	nn	27	SENT_310	[p19l1725t2053r1878b2081],
23	,	,	O	,	_	0	SENT_310	[p19l1725t2053r1878b2081],
24	100	CD	PERCENT	100	number	25	SENT_310	[p19l1889t2054r1962b2077],
25	%	NN	PERCENT	%	amod	27	SENT_310	[p19l1889t2054r1962b2077],
26	of6OO	NN	O	of6oo	nn	27	SENT_310	[p19l1970t2052r2053b2077],
27	mg	NN	O	mg	prep_at	14	SENT_310	[p19l2060t2060r2102b2084],

1	+	CC	O	+	_	0	SENT_311	[p19l271t2091r469b2122],
2	fa	NN	O	fa	_	0	SENT_311	[p19l271t2091r469b2122],
3	|	NN	O	|	nn	4	SENT_311	[p19l271t2091r469b2122],
4	daprevir	NN	O	daprevir	dep	2	SENT_311	[p19l271t2091r469b2122],
5	+	CC	O	+	_	0	SENT_311	[p19l271t2091r469b2122],
6	RBV	NN	O	rbv	conj_+	2	SENT_311	[p19l478t2091r677b2120],
7	>	JJR	O	>	npadvmod	8	SENT_311	[p19l478t2091r677b2120],
8	<	JJR	O	<	amod	6	SENT_311	[p19l478t2091r677b2120],
9	4weeks	CD	NUMBER	4weeks	dep	2	SENT_311	[p19l478t2091r677b2120],
10	,	,	O	,	_	0	SENT_311	[p19l478t2091r677b2120],
11	deleobuvir	NN	O	deleobuvir	appos	9	SENT_311	[p19l1518t2091r1667b2116],
12	then	RB	O	then	prep	11	SENT_311	[p19l270t2131r332b2156],
13	PEG+RBV	NN	O	peg+rbv	pobj	12	SENT_311	[p19l342t2132r470b2156],
14	x	CC	O	x	_	0	SENT_311	[p19l477t2137r494b2155],
15	24-48	CD	NUMBER	24-48	num	16	SENT_311	[p19l503t2133r585b2156],
16	weeks	NNS	NUMBER	week	pobj	12	SENT_311	[p19l593t2131r677b2156],

1	SOUND	NN	O	sound	_	0	SENT_312	[p19l9t2225r282b2268],
2	.	.	O	.	_	0	SENT_312	[p19l9t2225r282b2268],

1	—	NN	O	—	_	0	SENT_313	[p19l9t2225r282b2268],
2	.	.	O	.	_	0	SENT_313	[p19l9t2225r282b2268],

1	C2	NN	O	c2	dep	14	SENT_314	[p19l9t2225r282b2268],
2	De	NNP	O	De	nn	4	SENT_314	[p19l468t2223r1119b2280],
3	|	CD	NUMBER	|	num	4	SENT_314	[p19l468t2223r1119b2280],
4	eobuvir	NN	O	eobuvir	dep	1	SENT_314	[p19l468t2223r1119b2280],
5	+	CC	O	+	_	0	SENT_314	[p19l468t2223r1119b2280],
6	fa	NN	O	fa	nn	10	SENT_314	[p19l468t2223r1119b2280],
7	|	NN	O	|	nn	10	SENT_314	[p19l468t2223r1119b2280],
8	dapreviri	NN	O	daprevirus	nn	10	SENT_314	[p19l468t2223r1119b2280],
9	RBV	NN	O	rbv	nn	10	SENT_314	[p19l1136t2226r1232b2268],
10	Genotype	NN	O	genotype	conj_+	1	SENT_314	[p19l1403t2226r1651b2281],
11	1	CD	NUMBER	1	dep	10	SENT_314	[p19l1669t2227r1970b2275],
12	,	,	O	,	_	0	SENT_314	[p19l1669t2227r1970b2275],
13	treatment	NN	O	treatment	appos	1	SENT_314	[p19l1669t2227r1970b2275],
14	naive	JJ	O	naive	_	0	SENT_314	[p19l1986t2226r2116b2268],

1	ABT	NNP	O	ABT	dep	13	SENT_315	[p19l465t2404r713b2449],
2	—	CD	NUMBER	—	num	3	SENT_315	[p19l465t2404r713b2449],
3	450/r	NN	O	450/r	dep	1	SENT_315	[p19l465t2404r713b2449],
4	+	CC	O	+	_	0	SENT_315	[p19l726t2414r758b2447],
5	ABT	NNP	O	ABT	dep	1	SENT_315	[p19l772t2405r976b2447],
6	—	CD	NUMBER	—	number	7	SENT_315	[p19l772t2405r976b2447],
7	333	CD	NUMBER	333	dep	5	SENT_315	[p19l772t2405r976b2447],
8	+	CC	O	+	_	0	SENT_315	[p19l992t2414r1024b2447],
9	RBV	NN	O	rbv	dep	10	SENT_315	[p19l1041t2405r1137b2447],
10	>	JJR	O	>	conj_+	5	SENT_315	[p19l1150t2414r1181b2446],
11	<	JJR	O	<	amod	12	SENT_315	[p19l1150t2414r1181b2446],
12	Genotype	NN	O	genotype	dep	13	SENT_315	[p19l1403t2405r1651b2460],
13	1	CD	NUMBER	1	_	0	SENT_315	[p19l1669t2406r1705b2454],
14	,	,	O	,	_	0	SENT_315	[p19l1669t2406r1705b2454],
15	treatment	NN	O	treatment	appos	13	SENT_315	[p19l1718t2409r1970b2447],
16	12	CD	DURATION	12	num	17	SENT_315	[p19l470t2477r523b2518],
17	weeks	NNS	NUMBER	week	tmod	18	SENT_315	[p19l537t2474r692b2518],
18	naive	JJ	O	naive	amod	15	SENT_315	[p19l1405t2476r1548b2525],
19	,	,	O	,	_	0	SENT_315	[p19l1405t2476r1548b2525],
20	and	CC	O	and	_	0	SENT_315	[p19l1562t2474r1654b2518],
21	previous	JJ	O	previous	amod	25	SENT_315	[p19l1671t2476r1884b2530],
22	partial	JJ	O	partial	amod	25	SENT_315	[p19l1901t2474r2056b2530],
23	and	CC	O	and	_	0	SENT_315	[p19l1403t2546r1495b2591],
24	null	JJ	O	null	amod	25	SENT_315	[p19l1513t2546r1601b2591],
25	responders	NNS	O	responder	conj_and	13	SENT_315	[p19l1619t2546r1898b2602],

1	AVIATOR	NNP	O	AVIATOR	nn	2	SENT_316	[p19l8t2694r223b2737],
2	ABT	NNP	O	ABT	_	0	SENT_316	[p19l465t2694r694b2739],
3	—	NN	O	—	dep	2	SENT_316	[p19l465t2694r694b2739],
4	450	CD	NUMBER	450	num	3	SENT_316	[p19l465t2694r694b2739],
5	/	:	O	/	punct	2	SENT_316	[p19l465t2694r694b2739],
6	r	NN	O	r	dep	2	SENT_316	[p19l698t2706r713b2737],
7	+	CC	O	+	_	0	SENT_316	[p19l726t2704r758b2737],
8	ABT	NNP	O	ABT	dep	2	SENT_316	[p19l772t2695r1014b2737],
9	—	CD	NUMBER	—	number	10	SENT_316	[p19l772t2695r1014b2737],
10	267	CD	NUMBER	267	dep	8	SENT_316	[p19l772t2695r1014b2737],
11	+	CC	O	+	_	0	SENT_316	[p19l772t2695r1014b2737],
12	ABT	NNP	O	ABT	conj_+	6	SENT_316	[p19l1028t2695r1232b2737],
13	—	CD	NUMBER	—	number	14	SENT_316	[p19l1028t2695r1232b2737],
14	333	CD	NUMBER	333	num	15	SENT_316	[p19l1028t2695r1232b2737],
15	Genotype	NN	O	genotype	dep	12	SENT_316	[p19l1403t2695r1651b2750],
16	1	CD	NUMBER	1	num	17	SENT_316	[p19l1669t2696r1683b2737],
17	treatment	NN	O	treatment	npadvmod	18	SENT_316	[p19l1705t2700r1958b2737],
18	naive	JJ	O	naive	amod	20	SENT_316	[p19l1973t2695r2104b2737],
19	ir	NN	O	ir	nn	20	SENT_316	[p19l466t2773r498b2809],
20	RBV	NN	O	rbv	dep	12	SENT_316	[p19l515t2767r611b2809],
21	and	CC	O	and	_	0	SENT_316	[p19l1403t2765r1495b2809],
22	previous	JJ	O	previous	amod	25	SENT_316	[p19l1512t2767r1726b2821],
23	null	JJ	O	null	amod	25	SENT_316	[p19l1742t2765r1829b2809],
24	responders	NNS	O	responder	nn	25	SENT_316	[p19l1848t2765r2126b2821],
25	Asunaprevir	NN	O	asunaprevir	conj_and	6	SENT_316	[p19l465t2847r769b2901],
26	+	CC	O	+	_	0	SENT_316	[p19l782t2855r814b2888],
27	daclatasvir	NN	O	daclatasvir	nn	28	SENT_316	[p19l828t2844r1097b2889],
28	Genotype	NN	O	genotype	conj_and	6	SENT_316	[p19l1403t2846r1651b2902],
29	1	CD	NUMBER	1	dep	28	SENT_316	[p19l1669t2848r1705b2896],
30	,	,	O	,	_	0	SENT_316	[p19l1669t2848r1705b2896],
31	previous	JJ	O	previous	amod	32	SENT_316	[p19l1721t2847r1934b2901],
32	nonresponders	NNS	O	nonresponder	appos	29	SENT_316	[p19l1405t2916r1784b2972],

1	Asunaprevir	NN	O	asunaprevir	_	0	SENT_317	[p19l465t2998r769b3052],
2	+	CC	O	+	_	0	SENT_317	[p19l782t3007r814b3040],
3	daclatasvir	NN	O	daclatasvir	dep	1	SENT_317	[p19l829t2996r1097b3041],
4	+	CC	O	+	_	0	SENT_317	[p19l1110t3007r1142b3040],
5	Genotype	NN	O	genotype	dep	1	SENT_317	[p19l1403t2998r1651b3053],
6	1	CD	NUMBER	1	num	5	SENT_317	[p19l1670t3000r1705b3048],
7	,	,	O	,	_	0	SENT_317	[p19l1670t3000r1705b3048],
8	treatment	NN	O	treatment	nn	10	SENT_317	[p19l1718t3003r1971b3041],
9	naive	JJ	O	naive	amod	10	SENT_317	[p19l1986t2998r2117b3041],
10	BMS-791325	NN	O	bms-791325	appos	5	SENT_317	[p19l468t3069r779b3112],

1	Sofosbuvir	NNP	O	Sofosbuvir	nn	3	SENT_318	[p19l466t3173r733b3219],
2	i	FW	O	i	nn	3	SENT_318	[p19l746t3182r778b3218],
3	RBV	NNP	O	RBV	_	0	SENT_318	[p19l795t3176r891b3218],
4	x	CC	O	x	_	0	SENT_318	[p19l904t3185r935b3218],
5	12	CD	DURATION	12	num	6	SENT_318	[p19l954t3177r1007b3218],
6	weeks	NNS	NUMBER	week	conj_x	3	SENT_318	[p19l1022t3174r1176b3219],
7	Genotypes	NNP	O	Genotypes	dep	3	SENT_318	[p19l1403t3176r1675b3231],
8	2	CD	NUMBER	2	num	7	SENT_318	[p19l1690t3177r1716b3218],
9	and	CC	O	and	_	0	SENT_318	[p19l1731t3174r1823b3219],
10	3	CD	DATE	3	dep	3	SENT_318	[p19l1839t3177r1864b3219],

1	SVR12	NN	O	svr12	_	0	SENT_319	[p19l93t3403r284b3455],
2	No	DT	O	no	det	3	SENT_319	[p19l743t3403r827b3455],
3	improvement	NN	O	improvement	nsubj	13	SENT_319	[p19l847t3403r1270b3470],
4	in	IN	O	in	_	0	SENT_319	[p19l1289t3403r1340b3455],
5	SVR	NN	O	svr	prep_in	3	SENT_319	[p19l1361t3403r1476b3455],
6	with	IN	O	with	_	0	SENT_319	[p19l1491t3401r1626b3455],
7	change	NN	O	change	prep_with	5	SENT_319	[p19l1647t3401r1876b3471],
8	in	IN	O	in	_	0	SENT_319	[p19l1895t3403r1946b3455],
9	deleobuvir	NN	O	deleobuvir	nn	10	SENT_319	[p19l740t3489r1078b3545],
10	dose	NN	O	dose	prep_in	7	SENT_319	[p19l1095t3489r1257b3553],
11	,	,	O	,	_	0	SENT_319	[p19l1095t3489r1257b3553],
12	RBV	NN	O	rbv	appos	10	SENT_319	[p19l1277t3491r1396b3544],
13	increases	VBZ	O	increase	rcmod	1	SENT_319	[p19l1413t3492r1696b3545],
14	SVR	NN	O	svr	dobj	13	SENT_319	[p19l1715t3491r1830b3545],

1	Primary	JJ	O	primary	_	0	SENT_320	[p20l95t43r349b111],
2	:	:	O	:	_	0	SENT_320	[p20l95t43r349b111],
3	eRVR	NN	O	ervr	dep	1	SENT_320	[p20l367t43r540b104],
4	,	,	O	,	_	0	SENT_320	[p20l367t43r540b104],
5	eRVR	NN	O	ervr	appos	3	SENT_320	[p20l740t43r899b95],
6	highest	JJS	O	highest	dep	5	SENT_320	[p20l918t41r1149b110],
7	among	IN	O	among	_	0	SENT_320	[p20l1166t57r1384b110],
8	naive	JJ	O	naive	amod	9	SENT_320	[p20l1406t43r1569b95],
9	patients	NNS	O	patient	prep_among	6	SENT_320	[p20l1589t43r1853b110],
10	.	.	O	.	_	0	SENT_320	[p20l1589t43r1853b110],

1	SVR12	NN	O	svr12	_	0	SENT_321	[p20l1871t42r2062b95],
2	secondary	JJ	O	secondary	dep	1	SENT_321	[p20l93t129r431b199],
3	:	:	O	:	_	0	SENT_321	[p20l93t129r431b199],
4	SVR12	NN	O	svr12	dep	1	SENT_321	[p20l449t131r641b183],
5	>	JJR	O	>	amod	4	SENT_321	[p20l742t132r918b184],
6	90	CD	PERCENT	90	num	7	SENT_321	[p20l742t132r918b184],
7	%	NN	PERCENT	%	dep	5	SENT_321	[p20l742t132r918b184],
8	in	IN	O	in	_	0	SENT_321	[p20l938t131r988b183],
9	treatment-naive	JJ	O	treatment-naive	amod	10	SENT_321	[p20l1007t131r1512b183],
10	patients	NNS	O	patient	prep_in	4	SENT_321	[p20l1532t131r1781b198],
11	and	CC	O	and	_	0	SENT_321	[p20l1799t129r1913b183],
12	47	CD	PERCENT	47	num	13	SENT_321	[p20l1931t132r2066b184],
13	%	NN	PERCENT	%	prep_in	4	SENT_321	[p20l1931t132r2066b184],

1	in	IN	O	in	_	0	SENT_322	[p20l742t219r793b271],
2	previously	RB	DATE	previously	advmod	3	SENT_322	[p20l815t217r1136b287],
3	treated	VBN	O	treat	amod	4	SENT_322	[p20l1150t217r1372b271],
4	patients	NNS	O	patient	pobj	1	SENT_322	[p20l1395t219r1644b286],

1	SVR12	NN	O	svr12	nn	5	SENT_323	[p20l93t345r284b398],
2	and	CC	O	and	_	0	SENT_323	[p20l303t344r417b398],
3	SVR24	NN	O	svr24	conj_and	1	SENT_323	[p20l438t345r631b398],
4	High	JJ	O	high	amod	5	SENT_323	[p20l743t344r885b413],
5	response	NN	O	response	_	0	SENT_323	[p20l908t360r1186b413],
6	and	CC	O	and	_	0	SENT_323	[p20l1204t344r1318b398],
7	low	JJ	O	low	amod	8	SENT_323	[p20l1341t344r1450b398],
8	relapse	NN	O	relapse	conj_and	5	SENT_323	[p20l1468t344r1688b413],
9	when	WRB	O	when	advmod	10	SENT_323	[p20l1705t344r1876b398],
10	treated	VBN	O	treat	dep	5	SENT_323	[p20l1894t344r2117b398],
11	with	IN	O	with	_	0	SENT_323	[p20l739t432r873b486],
12	quadruple	NN	O	quadruple	nn	13	SENT_323	[p20l894t432r1218b501],
13	therapy	NN	O	therapy	prep_with	10	SENT_323	[p20l1234t432r1476b502],
14	for	IN	O	for	_	0	SENT_323	[p20l1490t431r1576b486],
15	1	CD	NUMBER	1	prep_for	13	SENT_323	[p20l1597t436r1614b486],
16	2-24	CD	NUMBER	2-24	num	17	SENT_323	[p20l1632t435r1782b485],
17	weeks	NNS	NUMBER	week	tmod	13	SENT_323	[p20l1797t432r1989b486],

1	SVR12	NNP	O	SVR12	nn	2	SENT_324	[p20l93t531r284b584],
2	First	NNP	ORDINAL	First	_	0	SENT_324	[p20l743t532r869b584],
3	study	VB	O	study	dep	2	SENT_324	[p20l886t529r1058b600],
4	to	TO	O	to	aux	5	SENT_324	[p20l1072t538r1134b584],
5	show	VB	O	show	xcomp	3	SENT_324	[p20l1153t529r1318b584],
6	SVR	NN	ORGANIZATION	svr	dobj	5	SENT_324	[p20l1335t531r1450b584],
7	with	IN	O	with	_	0	SENT_324	[p20l1466t529r1600b584],
8	DAA	NN	O	daa	nn	9	SENT_324	[p20l1623t529r1921b600],
9	—	NN	O	—	prep_with	5	SENT_324	[p20l1623t529r1921b600],
10	on	IN	O	on	_	0	SENT_324	[p20l1623t529r1921b600],
11	|	NN	O	|	nn	16	SENT_324	[p20l1623t529r1921b600],
12	y	NN	O	y	nn	16	SENT_324	[p20l1623t529r1921b600],
13	therapy	NN	O	therapy	nn	16	SENT_324	[p20l739t617r981b688],
14	(	CD	NUMBER	(	number	15	SENT_324	[p20l999t619r1144b680],
15	4/21	CD	NUMBER	4/21	num	16	SENT_324	[p20l999t619r1144b680],
16	patients	NNS	O	patient	prep_on	9	SENT_324	[p20l1176t619r1445b686],
17	)	IN	O	)	prep	5	SENT_324	[p20l1176t619r1445b686],

1	SVR12	NN	O	svr12	_	0	SENT_325	[p20l93t717r284b770],
2	High	JJ	O	high	amod	4	SENT_325	[p20l743t715r885b785],
3	SVR	NN	O	svr	nn	4	SENT_325	[p20l906t717r1022b770],
4	rates	NNS	O	rate	dep	1	SENT_325	[p20l1041t724r1186b770],
5	after	IN	O	after	_	0	SENT_325	[p20l1204t715r1348b770],
6	12	CD	NUMBER	12	nn	9	SENT_325	[p20l1369t719r1435b769],
7	and	CC	O	and	_	0	SENT_325	[p20l1454t715r1568b770],
8	24	CD	DURATION	24	nn	9	SENT_325	[p20l1589t719r1662b769],
9	weeks	NNS	NUMBER	week	prep_after	4	SENT_325	[p20l1678t715r1870b770],
10	of	IN	O	of	_	0	SENT_325	[p20l1888t715r1952b770],
11	treatment	NN	O	treatment	prep_of	9	SENT_325	[p20l739t813r1052b860],

1	SVR24	NN	O	svr24	nsubj	16	SENT_326	[p20l93t939r286b992],
2	100	CD	PERCENT	100	number	3	SENT_326	[p20l746t941r917b992],
3	%	NN	PERCENT	%	amod	5	SENT_326	[p20l746t941r917b992],
4	oftreatment	NN	O	oftreatment	nn	5	SENT_326	[p20l937t936r1543b992],
5	—	NN	O	—	dobj	6	SENT_326	[p20l937t936r1543b992],
6	naive	JJ	O	naive	dep	1	SENT_326	[p20l937t936r1543b992],
7	patients	NNS	O	patient	nsubj	8	SENT_326	[p20l1566t940r1826b1006],
8	achieved	VBD	O	achieve	ccomp	6	SENT_326	[p20l740t1025r1028b1080],
9	SVR	NNP	ORGANIZATION	SVR	dobj	8	SENT_326	[p20l1052t1027r1183b1088],
10	,	,	O	,	_	0	SENT_326	[p20l1052t1027r1183b1088],
11	73	CD	PERCENT	73	num	12	SENT_326	[p20l1202t1028r1333b1080],
12	%	NN	PERCENT	%	appos	9	SENT_326	[p20l1202t1028r1333b1080],
13	of	IN	O	of	_	0	SENT_326	[p20l1350t1024r1414b1080],
14	previous	JJ	O	previous	amod	15	SENT_326	[p20l1429t1028r1694b1094],
15	nonresponders	NNS	O	nonresponder	prep_of	12	SENT_326	[p20l743t1113r1215b1182],
16	achieved	VBD	O	achieve	_	0	SENT_326	[p20l1232t1113r1510b1168],
17	SVR	NN	ORGANIZATION	svr	dobj	16	SENT_326	[p20l1530t1115r1646b1168],
18	after	IN	O	after	_	0	SENT_326	[p20l1663t1113r1806b1168],
19	16	CD	DURATION	16	num	20	SENT_326	[p20l1827t1117r1895b1168],
20	weeks	NNS	NUMBER	week	prep_after	16	SENT_326	[p20l1911t1113r2104b1168],

1	LONESTAR	NNP	LOCATION	LONESTAR	nn	2	SENT_327	[p20l21t1216r163b1240],
2	Sofosbuvir	NNP	O	Sofosbuvir	dep	11	SENT_327	[p20l271t1215r417b1240],
3	+	CC	O	+	cc	4	SENT_327	[p20l424t1221r442b1240],
4	ledipasvir	NN	O	ledipasvir	dep	2	SENT_327	[p20l451t1215r583b1247],
5	i	FW	O	i	nn	7	SENT_327	[p20l590t1220r607b1240],
6	RBV	FW	O	rbv	nn	7	SENT_327	[p20l616t1216r669b1240],
7	Genotype	NN	O	genotype	dep	4	SENT_327	[p20l784t1216r920b1247],
8	1	CD	PERCENT	1	num	9	SENT_327	[p20l930t1217r937b1240],
9	SVR12	NN	PERCENT	svr12	dep	11	SENT_327	[p20l1232t1216r1317b1240],
10	95	CD	PERCENT	95	num	11	SENT_327	[p20l1518t1217r1576b1240],
11	%	NN	PERCENT	%	dep	16	SENT_327	[p20l1518t1217r1576b1240],
12	without	IN	O	without	_	0	SENT_327	[p20l1583t1215r1692b1240],
13	RBV	NN	O	rbv	nn	14	SENT_327	[p20l1700t1216r1753b1240],
14	X	NN	O	x	prep_without	11	SENT_327	[p20l1760t1222r1777b1240],
15	8	CD	DURATION	8	num	16	SENT_327	[p20l1785t1217r1800b1240],
16	weeks	NNS	NUMBER	week	_	0	SENT_327	[p20l1807t1215r1899b1244],
17	,	,	O	,	_	0	SENT_327	[p20l1807t1215r1899b1244],
18	95	CD	PERCENT	95	num	19	SENT_327	[p20l1907t1217r1965b1240],
19	%	NN	PERCENT	%	advmod	16	SENT_327	[p20l1907t1217r1965b1240],
20	in	IN	O	in	prep	19	SENT_327	[p20l1974t1217r1996b1240],
21	previously	RB	DATE	previously	pcomp	20	SENT_327	[p20l1519t1254r1660b1286],
22	treated	VBN	O	treat	partmod	16	SENT_327	[p20l1666t1254r1764b1279],
23	patients	NNS	O	patient	dobj	22	SENT_327	[p20l1774t1256r1884b1286],
24	after	IN	O	after	_	0	SENT_327	[p20l1892t1254r1955b1279],
25	12	CD	DURATION	12	num	26	SENT_327	[p20l1964t1256r1994b1279],
26	weeks	NNS	NUMBER	week	prep_after	22	SENT_327	[p20l2001t1254r2086b1279],

1	Tegobuvir	NN	O	tegobuvir	_	0	SENT_328	[p20l270t1296r409b1327],
2	+	CC	O	+	_	0	SENT_328	[p20l416t1302r434b1320],
3	GS-5885	NN	O	gs-5885	conj_+	1	SENT_328	[p20l442t1297r556b1320],
4	+	CC	O	+	_	0	SENT_328	[p20l564t1302r582b1320],
5	Noncirrhotic	NNP	O	Noncirrhotic	conj_+	1	SENT_328	[p20l785t1296r963b1324],
6	,	,	O	,	_	0	SENT_328	[p20l785t1296r963b1324],
7	genotype	NN	O	genotype	nn	9	SENT_328	[p20l970t1300r1103b1327],
8	1	CD	NUMBER	1	num	9	SENT_328	[p20l1113t1298r1121b1320],
9	SVR12	NN	O	svr12	appos	5	SENT_328	[p20l1233t1297r1317b1320],
10	81	CD	PERCENT	81	num	12	SENT_328	[p20l1518t1297r1576b1320],
11	%	NN	PERCENT	%	nn	12	SENT_328	[p20l1518t1297r1576b1320],
12	GS-9451	NN	O	gs-9451	dep	1	SENT_328	[p20l271t1336r380b1359],
13	+	CC	O	+	_	0	SENT_328	[p20l393t1341r411b1359],
14	RBV	NN	O	rbv	conj_+	12	SENT_328	[p20l420t1336r473b1359],

1	DAA	NNP	O	DAA	nsubj	8	SENT_329	[p20l21t1415r79b1439],
2	,	,	O	,	_	0	SENT_329	[p20l21t1415r79b1439],
3	direct-acting	JJ	O	direct-acting	amod	4	SENT_329	[p20l86t1414r238b1442],
4	antiviral	JJ	O	antiviral	appos	1	SENT_329	[p20l246t1414r348b1439],
5	;	:	O	;	_	0	SENT_329	[p20l246t1414r348b1439],
6	eRVR	NN	O	ervr	dep	4	SENT_329	[p20l355t1415r422b1439],
7	,	,	O	,	_	0	SENT_329	[p20l355t1415r422b1439],
8	extended	VBD	O	extend	_	0	SENT_329	[p20l429t1414r542b1436],
9	rapid	JJ	O	rapid	amod	11	SENT_329	[p20l551t1414r610b1442],
10	virologic	JJ	O	virologic	amod	11	SENT_329	[p20l618t1414r721b1442],
11	response	NN	O	response	dobj	8	SENT_329	[p20l729t1421r843b1442],
12	;	:	O	;	_	0	SENT_329	[p20l729t1421r843b1442],
13	PEG	NNP	O	PEG	nsubj	24	SENT_329	[p20l850t1415r902b1439],
14	,	,	O	,	_	0	SENT_329	[p20l850t1415r902b1439],
15	pegylated	VBN	O	pegylate	partmod	13	SENT_329	[p20l910t1414r1029b1442],
16	interferon-alfa	NN	O	interferon-alfa	dep	15	SENT_329	[p20l1037t1414r1215b1439],
17	;	:	O	;	_	0	SENT_329	[p20l1037t1414r1215b1439],
18	RBV	NN	O	rbv	dep	16	SENT_329	[p20l1223t1415r1272b1439],
19	,	,	O	,	_	0	SENT_329	[p20l1223t1415r1272b1439],
20	ribavirin	NNP	O	ribavirin	appos	18	SENT_329	[p20l1280t1414r1384b1439],
21	;	:	O	;	_	0	SENT_329	[p20l1280t1414r1384b1439],
22	SVR	NNP	ORGANIZATION	SVR	dep	16	SENT_329	[p20l1391t1415r1441b1439],
23	,	,	O	,	_	0	SENT_329	[p20l1391t1415r1441b1439],
24	sustained	VBD	O	sustain	parataxis	8	SENT_329	[p20l1448t1414r1562b1436],
25	virologic	JJ	O	virologic	amod	26	SENT_329	[p20l1569t1414r1673b1442],
26	response	NN	O	response	dobj	24	SENT_329	[p20l1681t1421r1794b1442],
27	.	.	O	.	_	0	SENT_329	[p20l1681t1421r1794b1442],

1	eRVR	NN	O	ervr	nsubjpass	3	SENT_330	[p20l83t1603r281b1661],
2	was	VBD	O	be	auxpass	3	SENT_330	[p20l298t1621r424b1661],
3	achieved	VBN	O	achieve	_	0	SENT_330	[p20l446t1598r746b1661],
4	in	IN	O	in	_	0	SENT_330	[p20l767t1604r833b1660],
5	89	CD	PERCENT	89	num	6	SENT_330	[p20l855t1604r996b1662],
6	%	NN	PERCENT	%	prep_in	3	SENT_330	[p20l855t1604r996b1662],
7	of	IN	O	of	_	0	SENT_330	[p20l1020t1598r1094b1661],
8	patients	NNS	O	patient	prep_of	6	SENT_330	[p20l1104t1604r1374b1681],
9	in	IN	O	in	_	0	SENT_330	[p20l1396t1604r1462b1660],
10	group	NN	O	group	prep_in	8	SENT_330	[p20l1483t1620r1684b1682],
11	1	CD	NUMBER	1	num	10	SENT_330	[p20l1712t1605r1737b1660],
12	and	CC	O	and	_	0	SENT_330	[p20l1765t1598r1891b1661],
13	in	IN	O	in	_	0	SENT_330	[p20l1911t1604r1978b1660],
14	79	CD	PERCENT	79	num	15	SENT_330	[p20l2001t1604r2141b1662],
15	%	NN	PERCENT	%	conj_and	6	SENT_330	[p20l2001t1604r2141b1662],
16	of	IN	O	of	_	0	SENT_330	[p20l9t1702r83b1765],
17	patients	NNS	O	patient	prep_of	15	SENT_330	[p20l93t1708r364b1785],
18	in	IN	O	in	_	0	SENT_330	[p20l386t1708r452b1764],
19	group	NN	O	group	prep_in	17	SENT_330	[p20l473t1724r674b1786],
20	2	CD	NUMBER	2	num	19	SENT_330	[p20l696t1709r751b1765],
21	.	.	O	.	_	0	SENT_330	[p20l696t1709r751b1765],

1	Among	IN	O	among	_	0	SENT_331	[p20l774t1706r1033b1786],
2	patients	NNS	O	patient	prep_among	10	SENT_331	[p20l1052t1708r1322b1785],
3	in	IN	O	in	_	0	SENT_331	[p20l1344t1708r1410b1764],
4	groups	NNS	O	group	prep_in	2	SENT_331	[p20l1431t1724r1665b1786],
5	1	CD	NUMBER	1	num	4	SENT_331	[p20l1693t1709r1718b1764],
6	and	CC	O	and	_	0	SENT_331	[p20l1746t1702r1872b1765],
7	2	CD	NUMBER	2	prep_in	2	SENT_331	[p20l1892t1709r1948b1774],
8	,	,	O	,	_	0	SENT_331	[p20l1892t1709r1948b1774],
9	none	NN	O	none	nsubj	10	SENT_331	[p20l1971t1725r2141b1765],
10	had	VBD	O	have	_	0	SENT_331	[p20l8t1805r139b1868],
11	viral	JJ	O	viral	amod	12	SENT_331	[p20l159t1805r320b1868],
12	breakthrough	NN	O	breakthrough	dobj	10	SENT_331	[p20l342t1805r848b1889],
13	,	,	O	,	_	0	SENT_331	[p20l342t1805r848b1889],
14	and	CC	O	and	_	0	SENT_331	[p20l875t1805r1005b1868],
15	none	NN	O	none	nsubj	19	SENT_331	[p20l1028t1828r1203b1868],
16	who	WP	O	who	nsubj	17	SENT_331	[p20l1226t1805r1377b1868],
17	completed	VBD	O	complete	rcmod	15	SENT_331	[p20l1403t1805r1773b1888],
18	treatment	NN	O	treatment	dobj	17	SENT_331	[p20l1795t1817r2143b1868],
19	had	VBD	O	have	conj_and	10	SENT_331	[p20l8t1908r135b1971],
20	viral	JJ	O	viral	amod	21	SENT_331	[p20l152t1908r308b1971],
21	relapse	NN	O	relapse	dobj	19	SENT_331	[p20l329t1908r582b1991],
22	.	.	O	.	_	0	SENT_331	[p20l329t1908r582b1991],

1	SVR12	NN	O	svr12	nsubj	4	SENT_332	[p20l607t1912r839b1971],
2	was	VBD	O	be	cop	4	SENT_332	[p20l860t1931r986b1971],
3	95	CD	PERCENT	95	num	4	SENT_332	[p20l1008t1913r1150b1973],
4	%	NN	PERCENT	%	_	0	SENT_332	[p20l1008t1913r1150b1973],
5	in	IN	O	in	_	0	SENT_332	[p20l1173t1914r1240b1970],
6	group	NN	O	group	prep_in	4	SENT_332	[p20l1261t1930r1461b1992],
7	1	CD	NUMBER	1	num	6	SENT_332	[p20l1490t1915r1514b1970],
8	and	CC	O	and	_	0	SENT_332	[p20l1542t1908r1669b1971],
9	93	CD	PERCENT	93	num	10	SENT_332	[p20l1689t1913r1831b1973],
10	%	NN	PERCENT	%	conj_and	4	SENT_332	[p20l1689t1913r1831b1973],
11	in	IN	O	in	_	0	SENT_332	[p20l1854t1914r1921b1970],
12	group	NN	O	group	prep_in	10	SENT_332	[p20l1942t1930r2142b1992],
13	2	CD	NUMBER	2	num	12	SENT_332	[p20l9t2018r64b2074],
14	.	.	O	.	_	0	SENT_332	[p20l9t2018r64b2074],

1	Group	NNP	O	Group	nsubj	3	SENT_333	[p20l94t2015r320b2094],
2	3	CD	NUMBER	3	num	1	SENT_333	[p20l348t2018r382b2074],
3	had	VBD	O	have	_	0	SENT_333	[p20l409t2011r541b2074],
4	eRVR	NN	O	ervr	dobj	3	SENT_333	[p20l565t2016r770b2074],
5	in	IN	O	in	_	0	SENT_333	[p20l793t2017r861b2073],
6	59	CD	PERCENT	59	num	7	SENT_333	[p20l887t2016r1033b2076],
7	%	NN	PERCENT	%	prep_in	4	SENT_333	[p20l887t2016r1033b2076],
8	and	CC	O	and	_	0	SENT_333	[p20l1060t2011r1191b2074],
9	SVR12	NN	O	svr12	prep_in	4	SENT_333	[p20l1216t2015r1455b2074],
10	in	IN	O	in	_	0	SENT_333	[p20l1482t2017r1551b2073],
11	47	CD	PERCENT	47	num	12	SENT_333	[p20l1575t2017r1722b2075],
12	%	NN	PERCENT	%	prep_in	3	SENT_333	[p20l1575t2017r1722b2075],
13	of	IN	O	of	_	0	SENT_333	[p20l1750t2011r1826b2074],
14	patients	NNS	O	patient	prep_of	12	SENT_333	[p20l1840t2017r2139b2094],
15	.	.	O	.	_	0	SENT_333	[p20l1840t2017r2139b2094],

1	Among	IN	O	among	_	0	SENT_334	[p20l8t2118r275b2198],
2	those	DT	O	those	det	3	SENT_334	[p20l297t2114r487b2177],
3	patients	NNS	O	patient	prep_among	19	SENT_334	[p20l512t2120r793b2197],
4	in	IN	O	in	_	0	SENT_334	[p20l818t2120r887b2176],
5	group	NN	O	group	prep_in	3	SENT_334	[p20l912t2136r1120b2198],
6	3	CD	NUMBER	3	num	5	SENT_334	[p20l1147t2121r1181b2177],
7	who	WP	O	who	nsubj	10	SENT_334	[p20l1207t2114r1359b2177],
8	did	VBD	O	do	aux	10	SENT_334	[p20l1386t2114r1501b2177],
9	not	RB	O	not	neg	10	SENT_334	[p20l1525t2126r1643b2177],
10	achieve	VB	O	achieve	rcmod	3	SENT_334	[p20l1668t2114r1930b2177],
11	RVR	NNP	MISC	RVR	dobj	10	SENT_334	[p20l1956t2119r2141b2186],
12	,	,	O	,	_	0	SENT_334	[p20l1956t2119r2141b2186],
13	six	CD	NUMBER	six	nsubj	19	SENT_334	[p20l9t2223r105b2280],
14	had	VBD	O	have	partmod	13	SENT_334	[p20l126t2217r257b2280],
15	virologic	JJ	O	virologic	amod	16	SENT_334	[p20l278t2217r591b2301],
16	breakthrough	NN	O	breakthrough	dobj	14	SENT_334	[p20l613t2217r1098b2301],
17	and	CC	O	and	_	0	SENT_334	[p20l1123t2217r1252b2280],
18	three	CD	NUMBER	three	conj_and	16	SENT_334	[p20l1274t2217r1454b2280],
19	relapsed	VBD	O	relapse	_	0	SENT_334	[p20l1479t2217r1788b2300],
20	.	.	O	.	_	0	SENT_334	[p20l1479t2217r1788b2300],

1	The	DT	O	the	det	4	SENT_335	[p20l1815t2217r1943b2280],
2	most	RBS	O	most	advmod	4	SENT_335	[p20l1967t2229r2141b2280],
3	common	JJ	O	common	amod	4	SENT_335	[p20l9t2343r320b2383],
4	AEs	NNS	O	ae	nsubj	5	SENT_335	[p20l343t2324r482b2383],
5	included	VBD	O	include	_	0	SENT_335	[p20l507t2320r811b2383],
6	abnormal	JJ	O	abnormal	amod	9	SENT_335	[p20l834t2320r1169b2383],
7	liver	NN	O	liver	nn	9	SENT_335	[p20l1191t2320r1345b2383],
8	function	NN	O	function	nn	9	SENT_335	[p20l1367t2320r1665b2383],
9	tests	NNS	O	test	dobj	5	SENT_335	[p20l1688t2332r1859b2392],
10	,	,	O	,	_	0	SENT_335	[p20l1688t2332r1859b2392],
11	fatigue	NN	O	fatigue	conj_and	9	SENT_335	[p20l1884t2320r2138b2404],
12	,	,	O	,	_	0	SENT_335	[p20l1884t2320r2138b2404],
13	nausea	NN	O	nausea	conj_and	9	SENT_335	[p20l8t2446r244b2486],
14	and	CC	O	and	_	0	SENT_335	[p20l265t2423r392b2486],
15	vomiting	NN	O	vomiting	conj_and	9	SENT_335	[p20l409t2429r741b2507],
16	,	,	O	,	_	0	SENT_335	[p20l409t2429r741b2507],
17	headache	NN	O	headache	conj_and	15	SENT_335	[p20l764t2423r1105b2495],
18	,	,	O	,	_	0	SENT_335	[p20l764t2423r1105b2495],
19	dizziness	NN	O	dizziness	conj_and	15	SENT_335	[p20l1129t2423r1456b2495],
20	,	,	O	,	_	0	SENT_335	[p20l1129t2423r1456b2495],
21	insomnia	NN	O	insomnia	conj_and	15	SENT_335	[p20l1480t2429r1821b2495],
22	,	,	O	,	_	0	SENT_335	[p20l1480t2429r1821b2495],
23	pruritus	NN	O	pruritus	conj_and	9	SENT_335	[p20l1843t2429r2142b2506],
24	,	,	O	,	_	0	SENT_335	[p20l1843t2429r2142b2506],
25	and	CC	O	and	_	0	SENT_335	[p20l9t2525r136b2589],
26	rash	NN	O	rash	conj_and	15	SENT_335	[p20l158t2517r385b2589],
27	.	.	O	.	_	0	SENT_335	[p20l158t2517r385b2589],

1	“	NN	O	“	_	0	SENT_336	[p20l158t2517r385b2589],

1	The	DT	O	the	det	3	SENT_337	[p20l82t2629r205b2692],
2	AVIATOR	NN	O	aviator	nn	3	SENT_337	[p20l225t2632r582b2692],
3	trial	NN	O	trial	nsubj	4	SENT_337	[p20l599t2629r737b2692],
4	used	VBD	O	use	_	0	SENT_337	[p20l756t2629r913b2692],
5	a	DT	O	a	det	6	SENT_337	[p20l933t2652r967b2692],
6	regimen	NN	O	regimen	nsubj	7	SENT_337	[p20l986t2635r1264b2713],
7	similar	JJ	O	similar	xcomp	4	SENT_337	[p20l1285t2629r1519b2692],
8	to	TO	O	to	_	0	SENT_337	[p20l1536t2641r1602b2692],
9	that	DT	O	that	prep_to	7	SENT_337	[p20l1622t2629r1754b2692],
10	of	IN	O	of	_	0	SENT_337	[p20l1773t2629r1846b2692],
11	Poordad	NNP	O	Poordad	prep_of	9	SENT_337	[p20l1857t2629r2144b2692],
12	et	FW	O	et	nn	13	SENT_337	[p20l10t2742r72b2795],
13	al.	FW	O	al.	dep	11	SENT_337	[p20l99t2731r203b2803],
14	,	,	O	,	_	0	SENT_337	[p20l99t2731r203b2803],
15	with	IN	O	with	_	0	SENT_337	[p20l234t2731r395b2795],
16	the	DT	O	the	det	17	SENT_337	[p20l424t2731r536b2795],
17	addition	NN	O	addition	prep_with	4	SENT_337	[p20l567t2731r873b2795],
18	of	IN	O	of	_	0	SENT_337	[p20l904t2731r981b2795],
19	ABT-267	NN	O	abt-267	prep_of	17	SENT_337	[p20l1000t2734r1348b2803],
20	,	,	O	,	_	0	SENT_337	[p20l1000t2734r1348b2803],
21	an	DT	O	a	det	23	SENT_337	[p20l1381t2754r1464b2795],
22	NSSA	NNP	ORGANIZATION	NSSA	nn	23	SENT_337	[p20l1493t2735r1706b2795],
23	inhibitor	NN	O	inhibitor	appos	19	SENT_337	[p20l1736t2723r2141b2795],
24	.	.	O	.	_	0	SENT_337	[p20l1736t2723r2141b2795],

1	“	NN	O	“	nn	2	SENT_338	[p20l1736t2723r2141b2795],
2	Genotype	NN	O	genotype	nsubjpass	13	SENT_338	[p20l10t2839r362b2919],
3	1	CD	NUMBER	1	dep	2	SENT_338	[p20l400t2842r451b2907],
4	,	,	O	,	_	0	SENT_338	[p20l400t2842r451b2907],
5	treatment	NN	O	treatment	nn	6	SENT_338	[p20l482t2841r1085b2907],
6	—	NN	O	—	conj_and	2	SENT_338	[p20l482t2841r1085b2907],
7	naive	JJ	O	naive	amod	6	SENT_338	[p20l482t2841r1085b2907],
8	,	,	O	,	_	0	SENT_338	[p20l482t2841r1085b2907],
9	and	CC	O	and	_	0	SENT_338	[p20l1118t2835r1250b2898],
10	null-responder	JJ	O	null-responder	amod	11	SENT_338	[p20l1279t2835r1827b2918],
11	patients	NNS	O	patient	conj_and	2	SENT_338	[p20l1854t2841r2141b2918],
12	were	VBD	O	be	auxpass	13	SENT_338	[p20l7t2961r169b3001],
13	enrolled	VBN	O	enrol	_	0	SENT_338	[p20l193t2938r495b3010],
14	,	,	O	,	_	0	SENT_338	[p20l193t2938r495b3010],
15	and	CC	O	and	_	0	SENT_338	[p20l520t2938r648b3001],
16	treatment-naive	JJ	O	treatment-naive	amod	17	SENT_338	[p20l668t2944r1223b3001],
17	patients	NNS	O	patient	nsubjpass	19	SENT_338	[p20l1245t2944r1517b3021],
18	were	VBD	O	be	auxpass	19	SENT_338	[p20l1539t2961r1701b3001],
19	randomized	VBN	O	randomize	conj_and	13	SENT_338	[p20l1725t2938r2144b3001],
20	to	TO	O	to	_	0	SENT_338	[p20l8t3053r75b3104],
21	one	CD	TIME	one	prep_to	19	SENT_338	[p20l102t3064r228b3104],
22	of	IN	TIME	of	_	0	SENT_338	[p20l253t3041r329b3104],
23	six	CD	TIME	six	num	25	SENT_338	[p20l345t3047r441b3104],
24	treatment	NN	O	treatment	nn	25	SENT_338	[p20l462t3053r810b3104],
25	arms	NNS	O	arm	prep_of	21	SENT_338	[p20l834t3064r1025b3113],
26	,	,	O	,	_	0	SENT_338	[p20l834t3064r1025b3113],
27	which	WDT	O	which	nsubj	28	SENT_338	[p20l1049t3041r1265b3104],
28	comprised	VBD	O	comprise	rcmod	25	SENT_338	[p20l1291t3041r1663b3124],
29	ABT-450	JJ	O	abt-450	amod	40	SENT_338	[p20l1686t3044r2035b3107],
30	/	:	O	/	punct	37	SENT_338	[p20l1686t3044r2035b3107],
31	r	NN	O	r	dep	37	SENT_338	[p20l2041t3064r2070b3103],
32	i	FW	O	i	nn	31	SENT_338	[p20l2096t3055r2139b3103],
33	ABT	FW	O	abt	nn	31	SENT_338	[p20l8t3147r327b3207],
34	—	FW	O	—	dep	31	SENT_338	[p20l8t3147r327b3207],
35	267	CD	NUMBER	267	num	36	SENT_338	[p20l8t3147r327b3207],
36	iABT	NN	O	iabt	dep	31	SENT_338	[p20l353t3147r719b3207],
37	—	NN	O	—	dep	29	SENT_338	[p20l353t3147r719b3207],
38	333	CD	NUMBER	333	num	37	SENT_338	[p20l353t3147r719b3207],
39	:	:	O	:	_	0	SENT_338	[p20l748t3158r791b3206],
40	RBV	NN	O	rbv	dobj	28	SENT_338	[p20l819t3149r982b3207],
41	for	IN	O	for	_	0	SENT_338	[p20l1005t3144r1106b3207],
42	8-24	CD	NUMBER	8-24	num	43	SENT_338	[p20l1131t3151r1299b3207],
43	weeks	NNS	NUMBER	week	prep_for	28	SENT_338	[p20l1321t3144r1550b3207],
44	.	.	O	.	_	0	SENT_338	[p20l1321t3144r1550b3207],

1	Null	JJ	O	null	amod	2	SENT_339	[p20l1576t3144r1730b3207],
2	responders	NNS	O	responder	nsubjpass	4	SENT_339	[p20l1754t3144r2142b3227],
3	were	VBD	O	be	auxpass	4	SENT_339	[p20l7t3270r170b3310],
4	treated	VBN	O	treat	_	0	SENT_339	[p20l193t3247r436b3310],
5	with	IN	O	with	_	0	SENT_339	[p20l457t3247r612b3310],
6	one	CD	NUMBER	one	prep_with	4	SENT_339	[p20l636t3270r760b3310],
7	of	IN	O	of	_	0	SENT_339	[p20l784t3247r859b3310],
8	the	DT	O	the	det	9	SENT_339	[p20l872t3247r980b3310],
9	regimens	NNS	O	regimen	prep_of	6	SENT_339	[p20l1004t3253r1323b3331],
10	comprising	VBG	O	comprise	xcomp	4	SENT_339	[p20l1347t3253r1743b3331],
11	ABT-450	NN	O	abt-450	dobj	10	SENT_339	[p20l1763t3250r2108b3313],
12	/	:	O	/	punct	13	SENT_339	[p20l1763t3250r2108b3313],
13	r	NN	O	r	dep	11	SENT_339	[p20l2113t3270r2143b3309],
14	+	CC	O	+	_	0	SENT_339	[p20l10t3369r53b3412],
15	ABT	NNP	O	ABT	dep	11	SENT_339	[p20l77t3353r391b3413],
16	—	CD	NUMBER	—	number	17	SENT_339	[p20l77t3353r391b3413],
17	267	CD	NUMBER	267	dep	11	SENT_339	[p20l77t3353r391b3413],
18	:	:	O	:	_	0	SENT_339	[p20l416t3364r458b3412],
19	ABT	NNP	O	ABT	dep	17	SENT_339	[p20l483t3353r794b3413],
20	—	CD	NUMBER	—	number	21	SENT_339	[p20l483t3353r794b3413],
21	333	CD	NUMBER	333	dep	19	SENT_339	[p20l483t3353r794b3413],
22	+	CC	O	+	_	0	SENT_339	[p20l822t3369r864b3412],
23	RBV	NN	O	rbv	conj_+	11	SENT_339	[p20l890t3355r1051b3413],
24	for	IN	O	for	_	0	SENT_339	[p20l1074t3350r1172b3413],
25	12	CD	NUMBER	12	num	28	SENT_339	[p20l1201t3357r1272b3412],
26	or	CC	O	or	_	0	SENT_339	[p20l1297t3373r1370b3413],
27	24	CD	DURATION	24	num	28	SENT_339	[p20l1392t3357r1472b3412],
28	weeks	NNS	NUMBER	week	prep_for	23	SENT_339	[p20l1493t3350r1717b3413],
29	.	.	O	.	_	0	SENT_339	[p20l1493t3350r1717b3413],

1	The	DT	O	the	det	3	SENT_340	[p20l1742t3350r1869b3413],
2	highest	JJS	O	highest	amod	3	SENT_340	[p20l1891t3350r2143b3434],
3	SVR12	NN	O	svr12	nsubj	10	SENT_340	[p20l10t3457r242b3516],
4	and	CC	O	and	_	0	SENT_340	[p20l268t3453r395b3516],
5	SVR24	NN	O	svr24	nn	6	SENT_340	[p20l417t3457r652b3516],
6	rates	NNS	O	rate	nsubj	10	SENT_340	[p20l675t3465r834b3516],
7	among	IN	O	among	_	0	SENT_340	[p20l859t3476r1095b3537],
8	treatment-naive	JJ	O	treatment-naive	amod	9	SENT_340	[p20l1115t3459r1666b3516],
9	patients	NNS	O	patient	prep_among	3	SENT_340	[p20l1688t3459r1958b3536],
10	were	VBD	O	be	_	0	SENT_340	[p20l1980t3476r2142b3516],
11	in	IN	O	in	_	0	SENT_340	[p20l9t3562r74b3618],
12	those	DT	O	those	prep_in	10	SENT_340	[p20l93t3556r273b3619],
13	on	IN	O	on	_	0	SENT_340	[p20l293t3579r378b3619],
14	quadruple	NN	O	quadruple	nn	15	SENT_340	[p20l399t3556r742b3639],
15	therapy	NN	O	therapy	prep_on	12	SENT_340	[p20l761t3556r1026b3640],
16	,	,	O	,	_	0	SENT_340	[p20l761t3556r1026b3640],
17	with	IN	O	with	_	0	SENT_340	[p20l1046t3556r1196b3619],
18	rates	NNS	O	rate	prep_with	10	SENT_340	[p20l1217t3568r1372b3619],
19	of	IN	O	of	_	0	SENT_340	[p20l1393t3556r1466b3619],
20	99	CD	NUMBER	99	prep_of	18	SENT_340	[p20l1477t3563r1552b3619],
21	and	CC	O	and	_	0	SENT_340	[p20l1574t3556r1698b3619],
22	96	CD	PERCENT	96	num	23	SENT_340	[p20l1718t3561r1877b3628],
23	%	NN	PERCENT	%	prep_of	18	SENT_340	[p20l1718t3561r1877b3628],
24	,	,	O	,	_	0	SENT_340	[p20l1718t3561r1877b3628],
25	respectively	RB	O	respectively	advmod	10	SENT_340	[p20l1899t3578r2139b3639, p20l8t3659r203b3743],
26	.	.	O	.	_	0	SENT_340	[p20l1899t3578r2139b3639, p20l8t3659r203b3743],

1	Among	IN	O	among	_	0	SENT_341	[p20l229t3663r490b3743],
2	null	JJ	O	null	amod	3	SENT_341	[p20l512t3659r646b3722],
3	responders	NNS	O	responder	pobj	1	SENT_341	[p20l668t3659r1068b3742],
4	,	,	O	,	_	0	SENT_341	[p20l668t3659r1068b3742],
5	the	DT	O	the	det	7	SENT_341	[p20l1091t3659r1199b3722],
6	highest	JJS	O	highest	amod	7	SENT_341	[p20l1221t3659r1473b3743],
7	SVR12	NN	O	svr12	pobj	1	SENT_341	[p20l1496t3663r1730b3722],
8	and	CC	O	and	_	0	SENT_341	[p20l1756t3659r1883b3722],
9	SVR24	NN	O	svr24	pobj	1	SENT_341	[p20l1906t3663r2142b3722],

1	rates	NNS	O	rate	nsubjpass	3	SENT_342	[p21l9t28r168b79],
2	were	VBD	O	be	auxpass	3	SENT_342	[p21l190t39r352b79],
3	seen	VBN	O	see	_	0	SENT_342	[p21l377t39r527b79],
4	in	IN	O	in	_	0	SENT_342	[p21l550t22r617b78],
5	those	DT	O	those	prep_in	3	SENT_342	[p21l639t16r824b79],
6	treated	VBN	O	treat	partmod	5	SENT_342	[p21l846t16r1086b79],
7	with	IN	O	with	_	0	SENT_342	[p21l1107t16r1261b79],
8	quadruple	NN	O	quadruple	nn	9	SENT_342	[p21l1284t16r1637b99],
9	therapy	NN	O	therapy	prep_with	6	SENT_342	[p21l1659t16r1924b100],
10	for	IN	O	for	_	0	SENT_342	[p21l1943t16r2041b79],
11	24	CD	DURATION	24	num	12	SENT_342	[p21l2064t23r2143b78],
12	weeks	NNS	NUMBER	week	prep_for	6	SENT_342	[p21l7t119r229b191],
13	,	,	O	,	_	0	SENT_342	[p21l7t119r229b191],
14	with	IN	O	with	_	0	SENT_342	[p21l252t119r405b182],
15	rates	NNS	O	rate	prep_with	6	SENT_342	[p21l428t131r586b182],
16	of	IN	O	of	_	0	SENT_342	[p21l609t119r683b182],
17	98	CD	NUMBER	98	prep_of	15	SENT_342	[p21l697t126r773b182],
18	and	CC	O	and	_	0	SENT_342	[p21l799t119r925b182],
19	93	CD	PERCENT	93	num	20	SENT_342	[p21l947t124r1109b191],
20	%	NN	PERCENT	%	prep_with	6	SENT_342	[p21l947t124r1109b191],
21	,	,	O	,	_	0	SENT_342	[p21l947t124r1109b191],
22	respectively	RB	O	respectively	advmod	20	SENT_342	[p21l1134t119r1546b203],
23	.	.	O	.	_	0	SENT_342	[p21l1134t119r1546b203],

1	No	DT	O	no	det	2	SENT_343	[p21l1571t124r1673b182],
2	relapses	NNS	O	relapse	nsubjpass	6	SENT_343	[p21l1697t119r1965b202],
3	after	IN	O	after	_	0	SENT_343	[p21l1989t119r2141b182],
4	treatment	NN	O	treatment	prep_after	2	SENT_343	[p21l8t234r343b285],
5	were	VBD	O	be	auxpass	6	SENT_343	[p21l361t245r521b285],
6	seen	VBN	O	see	_	0	SENT_343	[p21l544t245r692b285],
7	in	IN	O	in	_	0	SENT_343	[p21l713t228r780b284],
8	patients	NNS	O	patient	prep_in	6	SENT_343	[p21l799t228r1068b305],
9	who	WP	O	who	nsubj	10	SENT_343	[p21l1088t222r1234b285],
10	receive	VBP	O	receive	rcmod	8	SENT_343	[p21l1257t228r1492b285],
11	quadruple	NN	O	quadruple	nn	12	SENT_343	[p21l1514t222r1863b305],
12	therapy	NN	O	therapy	dobj	10	SENT_343	[p21l1883t222r2145b306],
13	for	IN	O	for	_	0	SENT_343	[p21l8t325r109b388],
14	either	CC	O	either	preconj	15	SENT_343	[p21l134t325r339b388],
15	12	CD	NUMBER	12	prep_for	12	SENT_343	[p21l371t332r443b387],
16	or	CC	O	or	_	0	SENT_343	[p21l471t348r545b388],
17	24	CD	DURATION	24	num	18	SENT_343	[p21l570t332r651b387],
18	weeks	NNS	NUMBER	week	prep_for	12	SENT_343	[p21l675t325r904b388],
19	.	.	O	.	_	0	SENT_343	[p21l675t325r904b388],

1	There	EX	O	there	expl	2	SENT_344	[p21l933t325r1132b388],
2	was	VBD	O	be	_	0	SENT_344	[p21l1156t348r1286b388],
3	no	DT	O	no	det	6	SENT_344	[p21l1312t348r1401b388],
4	clinically	RB	O	clinically	advmod	5	SENT_344	[p21l1428t325r1750b409],
5	signiﬁcant	JJ	O	signiﬁcant	amod	6	SENT_344	[p21l1773t325r2142b409],
6	dilference	NN	O	dilference	nsubj	2	SENT_344	[p21l9t428r342b491],
7	in	IN	O	in	_	0	SENT_344	[p21l362t434r428b490],
8	response	NN	O	response	prep_in	6	SENT_344	[p21l448t450r745b511],
9	based	VBN	O	base	partmod	8	SENT_344	[p21l763t428r958b491],
10	on	IN	O	on	_	0	SENT_344	[p21l977t451r1062b491],
11	sex	NN	O	sex	prep_on	9	SENT_344	[p21l1083t451r1205b500],
12	,	,	O	,	_	0	SENT_344	[p21l1083t451r1205b500],
13	HCV	NN	O	hcv	nn	14	SENT_344	[p21l1227t432r1405b491],
14	subtype	NN	O	subtype	prep_on	9	SENT_344	[p21l1426t428r1704b512],
15	,	,	O	,	_	0	SENT_344	[p21l1426t428r1704b512],
16	IL28B	NN	O	il28b	nn	17	SENT_344	[p21l1724t433r1927b491],
17	genotype	NN	O	genotype	prep_on	9	SENT_344	[p21l1950t451r2139b512, p21l8t543r174b615],
18	,	,	O	,	_	0	SENT_344	[p21l1950t451r2139b512, p21l8t543r174b615],
19	or	CC	O	or	_	0	SENT_344	[p21l200t554r273b594],
20	ﬁbrosis	NN	O	ﬁbrosis	nn	21	SENT_344	[p21l295t531r545b594],
21	stage	NN	O	stage	prep_on	9	SENT_344	[p21l570t543r757b615],
22	.	.	O	.	_	0	SENT_344	[p21l570t543r757b615],

1	Treatment	NN	O	treatment	nsubjpass	3	SENT_345	[p21l783t534r1144b594],
2	was	VBD	O	be	auxpass	3	SENT_345	[p21l1165t554r1293b594],
3	discontinued	VBN	O	discontinue	_	0	SENT_345	[p21l1317t531r1773b594],
4	in	IN	O	in	_	0	SENT_345	[p21l1795t537r1863b593],
5	2.4	CD	PERCENT	2.4	num	6	SENT_345	[p21l1886t536r2051b595],
6	%	NN	PERCENT	%	prep_in	3	SENT_345	[p21l1886t536r2051b595],
7	of	IN	O	of	_	0	SENT_345	[p21l2076t531r2151b594],
8	patients	NNS	O	patient	prep_of	6	SENT_345	[p21l7t640r274b717],
9	with	IN	O	with	mark	16	SENT_345	[p21l293t634r445b697],
10	hepatic	JJ	O	hepatic	amod	11	SENT_345	[p21l464t634r711b717],
11	cholestasis	NN	O	cholestasis	nsubj	16	SENT_345	[p21l731t634r1108b706],
12	,	,	O	,	_	0	SENT_345	[p21l731t634r1108b706],
13	homicidal	JJ	O	homicidal	amod	14	SENT_345	[p21l1129t634r1473b697],
14	ideation	NN	O	ideation	appos	11	SENT_345	[p21l1493t634r1787b706],
15	,	,	O	,	_	0	SENT_345	[p21l1493t634r1787b706],
16	decreased	VBD	O	decrease	dep	8	SENT_345	[p21l1810t634r2144b697],
17	creatinine	NN	O	creatinine	nn	18	SENT_345	[p21l9t743r365b800],
18	clearance	NN	O	clearance	dobj	16	SENT_345	[p21l393t737r743b809],
19	,	,	O	,	_	0	SENT_345	[p21l393t737r743b809],
20	or	CC	O	or	_	0	SENT_345	[p21l772t760r846b800],
21	jittery	JJ	O	jittery	amod	22	SENT_345	[p21l867t743r1088b821],
22	sensation	NN	O	sensation	prep_of	6	SENT_345	[p21l1112t743r1446b800],
23	being	VBG	O	be	auxpass	24	SENT_345	[p21l1471t737r1670b821],
24	attributed	VBN	O	attribute	partmod	22	SENT_345	[p21l1696t737r2048b800],
25	to	TO	O	to	_	0	SENT_345	[p21l2073t749r2141b800],
26	treatment	NN	O	treatment	prep_to	24	SENT_345	[p21l8t831r424b903],
27	.67	CD	NUMBER	.67	num	26	SENT_345	[p21l8t831r424b903],

1	The	DT	O	the	det	2	SENT_346	[p21l83t943r211b1006],
2	PI	NN	O	pi	nsubjpass	8	SENT_346	[p21l237t948r332b1015],
3	,	,	O	,	_	0	SENT_346	[p21l237t948r332b1015],
4	asunaprevir	NN	O	asunaprevir	appos	2	SENT_346	[p21l360t949r791b1026],
5	,	,	O	,	_	0	SENT_346	[p21l360t949r791b1026],
6	has	VBZ	O	have	aux	8	SENT_346	[p21l817t943r933b1006],
7	been	VBN	O	be	auxpass	8	SENT_346	[p21l957t943r1126b1006],
8	studied	VBN	O	study	_	0	SENT_346	[p21l1153t943r1413b1006],
9	in	IN	O	in	_	0	SENT_346	[p21l1438t949r1506b1005],
10	conjunction	NN	O	conjunction	prep_in	8	SENT_346	[p21l1533t949r1961b1027],
11	with	IN	O	with	_	0	SENT_346	[p21l1985t943r2142b1006],
12	daclatasvir	NN	O	daclatasvir	prep_with	8	SENT_346	[p21l10t1045r388b1117],
13	,	,	O	,	_	0	SENT_346	[p21l10t1045r388b1117],
14	an	DT	O	a	det	16	SENT_346	[p21l413t1068r492b1109],
15	NS5A	NN	O	ns5a	nn	16	SENT_346	[p21l514t1049r717b1109],
16	inhibitor	NN	O	inhibitor	appos	12	SENT_346	[p21l740t1045r1052b1109],
17	.	.	O	.	_	0	SENT_346	[p21l740t1045r1052b1109],

1	In	FW	O	in	nn	2	SENT_347	[p21l1076t1050r1144b1109],
2	vitro	FW	O	vitro	amod	3	SENT_347	[p21l1170t1051r1322b1109],
3	studies	NNS	O	study	nsubj	4	SENT_347	[p21l1346t1045r1581b1109],
4	showed	VBD	O	show	_	0	SENT_347	[p21l1604t1045r1862b1109],
5	that	IN	O	that	advmod	4	SENT_347	[p21l1882t1045r2016b1109],
6	the	DT	O	the	dep	5	SENT_347	[p21l2036t1045r2142b1109],

1	DAA	NNP	O	DAA	nn	2	SENT_348	[p21l10t1153r184b1211],
2	combination	NN	O	combination	nsubj	13	SENT_348	[p21l204t1149r652b1221],
3	,	,	O	,	_	0	SENT_348	[p21l204t1149r652b1221],
4	as	IN	O	as	mark	2	SENT_348	[p21l674t1172r738b1212],
5	compared	VBN	O	compare	_	0	SENT_348	[p21l759t1149r1097b1232],
6	with	IN	O	with	_	0	SENT_348	[p21l1115t1149r1266b1212],
7	treatment	NN	O	treatment	prep_compared_with	2	SENT_348	[p21l1285t1161r1616b1212],
8	with	IN	O	with	_	0	SENT_348	[p21l1634t1149r1785b1212],
9	each	DT	O	each	det	11	SENT_348	[p21l1805t1149r1957b1212],
10	individual	JJ	O	individual	amod	11	SENT_348	[p21l1977t1149r2140b1212, p21l7t1252r224b1315],
11	drug	NN	O	drug	prep_with	2	SENT_348	[p21l247t1252r429b1336],
12	,	,	O	,	_	0	SENT_348	[p21l247t1252r429b1336],
13	suppressed	VBD	O	suppress	_	0	SENT_348	[p21l455t1252r837b1335],
14	viral	JJ	O	viral	amod	15	SENT_348	[p21l856t1252r1015b1315],
15	replication	NN	O	replication	dobj	13	SENT_348	[p21l1037t1252r1411b1335],
16	against	IN	O	against	_	0	SENT_348	[p21l1435t1258r1678b1336],
17	recombinant	JJ	O	recombinant	amod	21	SENT_348	[p21l1701t1252r2145b1315],
18	genotype	NN	O	genotype	nn	21	SENT_348	[p21l9t1366r313b1438],
19	1a	NN	O	1a	nn	21	SENT_348	[p21l339t1361r424b1426],
20	,	,	O	,	_	0	SENT_348	[p21l339t1361r424b1426],
21	2a	NN	O	2a	prep_against	13	SENT_348	[p21l445t1361r536b1426],
22	,	,	O	,	_	0	SENT_348	[p21l445t1361r536b1426],
23	and	CC	O	and	_	0	SENT_348	[p21l558t1354r681b1417],
24	3a	NN	O	3a	nn	25	SENT_348	[p21l701t1361r775b1417],
25	HCVS	NNS	O	hcv	prep_against	13	SENT_348	[p21l794t1358r999b1417],
26	at	IN	O	at	_	0	SENT_348	[p21l1020t1366r1078b1417],
27	low	JJ	O	low	amod	29	SENT_348	[p21l1095t1354r1216b1417],
28	drug	NN	O	drug	nn	29	SENT_348	[p21l1233t1354r1391b1438],
29	concentrations	NNS	O	concentration	prep_at	13	SENT_348	[p21l1410t1346r1982b1417],
30	.	.	O	.	_	0	SENT_348	[p21l1410t1346r1982b1417],

1	“	NN	O	“	nsubj	6	SENT_349	[p21l1410t1346r1982b1417],
2	This	DT	O	this	det	3	SENT_349	[p21l2003t1354r2142b1417],
3	combination	NN	O	combination	dep	1	SENT_349	[p21l10t1457r441b1520],
4	was	VBD	O	be	cop	6	SENT_349	[p21l460t1480r584b1520],
5	the	DT	O	the	det	6	SENT_349	[p21l604t1457r710b1520],
6	ﬁrst	NN	O	ﬁrst	dep	21	SENT_349	[p21l730t1457r862b1520],
7	published	VBN	O	publish	partmod	6	SENT_349	[p21l880t1457r1213b1540],
8	study	NN	O	study	dobj	7	SENT_349	[p21l1233t1457r1418b1541],
9	to	TO	O	to	aux	10	SENT_349	[p21l1433t1469r1499b1520],
10	achieve	VB	O	achieve	xcomp	7	SENT_349	[p21l1521t1457r1771b1520],
11	SVR	NN	O	svr	dobj	10	SENT_349	[p21l1792t1461r1944b1520],
12	using	VBG	O	use	partmod	11	SENT_349	[p21l1962t1463r2146b1541],
13	solely	RB	O	solely	advmod	12	SENT_349	[p21l10t1559r204b1643],
14	DAA	NN	O	daa	nn	15	SENT_349	[p21l222t1563r398b1621],
15	therapy	NN	O	therapy	dobj	12	SENT_349	[p21l417t1551r751b1643],
16	.69	CD	NUMBER	.69	num	15	SENT_349	[p21l417t1551r751b1643],
17	The	DT	O	the	det	20	SENT_349	[p21l772t1559r897b1622],
18	phase	NN	O	phase	nn	20	SENT_349	[p21l917t1559r1112b1642],
19	II	CD	NUMBER	ii	num	20	SENT_349	[p21l1134t1564r1187b1621],
20	trial	NN	O	trial	nsubj	21	SENT_349	[p21l1208t1559r1349b1622],
21	enrolled	VBD	O	enrol	_	0	SENT_349	[p21l1370t1559r1652b1622],
22	21	CD	NUMBER	21	num	23	SENT_349	[p21l1672t1566r1745b1621],
23	genotype	NN	O	genotype	dobj	21	SENT_349	[p21l1772t1571r2084b1643],
24	1	CD	NUMBER	1	num	26	SENT_349	[p21l2112t1566r2136b1621],
25	previous	JJ	O	previous	amod	26	SENT_349	[p21l8t1669r300b1746],
26	nonresponders	NNS	O	nonresponder	nsubj	28	SENT_349	[p21l321t1663r833b1746],
27	to	TO	O	to	aux	28	SENT_349	[p21l853t1675r918b1726],
28	receive	VB	O	receive	infmod	23	SENT_349	[p21l940t1669r1175b1726],
29	asunaprevir	NN	O	asunaprevir	dobj	28	SENT_349	[p21l1197t1669r1598b1746],
30	and	CC	O	and	_	0	SENT_349	[p21l1618t1663r1744b1726],
31	daclatasvir	NN	O	daclatasvir	dobj	28	SENT_349	[p21l1764t1663r2139b1726],
32	.	.	O	.	_	0	SENT_349	[p21l1764t1663r2139b1726],

1	SVR	NN	ORGANIZATION	svr	nsubjpass	3	SENT_350	[p21l10t1770r168b1829],
2	was	VBD	O	be	auxpass	3	SENT_350	[p21l190t1789r320b1829],
3	achieved	VBN	O	achieve	_	0	SENT_350	[p21l349t1766r660b1829],
4	in	IN	O	in	_	0	SENT_350	[p21l686t1772r755b1828],
5	two	CD	NUMBER	two	num	7	SENT_350	[p21l780t1778r909b1829],
6	genotype	NN	O	genotype	nn	7	SENT_350	[p21l937t1778r1262b1850],
7	1a	NN	O	1a	prep_in	3	SENT_350	[p21l1295t1773r1367b1829],
8	and	CC	O	and	_	0	SENT_350	[p21l1393t1766r1524b1829],
9	two	CD	NUMBER	two	num	12	SENT_350	[p21l1548t1778r1678b1829],
10	genotype	NN	O	genotype	nn	12	SENT_350	[p21l1705t1778r2030b1850],
11	1b	NN	O	1b	nn	12	SENT_350	[p21l2064t1766r2139b1829],
12	patients	NNS	O	patient	prep_in	3	SENT_350	[p21l8t1876r294b1953],
13	.	.	O	.	_	0	SENT_350	[p21l8t1876r294b1953],

1	The	DT	O	the	dep	10	SENT_351	[p21l320t1870r446b1933],
2	remaining	VBG	O	remain	amod	1	SENT_351	[p21l468t1876r822b1954],
3	six	CD	NUMBER	six	num	6	SENT_351	[p21l844t1876r937b1933],
4	treatment	NN	O	treatment	nn	6	SENT_351	[p21l957t1882r1293b1933],
5	arm	NN	O	arm	nn	6	SENT_351	[p21l1315t1893r1451b1933],
6	patients	NNS	O	patient	nsubj	10	SENT_351	[p21l1472t1876r1742b1953],
7	were	VBD	O	be	cop	10	SENT_351	[p21l1763t1893r1924b1933],
8	genotype	NN	O	genotype	nn	10	SENT_351	[p21l1947t1893r2138b1954, p21l8t1984r161b2056],
9	1a	NN	O	1a	nn	10	SENT_351	[p21l195t1979r267b2035],
10	patients	NNS	O	patient	_	0	SENT_351	[p21l292t1978r574b2055],
11	and	CC	O	and	_	0	SENT_351	[p21l603t1972r734b2035],
12	experienced	VBD	O	experience	conj_and	10	SENT_351	[p21l761t1972r1196b2055],
13	viral	JJ	O	viral	amod	14	SENT_351	[p21l1220t1972r1382b2035],
14	breakthrough	NN	O	breakthrough	dobj	12	SENT_351	[p21l1407t1964r1986b2056],
15	.	.	O	.	_	0	SENT_351	[p21l1407t1964r1986b2056],

1	”	NN	O	”	nsubjpass	33	SENT_352	[p21l1407t1964r1986b2056],
2	The	DT	O	the	det	3	SENT_352	[p21l2014t1972r2142b2035],
3	attainment	NN	O	attainment	nsubj	16	SENT_352	[p21l10t2081r382b2138],
4	of	IN	O	of	_	0	SENT_352	[p21l404t2075r478b2138],
5	SVR	NN	ORGANIZATION	svr	prep_of	3	SENT_352	[p21l492t2079r645b2138],
6	with	IN	O	with	_	0	SENT_352	[p21l663t2075r816b2138],
7	the	DT	O	the	det	9	SENT_352	[p21l838t2075r944b2138],
8	two-DAA	JJ	O	two-daa	amod	9	SENT_352	[p21l966t2079r1303b2138],
9	combination	NN	O	combination	prep_with	5	SENT_352	[p21l1326t2075r1761b2138],
10	of	IN	O	of	_	0	SENT_352	[p21l1785t2075r1858b2138],
11	asunaprevir	NN	O	asunaprevir	prep_of	9	SENT_352	[p21l1872t2097r2139b2158, p21l10t2184r171b2241],
12	and	CC	O	and	_	0	SENT_352	[p21l193t2178r320b2241],
13	daclatasvir	NN	O	daclatasvir	prep_of	9	SENT_352	[p21l343t2178r711b2241],
14	is	VBZ	O	be	cop	16	SENT_352	[p21l733t2184r783b2241],
15	an	DT	O	a	det	16	SENT_352	[p21l807t2201r887b2241],
16	advancement	NN	O	advancement	rcmod	1	SENT_352	[p21l911t2178r1370b2241],
17	in	IN	O	in	_	0	SENT_352	[p21l1391t2184r1458b2240],
18	the	DT	O	the	det	19	SENT_352	[p21l1480t2178r1586b2241],
19	development	NN	O	development	prep_in	16	SENT_352	[p21l1610t2178r2056b2261],
20	of	IN	O	of	_	0	SENT_352	[p21l2078t2178r2152b2241],
21	an	DT	O	a	det	23	SENT_352	[p21l10t2304r89b2344],
22	IFN-free	JJ	MISC	ifn-free	amod	23	SENT_352	[p21l109t2281r401b2344],
23	regimen	NN	O	regimen	prep_of	19	SENT_352	[p21l421t2287r716b2365],
24	,	,	O	,	_	0	SENT_352	[p21l421t2287r716b2365],
25	and	CC	O	and	_	0	SENT_352	[p21l738t2281r862b2344],
26	these	DT	O	these	det	27	SENT_352	[p21l880t2281r1053b2344],
27	ﬁndings	NNS	O	ﬁndings	conj_and	16	SENT_352	[p21l1073t2281r1345b2365],
28	in	IN	O	in	_	0	SENT_352	[p21l1365t2287r1431b2343],
29	genotype	NN	O	genotype	nn	31	SENT_352	[p21l1450t2293r1757b2365],
30	1b	NN	O	1b	nn	31	SENT_352	[p21l1784t2281r1856b2344],
31	patients	NNS	O	patient	prep_in	27	SENT_352	[p21l1876t2287r2140b2364],
32	were	VBD	O	be	auxpass	33	SENT_352	[p21l8t2406r168b2446],
33	conﬁrmed	VBN	O	conﬁrmed	_	0	SENT_352	[p21l190t2383r546b2446],
34	in	IN	O	in	_	0	SENT_352	[p21l567t2389r632b2445],
35	two	CD	NUMBER	two	num	37	SENT_352	[p21l653t2395r778b2446],
36	subsequent	JJ	O	subsequent	amod	37	SENT_352	[p21l802t2383r1186b2466],
37	studies	NNS	O	study	prep_in	33	SENT_352	[p21l1207t2375r1601b2446],
38	.1670	CD	NUMBER	.1670	dep	37	SENT_352	[p21l1207t2375r1601b2446],

1	A	DT	O	a	det	3	SENT_353	[p21l82t2490r140b2548],
2	subsequent	JJ	O	subsequent	amod	3	SENT_353	[p21l166t2486r566b2569],
3	trial	NN	O	trial	_	0	SENT_353	[p21l589t2486r736b2549],
4	in	IN	O	in	_	0	SENT_353	[p21l761t2492r829b2548],
5	efforts	NNS	O	effort	prep_in	3	SENT_353	[p21l855t2486r1077b2549],
6	to	TO	O	to	aux	7	SENT_353	[p21l1102t2498r1170b2549],
7	discover	VB	O	discover	infmod	5	SENT_353	[p21l1197t2486r1493b2549],
8	a	DT	O	a	det	9	SENT_353	[p21l1518t2509r1554b2549],
9	PEG	NN	O	peg	dobj	7	SENT_353	[p21l1579t2490r1767b2549],
10	-	:	O	-	_	0	SENT_353	[p21l1579t2490r1767b2549],
11	and	CC	O	and	_	0	SENT_353	[p21l1796t2486r1926b2549],
12	RBV	NN	O	rbv	conj_and	3	SENT_353	[p21l1952t2491r2139b2549],
13	—	CD	NUMBER	—	num	15	SENT_353	[p21l1952t2491r2139b2549],
14	free	JJ	O	free	amod	15	SENT_353	[p21l9t2589r141b2652],
15	regimen	NN	O	regimen	nsubjpass	17	SENT_353	[p21l166t2595r458b2673],
16	was	VBD	O	be	auxpass	17	SENT_353	[p21l481t2612r611b2652],
17	conducted	VBN	O	conduct	rcmod	12	SENT_353	[p21l637t2589r1009b2652],
18	using	VBG	O	use	xcomp	17	SENT_353	[p21l1032t2595r1224b2673],
19	three	CD	NUMBER	three	num	20	SENT_353	[p21l1246t2589r1427b2652],
20	DAAS	NNP	O	DAAS	dobj	18	SENT_353	[p21l1453t2593r1682b2652],
21	:	:	O	:	_	0	SENT_353	[p21l1453t2593r1682b2652],
22	asunaprevir	NN	O	asunaprevir	dep	3	SENT_353	[p21l1711t2595r2141b2672],
23	,	,	O	,	_	0	SENT_353	[p21l1711t2595r2141b2672],
24	daclatasvir	NN	O	daclatasvir	appos	22	SENT_353	[p21l10t2691r387b2763],
25	,	,	O	,	_	0	SENT_353	[p21l10t2691r387b2763],
26	and	CC	O	and	_	0	SENT_353	[p21l410t2691r536b2755],
27	BMS	NNP	O	BMS	dep	3	SENT_353	[p21l556t2695r792b2755],
28	—	CD	NUMBER	—	num	27	SENT_353	[p21l556t2695r792b2755],
29	7	CD	NUMBER	7	number	30	SENT_353	[p21l556t2695r792b2755],
30	91325	CD	NUMBER	91325	dep	27	SENT_353	[p21l797t2698r1017b2763],
31	,	,	O	,	_	0	SENT_353	[p21l797t2698r1017b2763],
32	a	DT	O	a	det	35	SENT_353	[p21l1040t2714r1075b2755],
33	nonnucleoside	JJ	O	nonnucleoside	amod	35	SENT_353	[p21l1094t2691r1594b2755],
34	NSSB	NN	O	nssb	nn	35	SENT_353	[p21l1614t2695r1807b2755],
35	inhibitor	NN	O	inhibitor	appos	27	SENT_353	[p21l1829t2691r2141b2755],
36	.	.	O	.	_	0	SENT_353	[p21l1829t2691r2141b2755],

1	The	DT	O	the	det	2	SENT_354	[p21l9t2795r135b2858],
2	regimen	NN	O	regimen	nsubjpass	4	SENT_354	[p21l158t2801r441b2879],
3	was	VBD	O	be	auxpass	4	SENT_354	[p21l462t2818r589b2858],
4	tested	VBN	O	test	_	0	SENT_354	[p21l611t2795r813b2858],
5	in	IN	O	in	_	0	SENT_354	[p21l834t2801r901b2857],
6	genotype	NN	O	genotype	npadvmod	8	SENT_354	[p21l923t2807r1237b2879],
7	1	CD	NUMBER	1	num	6	SENT_354	[p21l1266t2802r1291b2857],
8	noncirrhotic	JJ	O	noncirrhotic	amod	10	SENT_354	[p21l1320t2795r1755b2858],
9	treatmentnaive	JJ	O	treatmentnaive	amod	10	SENT_354	[p21l1777t2807r2140b2858, p21l9t2904r193b2961],
10	patients	NNS	O	patient	prep_in	4	SENT_354	[p21l216t2904r512b2981],
11	.	.	O	.	_	0	SENT_354	[p21l216t2904r512b2981],

1	Asunaprevir	JJ	O	asunaprevir	amod	2	SENT_355	[p21l538t2902r975b2981],
2	(	NN	O	(	nsubjpass	28	SENT_355	[p21l1002t2899r1152b2974],
3	200	CD	NUMBER	200	num	4	SENT_355	[p21l1002t2899r1152b2974],
4	mg	NN	O	mg	npadvmod	5	SENT_355	[p21l1169t2921r1280b2982],
5	twice	RB	O	twice	advmod	8	SENT_355	[p21l1301t2904r1486b2961],
6	a	DT	DURATION	a	det	7	SENT_355	[p21l1510t2921r1546b2961],
7	day	NN	DURATION	day	pobj	5	SENT_355	[p21l1569t2898r1739b2982],
8	)	CD	NUMBER	)	dep	2	SENT_355	[p21l1569t2898r1739b2982],
9	,	,	O	,	_	0	SENT_355	[p21l1569t2898r1739b2982],
10	daclatasvir	NN	O	daclatasvir	conj_and	2	SENT_355	[p21l1766t2898r2144b2961],
11	(	CD	NUMBER	(	num	10	SENT_355	[p21l13t3002r123b3077],
12	60	CD	NUMBER	60	num	13	SENT_355	[p21l13t3002r123b3077],
13	mg	NN	O	mg	dep	10	SENT_355	[p21l143t3024r256b3085],
14	a	DT	DURATION	a	det	15	SENT_355	[p21l286t3024r321b3064],
15	day	NN	DURATION	day	dep	13	SENT_355	[p21l351t3001r527b3085],
16	)	CD	NUMBER	)	dep	13	SENT_355	[p21l351t3001r527b3085],
17	,	,	O	,	_	0	SENT_355	[p21l351t3001r527b3085],
18	and	CC	O	and	_	0	SENT_355	[p21l561t3001r693b3064],
19	BMS-791325	NN	O	bms-791325	nsubjpass	28	SENT_355	[p21l723t3005r1191b3064],
20	(	CD	NUMBER	(	number	21	SENT_355	[p21l1228t3001r1337b3078],
21	75	CD	NUMBER	75	num	22	SENT_355	[p21l1228t3001r1337b3078],
22	mg	NN	O	mg	npadvmod	23	SENT_355	[p21l1359t3024r1472b3085],
23	twice	RB	O	twice	advmod	25	SENT_355	[p21l1500t3007r1690b3064],
24	a	DT	DURATION	a	det	25	SENT_355	[p21l1722t3024r1757b3064],
25	day	NN	DURATION	day	tmod	19	SENT_355	[p21l1787t3001r1939b3085],
26	)	CD	NUMBER	)	dep	19	SENT_355	[p21l1787t3001r1939b3085],
27	were	VBD	O	be	auxpass	28	SENT_355	[p21l1972t3024r2142b3064],
28	administered	VBN	O	administer	_	0	SENT_355	[p21l10t3104r477b3167],
29	for	IN	O	for	_	0	SENT_355	[p21l501t3104r601b3167],
30	12	CD	NUMBER	12	num	33	SENT_355	[p21l632t3111r705b3166],
31	or	CC	O	or	_	0	SENT_355	[p21l732t3127r805b3167],
32	24	CD	DURATION	24	conj_or	30	SENT_355	[p21l830t3111r910b3166],
33	weeks	NNS	NUMBER	week	prep_for	28	SENT_355	[p21l934t3104r1162b3167],
34	.	.	O	.	_	0	SENT_355	[p21l934t3104r1162b3167],

1	Once	RB	DATE	once	advmod	6	SENT_356	[p21l1192t3108r1376b3167],
2	the	DT	O	the	det	4	SENT_356	[p21l1400t3104r1510b3167],
3	safety	NN	O	safety	nn	4	SENT_356	[p21l1536t3104r1739b3188],
4	proﬁle	NN	O	proﬁle	nsubjpass	6	SENT_356	[p21l1759t3104r1987b3187],
5	was	VBD	O	be	auxpass	6	SENT_356	[p21l2010t3127r2140b3167],
6	assessed	VBN	O	assess	dep	13	SENT_356	[p21l10t3207r308b3279],
7	,	,	O	,	_	0	SENT_356	[p21l10t3207r308b3279],
8	34	CD	NUMBER	34	num	10	SENT_356	[p21l333t3214r411b3270],
9	additional	JJ	O	additional	amod	10	SENT_356	[p21l434t3207r783b3270],
10	patients	NNS	O	patient	nsubjpass	13	SENT_356	[p21l803t3213r1073b3290],
11	were	VBD	O	be	auxpass	13	SENT_356	[p21l1094t3230r1255b3270],
12	randomly	RB	O	randomly	advmod	13	SENT_356	[p21l1278t3207r1614b3291],
13	assigned	VBN	O	assign	_	0	SENT_356	[p21l1634t3207r1925b3291],
14	to	TO	O	to	_	0	SENT_356	[p21l1946t3219r2012b3270],
15	the	DT	O	the	det	18	SENT_356	[p21l2035t3207r2141b3270],
16	same	JJ	O	same	amod	18	SENT_356	[p21l10t3333r185b3373],
17	drug	NN	O	drug	nn	18	SENT_356	[p21l210t3310r376b3394],
18	regimen	NNS	O	regimen	prep_to	13	SENT_356	[p21l398t3316r705b3394],
19	,	,	O	,	_	0	SENT_356	[p21l398t3316r705b3394],
20	except	IN	O	except	mark	28	SENT_356	[p21l731t3322r954b3393],
21	that	IN	O	that	dep	28	SENT_356	[p21l975t3310r1112b3373],
22	the	DT	O	the	det	23	SENT_356	[p21l1134t3310r1242b3373],
23	dose	NN	O	dose	nsubjpass	28	SENT_356	[p21l1267t3310r1424b3373],
24	of	IN	O	of	_	0	SENT_356	[p21l1449t3310r1524b3373],
25	BMS-7	NN	O	bms-7	prep_of	23	SENT_356	[p21l1538t3314r1780b3373],
26	91325	CD	NUMBER	91325	num	25	SENT_356	[p21l1785t3317r1990b3373],
27	was	VBD	O	be	auxpass	28	SENT_356	[p21l2014t3333r2143b3373],
28	increased	VBN	O	increase	advcl	13	SENT_356	[p21l9t3413r338b3476],
29	to	TO	O	to	_	0	SENT_356	[p21l359t3425r426b3476],
30	150	CD	NUMBER	150	num	31	SENT_356	[p21l457t3420r571b3476],
31	mg	NN	O	mg	prep_to	28	SENT_356	[p21l587t3436r697b3497],
32	twice	RB	O	twice	advmod	34	SENT_356	[p21l717t3419r899b3476],
33	a	DT	DURATION	a	det	34	SENT_356	[p21l923t3436r958b3476],
34	day	NN	DURATION	day	tmod	28	SENT_356	[p21l980t3413r1110b3497],
35	.	.	O	.	_	0	SENT_356	[p21l980t3413r1110b3497],

1	SVR	NN	ORGANIZATION	svr	nsubj	21	SENT_357	[p21l1137t3417r1292b3476],
2	for	IN	O	for	_	0	SENT_357	[p21l1312t3413r1411b3476],
3	patients	NNS	O	patient	prep_for	1	SENT_357	[p21l1431t3419r1704b3496],
4	treated	VBN	O	treat	partmod	3	SENT_357	[p21l1727t3413r1968b3476],
5	with	IN	O	with	_	0	SENT_357	[p21l1988t3413r2143b3476],
6	BMS-791325	NN	O	bms-791325	prep_with	4	SENT_357	[p21l10t3520r451b3579],
7	(	CD	NUMBER	(	num	6	SENT_357	[p21l478t3517r581b3592],
8	75	CD	NUMBER	75	num	9	SENT_357	[p21l478t3517r581b3592],
9	mg	NN	O	mg	npadvmod	10	SENT_357	[p21l598t3539r706b3600],
10	twice	RB	O	twice	advmod	6	SENT_357	[p21l724t3522r904b3579],
11	a	DT	DURATION	a	det	12	SENT_357	[p21l925t3539r960b3579],
12	day	NN	DURATION	day	pobj	10	SENT_357	[p21l980t3516r1123b3600],
13	)	CD	NUMBER	)	dep	6	SENT_357	[p21l980t3516r1123b3600],
14	for	IN	O	for	_	0	SENT_357	[p21l1147t3516r1245b3579],
15	24	CD	NUMBER	24	nn	18	SENT_357	[p21l1264t3523r1343b3578],
16	and	CC	O	and	_	0	SENT_357	[p21l1365t3516r1491b3579],
17	12	CD	DURATION	12	nn	18	SENT_357	[p21l1517t3523r1588b3578],
18	weeks	NNS	NUMBER	week	prep_for	13	SENT_357	[p21l1608t3516r1812b3579],
19	was	VBD	O	be	cop	21	SENT_357	[p21l1832t3539r1957b3579],
20	95	CD	PERCENT	95	num	21	SENT_357	[p21l1980t3522r2140b3581],
21	%	NN	PERCENT	%	_	0	SENT_357	[p21l1980t3522r2140b3581],
22	.	.	O	.	_	0	SENT_357	[p21l1980t3522r2140b3581],

1	The	DT	O	the	det	3	SENT_358	[p21l9t3619r134b3682],
2	SVR24	NN	O	svr24	nn	3	SENT_358	[p21l156t3623r389b3682],
3	rates	NNS	O	rate	nsubj	6	SENT_358	[p21l410t3631r568b3682],
4	were	VBD	O	be	cop	6	SENT_358	[p21l587t3642r747b3682],
5	88	CD	PERCENT	88	num	6	SENT_358	[p21l770t3625r911b3683],
6	%	NN	PERCENT	%	_	0	SENT_358	[p21l770t3625r911b3683],
7	for	IN	O	for	_	0	SENT_358	[p21l933t3619r1030b3682],
8	24	CD	DURATION	24	num	9	SENT_358	[p21l1050t3626r1129b3681],
9	weeks	NNS	NUMBER	week	prep_for	6	SENT_358	[p21l1147t3619r1351b3682],
10	of	IN	O	of	_	0	SENT_358	[p21l1373t3619r1447b3682],
11	therapy	NN	O	therapy	prep_of	9	SENT_358	[p21l1457t3619r1719b3703],
12	and	CC	O	and	_	0	SENT_358	[p21l1737t3619r1863b3682],
13	94	CD	PERCENT	94	num	14	SENT_358	[p21l1883t3624r2024b3683],
14	%	NN	PERCENT	%	prep_for	6	SENT_358	[p21l1883t3624r2024b3683],
15	for	IN	O	for	_	0	SENT_358	[p21l2047t3619r2144b3682],
16	12	CD	DURATION	12	num	17	SENT_358	[p21l16t3729r86b3784],
17	weeks	NNS	NUMBER	week	prep_for	14	SENT_358	[p21l106t3722r309b3785],
18	of	IN	O	of	_	0	SENT_358	[p21l330t3722r404b3785],
19	therapy	NN	O	therapy	prep_of	17	SENT_358	[p21l413t3722r680b3806],
20	.	.	O	.	_	0	SENT_358	[p21l413t3722r680b3806],

1	The	DT	O	the	det	2	SENT_359	[p21l704t3722r828b3785],
2	SVR36	NN	O	svr36	nsubj	5	SENT_359	[p21l850t3726r1080b3785],
3	was	VBD	O	be	cop	5	SENT_359	[p21l1100t3745r1225b3785],
4	88	CD	PERCENT	88	num	5	SENT_359	[p21l1248t3728r1387b3786],
5	%	NN	PERCENT	%	_	0	SENT_359	[p21l1248t3728r1387b3786],
6	in	IN	O	in	_	0	SENT_359	[p21l1410t3728r1476b3784],
7	the	DT	O	the	det	8	SENT_359	[p21l1495t3722r1601b3785],
8	patients	NNS	O	patient	prep_in	5	SENT_359	[p21l1620t3728r1888b3805],
9	treated	VBN	O	treat	partmod	8	SENT_359	[p21l1907t3722r2144b3785],
10	for	IN	O	for	_	0	SENT_359	[p22l9t16r108b79],
11	12	CD	DURATION	12	num	12	SENT_359	[p22l137t23r209b78],
12	weeks	NNS	NUMBER	week	prep_for	9	SENT_359	[p22l233t16r458b79],
13	.	.	O	.	_	0	SENT_359	[p22l233t16r458b79],

1	No	DT	O	no	det	3	SENT_360	[p22l484t21r588b79],
2	viral	JJ	O	viral	amod	3	SENT_360	[p22l609t16r768b79],
3	breakthrough	NN	O	breakthrough	nsubjpass	8	SENT_360	[p22l789t16r1268b100],
4	or	CC	O	or	_	0	SENT_360	[p22l1291t39r1364b79],
5	posttreatment	NN	O	posttreatment	nn	6	SENT_360	[p22l1386t28r1878b99],
6	relapse	NN	O	relapse	conj_or	3	SENT_360	[p22l1901t16r2142b99],
7	was	VBD	O	be	auxpass	8	SENT_360	[p22l8t142r139b182],
8	noted	VBN	O	note	_	0	SENT_360	[p22l169t119r376b182],
9	with	IN	O	with	_	0	SENT_360	[p22l403t119r563b182],
10	the	DT	O	the	det	15	SENT_360	[p22l592t119r703b182],
11	75	CD	NUMBER	75	number	12	SENT_360	[p22l735t127r966b203],
12	—	CD	NUMBER	—	num	15	SENT_360	[p22l735t127r966b203],
13	mg	NN	O	mg	nn	15	SENT_360	[p22l735t127r966b203],
14	twice-a-day	JJ	O	twice-a-day	amod	15	SENT_360	[p22l993t119r1422b203],
15	regimen	NN	O	regimen	prep_with	8	SENT_360	[p22l1449t125r1765b203],
16	.	.	O	.	_	0	SENT_360	[p22l1449t125r1765b203],

1	For	IN	O	for	_	0	SENT_361	[p22l1798t124r1920b182],
2	those	DT	O	those	pobj	1	SENT_361	[p22l1947t119r2140b182],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_362	[p22l21t268r140b289],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	_	0	SENT_362	[p22l149t268r374b289],
3	&	CC	O	&	_	0	SENT_362	[p22l381t268r601b289],
4	THERAPEUTlCS	NNP	O	THERAPEUTlCS	nn	6	SENT_362	[p22l381t268r601b289],
5	|	NNP	O	|	nn	6	SENT_362	[p22l611t266r613b296],
6	VOLUME	NNP	O	VOLUME	conj_and	2	SENT_362	[p22l621t268r729b289],
7	95	CD	NUMBER	95	num	8	SENT_362	[p22l737t268r764b289],
8	NUMBER	NN	O	number	dep	2	SENT_362	[p22l774t268r882b289],
9	1	CD	NUMBER	1	number	10	SENT_362	[p22l892t269r899b289],
10	]	CD	NUMBER	]	num	11	SENT_362	[p22l912t266r915b296],
11	JANUARY	NNP	DATE	JANUARY	dep	8	SENT_362	[p22l924t268r1042b289],
12	2014	CD	DATE	2014	num	13	SENT_362	[p22l1049t268r1108b289],
13	85	CD	DATE	85	dep	2	SENT_362	[p22l2109t268r2139b289],

1	3	LS	NUMBER	3	dep	7	SENT_363	[p22l1136t622r1252b641],
2	°	FW	O	°	nn	7	SENT_363	[p22l1136t622r1252b641],
3	f	FW	O	f	nn	7	SENT_363	[p22l1136t622r1252b641],
4	°	FW	O	°	nn	7	SENT_363	[p22l1136t622r1252b641],
5	SbUVli	FW	O	sbuvli	nn	7	SENT_363	[p22l1136t622r1252b641],
6	mple	FW	O	mple	nn	7	SENT_363	[p22l1259t623r1313b646],
7	Simeprevir	FW	O	simeprevir	_	0	SENT_363	[p22l1457t626r1575b650],
8	triple	JJ	O	triple	advmod	7	SENT_363	[p22l1582t627r1636b650],

1	GT1	NN	O	gt1	_	0	SENT_364	[p22l1121t682r1164b701],
2	,	,	O	,	_	0	SENT_364	[p22l1171t698r1174b704],
3	4	CD	NUMBER	4	appos	1	SENT_364	[p22l1183t683r1201b704],
4	,	,	O	,	_	0	SENT_364	[p22l1183t683r1201b704],
5	5	CD	NUMBER	5	appos	1	SENT_364	[p22l1211t683r1229b704],
6	,	,	O	,	_	0	SENT_364	[p22l1211t683r1229b704],
7	6	CD	NUMBER	6	appos	5	SENT_364	[p22l1239t683r1257b704],
8	,	,	O	,	_	0	SENT_364	[p22l1239t683r1257b704],
9	Naive	JJ	O	naive	amod	10	SENT_364	[p22l1268t682r1328b701],
10	GT1	NN	O	gt1	appos	5	SENT_364	[p22l1439t682r1482b701],
11	,	,	O	,	_	0	SENT_364	[p22l1488t698r1491b704],
12	Naive	JJ	O	naive	amod	14	SENT_364	[p22l1502t682r1568b704],
13	,	,	O	,	_	0	SENT_364	[p22l1502t682r1568b704],
14	Tx-Exp	JJ	O	tx-exp	dep	1	SENT_364	[p22l1576t682r1654b706],

1	Sofosbuvir	NN	O	sofosbuvir	_	0	SENT_365	[p22l1305t756r1421b775],
2	+	CC	O	+	cc	3	SENT_365	[p22l1428t761r1441b775],
3	RBV	NN	O	rbv	dep	1	SENT_365	[p22l1451t756r1500b775],

1	GT2/3	NN	O	gt2/3	_	0	SENT_366	[p22l1165t812r1239b834],
2	,	,	O	,	_	0	SENT_366	[p22l1165t812r1239b834],
3	Naive/Tx-EXP/IFN	NN	O	naive/tx-exp/ifn	nn	5	SENT_366	[p22l1249t812r1449b831],
4	ineligible	JJ	O	ineligible	amod	5	SENT_366	[p22l1460t812r1554b836],
5	Tx	NN	O	tx	appos	1	SENT_366	[p22l1561t812r1639b836],
6	.	.	O	.	_	0	SENT_366	[p22l1561t812r1639b836],

1	—	NN	O	—	_	0	SENT_367	[p22l1561t812r1639b836],
2	.	.	O	.	_	0	SENT_367	[p22l1561t812r1639b836],

1	Exp	NN	O	exp	_	0	SENT_368	[p22l1561t812r1639b836],
2	5	CD	NUMBER	5	num	3	SENT_368	[p22l1759t810r1767b826],
3	‘	NN	O	‘	dep	1	SENT_368	[p22l1791t813r1797b821],

1	Sofosbuvir	NNP	O	Sofosbuvir	_	0	SENT_369	[p22l841t879r957b898],
2	+	CC	O	+	rcmod	1	SENT_369	[p22l964t884r977b898],
3	.	.	O	.	_	0	SENT_369	[p22l1595t892r1598b895],

1	BMS	NN	O	bm	nn	2	SENT_370	[p22l215t891r266b910],
2	DCV/ASV/RBV	NN	O	dcv/asv/rbv	nsubj	9	SENT_370	[p22l276t891r451b911],
3	‘	CD	NUMBER	‘	number	4	SENT_370	[p22l276t891r451b911],
4	. . .	CD	NUMBER	. . .	dep	2	SENT_370	[p22l949t909r952b912],[p22l638t905r641b908],
5	Faldaprevir	NNP	O	Faldaprevir	nn	8	SENT_370	[p22l1487t892r1608b915],
6	DCV	NNP	O	DCV	nn	8	SENT_370	[p22l563t904r614b924],
7	triple	JJ	O	triple	amod	8	SENT_370	[p22l621t905r675b928],
8	|	NN	O	|	dep	2	SENT_370	[p22l857t909r962b933],
9	ed	VBD	O	ed	_	0	SENT_370	[p22l857t909r962b933],
10	.	.	O	.	_	0	SENT_370	[p22l857t909r962b933],

1	pesV	NN	O	pesv	_	0	SENT_371	[p22l857t909r962b933],
2	.	.	O	.	_	0	SENT_371	[p22l857t909r962b933],

1	r	NN	O	r	nn	2	SENT_372	[p22l857t909r962b933],
2	ABT	NNP	O	ABT	_	0	SENT_372	[p22l1126t904r1376b924],
3	—	CD	NUMBER	—	num	4	SENT_372	[p22l1126t904r1376b924],
4	450/267/333	CD	NUMBER	450/267/333	dep	2	SENT_372	[p22l1126t904r1376b924],
5	/	:	O	/	punct	2	SENT_372	[p22l1126t904r1376b924],
6	RBV	NN	O	rbv	dep	2	SENT_372	[p22l1126t904r1376b924],
7	(	CD	NUMBER	(	num	8	SENT_372	[p22l1455t921r1576b945],
8	BE01335	NN	O	be01335	dep	6	SENT_372	[p22l1455t921r1576b945],
9	)	CD	NUMBER	)	npadvmod	10	SENT_372	[p22l1455t921r1576b945],
10	triple	JJ	O	triple	amod	8	SENT_372	[p22l1584t922r1638b945],

1	GT1	NN	O	gt1	nn	3	SENT_373	[p22l221t951r263b970],
2	b	NN	O	b	nn	3	SENT_373	[p22l269t951r281b970],
3	Naive/Tx-Exp	NN	O	naive/tx-exp	_	0	SENT_373	[p22l291t951r446b975],
4	/	:	O	/	punct	6	SENT_373	[p22l291t951r446b975],
5	IFN	NN	O	ifn	dep	6	SENT_373	[p22l260t981r296b1000],
6	intolerant	JJ	O	intolerant	dep	3	SENT_373	[p22l306t981r407b1000],

1	.	.	O	.	_	0	SENT_374	[p22l911t972r913b975],

1	GT1	NN	O	gt1	_	0	SENT_375	[p22l1144t956r1196b978],
2	,	,	O	,	_	0	SENT_375	[p22l1144t956r1196b978],
3	N	NN	O	n	appos	1	SENT_375	[p22l1207t956r1222b975],
4	'	''	O	'	_	0	SENT_375	[p22l1239t956r1241b959],
5	,	,	O	,	_	0	SENT_375	[p22l1270t956r1296b978],
6	T	NN	O	t	appos	1	SENT_375	[p22l1270t956r1296b978],
7	-	:	O	-	_	0	SENT_375	[p22l1310t956r1333b975],
8	E	NN	O	e	dep	1	SENT_375	[p22l1310t956r1333b975],

1	GT1/2/3	NN	O	gt1/2/3	_	0	SENT_376	[p22l774t972r1045b994],
2	,	,	O	,	_	0	SENT_376	[p22l774t972r1045b994],
3	NaIve/TX-EXP	NN	O	naive/tx-exp	appos	1	SENT_376	[p22l774t972r1045b994],
4	/	:	O	/	punct	11	SENT_376	[p22l774t972r1045b994],
5	“	NN	O	“	dep	11	SENT_376	[p22l1224t961r1268b975],
6	'	''	O	'	_	0	SENT_376	[p22l1224t961r1268b975],
7	9	CD	NUMBER	9	number	9	SENT_376	[p22l1224t961r1268b975],
8	X	NN	O	x	dep	9	SENT_376	[p22l1297t961r1308b975],
9	X	NN	O	x	amod	5	SENT_376	[p22l1334t961r1359b980],
10	”	CD	NUMBER	”	num	11	SENT_376	[p22l1334t961r1359b980],
11	GT1	NN	O	gt1	dep	3	SENT_376	[p22l1439t978r1654b1002],
12	,	,	O	,	_	0	SENT_376	[p22l1439t978r1654b1002],
13	Nai	NNP	PERSON	Nai	appos	3	SENT_376	[p22l1439t978r1654b1002],
14	,	,	O	,	_	0	SENT_376	[p22l1439t978r1654b1002],
15	,	,	O	,	_	0	SENT_376	[p22l1439t978r1654b1002],
16	e_TX_EX	NN	O	e_tx_ex	dep	13	SENT_376	[p22l1439t978r1654b1002],
17	,	,	O	,	_	0	SENT_376	[p22l1439t978r1654b1002],
18	,	,	O	,	_	0	SENT_376	[p22l1439t978r1654b1002],
19	.	.	O	.	_	0	SENT_376	[p22l1759t979r1767b995],

1	IFN	NN	O	ifn	npadvmod	2	SENT_377	[p22l839t1002r875b1021],
2	ineligible	JJ	O	ineligible	_	0	SENT_377	[p22l886t1002r980b1026],

1	GT1	NN	O	gt1	_	0	SENT_378	[p22l531t962r584b981],
2	.	.	O	.	_	0	SENT_378	[p22l531t962r584b981],

1	Naive	JJ	O	naive	_	0	SENT_379	[p22l593t962r653b981],
2	only	RB	O	only	advmod	1	SENT_379	[p22l662t962r707b986],

1	Illustrated	NNP	O	Illustrated	_	0	SENT_380	[p22l1892t973r1914b1096],
2	by	IN	O	by	dep	1	SENT_380	[p22l1892t934r1920b963],
3	Zina	NNP	PERSON	Zina	nn	4	SENT_380	[p22l1892t870r1914b925],
4	Deretsky	NNP	PERSON	Deretsky	pobj	2	SENT_380	[p22l1892t746r1920b859],

1	Figure	NN	O	figure	_	0	SENT_381	[p22l21t1143r111b1173],
2	2	CD	NUMBER	2	num	4	SENT_381	[p22l119t1144r134b1166],
3	Projected	NNP	O	Projected	nn	4	SENT_381	[p22l159t1142r283b1173],
4	timeline	NN	O	timeline	dep	1	SENT_381	[p22l291t1142r400b1166],
5	of	IN	O	of	_	0	SENT_381	[p22l408t1142r436b1166],
6	FDA	NNP	ORGANIZATION	FDA	nn	7	SENT_381	[p22l442t1143r496b1166],
7	approval	NN	O	approval	prep_of	4	SENT_381	[p22l504t1142r619b1172],
8	for	IN	O	for	_	0	SENT_381	[p22l627t1142r664b1166],
9	new	JJ	O	new	amod	14	SENT_381	[p22l672t1150r727b1166],
10	hepatitis	NN	O	hepatitis	nn	14	SENT_381	[p22l736t1142r849b1172],
11	C	NN	O	c	nn	14	SENT_381	[p22l857t1143r874b1166],
12	virus	NN	O	virus	nn	14	SENT_381	[p22l881t1144r944b1166],
13	treatment	NN	O	treatment	nn	14	SENT_381	[p22l951t1146r1085b1166],
14	regimens	NNS	O	regimen	prep_for	1	SENT_381	[p22l1093t1144r1222b1173],
15	.	.	O	.	_	0	SENT_381	[p22l1093t1144r1222b1173],

1	ASV	NNP	ORGANIZATION	ASV	_	0	SENT_382	[p22l1229t1143r1286b1170],
2	,	,	O	,	_	0	SENT_382	[p22l1229t1143r1286b1170],
3	asunaprevir	NN	O	asunaprevir	appos	1	SENT_382	[p22l1294t1144r1456b1172],
4	;	:	O	;	_	0	SENT_382	[p22l1294t1144r1456b1172],
5	BMS	NNP	ORGANIZATION	BMS	dep	1	SENT_382	[p22l1465t1143r1528b1170],
6	,	,	O	,	_	0	SENT_382	[p22l1465t1143r1528b1170],
7	Bristol	NNP	LOCATION	Bristol	appos	5	SENT_382	[p22l1537t1142r1708b1173],
8	.	.	O	.	_	0	SENT_382	[p22l1537t1142r1708b1173],

1	—	NN	O	—	_	0	SENT_383	[p22l1537t1142r1708b1173],
2	.	.	O	.	_	0	SENT_383	[p22l1537t1142r1708b1173],

1	Myers	NNP	PERSON	Myers	nn	2	SENT_384	[p22l1537t1142r1708b1173],
2	Squibb	NNP	PERSON	Squibb	_	0	SENT_384	[p22l1716t1142r1817b1172],
3	;	:	O	;	_	0	SENT_384	[p22l1716t1142r1817b1172],
4	DCV	NNP	O	DCV	dep	2	SENT_384	[p22l1826t1143r1886b1170],
5	,	,	O	,	_	0	SENT_384	[p22l1826t1143r1886b1170],
6	daclatasvir	NN	O	daclatasvir	appos	4	SENT_384	[p22l1894t1142r2042b1170],
7	;	:	O	;	_	0	SENT_384	[p22l1894t1142r2042b1170],
8	FDA	NNP	ORGANIZATION	FDA	dep	2	SENT_384	[p22l11t1198r135b1252],
9	,	,	O	,	_	0	SENT_384	[p22l11t1198r135b1252],
10	US	NNP	ORGANIZATION	US	nn	11	SENT_384	[p22l154t1197r223b1245],
11	Food	NNP	ORGANIZATION	Food	dep	2	SENT_384	[p22l243t1196r375b1245],
12	and	CC	ORGANIZATION	and	_	0	SENT_384	[p22l394t1196r495b1245],
13	Drug	NNP	ORGANIZATION	Drug	nn	14	SENT_384	[p22l516t1198r648b1258],
14	Administration	NNP	ORGANIZATION	Administration	dep	2	SENT_384	[p22l666t1196r1091b1252],
15	;	:	O	;	_	0	SENT_384	[p22l666t1196r1091b1252],
16	IFN	NN	ORGANIZATION	ifn	dep	2	SENT_384	[p22l1110t1198r1209b1252],
17	,	,	O	,	_	0	SENT_384	[p22l1110t1198r1209b1252],
18	interferon	NN	O	interferon	appos	16	SENT_384	[p22l1227t1195r1513b1252],
19	;	:	O	;	_	0	SENT_384	[p22l1227t1195r1513b1252],
20	RBV	NN	O	rbv	dep	2	SENT_384	[p22l1532t1198r1644b1252],
21	,	,	O	,	_	0	SENT_384	[p22l1532t1198r1644b1252],
22	ribavirin	NNP	O	ribavirin	appos	20	SENT_384	[p22l1663t1196r1899b1245],
23	.	.	O	.	_	0	SENT_384	[p22l1663t1196r1899b1245],

1	treated	VBN	O	treat	partmod	21	SENT_385	[p22l8t1361r246b1424],
2	with	IN	O	with	_	0	SENT_385	[p22l265t1361r418b1424],
3	BMS-7	NN	O	bms-7	prep_with	1	SENT_385	[p22l440t1365r676b1424],
4	91325	CD	NUMBER	91325	num	3	SENT_385	[p22l681t1368r881b1424],
5	at	IN	O	at	_	0	SENT_385	[p22l907t1373r966b1424],
6	150	CD	NUMBER	150	num	7	SENT_385	[p22l994t1368r1106b1424],
7	mg	NN	O	mg	prep_at	3	SENT_385	[p22l1122t1384r1231b1445],
8	twice	RB	O	twice	advmod	10	SENT_385	[p22l1250t1367r1429b1424],
9	a	DT	DURATION	a	det	10	SENT_385	[p22l1453t1384r1487b1424],
10	day	NN	DURATION	day	tmod	1	SENT_385	[p22l1509t1361r1638b1445],
11	,	,	O	,	_	0	SENT_385	[p22l1509t1361r1638b1445],
12	the	DT	O	the	det	13	SENT_385	[p22l1660t1361r1767b1424],
13	SVR12	NN	O	svr12	nsubj	21	SENT_385	[p22l1790t1365r2022b1424],
14	for	IN	O	for	_	0	SENT_385	[p22l2046t1361r2143b1424],
15	the	DT	O	the	det	18	SENT_385	[p22l8t1464r117b1527],
16	12-week	JJ	DURATION	12-week	amod	18	SENT_385	[p22l148t1464r437b1527],
17	treatment	NN	O	treatment	nn	18	SENT_385	[p22l457t1476r803b1527],
18	group	NN	O	group	prep_for	13	SENT_385	[p22l826t1486r1031b1548],
19	was	VBD	O	be	cop	21	SENT_385	[p22l1055t1487r1184b1527],
20	89	CD	PERCENT	89	num	21	SENT_385	[p22l1210t1470r1374b1529],
21	%	NN	PERCENT	%	_	0	SENT_385	[p22l1210t1470r1374b1529],
22	.	.	O	.	_	0	SENT_385	[p22l1210t1470r1374b1529],

1	Data	NNS	O	datum	nsubj	9	SENT_386	[p22l1402t1469r1568b1527],
2	for	IN	O	for	_	0	SENT_386	[p22l1591t1464r1691b1527],
3	the	DT	O	the	det	6	SENT_386	[p22l1713t1464r1822b1527],
4	24-week	JJ	DURATION	24-week	amod	6	SENT_386	[p22l1847t1464r2143b1527],
5	treatment	NN	O	treatment	nn	6	SENT_386	[p22l8t1579r346b1630],
6	arm	NN	O	arm	prep_for	1	SENT_386	[p22l368t1590r505b1630],
7	are	VBP	O	be	cop	9	SENT_386	[p22l528t1590r629b1630],
8	still	RB	O	still	advmod	9	SENT_386	[p22l653t1567r776b1630],
9	pending	VBG	O	pend	_	0	SENT_386	[p22l797t1567r1099b1651],
10	.	.	O	.	_	0	SENT_386	[p22l797t1567r1099b1651],

1	With	IN	O	with	_	0	SENT_387	[p22l1124t1567r1298b1630],
2	the	DT	O	the	det	7	SENT_387	[p22l1320t1567r1427b1630],
3	150-mg	JJ	O	150-mg	amod	4	SENT_387	[p22l1457t1574r1716b1651],
4	twice	JJ	O	twice	amod	7	SENT_387	[p22l1736t1567r2144b1651],
5	—	NN	O	—	nn	7	SENT_387	[p22l1736t1567r2144b1651],
6	a-day	NN	O	a-day	nn	7	SENT_387	[p22l1736t1567r2144b1651],
7	regimen	NN	O	regimen	prep_with	13	SENT_387	[p22l9t1676r318b1754],
8	,	,	O	,	_	0	SENT_387	[p22l9t1676r318b1754],
9	9	CD	PERCENT	9	num	10	SENT_387	[p22l345t1675r448b1735],
10	%	NN	PERCENT	%	nsubj	13	SENT_387	[p22l345t1675r448b1735],
11	of	IN	O	of	_	0	SENT_387	[p22l475t1670r551b1733],
12	patients	NNS	O	patient	prep_of	10	SENT_387	[p22l565t1676r842b1753],
13	had	VBD	O	have	conj_or	13	SENT_387	[p22l866t1670r998b1733],
14	virologic	JJ	O	virologic	amod	15	SENT_387	[p22l1019t1670r1332b1754],
15	relapse	NN	O	relapse	dobj	13	SENT_387	[p22l1357t1670r1600b1753],
16	during	IN	O	during	_	0	SENT_387	[p22l1626t1670r1863b1754],
17	or	CC	O	or	_	0	SENT_387	[p22l1886t1693r1960b1733],
18	after	IN	O	after	_	0	SENT_387	[p22l1985t1670r2141b1733],
19	treatment	NN	O	treatment	prep_during	13	SENT_387	[p22l8t1784r352b1836],
20	.	.	O	.	_	0	SENT_387	[p22l8t1784r352b1836],

1	AEs	NNS	O	ae	nsubj	3	SENT_388	[p22l374t1776r509b1836],
2	were	VBD	O	be	cop	3	SENT_388	[p22l527t1795r685b1836],
3	mild	JJ	O	mild	_	0	SENT_388	[p22l705t1772r862b1836],
4	to	TO	O	to	_	0	SENT_388	[p22l880t1784r944b1836],
5	moderate	JJ	O	moderate	prep_to	3	SENT_388	[p22l965t1772r1301b1844],
6	,	,	O	,	_	0	SENT_388	[p22l965t1772r1301b1844],
7	with	IN	O	with	_	0	SENT_388	[p22l1321t1772r1471b1836],
8	headache	NN	O	headache	prep_with	3	SENT_388	[p22l1490t1772r1822b1844],
9	,	,	O	,	_	0	SENT_388	[p22l1490t1772r1822b1844],
10	asthenia	NN	O	asthenia	prep_with	3	SENT_388	[p22l1844t1772r2139b1844],
11	,	,	O	,	_	0	SENT_388	[p22l1844t1772r2139b1844],
12	diarrhea	NN	O	diarrhea	prep_with	3	SENT_388	[p22l9t1875r312b1947],
13	,	,	O	,	_	0	SENT_388	[p22l9t1875r312b1947],
14	and	CC	O	and	_	0	SENT_388	[p22l335t1875r460b1938],
15	nausea	NN	O	nausea	conj_and	8	SENT_388	[p22l479t1898r711b1938],
16	being	VBG	O	be	auxpass	20	SENT_388	[p22l729t1875r919b1959],
17	the	DT	O	the	dep	18	SENT_388	[p22l937t1875r1042b1938],
18	most	RBS	O	most	advmod	20	SENT_388	[p22l1062t1887r1231b1938],
19	commonly	RB	O	commonly	advmod	20	SENT_388	[p22l1251t1875r1620b1959],
20	encountered	VBN	O	encounter	partmod	8	SENT_388	[p22l1638t1867r2138b1938],
21	.	.	O	.	_	0	SENT_388	[p22l1638t1867r2138b1938],

1	“	NN	O	“	nsubj	23	SENT_389	[p22l1638t1867r2138b1938],
2	In	IN	O	in	_	0	SENT_389	[p22l83t1983r156b2040],
3	a	DT	O	a	det	5	SENT_389	[p22l187t2001r222b2041],
4	smaller	JJR	O	smaller	amod	5	SENT_389	[p22l251t1978r516b2041],
5	study	NN	O	study	prep_in	23	SENT_389	[p22l546t1978r742b2062],
6	of	IN	O	of	_	0	SENT_389	[p22l769t1978r845b2041],
7	10	CD	NUMBER	10	num	8	SENT_389	[p22l872t1985r946b2041],
8	genotype	NN	O	genotype	prep_of	5	SENT_389	[p22l977t1990r1306b2062],
9	2	CD	NUMBER	2	num	12	SENT_389	[p22l1336t1985r1372b2040],
10	and	CC	O	and	_	0	SENT_389	[p22l1404t1978r1536b2041],
11	3	CD	NUMBER	3	num	12	SENT_389	[p22l1566t1985r1600b2041],
12	patients	NNS	O	patient	nsubj	23	SENT_389	[p22l1632t1984r1918b2061],
13	given	VBN	O	give	prep	12	SENT_389	[p22l1948t1984r2141b2062],
14	sofosbuvir	NN	O	sofosbuvir	npadvmod	17	SENT_389	[p22l10t2080r391b2144],
15	and	CC	O	and	_	0	SENT_389	[p22l422t2080r554b2144],
16	RBV	NN	O	rbv	npadvmod	17	SENT_389	[p22l585t2085r751b2144],
17	for	IN	O	for	pcomp	13	SENT_389	[p22l781t2080r885b2144],
18	12	CD	DURATION	12	num	19	SENT_389	[p22l922t2087r996b2143],
19	weeks	NNS	NUMBER	week	pobj	17	SENT_389	[p22l1027t2080r1264b2152],
20	,	,	O	,	_	0	SENT_389	[p22l1027t2080r1264b2152],
21	100	CD	PERCENT	100	num	22	SENT_389	[p22l1303t2085r1490b2145],
22	%	NN	PERCENT	%	appos	19	SENT_389	[p22l1303t2085r1490b2145],
23	achieved	VBD	O	achieve	_	0	SENT_389	[p22l1524t2080r1843b2144],
24	SVR24	NN	O	svr24	dobj	23	SENT_389	[p22l1874t2084r2139b2144],
25	.	.	O	.	_	0	SENT_389	[p22l1874t2084r2139b2144],

1	Ten	CD	NUMBER	ten	num	2	SENT_390	[p22l8t2187r136b2247],
2	patients	NNS	O	patient	nsubjpass	5	SENT_390	[p22l158t2190r433b2267],
3	were	VBD	O	be	auxpass	5	SENT_390	[p22l455t2207r619b2247],
4	also	RB	O	also	advmod	5	SENT_390	[p22l643t2184r777b2247],
5	treated	VBN	O	treat	_	0	SENT_390	[p22l801t2184r1044b2247],
6	with	IN	O	with	_	0	SENT_390	[p22l1064t2184r1220b2247],
7	sofosbuvir	JJ	O	sofosbuvir	amod	10	SENT_390	[p22l1244t2184r1608b2247],
8	(	NN	O	(	nn	10	SENT_390	[p22l1634t2185r1782b2260],
9	400	CD	NUMBER	400	num	10	SENT_390	[p22l1634t2185r1782b2260],
10	mg	NN	O	mg	prep_with	5	SENT_390	[p22l1800t2207r1911b2268],
11	a	DT	DURATION	a	det	14	SENT_390	[p22l1934t2207r1969b2247],
12	day	NN	DURATION	day	nn	14	SENT_390	[p22l1991t2184r2138b2268],
13	)	CD	NUMBER	)	num	14	SENT_390	[p22l1991t2184r2138b2268],
14	monotherapy	NN	O	monotherapy	dobj	5	SENT_390	[p22l8t2287r480b2371],
15	for	IN	O	for	_	0	SENT_390	[p22l499t2287r598b2350],
16	12	CD	DURATION	12	num	17	SENT_390	[p22l627t2294r699b2349],
17	weeks	NNS	NUMBER	week	prep_for	14	SENT_390	[p22l721t2287r947b2359],
18	,	,	O	,	_	0	SENT_390	[p22l721t2287r947b2359],
19	and	CC	O	and	_	0	SENT_390	[p22l973t2287r1101b2350],
20	60	CD	PERCENT	60	num	21	SENT_390	[p22l1123t2292r1267b2352],
21	%	NN	PERCENT	%	nsubj	22	SENT_390	[p22l1123t2292r1267b2352],
22	attained	VBD	O	attain	conj_and	5	SENT_390	[p22l1293t2287r1573b2350],
23	SVR24	NN	O	svr24	dobj	22	SENT_390	[p22l1596t2291r1849b2350],
24	.	.	O	.	_	0	SENT_390	[p22l1596t2291r1849b2350],

1	Further	JJ	O	further	amod	2	SENT_391	[p22l1877t2287r2141b2350],
2	studies	NNS	O	study	nsubjpass	28	SENT_391	[p22l10t2390r250b2453],
3	of	IN	O	of	_	0	SENT_391	[p22l275t2390r351b2453],
4	HCV	NNP	O	HCV	nn	5	SENT_391	[p22l365t2394r548b2453],
5	genotype	NN	O	genotype	prep_of	2	SENT_391	[p22l572t2402r891b2474],
6	2	CD	NUMBER	2	num	5	SENT_391	[p22l916t2397r952b2452],
7	and	CC	O	and	_	0	SENT_391	[p22l978t2390r1107b2453],
8	3	CD	NUMBER	3	num	9	SENT_391	[p22l1131t2397r1165b2453],
9	patients	NNS	O	patient	conj_and	5	SENT_391	[p22l1191t2396r1467b2473],
10	who	WP	O	who	nsubj	13	SENT_391	[p22l1489t2390r1639b2453],
11	were	VBD	O	be	cop	13	SENT_391	[p22l1662t2413r1827b2453],
12	not	RB	O	not	neg	13	SENT_391	[p22l1851t2402r1967b2453],
13	candidates	NNS	O	candidate	rcmod	9	SENT_391	[p22l1990t2413r2138b2453, p22l9t2493r258b2556],
14	for	IN	O	for	_	0	SENT_391	[p22l284t2493r384b2556],
15	treatment	NN	O	treatment	prep_for	13	SENT_391	[p22l407t2505r755b2556],
16	with	IN	O	with	_	0	SENT_391	[p22l777t2493r935b2556],
17	PEG	NN	O	peg	prep_with	15	SENT_391	[p22l961t2497r1120b2556],
18	or	CC	O	or	_	0	SENT_391	[p22l1145t2516r1219b2556],
19	who	WP	O	who	nsubj	20	SENT_391	[p22l1242t2493r1392b2556],
20	had	VBD	O	have	conj_or	13	SENT_391	[p22l1418t2493r1549b2556],
21	previous	JJ	O	previous	amod	25	SENT_391	[p22l1572t2499r1875b2576],
22	nonresponse	JJ	O	nonresponse	amod	25	SENT_391	[p22l1901t2516r2138b2556, p22l9t2618r237b2679],
23	to	TO	O	to	_	0	SENT_391	[p22l257t2608r321b2659],
24	PEG	NN	O	peg	prep_to	22	SENT_391	[p22l344t2600r496b2659],
25	treatment	NN	O	treatment	dobj	20	SENT_391	[p22l515t2608r846b2659],
26	were	VBD	O	be	auxpass	28	SENT_391	[p22l863t2619r1021b2659],
27	also	RB	O	also	advmod	28	SENT_391	[p22l1042t2596r1171b2659],
28	evaluated	VBN	O	evaluate	_	0	SENT_391	[p22l1193t2596r1512b2659],
29	for	IN	O	for	_	0	SENT_391	[p22l1531t2596r1627b2659],
30	treatment	NN	O	treatment	prep_for	28	SENT_391	[p22l1645t2608r1976b2659],
31	with	IN	O	with	_	0	SENT_391	[p22l1993t2596r2144b2659],
32	sofosbuvir	NN	O	sofosbuvir	prep_with	30	SENT_391	[p22l9t2699r361b2762],
33	and	CC	O	and	_	0	SENT_391	[p22l380t2699r505b2762],
34	RBV	NN	O	rbv	conj_and	32	SENT_391	[p22l524t2704r682b2762],
35	alone	RB	O	alone	advmod	28	SENT_391	[p22l702t2699r898b2762],
36	.	.	O	.	_	0	SENT_391	[p22l702t2699r898b2762],

1	For	IN	O	for	_	0	SENT_392	[p22l921t2704r1036b2762],
2	those	DT	O	those	prep_for	14	SENT_392	[p22l1054t2699r1234b2762],
3	in	IN	O	in	_	0	SENT_392	[p22l1254t2705r1320b2761],
4	whom	WP	O	whom	rel	10	SENT_392	[p22l1338t2699r1553b2762],
5	PEG	NN	O	peg	nn	6	SENT_392	[p22l1573t2703r1726b2762],
6	therapy	NN	O	therapy	nsubj	10	SENT_392	[p22l1745t2699r2004b2783],
7	was	VBD	O	be	cop	10	SENT_392	[p22l2018t2722r2142b2762],
8	not	RB	O	not	neg	10	SENT_392	[p22l8t2814r126b2865],
9	an	DT	O	a	det	10	SENT_392	[p22l150t2825r232b2865],
10	option	NN	O	option	rcmod	2	SENT_392	[p22l258t2808r507b2885],
11	,	,	O	,	_	0	SENT_392	[p22l258t2808r507b2885],
12	78	CD	PERCENT	78	num	13	SENT_392	[p22l535t2808r680b2867],
13	%	NN	PERCENT	%	nsubj	14	SENT_392	[p22l535t2808r680b2867],
14	had	VBD	O	have	_	0	SENT_392	[p22l705t2802r837b2865],
15	SVR12	NN	O	svr12	dobj	14	SENT_392	[p22l861t2806r1100b2865],
16	after	IN	O	after	_	0	SENT_392	[p22l1127t2802r1284b2865],
17	sofosbuvir	NN	O	sofosbuvir	prep_after	15	SENT_392	[p22l1309t2802r1677b2865],
18	and	CC	O	and	_	0	SENT_392	[p22l1702t2802r1832b2865],
19	RBV	NN	O	rbv	conj_and	17	SENT_392	[p22l1856t2807r2020b2865],
20	for	IN	O	for	_	0	SENT_392	[p22l2044t2802r2144b2865],
21	12	CD	DURATION	12	num	22	SENT_392	[p22l15t2912r87b2967],
22	weeks	NNS	NUMBER	week	prep_for	14	SENT_392	[p22l110t2905r334b2968],
23	.	.	O	.	_	0	SENT_392	[p22l110t2905r334b2968],

1	Previous	JJ	O	previous	amod	2	SENT_393	[p22l361t2910r660b2968],
2	nonresponders	NNS	O	nonresponder	nsubj	3	SENT_393	[p22l684t2905r1204b2988],
3	had	VBD	O	have	_	0	SENT_393	[p22l1226t2905r1356b2968],
4	SVR12	NN	O	svr12	nn	5	SENT_393	[p22l1379t2909r1613b2968],
5	rates	NNS	O	rate	dobj	3	SENT_393	[p22l1639t2917r1799b2968],
6	of	IN	O	of	_	0	SENT_393	[p22l1823t2905r1897b2968],
7	50	CD	NUMBER	50	prep_of	5	SENT_393	[p22l1912t2912r1989b2968],
8	and	CC	O	and	_	0	SENT_393	[p22l2015t2905r2142b2968],
9	73	CD	PERCENT	73	num	10	SENT_393	[p22l10t3013r154b3072],
10	%	NN	PERCENT	%	prep_of	5	SENT_393	[p22l10t3013r154b3072],
11	after	IN	O	after	_	0	SENT_393	[p22l181t3008r338b3071],
12	12	CD	NUMBER	12	nn	15	SENT_393	[p22l368t3015r440b3070],
13	and	CC	O	and	_	0	SENT_393	[p22l466t3008r596b3071],
14	16	CD	DURATION	16	nn	15	SENT_393	[p22l626t3014r699b3071],
15	weeks	NNS	NUMBER	week	prep_after	3	SENT_393	[p22l722t3008r932b3071],
16	of	IN	O	of	_	0	SENT_393	[p22l957t3008r1033b3071],
17	therapy	NN	O	therapy	prep_of	15	SENT_393	[p22l1046t3008r1324b3092],
18	,	,	O	,	_	0	SENT_393	[p22l1046t3008r1324b3092],
19	respectively	RB	O	respectively	advmod	3	SENT_393	[p22l1350t3008r1782b3092],
20	.	.	O	.	_	0	SENT_393	[p22l1350t3008r1782b3092],

1	Response	NN	O	response	nsubj	5	SENT_394	[p22l1810t3013r2141b3091],
2	to	TO	O	to	_	0	SENT_394	[p22l8t3123r74b3174],
3	treatment	NN	O	treatment	prep_to	1	SENT_394	[p22l97t3123r436b3174],
4	was	VBD	O	be	cop	5	SENT_394	[p22l457t3134r584b3174],
5	higher	JJR	O	higher	conj_and	5	SENT_394	[p22l606t3111r832b3195],
6	in	IN	O	in	_	0	SENT_394	[p22l854t3117r921b3173],
7	those	DT	O	those	prep_in	5	SENT_394	[p22l943t3111r1128b3174],
8	with	IN	O	with	_	0	SENT_394	[p22l1149t3111r1303b3174],
9	genotype	NN	O	genotype	prep_with	7	SENT_394	[p22l1326t3123r1641b3195],
10	2	CD	NUMBER	2	num	9	SENT_394	[p22l1664t3118r1700b3173],
11	and	CC	O	and	_	0	SENT_394	[p22l1726t3111r1853b3174],
12	without	IN	O	without	_	0	SENT_394	[p22l1874t3111r2144b3174],
13	cirrhosis	NN	O	cirrhosis	prep_without	5	SENT_394	[p22l9t3205r386b3277],
14	.72	CD	NUMBER	.72	num	13	SENT_394	[p22l9t3205r386b3277],

1	Further	JJ	O	further	amod	2	SENT_395	[p23l83t27r348b90],
2	investigation	NN	O	investigation	nsubjpass	10	SENT_395	[p23l371t33r818b111],
3	of	IN	O	of	_	0	SENT_395	[p23l842t27r917b90],
4	the	DT	O	the	det	8	SENT_395	[p23l929t27r1038b90],
5	sofosbuvir	NN	O	sofosbuvir	nn	8	SENT_395	[p23l1062t27r1425b90],
6	and	CC	O	and	_	0	SENT_395	[p23l1448t27r1576b90],
7	ledipasvir	NN	O	ledipasvir	nn	8	SENT_395	[p23l1597t27r1940b110],
8	combination	NN	O	combination	prep_of	2	SENT_395	[p23l1962t50r2139b90, p23l7t130r310b193],
9	was	VBD	O	be	auxpass	10	SENT_395	[p23l337t153r468b193],
10	performed	VBN	O	perform	_	0	SENT_395	[p23l497t130r883b213],
11	in	IN	O	in	_	0	SENT_395	[p23l911t136r980b192],
12	the	DT	O	the	det	13	SENT_395	[p23l1008t130r1119b193],
13	phase	NN	O	phase	prep_in	10	SENT_395	[p23l1147t130r1352b213],
14	II	CD	NUMBER	ii	num	16	SENT_395	[p23l1381t135r1437b192],
15	LONESTAR	NNP	LOCATION	LONESTAR	nn	16	SENT_395	[p23l1467t133r1908b193],
16	study	NN	O	study	dep	13	SENT_395	[p23l1935t130r2139b214],
17	.	.	O	.	_	0	SENT_395	[p23l1935t130r2139b214],

1	No	DT	O	no	det	2	SENT_396	[p23l8t238r111b296],
2	data	NNS	O	datum	nsubjpass	5	SENT_396	[p23l136t233r283b296],
3	have	VBP	O	have	aux	5	SENT_396	[p23l304t233r462b296],
4	been	VBN	O	be	auxpass	5	SENT_396	[p23l484t233r651b296],
5	published	VBN	O	publish	dep	30	SENT_396	[p23l673t233r1016b316],
6	to	TO	O	to	_	0	SENT_396	[p23l1037t245r1104b296],
7	date	NN	O	date	prep_to	5	SENT_396	[p23l1130t233r1291b305],
8	,	,	O	,	_	0	SENT_396	[p23l1130t233r1291b305],
9	but	CC	O	but	_	0	SENT_396	[p23l1314t233r1429b296],
10	according	VBG	O	accord	_	0	SENT_396	[p23l1452t233r1797b317],
11	to	TO	O	to	prepc_according_to	26	SENT_396	[p23l1818t245r1884b296],
12	a	DT	O	a	det	14	SENT_396	[p23l1910t256r1945b296],
13	press	NN	O	press	nn	14	SENT_396	[p23l1966t255r2141b316],
14	release	NN	O	release	pobj	26	SENT_396	[p23l9t336r244b399],
15	from	IN	O	from	_	0	SENT_396	[p23l268t336r440b399],
16	Gilead	NNP	ORGANIZATION	Gilead	nn	17	SENT_396	[p23l465t336r694b399],
17	Sciences	NNPS	ORGANIZATION	Sciences	prep_from	14	SENT_396	[p23l718t340r1030b408],
18	,	,	O	,	_	0	SENT_396	[p23l718t340r1030b408],
19	the	DT	O	the	det	20	SENT_396	[p23l1054t336r1163b399],
20	sponsor	NN	O	sponsor	ccomp	26	SENT_396	[p23l1188t358r1466b419],
21	of	IN	O	of	dep	20	SENT_396	[p23l1489t336r1565b399],
22	the	DT	O	the	det	24	SENT_396	[p23l1578t336r1687b399],
23	LONESTAR	NNP	ORGANIZATION	LONESTAR	nn	24	SENT_396	[p23l1711t339r2144b399],
24	study	NN	O	study	pobj	21	SENT_396	[p23l9t439r206b523],
25	,	,	O	,	_	0	SENT_396	[p23l9t439r206b523],
26	results	VBZ	O	result	dep	30	SENT_396	[p23l228t439r443b502],
27	from	IN	O	from	_	0	SENT_396	[p23l463t439r627b502],
28	the	DT	O	the	det	29	SENT_396	[p23l646t439r751b502],
29	trial	NN	O	trial	prep_from	26	SENT_396	[p23l770t439r908b502],
30	suggest	VBP	O	suggest	_	0	SENT_396	[p23l928t451r1171b523],
31	that	IN	O	that	complm	34	SENT_396	[p23l1189t439r1320b502],
32	the	DT	O	the	det	33	SENT_396	[p23l1338t439r1442b502],
33	combination	NN	O	combination	nsubj	34	SENT_396	[p23l1463t439r1889b502],
34	has	VBZ	O	have	ccomp	30	SENT_396	[p23l1908t439r2018b502],
35	the	DT	O	the	det	40	SENT_396	[p23l2037t439r2142b502],
36	potential	JJ	O	potential	amod	40	SENT_396	[p23l7t542r313b625],
37	to	TO	O	to	aux	38	SENT_396	[p23l333t554r399b605],
38	cure	VB	O	cure	xcomp	36	SENT_396	[p23l422t565r568b605],
39	most	RBS	O	most	advmod	38	SENT_396	[p23l589t554r759b605],
40	genotype	NN	O	genotype	dobj	34	SENT_396	[p23l780t554r1091b626],
41	1	CD	NUMBER	1	num	42	SENT_396	[p23l1120t549r1144b604],
42	patients	NNS	O	patient	nsubj	30	SENT_396	[p23l1171t548r1440b625],
43	within	IN	O	within	_	0	SENT_396	[p23l1460t542r1683b605],
44	a	DT	O	a	det	47	SENT_396	[p23l1706t565r1740b605],
45	short	JJ	O	short	amod	47	SENT_396	[p23l1761t542r1937b605],
46	treatment	NN	O	treatment	nn	47	SENT_396	[p23l1957t554r2139b605, p23l8t657r184b708],
47	duration	NN	O	duration	prep_within	42	SENT_396	[p23l204t645r512b708],
48	.	.	O	.	_	0	SENT_396	[p23l204t645r512b708],

1	SVR4	NN	O	svr4	nsubj	8	SENT_397	[p23l536t649r727b708],
2	and	CC	O	and	_	0	SENT_397	[p23l748t645r873b708],
3	SVR8	NN	O	svr8	nsubj	8	SENT_397	[p23l893t649r1082b708],
4	were	VBD	O	be	cop	8	SENT_397	[p23l1103t668r1262b708],
5	the	DT	O	the	det	8	SENT_397	[p23l1281t645r1387b708],
6	primary	JJ	O	primary	amod	8	SENT_397	[p23l1406t651r1687b729],
7	end	NN	O	end	nn	8	SENT_397	[p23l1704t645r1829b708],
8	points	NNS	O	point	_	0	SENT_397	[p23l1847t651r2058b728],
9	of	IN	O	of	_	0	SENT_397	[p23l2079t645r2153b708],
10	the	DT	O	the	det	11	SENT_397	[p23l8t748r114b811],
11	study	NN	O	study	prep_of	8	SENT_397	[p23l138t748r324b832],
12	in	IN	O	in	_	0	SENT_397	[p23l343t754r409b810],
13	which	WDT	O	which	rel	27	SENT_397	[p23l431t748r640b811],
14	60	CD	NUMBER	60	num	16	SENT_397	[p23l663t754r740b811],
15	treatment	NN	O	treatment	nn	16	SENT_397	[p23l763t754r1311b811],
16	—	NN	O	—	nsubjpass	27	SENT_397	[p23l763t754r1311b811],
17	naive	JJ	O	naive	amod	16	SENT_397	[p23l763t754r1311b811],
18	and	CC	O	and	_	0	SENT_397	[p23l1335t748r1461b811],
19	40	CD	NUMBER	40	num	25	SENT_397	[p23l1482t755r1561b811],
20	treatment	NN	O	treatment	nn	23	SENT_397	[p23l1584t760r2137b831],
21	—	CD	NUMBER	—	num	23	SENT_397	[p23l1584t760r2137b831],
22	eXpe	NN	O	expe	nn	23	SENT_397	[p23l1584t760r2137b831],
23	—	NN	O	—	nn	25	SENT_397	[p23l1584t760r2137b831],
24	rienced	JJ	O	rienced	amod	25	SENT_397	[p23l9t851r274b914],
25	patients	NNS	O	patient	nsubjpass	27	SENT_397	[p23l297t857r577b934],
26	were	VBD	O	be	auxpass	27	SENT_397	[p23l601t874r767b914],
27	treated	VBN	O	treat	conj_or	27	SENT_397	[p23l792t851r1040b914],
28	with	IN	O	with	_	0	SENT_397	[p23l1062t851r1220b914],
29	sofosbuvir	NN	O	sofosbuvir	prep_with	27	SENT_397	[p23l1246t851r1616b914],
30	and	CC	O	and	_	0	SENT_397	[p23l1642t851r1772b914],
31	ledipasvir	NN	O	ledipasvir	prep_with	27	SENT_397	[p23l1795t851r2145b934],
32	with	IN	O	with	_	0	SENT_397	[p23l7t954r158b1017],
33	or	CC	O	or	_	0	SENT_397	[p23l178t977r249b1017],
34	without	IN	O	without	_	0	SENT_397	[p23l266t954r531b1017],
35	RBV	NN	O	rbv	prep_with	27	SENT_397	[p23l550t959r708b1017],
36	for	IN	O	for	_	0	SENT_397	[p23l727t954r823b1017],
37	8	CD	NUMBER	8	num	40	SENT_397	[p23l844t961r878b1017],
38	or	CC	O	or	_	0	SENT_397	[p23l900t977r971b1017],
39	12	CD	DURATION	12	conj_or	37	SENT_397	[p23l997t961r1067b1016],
40	weeks	NNS	NUMBER	week	prep_for	27	SENT_397	[p23l1087t954r1305b1017],
41	.	.	O	.	_	0	SENT_397	[p23l1087t954r1305b1017],

1	Among	IN	O	among	_	0	SENT_398	[p23l1327t958r1583b1038],
2	treatment-naive	JJ	O	treatment-naive	amod	3	SENT_398	[p23l1600t960r2141b1017],
3	patients	NNS	O	patient	prep_among	11	SENT_398	[p23l7t1063r295b1140],
4	,	,	O	,	_	0	SENT_398	[p23l7t1063r295b1140],
5	8	CD	DURATION	8	num	6	SENT_398	[p23l319t1064r353b1120],
6	weeks	NNS	NUMBER	week	nsubj	11	SENT_398	[p23l374t1057r578b1120],
7	of	IN	O	of	_	0	SENT_398	[p23l601t1057r674b1120],
8	ledipasvir	NN	O	ledipasvir	prep_of	6	SENT_398	[p23l684t1057r1020b1140],
9	and	CC	O	and	_	0	SENT_398	[p23l1041t1057r1166b1120],
10	sofosbuvir	NN	O	sofosbuvir	prep_of	6	SENT_398	[p23l1188t1057r1544b1120],
11	resulted	VBD	O	result	_	0	SENT_398	[p23l1564t1057r1835b1120],
12	in	IN	O	in	_	0	SENT_398	[p23l1855t1063r1922b1119],
13	a	DT	O	a	det	17	SENT_398	[p23l1943t1080r1978b1120],
14	95	CD	PERCENT	95	number	15	SENT_398	[p23l1998t1063r2140b1122],
15	%	NN	PERCENT	%	amod	17	SENT_398	[p23l1998t1063r2140b1122],
16	SVR8	CD	NUMBER	svr8	num	17	SENT_398	[p23l10t1164r202b1223],
17	rate	NN	O	rate	prep_in	11	SENT_398	[p23l227t1172r373b1232],
18	,	,	O	,	_	0	SENT_398	[p23l227t1172r373b1232],
19	and	CC	O	and	_	0	SENT_398	[p23l399t1160r527b1223],
20	12	CD	DURATION	12	num	21	SENT_398	[p23l555t1167r627b1222],
21	weeks	NNS	NUMBER	week	nsubj	29	SENT_398	[p23l650t1160r856b1223],
22	of	IN	O	of	_	0	SENT_398	[p23l881t1160r955b1223],
23	ledipasvir	NN	O	ledipasvir	prep_of	21	SENT_398	[p23l967t1160r1308b1243],
24	and	CC	O	and	_	0	SENT_398	[p23l1331t1160r1458b1223],
25	sofosbuvir	NN	O	sofosbuvir	prep_of	21	SENT_398	[p23l1481t1160r1842b1223],
26	in	IN	O	in	_	0	SENT_398	[p23l1865t1166r1931b1222],
27	treatment-experienced	JJ	O	treatment-experienced	amod	28	SENT_398	[p23l1954t1172r2139b1223, p23l8t1263r644b1346],
28	patients	NNS	O	patient	prep_in	23	SENT_398	[p23l664t1269r937b1346],
29	resulted	VBD	O	result	conj_and	11	SENT_398	[p23l961t1263r1237b1326],
30	in	IN	O	in	_	0	SENT_398	[p23l1259t1269r1326b1325],
31	a	DT	O	a	det	35	SENT_398	[p23l1350t1286r1385b1326],
32	95	CD	PERCENT	95	number	33	SENT_398	[p23l1407t1268r1551b1328],
33	%	NN	PERCENT	%	amod	35	SENT_398	[p23l1407t1268r1551b1328],
34	SVR4	CD	NUMBER	svr4	num	35	SENT_398	[p23l1577t1267r1772b1326],
35	rate	NN	O	rate	prep_in	29	SENT_398	[p23l1795t1275r1940b1326],
36	.	.	O	.	_	0	SENT_398	[p23l1795t1275r1940b1326],

1	Final	JJ	O	final	amod	2	SENT_399	[p23l1967t1263r2141b1326],
2	results	NNS	O	result	nsubj	3	SENT_399	[p23l9t1366r228b1429],
3	are	VBP	O	be	_	0	SENT_399	[p23l250t1389r350b1429],
4	yet	RB	O	yet	advmod	3	SENT_399	[p23l368t1378r470b1450],
5	to	TO	O	to	aux	7	SENT_399	[p23l488t1378r554b1429],
6	be	VB	O	be	auxpass	7	SENT_399	[p23l574t1366r653b1429],
7	published	VBN	O	publish	xcomp	3	SENT_399	[p23l673t1366r1025b1449],
8	;	:	O	;	_	0	SENT_399	[p23l673t1366r1025b1449],
9	however	RB	O	however	advmod	15	SENT_399	[p23l1047t1366r1349b1438],
10	,	,	O	,	_	0	SENT_399	[p23l1047t1366r1349b1438],
11	the	DT	O	the	det	13	SENT_399	[p23l1370t1366r1476b1429],
12	preliminary	JJ	O	preliminary	amod	13	SENT_399	[p23l1496t1366r1905b1450],
13	results	NNS	O	result	nsubj	15	SENT_399	[p23l1923t1366r2142b1429],
14	have	VBP	O	have	aux	15	SENT_399	[p23l8t1469r162b1532],
15	led	VBN	O	lead	parataxis	3	SENT_399	[p23l182t1469r284b1532],
16	to	TO	O	to	_	0	SENT_399	[p23l302t1481r368b1532],
17	the	DT	O	the	det	18	SENT_399	[p23l389t1469r494b1532],
18	development	NN	O	development	prep_to	15	SENT_399	[p23l516t1469r958b1552],
19	of	IN	O	of	_	0	SENT_399	[p23l978t1469r1051b1532],
20	phase	NN	O	phase	nn	22	SENT_399	[p23l1061t1469r1255b1552],
21	III	CD	NUMBER	iii	num	22	SENT_399	[p23l1276t1474r1358b1531],
22	trials	NNS	O	trial	prep_of	18	SENT_399	[p23l1379t1469r1875b1541],
23	.	.	O	.	_	0	SENT_399	[p23l1379t1469r1875b1541],

1	—	NN	O	—	_	0	SENT_400	[p23l1379t1469r1875b1541],
2	.	.	O	.	_	0	SENT_400	[p23l1379t1469r1875b1541],

1	ION	NN	O	ion	_	0	SENT_401	[p23l1379t1469r1875b1541],
2	.	.	O	.	_	0	SENT_401	[p23l1379t1469r1875b1541],

1	—	NN	O	—	_	0	SENT_402	[p23l1379t1469r1875b1541],
2	.	.	O	.	_	0	SENT_402	[p23l1379t1469r1875b1541],

1	1	CD	NUMBER	1	nsubj	37	SENT_403	[p23l1379t1469r1875b1541],
2	,	,	O	,	_	0	SENT_403	[p23l1379t1469r1875b1541],
3	ION	NN	O	ion	nn	4	SENT_403	[p23l1898t1473r2139b1541],
4	—	NN	O	—	appos	1	SENT_403	[p23l1898t1473r2139b1541],
5	2	CD	NUMBER	2	dep	4	SENT_403	[p23l1898t1473r2139b1541],
6	,	,	O	,	_	0	SENT_403	[p23l1898t1473r2139b1541],
7	and	CC	O	and	_	0	SENT_403	[p23l9t1572r133b1635],
8	ION	NNP	O	ION	conj_and	4	SENT_403	[p23l153t1572r658b1635],
9	—	CD	NUMBER	—	number	10	SENT_403	[p23l153t1572r658b1635],
10	3	CD	NUMBER	3	num	11	SENT_403	[p23l153t1572r658b1635],
11	—	NN	O	—	dep	8	SENT_403	[p23l153t1572r658b1635],
12	which	WDT	O	which	nsubj	13	SENT_403	[p23l153t1572r658b1635],
13	plan	VBP	O	plan	rcmod	1	SENT_403	[p23l677t1572r822b1655],
14	to	TO	O	to	aux	16	SENT_403	[p23l841t1584r906b1635],
15	further	JJ	O	further	advmod	16	SENT_403	[p23l927t1572r1166b1635],
16	evaluate	VB	O	evaluate	conj_and	16	SENT_403	[p23l1185t1572r1457b1635],
17	the	DT	O	the	det	21	SENT_403	[p23l1476t1572r1580b1635],
18	f1Xed	JJ	O	f1xed	amod	21	SENT_403	[p23l1600t1572r1948b1635],
19	—	NN	O	—	nn	21	SENT_403	[p23l1600t1572r1948b1635],
20	dose	NN	O	dose	nn	21	SENT_403	[p23l1600t1572r1948b1635],
21	combination	NN	O	combination	dobj	16	SENT_403	[p23l1968t1595r2139b1635, p23l7t1674r294b1737],
22	of	IN	O	of	_	0	SENT_403	[p23l316t1674r390b1737],
23	sofosbuvir	NN	O	sofosbuvir	prep_of	21	SENT_403	[p23l403t1674r759b1737],
24	and	CC	O	and	_	0	SENT_403	[p23l780t1674r906b1737],
25	ledipasvir	NN	O	ledipasvir	prep_of	21	SENT_403	[p23l925t1674r1261b1757],
26	with	IN	O	with	_	0	SENT_403	[p23l1280t1674r1432b1737],
27	and	CC	O	and	_	0	SENT_403	[p23l1454t1674r1580b1737],
28	without	IN	O	without	_	0	SENT_403	[p23l1599t1674r1867b1737],
29	RBV	NN	O	rbv	prep_with	16	SENT_403	[p23l1888t1666r2115b1737],
30	.73	CD	NUMBER	.73	num	33	SENT_403	[p23l1888t1666r2115b1737],
31	IFN-free	JJ	O	ifn-free	amod	33	SENT_403	[p23l82t1777r370b1840],
32	all-oral	JJ	O	all-oral	amod	33	SENT_403	[p23l389t1777r625b1840],
33	regimens	NNS	O	regimen	dep	1	SENT_403	[p23l643t1783r946b1861],
34	are	VBP	O	be	cop	37	SENT_403	[p23l966t1800r1063b1840],
35	the	DT	O	the	det	37	SENT_403	[p23l1081t1777r1184b1840],
36	likely	JJ	O	likely	amod	37	SENT_403	[p23l1201t1777r1381b1861],
37	future	NN	DATE	future	_	0	SENT_403	[p23l1395t1777r1595b1840],
38	of	IN	O	of	_	0	SENT_403	[p23l1614t1777r1687b1840],
39	chronic	JJ	O	chronic	amod	41	SENT_403	[p23l1696t1777r1947b1840],
40	HCV	NN	O	hcv	nn	41	SENT_403	[p23l1966t1781r2142b1840],
41	treatment	NN	O	treatment	prep_of	37	SENT_403	[p23l8t1892r344b1943],
42	in	IN	O	in	_	0	SENT_403	[p23l365t1886r432b1942],
43	the	DT	O	the	det	45	SENT_403	[p23l453t1880r560b1943],
44	United	NNP	LOCATION	United	nn	45	SENT_403	[p23l583t1880r819b1943],
45	States	NNPS	LOCATION	States	prep_in	41	SENT_403	[p23l841t1884r1033b1943],
46	and	CC	O	and	_	0	SENT_403	[p23l1057t1880r1184b1943],
47	should	MD	O	should	aux	49	SENT_403	[p23l1206t1880r1437b1943],
48	be	VB	O	be	cop	49	SENT_403	[p23l1456t1880r1536b1943],
49	available	JJ	O	available	conj_and	37	SENT_403	[p23l1560t1880r1853b1943],
50	by	IN	O	by	_	0	SENT_403	[p23l1874t1880r1958b1964],
51	early	JJ	DATE	early	amod	52	SENT_403	[p23l1978t1880r2145b1964],
52	2015	CD	DATE	2015	prep_by	49	SENT_403	[p23l9t1990r164b2046],
53	(	CD	NUMBER	(	num	56	SENT_403	[p23l188t1983r438b2066],
54	Figure	NN	O	figure	nn	56	SENT_403	[p23l188t1983r438b2066],
55	2	CD	NUMBER	2	num	56	SENT_403	[p23l455t1984r538b2059],
56	)	NN	O	)	nsubj	49	SENT_403	[p23l455t1984r538b2059],
57	.	.	O	.	_	0	SENT_403	[p23l455t1984r538b2059],

1	Current	JJ	DATE	current	amod	2	SENT_404	[p23l560t1987r822b2046],
2	therapy	NN	O	therapy	nsubjpass	4	SENT_404	[p23l838t1983r1092b2067],
3	is	VBZ	O	be	auxpass	4	SENT_404	[p23l1107t1989r1155b2046],
4	limited	VBN	O	limit	_	0	SENT_404	[p23l1172t1983r1410b2046],
5	by	IN	O	by	_	0	SENT_404	[p23l1424t1983r1507b2067],
6	the	DT	O	the	det	7	SENT_404	[p23l1520t1983r1624b2046],
7	use	NN	O	use	agent	4	SENT_404	[p23l1642t2006r1750b2046],
8	of	IN	O	of	_	0	SENT_404	[p23l1769t1983r1841b2046],
9	PEG	NN	O	peg	prep_of	7	SENT_404	[p23l1850t1987r2002b2046],
10	and	CC	O	and	_	0	SENT_404	[p23l2020t1983r2144b2046],
11	RBV	NN	O	rbv	prep_of	7	SENT_404	[p23l9t2090r164b2149],
12	due	JJ	O	due	_	0	SENT_404	[p23l182t2085r300b2149],
13	to	TO	O	to	_	0	SENT_404	[p23l317t2097r380b2149],
14	a	DT	O	a	det	16	SENT_404	[p23l400t2108r434b2149],
15	substantial	JJ	O	substantial	amod	16	SENT_404	[p23l452t2085r802b2149],
16	number	NN	O	number	prep_due_to	4	SENT_404	[p23l819t2085r1081b2149],
17	of	IN	O	of	_	0	SENT_404	[p23l1098t2085r1169b2149],
18	contraindications	NNS	O	contraindication	prep_of	16	SENT_404	[p23l1178t2085r1749b2149],
19	to	TO	O	to	aux	20	SENT_404	[p23l1766t2097r1830b2149],
20	use	VB	O	use	infmod	18	SENT_404	[p23l1848t2108r1972b2157],
21	,	,	O	,	_	0	SENT_404	[p23l1848t2108r1972b2157],
22	AEs	NNS	O	ae	conj_and	18	SENT_404	[p23l1990t2089r2140b2157],
23	,	,	O	,	_	0	SENT_404	[p23l1990t2089r2140b2157],
24	and	CC	O	and	_	0	SENT_404	[p23l9t2188r133b2251],
25	failure	NN	O	failure	conj_and	18	SENT_404	[p23l150t2188r359b2251],
26	to	TO	O	to	aux	27	SENT_404	[p23l377t2200r442b2251],
27	achieve	VB	O	achieve	infmod	25	SENT_404	[p23l462t2188r706b2251],
28	SVR	NNP	O	SVR	dobj	27	SENT_404	[p23l726t2192r890b2251],
29	.	.	O	.	_	0	SENT_404	[p23l726t2192r890b2251],

1	Numerous	JJ	O	numerous	amod	2	SENT_405	[p23l911t2193r1264b2251],
2	DAAs	NNS	O	daa	nsubj	8	SENT_405	[p23l1284t2192r1485b2251],
3	with	IN	O	with	_	0	SENT_405	[p23l1503t2188r1651b2251],
4	varied	JJ	O	varied	amod	5	SENT_405	[p23l1667t2188r1876b2251],
5	mechanisms	NNS	O	mechanism	prep_with	2	SENT_405	[p23l1894t2188r2138b2251, p23l8t2297r207b2354],
6	of	IN	O	of	_	0	SENT_405	[p23l230t2291r304b2354],
7	action	NN	O	action	prep_of	5	SENT_405	[p23l316t2297r525b2354],
8	are	VBP	O	be	_	0	SENT_405	[p23l547t2314r647b2354],
9	currently	RB	DATE	currently	advmod	8	SENT_405	[p23l668t2291r982b2375],
10	in	IN	O	in	_	0	SENT_405	[p23l1000t2297r1066b2353],
11	development	NN	O	development	prep_in	8	SENT_405	[p23l1088t2291r1545b2374],
12	.	.	O	.	_	0	SENT_405	[p23l1088t2291r1545b2374],

1	Combinations	NNS	O	combination	_	0	SENT_406	[p23l1570t2291r2055b2354],
2	of	IN	O	of	prep	1	SENT_406	[p23l2077t2291r2151b2354],

1	86	CD	NUMBER	86	nsubjpass	14	SENT_407	[p23l8t2510r72b2551],
2	these	DT	O	these	det	3	SENT_407	[p23l7t2591r180b2654],
3	medications	NNS	O	medication	dep	1	SENT_407	[p23l201t2591r611b2654],
4	allow	VBP	O	allow	_	0	SENT_407	[p23l633t2591r814b2654],
5	for	IN	O	for	_	0	SENT_407	[p23l831t2591r927b2654],
6	more	JJR	O	more	prep_for	4	SENT_407	[p23l946t2614r1122b2654],
7	speciﬁcally	RB	O	speciﬁcally	advmod	8	SENT_407	[p23l1144t2591r1515b2675],
8	targeted	VBN	O	target	partmod	6	SENT_407	[p23l1531t2591r1805b2675],
9	treatment	NN	O	treatment	dobj	8	SENT_407	[p23l1823t2603r2154b2654],
10	of	IN	O	of	_	0	SENT_407	[p23l9t2694r81b2757],
11	HCV	NN	O	hcv	prep_of	9	SENT_407	[p23l92t2698r269b2757],
12	and	CC	O	and	_	0	SENT_407	[p23l288t2694r412b2757],
13	are	VBP	O	be	auxpass	14	SENT_407	[p23l431t2717r529b2757],
14	aimed	VBN	O	aim	conj_and	4	SENT_407	[p23l549t2694r754b2757],
15	at	IN	O	at	_	0	SENT_407	[p23l774t2706r831b2757],
16	achieving	VBG	O	achieve	prepc_at	14	SENT_407	[p23l850t2694r1170b2778],
17	higher	JJR	O	higher	amod	18	SENT_407	[p23l1186t2694r1403b2778],
18	rates	NNS	O	rate	dobj	16	SENT_407	[p23l1421t2706r1575b2757],
19	of	IN	O	of	_	0	SENT_407	[p23l1595t2694r1668b2757],
20	SVR	NN	O	svr	prep_of	18	SENT_407	[p23l1679t2698r1844b2757],
21	.	.	O	.	_	0	SENT_407	[p23l1679t2698r1844b2757],

1	CONFLICT	NN	O	conflict	nsubj	6	SENT_408	[p23l9t2864r322b2913],
2	OF	IN	O	of	_	0	SENT_408	[p23l337t2864r420b2913],
3	INTEREST	NN	O	interest	nn	4	SENT_408	[p23l439t2864r738b2912],
4	P.J.P.	NN	O	p.j.p.	prep_of	1	SENT_408	[p23l11t2951r124b2999],
5	has	VBZ	O	have	aux	6	SENT_408	[p23l142t2948r234b2999],
6	received	VBN	O	receive	_	0	SENT_408	[p23l252t2948r486b2999],
7	research	NN	O	research	nn	8	SENT_408	[p23l506t2948r739b2999],
8	grants	NNS	O	grant	dobj	6	SENT_408	[p23l757t2956r933b3013],
9	and	CC	O	and	_	0	SENT_408	[p23l949t2948r1053b2999],
10	is	VBZ	O	be	cop	12	SENT_408	[p23l1073t2951r1109b2999],
11	a	DT	O	a	det	12	SENT_408	[p23l1125t2964r1152b2999],
12	consultant	NN	O	consultant	conj_and	6	SENT_408	[p23l1170t2948r1470b2999],
13	for	IN	O	for	_	0	SENT_408	[p23l1483t2948r1561b2999],
14	Gi	NN	O	gi	nn	16	SENT_408	[p23l1576t2948r1974b3007],
15	|	CD	NUMBER	|	num	16	SENT_408	[p23l1576t2948r1974b3007],
16	ead	NN	O	ead	prep_for	12	SENT_408	[p23l1576t2948r1974b3007],
17	,	,	O	,	_	0	SENT_408	[p23l1576t2948r1974b3007],
18	Vertex	NNP	ORGANIZATION	Vertex	nn	26	SENT_408	[p23l1576t2948r1974b3007],
19	,	,	O	,	_	0	SENT_408	[p23l1576t2948r1974b3007],
20	Genentech	NNP	ORGANIZATION	Genentech	appos	26	SENT_408	[p23l8t3035r333b3093],
21	,	,	O	,	_	0	SENT_408	[p23l8t3035r333b3093],
22	Janssen	NNP	PERSON	Janssen	appos	26	SENT_408	[p23l347t3037r583b3093],
23	,	,	O	,	_	0	SENT_408	[p23l347t3037r583b3093],
24	Boehringer	NNP	O	Boehringer	appos	26	SENT_408	[p23l601t3035r935b3099],
25	—	CD	NUMBER	—	num	26	SENT_408	[p23l601t3035r935b3099],
26	Ingelheim	NNP	O	Ingelheim	prep_for	12	SENT_408	[p23l953t3035r1251b3099],
27	,	,	O	,	_	0	SENT_408	[p23l953t3035r1251b3099],
28	Bristol	NNP	LOCATION	Bristol	nn	31	SENT_408	[p23l1268t3035r1462b3086],
29	—	NNP	O	—	nn	31	SENT_408	[p23l1268t3035r1462b3086],
30	Myers	NNP	PERSON	Myers	nn	31	SENT_408	[p23l1479t3037r1645b3100],
31	Squibb	NNP	PERSON	Squibb	prep_for	12	SENT_408	[p23l1661t3035r1874b3099],
32	,	,	O	,	_	0	SENT_408	[p23l1661t3035r1874b3099],
33	and	CC	O	and	_	0	SENT_408	[p23l1889t3035r1993b3086],
34	Abbott	NNP	PERSON	Abbott	conj_and	16	SENT_408	[p23l8t3120r221b3171],
35	.	.	O	.	_	0	SENT_408	[p23l8t3120r221b3171],

1	He	PRP	O	he	nsubj	5	SENT_409	[p23l239t3122r312b3171],
2	also	RB	O	also	advmod	5	SENT_409	[p23l328t3120r437b3171],
3	is	VBZ	O	be	cop	5	SENT_409	[p23l455t3123r492b3171],
4	a	DT	O	a	det	5	SENT_409	[p23l508t3135r535b3171],
5	speaker	NN	O	speaker	_	0	SENT_409	[p23l553t3120r773b3184],
6	for	IN	O	for	_	0	SENT_409	[p23l785t3119r863b3171],
7	Vertex	NNP	ORGANIZATION	Vertex	nn	13	SENT_409	[p23l873t3122r1068b3179],
8	,	,	O	,	_	0	SENT_409	[p23l873t3122r1068b3179],
9	Merck	NNP	PERSON	Merck	appos	13	SENT_409	[p23l1085t3120r1269b3179],
10	,	,	O	,	_	0	SENT_409	[p23l1085t3120r1269b3179],
11	Genentech	NNP	ORGANIZATION	Genentech	appos	13	SENT_409	[p23l1284t3120r1610b3179],
12	,	,	O	,	_	0	SENT_409	[p23l1284t3120r1610b3179],
13	Gilead	NNP	ORGANIZATION	Gilead	prep_for	5	SENT_409	[p23l1626t3120r1818b3179],
14	,	,	O	,	_	0	SENT_409	[p23l1626t3120r1818b3179],
15	and	CC	O	and	_	0	SENT_409	[p23l1833t3120r1937b3171],
16	Janssen	NNP	PERSON	Janssen	conj_and	13	SENT_409	[p23l6t3208r242b3256],
17	.	.	O	.	_	0	SENT_409	[p23l6t3208r242b3256],

1	J.S.A.	NNP	O	J.S.A.	nsubj	2	SENT_410	[p23l255t3207r396b3256],
2	declared	VBD	O	declare	_	0	SENT_410	[p23l411t3205r653b3256],
3	no	DT	O	no	det	4	SENT_410	[p23l673t3220r743b3256],
4	conflict	NN	O	conflict	dobj	2	SENT_410	[p23l759t3205r968b3256],
5	of	IN	O	of	_	0	SENT_410	[p23l983t3205r1041b3256],
6	interest	NN	O	interest	prep_of	4	SENT_410	[p23l1054t3208r1278b3256],
7	.	.	O	.	_	0	SENT_410	[p23l1054t3208r1278b3256],

1	©	RB	O	©	dep	2	SENT_411	[p23l8t3415r48b3456],
2	2014	CD	DATE	2014	dep	4	SENT_411	[p23l64t3414r194b3458],
3	American	NNP	ORGANIZATION	American	nn	4	SENT_411	[p23l207t3414r461b3458],
4	Society	NNP	ORGANIZATION	Society	_	0	SENT_411	[p23l480t3413r675b3472],
5	for	IN	O	for	_	0	SENT_411	[p23l687t3411r760b3458],
6	Clinical	JJ	O	clinical	amod	7	SENT_411	[p23l775t3411r963b3458],
7	Pharmacology	NN	O	pharmacology	prep_for	4	SENT_411	[p23l984t3411r1370b3472],
8	and	CC	O	and	_	0	SENT_411	[p23l1384t3411r1482b3458],
9	Therapeutics	NNS	O	therapeutics	prep_for	4	SENT_411	[p23l1494t3411r1843b3470],

1	1	LS	NUMBER	1	_	0	SENT_412	[p23l13t3594r50b3640],
2	.	.	O	.	_	0	SENT_412	[p23l13t3594r50b3640],

1	Getchell	NNP	ORGANIZATION	Getchell	_	0	SENT_413	[p23l130t3590r358b3648],
2	,	,	O	,	_	0	SENT_413	[p23l130t3590r358b3648],
3	J.P.	NNP	O	J.P.	nn	4	SENT_413	[p23l370t3593r442b3640],
4	etal	NN	O	etal	appos	1	SENT_413	[p23l456t3590r571b3640],
5	.	.	O	.	_	0	SENT_413	[p23l456t3590r571b3640],

1	Testing	VBG	O	test	_	0	SENT_414	[p23l580t3593r768b3654],
2	for	IN	O	for	_	0	SENT_414	[p23l783t3590r855b3640],
3	HCV	NN	O	hcv	nn	4	SENT_414	[p23l870t3592r981b3640],
4	infection	NN	O	infection	prep_for	1	SENT_414	[p23l995t3590r1238b3640],
5	:	:	O	:	_	0	SENT_414	[p23l995t3590r1238b3640],
6	An	DT	O	a	dep	1	SENT_414	[p23l1252t3593r1321b3640],
7	update	VBP	O	update	dep	6	SENT_414	[p23l1339t3590r1524b3653],
8	of	IN	O	of	_	0	SENT_414	[p23l1538t3590r1593b3640],
9	guidance	NN	O	guidance	prep_of	7	SENT_414	[p23l1602t3590r1846b3654],
10	for	IN	O	for	_	0	SENT_414	[p23l1858t3590r1931b3640],
11	clinicians	NNS	O	clinician	prep_for	9	SENT_414	[p23l131t3667r370b3717],
12	and	CC	O	and	_	0	SENT_414	[p23l384t3667r480b3717],
13	laboratorians	NNS	O	laboratorian	prep_for	9	SENT_414	[p23l499t3667r855b3717],
14	.	.	O	.	_	0	SENT_414	[p23l499t3667r855b3717],

1	MMWR	NN	O	mmwr	_	0	SENT_415	[p23l869t3670r1054b3716],
2	62	CD	NUMBER	62	num	1	SENT_415	[p23l1066t3671r1147b3724],
3	,	,	O	,	_	0	SENT_415	[p23l1066t3671r1147b3724],
4	362-365	CD	NUMBER	362-365	number	5	SENT_415	[p23l1161t3671r1383b3717],
5	(	CD	NUMBER	(	appos	1	SENT_415	[p23l1401t3668r1575b3724],
6	2013	CD	DATE	2013	num	7	SENT_415	[p23l1401t3668r1575b3724],
7	)	NN	O	)	dep	5	SENT_415	[p23l1401t3668r1575b3724],
8	.	.	O	.	_	0	SENT_415	[p23l1401t3668r1575b3724],

1	Ghany	NNP	PERSON	Ghany	_	0	SENT_416	[p24l130t17r311b81],
2	,	,	O	,	_	0	SENT_416	[p24l130t17r311b81],
3	M.G.	NNP	LOCATION	M.G.	conj_and	1	SENT_416	[p24l328t19r457b75],
4	,	,	O	,	_	0	SENT_416	[p24l328t19r457b75],
5	Nelson	NNP	PERSON	Nelson	conj_and	1	SENT_416	[p24l476t17r670b75],
6	,	,	O	,	_	0	SENT_416	[p24l476t17r670b75],
7	D.R.	NNP	LOCATION	D.R.	conj_and	1	SENT_416	[p24l688t20r798b75],
8	,	,	O	,	_	0	SENT_416	[p24l688t20r798b75],
9	Strader	NNP	PERSON	Strader	conj_and	1	SENT_416	[p24l814t17r1016b75],
10	,	,	O	,	_	0	SENT_416	[p24l814t17r1016b75],
11	D.B.	NNP	LOCATION	D.B.	conj_and	1	SENT_416	[p24l1034t20r1144b75],
12	,	,	O	,	_	0	SENT_416	[p24l1034t20r1144b75],
13	Thomas	NNP	PERSON	Thomas	conj_and	1	SENT_416	[p24l1154t17r1379b75],
14	,	,	O	,	_	0	SENT_416	[p24l1154t17r1379b75],
15	D.L.	NNP	ORGANIZATION	D.L.	conj_and	1	SENT_416	[p24l1398t20r1490b67],
16	&	CC	ORGANIZATION	&	_	0	SENT_416	[p24l1505t19r1542b67],
17	Seeff	NNP	ORGANIZATION	Seeff	conj_and	1	SENT_416	[p24l1557t17r1698b75],
18	,	,	O	,	_	0	SENT_416	[p24l1557t17r1698b75],
19	L.B.	NNP	LOCATION	L.B.	appos	1	SENT_416	[p24l1716t20r1816b75],
20	;	:	O	;	_	0	SENT_416	[p24l1716t20r1816b75],
21	American	NNP	ORGANIZATION	American	nn	22	SENT_416	[p24l1831t20r2084b67],
22	Association	NNP	ORGANIZATION	Association	dep	1	SENT_416	[p24l131t98r435b145],
23	for	IN	ORGANIZATION	for	_	0	SENT_416	[p24l452t95r525b145],
24	Study	NNP	ORGANIZATION	Study	prep_for	22	SENT_416	[p24l540t95r693b159],
25	of	IN	ORGANIZATION	of	_	0	SENT_416	[p24l707t95r762b145],
26	Liver	NN	ORGANIZATION	liver	nn	27	SENT_416	[p24l776t98r901b145],
27	Diseases	NNS	ORGANIZATION	disease	prep_of	24	SENT_416	[p24l917t98r1156b145],
28	.	.	O	.	_	0	SENT_416	[p24l917t98r1156b145],

1	An	DT	O	a	_	0	SENT_417	[p24l1171t98r1241b145],
2	update	VBP	O	update	dep	1	SENT_417	[p24l1260t95r1448b158],
3	on	IN	O	on	_	0	SENT_417	[p24l1464t110r1529b145],
4	treatment	NN	O	treatment	prep_on	2	SENT_417	[p24l1545t103r1814b145],
5	of	IN	O	of	_	0	SENT_417	[p24l1829t95r1884b145],
6	genotype	NN	O	genotype	nn	12	SENT_417	[p24l131t181r389b237],
7	1	CD	NUMBER	1	num	12	SENT_417	[p24l409t177r424b222],
8	chronic	JJ	O	chronic	amod	12	SENT_417	[p24l450t173r648b223],
9	hepatitis	NN	O	hepatitis	nn	12	SENT_417	[p24l665t173r895b236],
10	C	NN	O	c	nn	12	SENT_417	[p24l910t175r944b223],
11	virus	NN	O	virus	nn	12	SENT_417	[p24l958t176r1084b223],
12	infection	NN	O	infection	prep_of	4	SENT_417	[p24l1102t173r1350b223],
13	:	:	O	:	_	0	SENT_417	[p24l1102t173r1350b223],
14	2011	CD	DATE	2011	num	16	SENT_417	[p24l1366t177r1484b223],
15	practice	NN	O	practice	nn	16	SENT_417	[p24l1512t176r1723b236],
16	guideline	NN	O	guideline	parataxis	2	SENT_417	[p24l1739t173r1991b237],
17	by	IN	O	by	_	0	SENT_417	[p24l2008t173r2071b237],
18	the	DT	O	the	det	20	SENT_417	[p24l130t251r217b301],
19	American	NNP	ORGANIZATION	American	nn	20	SENT_417	[p24l232t254r485b301],
20	Association	NNP	ORGANIZATION	Association	prep_by	16	SENT_417	[p24l503t254r807b301],
21	for	IN	O	for	_	0	SENT_417	[p24l824t251r898b301],
22	the	DT	O	the	det	23	SENT_417	[p24l910t251r998b301],
23	Study	NN	O	study	prep_for	16	SENT_417	[p24l1013t251r1167b315],
24	of	IN	O	of	_	0	SENT_417	[p24l1181t251r1236b301],
25	Liver	NN	O	liver	nn	26	SENT_417	[p24l1249t254r1374b301],
26	Diseases	NNS	O	disease	prep_of	16	SENT_417	[p24l1391t254r1629b301],
27	.	.	O	.	_	0	SENT_417	[p24l1391t254r1629b301],

1	Hepatology	NNP	O	Hepatology	_	0	SENT_418	[p24l1645t251r1949b315],
2	54	CD	NUMBER	54	num	1	SENT_418	[p24l1961t255r2042b309],
3	,	,	O	,	_	0	SENT_418	[p24l1961t255r2042b309],
4	1433-1444	CD	DATE	1433-1444	num	1	SENT_418	[p24l135t332r426b378],
5	(	NN	O	(	dep	1	SENT_418	[p24l443t329r545b385],
6	201	CD	NUMBER	201	number	7	SENT_418	[p24l443t329r545b385],
7	1	CD	NUMBER	1	num	8	SENT_418	[p24l564t329r621b385],
8	)	NN	O	)	dep	5	SENT_418	[p24l564t329r621b385],
9	.	.	O	.	_	0	SENT_418	[p24l564t329r621b385],

1	Ngo	NNP	O	Ngo	_	0	SENT_419	[p24l132t409r488b470],
2	.	.	O	.	_	0	SENT_419	[p24l132t409r488b470],

1	—	NN	O	—	_	0	SENT_420	[p24l132t409r488b470],
2	.	.	O	.	_	0	SENT_420	[p24l132t409r488b470],

1	Metzger	NNP	PERSON	Metzger	tmod	20	SENT_421	[p24l132t409r488b470],
2	,	,	O	,	_	0	SENT_421	[p24l132t409r488b470],
3	Q.	NNP	O	Q.	conj_and	1	SENT_421	[p24l503t408r567b464],
4	,	,	O	,	_	0	SENT_421	[p24l503t408r567b464],
5	Ward	NNP	PERSON	Ward	conj_and	1	SENT_421	[p24l578t406r726b464],
6	,	,	O	,	_	0	SENT_421	[p24l578t406r726b464],
7	J.W.	NNP	ORGANIZATION	J.W.	conj_and	1	SENT_421	[p24l739t409r836b456],
8	&	CC	ORGANIZATION	&	_	0	SENT_421	[p24l850t406r1150b464],
9	Va	NNP	ORGANIZATION	Va	tmod	20	SENT_421	[p24l850t406r1150b464],
10	|	CD	NUMBER	|	num	11	SENT_421	[p24l850t406r1150b464],
11	diserri	NN	O	diserrus	dep	1	SENT_421	[p24l850t406r1150b464],
12	,	,	O	,	_	0	SENT_421	[p24l850t406r1150b464],
13	R.O.	NNP	O	R.O.	nn	17	SENT_421	[p24l1167t408r1262b456],
14	Expanded	NNP	O	Expanded	nn	17	SENT_421	[p24l1279t406r1538b469],
15	hepatitis	NNP	O	hepatitis	nn	17	SENT_421	[p24l1557t406r1781b469],
16	C	NN	O	c	nn	17	SENT_421	[p24l1796t408r1829b456],
17	virus	NN	O	virus	nsubj	20	SENT_421	[p24l1842t409r1966b456],
18	screening	JJ	O	screening	amod	19	SENT_421	[p24l131t487r383b548],
19	recommendations	NNS	O	recommendation	dep	17	SENT_421	[p24l402t484r883b534],
20	promote	VBP	O	promote	_	0	SENT_421	[p24l900t492r1126b547],
21	opportunities	NNS	O	opportunity	dobj	20	SENT_421	[p24l1140t487r1500b547],
22	for	IN	O	for	_	0	SENT_421	[p24l1513t484r1585b534],
23	care	NN	O	care	prep_for	21	SENT_421	[p24l1599t499r1706b534],
24	and	CC	O	and	_	0	SENT_421	[p24l1720t484r1816b534],
25	cure	NN	O	cure	prep_for	21	SENT_421	[p24l1833t487r2083b534],
26	.	.	O	.	_	0	SENT_421	[p24l1833t487r2083b534],

1	Ann	NNP	PERSON	Ann	_	0	SENT_422	[p24l1833t487r2083b534],
2	.	.	O	.	_	0	SENT_422	[p24l1833t487r2083b534],

1	Intern	NNP	O	Intern	_	0	SENT_423	[p24l131t564r289b611],
2	.	.	O	.	_	0	SENT_423	[p24l131t564r289b611],

1	Med	NNP	O	Med	_	0	SENT_424	[p24l303t561r426b611],
2	.	.	O	.	_	0	SENT_424	[p24l303t561r426b611],

1	159	CD	NUMBER	159	_	0	SENT_425	[p24l443t565r555b618],
2	,	,	O	,	_	0	SENT_425	[p24l443t565r555b618],
3	364-365	CD	NUMBER	364-365	num	4	SENT_425	[p24l570t565r792b611],
4	(	NN	O	(	appos	1	SENT_425	[p24l810t562r910b618],
5	201	CD	NUMBER	201	number	6	SENT_425	[p24l810t562r910b618],
6	3	CD	NUMBER	3	num	7	SENT_425	[p24l925t562r984b618],
7	)	NN	O	)	dep	4	SENT_425	[p24l925t562r984b618],
8	.	.	O	.	_	0	SENT_425	[p24l925t562r984b618],

1	Simmonds	NNP	PERSON	Simmonds	nn	4	SENT_426	[p24l130t639r422b697],
2	,	,	O	,	_	0	SENT_426	[p24l130t639r422b697],
3	P.	NNP	O	P.	appos	4	SENT_426	[p24l439t642r471b689],
4	Genetic	NNP	O	Genetic	_	0	SENT_426	[p24l485t641r686b689],
5	diversity	NN	O	diversity	dep	4	SENT_426	[p24l701t639r923b703],
6	and	CC	O	and	_	0	SENT_426	[p24l936t639r1032b689],
7	evolution	NN	O	evolution	dep	4	SENT_426	[p24l1049t639r1296b689],
8	of	IN	O	of	_	0	SENT_426	[p24l1312t639r1367b689],
9	hepatitis	NN	O	hepatitis	nn	11	SENT_426	[p24l1378t639r1603b702],
10	C	NN	O	c	nn	11	SENT_426	[p24l1617t641r1651b689],
11	virus	NN	O	virus	prep_of	5	SENT_426	[p24l1663t642r1842b689],
12	—	CD	NUMBER	—	number	13	SENT_426	[p24l1663t642r1842b689],
13	1	CD	NUMBER	1	dep	4	SENT_426	[p24l1663t642r1842b689],
14	5	CD	DURATION	5	num	15	SENT_426	[p24l1856t643r1882b689],
15	years	NNS	NUMBER	year	dep	16	SENT_426	[p24l1898t654r2033b703],
16	on	IN	O	on	prep	13	SENT_426	[p24l2048t654r2127b689],
17	.	.	O	.	_	0	SENT_426	[p24l2048t654r2127b689],

1	J.	NNP	O	J.	nn	3	SENT_427	[p24l127t719r161b766],
2	Gen.	NNP	O	Gen.	nn	3	SENT_427	[p24l177t718r286b766],
3	Virol	NNP	PERSON	Virol	_	0	SENT_427	[p24l305t716r426b766],
4	.	.	O	.	_	0	SENT_427	[p24l305t716r426b766],

1	85	CD	NUMBER	85	_	0	SENT_428	[p24l440t720r520b773],
2	,	,	O	,	_	0	SENT_428	[p24l440t720r520b773],
3	31	CD	NUMBER	31	num	4	SENT_428	[p24l536t720r586b766],
4	73-3188	CD	NUMBER	73-3188	appos	1	SENT_428	[p24l602t720r824b766],
5	(	CD	NUMBER	(	num	7	SENT_428	[p24l840t717r1015b773],
6	2004	CD	DATE	2004	num	7	SENT_428	[p24l840t717r1015b773],
7	)	NN	O	)	dep	4	SENT_428	[p24l840t717r1015b773],
8	.	.	O	.	_	0	SENT_428	[p24l840t717r1015b773],

1	Ge	NNP	O	Ge	_	0	SENT_429	[p24l129t796r211b852],
2	,	,	O	,	_	0	SENT_429	[p24l129t796r211b852],
3	D.	NNP	O	D.	nn	4	SENT_429	[p24l228t797r275b844],
4	etal	NNP	O	etal	appos	1	SENT_429	[p24l289t794r404b844],
5	.	.	O	.	_	0	SENT_429	[p24l289t794r404b844],

1	Genetic	JJ	O	genetic	amod	2	SENT_430	[p24l418t796r620b844],
2	variation	NN	O	variation	nsubj	6	SENT_430	[p24l633t797r861b844],
3	in	IN	O	in	_	0	SENT_430	[p24l880t797r922b844],
4	|	CD	NUMBER	|	num	5	SENT_430	[p24l941t797r1079b844],
5	L28B	NN	O	l28b	prep_in	2	SENT_430	[p24l941t797r1079b844],
6	predicts	VBZ	O	predict	_	0	SENT_430	[p24l1096t794r1305b857],
7	hepatitis	NN	O	hepatitis	nn	8	SENT_430	[p24l1321t794r1546b857],
8	C	NN	O	c	dobj	6	SENT_430	[p24l1560t796r1594b844],
9	treatment	NN	O	treatment	nn	10	SENT_430	[p24l1607t794r2104b844],
10	—	NN	O	—	nsubj	11	SENT_430	[p24l1607t794r2104b844],
11	induced	VBD	O	induce	rcmod	8	SENT_430	[p24l1607t794r2104b844],
12	viral	JJ	O	viral	amod	13	SENT_430	[p24l130t871r236b921],
13	clearance	NN	O	clearance	dobj	11	SENT_430	[p24l253t871r514b921],
14	.	.	O	.	_	0	SENT_430	[p24l253t871r514b921],

1	Nature	NNP	O	Nature	_	0	SENT_431	[p24l528t874r701b921],
2	461	CD	NUMBER	461	num	1	SENT_431	[p24l713t875r829b928],
3	,	,	O	,	_	0	SENT_431	[p24l713t875r829b928],
4	399-401	CD	NUMBER	399-401	num	1	SENT_431	[p24l844t875r1058b921],
5	(	CD	NUMBER	(	num	7	SENT_431	[p24l1084t872r1258b928],
6	2009	CD	DATE	2009	num	7	SENT_431	[p24l1084t872r1258b928],
7	)	NN	O	)	dep	1	SENT_431	[p24l1084t872r1258b928],
8	.	.	O	.	_	0	SENT_431	[p24l1084t872r1258b928],

1	Poordad	NNP	O	Poordad	_	0	SENT_432	[p24l132t949r363b1007],
2	,	,	O	,	_	0	SENT_432	[p24l132t949r363b1007],
3	R.	NNP	O	R.	nn	4	SENT_432	[p24l380t952r421b999],
4	etal	NN	O	etal	appos	1	SENT_432	[p24l435t949r550b999],
5	.	.	O	.	_	0	SENT_432	[p24l435t949r550b999],

1	Boceprevirfor	NNP	MISC	Boceprevirfor	nsubj	2	SENT_433	[p24l566t949r930b1012],
2	untreated	JJ	O	untreated	_	0	SENT_433	[p24l945t949r1199b999],
3	chronic	JJ	O	chronic	amod	5	SENT_433	[p24l1215t949r1410b999],
4	HCV	NN	O	hcv	nn	5	SENT_433	[p24l1426t951r1537b999],
5	genotype	NN	O	genotype	iobj	2	SENT_433	[p24l1549t957r1803b1013],
6	1	CD	NUMBER	1	num	7	SENT_433	[p24l1822t953r1836b998],
7	infection	NN	O	infection	dobj	2	SENT_433	[p24l1862t949r2105b999],
8	.	.	O	.	_	0	SENT_433	[p24l1862t949r2105b999],

1	N.	NNP	O	N.	nn	2	SENT_434	[p24l131t1030r178b1077],
2	Engl	NNP	O	Engl	_	0	SENT_434	[p24l193t1028r311b1091],
3	.	.	O	.	_	0	SENT_434	[p24l193t1028r311b1091],

1	J.	NNP	O	J.	nn	2	SENT_435	[p24l322t1030r357b1077],
2	Med	NNP	O	Med	_	0	SENT_435	[p24l370t1028r493b1077],
3	.	.	O	.	_	0	SENT_435	[p24l370t1028r493b1077],

1	364	CD	NUMBER	364	_	0	SENT_436	[p24l508t1031r623b1085],
2	,	,	O	,	_	0	SENT_436	[p24l508t1031r623b1085],
3	1	CD	NUMBER	1	num	5	SENT_436	[p24l642t1032r656b1077],
4	195-1206	CD	NUMBER	195-1206	num	5	SENT_436	[p24l675t1031r927b1077],
5	(	NN	O	(	appos	1	SENT_436	[p24l943t1029r1044b1085],
6	201	CD	NUMBER	201	number	7	SENT_436	[p24l943t1029r1044b1085],
7	1	CD	NUMBER	1	num	8	SENT_436	[p24l1062t1029r1117b1085],
8	)	NN	O	)	dep	5	SENT_436	[p24l1062t1029r1117b1085],
9	.	.	O	.	_	0	SENT_436	[p24l1062t1029r1117b1085],

1	Chung	NNP	PERSON	Chung	_	0	SENT_437	[p24l129t1106r316b1169],
2	,	,	O	,	_	0	SENT_437	[p24l129t1106r316b1169],
3	R.T.	NNP	PERSON	R.T.	appos	1	SENT_437	[p24l333t1108r415b1155],
4	.	.	O	.	_	0	SENT_437	[p24l333t1108r415b1155],

1	A	DT	O	a	det	3	SENT_438	[p24l429t1108r465b1155],
2	watershed	JJ	O	watershed	amod	3	SENT_438	[p24l478t1106r752b1155],
3	moment	NN	O	moment	_	0	SENT_438	[p24l770t1113r995b1155],
4	in	IN	O	in	_	0	SENT_438	[p24l1010t1108r1053b1155],
5	the	DT	O	the	det	6	SENT_438	[p24l1068t1106r1153b1155],
6	treatment	NN	O	treatment	prep_in	3	SENT_438	[p24l1166t1113r1430b1155],
7	of	IN	O	of	_	0	SENT_438	[p24l1444t1105r1499b1155],
8	hepatitis	NNP	O	hepatitis	nn	11	SENT_438	[p24l1511t1106r1735b1168],
9	C.	NNP	O	C.	nn	11	SENT_438	[p24l1750t1107r1796b1155],
10	N.	NNP	O	N.	nn	11	SENT_438	[p24l1810t1108r1857b1155],
11	Engl	NNP	O	Engl	prep_of	3	SENT_438	[p24l1873t1106r1991b1169],
12	.	.	O	.	_	0	SENT_438	[p24l1873t1106r1991b1169],

1	J.	NNP	O	J.	nn	2	SENT_439	[p24l2002t1108r2036b1155],
2	Med	NNP	O	Med	_	0	SENT_439	[p24l130t1183r252b1232],
3	.	.	O	.	_	0	SENT_439	[p24l130t1183r252b1232],

1	366	CD	NUMBER	366	_	0	SENT_440	[p24l267t1186r382b1239],
2	,	,	O	,	_	0	SENT_440	[p24l267t1186r382b1239],
3	273-275	CD	NUMBER	273-275	number	4	SENT_440	[p24l397t1186r618b1232],
4	(	CD	NUMBER	(	appos	1	SENT_440	[p24l636t1184r810b1239],
5	2012	CD	DATE	2012	num	6	SENT_440	[p24l636t1184r810b1239],
6	)	NN	O	)	dep	4	SENT_440	[p24l636t1184r810b1239],
7	.	.	O	.	_	0	SENT_440	[p24l636t1184r810b1239],

1	Poordad	NNP	O	Poordad	_	0	SENT_441	[p24l132t1261r372b1318],
2	,	,	O	,	_	0	SENT_441	[p24l132t1261r372b1318],
3	F.	NNP	ORGANIZATION	F.	conj_and	1	SENT_441	[p24l391t1263r424b1310],
4	&	CC	ORGANIZATION	&	_	0	SENT_441	[p24l441t1262r477b1310],
5	Dieterich	NNP	ORGANIZATION	Dieterich	conj_and	1	SENT_441	[p24l495t1261r755b1318],
6	,	,	O	,	_	0	SENT_441	[p24l495t1261r755b1318],
7	D.	NNP	O	D.	appos	1	SENT_441	[p24l774t1263r823b1310],
8	Treating	VBG	O	treat	dep	7	SENT_441	[p24l834t1263r1058b1324],
9	hepatitis	NN	O	hepatitis	nn	10	SENT_441	[p24l1079t1261r1314b1323],
10	C	NN	O	c	dobj	8	SENT_441	[p24l1331t1262r1379b1310],
11	:	:	O	:	_	0	SENT_441	[p24l1331t1262r1379b1310],
12	current	JJ	DATE	current	amod	13	SENT_441	[p24l1395t1268r1593b1310],
13	standard	NN	O	standard	dep	10	SENT_441	[p24l1609t1261r1847b1310],
14	of	IN	O	of	_	0	SENT_441	[p24l1866t1260r1922b1310],
15	care	NN	O	care	prep_of	13	SENT_441	[p24l1934t1275r2045b1310],
16	and	CC	O	and	_	0	SENT_441	[p24l131t1339r229b1388],
17	emerging	VBG	O	emerge	dep	7	SENT_441	[p24l249t1341r510b1402],
18	direct-acting	JJ	O	direct-acting	amod	20	SENT_441	[p24l529t1339r877b1402],
19	antiviral	JJ	O	antiviral	amod	20	SENT_441	[p24l896t1339r1114b1388],
20	agents	NNS	O	agent	dobj	17	SENT_441	[p24l1133t1346r1328b1402],
21	.	.	O	.	_	0	SENT_441	[p24l1133t1346r1328b1402],

1	J.	NNP	O	J.	_	0	SENT_442	[p24l1341t1341r1377b1388],
2	Viral	JJ	O	viral	amod	3	SENT_442	[p24l1398t1339r1515b1388],
3	Hepat	NN	O	hepat	dep	1	SENT_442	[p24l1526t1341r1698b1401],
4	.	.	O	.	_	0	SENT_442	[p24l1526t1341r1698b1401],

1	19	CD	NUMBER	19	_	0	SENT_443	[p24l1717t1342r1797b1396],
2	,	,	O	,	_	0	SENT_443	[p24l1717t1342r1797b1396],
3	449-464	CD	NUMBER	449-464	number	4	SENT_443	[p24l1812t1342r2047b1388],
4	(	CD	NUMBER	(	appos	1	SENT_443	[p24l133t1417r314b1472],
5	2012	CD	DATE	2012	num	6	SENT_443	[p24l133t1417r314b1472],
6	)	NN	O	)	dep	4	SENT_443	[p24l133t1417r314b1472],
7	.	.	O	.	_	0	SENT_443	[p24l133t1417r314b1472],

1	Pockros	NNP	O	Pockros	nn	4	SENT_444	[p24l132t1494r345b1551],
2	,	,	O	,	_	0	SENT_444	[p24l132t1494r345b1551],
3	P.J.	NNP	O	P.J.	appos	4	SENT_444	[p24l362t1496r429b1543],
4	New	NNP	O	New	_	0	SENT_444	[p24l446t1496r561b1543],
5	direct-acting	JJ	O	direct-acting	amod	6	SENT_444	[p24l575t1494r907b1557],
6	antivirals	NNS	O	antiviral	dep	4	SENT_444	[p24l924t1494r1158b1543],
7	in	IN	O	in	_	0	SENT_444	[p24l1175t1496r1217b1543],
8	the	DT	O	the	det	9	SENT_444	[p24l1232t1494r1318b1543],
9	development	NN	O	development	prep_in	6	SENT_444	[p24l1332t1494r1686b1556],
10	for	IN	O	for	_	0	SENT_444	[p24l1699t1493r1771b1543],
11	hepatitis	NN	O	hepatitis	nn	14	SENT_444	[p24l1786t1494r2011b1556],
12	C	NN	O	c	nn	14	SENT_444	[p24l2025t1495r2058b1543],
13	virus	NN	O	virus	nn	14	SENT_444	[p24l130t1574r253b1622],
14	infection	NN	O	infection	prep_for	9	SENT_444	[p24l269t1571r512b1622],
15	.	.	O	.	_	0	SENT_444	[p24l269t1571r512b1622],

1	Therap	NNP	O	Therap	_	0	SENT_445	[p24l528t1572r711b1634],
2	.	.	O	.	_	0	SENT_445	[p24l528t1572r711b1634],

1	Adv	NNP	O	Adv	_	0	SENT_446	[p24l722t1572r829b1621],
2	.	.	O	.	_	0	SENT_446	[p24l722t1572r829b1621],

1	Gastroenterol	NNP	PERSON	Gastroenterol	_	0	SENT_447	[p24l845t1572r1202b1622],
2	.	.	O	.	_	0	SENT_447	[p24l845t1572r1202b1622],

1	3	CD	NUMBER	3	_	0	SENT_448	[p24l1216t1575r1261b1629],
2	,	,	O	,	_	0	SENT_448	[p24l1216t1575r1261b1629],
3	191-202	CD	NUMBER	191-202	number	4	SENT_448	[p24l1280t1575r1498b1621],
4	(	CD	NUMBER	(	appos	1	SENT_448	[p24l1515t1573r1690b1629],
5	2010	CD	DATE	2010	num	6	SENT_448	[p24l1515t1573r1690b1629],
6	)	NN	O	)	dep	4	SENT_448	[p24l1515t1573r1690b1629],
7	.	.	O	.	_	0	SENT_448	[p24l1515t1573r1690b1629],

1	US	NNP	ORGANIZATION	US	nn	2	SENT_449	[p24l132t1651r198b1699],
2	Food	NNP	ORGANIZATION	Food	_	0	SENT_449	[p24l217t1650r346b1699],
3	and	CC	ORGANIZATION	and	_	0	SENT_449	[p24l363t1650r461b1699],
4	Drug	NNP	ORGANIZATION	Drug	nn	5	SENT_449	[p24l481t1652r608b1713],
5	Administration	NNP	ORGANIZATION	Administration	conj_and	2	SENT_449	[p24l626t1650r1040b1699],
6	.	.	O	.	_	0	SENT_449	[p24l626t1650r1040b1699],

1	Approval	NN	O	approval	_	0	SENT_450	[p24l1055t1650r1296b1712],
2	of	IN	O	of	_	0	SENT_450	[p24l1314t1649r1369b1699],
3	Victrelis	NNP	PERSON	Victrelis	prep_of	1	SENT_450	[p24l1376t1650r1585b1699],
4	(	CD	NUMBER	(	num	3	SENT_450	[p24l1603t1650r1924b1712],
5	boceprevir	NN	O	boceprevir	dep	1	SENT_450	[p24l1603t1650r1924b1712],
6	)	CD	NUMBER	)	num	5	SENT_450	[p24l1603t1650r1924b1712],
7	a	DT	O	a	det	8	SENT_450	[p24l131t1742r156b1777],
8	direct	JJ	O	direct	dep	5	SENT_450	[p24l173t1728r326b1777],
9	acting	VBG	O	act	partmod	1	SENT_450	[p24l341t1730r505b1791],
10	antiviral	JJ	O	antiviral	amod	13	SENT_450	[p24l523t1728r735b1777],
11	drug	NN	O	drug	nn	13	SENT_450	[p24l753t1728r877b1791],
12	(	NN	O	(	nn	13	SENT_450	[p24l896t1729r1046b1785],
13	DAA	NN	O	daa	dobj	9	SENT_450	[p24l896t1729r1046b1785],
14	)	CD	NUMBER	)	num	13	SENT_450	[p24l896t1729r1046b1785],
15	to	TO	O	to	aux	16	SENT_450	[p24l1062t1735r1116b1777],
16	treat	VB	O	treat	xcomp	9	SENT_450	[p24l1131t1735r1255b1777],
17	hepatitis	NN	O	hepatitis	dobj	16	SENT_450	[p24l1273t1728r1502b1790],
18	C	NN	O	c	prep	16	SENT_450	[p24l1518t1729r1552b1777],
19	virus	NN	O	virus	nn	22	SENT_450	[p24l1566t1730r1692b1777],
20	(	CD	NUMBER	(	num	22	SENT_450	[p24l1710t1729r1875b1785],
21	HCV	NN	O	hcv	nn	22	SENT_450	[p24l1710t1729r1875b1785],
22	)	NN	O	)	dep	18	SENT_450	[p24l1710t1729r1875b1785],
23	.	.	O	.	_	0	SENT_450	[p24l1710t1729r1875b1785],

1	.	.	O	.	_	0	SENT_451	[p24l417t1887r497b1933],

1	Accessed	VBN	O	access	_	0	SENT_452	[p24l512t1884r756b1933],
2	1	CD	DATE	1	num	3	SENT_452	[p24l779t1888r793b1933],
3	August	NNP	DATE	August	tmod	1	SENT_452	[p24l818t1886r1009b1947],
4	201	CD	NUMBER	201	num	3	SENT_452	[p24l1025t1887r1109b1933],
5	3	CD	NUMBER	3	dep	3	SENT_452	[p24l1125t1887r1167b1933],
6	.	.	O	.	_	0	SENT_452	[p24l1125t1887r1167b1933],

1	US	NNP	ORGANIZATION	US	nn	2	SENT_453	[p24l132t1963r198b2011],
2	Food	NNP	ORGANIZATION	Food	_	0	SENT_453	[p24l215t1962r342b2011],
3	and	CC	ORGANIZATION	and	_	0	SENT_453	[p24l358t1962r454b2011],
4	Drug	NNP	ORGANIZATION	Drug	nn	5	SENT_453	[p24l473t1964r599b2025],
5	Administration	NNP	ORGANIZATION	Administration	conj_and	2	SENT_453	[p24l614t1962r1020b2011],
6	.	.	O	.	_	0	SENT_453	[p24l614t1962r1020b2011],

1	Approval	NN	O	approval	_	0	SENT_454	[p24l1034t1962r1270b2024],
2	of	IN	O	of	_	0	SENT_454	[p24l1287t1961r1342b2011],
3	lncivek	NN	O	lncivek	nn	5	SENT_454	[p24l1353t1962r1536b2011],
4	(	CD	NUMBER	(	num	5	SENT_454	[p24l1549t1962r1830b2024],
5	telaprevir	NN	O	telaprevir	prep_of	1	SENT_454	[p24l1549t1962r1830b2024],
6	)	CD	NUMBER	)	num	5	SENT_454	[p24l1549t1962r1830b2024],
7	a	DT	O	a	det	8	SENT_454	[p24l1846t1976r1872b2011],
8	direct	JJ	O	direct	dep	1	SENT_454	[p24l1888t1962r2038b2011],
9	acting	VBG	O	act	partmod	1	SENT_454	[p24l131t2042r292b2103],
10	antiviral	JJ	O	antiviral	amod	13	SENT_454	[p24l308t2040r515b2089],
11	drug	NN	O	drug	nn	13	SENT_454	[p24l532t2040r653b2103],
12	(	NN	O	(	nn	13	SENT_454	[p24l671t2041r819b2097],
13	DAA	NN	O	daa	dobj	9	SENT_454	[p24l671t2041r819b2097],
14	)	CD	NUMBER	)	num	13	SENT_454	[p24l671t2041r819b2097],
15	to	TO	O	to	aux	16	SENT_454	[p24l834t2047r886b2089],
16	treat	VB	O	treat	xcomp	9	SENT_454	[p24l900t2047r1023b2089],
17	hepatitis	NN	O	hepatitis	dobj	16	SENT_454	[p24l1038t2040r1263b2102],
18	C	NN	O	c	prep	16	SENT_454	[p24l1277t2041r1310b2089],
19	virus	NN	O	virus	nn	22	SENT_454	[p24l1324t2042r1447b2089],
20	(	CD	NUMBER	(	num	22	SENT_454	[p24l1463t2041r1625b2097],
21	HCV	NN	O	hcv	nn	22	SENT_454	[p24l1463t2041r1625b2097],
22	)	NN	O	)	dep	18	SENT_454	[p24l1463t2041r1625b2097],
23	.	.	O	.	_	0	SENT_454	[p24l1463t2041r1625b2097],

1	.	.	O	.	_	0	SENT_455	[p24l131t2117r1883b2181],

1	Accessed	VBN	O	access	_	0	SENT_456	[p24l1896t2118r2136b2167],
2	1	CD	DATE	1	num	3	SENT_456	[p24l135t2200r150b2244],
3	August	NNP	DATE	August	tmod	1	SENT_456	[p24l173t2198r361b2258],
4	201	CD	NUMBER	201	num	3	SENT_456	[p24l375t2199r459b2245],
5	3	CD	NUMBER	3	dep	3	SENT_456	[p24l473t2199r515b2245],
6	.	.	O	.	_	0	SENT_456	[p24l473t2199r515b2245],

1	Jacobson	NNP	PERSON	Jacobson	_	0	SENT_457	[p24l127t2273r398b2330],
2	,	,	O	,	_	0	SENT_457	[p24l127t2273r398b2330],
3	|	CD	NUMBER	|	appos	1	SENT_457	[p24l417t2275r507b2322],
4	.	.	O	.	_	0	SENT_457	[p24l417t2275r507b2322],

1	M.	NNP	O	M.	nn	2	SENT_458	[p24l417t2275r507b2322],
2	etal.	NNP	O	etal.	_	0	SENT_458	[p24l524t2273r660b2330],
3	;	:	O	;	_	0	SENT_458	[p24l524t2273r660b2330],
4	ADVANCE	NNP	O	ADVANCE	nn	6	SENT_458	[p24l676t2274r943b2322],
5	Study	NNP	O	Study	nn	6	SENT_458	[p24l960t2273r1116b2336],
6	Team	NNP	O	Team	dep	2	SENT_458	[p24l1127t2273r1569b2335],
7	.	.	O	.	_	0	SENT_458	[p24l1127t2273r1569b2335],

1	Te	FW	O	te	_	0	SENT_459	[p24l1127t2273r1569b2335],
2	|	FW	O	|	nn	3	SENT_459	[p24l1127t2273r1569b2335],
3	aprevir	FW	O	aprevir	dep	1	SENT_459	[p24l1127t2273r1569b2335],
4	for	IN	O	for	_	0	SENT_459	[p24l1583t2272r1658b2322],
5	previously	RB	DATE	previously	advmod	6	SENT_459	[p24l1676t2273r1956b2336],
6	untreated	JJ	O	untreated	amod	9	SENT_459	[p24l133t2351r397b2400],
7	chronic	JJ	O	chronic	amod	9	SENT_459	[p24l416t2351r618b2400],
8	hepatitis	NN	O	hepatitis	nn	9	SENT_459	[p24l637t2351r871b2413],
9	C	NN	O	c	prep_for	3	SENT_459	[p24l888t2352r922b2400],
10	virus	NN	O	virus	nn	11	SENT_459	[p24l937t2353r1066b2400],
11	infection	NN	O	infection	dep	3	SENT_459	[p24l1085t2350r1339b2400],
12	.	.	O	.	_	0	SENT_459	[p24l1085t2350r1339b2400],

1	N.	NNP	O	N.	nn	2	SENT_460	[p24l1356t2353r1405b2400],
2	Engl	NNP	O	Engl	_	0	SENT_460	[p24l1422t2351r1546b2414],
3	.	.	O	.	_	0	SENT_460	[p24l1422t2351r1546b2414],

1	J.	NNP	O	J.	nn	2	SENT_461	[p24l1559t2353r1595b2400],
2	Med	NNP	O	Med	_	0	SENT_461	[p24l1611t2351r1738b2400],
3	.	.	O	.	_	0	SENT_461	[p24l1611t2351r1738b2400],

1	364	CD	NUMBER	364	_	0	SENT_462	[p24l1755t2354r1874b2408],
2	,	,	O	,	_	0	SENT_462	[p24l1755t2354r1874b2408],
3	24052416	CD	NUMBER	24052416	num	4	SENT_462	[p24l1891t2354r2055b2400, p24l131t2431r261b2477],
4	(	NN	O	(	appos	1	SENT_462	[p24l280t2429r384b2484],
5	201	CD	NUMBER	201	number	6	SENT_462	[p24l280t2429r384b2484],
6	1	CD	NUMBER	1	num	7	SENT_462	[p24l404t2429r462b2484],
7	)	NN	O	)	dep	4	SENT_462	[p24l404t2429r462b2484],
8	.	.	O	.	_	0	SENT_462	[p24l404t2429r462b2484],

1	Zeuzem	NNP	O	Zeuzem	_	0	SENT_463	[p24l129t2508r352b2563],
2	,	,	O	,	_	0	SENT_463	[p24l129t2508r352b2563],
3	S.	NNP	O	S.	nn	5	SENT_463	[p24l366t2507r406b2555],
4	et	NNP	O	et	nn	5	SENT_463	[p24l421t2513r470b2555],
5	aI	NNP	O	aI	appos	1	SENT_463	[p24l479t2505r888b2568],
6	.	.	O	.	_	0	SENT_463	[p24l479t2505r888b2568],

1	Te	FW	O	te	nsubj	5	SENT_464	[p24l479t2505r888b2568],
2	|	FW	O	|	nn	3	SENT_464	[p24l479t2505r888b2568],
3	aprevirfor	FW	O	aprevirfor	dep	1	SENT_464	[p24l479t2505r888b2568],
4	previously	RB	DATE	previously	advmod	5	SENT_464	[p24l903t2506r1172b2569],
5	treated	VBN	O	treat	_	0	SENT_464	[p24l1184t2506r1371b2555],
6	chronic	JJ	O	chronic	amod	8	SENT_464	[p24l1388t2506r1582b2555],
7	HCV	NN	O	hcv	nn	8	SENT_464	[p24l1598t2507r1709b2555],
8	infection	NN	O	infection	dobj	5	SENT_464	[p24l1723t2505r1966b2555],
9	.	.	O	.	_	0	SENT_464	[p24l1723t2505r1966b2555],

1	N.	NNP	O	N.	nn	2	SENT_465	[p24l1980t2508r2027b2555],
2	Engl	NNP	O	Engl	_	0	SENT_465	[p24l130t2584r248b2647],
3	.	.	O	.	_	0	SENT_465	[p24l130t2584r248b2647],

1	J.	NNP	O	J.	nn	2	SENT_466	[p24l259t2586r294b2634],
2	Med	NNP	O	Med	_	0	SENT_466	[p24l308t2584r430b2634],
3	.	.	O	.	_	0	SENT_466	[p24l308t2584r430b2634],

1	362	CD	NUMBER	362	_	0	SENT_467	[p24l445t2587r560b2641],
2	,	,	O	,	_	0	SENT_467	[p24l445t2587r560b2641],
3	1292-1303	CD	DATE	1292-1303	number	4	SENT_467	[p24l579t2587r862b2634],
4	(	CD	NUMBER	(	appos	1	SENT_467	[p24l880t2585r1054b2641],
5	2010	CD	DATE	2010	num	6	SENT_467	[p24l880t2585r1054b2641],
6	)	NN	O	)	dep	4	SENT_467	[p24l880t2585r1054b2641],
7	.	.	O	.	_	0	SENT_467	[p24l880t2585r1054b2641],

1	Bacon	NNP	PERSON	Bacon	nn	3	SENT_468	[p24l132t2664r302b2719],
2	,	,	O	,	_	0	SENT_468	[p24l132t2664r302b2719],
3	B.R.	NNP	O	B.R.	_	0	SENT_468	[p24l319t2664r406b2712],
4	et	FW	O	et	nn	5	SENT_468	[p24l421t2669r470b2712],
5	aI.	FW	O	ai.	dep	3	SENT_468	[p24l479t2662r549b2719],
6	;	:	O	;	_	0	SENT_468	[p24l479t2662r549b2719],
7	HCV	NN	O	hcv	dep	3	SENT_468	[p24l565t2664r676b2712],
8	RESPOND-2	NN	O	respond-2	nn	9	SENT_468	[p24l691t2664r996b2712],
9	Investigators	NNS	O	investigator	dep	7	SENT_468	[p24l1014t2664r1360b2725],
10	.	.	O	.	_	0	SENT_468	[p24l1014t2664r1360b2725],

1	Boceprevir	NNP	O	Boceprevir	nsubj	4	SENT_469	[p24l1377t2664r1656b2724],
2	for	IN	O	for	prep	1	SENT_469	[p24l1668t2661r1741b2712],
3	previously	RB	DATE	previously	pcomp	2	SENT_469	[p24l1756t2662r2025b2726],
4	treated	VBN	O	treat	_	0	SENT_469	[p24l129t2740r317b2790],
5	chronic	JJ	O	chronic	amod	9	SENT_469	[p24l333t2740r527b2790],
6	HCV	NN	O	hcv	nn	9	SENT_469	[p24l543t2742r654b2790],
7	genotype	NN	O	genotype	nn	9	SENT_469	[p24l667t2747r920b2803],
8	1	CD	NUMBER	1	num	9	SENT_469	[p24l939t2744r954b2789],
9	infection	NN	O	infection	dobj	4	SENT_469	[p24l980t2739r1223b2790],
10	.	.	O	.	_	0	SENT_469	[p24l980t2739r1223b2790],

1	N.	NNP	O	N.	nn	2	SENT_470	[p24l1237t2742r1284b2790],
2	Engl	NNP	O	Engl	_	0	SENT_470	[p24l1299t2740r1418b2803],
3	.	.	O	.	_	0	SENT_470	[p24l1299t2740r1418b2803],

1	J.	NNP	O	J.	nn	2	SENT_471	[p24l1428t2742r1463b2790],
2	Med	NNP	O	Med	_	0	SENT_471	[p24l1477t2740r1599b2790],
3	.	.	O	.	_	0	SENT_471	[p24l1477t2740r1599b2790],

1	364	CD	NUMBER	364	_	0	SENT_472	[p24l1614t2743r1729b2797],
2	,	,	O	,	_	0	SENT_472	[p24l1614t2743r1729b2797],
3	1207-1217	CD	DATE	1207-1217	num	4	SENT_472	[p24l1748t2743r2032b2790],
4	(	NN	O	(	appos	1	SENT_472	[p24l132t2818r232b2873],
5	201	CD	NUMBER	201	number	6	SENT_472	[p24l132t2818r232b2873],
6	1	CD	NUMBER	1	num	7	SENT_472	[p24l251t2818r306b2873],
7	)	NN	O	)	dep	4	SENT_472	[p24l251t2818r306b2873],
8	.	.	O	.	_	0	SENT_472	[p24l251t2818r306b2873],

1	FDA	NNP	ORGANIZATION	FDA	nn	4	SENT_473	[p24l131t2897r237b2944],
2	Drug	NNP	O	Drug	nn	4	SENT_473	[p24l254t2897r379b2958],
3	Safety	NNP	O	Safety	nn	4	SENT_473	[p24l396t2894r557b2959],
4	Communication	NNP	O	Communication	_	0	SENT_473	[p24l570t2897r1007b2945],
5	.	.	O	.	_	0	SENT_473	[p24l570t2897r1007b2945],

1	Serious	JJ	O	serious	amod	3	SENT_474	[p24l1022t2897r1212b2945],
2	skin	NN	O	skin	nn	3	SENT_474	[p24l1227t2895r1327b2945],
3	reactions	NNS	O	reaction	nsubj	12	SENT_474	[p24l1345t2897r1583b2945],
4	after	IN	O	after	_	0	SENT_474	[p24l1598t2894r1718b2945],
5	combination	NN	O	combination	nn	6	SENT_474	[p24l1731t2895r2065b2945],
6	treatment	NN	O	treatment	prep_after	3	SENT_474	[p24l129t2980r393b3023],
7	with	IN	O	with	_	0	SENT_474	[p24l406t2973r519b3023],
8	the	DT	O	the	det	11	SENT_474	[p24l534t2973r620b3023],
9	Hepatitis	NNP	O	Hepatitis	nn	11	SENT_474	[p24l637t2975r867b3035],
10	C	NNP	O	C	nn	11	SENT_474	[p24l882t2975r915b3023],
11	drugs	NNS	O	drug	prep_with	6	SENT_474	[p24l930t2973r1078b3036],
12	lncivek	VBP	O	lncivek	_	0	SENT_474	[p24l1095t2973r1277b3023],
13	(	CD	NUMBER	(	num	15	SENT_474	[p24l1291t2973r1587b3035],
14	telaprevir	NN	O	telaprevir	nn	15	SENT_474	[p24l1291t2973r1587b3035],
15	)	NN	O	)	dobj	12	SENT_474	[p24l1291t2973r1587b3035],
16	,	,	O	,	_	0	SENT_474	[p24l1291t2973r1587b3035],
17	peginterferon	NN	O	peginterferon	nn	18	SENT_474	[p24l1603t2972r1964b3036],
18	alfa	NN	O	alfa	dobj	12	SENT_474	[p24l1980t2972r2084b3030],
19	,	,	O	,	_	0	SENT_474	[p24l1980t2972r2084b3030],
20	and	CC	O	and	_	0	SENT_474	[p24l130t3051r226b3101],
21	ribavirin	NNP	O	ribavirin	dobj	12	SENT_474	[p24l245t3051r471b3101],
22	.	.	O	.	_	0	SENT_474	[p24l245t3051r471b3101],

1	(	NN	O	(	_	0	SENT_475	[p24l132t3130r232b3186],
2	201	CD	NUMBER	201	number	3	SENT_475	[p24l132t3130r232b3186],
3	2	CD	NUMBER	2	dep	1	SENT_475	[p24l247t3130r306b3186],
4	)	NN	O	)	dep	3	SENT_475	[p24l247t3130r306b3186],
5	.	.	O	.	_	0	SENT_475	[p24l247t3130r306b3186],

1	Accessed	VBN	O	access	_	0	SENT_476	[p24l320t3129r559b3179],
2	2	CD	DATE	2	num	3	SENT_476	[p24l576t3132r604b3178],
3	August	NNP	DATE	August	tmod	1	SENT_476	[p24l618t3131r806b3192],
4	201	CD	NUMBER	201	num	3	SENT_476	[p24l820t3132r904b3179],
5	3	CD	NUMBER	3	dep	3	SENT_476	[p24l918t3132r960b3179],
6	.	.	O	.	_	0	SENT_476	[p24l918t3132r960b3179],

1	VOLUME	NN	O	volume	nn	3	SENT_477	[p24l543t3330r768b3372],
2	95	CD	NUMBER	95	num	3	SENT_477	[p24l785t3331r842b3372],
3	NUMBER	NN	O	number	_	0	SENT_477	[p24l863t3330r1087b3372],
4	1	CD	NUMBER	1	number	5	SENT_477	[p24l1109t3332r1122b3372],
5	|	CD	NUMBER	|	dep	3	SENT_477	[p24l1151t3326r1156b3387],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_477	[p24l1175t3330r1420b3372],
7	2014	CD	DATE	2014	num	6	SENT_477	[p24l1437t3331r1558b3372],
8	|	CD	NUMBER	|	num	9	SENT_477	[p24l1577t3326r1581b3387],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_477	[p24l1600t3330r2152b3383],

1	Suzuki	NNP	PERSON	Suzuki	_	0	SENT_478	[p25l128t86r312b143],
2	,	,	O	,	_	0	SENT_478	[p25l128t86r312b143],
3	F.	NNP	O	F.	nn	4	SENT_478	[p25l329t88r361b135],
4	etal	NNP	O	etal	appos	1	SENT_478	[p25l375t86r490b135],
5	.	.	O	.	_	0	SENT_478	[p25l375t86r490b135],

1	Prevalence	NN	O	prevalence	_	0	SENT_479	[p25l507t86r790b135],
2	of	IN	O	of	_	0	SENT_479	[p25l804t85r859b135],
3	hepatitis	NN	O	hepatitis	nn	6	SENT_479	[p25l871t86r1096b148],
4	C	NN	O	c	nn	6	SENT_479	[p25l1110t87r1144b135],
5	virus	NN	O	virus	nn	6	SENT_479	[p25l1157t88r1281b136],
6	variants	NNS	O	variant	prep_of	1	SENT_479	[p25l1294t88r1501b135],
7	resistant	JJ	O	resistant	amod	1	SENT_479	[p25l1517t88r1738b136],
8	to	TO	O	to	_	0	SENT_479	[p25l1750t93r1803b135],
9	NS3	NN	O	ns3	nn	11	SENT_479	[p25l1820t87r1918b135],
10	protease	NN	O	protease	nn	11	SENT_479	[p25l131t171r358b226],
11	inhibitors	NNS	O	inhibitor	prep_to	7	SENT_479	[p25l374t164r622b213],
12	or	CC	O	or	_	0	SENT_479	[p25l637t178r690b213],
13	the	DT	O	the	det	18	SENT_479	[p25l702t164r788b213],
14	NS5A	NN	O	ns5a	nn	18	SENT_479	[p25l805t165r944b213],
15	inhibitor	NN	O	inhibitor	nn	18	SENT_479	[p25l960t164r1184b213],
16	(	NN	O	(	nn	18	SENT_479	[p25l1199t165r1562b221],
17	BMS-790052	NN	O	bms-790052	nn	18	SENT_479	[p25l1199t165r1562b221],
18	)	NN	O	)	prep_to	7	SENT_479	[p25l1199t165r1562b221],
19	in	IN	O	in	_	0	SENT_479	[p25l1579t166r1622b213],
20	hepatitis	NN	O	hepatitis	nn	21	SENT_479	[p25l1641t164r1866b226],
21	patients	NNS	O	patient	prep_in	18	SENT_479	[p25l1883t166r2093b226],
22	with	IN	O	with	_	0	SENT_479	[p25l128t242r242b291],
23	genotype	NN	O	genotype	prep_with	21	SENT_479	[p25l259t249r513b305],
24	1	CD	NUMBER	1	num	23	SENT_479	[p25l532t246r547b291],
25	b.	NNP	NUMBER	b.	nn	27	SENT_479	[p25l563t242r605b291],
26	J.	NNP	PERSON	J.	nn	27	SENT_479	[p25l615t244r650b291],
27	Clin	NNP	PERSON	Clin	dep	18	SENT_479	[p25l665t242r770b291],
28	.	.	O	.	_	0	SENT_479	[p25l665t242r770b291],

1	Virol	NNP	PERSON	Virol	_	0	SENT_480	[p25l788t242r911b291],
2	.	.	O	.	_	0	SENT_480	[p25l788t242r911b291],

1	54	CD	NUMBER	54	_	0	SENT_481	[p25l925t246r1005b299],
2	,	,	O	,	_	0	SENT_481	[p25l925t246r1005b299],
3	352-354	CD	NUMBER	352-354	number	4	SENT_481	[p25l1020t245r1245b291],
4	(	CD	NUMBER	(	appos	1	SENT_481	[p25l1261t243r1435b299],
5	2012	CD	DATE	2012	num	6	SENT_481	[p25l1261t243r1435b299],
6	)	NN	O	)	dep	4	SENT_481	[p25l1261t243r1435b299],
7	.	.	O	.	_	0	SENT_481	[p25l1261t243r1435b299],

1	Ali	NNP	PERSON	Ali	_	0	SENT_482	[p25l127t320r206b377],
2	,	,	O	,	_	0	SENT_482	[p25l127t320r206b377],
3	A.	NNP	O	A.	nn	4	SENT_482	[p25l220t322r269b369],
4	et	NNP	O	et	appos	1	SENT_482	[p25l283t327r332b369],
5	al.	FW	O	al.	dep	4	SENT_482	[p25l341t320r398b369],
6	.	.	O	.	_	0	SENT_482	[p25l341t320r398b369],

1	Evaluating	VBG	O	evaluate	_	0	SENT_483	[p25l415t320r686b383],
2	the	DT	O	the	det	3	SENT_483	[p25l702t320r788b369],
3	role	NN	O	role	dobj	1	SENT_483	[p25l804t320r900b369],
4	of	IN	O	of	_	0	SENT_483	[p25l915t319r970b369],
5	macrocycles	NNS	O	macrocycle	prep_of	3	SENT_483	[p25l981t320r1303b383],
6	in	IN	O	in	_	0	SENT_483	[p25l1319t322r1362b369],
7	the	DT	O	the	det	8	SENT_483	[p25l1378t320r1464b369],
8	susceptibility	NN	O	susceptibility	prep_in	5	SENT_483	[p25l1478t320r1826b383],
9	of	IN	O	of	_	0	SENT_483	[p25l1839t319r1894b369],
10	hepatitis	NN	O	hepatitis	nn	15	SENT_483	[p25l1905t320r2130b382],
11	C	NN	O	c	nn	15	SENT_483	[p25l129t399r163b447],
12	virus	NN	O	virus	nn	15	SENT_483	[p25l176t400r300b447],
13	NS3/4A	NN	O	ns3/4a	nn	15	SENT_483	[p25l317t399r512b449],
14	protease	NN	O	protease	nn	15	SENT_483	[p25l527t405r754b460],
15	inhibitors	NNS	O	inhibitor	prep_of	8	SENT_483	[p25l770t398r1018b447],
16	to	TO	O	to	_	0	SENT_483	[p25l1031t405r1084b447],
17	drug	NN	O	drug	nn	18	SENT_483	[p25l1099t398r1220b461],
18	resistance	NN	O	resistance	prep_to	1	SENT_483	[p25l1239t400r1511b447],
19	.	.	O	.	_	0	SENT_483	[p25l1239t400r1511b447],

1	ACS	NNP	ORGANIZATION	ACS	nn	2	SENT_484	[p25l1521t399r1623b447],
2	Chem	NNP	ORGANIZATION	Chem	_	0	SENT_484	[p25l1635t398r1792b447],
3	.	.	O	.	_	0	SENT_484	[p25l1635t398r1792b447],

1	Biol	NNP	O	Biol	_	0	SENT_485	[p25l1807t398r1912b447],
2	.	.	O	.	_	0	SENT_485	[p25l1807t398r1912b447],

1	8	CD	NUMBER	8	_	0	SENT_486	[p25l1925t401r1970b455],
2	,	,	O	,	_	0	SENT_486	[p25l1925t401r1970b455],
3	1469-1478	CD	DATE	1469-1478	number	4	SENT_486	[p25l134t478r420b524],
4	(	CD	NUMBER	(	appos	1	SENT_486	[p25l436t476r610b531],
5	2013	CD	DATE	2013	num	6	SENT_486	[p25l436t476r610b531],
6	)	NN	O	)	dep	4	SENT_486	[p25l436t476r610b531],
7	.	.	O	.	_	0	SENT_486	[p25l436t476r610b531],

1	Hunt	NNP	O	Hunt	_	0	SENT_487	[p25l130t555r270b610],
2	,	,	O	,	_	0	SENT_487	[p25l130t555r270b610],
3	D.	NNP	O	D.	conj_and	1	SENT_487	[p25l287t555r334b602],
4	&	CC	O	&	_	0	SENT_487	[p25l349t554r385b602],
5	Pockros	NNP	O	Pockros	conj_and	1	SENT_487	[p25l401t553r614b610],
6	,	,	O	,	_	0	SENT_487	[p25l401t553r614b610],
7	P.	NNP	O	P.	appos	1	SENT_487	[p25l631t555r663b602],
8	What	WP	O	what	nsubj	13	SENT_487	[p25l674t553r813b602],
9	are	VBP	O	be	cop	13	SENT_487	[p25l826t567r906b602],
10	the	DT	O	the	det	13	SENT_487	[p25l919t553r1005b602],
11	promising	JJ	O	promising	amod	13	SENT_487	[p25l1021t555r1285b616],
12	new	JJ	O	new	amod	13	SENT_487	[p25l1303t567r1413b602],
13	therapies	NNS	O	therapy	rcmod	7	SENT_487	[p25l1425t553r1670b615],
14	in	IN	O	in	_	0	SENT_487	[p25l1687t555r1729b602],
15	the	DT	O	the	det	16	SENT_487	[p25l1745t553r1831b602],
16	ﬁeld	NN	O	ﬁeld	prep_in	13	SENT_487	[p25l1844t552r1956b602],
17	of	IN	O	of	_	0	SENT_487	[p25l1972t552r2027b602],
18	chronic	JJ	O	chronic	amod	20	SENT_487	[p25l129t631r324b680],
19	hepatitis	NN	O	hepatitis	nn	20	SENT_487	[p25l340t631r565b693],
20	C	NN	O	c	prep_of	16	SENT_487	[p25l580t632r613b680],
21	after	IN	O	after	_	0	SENT_487	[p25l628t630r749b680],
22	the	DT	O	the	det	25	SENT_487	[p25l761t631r846b680],
23	ﬁrst-generation	JJ	O	ﬁrst-generation	amod	25	SENT_487	[p25l859t630r1268b694],
24	direct-acting	JJ	O	direct-acting	amod	25	SENT_487	[p25l1285t631r1618b694],
25	antivirals	NNS	O	antiviral	prep_after	20	SENT_487	[p25l1635t631r1895b680],
26	?	.	O	?	_	0	SENT_487	[p25l1635t631r1895b680],

1	Curr	NN	O	curr	_	0	SENT_488	[p25l1911t632r2024b680],
2	.	.	O	.	_	0	SENT_488	[p25l1911t632r2024b680],

1	Gastroenterol	NNP	PERSON	Gastroenterol	_	0	SENT_489	[p25l130t709r486b758],
2	.	.	O	.	_	0	SENT_489	[p25l130t709r486b758],

1	Rep.	NNP	O	Rep.	_	0	SENT_490	[p25l500t711r606b771],
2	15	CD	NUMBER	15	num	1	SENT_490	[p25l623t713r701b766],
3	,	,	O	,	_	0	SENT_490	[p25l623t713r701b766],
4	303	CD	NUMBER	303	num	1	SENT_490	[p25l715t712r807b758],
5	(	NN	O	(	dep	1	SENT_490	[p25l826t710r926b766],
6	201	CD	NUMBER	201	number	7	SENT_490	[p25l826t710r926b766],
7	3	CD	NUMBER	3	num	8	SENT_490	[p25l941t710r1000b766],
8	)	NN	O	)	dep	5	SENT_490	[p25l941t710r1000b766],
9	.	.	O	.	_	0	SENT_490	[p25l941t710r1000b766],

1	Bronowicki	NNP	PERSON	Bronowicki	_	0	SENT_491	[p25l130t787r434b844],
2	,	,	O	,	_	0	SENT_491	[p25l130t787r434b844],
3	J.P	NNP	O	J.P	nn	4	SENT_491	[p25l446t789r518b836],
4	etal	NN	O	etal	appos	1	SENT_491	[p25l532t787r647b836],
5	.	.	O	.	_	0	SENT_491	[p25l532t787r647b836],

1	Randomized	VBN	O	randomize	_	0	SENT_492	[p25l664t787r991b836],
2	study	NN	O	study	dobj	1	SENT_492	[p25l1009t787r1153b850],
3	of	IN	O	of	_	0	SENT_492	[p25l1167t786r1221b836],
4	asunaprevir	NN	O	asunaprevir	prep_of	2	SENT_492	[p25l1230t789r1541b849],
5	plus	CC	O	plus	_	0	SENT_492	[p25l1555t787r1661b849],
6	peginterferon	NN	O	peginterferon	nn	7	SENT_492	[p25l1678t786r2039b850],
7	alfa	NN	O	alfa	dobj	1	SENT_492	[p25l2056t786r2146b836],
8	and	CC	O	and	_	0	SENT_492	[p25l129t865r226b914],
9	ribavirin	NNP	O	ribavirin	conj_plus	2	SENT_492	[p25l244t865r455b914],
10	for	IN	O	for	_	0	SENT_492	[p25l471t864r543b914],
11	previously	RB	DATE	previously	advmod	12	SENT_492	[p25l558t865r829b928],
12	untreated	JJ	O	untreated	amod	13	SENT_492	[p25l844t865r1099b914],
13	genotype	NN	O	genotype	prep_for	1	SENT_492	[p25l1115t872r1370b928],
14	1	CD	NUMBER	1	num	16	SENT_492	[p25l1389t869r1403b914],
15	chronic	JJ	O	chronic	amod	16	SENT_492	[p25l1428t865r1622b914],
16	hepatitis	NN	O	hepatitis	dep	13	SENT_492	[p25l1639t865r1864b927],
17	C.	NNP	PERSON	C.	nn	18	SENT_492	[p25l1878t866r2112b914],
18	Antivir	NNP	PERSON	Antivir	dep	16	SENT_492	[p25l1878t866r2112b914],
19	.	.	O	.	_	0	SENT_492	[p25l1878t866r2112b914],

1	Ther	NNP	O	Ther	_	0	SENT_493	[p25l131t942r248b991],
2	.	.	O	.	_	0	SENT_493	[p25l131t942r248b991],

1	(	NN	O	(	nn	2	SENT_494	[p25l265t942r434b998],
2	Lond	NN	O	lond	_	0	SENT_494	[p25l265t942r434b998],
3	.	.	O	.	_	0	SENT_494	[p25l265t942r434b998],
4	)	SYM	O	)	dep	2	SENT_494	[p25l265t942r434b998],

1	(	RB	O	(	dep	2	SENT_495	[p25l451t943r611b998],
2	2013	CD	DATE	2013	dep	4	SENT_495	[p25l451t943r611b998],
3	)	CD	NUMBER	)	num	4	SENT_495	[p25l451t943r611b998],
4	(	NN	O	(	dep	6	SENT_495	[p25l629t942r1235b998],
5	doi	FW	O	doi	dep	4	SENT_495	[p25l629t942r1235b998],
6	:10.3851	CD	NUMBER	:10.3851	_	0	SENT_495	[p25l629t942r1235b998],
7	/	:	O	/	punct	6	SENT_495	[p25l629t942r1235b998],
8	|	CD	NUMBER	|	num	9	SENT_495	[p25l629t942r1235b998],
9	MP2660	NN	O	mp2660	dep	6	SENT_495	[p25l629t942r1235b998],
10	)	NN	O	)	dep	9	SENT_495	[p25l629t942r1235b998],
11	.	.	O	.	_	0	SENT_495	[p25l629t942r1235b998],

1	Reesink	NNP	ORGANIZATION	Reesink	_	0	SENT_496	[p25l130t1020r342b1077],
2	,	,	O	,	_	0	SENT_496	[p25l130t1020r342b1077],
3	H.W.	NNP	O	H.W.	nn	4	SENT_496	[p25l359t1022r471b1069],
4	etal	NN	O	etal	appos	1	SENT_496	[p25l485t1020r601b1069],
5	.	.	O	.	_	0	SENT_496	[p25l485t1020r601b1069],

1	Rapid	JJ	O	rapid	amod	3	SENT_497	[p25l618t1020r762b1082],
2	HCV-RNA	NN	O	hcv-rna	nn	3	SENT_497	[p25l781t1021r1025b1069],
3	decline	NN	O	decline	_	0	SENT_497	[p25l1039t1020r1229b1069],
4	with	IN	O	with	prep	3	SENT_497	[p25l1243t1020r1356b1069],
5	once	RB	DATE	once	pobj	4	SENT_497	[p25l1373t1034r1499b1069],
6	dai	FW	O	dai	nn	8	SENT_497	[p25l1514t1020r1876b1084],
7	|	FW	O	|	nn	8	SENT_497	[p25l1514t1020r1876b1084],
8	yTMC435	NN	O	ytmc435	dep	3	SENT_497	[p25l1514t1020r1876b1084],
9	:	:	O	:	_	0	SENT_497	[p25l1514t1020r1876b1084],
10	a	DT	O	a	det	11	SENT_497	[p25l1891t1034r1916b1069],
11	phase	NN	O	phase	dep	3	SENT_497	[p25l1934t1020r2088b1082],
12	I	PRP	O	I	nsubj	13	SENT_497	[p25l132t1100r138b1147],
13	study	VBP	O	study	rcmod	11	SENT_497	[p25l155t1098r301b1161],
14	in	IN	O	in	_	0	SENT_497	[p25l315t1100r358b1147],
15	healthy	JJ	O	healthy	amod	16	SENT_497	[p25l377t1098r571b1162],
16	volunteers	NNS	O	volunteer	prep_in	13	SENT_497	[p25l583t1098r861b1147],
17	and	CC	O	and	_	0	SENT_497	[p25l875t1098r972b1147],
18	hepatitis	NN	O	hepatitis	nn	20	SENT_497	[p25l991t1098r1216b1160],
19	C	NN	O	c	nn	20	SENT_497	[p25l1230t1099r1264b1147],
20	patients	NNS	O	patient	prep_in	13	SENT_497	[p25l1280t1100r1503b1160],
21	.	.	O	.	_	0	SENT_497	[p25l1280t1100r1503b1160],

1	Gastroenterology	NN	O	gastroenterology	_	0	SENT_498	[p25l1518t1098r1962b1162],
2	138	CD	NUMBER	138	num	1	SENT_498	[p25l1976t1101r2088b1155],
3	,	,	O	,	_	0	SENT_498	[p25l1976t1101r2088b1155],
4	913-921	CD	NUMBER	913-921	number	5	SENT_498	[p25l129t1178r344b1224],
5	(	CD	NUMBER	(	appos	1	SENT_498	[p25l370t1176r545b1231],
6	2010	CD	DATE	2010	num	7	SENT_498	[p25l370t1176r545b1231],
7	)	NN	O	)	dep	5	SENT_498	[p25l370t1176r545b1231],
8	.	.	O	.	_	0	SENT_498	[p25l370t1176r545b1231],

1	Manns	NNP	PERSON	Manns	_	0	SENT_499	[p25l129t1255r315b1310],
2	,	,	O	,	_	0	SENT_499	[p25l129t1255r315b1310],
3	M.	NNP	O	M.	nn	4	SENT_499	[p25l331t1255r391b1302],
4	etal	NNP	O	etal	appos	1	SENT_499	[p25l405t1253r520b1303],
5	.	.	O	.	_	0	SENT_499	[p25l405t1253r520b1303],

1	Rapid	JJ	O	rapid	amod	3	SENT_500	[p25l537t1253r681b1315],
2	viral	JJ	O	viral	amod	3	SENT_500	[p25l697t1253r803b1303],
3	response	NN	O	response	nsubj	9	SENT_500	[p25l822t1268r1058b1315],
4	of	IN	O	of	_	0	SENT_500	[p25l1073t1252r1127b1302],
5	once-dai	JJ	O	once-dai	amod	7	SENT_500	[p25l1137t1253r1637b1317],
6	|	NN	O	|	nn	7	SENT_500	[p25l1137t1253r1637b1317],
7	yTMC435	NN	O	ytmc435	prep_of	3	SENT_500	[p25l1137t1253r1637b1317],
8	plus	CC	O	plus	advmod	7	SENT_500	[p25l1656t1253r1761b1315],
9	pegylated	VBN	O	pegylate	_	0	SENT_500	[p25l1778t1253r2039b1316],
10	interferon/ribavirin	NN	O	interferon/ribavirin	tmod	9	SENT_500	[p25l131t1330r630b1383],
11	in	IN	O	in	_	0	SENT_500	[p25l648t1333r691b1380],
12	hepatitis	NN	O	hepatitis	nn	15	SENT_500	[p25l710t1331r935b1393],
13	C	NN	O	c	nn	15	SENT_500	[p25l949t1333r983b1381],
14	genotype-1	NN	O	genotype-1	nn	15	SENT_500	[p25l997t1335r1296b1394],
15	patients	NNS	O	patient	prep_in	10	SENT_500	[p25l1322t1333r1545b1393],
16	:	:	O	:	_	0	SENT_500	[p25l1322t1333r1545b1393],
17	a	DT	O	a	det	19	SENT_500	[p25l1560t1346r1586b1381],
18	randomized	JJ	O	randomized	amod	19	SENT_500	[p25l1603t1331r1917b1381],
19	trial	NN	O	trial	dep	10	SENT_500	[p25l1932t1331r2044b1381],
20	.	.	O	.	_	0	SENT_500	[p25l1932t1331r2044b1381],

1	Antivir	NNP	O	Antivir	_	0	SENT_501	[p25l125t1410r303b1457],
2	.	.	O	.	_	0	SENT_501	[p25l125t1410r303b1457],

1	Ther	NNP	O	Ther	_	0	SENT_502	[p25l320t1408r436b1457],
2	.	.	O	.	_	0	SENT_502	[p25l320t1408r436b1457],

1	(	NN	O	(	nn	2	SENT_503	[p25l453t1408r623b1464],
2	Lond	NN	O	lond	_	0	SENT_503	[p25l453t1408r623b1464],
3	.	.	O	.	_	0	SENT_503	[p25l453t1408r623b1464],
4	)	SYM	O	)	dep	2	SENT_503	[p25l453t1408r623b1464],

1	16	CD	NUMBER	16	_	0	SENT_504	[p25l641t1411r718b1464],
2	,	,	O	,	_	0	SENT_504	[p25l641t1411r718b1464],
3	1021-1033	CD	DATE	1021-1033	num	4	SENT_504	[p25l737t1411r1021b1457],
4	(	NN	O	(	appos	1	SENT_504	[p25l1039t1409r1140b1464],
5	201	CD	NUMBER	201	number	6	SENT_504	[p25l1039t1409r1140b1464],
6	1	CD	NUMBER	1	num	7	SENT_504	[p25l1158t1409r1214b1464],
7	)	NN	O	)	dep	4	SENT_504	[p25l1158t1409r1214b1464],
8	.	.	O	.	_	0	SENT_504	[p25l1158t1409r1214b1464],

1	Zeuzem	NNP	O	Zeuzem	_	0	SENT_505	[p25l127t1488r351b1543],
2	,	,	O	,	_	0	SENT_505	[p25l127t1488r351b1543],
3	S.	NNP	O	S.	nn	4	SENT_505	[p25l366t1487r406b1535],
4	etal	NNP	O	etal	appos	1	SENT_505	[p25l421t1486r760b1535],
5	.	.	O	.	_	0	SENT_505	[p25l421t1486r760b1535],

1	TMC435	NN	O	tmc435	_	0	SENT_506	[p25l421t1486r760b1535],
2	in	IN	O	in	_	0	SENT_506	[p25l779t1488r821b1535],
3	HCV	NNP	O	HCV	nn	4	SENT_506	[p25l840t1488r951b1535],
4	genotype	NN	O	genotype	prep_in	1	SENT_506	[p25l964t1493r1218b1550],
5	1	CD	NUMBER	1	num	6	SENT_506	[p25l1237t1490r1252b1535],
6	patients	NNS	O	patient	dep	4	SENT_506	[p25l1278t1488r1488b1548],
7	who	WP	O	who	nsubj	9	SENT_506	[p25l1502t1486r1617b1535],
8	have	VBP	O	have	aux	9	SENT_506	[p25l1634t1486r1755b1535],
9	failed	VBN	O	fail	rcmod	1	SENT_506	[p25l1768t1485r1911b1536],
10	previous	JJ	O	previous	dobj	9	SENT_506	[p25l1929t1488r2153b1548],
11	pegylated	VBN	O	pegylate	partmod	10	SENT_506	[p25l131t1564r392b1628],
12	interferon/ribavirin	NN	O	interferon/ribavirin	nn	13	SENT_506	[p25l410t1563r909b1616],
13	treatment	NN	O	treatment	dobj	11	SENT_506	[p25l924t1571r1202b1621],
14	;	:	O	;	_	0	SENT_506	[p25l924t1571r1202b1621],
15	ﬁnal	JJ	O	ﬁnal	amod	17	SENT_506	[p25l1214t1563r1324b1613],
16	SVR24	NN	O	svr24	nn	17	SENT_506	[p25l1341t1565r1505b1613],
17	results	NNS	O	result	dep	1	SENT_506	[p25l1521t1564r1688b1614],
18	of	IN	O	of	_	0	SENT_506	[p25l1703t1563r1758b1613],
19	the	DT	O	the	det	21	SENT_506	[p25l1766t1564r1852b1613],
20	ASPIRE	NN	O	aspire	nn	21	SENT_506	[p25l1866t1566r2049b1613],
21	trial	NN	O	trial	prep_of	17	SENT_506	[p25l128t1642r240b1692],
22	.	.	O	.	_	0	SENT_506	[p25l128t1642r240b1692],

1	Presented	VBN	O	present	_	0	SENT_507	[p25l257t1642r515b1692],
2	at	IN	O	at	_	0	SENT_507	[p25l531t1649r580b1692],
3	the	DT	O	the	det	5	SENT_507	[p25l593t1642r679b1692],
4	47th	JJ	ORDINAL	47th	amod	5	SENT_507	[p25l691t1642r809b1692],
5	Annual	JJ	SET	annual	prep_at	1	SENT_507	[p25l825t1642r1010b1692],
6	Meeting	VBG	O	meet	partmod	5	SENT_507	[p25l1029t1644r1244b1705],
7	of	IN	O	of	_	0	SENT_507	[p25l1261t1641r1315b1692],
8	the	DT	O	the	det	10	SENT_507	[p25l1324t1642r1410b1692],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_507	[p25l1427t1644r1675b1704],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_507	[p25l1690t1644r1990b1692],
11	for	IN	O	for	_	0	SENT_507	[p25l2004t1641r2077b1692],
12	the	DT	O	the	det	13	SENT_507	[p25l128t1720r214b1769],
13	Study	NN	O	study	prep_for	10	SENT_507	[p25l229t1720r380b1784],
14	of	IN	O	of	_	0	SENT_507	[p25l393t1719r447b1769],
15	the	DT	O	the	det	16	SENT_507	[p25l456t1720r542b1769],
16	Liver	NN	O	liver	prep_of	13	SENT_507	[p25l559t1722r690b1777],
17	,	,	O	,	_	0	SENT_507	[p25l559t1722r690b1777],
18	Barcelona	NNP	ORGANIZATION	Barcelona	appos	16	SENT_507	[p25l707t1720r976b1777],
19	,	,	O	,	_	0	SENT_507	[p25l707t1720r976b1777],
20	Spain	NNP	LOCATION	Spain	appos	16	SENT_507	[p25l990t1722r1148b1782],
21	,	,	O	,	_	0	SENT_507	[p25l990t1722r1148b1782],
22	18-22	CD	DATE	18-22	num	23	SENT_507	[p25l1167t1723r1321b1769],
23	April	NNP	DATE	April	appos	16	SENT_507	[p25l1336t1720r1456b1782],
24	201	CD	NUMBER	201	num	23	SENT_507	[p25l1473t1723r1557b1769],
25	2	CD	NUMBER	2	dep	23	SENT_507	[p25l1572t1723r1613b1769],
26	.	.	O	.	_	0	SENT_507	[p25l1572t1723r1613b1769],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_508	[p25l1627t1720r1776b1769],
2	.	.	O	.	_	0	SENT_508	[p25l1627t1720r1776b1769],

1	2	LS	NUMBER	2	_	0	SENT_509	[p25l1791t1723r1832b1769],
2	.	.	O	.	_	0	SENT_509	[p25l1791t1723r1832b1769],

1	Fried	NNP	O	Fried	_	0	SENT_510	[p25l130t1798r270b1855],
2	,	,	O	,	_	0	SENT_510	[p25l130t1798r270b1855],
3	M.W.	NNP	O	M.W.	nn	4	SENT_510	[p25l286t1800r408b1847],
4	etal	NNP	O	etal	appos	1	SENT_510	[p25l423t1798r538b1847],
5	.	.	O	.	_	0	SENT_510	[p25l423t1798r538b1847],

1	Once-daily	JJ	O	once-daily	amod	5	SENT_511	[p25l552t1798r839b1861],
2	simeprevir	JJ	O	simeprevir	amod	5	SENT_511	[p25l852t1800r1130b1860],
3	(	NN	O	(	nn	5	SENT_511	[p25l1145t1799r1395b1855],
4	TMC435	NN	O	tmc435	nn	5	SENT_511	[p25l1145t1799r1395b1855],
5	)	NN	O	)	nsubj	7	SENT_511	[p25l1145t1799r1395b1855],
6	with	IN	O	with	prep	5	SENT_511	[p25l1410t1798r1524b1847],
7	pegylated	VBN	O	pegylate	_	0	SENT_511	[p25l1543t1798r1803b1861],
8	interferon	NN	O	interferon	dobj	7	SENT_511	[p25l1821t1797r2079b1847],
9	and	CC	O	and	_	0	SENT_511	[p25l129t1876r226b1925],
10	ribavirin	NNP	O	ribavirin	dobj	7	SENT_511	[p25l244t1876r455b1925],
11	in	IN	O	in	_	0	SENT_511	[p25l474t1878r516b1925],
12	treatment-Na	NN	MISC	treatment-na	prep_in	10	SENT_511	[p25l532t1878r964b1925],
13	'	''	O	'	_	0	SENT_511	[p25l532t1878r964b1925],
14	ive	JJ	O	ive	amod	15	SENT_511	[p25l532t1878r964b1925],
15	genotype	NN	O	genotype	dobj	7	SENT_511	[p25l979t1883r1234b1939],
16	1	CD	NUMBER	1	num	18	SENT_511	[p25l1252t1880r1267b1925],
17	hepatitis	NN	O	hepatitis	nn	18	SENT_511	[p25l1293t1876r1518b1938],
18	C	NN	O	c	dep	15	SENT_511	[p25l1533t1876r1686b1925],
19	:	:	O	:	_	0	SENT_511	[p25l1533t1876r1686b1925],
20	The	DT	O	the	nsubj	21	SENT_511	[p25l1533t1876r1686b1925],
21	randomized	VBN	O	randomize	parataxis	7	SENT_511	[p25l1703t1876r2016b1925],
22	PILLAR	NN	O	pillar	nn	23	SENT_511	[p25l132t1956r309b2003],
23	study	NN	O	study	dobj	21	SENT_511	[p25l323t1954r477b2018],
24	.	.	O	.	_	0	SENT_511	[p25l323t1954r477b2018],

1	Hepatology	NNP	O	Hepatology	dep	6	SENT_512	[p25l491t1954r790b2018],
2	(	CD	NUMBER	(	num	1	SENT_512	[p25l802t1955r903b2011],
3	201	CD	NUMBER	201	dep	1	SENT_512	[p25l802t1955r903b2011],
4	3	CD	NUMBER	3	num	5	SENT_512	[p25l918t1955r962b2011],
5	)	NN	O	)	dep	6	SENT_512	[p25l918t1955r962b2011],
6	(	CD	NUMBER	(	dep	8	SENT_512	[p25l980t1954r1633b2016],
7	doi	FW	O	doi	dep	6	SENT_512	[p25l980t1954r1633b2016],
8	:10.1002	CD	NUMBER	:10.1002	_	0	SENT_512	[p25l980t1954r1633b2016],
9	/	:	O	/	punct	8	SENT_512	[p25l980t1954r1633b2016],
10	hep	NN	O	hep	dep	8	SENT_512	[p25l980t1954r1633b2016],
11	.26641	CD	NUMBER	.26641	num	12	SENT_512	[p25l980t1954r1633b2016],
12	)	NN	O	)	dep	10	SENT_512	[p25l980t1954r1633b2016],
13	.	.	O	.	_	0	SENT_512	[p25l980t1954r1633b2016],

1	Jacobson	NNP	PERSON	Jacobson	nn	3	SENT_513	[p25l126t2032r387b2089],
2	,	,	O	,	_	0	SENT_513	[p25l126t2032r387b2089],
3	I.	NNP	O	I.	_	0	SENT_513	[p25l404t2034r425b2082],
4	et	FW	O	et	nn	5	SENT_513	[p25l440t2039r489b2082],
5	al.	FW	O	al.	dep	3	SENT_513	[p25l498t2032r555b2082],
6	.	.	O	.	_	0	SENT_513	[p25l498t2032r555b2082],

1	Simeprevir	NNP	O	Simeprevir	_	0	SENT_514	[p25l570t2034r853b2094],
2	(	CD	NUMBER	(	num	4	SENT_514	[p25l868t2033r1119b2089],
3	TMC435	NN	O	tmc435	nn	4	SENT_514	[p25l868t2033r1119b2089],
4	)	NN	O	)	dep	1	SENT_514	[p25l868t2033r1119b2089],
5	with	IN	O	with	_	0	SENT_514	[p25l1134t2032r1247b2082],
6	peginterferon/ribavirin	NN	O	peginterferon/ribavirin	prep_with	4	SENT_514	[p25l1266t2031r1869b2095],
7	for	IN	O	for	_	0	SENT_514	[p25l1883t2031r1956b2082],
8	chronic	JJ	O	chronic	amod	10	SENT_514	[p25l129t2110r324b2159],
9	HCV	NN	O	hcv	nn	10	SENT_514	[p25l340t2111r451b2159],
10	genotype	NN	O	genotype	prep_for	6	SENT_514	[p25l464t2117r719b2173],
11	1	CD	NUMBER	1	num	12	SENT_514	[p25l737t2114r752b2159],
12	infection	NN	O	infection	dep	1	SENT_514	[p25l778t2109r1006b2160],
13	in	IN	O	in	_	0	SENT_514	[p25l1024t2112r1067b2159],
14	treatment-naive	JJ	O	treatment-naive	amod	15	SENT_514	[p25l1082t2112r1508b2159],
15	patients	NNS	O	patient	prep_in	12	SENT_514	[p25l1525t2112r1748b2172],
16	:	:	O	:	_	0	SENT_514	[p25l1525t2112r1748b2172],
17	results	NNS	O	result	dep	12	SENT_514	[p25l1765t2110r1933b2160],
18	from	IN	O	from	_	0	SENT_514	[p25l127t2187r251b2238],
19	QUEST-1	NN	O	quest-1	prep_from	17	SENT_514	[p25l267t2190r506b2245],
20	,	,	O	,	_	0	SENT_514	[p25l267t2190r506b2245],
21	a	DT	O	a	det	24	SENT_514	[p25l520t2203r545b2238],
22	phase	NN	O	phase	nn	24	SENT_514	[p25l563t2188r717b2250],
23	III	CD	NUMBER	iii	num	24	SENT_514	[p25l734t2190r771b2237],
24	trial	NN	O	trial	appos	1	SENT_514	[p25l786t2188r899b2238],
25	.	.	O	.	_	0	SENT_514	[p25l786t2188r899b2238],

1	Presented	VBN	O	present	_	0	SENT_515	[p25l916t2188r1173b2238],
2	at	IN	O	at	_	0	SENT_515	[p25l1190t2195r1239b2238],
3	the	DT	O	the	det	5	SENT_515	[p25l1251t2188r1337b2238],
4	48th	JJ	ORDINAL	48th	amod	5	SENT_515	[p25l1350t2188r1468b2238],
5	Annual	JJ	SET	annual	prep_at	1	SENT_515	[p25l1484t2188r1669b2238],
6	Meeting	VBG	O	meet	partmod	5	SENT_515	[p25l1687t2190r1902b2251],
7	of	IN	O	of	_	0	SENT_515	[p25l1919t2187r1974b2238],
8	the	DT	O	the	det	10	SENT_515	[p25l1982t2188r2068b2238],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_515	[p25l131t2268r379b2328],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_515	[p25l395t2268r695b2315],
11	for	IN	O	for	_	0	SENT_515	[p25l709t2265r782b2315],
12	the	DT	O	the	det	13	SENT_515	[p25l794t2266r880b2315],
13	Study	NN	O	study	prep_for	10	SENT_515	[p25l895t2266r1046b2329],
14	of	IN	O	of	_	0	SENT_515	[p25l1059t2265r1113b2315],
15	the	DT	O	the	det	16	SENT_515	[p25l1122t2266r1208b2315],
16	Liver	NN	O	liver	prep_of	13	SENT_515	[p25l1225t2268r1356b2323],
17	,	,	O	,	_	0	SENT_515	[p25l1225t2268r1356b2323],
18	Amsterdam	NNP	LOCATION	Amsterdam	appos	16	SENT_515	[p25l1369t2266r1797b2323],
19	,	,	O	,	_	0	SENT_515	[p25l1369t2266r1797b2323],
20	The	DT	LOCATION	the	det	21	SENT_515	[p25l1369t2266r1797b2323],
21	Netherlands	NNP	LOCATION	Netherlands	appos	16	SENT_515	[p25l1814t2266r2146b2323],
22	,	,	O	,	_	0	SENT_515	[p25l1814t2266r2146b2323],
23	24-28	CD	DATE	24-28	appos	16	SENT_515	[p25l129t2347r288b2394],
24	April	NNP	DATE	April	tmod	6	SENT_515	[p25l302t2344r423b2406],
25	2013	CD	DATE	2013	num	24	SENT_515	[p25l440t2344r742b2394],
26	.	.	O	.	_	0	SENT_515	[p25l440t2344r742b2394],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_516	[p25l440t2344r742b2394],
2	.	.	O	.	_	0	SENT_516	[p25l440t2344r742b2394],

1	1525	CD	DATE	1525	_	0	SENT_517	[p25l761t2347r897b2394],
2	.	.	O	.	_	0	SENT_517	[p25l761t2347r897b2394],

1	Manns	NNP	PERSON	Manns	_	0	SENT_518	[p25l129t2424r315b2479],
2	,	,	O	,	_	0	SENT_518	[p25l129t2424r315b2479],
3	M.	NNP	O	M.	nn	4	SENT_518	[p25l331t2424r390b2472],
4	etal	NNP	O	etal	appos	1	SENT_518	[p25l404t2422r520b2472],
5	.	.	O	.	_	0	SENT_518	[p25l404t2422r520b2472],

1	Simeprevir	NNP	O	Simeprevir	_	0	SENT_519	[p25l534t2424r818b2484],
2	(	CD	NUMBER	(	num	4	SENT_519	[p25l833t2423r1083b2479],
3	TMC435	NN	O	tmc435	nn	4	SENT_519	[p25l833t2423r1083b2479],
4	)	NN	O	)	dep	1	SENT_519	[p25l833t2423r1083b2479],
5	with	IN	O	with	_	0	SENT_519	[p25l1099t2422r1212b2472],
6	peginterferon/ribavirin	NN	O	peginterferon/ribavirin	prep_with	4	SENT_519	[p25l1231t2421r1833b2485],
7	for	IN	O	for	_	0	SENT_519	[p25l1848t2421r1921b2472],
8	treatment	NN	O	treatment	prep_for	6	SENT_519	[p25l128t2507r393b2550],
9	of	IN	O	of	_	0	SENT_519	[p25l406t2499r461b2550],
10	chronic	JJ	O	chronic	amod	11	SENT_519	[p25l471t2500r665b2550],
11	HCV	NN	O	hcv	prep_of	8	SENT_519	[p25l682t2502r793b2550],
12	genotype-1	NN	O	genotype-1	nn	13	SENT_519	[p25l805t2504r1104b2563],
13	infection	NN	O	infection	dep	1	SENT_519	[p25l1130t2499r1358b2550],
14	in	IN	O	in	_	0	SENT_519	[p25l1376t2502r1419b2549],
15	treatment-naive	JJ	O	treatment-naive	amod	16	SENT_519	[p25l1434t2502r1861b2550],
16	patients	NNS	O	patient	prep_in	13	SENT_519	[p25l1877t2502r2100b2562],
17	:	:	O	:	_	0	SENT_519	[p25l1877t2502r2100b2562],
18	results	NNS	O	result	dep	13	SENT_519	[p25l131t2577r299b2627],
19	from	IN	O	from	_	0	SENT_519	[p25l312t2576r435b2627],
20	QUEST	NN	O	quest	nn	21	SENT_519	[p25l451t2579r690b2634],
21	—	NN	O	—	prep_from	18	SENT_519	[p25l451t2579r690b2634],
22	2	CD	NUMBER	2	num	21	SENT_519	[p25l451t2579r690b2634],
23	,	,	O	,	_	0	SENT_519	[p25l451t2579r690b2634],
24	a	DT	O	a	det	27	SENT_519	[p25l704t2592r729b2627],
25	phase	NN	O	phase	nn	27	SENT_519	[p25l748t2577r902b2639],
26	III	CD	NUMBER	iii	num	27	SENT_519	[p25l918t2579r955b2626],
27	trial	NN	O	trial	appos	1	SENT_519	[p25l971t2577r1083b2627],
28	.	.	O	.	_	0	SENT_519	[p25l971t2577r1083b2627],

1	Presented	VBN	O	present	_	0	SENT_520	[p25l1100t2577r1358b2627],
2	at	IN	O	at	_	0	SENT_520	[p25l1374t2585r1423b2627],
3	the	DT	O	the	det	5	SENT_520	[p25l1435t2577r1521b2627],
4	48th	JJ	ORDINAL	48th	amod	5	SENT_520	[p25l1534t2577r1652b2627],
5	Annual	JJ	SET	annual	prep_at	1	SENT_520	[p25l1668t2577r1853b2627],
6	Meeting	VBG	O	meet	partmod	5	SENT_520	[p25l1871t2579r2087b2640],
7	of	IN	O	of	_	0	SENT_520	[p25l129t2654r184b2705],
8	the	DT	O	the	det	12	SENT_520	[p25l192t2655r278b2705],
9	European	JJ	ORGANIZATION	european	amod	12	SENT_520	[p25l295t2657r543b2717],
10	Association	NNP	ORGANIZATION	Association	nn	12	SENT_520	[p25l559t2657r858b2705],
11	forthe	NN	O	forthe	nn	12	SENT_520	[p25l873t2654r1043b2705],
12	Study	NN	O	study	prep_of	6	SENT_520	[p25l1058t2655r1209b2719],
13	of	IN	O	of	_	0	SENT_520	[p25l1222t2654r1277b2705],
14	the	DT	O	the	det	15	SENT_520	[p25l1285t2655r1371b2705],
15	Liver	NN	O	liver	prep_of	12	SENT_520	[p25l1388t2657r1519b2712],
16	,	,	O	,	_	0	SENT_520	[p25l1388t2657r1519b2712],
17	Amsterdam	NNP	LOCATION	Amsterdam	appos	15	SENT_520	[p25l1533t2655r1960b2712],
18	,	,	O	,	_	0	SENT_520	[p25l1533t2655r1960b2712],
19	The	DT	LOCATION	the	det	20	SENT_520	[p25l1533t2655r1960b2712],
20	Netherlands	NNP	LOCATION	Netherlands	appos	15	SENT_520	[p25l131t2733r464b2790],
21	,	,	O	,	_	0	SENT_520	[p25l131t2733r464b2790],
22	24-28	CD	DATE	24-28	appos	15	SENT_520	[p25l479t2736r637b2783],
23	April	NNP	DATE	April	tmod	6	SENT_520	[p25l651t2733r772b2795],
24	2013	CD	DATE	2013	num	23	SENT_520	[p25l789t2733r1092b2783],
25	.	.	O	.	_	0	SENT_520	[p25l789t2733r1092b2783],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_521	[p25l789t2733r1092b2783],
2	.	.	O	.	_	0	SENT_521	[p25l789t2733r1092b2783],

1	1413	CD	DATE	1413	_	0	SENT_522	[p25l1110t2736r1246b2783],
2	.	.	O	.	_	0	SENT_522	[p25l1110t2736r1246b2783],

1	Lawitz	NNP	PERSON	Lawitz	nn	3	SENT_523	[p25l130t2813r307b2868],
2	,	,	O	,	_	0	SENT_523	[p25l130t2813r307b2868],
3	E.	NNP	O	E.	_	0	SENT_523	[p25l324t2813r362b2861],
4	et	FW	O	et	nn	5	SENT_523	[p25l377t2819r425b2861],
5	al.	FW	O	al.	dep	3	SENT_523	[p25l434t2811r491b2861],
6	.	.	O	.	_	0	SENT_523	[p25l434t2811r491b2861],

1	Simeprevir	NNP	O	Simeprevir	_	0	SENT_524	[p25l506t2813r790b2873],
2	(	CD	NUMBER	(	num	4	SENT_524	[p25l805t2812r1055b2868],
3	TMC435	NN	O	tmc435	nn	4	SENT_524	[p25l805t2812r1055b2868],
4	)	NN	O	)	dep	1	SENT_524	[p25l805t2812r1055b2868],
5	with	IN	O	with	_	0	SENT_524	[p25l1070t2811r1184b2861],
6	peginterferon/ribavirin	NN	O	peginterferon/ribavirin	prep_with	4	SENT_524	[p25l1203t2810r1805b2874],
7	for	IN	O	for	_	0	SENT_524	[p25l1820t2810r1893b2861],
8	treatment	NN	O	treatment	prep_for	6	SENT_524	[p25l128t2896r392b2939],
9	of	IN	O	of	_	0	SENT_524	[p25l406t2888r461b2939],
10	chronic	JJ	O	chronic	amod	14	SENT_524	[p25l471t2889r665b2939],
11	HCV	NN	O	hcv	nn	14	SENT_524	[p25l682t2891r793b2939],
12	genotype	NN	O	genotype	nn	14	SENT_524	[p25l805t2897r1060b2953],
13	1	CD	NUMBER	1	num	14	SENT_524	[p25l1079t2893r1093b2938],
14	infection	NN	O	infection	prep_of	8	SENT_524	[p25l1119t2888r1348b2939],
15	in	IN	O	in	_	0	SENT_524	[p25l1365t2891r1408b2938],
16	patients	NNS	O	patient	prep_in	1	SENT_524	[p25l1427t2891r1637b2951],
17	who	WP	O	who	nsubj	18	SENT_524	[p25l1650t2889r1765b2939],
18	relapsed	VBD	O	relapse	rcmod	16	SENT_524	[p25l1782t2889r2002b2951],
19	after	IN	O	after	_	0	SENT_524	[p25l2018t2888r2139b2939],
20	previous	JJ	O	previous	amod	22	SENT_524	[p25l131t2969r355b3029],
21	interferon	NN	O	interferon	nn	22	SENT_524	[p25l371t2966r809b3017],
22	—	NN	O	—	prep_after	18	SENT_524	[p25l371t2966r809b3017],
23	based	VBN	O	base	partmod	22	SENT_524	[p25l371t2966r809b3017],
24	therapy	NN	O	therapy	dobj	23	SENT_524	[p25l824t2967r1042b3031],
25	:	:	O	:	_	0	SENT_524	[p25l824t2967r1042b3031],
26	results	NNS	O	result	dep	1	SENT_524	[p25l1058t2967r1226b3017],
27	from	IN	O	from	_	0	SENT_524	[p25l1240t2966r1362b3017],
28	PROMISE	NNP	O	PROMISE	prep_from	26	SENT_524	[p25l1381t2969r1630b3024],
29	,	,	O	,	_	0	SENT_524	[p25l1381t2969r1630b3024],
30	a	DT	O	a	det	33	SENT_524	[p25l1644t2982r1670b3017],
31	phase	NN	O	phase	nn	33	SENT_524	[p25l1688t2967r1842b3029],
32	III	CD	NUMBER	iii	num	33	SENT_524	[p25l1859t2969r1895b3016],
33	trial	NN	O	trial	appos	28	SENT_524	[p25l1911t2967r2023b3017],
34	.	.	O	.	_	0	SENT_524	[p25l1911t2967r2023b3017],

1	Presented	VBN	O	present	_	0	SENT_525	[p25l131t3045r389b3095],
2	at	IN	O	at	_	0	SENT_525	[p25l406t3052r454b3095],
3	Digestive	JJ	O	digestive	amod	5	SENT_525	[p25l471t3047r712b3108],
4	Diseases	NNS	O	disease	nn	5	SENT_525	[p25l730t3047r951b3095],
5	Week	NN	DURATION	week	prep_at	1	SENT_525	[p25l962t3045r1119b3102],
6	,	,	O	,	_	0	SENT_525	[p25l962t3045r1119b3102],
7	Orlando	NNP	LOCATION	Orlando	appos	5	SENT_525	[p25l1134t3045r1359b3102],
8	,	,	O	,	_	0	SENT_525	[p25l1134t3045r1359b3102],
9	Florida	NNP	LOCATION	Florida	appos	5	SENT_525	[p25l1376t3045r1565b3102],
10	,	,	O	,	_	0	SENT_525	[p25l1376t3045r1565b3102],
11	18-21	CD	NUMBER	18-21	appos	5	SENT_525	[p25l1584t3048r1729b3095],
12	May	NNP	DATE	May	tmod	1	SENT_525	[p25l1755t3047r1864b3109],
13	2013	CD	DATE	2013	num	12	SENT_525	[p25l1877t3048r2016b3095],
14	.	.	O	.	_	0	SENT_525	[p25l1877t3048r2016b3095],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_526	[p25l128t3122r277b3171],
2	.	.	O	.	_	0	SENT_526	[p25l128t3122r277b3171],

1	869b	NN	O	869b	_	0	SENT_527	[p25l292t3122r434b3171],
2	,	,	O	,	_	0	SENT_527	[p25l292t3122r434b3171],

1	Berger	NNP	PERSON	Berger	_	0	SENT_528	[p26l130t24r309b85],
2	,	,	O	,	_	0	SENT_528	[p26l130t24r309b85],
3	K.L.	NNP	PERSON	K.L.	nn	4	SENT_528	[p26l326t24r412b72],
4	etal	NNP	O	etal	appos	1	SENT_528	[p26l426t22r541b72],
5	.	.	O	.	_	0	SENT_528	[p26l426t22r541b72],

1	Viral	JJ	O	viral	amod	2	SENT_529	[p26l551t22r662b72],
2	Resistance	NN	O	resistance	nsubj	11	SENT_529	[p26l682t24r955b72],
3	in	IN	O	in	_	0	SENT_529	[p26l971t24r1013b71],
4	Hepatitis	NNP	O	Hepatitis	nn	7	SENT_529	[p26l1033t24r1264b84],
5	C	NNP	O	C	nn	7	SENT_529	[p26l1278t24r1311b72],
6	Virus	NN	O	virus	nn	7	SENT_529	[p26l1322t24r1450b72],
7	Genotype	NN	O	genotype	prep_in	2	SENT_529	[p26l1465t24r1726b86],
8	1	CD	NUMBER	1	number	9	SENT_529	[p26l1744t21r2005b72],
9	—	CD	NUMBER	—	dep	10	SENT_529	[p26l1744t21r2005b72],
10	|	NN	O	|	dep	7	SENT_529	[p26l1744t21r2005b72],
11	nfected	VBD	O	nfect	_	0	SENT_529	[p26l1744t21r2005b72],
12	Patients	NNS	O	patient	dobj	11	SENT_529	[p26l131t102r337b150],
13	Receiving	VBG	O	receive	xcomp	11	SENT_529	[p26l354t102r604b163],
14	the	DT	O	the	det	22	SENT_529	[p26l619t100r705b150],
15	NS3	NN	MISC	ns3	nn	22	SENT_529	[p26l722t102r821b150],
16	Protease	NN	MISC	protease	nn	22	SENT_529	[p26l839t102r1062b150],
17	Inhibitor	NN	MISC	inhibitor	nn	22	SENT_529	[p26l1079t100r1303b150],
18	Fa	NN	MISC	fa	nn	22	SENT_529	[p26l1319t100r1684b162],
19	|	NN	O	|	nn	22	SENT_529	[p26l1319t100r1684b162],
20	daprevir	NN	O	daprevir	nn	22	SENT_529	[p26l1319t100r1684b162],
21	(	NN	O	(	nn	22	SENT_529	[p26l1319t100r1684b162],
22	B	NN	O	b	iobj	13	SENT_529	[p26l1319t100r1684b162],
23	|	CD	NUMBER	|	number	24	SENT_529	[p26l1319t100r1684b162],
24	201335	CD	NUMBER	201335	dep	25	SENT_529	[p26l1701t101r1910b157],
25	)	NN	O	)	amod	22	SENT_529	[p26l1701t101r1910b157],
26	in	IN	O	in	_	0	SENT_529	[p26l1927t102r1970b149],
27	a	DT	O	a	det	30	SENT_529	[p26l1987t115r2012b150],
28	Phase	NN	O	phase	nn	30	SENT_529	[p26l131t178r282b228],
29	1	CD	NUMBER	1	num	30	SENT_529	[p26l301t182r315b227],
30	b	NN	O	b	prep_in	25	SENT_529	[p26l332t178r362b228],
31	Mu	NN	O	mu	nn	33	SENT_529	[p26l378t178r931b241],
32	|	CD	NUMBER	|	num	33	SENT_529	[p26l378t178r931b241],
33	tip	NN	O	tip	dobj	13	SENT_529	[p26l378t178r931b241],
34	|	CD	NUMBER	|	dobj	13	SENT_529	[p26l378t178r931b241],
35	e	LS	O	e	dep	34	SENT_529	[p26l378t178r931b241],
36	.	.	O	.	_	0	SENT_529	[p26l378t178r931b241],

1	—	NN	O	—	_	0	SENT_530	[p26l378t178r931b241],
2	.	.	O	.	_	0	SENT_530	[p26l378t178r931b241],

1	Rising	VBG	O	rise	_	0	SENT_531	[p26l378t178r931b241],
2	.	.	O	.	_	0	SENT_531	[p26l378t178r931b241],

1	—	NN	O	—	_	0	SENT_532	[p26l378t178r931b241],
2	.	.	O	.	_	0	SENT_532	[p26l378t178r931b241],

1	Dose	NN	O	dose	_	0	SENT_533	[p26l378t178r931b241],
2	Study	NN	O	study	dep	1	SENT_533	[p26l946t178r1105b242],
3	.	.	O	.	_	0	SENT_533	[p26l946t178r1105b242],

1	Antimicrob	NNP	PERSON	Antimicrob	_	0	SENT_534	[p26l1116t178r1411b228],
2	.	.	O	.	_	0	SENT_534	[p26l1116t178r1411b228],

1	Agents	NNS	O	agent	_	0	SENT_535	[p26l1423t180r1599b241],
2	Chemother	NNP	O	Chemother	dep	1	SENT_535	[p26l1612t178r1907b228],
3	.	.	O	.	_	0	SENT_535	[p26l1612t178r1907b228],

1	57	CD	NUMBER	57	_	0	SENT_536	[p26l1922t182r2002b235],
2	,	,	O	,	_	0	SENT_536	[p26l1922t182r2002b235],
3	4928-4936	CD	DURATION	4928-4936	num	4	SENT_536	[p26l127t258r420b304],
4	(	NN	O	(	appos	1	SENT_536	[p26l435t256r536b311],
5	201	CD	NUMBER	201	number	6	SENT_536	[p26l435t256r536b311],
6	3	CD	NUMBER	3	num	7	SENT_536	[p26l551t256r610b311],
7	)	NN	O	)	dep	4	SENT_536	[p26l551t256r610b311],
8	.	.	O	.	_	0	SENT_536	[p26l551t256r610b311],

1	Manns	NNP	PERSON	Manns	_	0	SENT_537	[p26l129t335r315b390],
2	,	,	O	,	_	0	SENT_537	[p26l129t335r315b390],
3	M.P.	NNP	O	M.P.	nn	4	SENT_537	[p26l331t335r428b383],
4	etal	NNP	O	etal	appos	1	SENT_537	[p26l442t333r557b383],
5	.	.	O	.	_	0	SENT_537	[p26l442t333r557b383],

1	Potency	NN	O	potency	_	0	SENT_538	[p26l574t335r794b397],
2	,	,	O	,	_	0	SENT_538	[p26l574t335r794b397],
3	safety	NN	O	safety	conj_and	1	SENT_538	[p26l808t332r973b397],
4	,	,	O	,	_	0	SENT_538	[p26l808t332r973b397],
5	and	CC	O	and	_	0	SENT_538	[p26l987t333r1083b383],
6	pharmacokinetics	NNS	O	pharmacokinetic	conj_and	1	SENT_538	[p26l1102t333r1570b395],
7	of	IN	O	of	_	0	SENT_538	[p26l1585t332r1639b383],
8	the	DT	O	the	det	11	SENT_538	[p26l1647t333r1733b383],
9	NS3/4A	NN	O	ns3/4a	nn	11	SENT_538	[p26l1751t335r1945b385],
10	protease	NN	O	protease	nn	11	SENT_538	[p26l131t419r357b473],
11	inhibitor	NN	O	inhibitor	prep_of	6	SENT_538	[p26l374t411r598b461],
12	B1201	NN	O	b1201	dep	1	SENT_538	[p26l613t413r745b461],
13	335	CD	NUMBER	335	num	12	SENT_538	[p26l759t414r851b461],
14	in	IN	O	in	_	0	SENT_538	[p26l869t413r912b460],
15	patients	NNS	O	patient	prep_in	12	SENT_538	[p26l930t413r1141b473],
16	with	IN	O	with	_	0	SENT_538	[p26l1154t411r1268b461],
17	chronic	JJ	O	chronic	amod	22	SENT_538	[p26l1285t411r1479b461],
18	HCV	NN	O	hcv	nn	22	SENT_538	[p26l1496t413r1607b461],
19	genotype	NN	O	genotype	nn	22	SENT_538	[p26l1619t415r1918b475],
20	—	NN	O	—	nn	22	SENT_538	[p26l1619t415r1918b475],
21	1	CD	NUMBER	1	num	22	SENT_538	[p26l1619t415r1918b475],
22	infection	NN	O	infection	prep_with	15	SENT_538	[p26l130t488r419b539],
23	.	.	O	.	_	0	SENT_538	[p26l130t488r419b539],

1	J.	NNP	PERSON	J.	nn	2	SENT_539	[p26l130t488r419b539],
2	Hepatol	NNP	PERSON	Hepatol	_	0	SENT_539	[p26l434t489r647b551],
3	.	.	O	.	_	0	SENT_539	[p26l434t489r647b551],

1	54	CD	NUMBER	54	_	0	SENT_540	[p26l661t493r741b546],
2	,	,	O	,	_	0	SENT_540	[p26l661t493r741b546],
3	1	CD	NUMBER	1	number	4	SENT_540	[p26l760t493r774b538],
4	1	CD	NUMBER	1	appos	1	SENT_540	[p26l793t493r807b538],
5	14-1	CD	NUMBER	14-1	num	7	SENT_540	[p26l825t493r937b538],
6	122	CD	NUMBER	122	num	7	SENT_540	[p26l956t492r1045b538],
7	(	NN	O	(	dep	4	SENT_540	[p26l1062t490r1163b546],
8	201	CD	NUMBER	201	number	9	SENT_540	[p26l1062t490r1163b546],
9	1	CD	NUMBER	1	num	10	SENT_540	[p26l1181t490r1237b546],
10	)	NN	O	)	dep	4	SENT_540	[p26l1181t490r1237b546],
11	.	.	O	.	_	0	SENT_540	[p26l1181t490r1237b546],

1	Sulkowski	NNP	PERSON	Sulkowski	_	0	SENT_541	[p26l128t567r401b624],
2	,	,	O	,	_	0	SENT_541	[p26l128t567r401b624],
3	M.S.	NNP	LOCATION	M.S.	nn	4	SENT_541	[p26l416t569r520b617],
4	etal	NNP	O	etal	appos	1	SENT_541	[p26l534t567r650b617],
5	.	.	O	.	_	0	SENT_541	[p26l534t567r650b617],

1	Faldaprevir	NNP	O	Faldaprevir	_	0	SENT_542	[p26l666t567r957b629],
2	combined	VBN	O	combine	partmod	1	SENT_542	[p26l970t567r1236b617],
3	with	IN	O	with	_	0	SENT_542	[p26l1251t567r1365b617],
4	pegylated	VBN	O	pegylate	prepc_with	2	SENT_542	[p26l1383t567r1644b631],
5	interferon	NN	O	interferon	dobj	4	SENT_542	[p26l1662t566r1920b617],
6	a	DT	O	a	det	10	SENT_542	[p26l1937t566r2109b617],
7	|	NN	O	|	nn	10	SENT_542	[p26l1937t566r2109b617],
8	fa	NN	O	fa	nn	10	SENT_542	[p26l1937t566r2109b617],
9	—	CD	NUMBER	—	num	10	SENT_542	[p26l1937t566r2109b617],
10	2a	NN	O	2a	dep	5	SENT_542	[p26l1937t566r2109b617],
11	and	CC	O	and	_	0	SENT_542	[p26l129t645r225b695],
12	ribavirin	NNP	O	ribavirin	conj_and	5	SENT_542	[p26l244t645r455b695],
13	in	IN	O	in	_	0	SENT_542	[p26l473t647r516b694],
14	treatment	NN	O	treatment	npadvmod	16	SENT_542	[p26l531t648r958b695],
15	—	CD	NUMBER	—	num	14	SENT_542	[p26l531t648r958b695],
16	naive	JJ	O	naive	amod	17	SENT_542	[p26l531t648r958b695],
17	patients	NNS	O	patient	prep_in	12	SENT_542	[p26l974t647r1184b707],
18	with	IN	O	with	_	0	SENT_542	[p26l1198t645r1311b695],
19	chronic	JJ	O	chronic	amod	22	SENT_542	[p26l1328t645r1522b695],
20	genotype	NN	O	genotype	nn	22	SENT_542	[p26l1537t653r1791b709],
21	1	CD	NUMBER	1	num	22	SENT_542	[p26l1810t649r1825b694],
22	HCV	NN	O	hcv	prep_with	4	SENT_542	[p26l1851t647r1972b695],
23	:	:	O	:	_	0	SENT_542	[p26l1851t647r1972b695],
24	S	NN	O	s	dep	1	SENT_542	[p26l129t725r355b773],
25	|	CD	NUMBER	|	num	24	SENT_542	[p26l129t725r355b773],
26	LEN	NNP	PERSON	LEN	dep	24	SENT_542	[p26l129t725r355b773],
27	.	.	O	.	_	0	SENT_542	[p26l129t725r355b773],

1	—	NN	O	—	_	0	SENT_543	[p26l129t725r355b773],
2	.	.	O	.	_	0	SENT_543	[p26l129t725r355b773],

1	C1	NN	O	c1	_	0	SENT_544	[p26l129t725r355b773],
2	trial	NN	O	trial	dep	1	SENT_544	[p26l379t723r491b773],
3	.	.	O	.	_	0	SENT_544	[p26l379t723r491b773],

1	Hepatology	NNP	O	Hepatology	_	0	SENT_545	[p26l505t723r804b787],
2	57	CD	NUMBER	57	num	1	SENT_545	[p26l815t727r895b780],
3	,	,	O	,	_	0	SENT_545	[p26l815t727r895b780],
4	2143-2154	CD	DATE	2143-2154	num	1	SENT_545	[p26l910t726r1200b773],
5	(	NN	O	(	dep	1	SENT_545	[p26l1216t724r1316b780],
6	201	CD	NUMBER	201	number	7	SENT_545	[p26l1216t724r1316b780],
7	3	CD	NUMBER	3	num	8	SENT_545	[p26l1331t724r1390b780],
8	)	NN	O	)	dep	5	SENT_545	[p26l1331t724r1390b780],
9	.	.	O	.	_	0	SENT_545	[p26l1331t724r1390b780],

1	Sulkowski	NNP	PERSON	Sulkowski	_	0	SENT_546	[p26l128t801r401b858],
2	,	,	O	,	_	0	SENT_546	[p26l128t801r401b858],
3	M.S.	NNP	LOCATION	M.S.	nn	4	SENT_546	[p26l416t803r520b851],
4	etal	NNP	O	etal	appos	1	SENT_546	[p26l534t801r650b851],
5	.	.	O	.	_	0	SENT_546	[p26l534t801r650b851],

1	Faldaprevir	NNP	O	Faldaprevir	_	0	SENT_547	[p26l666t801r957b863],
2	combined	VBN	O	combine	partmod	1	SENT_547	[p26l970t801r1236b851],
3	with	IN	O	with	_	0	SENT_547	[p26l1251t801r1365b851],
4	peginterferon	NN	O	peginterferon	prep_with	2	SENT_547	[p26l1383t800r1745b864],
5	a	DT	O	a	det	9	SENT_547	[p26l1761t800r1934b851],
6	|	NN	O	|	nn	9	SENT_547	[p26l1761t800r1934b851],
7	fa	NN	O	fa	nn	9	SENT_547	[p26l1761t800r1934b851],
8	—	CD	NUMBER	—	num	9	SENT_547	[p26l1761t800r1934b851],
9	2a	NN	O	2a	dep	1	SENT_547	[p26l1761t800r1934b851],
10	and	CC	O	and	_	0	SENT_547	[p26l129t879r225b929],
11	ribavirin	NNP	O	ribavirin	dep	1	SENT_547	[p26l244t879r455b929],
12	in	IN	O	in	_	0	SENT_547	[p26l473t881r516b928],
13	chronic	JJ	O	chronic	amod	20	SENT_547	[p26l533t879r727b929],
14	hepatitis	NN	O	hepatitis	nn	20	SENT_547	[p26l743t879r968b941],
15	C	NN	O	c	nn	20	SENT_547	[p26l983t881r1017b929],
16	virus	NN	O	virus	nn	20	SENT_547	[p26l1030t881r1153b929],
17	genotype	NN	O	genotype	nn	20	SENT_547	[p26l1169t883r1467b943],
18	—	NN	O	—	nn	20	SENT_547	[p26l1169t883r1467b943],
19	1	CD	NUMBER	1	num	20	SENT_547	[p26l1169t883r1467b943],
20	patients	NNS	O	patient	prep_in	11	SENT_547	[p26l1494t881r1704b941],
21	with	IN	O	with	_	0	SENT_547	[p26l1717t879r1831b929],
22	prior	JJ	O	prior	amod	23	SENT_547	[p26l1849t881r1973b942],
23	nonresponse	JJ	O	nonresponse	prep_with	20	SENT_547	[p26l131t972r486b1020],
24	:	:	O	:	_	0	SENT_547	[p26l131t972r486b1020],
25	S	NN	O	s	dep	1	SENT_547	[p26l501t959r736b1007],
26	|	CD	NUMBER	|	num	25	SENT_547	[p26l501t959r736b1007],
27	LEN	NNP	O	LEN	dep	25	SENT_547	[p26l501t959r736b1007],
28	.	.	O	.	_	0	SENT_547	[p26l501t959r736b1007],

1	—	NN	O	—	_	0	SENT_548	[p26l501t959r736b1007],
2	.	.	O	.	_	0	SENT_548	[p26l501t959r736b1007],

1	C2	NN	O	c2	_	0	SENT_549	[p26l501t959r736b1007],
2	trial	NN	O	trial	dep	1	SENT_549	[p26l750t957r862b1007],
3	.	.	O	.	_	0	SENT_549	[p26l750t957r862b1007],

1	Hepatology	NNP	O	Hepatology	_	0	SENT_550	[p26l877t957r1175b1021],
2	57	CD	NUMBER	57	num	1	SENT_550	[p26l1186t961r1266b1015],
3	,	,	O	,	_	0	SENT_550	[p26l1186t961r1266b1015],
4	2155-2163	CD	DATE	2155-2163	num	1	SENT_550	[p26l1281t960r1569b1007],
5	(	CD	NUMBER	(	num	7	SENT_550	[p26l1587t958r1762b1015],
6	2013	CD	DATE	2013	num	7	SENT_550	[p26l1587t958r1762b1015],
7	)	NN	O	)	dep	1	SENT_550	[p26l1587t958r1762b1015],
8	.	.	O	.	_	0	SENT_550	[p26l1587t958r1762b1015],

1	Ferenci	NNP	PERSON	Ferenci	_	0	SENT_551	[p26l130t1038r326b1093],
2	,	,	O	,	_	0	SENT_551	[p26l130t1038r326b1093],
3	P.	NNP	O	P.	nn	4	SENT_551	[p26l342t1037r374b1085],
4	etal	NN	O	etal	appos	1	SENT_551	[p26l387t1035r501b1085],
5	.	.	O	.	_	0	SENT_551	[p26l387t1035r501b1085],

1	Faldaprevir	NNP	O	Faldaprevir	nsubj	3	SENT_552	[p26l518t1035r805b1098],
2	plus	CC	O	plus	advmod	3	SENT_552	[p26l819t1035r924b1098],
3	pegylated	VBN	O	pegylate	dep	38	SENT_552	[p26l940t1035r1198b1099],
4	interferon	NN	O	interferon	dobj	3	SENT_552	[p26l1216t1035r1471b1085],
5	a	DT	O	a	det	9	SENT_552	[p26l1486t1035r1657b1085],
6	|	NN	O	|	nn	9	SENT_552	[p26l1486t1035r1657b1085],
7	fa	NN	O	fa	nn	9	SENT_552	[p26l1486t1035r1657b1085],
8	—	CD	NUMBER	—	num	9	SENT_552	[p26l1486t1035r1657b1085],
9	2a	NN	O	2a	dep	4	SENT_552	[p26l1486t1035r1657b1085],
10	and	CC	O	and	_	0	SENT_552	[p26l1672t1035r1768b1085],
11	ribavirin	NNP	O	ribavirin	conj_and	4	SENT_552	[p26l1786t1035r1995b1085],
12	in	IN	O	in	_	0	SENT_552	[p26l130t1116r173b1162],
13	chronic	JJ	O	chronic	amod	19	SENT_552	[p26l189t1113r381b1163],
14	HCV	NN	O	hcv	nn	19	SENT_552	[p26l397t1115r508b1163],
15	genotype	NN	O	genotype	nn	19	SENT_552	[p26l520t1117r815b1177],
16	—	NN	O	—	nn	19	SENT_552	[p26l520t1117r815b1177],
17	1	CD	NUMBER	1	num	19	SENT_552	[p26l520t1117r815b1177],
18	treatment	NN	O	treatment	nn	19	SENT_552	[p26l838t1116r1260b1163],
19	—	NN	O	—	prep_in	11	SENT_552	[p26l838t1116r1260b1163],
20	naive	JJ	O	naive	amod	19	SENT_552	[p26l838t1116r1260b1163],
21	patients	NNS	O	patient	dep	20	SENT_552	[p26l1275t1116r1496b1176],
22	:	:	O	:	_	0	SENT_552	[p26l1275t1116r1496b1176],
23	ﬁnal	JJ	O	ﬁnal	amod	24	SENT_552	[p26l1508t1113r1617b1163],
24	results	NNS	O	result	dep	21	SENT_552	[p26l1636t1113r1801b1163],
25	from	IN	O	from	_	0	SENT_552	[p26l1814t1113r1936b1163],
26	STARTVerso	NN	O	startverso	nn	27	SENT_552	[p26l129t1191r462b1249],
27	|	NN	O	|	prep_from	24	SENT_552	[p26l129t1191r462b1249],
28	,	,	O	,	_	0	SENT_552	[p26l129t1191r462b1249],
29	a	DT	O	a	appos	21	SENT_552	[p26l476t1206r501b1241],
30	randomized	VBN	O	randomize	partmod	29	SENT_552	[p26l519t1191r843b1249],
31	,	,	O	,	_	0	SENT_552	[p26l519t1191r843b1249],
32	double	JJ	O	double	nsubj	38	SENT_552	[p26l857t1191r1210b1249],
33	—	RB	O	—	advmod	34	SENT_552	[p26l857t1191r1210b1249],
34	blind	JJ	O	blind	amod	32	SENT_552	[p26l857t1191r1210b1249],
35	,	,	O	,	_	0	SENT_552	[p26l857t1191r1210b1249],
36	placebo	NN	O	placebo	nn	37	SENT_552	[p26l1226t1191r1721b1254],
37	—	NN	O	—	appos	32	SENT_552	[p26l1226t1191r1721b1254],
38	controlled	JJ	O	controlled	_	0	SENT_552	[p26l1226t1191r1721b1254],
39	phase	NN	O	phase	iobj	38	SENT_552	[p26l1739t1191r1891b1254],
40	III	CD	NUMBER	iii	num	41	SENT_552	[p26l1907t1194r1943b1240],
41	trial	NN	O	trial	dobj	38	SENT_552	[p26l1958t1191r2069b1241],
42	.	.	O	.	_	0	SENT_552	[p26l1958t1191r2069b1241],

1	Presented	VBN	O	present	_	0	SENT_553	[p26l131t1269r386b1319],
2	at	IN	O	at	_	0	SENT_553	[p26l402t1277r450b1319],
3	the	DT	O	the	det	5	SENT_553	[p26l462t1269r548b1319],
4	48th	JJ	ORDINAL	48th	amod	5	SENT_553	[p26l560t1269r677b1319],
5	Annual	JJ	SET	annual	prep_at	1	SENT_553	[p26l692t1269r875b1319],
6	Meeting	VBG	O	meet	partmod	5	SENT_553	[p26l893t1272r1107b1332],
7	of	IN	O	of	_	0	SENT_553	[p26l1123t1269r1177b1319],
8	the	DT	O	the	det	10	SENT_553	[p26l1185t1269r1270b1319],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_553	[p26l1287t1272r1532b1332],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_553	[p26l1547t1272r1843b1319],
11	for	IN	O	for	_	0	SENT_553	[p26l1857t1269r1930b1319],
12	the	DT	O	the	det	13	SENT_553	[p26l1941t1269r2026b1319],
13	Study	NN	O	study	prep_for	10	SENT_553	[p26l129t1347r279b1411],
14	of	IN	O	of	_	0	SENT_553	[p26l291t1347r346b1397],
15	the	DT	O	the	det	16	SENT_553	[p26l353t1347r439b1397],
16	Liver	NN	O	liver	prep_of	13	SENT_553	[p26l455t1350r584b1405],
17	,	,	O	,	_	0	SENT_553	[p26l455t1350r584b1405],
18	Amsterdam	NNP	LOCATION	Amsterdam	appos	16	SENT_553	[p26l597t1347r1021b1405],
19	,	,	O	,	_	0	SENT_553	[p26l597t1347r1021b1405],
20	The	DT	LOCATION	the	det	21	SENT_553	[p26l597t1347r1021b1405],
21	Netherlands	NNP	LOCATION	Netherlands	appos	16	SENT_553	[p26l1037t1347r1365b1405],
22	,	,	O	,	_	0	SENT_553	[p26l1037t1347r1365b1405],
23	24-28	CD	DATE	24-28	appos	16	SENT_553	[p26l1380t1350r1537b1397],
24	April	NNP	DATE	April	tmod	6	SENT_553	[p26l1550t1347r1669b1410],
25	2013	CD	DATE	2013	num	24	SENT_553	[p26l1686t1347r1985b1397],
26	.	.	O	.	_	0	SENT_553	[p26l1686t1347r1985b1397],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_554	[p26l1686t1347r1985b1397],
2	.	.	O	.	_	0	SENT_554	[p26l1686t1347r1985b1397],

1	1416	CD	DATE	1416	_	0	SENT_555	[p26l2003t1351r2138b1397],
2	.	.	O	.	_	0	SENT_555	[p26l2003t1351r2138b1397],

1	Summa	NNP	PERSON	Summa	_	0	SENT_556	[p26l128t1425r523b1483],
2	,	,	O	,	_	0	SENT_556	[p26l128t1425r523b1483],
3	V.	NNP	O	V.	nn	4	SENT_556	[p26l128t1425r523b1483],
4	etaI	NNP	O	etaI	appos	1	SENT_556	[p26l128t1425r523b1483],
5	.	.	O	.	_	0	SENT_556	[p26l128t1425r523b1483],

1	MK	NN	O	mk	_	0	SENT_557	[p26l540t1428r823b1483],
2	—	CD	NUMBER	—	number	3	SENT_557	[p26l540t1428r823b1483],
3	5172	CD	NUMBER	5172	dep	1	SENT_557	[p26l540t1428r823b1483],
4	,	,	O	,	_	0	SENT_557	[p26l540t1428r823b1483],
5	a	DT	O	a	det	7	SENT_557	[p26l540t1428r823b1483],
6	selective	JJ	O	selective	amod	7	SENT_557	[p26l839t1425r1067b1475],
7	inhibitor	NN	O	inhibitor	appos	1	SENT_557	[p26l1083t1425r1307b1475],
8	of	IN	O	of	_	0	SENT_557	[p26l1320t1425r1374b1475],
9	hepatitis	NN	O	hepatitis	nn	13	SENT_557	[p26l1386t1425r1611b1488],
10	C	NN	O	c	nn	13	SENT_557	[p26l1626t1427r1659b1475],
11	virus	NN	O	virus	nn	13	SENT_557	[p26l1672t1428r1796b1475],
12	NS3/4a	NN	O	ns3/4a	nn	13	SENT_557	[p26l1813t1427r1997b1477],
13	protease	NN	O	protease	prep_of	7	SENT_557	[p26l131t1511r357b1566],
14	with	IN	O	with	_	0	SENT_557	[p26l371t1503r484b1553],
15	broad	JJ	O	broad	amod	16	SENT_557	[p26l503t1503r653b1553],
16	activity	NN	O	activity	prep_with	13	SENT_557	[p26l670t1506r861b1567],
17	across	IN	O	across	_	0	SENT_557	[p26l873t1518r1034b1553],
18	genotypes	NNS	O	genotype	nn	21	SENT_557	[p26l1049t1511r1329b1567],
19	and	CC	O	and	_	0	SENT_557	[p26l1343t1503r1440b1553],
20	resistant	JJ	O	resistant	conj_and	18	SENT_557	[p26l1459t1506r1679b1553],
21	variants	NNS	O	variant	prep_across	16	SENT_557	[p26l1691t1506r1911b1553],
22	.	.	O	.	_	0	SENT_557	[p26l1691t1506r1911b1553],

1	Antimicrob	NNP	PERSON	Antimicrob	_	0	SENT_558	[p26l125t1581r420b1631],
2	.	.	O	.	_	0	SENT_558	[p26l125t1581r420b1631],

1	Agents	NNS	O	agent	_	0	SENT_559	[p26l431t1584r608b1644],
2	Chemother	NNP	O	Chemother	dep	1	SENT_559	[p26l621t1581r916b1631],
3	.	.	O	.	_	0	SENT_559	[p26l621t1581r916b1631],

1	56	CD	NUMBER	56	_	0	SENT_560	[p26l931t1585r1011b1639],
2	,	,	O	,	_	0	SENT_560	[p26l931t1585r1011b1639],
3	4161	CD	DURATION	4161	number	4	SENT_560	[p26l1023t1585r1142b1631],
4	-4167	CD	DURATION	-4167	appos	1	SENT_560	[p26l1156t1585r1315b1631],
5	(	CD	NUMBER	(	num	7	SENT_560	[p26l1332t1582r1506b1639],
6	2012	CD	DATE	2012	num	7	SENT_560	[p26l1332t1582r1506b1639],
7	)	NN	O	)	dep	4	SENT_560	[p26l1332t1582r1506b1639],
8	.	.	O	.	_	0	SENT_560	[p26l1332t1582r1506b1639],

1	Petry	NNP	PERSON	Petry	_	0	SENT_561	[p26l130t1661r272b1723],
2	,	,	O	,	_	0	SENT_561	[p26l130t1661r272b1723],
3	A.	NNP	O	A.	nn	4	SENT_561	[p26l286t1662r335b1709],
4	et	NNP	O	et	appos	1	SENT_561	[p26l349t1667r398b1709],
5	al.	FW	O	al.	dep	4	SENT_561	[p26l407t1659r464b1709],
6	.	.	O	.	_	0	SENT_561	[p26l407t1659r464b1709],

1	Safety	NN	O	safety	nn	4	SENT_562	[p26l479t1659r640b1723],
2	and	CC	O	and	_	0	SENT_562	[p26l653t1659r749b1709],
3	antiviral	JJ	O	antiviral	conj_and	1	SENT_562	[p26l766t1659r973b1709],
4	activity	NN	O	activity	_	0	SENT_562	[p26l990t1662r1181b1723],
5	of	IN	O	of	_	0	SENT_562	[p26l1194t1659r1248b1709],
6	MK	NN	O	mk	prep_of	4	SENT_562	[p26l1260t1662r1414b1709],
7	—	CD	NUMBER	—	num	6	SENT_562	[p26l1260t1662r1414b1709],
8	51	CD	NUMBER	51	number	9	SENT_562	[p26l1260t1662r1414b1709],
9	72	CD	NUMBER	72	num	6	SENT_562	[p26l1429t1663r1503b1717],
10	,	,	O	,	_	0	SENT_562	[p26l1429t1663r1503b1717],
11	a	DT	O	a	det	16	SENT_562	[p26l1517t1674r1543b1709],
12	novel	JJ	O	novel	amod	16	SENT_562	[p26l1561t1659r1700b1709],
13	HCV	NN	O	hcv	nn	16	SENT_562	[p26l1719t1661r1830b1709],
14	NS3/4a	NN	O	ns3/4a	nn	16	SENT_562	[p26l1845t1661r2029b1711],
15	protease	NN	O	protease	nn	16	SENT_562	[p26l131t1745r357b1800],
16	inhibitor	NN	O	inhibitor	appos	4	SENT_562	[p26l373t1737r598b1787],
17	with	IN	O	with	_	0	SENT_562	[p26l610t1737r723b1787],
18	potent	JJ	O	potent	amod	19	SENT_562	[p26l741t1745r917b1800],
19	activity	NN	O	activity	prep_with	16	SENT_562	[p26l930t1740r1122b1801],
20	against	IN	O	against	_	0	SENT_562	[p26l1134t1740r1325b1800],
21	known	VBN	O	know	amod	23	SENT_562	[p26l1341t1737r1517b1787],
22	resistance	NN	O	resistance	nn	23	SENT_562	[p26l1535t1740r1794b1787],
23	mutants	NNS	O	mutant	prep_against	19	SENT_562	[p26l1811t1745r2039b1795],
24	,	,	O	,	_	0	SENT_562	[p26l1811t1745r2039b1795],
25	in	IN	O	in	_	0	SENT_562	[p26l130t1818r173b1864],
26	genotype	NN	O	genotype	prep_in	4	SENT_562	[p26l190t1823r444b1879],
27	1	CD	NUMBER	1	num	26	SENT_562	[p26l463t1819r477b1864],
28	and	CC	O	and	_	0	SENT_562	[p26l502t1815r598b1865],
29	3	CD	NUMBER	3	num	33	SENT_562	[p26l616t1819r642b1865],
30	HCV	NN	O	hcv	nn	33	SENT_562	[p26l661t1815r1004b1865],
31	—	NN	O	—	nn	33	SENT_562	[p26l661t1815r1004b1865],
32	infected	JJ	O	infected	amod	33	SENT_562	[p26l661t1815r1004b1865],
33	patients	NNS	O	patient	prep_in	4	SENT_562	[p26l1023t1818r1246b1878],
34	.	.	O	.	_	0	SENT_562	[p26l1023t1818r1246b1878],

1	Presented	VBN	O	present	_	0	SENT_563	[p26l1263t1815r1521b1865],
2	at	IN	O	at	_	0	SENT_563	[p26l1537t1823r1586b1865],
3	the	DT	O	the	det	5	SENT_563	[p26l1598t1815r1684b1865],
4	61	CD	NUMBER	61	num	5	SENT_563	[p26l1698t1819r1750b1865],
5	st	NN	O	st	prep_at	1	SENT_563	[p26l1764t1823r1807b1865],
6	Annual	JJ	SET	annual	dobj	1	SENT_563	[p26l1820t1815r2005b1865],
7	Meeting	VBG	O	meet	partmod	6	SENT_563	[p26l130t1896r346b1956],
8	of	IN	O	of	_	0	SENT_563	[p26l362t1893r417b1943],
9	the	DT	O	the	det	11	SENT_563	[p26l425t1893r511b1943],
10	American	NNP	ORGANIZATION	American	nn	11	SENT_563	[p26l525t1896r775b1943],
11	Association	NNP	ORGANIZATION	Association	prep_of	7	SENT_563	[p26l791t1896r1090b1943],
12	for	IN	ORGANIZATION	for	_	0	SENT_563	[p26l1105t1893r1178b1943],
13	the	DT	ORGANIZATION	the	det	14	SENT_563	[p26l1190t1893r1276b1943],
14	Study	NN	ORGANIZATION	study	prep_for	11	SENT_563	[p26l1291t1893r1442b1957],
15	of	IN	ORGANIZATION	of	_	0	SENT_563	[p26l1455t1893r1509b1943],
16	Liver	NN	ORGANIZATION	liver	nn	17	SENT_563	[p26l1521t1896r1644b1943],
17	Disease	NN	ORGANIZATION	disease	prep_of	14	SENT_563	[p26l1660t1895r1868b1951],
18	,	,	O	,	_	0	SENT_563	[p26l1660t1895r1868b1951],
19	Boston	NNP	LOCATION	Boston	nn	21	SENT_563	[p26l1885t1895r2078b1951],
20	,	,	O	,	_	0	SENT_563	[p26l1885t1895r2078b1951],
21	Massachusetts	NNP	LOCATION	Massachusetts	appos	17	SENT_563	[p26l130t1970r525b2027],
22	,	,	O	,	_	0	SENT_563	[p26l130t1970r525b2027],
23	November	NNP	DATE	November	tmod	7	SENT_563	[p26l542t1970r819b2019],
24	2010	CD	DATE	2010	num	23	SENT_563	[p26l832t1973r972b2019],
25	.	.	O	.	_	0	SENT_563	[p26l832t1973r972b2019],

1	Manns	NNP	PERSON	Manns	_	0	SENT_564	[p26l129t2051r314b2106],
2	,	,	O	,	_	0	SENT_564	[p26l129t2051r314b2106],
3	M.	NNP	O	M.	nn	4	SENT_564	[p26l331t2051r390b2098],
4	etal	NNP	O	etal	appos	1	SENT_564	[p26l404t2048r519b2098],
5	.	.	O	.	_	0	SENT_564	[p26l404t2048r519b2098],

1	High	JJ	O	high	amod	4	SENT_565	[p26l536t2048r656b2111],
2	sustained	JJ	O	sustained	amod	4	SENT_565	[p26l673t2048r922b2098],
3	viral	JJ	O	viral	amod	4	SENT_565	[p26l938t2048r1045b2098],
4	response	NN	O	response	_	0	SENT_565	[p26l1063t2063r1299b2111],
5	at	IN	O	at	_	0	SENT_565	[p26l1313t2056r1362b2098],
6	12	CD	NUMBER	12	prep_at	4	SENT_565	[p26l1380t2051r1457b2097],
7	-	:	O	-	_	0	SENT_565	[p26l1380t2051r1457b2097],
8	and	CC	O	and	cc	9	SENT_565	[p26l1471t2048r1568b2098],
9	24	CD	NUMBER	24	num	14	SENT_565	[p26l1585t2048r2072b2111],
10	—	NN	O	—	nn	14	SENT_565	[p26l1585t2048r2072b2111],
11	weekfo	NN	O	weekfo	nn	14	SENT_565	[p26l1585t2048r2072b2111],
12	|	CD	NUMBER	|	num	14	SENT_565	[p26l1585t2048r2072b2111],
13	|	NN	O	|	nn	14	SENT_565	[p26l1585t2048r2072b2111],
14	ow	NN	O	ow	dep	4	SENT_565	[p26l1585t2048r2072b2111],
15	—	CD	NUMBER	—	npadvmod	16	SENT_565	[p26l1585t2048r2072b2111],
16	up	IN	O	up	advmod	14	SENT_565	[p26l1585t2048r2072b2111],
17	of	IN	O	of	_	0	SENT_565	[p26l2086t2048r2141b2098],
18	MK	NN	O	mk	prep_of	14	SENT_565	[p26l130t2129r359b2176],
19	—	CD	NUMBER	—	number	20	SENT_565	[p26l130t2129r359b2176],
20	5172	CD	NUMBER	5172	num	18	SENT_565	[p26l130t2129r359b2176],
21	with	IN	O	with	_	0	SENT_565	[p26l374t2126r488b2176],
22	pegylated	VBN	O	pegylate	prepc_with	14	SENT_565	[p26l506t2126r767b2190],
23	interferon	NN	O	interferon	dobj	22	SENT_565	[p26l785t2126r1043b2176],
24	a	DT	O	a	det	26	SENT_565	[p26l1059t2126r1239b2176],
25	|	NN	O	|	nn	26	SENT_565	[p26l1059t2126r1239b2176],
26	fa	NN	O	fa	dep	23	SENT_565	[p26l1059t2126r1239b2176],
27	—	CD	NUMBER	—	num	28	SENT_565	[p26l1059t2126r1239b2176],
28	2b	NN	O	2b	dep	33	SENT_565	[p26l1059t2126r1239b2176],
29	and	CC	O	and	_	0	SENT_565	[p26l1253t2126r1350b2176],
30	ribavirin	NNP	O	ribavirin	conj_and	28	SENT_565	[p26l1368t2126r1580b2176],
31	(	CD	NUMBER	(	num	32	SENT_565	[p26l1598t2127r1695b2184],
32	PR	NN	O	pr	dep	33	SENT_565	[p26l1598t2127r1695b2184],
33	)	NN	O	)	dep	39	SENT_565	[p26l1598t2127r1695b2184],
34	in	IN	O	in	_	0	SENT_565	[p26l1713t2129r1756b2175],
35	HCV	NNP	O	HCV	prep_in	33	SENT_565	[p26l1775t2128r1886b2176],
36	genotype	NN	O	genotype	nn	39	SENT_565	[p26l1898t2134r2153b2190],
37	1	CD	NUMBER	1	num	39	SENT_565	[p26l133t2208r147b2253],
38	treatment	NN	O	treatment	nn	39	SENT_565	[p26l171t2207r597b2254],
39	—	NN	O	—	dep	23	SENT_565	[p26l171t2207r597b2254],
40	naive	JJ	O	naive	amod	41	SENT_565	[p26l171t2207r597b2254],
41	non	JJ	O	non	amod	42	SENT_565	[p26l614t2204r955b2254],
42	—	NN	O	—	dep	39	SENT_565	[p26l614t2204r955b2254],
43	cirrhotic	JJ	O	cirrhotic	amod	44	SENT_565	[p26l614t2204r955b2254],
44	patient	NN	O	patient	dep	42	SENT_565	[p26l971t2207r1169b2267],
45	.	.	O	.	_	0	SENT_565	[p26l971t2207r1169b2267],

1	Presented	VBN	O	present	_	0	SENT_566	[p26l1186t2204r1444b2254],
2	at	IN	O	at	_	0	SENT_566	[p26l1460t2212r1509b2254],
3	the	DT	O	the	det	5	SENT_566	[p26l1522t2204r1608b2254],
4	48th	JJ	ORDINAL	48th	amod	5	SENT_566	[p26l1620t2204r1738b2254],
5	Annual	JJ	SET	annual	prep_at	1	SENT_566	[p26l1754t2204r1939b2254],
6	Meeting	VBG	O	meet	partmod	5	SENT_566	[p26l130t2285r346b2345],
7	of	IN	O	of	_	0	SENT_566	[p26l362t2282r417b2332],
8	the	DT	O	the	det	10	SENT_566	[p26l425t2282r511b2332],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_566	[p26l528t2285r776b2345],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_566	[p26l792t2285r1091b2332],
11	for	IN	O	for	_	0	SENT_566	[p26l1106t2282r1179b2332],
12	the	DT	O	the	det	13	SENT_566	[p26l1191t2282r1277b2332],
13	Study	NN	O	study	prep_for	10	SENT_566	[p26l1291t2282r1443b2346],
14	of	IN	O	of	_	0	SENT_566	[p26l1455t2282r1510b2332],
15	the	DT	O	the	det	16	SENT_566	[p26l1518t2282r1604b2332],
16	Liver	NN	O	liver	prep_of	13	SENT_566	[p26l1621t2285r1752b2340],
17	,	,	O	,	_	0	SENT_566	[p26l1621t2285r1752b2340],
18	Amsterdam	NNP	LOCATION	Amsterdam	appos	16	SENT_566	[p26l1766t2282r2086b2340],
19	,	,	O	,	_	0	SENT_566	[p26l1766t2282r2086b2340],
20	The	DT	LOCATION	the	det	21	SENT_566	[p26l126t2360r224b2410],
21	Netherlands	NNP	LOCATION	Netherlands	appos	16	SENT_566	[p26l241t2360r573b2418],
22	,	,	O	,	_	0	SENT_566	[p26l241t2360r573b2418],
23	24-28	CD	DATE	24-28	appos	16	SENT_566	[p26l588t2363r746b2410],
24	April	NNP	DATE	April	tmod	6	SENT_566	[p26l760t2360r881b2423],
25	2013	CD	DATE	2013	num	24	SENT_566	[p26l898t2360r1200b2410],
26	.	.	O	.	_	0	SENT_566	[p26l898t2360r1200b2410],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_567	[p26l898t2360r1200b2410],
2	.	.	O	.	_	0	SENT_567	[p26l898t2360r1200b2410],

1	66	CD	NUMBER	66	_	0	SENT_568	[p26l1215t2364r1290b2410],
2	.	.	O	.	_	0	SENT_568	[p26l1215t2364r1290b2410],

1	Evans	NNP	PERSON	Evans	nsubj	20	SENT_569	[p26l130t2441r288b2496],
2	,	,	O	,	_	0	SENT_569	[p26l130t2441r288b2496],
3	M.J.	NNP	LOCATION	M.J.	conj_and	1	SENT_569	[p26l304t2441r413b2496],
4	,	,	O	,	_	0	SENT_569	[p26l304t2441r413b2496],
5	Rice	NNP	PERSON	Rice	conj_and	1	SENT_569	[p26l430t2440r545b2496],
6	,	,	O	,	_	0	SENT_569	[p26l430t2440r545b2496],
7	C.M.	NNP	ORGANIZATION	C.M.	conj_and	1	SENT_569	[p26l560t2440r671b2488],
8	&	CC	ORGANIZATION	&	_	0	SENT_569	[p26l685t2440r722b2488],
9	Goff	NNP	ORGANIZATION	Goff	conj_and	1	SENT_569	[p26l735t2438r856b2496],
10	,	,	O	,	_	0	SENT_569	[p26l735t2438r856b2496],
11	S.P.	NNP	O	S.P.	nn	12	SENT_569	[p26l871t2440r949b2488],
12	Phosphorylation	NN	O	phosphorylation	appos	1	SENT_569	[p26l966t2438r1398b2502],
13	of	IN	O	of	_	0	SENT_569	[p26l1415t2438r1469b2488],
14	hepatitis	NN	O	hepatitis	nn	16	SENT_569	[p26l1481t2438r1706b2501],
15	C	NN	O	c	nn	16	SENT_569	[p26l1721t2440r1754b2488],
16	virus	NN	O	virus	nn	19	SENT_569	[p26l1767t2441r1891b2488],
17	nonstructural	JJ	O	nonstructural	amod	19	SENT_569	[p26l131t2516r483b2566],
18	protein	NN	O	protein	nn	19	SENT_569	[p26l501t2519r688b2579],
19	5A	NN	O	5a	prep_of	12	SENT_569	[p26l705t2519r773b2566],
20	modulates	VBZ	O	modulate	_	0	SENT_569	[p26l789t2516r1066b2566],
21	its	PRP$	O	its	poss	23	SENT_569	[p26l1083t2519r1138b2566],
22	protein	NN	O	protein	nn	23	SENT_569	[p26l1155t2519r1341b2579],
23	interactions	NNS	O	interaction	dobj	20	SENT_569	[p26l1359t2519r1668b2566],
24	and	CC	O	and	_	0	SENT_569	[p26l1683t2516r1780b2566],
25	viral	JJ	O	viral	amod	27	SENT_569	[p26l1795t2516r1901b2566],
26	RNA	NN	O	rna	nn	27	SENT_569	[p26l1921t2518r2031b2566],
27	replication	NN	O	replication	dobj	20	SENT_569	[p26l131t2594r421b2657],
28	.	.	O	.	_	0	SENT_569	[p26l131t2594r421b2657],

1	Proc	NNP	O	Proc	_	0	SENT_570	[p26l435t2596r555b2644],
2	.	.	O	.	_	0	SENT_570	[p26l435t2596r555b2644],

1	Natl.	NNP	O	Natl.	nn	2	SENT_571	[p26l569t2594r684b2644],
2	Acad	NNP	O	Acad	_	0	SENT_571	[p26l695t2594r834b2644],
3	.	.	O	.	_	0	SENT_571	[p26l695t2594r834b2644],

1	Sci	NNP	O	Sci	_	0	SENT_572	[p26l848t2596r928b2644],
2	.	.	O	.	_	0	SENT_572	[p26l848t2596r928b2644],

1	U.S.A.	NNP	O	U.S.A.	_	0	SENT_573	[p26l946t2596r1086b2644],
2	101	CD	NUMBER	101	num	1	SENT_573	[p26l1104t2598r1216b2652],
3	,	,	O	,	_	0	SENT_573	[p26l1104t2598r1216b2652],
4	13038-13043	CD	NUMBER	13038-13043	num	1	SENT_573	[p26l1235t2598r1585b2644],
5	(	CD	NUMBER	(	num	7	SENT_573	[p26l1603t2595r1777b2652],
6	2004	CD	DATE	2004	num	7	SENT_573	[p26l1603t2595r1777b2652],
7	)	NN	O	)	dep	1	SENT_573	[p26l1603t2595r1777b2652],
8	.	.	O	.	_	0	SENT_573	[p26l1603t2595r1777b2652],

1	Te	FW	O	te	_	0	SENT_574	[p26l128t2672r598b2735],
2	|	FW	O	|	nn	4	SENT_574	[p26l128t2672r598b2735],
3	|	FW	O	|	nn	4	SENT_574	[p26l128t2672r598b2735],
4	inghuisen	NN	O	inghuisen	dep	1	SENT_574	[p26l128t2672r598b2735],
5	,	,	O	,	_	0	SENT_574	[p26l128t2672r598b2735],
6	T.L.	NNP	PERSON	T.L.	appos	4	SENT_574	[p26l128t2672r598b2735],
7	,	,	O	,	_	0	SENT_574	[p26l128t2672r598b2735],
8	Foss	NNP	PERSON	Foss	conj_and	6	SENT_574	[p26l614t2675r735b2730],
9	,	,	O	,	_	0	SENT_574	[p26l614t2675r735b2730],
10	K.L.	NNP	ORGANIZATION	K.L.	conj_and	6	SENT_574	[p26l752t2675r838b2722],
11	&	CC	ORGANIZATION	&	_	0	SENT_574	[p26l852t2672r1190b2736],
12	Treadaway	NNP	ORGANIZATION	Treadaway	conj_and	6	SENT_574	[p26l852t2672r1190b2736],
13	,	,	O	,	_	0	SENT_574	[p26l852t2672r1190b2736],
14	J.	NNP	O	J.	nn	15	SENT_574	[p26l1202t2675r1236b2722],
15	Regulation	NNP	O	Regulation	appos	4	SENT_574	[p26l1253t2672r1534b2735],
16	of	IN	O	of	_	0	SENT_574	[p26l1551t2672r1605b2722],
17	hepatitis	NNP	O	hepatitis	nn	20	SENT_574	[p26l1617t2672r1841b2735],
18	C	NNP	O	C	nn	20	SENT_574	[p26l1856t2674r1889b2722],
19	virion	NN	O	virion	nn	20	SENT_574	[p26l1903t2675r2050b2722],
20	production	NN	O	production	prep_of	15	SENT_574	[p26l134t2750r425b2813],
21	via	IN	O	via	_	0	SENT_574	[p26l440t2753r512b2800],
22	phosphorylation	NN	O	phosphorylation	prep_via	20	SENT_574	[p26l530t2750r965b2814],
23	of	IN	O	of	_	0	SENT_574	[p26l981t2750r1036b2800],
24	the	DT	O	the	det	26	SENT_574	[p26l1044t2750r1130b2800],
25	NS5A	NN	O	ns5a	nn	26	SENT_574	[p26l1147t2752r1287b2800],
26	protein	NN	O	protein	prep_of	4	SENT_574	[p26l1303t2753r1504b2813],
27	.	.	O	.	_	0	SENT_574	[p26l1303t2753r1504b2813],

1	PLoS	NN	O	plo	_	0	SENT_575	[p26l1518t2752r1638b2800],
2	Pathog	NN	O	pathog	dep	1	SENT_575	[p26l1649t2750r1843b2814],
3	.	.	O	.	_	0	SENT_575	[p26l1649t2750r1843b2814],

1	4	CD	NUMBER	4	_	0	SENT_576	[p26l1857t2754r1903b2808],
2	,	,	O	,	_	0	SENT_576	[p26l1857t2754r1903b2808],
3	e1000032	NN	O	e1000032	appos	1	SENT_576	[p26l132t2831r388b2877],
4	(	CD	NUMBER	(	num	3	SENT_576	[p26l405t2828r580b2884],
5	2008	CD	DATE	2008	num	6	SENT_576	[p26l405t2828r580b2884],
6	)	NN	O	)	dep	3	SENT_576	[p26l405t2828r580b2884],
7	.	.	O	.	_	0	SENT_576	[p26l405t2828r580b2884],

1	Gao	NNP	O	Gao	_	0	SENT_577	[p26l131t2907r246b2963],
2	,	,	O	,	_	0	SENT_577	[p26l131t2907r246b2963],
3	M.	NNP	O	M.	nn	4	SENT_577	[p26l262t2908r321b2955],
4	etal	NNP	O	etal	appos	1	SENT_577	[p26l335t2905r450b2955],
5	.	.	O	.	_	0	SENT_577	[p26l335t2905r450b2955],

1	Chemical	NNP	O	Chemical	nn	3	SENT_578	[p26l465t2905r705b2955],
2	genetics	NNS	O	genetics	nn	3	SENT_578	[p26l722t2908r942b2969],
3	strategy	NN	O	strategy	nsubj	4	SENT_578	[p26l957t2913r1170b2969],
4	identiﬁes	VBZ	O	identiﬁes	_	0	SENT_578	[p26l1185t2905r1423b2955],
5	an	DT	O	a	det	8	SENT_578	[p26l1438t2920r1498b2955],
6	HCV	NN	O	hcv	nn	8	SENT_578	[p26l1517t2907r1628b2955],
7	NS5A	NN	O	ns5a	nn	8	SENT_578	[p26l1643t2907r1783b2955],
8	inhibitor	NN	O	inhibitor	dobj	4	SENT_578	[p26l1798t2905r2022b2955],
9	with	IN	O	with	_	0	SENT_578	[p26l2034t2905r2147b2955],
10	a	DT	O	a	det	13	SENT_578	[p26l132t2998r157b3033],
11	potent	JJ	O	potent	amod	13	SENT_578	[p26l176t2991r350b3046],
12	clinical	JJ	O	clinical	amod	13	SENT_578	[p26l364t2983r540b3033],
13	effect	NN	O	effect	prep_with	4	SENT_578	[p26l558t2983r717b3033],
14	.	.	O	.	_	0	SENT_578	[p26l558t2983r717b3033],

1	Nature	NNP	O	Nature	_	0	SENT_579	[p26l731t2986r905b3033],
2	465	CD	NUMBER	465	num	1	SENT_579	[p26l917t2987r1033b3041],
3	,	,	O	,	_	0	SENT_579	[p26l917t2987r1033b3041],
4	96-100	CD	NUMBER	96-100	num	1	SENT_579	[p26l1048t2987r1239b3033],
5	(	CD	NUMBER	(	num	7	SENT_579	[p26l1256t2984r1430b3041],
6	2010	CD	DATE	2010	num	7	SENT_579	[p26l1256t2984r1430b3041],
7	)	NN	O	)	dep	1	SENT_579	[p26l1256t2984r1430b3041],
8	.	.	O	.	_	0	SENT_579	[p26l1256t2984r1430b3041],

1	Pol	NN	O	pol	_	0	SENT_580	[p26l133t3061r221b3119],
2	,	,	O	,	_	0	SENT_580	[p26l133t3061r221b3119],
3	S.	NNP	O	S.	nn	4	SENT_580	[p26l236t3063r276b3111],
4	etal	NNP	O	etal	appos	1	SENT_580	[p26l291t3061r406b3111],
5	.	.	O	.	_	0	SENT_580	[p26l291t3061r406b3111],

1	Daclatasvirfor	NNP	PERSON	Daclatasvirfor	nsubj	8	SENT_581	[p26l423t3061r792b3111],
2	previously	RB	DATE	previously	advmod	3	SENT_581	[p26l807t3061r1077b3125],
3	untreated	JJ	O	untreated	amod	1	SENT_581	[p26l1092t3061r1347b3111],
4	chronic	JJ	O	chronic	amod	8	SENT_581	[p26l1363t3061r1557b3111],
5	hepatitis	NN	O	hepatitis	nn	8	SENT_581	[p26l1574t3061r1798b3124],
6	C	NN	O	c	nn	8	SENT_581	[p26l1813t3063r1846b3111],
7	genotype	NN	O	genotype	nn	8	SENT_581	[p26l132t3143r430b3203],
8	—	NN	O	—	_	0	SENT_581	[p26l132t3143r430b3203],
9	1	CD	NUMBER	1	num	10	SENT_581	[p26l132t3143r430b3203],
10	infection	NN	O	infection	dep	8	SENT_581	[p26l456t3139r699b3189],
11	:	:	O	:	_	0	SENT_581	[p26l456t3139r699b3189],
12	a	DT	O	a	dep	8	SENT_581	[p26l714t3154r739b3189],
13	randomised	VBN	O	randomise	partmod	12	SENT_581	[p26l757t3139r1083b3197],
14	,	,	O	,	_	0	SENT_581	[p26l757t3139r1083b3197],
15	para	NN	O	para	nn	17	SENT_581	[p26l1099t3139r1482b3203],
16	|	CD	NUMBER	|	num	15	SENT_581	[p26l1099t3139r1482b3203],
17	|	NN	O	|	dobj	8	SENT_581	[p26l1099t3139r1482b3203],
18	e	SYM	O	e	dep	19	SENT_581	[p26l1099t3139r1482b3203],
19	|	CD	NUMBER	|	dep	17	SENT_581	[p26l1099t3139r1482b3203],
20	.	.	O	.	_	0	SENT_581	[p26l1099t3139r1482b3203],

1	—	NN	O	—	_	0	SENT_582	[p26l1099t3139r1482b3203],
2	.	.	O	.	_	0	SENT_582	[p26l1099t3139r1482b3203],

1	group	NN	O	group	_	0	SENT_583	[p26l1099t3139r1482b3203],
2	,	,	O	,	_	0	SENT_583	[p26l1099t3139r1482b3203],
3	doub	NN	O	doub	nn	4	SENT_583	[p26l1497t3139r1853b3197],
4	|	NN	O	|	appos	1	SENT_583	[p26l1497t3139r1853b3197],
5	e	SYM	O	e	dep	7	SENT_583	[p26l1497t3139r1853b3197],
6	—	CD	NUMBER	—	num	7	SENT_583	[p26l1497t3139r1853b3197],
7	b	NN	O	b	dep	9	SENT_583	[p26l1497t3139r1853b3197],
8	|	CD	NUMBER	|	num	9	SENT_583	[p26l1497t3139r1853b3197],
9	ind	NN	O	ind	dep	1	SENT_583	[p26l1497t3139r1853b3197],
10	,	,	O	,	_	0	SENT_583	[p26l1497t3139r1853b3197],
11	placebocontrolled	JJ	O	placebocontrolled	appos	9	SENT_583	[p26l1869t3139r2098b3202, p26l132t3217r413b3275],
12	,	,	O	,	_	0	SENT_583	[p26l1869t3139r2098b3202, p26l132t3217r413b3275],
13	dose	NN	O	dose	nn	15	SENT_583	[p26l427t3217r776b3281],
14	—	NN	O	—	nn	15	SENT_583	[p26l427t3217r776b3281],
15	ﬁnding	NN	O	ﬁnding	appos	9	SENT_583	[p26l427t3217r776b3281],
16	,	,	O	,	_	0	SENT_583	[p26l427t3217r776b3281],
17	phase	NN	O	phase	nn	19	SENT_583	[p26l792t3217r946b3280],
18	2a	NN	O	2a	nn	19	SENT_583	[p26l961t3221r1019b3267],
19	trial	NN	O	trial	appos	9	SENT_583	[p26l1033t3217r1145b3267],
20	.	.	O	.	_	0	SENT_583	[p26l1033t3217r1145b3267],

1	Lancetlnfect	NNP	O	Lancetlnfect	_	0	SENT_584	[p26l1160t3217r1490b3267],
2	.	.	O	.	_	0	SENT_584	[p26l1160t3217r1490b3267],

1	Dis	NNP	O	Dis	_	0	SENT_585	[p26l1504t3219r1594b3267],
2	.	.	O	.	_	0	SENT_585	[p26l1504t3219r1594b3267],

1	12	CD	NUMBER	12	_	0	SENT_586	[p26l1611t3221r1688b3275],
2	,	,	O	,	_	0	SENT_586	[p26l1611t3221r1688b3275],
3	671-677	CD	NUMBER	671-677	number	4	SENT_586	[p26l1702t3221r1926b3267],
4	(	CD	NUMBER	(	appos	1	SENT_586	[p26l1943t3218r2117b3275],
5	2012	CD	DATE	2012	num	6	SENT_586	[p26l1943t3218r2117b3275],
6	)	NN	O	)	dep	4	SENT_586	[p26l1943t3218r2117b3275],
7	.	.	O	.	_	0	SENT_586	[p26l1943t3218r2117b3275],

1	Hezode	NNP	O	Hezode	_	0	SENT_587	[p26l133t3295r342b3353],
2	,	,	O	,	_	0	SENT_587	[p26l133t3295r342b3353],
3	C.	NNP	O	C.	nn	4	SENT_587	[p26l357t3297r403b3345],
4	etal	NNP	O	etal	appos	1	SENT_587	[p26l417t3295r532b3345],
5	.	.	O	.	_	0	SENT_587	[p26l417t3295r532b3345],

1	BMS	NNP	O	BMS	nsubj	25	SENT_588	[p26l549t3297r890b3353],
2	—	CD	NUMBER	—	number	3	SENT_588	[p26l549t3297r890b3353],
3	790052	CD	NUMBER	790052	dep	1	SENT_588	[p26l549t3297r890b3353],
4	,	,	O	,	_	0	SENT_588	[p26l549t3297r890b3353],
5	a	DT	O	a	det	9	SENT_588	[p26l904t3310r929b3345],
6	NS5A	NN	O	ns5a	nn	9	SENT_588	[p26l948t3297r1088b3345],
7	replication	NN	O	replication	nn	9	SENT_588	[p26l1103t3295r1379b3358],
8	complex	NN	O	complex	nn	9	SENT_588	[p26l1395t3295r1622b3358],
9	inhibitor	NN	O	inhibitor	appos	1	SENT_588	[p26l1637t3295r1869b3353],
10	,	,	O	,	_	0	SENT_588	[p26l1637t3295r1869b3353],
11	combined	VBN	O	combine	partmod	1	SENT_588	[p26l1883t3295r2148b3345],
12	with	IN	O	with	_	0	SENT_588	[p26l131t3373r245b3423],
13	peginterferon	NN	O	peginterferon	prep_with	11	SENT_588	[p26l263t3373r624b3437],
14	a	DT	O	a	det	18	SENT_588	[p26l640t3373r813b3423],
15	|	NN	O	|	nn	18	SENT_588	[p26l640t3373r813b3423],
16	fa	NN	O	fa	nn	18	SENT_588	[p26l640t3373r813b3423],
17	—	CD	NUMBER	—	num	18	SENT_588	[p26l640t3373r813b3423],
18	2a	NN	O	2a	dep	13	SENT_588	[p26l640t3373r813b3423],
19	and	CC	O	and	_	0	SENT_588	[p26l829t3373r925b3423],
20	ribavirin	NNP	O	ribavirin	prep_with	11	SENT_588	[p26l944t3373r1155b3423],
21	in	IN	O	in	_	0	SENT_588	[p26l1173t3376r1215b3423],
22	treatment	NN	O	treatment	prep_in	20	SENT_588	[p26l1231t3376r1657b3423],
23	—	CD	NUMBER	—	num	24	SENT_588	[p26l1231t3376r1657b3423],
24	nai	NNS	O	naus	dep	1	SENT_588	[p26l1231t3376r1657b3423],
25	've	VBP	O	have	_	0	SENT_588	[p26l1231t3376r1657b3423],
26	HCV	NN	O	hcv	nn	27	SENT_588	[p26l1673t3375r1785b3423],
27	genotype	NN	O	genotype	dobj	25	SENT_588	[p26l1797t3381r2051b3437],
28	1	CD	NUMBER	1	num	31	SENT_588	[p26l2070t3377r2084b3422],
29	or	CC	O	or	_	0	SENT_588	[p26l132t3466r186b3501],
30	4	CD	NUMBER	4	conj_or	28	SENT_588	[p26l197t3455r228b3500],
31	patients	NNS	O	patient	dep	27	SENT_588	[p26l244t3454r467b3514],
32	:	:	O	:	_	0	SENT_588	[p26l244t3454r467b3514],
33	phase	NN	O	phase	nn	35	SENT_588	[p26l484t3451r637b3514],
34	2b	NN	O	2b	nn	35	SENT_588	[p26l652t3451r717b3501],
35	A	NN	O	a	dep	27	SENT_588	[p26l731t3454r978b3501],
36	|	CD	NUMBER	|	number	37	SENT_588	[p26l731t3454r978b3501],
37	444010	CD	NUMBER	444010	num	38	SENT_588	[p26l731t3454r978b3501],
38	study	NN	O	study	dep	35	SENT_588	[p26l993t3451r1138b3515],
39	interim	JJ	O	interim	amod	40	SENT_588	[p26l1152t3454r1336b3501],
40	week	NN	DURATION	week	tmod	35	SENT_588	[p26l1352t3451r1492b3501],
41	12	CD	NUMBER	12	num	42	SENT_588	[p26l1508t3455r1564b3500],
42	results	NNS	O	result	dep	35	SENT_588	[p26l1582t3451r1762b3501],
43	.	.	O	.	_	0	SENT_588	[p26l1582t3451r1762b3501],

1	Hepatology	NNP	O	Hepatology	_	0	SENT_589	[p26l1776t3451r2074b3515],
2	54,115	CD	NUMBER	54,115	number	3	SENT_589	[p26l132t3529r511b3585],
3	(	CD	NUMBER	(	dep	1	SENT_589	[p26l132t3529r511b3585],
4	2011	CD	DATE	2011	num	5	SENT_589	[p26l132t3529r511b3585],
5	)	NN	O	)	dep	3	SENT_589	[p26l132t3529r511b3585],
6	.	.	O	.	_	0	SENT_589	[p26l132t3529r511b3585],

1	Lawitz	NNP	PERSON	Lawitz	nn	3	SENT_590	[p27l133t20r310b75],
2	,	,	O	,	_	0	SENT_590	[p27l133t20r310b75],
3	E.J.	NNP	O	E.J.	dep	4	SENT_590	[p27l327t20r401b67],
4	etal	JJ	O	etal	_	0	SENT_590	[p27l415t17r530b67],
5	.	.	O	.	_	0	SENT_590	[p27l415t17r530b67],

1	A	DT	O	a	det	2	SENT_591	[p27l544t20r580b66],
2	phase	NN	O	phase	dep	9	SENT_591	[p27l596t17r750b80],
3	1	CD	NUMBER	1	num	2	SENT_591	[p27l769t21r806b75],
4	,	,	O	,	_	0	SENT_591	[p27l769t21r806b75],
5	randomized	VBN	O	randomize	partmod	2	SENT_591	[p27l823t17r1150b75],
6	,	,	O	,	_	0	SENT_591	[p27l823t17r1150b75],
7	placebo	NN	O	placebo	nn	8	SENT_591	[p27l1166t17r1680b80],
8	—	NN	O	—	nsubj	9	SENT_591	[p27l1166t17r1680b80],
9	controlled	VBN	O	control	_	0	SENT_591	[p27l1166t17r1680b80],
10	,	,	O	,	_	0	SENT_591	[p27l1166t17r1680b80],
11	3-day	JJ	DURATION	3-day	amod	14	SENT_591	[p27l1695t17r1851b81],
12	,	,	O	,	_	0	SENT_591	[p27l1695t17r1851b81],
13	doseranging	JJ	O	doseranging	amod	14	SENT_591	[p27l1865t17r2011b67, p27l134t98r334b159],
14	study	NN	O	study	dep	18	SENT_591	[p27l351t95r495b159],
15	of	IN	O	of	_	0	SENT_591	[p27l509t95r563b145],
16	GS	NN	O	g	prep_of	14	SENT_591	[p27l572t97r805b153],
17	—	CD	NUMBER	—	dep	18	SENT_591	[p27l572t97r805b153],
18	5885	CD	NUMBER	5885	dep	31	SENT_591	[p27l572t97r805b153],
19	,	,	O	,	_	0	SENT_591	[p27l572t97r805b153],
20	an	DT	O	a	det	22	SENT_591	[p27l820t110r880b145],
21	NS5A	NN	O	ns5a	nn	22	SENT_591	[p27l899t97r1039b145],
22	inhibitor	NN	O	inhibitor	appos	18	SENT_591	[p27l1054t95r1286b153],
23	,	,	O	,	_	0	SENT_591	[p27l1054t95r1286b153],
24	in	IN	O	in	_	0	SENT_591	[p27l1302t98r1345b144],
25	patients	NNS	O	patient	prep_in	18	SENT_591	[p27l1363t98r1573b158],
26	with	IN	O	with	_	0	SENT_591	[p27l1587t95r1700b145],
27	genotype	NN	O	genotype	nn	29	SENT_591	[p27l1717t103r1971b159],
28	1	CD	NUMBER	1	num	29	SENT_591	[p27l1990t99r2004b145],
29	hepatitis	NN	O	hepatitis	prep_with	25	SENT_591	[p27l134t173r359b236],
30	C.J.	NNP	PERSON	C.J.	nn	31	SENT_591	[p27l373t175r464b223],
31	Hepatol	NNP	PERSON	Hepatol	dep	9	SENT_591	[p27l479t173r692b236],
32	.	.	O	.	_	0	SENT_591	[p27l479t173r692b236],

1	57	CD	NUMBER	57	_	0	SENT_592	[p27l707t177r786b231],
2	,	,	O	,	_	0	SENT_592	[p27l707t177r786b231],
3	24-31	CD	NUMBER	24-31	number	4	SENT_592	[p27l801t177r950b223],
4	(	CD	NUMBER	(	appos	1	SENT_592	[p27l976t174r1150b231],
5	2012	CD	DATE	2012	num	6	SENT_592	[p27l976t174r1150b231],
6	)	NN	O	)	dep	4	SENT_592	[p27l976t174r1150b231],
7	.	.	O	.	_	0	SENT_592	[p27l976t174r1150b231],

1	Bourliere	NNP	O	Bourliere	_	0	SENT_593	[p27l133t251r379b309],
2	,	,	O	,	_	0	SENT_593	[p27l133t251r379b309],
3	M.	NNP	O	M.	nn	4	SENT_593	[p27l394t254r454b301],
4	etal	NNP	O	etal	appos	1	SENT_593	[p27l468t251r583b301],
5	.	.	O	.	_	0	SENT_593	[p27l468t251r583b301],

1	Chronic	JJ	O	chronic	amod	3	SENT_594	[p27l597t251r800b301],
2	hepatitis	NN	O	hepatitis	nn	3	SENT_594	[p27l816t251r1041b314],
3	C	NN	O	c	_	0	SENT_594	[p27l1056t253r1102b301],
4	:	:	O	:	_	0	SENT_594	[p27l1056t253r1102b301],
5	treatments	NNS	O	treatment	dep	3	SENT_594	[p27l1115t259r1404b301],
6	of	IN	O	of	_	0	SENT_594	[p27l1418t251r1473b301],
7	the	DT	DATE	the	det	8	SENT_594	[p27l1481t251r1567b301],
8	future	NN	DATE	future	prep_of	5	SENT_594	[p27l1580t251r1752b301],
9	.	.	O	.	_	0	SENT_594	[p27l1580t251r1752b301],

1	Clin	NNP	O	Clin	_	0	SENT_595	[p27l1767t251r1872b301],
2	.	.	O	.	_	0	SENT_595	[p27l1767t251r1872b301],

1	Res	NNP	O	Res	_	0	SENT_596	[p27l1887t254r1980b301],
2	.	.	O	.	_	0	SENT_596	[p27l1887t254r1980b301],

1	Hepatol	NNP	O	Hepatol	_	0	SENT_597	[p27l132t329r341b392],
2	.	.	O	.	_	0	SENT_597	[p27l132t329r341b392],

1	Gastroenterol	NNP	PERSON	Gastroenterol	_	0	SENT_598	[p27l357t329r715b379],
2	.	.	O	.	_	0	SENT_598	[p27l357t329r715b379],

1	35	CD	NUMBER	35	num	2	SENT_599	[p27l730t333r795b379],
2	(	CD	NUMBER	(	_	0	SENT_599	[p27l812t329r985b392],
3	suppl	NN	O	suppl	dep	2	SENT_599	[p27l812t329r985b392],
4	.	.	O	.	_	0	SENT_599	[p27l812t329r985b392],

1	2	CD	NUMBER	2	num	2	SENT_600	[p27l1000t330r1060b387],
2	)	CD	NUMBER	)	_	0	SENT_600	[p27l1000t330r1060b387],
3	,	,	O	,	_	0	SENT_600	[p27l1000t330r1060b387],
4	584-595	CD	NUMBER	584-595	num	5	SENT_600	[p27l1074t331r1294b379],
5	(	NN	O	(	appos	2	SENT_600	[p27l1312t330r1413b387],
6	201	CD	NUMBER	201	number	7	SENT_600	[p27l1312t330r1413b387],
7	1	CD	NUMBER	1	num	8	SENT_600	[p27l1431t330r1486b387],
8	)	NN	O	)	dep	5	SENT_600	[p27l1431t330r1486b387],
9	.	.	O	.	_	0	SENT_600	[p27l1431t330r1486b387],

1	Lam	NNP	PERSON	Lam	_	0	SENT_601	[p27l133t410r254b465],
2	,	,	O	,	_	0	SENT_601	[p27l133t410r254b465],
3	A.M.	NNP	O	A.M.	nn	4	SENT_601	[p27l268t410r381b457],
4	etal	NN	O	etal	appos	1	SENT_601	[p27l395t407r510b457],
5	.	.	O	.	_	0	SENT_601	[p27l395t407r510b457],

1	PS	NNP	O	PS	nn	2	SENT_602	[p27l527t409r717b457],
2	|	NNP	O	|	_	0	SENT_602	[p27l527t409r717b457],
3	.	.	O	.	_	0	SENT_602	[p27l527t409r717b457],

1	—	NN	O	—	_	0	SENT_603	[p27l527t409r717b457],
2	.	.	O	.	_	0	SENT_603	[p27l527t409r717b457],

1	785	CD	NUMBER	785	num	2	SENT_604	[p27l527t409r717b457],
2	1	CD	NUMBER	1	_	0	SENT_604	[p27l727t411r742b456],
3	,	,	O	,	_	0	SENT_604	[p27l754t447r765b465],
4	a	DT	O	a	det	6	SENT_604	[p27l779t422r804b457],
5	pron	NN	O	pron	nn	6	SENT_604	[p27l823t422r941b470],
6	ucleotide	NN	O	ucleotide	appos	2	SENT_604	[p27l950t407r1193b457],
7	of	IN	O	of	_	0	SENT_604	[p27l1208t407r1262b457],
8	beta	NN	O	beta	prep_of	6	SENT_604	[p27l1273t407r2086b471],
9	.	.	O	.	_	0	SENT_604	[p27l1273t407r2086b471],

1	—	NN	O	—	_	0	SENT_605	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_605	[p27l1273t407r2086b471],

1	D	NN	O	d	_	0	SENT_606	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_606	[p27l1273t407r2086b471],

1	—	NN	O	—	_	0	SENT_607	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_607	[p27l1273t407r2086b471],

1	2	CD	NUMBER	2	num	2	SENT_608	[p27l1273t407r2086b471],
2	’	CD	NUMBER	’	_	0	SENT_608	[p27l1273t407r2086b471],
3	.	.	O	.	_	0	SENT_608	[p27l1273t407r2086b471],

1	—	NN	O	—	_	0	SENT_609	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_609	[p27l1273t407r2086b471],

1	deoxy	NN	O	deoxy	_	0	SENT_610	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_610	[p27l1273t407r2086b471],

1	—	NN	O	—	_	0	SENT_611	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_611	[p27l1273t407r2086b471],

1	2	CD	NUMBER	2	num	2	SENT_612	[p27l1273t407r2086b471],
2	’	CD	NUMBER	’	_	0	SENT_612	[p27l1273t407r2086b471],
3	.	.	O	.	_	0	SENT_612	[p27l1273t407r2086b471],

1	—	NN	O	—	_	0	SENT_613	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_613	[p27l1273t407r2086b471],

1	ﬂuoro	NN	O	ﬂuoro	_	0	SENT_614	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_614	[p27l1273t407r2086b471],

1	—	NN	O	—	_	0	SENT_615	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_615	[p27l1273t407r2086b471],

1	2	CD	NUMBER	2	num	2	SENT_616	[p27l1273t407r2086b471],
2	’	CD	NUMBER	’	_	0	SENT_616	[p27l1273t407r2086b471],
3	.	.	O	.	_	0	SENT_616	[p27l1273t407r2086b471],

1	—	NN	O	—	_	0	SENT_617	[p27l1273t407r2086b471],
2	.	.	O	.	_	0	SENT_617	[p27l1273t407r2086b471],

1	C	NN	O	c	nn	3	SENT_618	[p27l1273t407r2086b471],
2	methyluridine	NN	O	methyluridine	nn	3	SENT_618	[p27l134t485r503b549],
3	monophosphate	NN	O	monophosphate	nsubj	17	SENT_618	[p27l519t485r972b548],
4	,	,	O	,	_	0	SENT_618	[p27l519t485r972b548],
5	is	VBZ	O	be	cop	17	SENT_618	[p27l988t488r1022b535],
6	a	DT	O	a	det	17	SENT_618	[p27l1037t500r1062b535],
7	potent	JJ	O	potent	amod	17	SENT_618	[p27l1080t493r1255b548],
8	and	CC	O	and	_	0	SENT_618	[p27l1268t485r1365b535],
9	pan	NN	O	pan	nn	12	SENT_618	[p27l1384t493r1759b549],
10	—	CD	NUMBER	—	num	12	SENT_618	[p27l1384t493r1759b549],
11	genotype	NN	O	genotype	nn	12	SENT_618	[p27l1384t493r1759b549],
12	inhibitor	NN	O	inhibitor	amod	17	SENT_618	[p27l1775t485r1999b535],
13	of	IN	O	of	_	0	SENT_618	[p27l2012t485r2066b535],
14	hepatitis	NN	O	hepatitis	nn	15	SENT_618	[p27l134t563r359b626],
15	C	NN	O	c	prep_of	12	SENT_618	[p27l373t565r407b613],
16	virus	NN	O	virus	nn	17	SENT_618	[p27l420t566r543b613],
17	replication	NN	O	replication	_	0	SENT_618	[p27l560t563r851b626],
18	.	.	O	.	_	0	SENT_618	[p27l560t563r851b626],

1	Antimicrob	NNP	PERSON	Antimicrob	_	0	SENT_619	[p27l861t563r1156b613],
2	.	.	O	.	_	0	SENT_619	[p27l861t563r1156b613],

1	Agents	NNS	O	agent	_	0	SENT_620	[p27l1167t566r1344b627],
2	Chemother	NNP	O	Chemother	dep	1	SENT_620	[p27l1357t563r1651b613],
3	.	.	O	.	_	0	SENT_620	[p27l1357t563r1651b613],

1	54	CD	NUMBER	54	_	0	SENT_621	[p27l1666t567r1745b621],
2	,	,	O	,	_	0	SENT_621	[p27l1666t567r1745b621],
3	3187-3196	CD	DURATION	3187-3196	number	4	SENT_621	[p27l1761t567r2050b613],
4	(	CD	NUMBER	(	appos	1	SENT_621	[p27l134t642r308b697],
5	2010	CD	DATE	2010	num	6	SENT_621	[p27l134t642r308b697],
6	)	NN	O	)	dep	4	SENT_621	[p27l134t642r308b697],
7	.	.	O	.	_	0	SENT_621	[p27l134t642r308b697],

1	Soﬁa	NNP	O	Soﬁa	_	0	SENT_622	[p27l131t718r271b776],
2	,	,	O	,	_	0	SENT_622	[p27l131t718r271b776],
3	M.J.	NNP	O	M.J.	nn	4	SENT_622	[p27l286t721r381b768],
4	etal	NNP	O	etal	appos	1	SENT_622	[p27l396t719r510b768],
5	.	.	O	.	_	0	SENT_622	[p27l396t719r510b768],

1	Discovery	NNP	O	Discovery	_	0	SENT_623	[p27l527t721r782b782],
2	of	IN	O	of	dep	1	SENT_623	[p27l795t718r850b768],
3	a	DT	O	a	det	5	SENT_623	[p27l859t733r885b768],
4	B-d	JJ	O	b-d	amod	5	SENT_623	[p27l903t718r2103b782],
5	—	NN	O	—	pobj	2	SENT_623	[p27l903t718r2103b782],
6	2	CD	NUMBER	2	num	5	SENT_623	[p27l903t718r2103b782],
7	’	SYM	O	’	dep	5	SENT_623	[p27l903t718r2103b782],
8	-	:	O	-	_	0	SENT_623	[p27l903t718r2103b782],
9	deoxy-2	NN	O	deoxy-2	dep	1	SENT_623	[p27l903t718r2103b782],
10	’	SYM	O	’	dep	22	SENT_623	[p27l903t718r2103b782],
11	-	:	O	-	_	0	SENT_623	[p27l903t718r2103b782],
12	a-ﬂuoro-2	NN	O	a-ﬂuoro-2	npadvmod	22	SENT_623	[p27l903t718r2103b782],
13	’	CD	NUMBER	’	num	14	SENT_623	[p27l903t718r2103b782],
14	-13	CD	NUMBER	-13	dep	12	SENT_623	[p27l903t718r2103b782],
15	-	:	O	-	_	0	SENT_623	[p27l903t718r2103b782],
16	C-methyluridine	NN	O	c-methyluridine	nn	21	SENT_623	[p27l903t718r2103b782],
17	nucleotide	NN	O	nucleotide	nn	21	SENT_623	[p27l134t797r413b846],
18	prodrug	NN	O	prodrug	nn	21	SENT_623	[p27l429t797r640b860],
19	(	CD	NUMBER	(	num	21	SENT_623	[p27l659t798r918b854],
20	PSI-7977	NN	O	psi-7977	nn	21	SENT_623	[p27l659t798r918b854],
21	)	NN	O	)	dep	14	SENT_623	[p27l659t798r918b854],
22	for	IN	O	for	dep	9	SENT_623	[p27l933t796r1006b846],
23	the	DT	O	the	det	24	SENT_623	[p27l1017t797r1103b846],
24	treatment	NN	O	treatment	pobj	22	SENT_623	[p27l1116t804r1380b846],
25	of	IN	O	of	_	0	SENT_623	[p27l1394t796r1449b846],
26	hepatitis	NN	O	hepatitis	nn	28	SENT_623	[p27l1460t797r1685b859],
27	C	NN	O	c	nn	28	SENT_623	[p27l1700t798r1733b846],
28	virus	NN	O	virus	prep_of	24	SENT_623	[p27l1746t799r1882b846],
29	.	.	O	.	_	0	SENT_623	[p27l1746t799r1882b846],

1	J.	NNP	O	J.	nn	2	SENT_624	[p27l1893t799r1927b846],
2	Med	NNP	O	Med	_	0	SENT_624	[p27l1941t797r2061b846],
3	.	.	O	.	_	0	SENT_624	[p27l1941t797r2061b846],

1	Chem	NNP	O	Chem	_	0	SENT_625	[p27l132t874r291b923],
2	.	.	O	.	_	0	SENT_625	[p27l132t874r291b923],

1	53	CD	NUMBER	53	_	0	SENT_626	[p27l306t877r386b930],
2	,	,	O	,	_	0	SENT_626	[p27l306t877r386b930],
3	7202-7218	CD	DURATION	7202-7218	number	4	SENT_626	[p27l401t877r690b923],
4	(	CD	NUMBER	(	appos	1	SENT_626	[p27l706t875r880b930],
5	2010	CD	DATE	2010	num	6	SENT_626	[p27l706t875r880b930],
6	)	NN	O	)	dep	4	SENT_626	[p27l706t875r880b930],
7	.	.	O	.	_	0	SENT_626	[p27l706t875r880b930],

1	Lawitz	NNP	PERSON	Lawitz	_	0	SENT_627	[p27l133t954r316b1009],
2	,	,	O	,	_	0	SENT_627	[p27l133t954r316b1009],
3	E.	NNP	O	E.	nn	4	SENT_627	[p27l334t954r373b1001],
4	etal	NN	O	etal	appos	1	SENT_627	[p27l390t952r509b1001],
5	.	.	O	.	_	0	SENT_627	[p27l390t952r509b1001],

1	Once	RB	DATE	once	advmod	9	SENT_628	[p27l526t953r664b1001],
2	daily	JJ	SET	daily	amod	4	SENT_628	[p27l681t952r809b1015],
3	dual-nucleotide	NN	O	dual-nucleotide	nn	4	SENT_628	[p27l824t952r1254b1001],
4	combination	NN	O	combination	nsubj	9	SENT_628	[p27l1271t952r1614b1001],
5	of	IN	O	of	_	0	SENT_628	[p27l1633t951r1688b1001],
6	PSI-38	NN	O	psi-38	prep_of	4	SENT_628	[p27l1702t953r1866b1001],
7	and	CC	O	and	_	0	SENT_628	[p27l1883t952r1981b1001],
8	PSI-7977	NN	O	psi-7977	prep_of	4	SENT_628	[p27l134t1031r365b1079],
9	provides	VBZ	O	provide	dep	25	SENT_628	[p27l384t1030r614b1092],
10	94	CD	PERCENT	94	num	11	SENT_628	[p27l631t1033r746b1080],
11	%	NN	PERCENT	%	iobj	9	SENT_628	[p27l631t1033r746b1080],
12	HCV	NN	O	hcv	dobj	9	SENT_628	[p27l764t1031r877b1079],
13	RNA	NN	O	rna	amod	12	SENT_628	[p27l894t1032r1006b1079],
14	<	JJR	O	<	dep	13	SENT_628	[p27l1023t1031r1172b1079],
15	LOD	CD	NUMBER	lod	npadvmod	16	SENT_628	[p27l1023t1031r1172b1079],
16	at	IN	O	at	advmod	12	SENT_628	[p27l1189t1037r1238b1079],
17	day	NN	DURATION	day	dep	12	SENT_628	[p27l1254t1030r1350b1093],
18	14	CD	NUMBER	14	num	17	SENT_628	[p27l1369t1034r1442b1079],
19	:	:	O	:	_	0	SENT_628	[p27l1369t1034r1442b1079],
20	ﬁrst	CD	NUMBER	ﬁrst	num	21	SENT_628	[p27l1456t1029r1558b1079],
21	purine/pyrimidine	NN	O	purine/pyrimidine	dep	12	SENT_628	[p27l1575t1030r2070b1093],
22	clinical	JJ	O	clinical	amod	24	SENT_628	[p27l132t1108r315b1157],
23	combination	NN	O	combination	nn	24	SENT_628	[p27l334t1108r677b1157],
24	data	NNS	O	datum	nsubj	25	SENT_628	[p27l696t1108r812b1157],
25	(	VBP	O	(	_	0	SENT_628	[p27l831t1108r948b1165],
26	The	DT	O	the	det	29	SENT_628	[p27l831t1108r948b1165],
27	NUCLEAR	NN	O	nuclear	nn	29	SENT_628	[p27l967t1109r1223b1157],
28	study	NN	O	study	nn	29	SENT_628	[p27l1239t1108r1466b1171],
29	)	NN	O	)	dobj	25	SENT_628	[p27l1239t1108r1466b1171],
30	.	.	O	.	_	0	SENT_628	[p27l1239t1108r1466b1171],

1	J.	NNP	PERSON	J.	nn	2	SENT_629	[p27l1239t1108r1466b1171],
2	Hepatol	NNP	PERSON	Hepatol	_	0	SENT_629	[p27l1483t1108r1702b1170],
3	.	.	O	.	_	0	SENT_629	[p27l1483t1108r1702b1170],

1	54	CD	NUMBER	54	_	0	SENT_630	[p27l1719t1112r1787b1157],
2	(	CD	NUMBER	(	dep	1	SENT_630	[p27l1805t1108r2016b1170],
3	suppl	NN	O	suppl	dep	2	SENT_630	[p27l1805t1108r2016b1170],
4	.	.	O	.	_	0	SENT_630	[p27l1805t1108r2016b1170],
5	)	SYM	O	)	dep	1	SENT_630	[p27l1805t1108r2016b1170],

1	,	,	O	,	_	0	SENT_631	[p27l1805t1108r2016b1170],
2	S543	NN	O	s543	_	0	SENT_631	[p27l132t1186r259b1234],
3	(	NN	O	(	dep	2	SENT_631	[p27l279t1186r382b1241],
4	201	CD	NUMBER	201	num	5	SENT_631	[p27l279t1186r382b1241],
5	1	CD	NUMBER	1	dep	2	SENT_631	[p27l401t1186r459b1241],
6	)	NN	O	)	dep	5	SENT_631	[p27l401t1186r459b1241],
7	.	.	O	.	_	0	SENT_631	[p27l401t1186r459b1241],

1	Lawitz	NNP	PERSON	Lawitz	nn	3	SENT_632	[p27l133t1265r310b1320],
2	,	,	O	,	_	0	SENT_632	[p27l133t1265r310b1320],
3	E.	NNP	O	E.	_	0	SENT_632	[p27l327t1265r365b1312],
4	et	FW	O	et	nn	5	SENT_632	[p27l379t1270r428b1313],
5	al.	FW	O	al.	dep	3	SENT_632	[p27l437t1263r494b1313],
6	.	.	O	.	_	0	SENT_632	[p27l437t1263r494b1313],

1	The	DT	O	the	det	2	SENT_633	[p27l503t1263r601b1313],
2	effect	NN	O	effect	_	0	SENT_633	[p27l615t1262r763b1313],
3	of	IN	O	of	_	0	SENT_633	[p27l776t1262r831b1312],
4	hepatic	JJ	O	hepatic	amod	5	SENT_633	[p27l843t1263r1035b1325],
5	impairment	NN	O	impairment	prep_of	2	SENT_633	[p27l1051t1265r1359b1325],
6	in	IN	O	in	_	0	SENT_633	[p27l1374t1265r1417b1312],
7	the	DT	O	the	det	8	SENT_633	[p27l1432t1263r1518b1313],
8	pharmacokinetics	NNS	O	pharmacokinetic	prep_in	2	SENT_633	[p27l1534t1263r2002b1325],
9	and	CC	O	and	_	0	SENT_633	[p27l2016t1263r2113b1312],
10	antiviral	JJ	O	antiviral	amod	11	SENT_633	[p27l132t1341r339b1390],
11	activity	NN	O	activity	conj_and	8	SENT_633	[p27l355t1343r546b1404],
12	of	IN	O	of	_	0	SENT_633	[p27l559t1340r614b1390],
13	PS	NNP	O	PS	nn	14	SENT_633	[p27l626t1342r850b1390],
14	|	NNP	O	|	prep_of	8	SENT_633	[p27l626t1342r850b1390],
15	.	.	O	.	_	0	SENT_633	[p27l626t1342r850b1390],

1	—	NN	O	—	_	0	SENT_634	[p27l626t1342r850b1390],
2	.	.	O	.	_	0	SENT_634	[p27l626t1342r850b1390],

1	7977	CD	NUMBER	7977	nsubj	7	SENT_635	[p27l626t1342r850b1390],
2	in	IN	O	in	_	0	SENT_635	[p27l866t1343r909b1390],
3	hepatitis	NN	O	hepatitis	nn	6	SENT_635	[p27l928t1341r1153b1403],
4	C	NN	O	c	nn	6	SENT_635	[p27l1167t1342r1200b1390],
5	infected	JJ	O	infected	amod	6	SENT_635	[p27l1216t1340r1427b1390],
6	subjects	NNS	O	subject	prep_in	1	SENT_635	[p27l1443t1341r1659b1404],
7	treated	VBN	O	treat	_	0	SENT_635	[p27l1672t1341r1860b1390],
8	for	IN	O	for	_	0	SENT_635	[p27l1874t1340r1947b1390],
9	several	JJ	DURATION	several	amod	10	SENT_635	[p27l1960t1341r2139b1390],
10	days	NNS	DURATION	day	prep_for	7	SENT_635	[p27l132t1419r262b1482],
11	.	.	O	.	_	0	SENT_635	[p27l132t1419r262b1482],

1	Presented	VBN	O	present	_	0	SENT_636	[p27l278t1419r536b1468],
2	at	IN	O	at	_	0	SENT_636	[p27l552t1426r601b1468],
3	the	DT	O	the	det	5	SENT_636	[p27l613t1419r699b1468],
4	47th	JJ	ORDINAL	47th	amod	5	SENT_636	[p27l712t1419r829b1468],
5	Annual	JJ	SET	annual	prep_at	1	SENT_636	[p27l845t1419r1030b1468],
6	Meeting	VBG	O	meet	partmod	5	SENT_636	[p27l1048t1421r1264b1482],
7	of	IN	O	of	_	0	SENT_636	[p27l1281t1418r1335b1468],
8	the	DT	O	the	det	10	SENT_636	[p27l1343t1419r1429b1468],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_636	[p27l1446t1421r1693b1481],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_636	[p27l1709t1421r2008b1468],
11	for	IN	O	for	_	0	SENT_636	[p27l2023t1418r2096b1468],
12	the	DT	O	the	det	13	SENT_636	[p27l130t1497r216b1546],
13	Study	NN	O	study	prep_for	10	SENT_636	[p27l231t1497r382b1560],
14	of	IN	O	of	_	0	SENT_636	[p27l395t1496r450b1546],
15	the	DT	O	the	det	16	SENT_636	[p27l458t1497r544b1546],
16	Liver	NN	O	liver	prep_of	13	SENT_636	[p27l561t1499r692b1554],
17	,	,	O	,	_	0	SENT_636	[p27l561t1499r692b1554],
18	Barcelona	NNP	ORGANIZATION	Barcelona	appos	16	SENT_636	[p27l708t1497r977b1554],
19	,	,	O	,	_	0	SENT_636	[p27l708t1497r977b1554],
20	Spain	NNP	LOCATION	Spain	appos	16	SENT_636	[p27l992t1498r1149b1559],
21	,	,	O	,	_	0	SENT_636	[p27l992t1498r1149b1559],
22	18-22	CD	DATE	18-22	appos	16	SENT_636	[p27l1168t1500r1322b1546],
23	April	NNP	DATE	April	tmod	6	SENT_636	[p27l1336t1497r1456b1559],
24	2012	CD	DATE	2012	num	23	SENT_636	[p27l1474t1497r1776b1546],
25	.	.	O	.	_	0	SENT_636	[p27l1474t1497r1776b1546],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_637	[p27l1474t1497r1776b1546],
2	.	.	O	.	_	0	SENT_637	[p27l1474t1497r1776b1546],

1	1	CD	NUMBER	1	num	2	SENT_638	[p27l1795t1501r1809b1546],
2	130	CD	NUMBER	130	_	0	SENT_638	[p27l1828t1500r1930b1546],
3	.	.	O	.	_	0	SENT_638	[p27l1828t1500r1930b1546],

1	Kowdley	NNP	LOCATION	Kowdley	_	0	SENT_639	[p27l133t1575r366b1638],
2	,	,	O	,	_	0	SENT_639	[p27l133t1575r366b1638],
3	K.V.	NNP	O	K.V.	nn	4	SENT_639	[p27l382t1577r470b1624],
4	etal	NN	O	etal	appos	1	SENT_639	[p27l484t1575r599b1624],
5	.	.	O	.	_	0	SENT_639	[p27l484t1575r599b1624],

1	Sofosbuvir	NN	O	sofosbuvir	_	0	SENT_640	[p27l614t1574r894b1624],
2	with	IN	O	with	prep	1	SENT_640	[p27l905t1575r1019b1624],
3	pegylated	VBN	O	pegylate	partmod	1	SENT_640	[p27l1038t1575r1298b1638],
4	interferon	NN	O	interferon	nn	5	SENT_640	[p27l1316t1574r1573b1624],
5	alfa-2a	NN	O	alfa-2a	dobj	3	SENT_640	[p27l1590t1574r1762b1624],
6	and	CC	O	and	_	0	SENT_640	[p27l1778t1575r1875b1624],
7	ribavirin	NNP	O	ribavirin	conj_and	5	SENT_640	[p27l1893t1575r2104b1624],
8	for	IN	O	for	_	0	SENT_640	[p27l130t1652r203b1702],
9	treatment-naive	JJ	O	treatment-naive	amod	10	SENT_640	[p27l214t1655r640b1702],
10	patients	NNS	O	patient	prep_for	3	SENT_640	[p27l657t1655r866b1715],
11	with	IN	O	with	_	0	SENT_640	[p27l880t1653r993b1702],
12	hepatitis	NN	O	hepatitis	nn	15	SENT_640	[p27l1012t1653r1237b1715],
13	C	NN	O	c	nn	15	SENT_640	[p27l1251t1654r1285b1702],
14	genotype-1	NN	O	genotype-1	nn	15	SENT_640	[p27l1299t1657r1597b1716],
15	infection	NN	O	infection	prep_with	3	SENT_640	[p27l1624t1652r1851b1702],
16	(	CD	NUMBER	(	num	17	SENT_640	[p27l1869t1654r2125b1710],
17	ATOMIC	NN	O	atomic	dep	1	SENT_640	[p27l1869t1654r2125b1710],
18	)	CD	NUMBER	)	dep	17	SENT_640	[p27l1869t1654r2125b1710],
19	:	:	O	:	_	0	SENT_640	[p27l1869t1654r2125b1710],
20	an	DT	O	a	det	26	SENT_640	[p27l132t1745r192b1780],
21	open-label	JJ	O	open-label	amod	26	SENT_640	[p27l209t1731r504b1793],
22	,	,	O	,	_	0	SENT_640	[p27l209t1731r504b1793],
23	randomised	JJ	O	randomised	amod	26	SENT_640	[p27l520t1731r846b1788],
24	,	,	O	,	_	0	SENT_640	[p27l520t1731r846b1788],
25	multicentre	JJ	O	multicentre	amod	26	SENT_640	[p27l862t1731r1164b1781],
26	phase	NN	O	phase	dep	1	SENT_640	[p27l1181t1731r1334b1793],
27	2	CD	NUMBER	2	num	28	SENT_640	[p27l1349t1734r1377b1780],
28	trial	NN	O	trial	dep	26	SENT_640	[p27l1391t1731r1503b1780],
29	.	.	O	.	_	0	SENT_640	[p27l1391t1731r1503b1780],

1	Lancet	NNP	O	Lancet	_	0	SENT_641	[p27l1517t1733r1688b1780],
2	381	CD	NUMBER	381	num	1	SENT_641	[p27l1699t1734r1814b1788],
3	,	,	O	,	_	0	SENT_641	[p27l1699t1734r1814b1788],
4	21	CD	NUMBER	21	num	1	SENT_641	[p27l1829t1734r1880b1780],
5	00-21	CD	NUMBER	00-21	number	6	SENT_641	[p27l1894t1734r2043b1780],
6	07	CD	NUMBER	07	dep	1	SENT_641	[p27l2057t1734r2118b1780],
7	(	CD	NUMBER	(	num	9	SENT_641	[p27l133t1809r308b1864],
8	2013	CD	DATE	2013	num	9	SENT_641	[p27l133t1809r308b1864],
9	)	NN	O	)	dep	6	SENT_641	[p27l133t1809r308b1864],
10	.	.	O	.	_	0	SENT_641	[p27l133t1809r308b1864],

1	Lawitz	NNP	PERSON	Lawitz	nn	3	SENT_642	[p27l133t1888r310b1943],
2	,	,	O	,	_	0	SENT_642	[p27l133t1888r310b1943],
3	E.	NNP	O	E.	_	0	SENT_642	[p27l327t1888r364b1935],
4	et	FW	O	et	nn	5	SENT_642	[p27l379t1893r428b1935],
5	al.	FW	O	al.	dep	3	SENT_642	[p27l437t1886r493b1935],
6	.	.	O	.	_	0	SENT_642	[p27l437t1886r493b1935],

1	Sofosbuvir	NNP	O	Sofosbuvir	nsubj	16	SENT_643	[p27l509t1885r788b1935],
2	in	IN	O	in	_	0	SENT_643	[p27l803t1888r846b1935],
3	combination	NN	O	combination	prep_in	1	SENT_643	[p27l862t1886r1196b1935],
4	with	IN	O	with	_	0	SENT_643	[p27l1212t1886r1325b1935],
5	peginterferon	NN	O	peginterferon	nn	6	SENT_643	[p27l1343t1885r1704b1949],
6	alfa-2a	NN	O	alfa-2a	prep_with	3	SENT_643	[p27l1721t1885r1893b1935],
7	and	CC	O	and	_	0	SENT_643	[p27l1909t1886r2006b1935],
8	ribavirin	NNP	O	ribavirin	conj_and	3	SENT_643	[p27l134t1964r345b2013],
9	for	IN	O	for	_	0	SENT_643	[p27l359t1963r432b2013],
10	non-cirrhotic	JJ	O	non-cirrhotic	amod	13	SENT_643	[p27l447t1964r800b2021],
11	,	,	O	,	_	0	SENT_643	[p27l447t1964r800b2021],
12	treatment-naive	JJ	O	treatment-naive	amod	13	SENT_643	[p27l813t1966r1239b2013],
13	patients	NNS	O	patient	prep_for	8	SENT_643	[p27l1256t1966r1466b2026],
14	with	IN	O	with	_	0	SENT_643	[p27l1479t1964r1593b2013],
15	genotypes	NNS	O	genotype	prep_with	13	SENT_643	[p27l1609t1971r1888b2027],
16	1	CD	NUMBER	1	_	0	SENT_643	[p27l1907t1968r1945b2021],
17	,	,	O	,	_	0	SENT_643	[p27l1907t1968r1945b2021],
18	2	CD	NUMBER	2	num	16	SENT_643	[p27l1960t1967r2001b2021],
19	,	,	O	,	_	0	SENT_643	[p27l1960t1967r2001b2021],
20	and	CC	NUMBER	and	_	0	SENT_643	[p27l2015t1964r2112b2013],
21	3	CD	NUMBER	3	conj_and	16	SENT_643	[p27l132t2045r158b2091],
22	hepatitis	NN	O	hepatitis	nn	24	SENT_643	[p27l177t2042r402b2104],
23	C	NN	O	c	nn	24	SENT_643	[p27l417t2043r450b2092],
24	infection	NN	O	infection	dep	16	SENT_643	[p27l466t2041r709b2091],
25	:	:	O	:	_	0	SENT_643	[p27l466t2041r709b2091],
26	a	DT	O	a	dep	16	SENT_643	[p27l723t2056r749b2091],
27	randomised	VBN	O	randomise	partmod	26	SENT_643	[p27l767t2042r1092b2099],
28	,	,	O	,	_	0	SENT_643	[p27l767t2042r1092b2099],
29	double-blind	JJ	O	double-blind	amod	33	SENT_643	[p27l1107t2042r1464b2099],
30	,	,	O	,	_	0	SENT_643	[p27l1107t2042r1464b2099],
31	phase	NN	O	phase	dep	33	SENT_643	[p27l1480t2042r1634b2104],
32	2	CD	NUMBER	2	num	31	SENT_643	[p27l1648t2045r1676b2091],
33	trial	NN	O	trial	dobj	16	SENT_643	[p27l1690t2042r1802b2091],
34	.	.	O	.	_	0	SENT_643	[p27l1690t2042r1802b2091],

1	Lancet	NNP	O	Lancet	nn	2	SENT_644	[p27l1816t2044r1987b2091],
2	Infect	NNP	O	Infect	_	0	SENT_644	[p27l1996t2041r2146b2091],
3	.	.	O	.	_	0	SENT_644	[p27l1996t2041r2146b2091],

1	Dis	NNP	O	Dis	_	0	SENT_645	[p27l131t2121r221b2168],
2	.	.	O	.	_	0	SENT_645	[p27l131t2121r221b2168],

1	13	CD	NUMBER	13	_	0	SENT_646	[p27l238t2122r315b2175],
2	,	,	O	,	_	0	SENT_646	[p27l238t2122r315b2175],
3	401	CD	NUMBER	401	number	4	SENT_646	[p27l328t2122r414b2168],
4	-408	CD	NUMBER	-408	appos	1	SENT_646	[p27l427t2122r554b2168],
5	(	CD	NUMBER	(	num	7	SENT_646	[p27l570t2120r745b2175],
6	2013	CD	DATE	2013	num	7	SENT_646	[p27l570t2120r745b2175],
7	)	NN	O	)	dep	4	SENT_646	[p27l570t2120r745b2175],
8	.	.	O	.	_	0	SENT_646	[p27l570t2120r745b2175],

1	Gane	NNP	O	Gane	nn	3	SENT_647	[p27l130t2199r279b2254],
2	,	,	O	,	_	0	SENT_647	[p27l130t2199r279b2254],
3	E.J.	NNP	O	E.J.	dep	4	SENT_647	[p27l295t2199r369b2247],
4	etal	JJ	O	etal	_	0	SENT_647	[p27l383t2197r498b2247],
5	.	.	O	.	_	0	SENT_647	[p27l383t2197r498b2247],

1	Nucleotide	NN	O	nucleotide	nn	4	SENT_648	[p27l515t2197r800b2247],
2	polymerase	NN	O	polymerase	nn	4	SENT_648	[p27l817t2197r1121b2261],
3	inhibitor	NN	O	inhibitor	nn	4	SENT_648	[p27l1137t2197r1361b2246],
4	sofosbuvir	NN	O	sofosbuvir	_	0	SENT_648	[p27l1374t2196r1647b2247],
5	plus	CC	O	plus	prep	4	SENT_648	[p27l1662t2197r1768b2259],
6	ribavirin	NNP	O	ribavirin	dep	5	SENT_648	[p27l1784t2197r1996b2246],
7	for	IN	O	for	_	0	SENT_648	[p27l2010t2196r2083b2246],
8	hepatitis	NNP	O	hepatitis	nn	11	SENT_648	[p27l134t2275r359b2337],
9	C.	NNP	PERSON	C.	nn	11	SENT_648	[p27l373t2276r419b2325],
10	N.	NNP	PERSON	N.	nn	11	SENT_648	[p27l434t2277r481b2325],
11	Engl	NNP	PERSON	Engl	prep_for	4	SENT_648	[p27l496t2275r615b2338],
12	.	.	O	.	_	0	SENT_648	[p27l496t2275r615b2338],

1	J.	NNP	O	J.	nn	2	SENT_649	[p27l625t2277r660b2325],
2	Med	NNP	O	Med	_	0	SENT_649	[p27l674t2275r797b2325],
3	.	.	O	.	_	0	SENT_649	[p27l674t2275r797b2325],

1	368	CD	NUMBER	368	_	0	SENT_650	[p27l811t2278r927b2332],
2	,	,	O	,	_	0	SENT_650	[p27l811t2278r927b2332],
3	34-44	CD	NUMBER	34-44	number	4	SENT_650	[p27l942t2278r1101b2325],
4	(	CD	NUMBER	(	appos	1	SENT_650	[p27l1116t2276r1290b2332],
5	2013	CD	DATE	2013	num	6	SENT_650	[p27l1116t2276r1290b2332],
6	)	NN	O	)	dep	4	SENT_650	[p27l1116t2276r1290b2332],
7	.	.	O	.	_	0	SENT_650	[p27l1116t2276r1290b2332],

1	Lawitz	NNP	PERSON	Lawitz	_	0	SENT_651	[p27l133t2355r310b2410],
2	,	,	O	,	_	0	SENT_651	[p27l133t2355r310b2410],
3	E.	NNP	O	E.	nn	4	SENT_651	[p27l327t2355r364b2402],
4	etal	NN	O	etal	appos	1	SENT_651	[p27l378t2353r493b2403],
5	.	.	O	.	_	0	SENT_651	[p27l378t2353r493b2403],

1	Sofosbuvir	NNP	O	Sofosbuvir	nsubj	7	SENT_652	[p27l509t2352r788b2403],
2	for	IN	O	for	_	0	SENT_652	[p27l800t2352r872b2403],
3	previously	RB	DATE	previously	advmod	4	SENT_652	[p27l887t2353r1157b2417],
4	untreated	JJ	O	untreated	amod	6	SENT_652	[p27l1172t2353r1427b2403],
5	chronic	JJ	O	chronic	amod	6	SENT_652	[p27l1443t2353r1638b2402],
6	hepatitis	NN	O	hepatitis	prep_for	1	SENT_652	[p27l1654t2353r1878b2415],
7	C	NN	O	c	_	0	SENT_652	[p27l1893t2355r1927b2402],
8	infection	NN	O	infection	dobj	7	SENT_652	[p27l133t2430r376b2481],
9	.	.	O	.	_	0	SENT_652	[p27l133t2430r376b2481],

1	N.	NNP	O	N.	nn	2	SENT_653	[p27l391t2433r438b2481],
2	Engl	NNP	O	Engl	_	0	SENT_653	[p27l453t2431r572b2494],
3	.	.	O	.	_	0	SENT_653	[p27l453t2431r572b2494],

1	J.	NNP	O	J.	nn	2	SENT_654	[p27l583t2433r617b2481],
2	Med	NNP	O	Med	_	0	SENT_654	[p27l631t2431r754b2481],
3	.	.	O	.	_	0	SENT_654	[p27l631t2431r754b2481],

1	368	CD	NUMBER	368	_	0	SENT_655	[p27l768t2434r884b2488],
2	,	,	O	,	_	0	SENT_655	[p27l768t2434r884b2488],
3	1878-1887	CD	DATE	1878-1887	number	4	SENT_655	[p27l902t2434r1187b2481],
4	(	CD	NUMBER	(	appos	1	SENT_655	[p27l1204t2432r1378b2488],
5	2013	CD	DATE	2013	num	6	SENT_655	[p27l1204t2432r1378b2488],
6	)	NN	O	)	dep	4	SENT_655	[p27l1204t2432r1378b2488],
7	.	.	O	.	_	0	SENT_655	[p27l1204t2432r1378b2488],

1	Jacobsen	NNP	PERSON	Jacobsen	nn	3	SENT_656	[p27l128t2509r386b2566],
2	,	,	O	,	_	0	SENT_656	[p27l128t2509r386b2566],
3	I.	NNP	O	I.	_	0	SENT_656	[p27l402t2511r424b2558],
4	et	FW	O	et	nn	5	SENT_656	[p27l439t2516r487b2558],
5	al.	FW	O	al.	dep	3	SENT_656	[p27l496t2509r554b2559],
6	.	.	O	.	_	0	SENT_656	[p27l496t2509r554b2559],

1	PSI-7977	NN	O	psi-7977	nn	4	SENT_657	[p27l570t2510r795b2559],
2	400mg	CD	NUMBER	400mg	num	4	SENT_657	[p27l808t2512r991b2572],
3	QD	NN	O	qd	nn	4	SENT_657	[p27l1007t2511r1090b2565],
4	safety	NN	O	safety	nsubj	12	SENT_657	[p27l1105t2508r1260b2573],
5	and	CC	O	and	_	0	SENT_657	[p27l1272t2509r1369b2558],
6	tolerability	NN	O	tolerability	nsubj	12	SENT_657	[p27l1384t2509r1669b2573],
7	in	IN	O	in	_	0	SENT_657	[p27l1683t2511r1726b2558],
8	the	DT	O	the	det	9	SENT_657	[p27l1741t2509r1827b2558],
9	ﬁrst	NN	O	ﬁrst	prep_in	6	SENT_657	[p27l1840t2508r1939b2559],
10	450	CD	NUMBER	450	num	11	SENT_657	[p27l1951t2512r2047b2558],
11	patients	NNS	O	patient	dep	6	SENT_657	[p27l134t2589r343b2649],
12	treated	VBN	O	treat	_	0	SENT_657	[p27l357t2587r544b2637],
13	for	IN	O	for	_	0	SENT_657	[p27l559t2586r632b2637],
14	12	CD	DURATION	12	num	15	SENT_657	[p27l649t2590r705b2636],
15	weeks	NNS	NUMBER	week	prep_for	12	SENT_657	[p27l720t2587r895b2637],
16	.	.	O	.	_	0	SENT_657	[p27l720t2587r895b2637],

1	Presented	VBN	O	present	_	0	SENT_658	[p27l912t2587r1169b2637],
2	at	IN	O	at	_	0	SENT_658	[p27l1186t2594r1234b2637],
3	the	DT	O	the	det	5	SENT_658	[p27l1246t2587r1332b2637],
4	47th	JJ	ORDINAL	47th	amod	5	SENT_658	[p27l1345t2587r1463b2637],
5	Annual	JJ	SET	annual	prep_at	1	SENT_658	[p27l1479t2587r1664b2637],
6	Meeting	VBG	O	meet	partmod	5	SENT_658	[p27l1682t2589r1898b2650],
7	of	IN	O	of	_	0	SENT_658	[p27l1914t2586r1969b2637],
8	the	DT	O	the	det	10	SENT_658	[p27l1977t2587r2063b2637],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_658	[p27l134t2667r382b2727],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_658	[p27l397t2667r696b2715],
11	for	IN	O	for	_	0	SENT_658	[p27l711t2664r784b2715],
12	the	DT	O	the	det	13	SENT_658	[p27l795t2665r881b2715],
13	Study	NN	O	study	prep_for	10	SENT_658	[p27l896t2665r1047b2729],
14	of	IN	O	of	_	0	SENT_658	[p27l1060t2664r1114b2714],
15	the	DT	O	the	det	16	SENT_658	[p27l1123t2665r1209b2714],
16	Liver	NN	O	liver	prep_of	13	SENT_658	[p27l1225t2667r1356b2722],
17	,	,	O	,	_	0	SENT_658	[p27l1225t2667r1356b2722],
18	Barcelona	NNP	ORGANIZATION	Barcelona	appos	16	SENT_658	[p27l1373t2665r1642b2722],
19	,	,	O	,	_	0	SENT_658	[p27l1373t2665r1642b2722],
20	Spain	NNP	LOCATION	Spain	appos	16	SENT_658	[p27l1656t2666r1814b2727],
21	,	,	O	,	_	0	SENT_658	[p27l1656t2666r1814b2727],
22	18-22	CD	DATE	18-22	appos	16	SENT_658	[p27l1833t2668r1986b2714],
23	April	NNP	DATE	April	tmod	6	SENT_658	[p27l2001t2665r2121b2727],
24	2012	CD	DATE	2012	num	23	SENT_658	[p27l132t2742r434b2791],
25	.	.	O	.	_	0	SENT_658	[p27l132t2742r434b2791],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_659	[p27l132t2742r434b2791],
2	.	.	O	.	_	0	SENT_659	[p27l132t2742r434b2791],

1	1	CD	NUMBER	1	num	2	SENT_660	[p27l453t2746r467b2790],
2	120	CD	NUMBER	120	_	0	SENT_660	[p27l486t2745r588b2791],
3	.	.	O	.	_	0	SENT_660	[p27l486t2745r588b2791],

1	Lawitz	NNP	PERSON	Lawitz	_	0	SENT_661	[p27l133t2822r310b2877],
2	,	,	O	,	_	0	SENT_661	[p27l133t2822r310b2877],
3	E.	NNP	O	E.	nn	4	SENT_661	[p27l327t2822r364b2869],
4	etal	NN	O	etal	appos	1	SENT_661	[p27l378t2820r493b2869],
5	.	.	O	.	_	0	SENT_661	[p27l378t2820r493b2869],

1	Once	RB	DATE	once	advmod	8	SENT_662	[p27l508t2822r644b2869],
2	daily	JJ	SET	daily	amod	3	SENT_662	[p27l658t2820r782b2884],
3	PSI-7977	NN	MISC	psi-7977	nsubj	8	SENT_662	[p27l798t2821r1021b2869],
4	plus	CC	O	plus	prep	3	SENT_662	[p27l1039t2820r1144b2882],
5	Peg/RBV	NN	O	peg/rbv	dep	4	SENT_662	[p27l1162t2821r1384b2883],
6	in	IN	O	in	_	0	SENT_662	[p27l1398t2822r1441b2869],
7	treatment-nai	NNS	O	treatment-naus	prep_in	5	SENT_662	[p27l1456t2822r1881b2869],
8	've	VBP	O	have	csubj	24	SENT_662	[p27l1456t2822r1881b2869],
9	patients	NNS	O	patient	dobj	8	SENT_662	[p27l1898t2822r2107b2882],
10	with	IN	O	with	_	0	SENT_662	[p27l131t2898r244b2948],
11	HCV	NN	O	hcv	nn	12	SENT_662	[p27l263t2900r374b2948],
12	GT1	NN	O	gt1	prep_with	9	SENT_662	[p27l386t2900r478b2947],
13	:	:	O	:	_	0	SENT_662	[p27l493t2915r501b2948],
14	Robust	JJ	O	robust	amod	15	SENT_662	[p27l518t2898r700b2948],
15	end	NN	O	end	dep	9	SENT_662	[p27l713t2898r811b2948],
16	of	IN	O	of	_	0	SENT_662	[p27l828t2897r882b2948],
17	treatment	NN	O	treatment	nn	19	SENT_662	[p27l890t2905r1155b2948],
18	response	NN	O	response	nn	19	SENT_662	[p27l1170t2913r1406b2960],
19	rates	NNS	O	rate	prep_of	15	SENT_662	[p27l1422t2905r1545b2948],
20	are	VBP	O	be	cop	24	SENT_662	[p27l1559t2913r1639b2948],
21	sustained	JJ	O	sustained	amod	24	SENT_662	[p27l1653t2898r1903b2948],
22	post	NN	O	post	nn	24	SENT_662	[p27l134t2983r543b3038],
23	—	NN	O	—	nn	24	SENT_662	[p27l134t2983r543b3038],
24	treatment	NN	O	treatment	_	0	SENT_662	[p27l134t2983r543b3038],
25	.	.	O	.	_	0	SENT_662	[p27l134t2983r543b3038],

1	Presented	VBN	O	present	_	0	SENT_663	[p27l560t2976r818b3026],
2	at	IN	O	at	_	0	SENT_663	[p27l834t2983r883b3026],
3	the	DT	O	the	det	5	SENT_663	[p27l895t2976r981b3026],
4	62nd	JJ	ORDINAL	62nd	amod	5	SENT_663	[p27l995t2976r1126b3026],
5	Annual	JJ	SET	annual	prep_at	1	SENT_663	[p27l1142t2976r1327b3026],
6	Meeting	VBG	O	meet	partmod	5	SENT_663	[p27l1345t2978r1561b3039],
7	of	IN	O	of	_	0	SENT_663	[p27l1577t2975r1632b3026],
8	the	DT	O	the	det	10	SENT_663	[p27l1640t2976r1726b3026],
9	American	NNP	O	American	nn	10	SENT_663	[p27l1740t2978r1989b3026],
10	Association	NNP	O	Association	prep_of	6	SENT_663	[p27l131t3056r430b3104],
11	for	IN	O	for	_	0	SENT_663	[p27l445t3053r517b3103],
12	the	DT	O	the	det	13	SENT_663	[p27l529t3054r615b3103],
13	Study	NN	O	study	prep_for	10	SENT_663	[p27l630t3054r780b3118],
14	of	IN	O	of	_	0	SENT_663	[p27l793t3053r848b3103],
15	Liver	NN	O	liver	nn	16	SENT_663	[p27l860t3056r983b3104],
16	Diseases	NNS	O	disease	prep_of	13	SENT_663	[p27l998t3056r1232b3111],
17	,	,	O	,	_	0	SENT_663	[p27l998t3056r1232b3111],
18	San	NNP	LOCATION	San	nn	19	SENT_663	[p27l1247t3055r1338b3103],
19	Francisco	NNP	LOCATION	Francisco	appos	16	SENT_663	[p27l1357t3056r1610b3111],
20	,	,	O	,	_	0	SENT_663	[p27l1357t3056r1610b3111],
21	California	NNP	LOCATION	California	appos	16	SENT_663	[p27l1624t3053r1885b3111],
22	,	,	O	,	_	0	SENT_663	[p27l1624t3053r1885b3111],
23	4-8	CD	NUMBER	4-8	num	24	SENT_663	[p27l1898t3057r1993b3103],
24	November	NNP	DATE	November	appos	16	SENT_663	[p27l134t3131r410b3180],
25	201	CD	NUMBER	201	number	26	SENT_663	[p27l424t3134r508b3180],
26	1	CD	NUMBER	1	dep	24	SENT_663	[p27l526t3135r540b3179],
27	.	.	O	.	_	0	SENT_663	[p27l555t3171r563b3180],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_664	[p27l577t3131r726b3180],
2	.	.	O	.	_	0	SENT_664	[p27l577t3131r726b3180],

1	225	CD	NUMBER	225	_	0	SENT_665	[p27l741t3134r847b3180],
2	.	.	O	.	_	0	SENT_665	[p27l741t3134r847b3180],

1	Wedenmeyer	NNP	O	Wedenmeyer	nn	3	SENT_666	[p28l129t22r491b85],
2	,	,	O	,	_	0	SENT_666	[p28l129t22r491b85],
3	H.	NNP	O	H.	_	0	SENT_666	[p28l508t24r556b71],
4	et	FW	O	et	nn	5	SENT_666	[p28l570t29r619b72],
5	al.	FW	O	al.	dep	3	SENT_666	[p28l628t22r685b71],
6	.	.	O	.	_	0	SENT_666	[p28l628t22r685b71],

1	PROPEL	VB	O	propel	_	0	SENT_667	[p28l702t24r917b71],
2	:	:	O	:	_	0	SENT_667	[p28l702t24r917b71],
3	A	DT	O	a	det	5	SENT_667	[p28l930t24r967b71],
4	randomized	JJ	O	randomized	amod	5	SENT_667	[p28l983t22r1296b71],
5	trial	NN	O	trial	dobj	1	SENT_667	[p28l1311t22r1408b71],
6	of	IN	O	of	_	0	SENT_667	[p28l1425t21r1479b71],
7	mericitabine	NN	O	mericitabine	prep_of	5	SENT_667	[p28l1491t22r1820b71],
8	plus	CC	O	plus	_	0	SENT_667	[p28l1837t22r1942b84],
9	peginterferon	NN	O	peginterferon	dobj	1	SENT_667	[p28l133t99r494b163],
10	alpha-2a	NN	O	alpha-2a	dep	9	SENT_667	[p28l511t100r977b162],
11	/	:	O	/	punct	19	SENT_667	[p28l511t100r977b162],
12	ribavirin	NNP	O	ribavirin	nn	13	SENT_667	[p28l511t100r977b162],
13	therapy	NN	O	therapy	dep	19	SENT_667	[p28l992t100r1197b164],
14	in	IN	O	in	_	0	SENT_667	[p28l1211t102r1254b149],
15	treatment-naive	JJ	O	treatment-naive	amod	17	SENT_667	[p28l1269t102r1694b150],
16	HCV	NN	O	hcv	nn	17	SENT_667	[p28l1712t102r1822b149],
17	genotype	NN	O	genotype	prep_in	13	SENT_667	[p28l1835t107r2089b163],
18	1/4	CD	NUMBER	1/4	num	19	SENT_667	[p28l136t179r216b230],
19	patients	NNS	O	patient	dep	5	SENT_667	[p28l231t180r454b240],
20	.	.	O	.	_	0	SENT_667	[p28l231t180r454b240],

1	Hepatology	NNP	O	Hepatology	_	0	SENT_668	[p28l468t178r766b242],
2	58	CD	NUMBER	58	num	1	SENT_668	[p28l777t181r857b235],
3	,	,	O	,	_	0	SENT_668	[p28l777t181r857b235],
4	524-537	CD	NUMBER	524-537	num	1	SENT_668	[p28l872t181r1095b227],
5	(	CD	NUMBER	(	num	7	SENT_668	[p28l1112t179r1286b235],
6	2013	CD	DATE	2013	num	7	SENT_668	[p28l1112t179r1286b235],
7	)	NN	O	)	dep	1	SENT_668	[p28l1112t179r1286b235],
8	.	.	O	.	_	0	SENT_668	[p28l1112t179r1286b235],

1	Pockros	NNP	O	Pockros	nn	3	SENT_669	[p28l132t256r346b313],
2	,	,	O	,	_	0	SENT_669	[p28l132t256r346b313],
3	P.J.	NNP	PERSON	P.J.	_	0	SENT_669	[p28l363t258r430b306],
4	et	FW	O	et	nn	5	SENT_669	[p28l444t263r493b306],
5	al.	FW	O	al.	dep	3	SENT_669	[p28l502t256r573b313],
6	;	:	O	;	_	0	SENT_669	[p28l502t256r573b313],
7	JUMP-C	NNP	O	JUMP-C	dep	3	SENT_669	[p28l585t258r790b306],
8	Investigators	NNS	O	investigator	dep	7	SENT_669	[p28l806t258r1154b319],
9	.	.	O	.	_	0	SENT_669	[p28l806t258r1154b319],

1	JUMP-C	NN	O	jump-c	_	0	SENT_670	[p28l1166t257r1383b306],
2	:	:	O	:	_	0	SENT_670	[p28l1166t257r1383b306],
3	a	DT	O	a	det	5	SENT_670	[p28l1398t271r1423b306],
4	randomized	JJ	O	randomized	amod	5	SENT_670	[p28l1441t256r1754b306],
5	trial	NN	O	trial	dep	1	SENT_670	[p28l1769t256r1866b306],
6	of	IN	O	of	_	0	SENT_670	[p28l1884t255r1938b306],
7	mericitabine	NN	O	mericitabine	prep_of	5	SENT_670	[p28l133t334r462b384],
8	plus	CC	O	plus	advmod	9	SENT_670	[p28l479t334r584b396],
9	pegylated	VBN	O	pegylate	partmod	7	SENT_670	[p28l601t334r861b397],
10	interferon	NN	O	interferon	nn	11	SENT_670	[p28l879t333r1137b384],
11	alpha-2a	NN	O	alpha-2a	dobj	9	SENT_670	[p28l1153t334r1619b396],
12	/	:	O	/	punct	22	SENT_670	[p28l1153t334r1619b396],
13	ribavirin	NNP	O	ribavirin	dep	22	SENT_670	[p28l1153t334r1619b396],
14	for	IN	O	for	_	0	SENT_670	[p28l1634t333r1707b384],
15	24	CD	DURATION	24	num	16	SENT_670	[p28l1720t337r1782b383],
16	weeks	NNS	NUMBER	week	prep_for	13	SENT_670	[p28l1795t334r1957b384],
17	in	IN	O	in	_	0	SENT_670	[p28l1973t336r2016b383],
18	treatment-naive	JJ	O	treatment-naive	amod	20	SENT_670	[p28l130t414r556b461],
19	HCV	NN	O	hcv	nn	20	SENT_670	[p28l572t413r684b461],
20	genotype	NN	O	genotype	prep_in	16	SENT_670	[p28l696t419r950b476],
21	1/4	CD	NUMBER	1/4	num	22	SENT_670	[p28l969t413r1049b464],
22	patients	NNS	O	patient	dep	11	SENT_670	[p28l1065t414r1287b474],
23	.	.	O	.	_	0	SENT_670	[p28l1065t414r1287b474],

1	Hepatology	NNP	O	Hepatology	_	0	SENT_671	[p28l1301t412r1599b476],
2	58	CD	NUMBER	58	num	1	SENT_671	[p28l1610t415r1690b469],
3	,	,	O	,	_	0	SENT_671	[p28l1610t415r1690b469],
4	514-523	CD	NUMBER	514-523	num	1	SENT_671	[p28l1705t415r1927b461],
5	(	CD	NUMBER	(	num	7	SENT_671	[p28l1945t413r2119b469],
6	2013	CD	DATE	2013	num	7	SENT_671	[p28l1945t413r2119b469],
7	)	NN	O	)	dep	1	SENT_671	[p28l1945t413r2119b469],
8	.	.	O	.	_	0	SENT_671	[p28l1945t413r2119b469],

1	Larrey	NNP	PERSON	Larrey	nn	3	SENT_672	[p28l132t492r302b554],
2	,	,	O	,	_	0	SENT_672	[p28l132t492r302b554],
3	D.	NNP	O	D.	_	0	SENT_672	[p28l320t492r367b539],
4	et	FW	O	et	nn	5	SENT_672	[p28l382t497r431b539],
5	al.	FW	O	al.	dep	3	SENT_672	[p28l441t490r513b547],
6	;	:	O	;	_	0	SENT_672	[p28l441t490r513b547],
7	BI	NNP	O	BI	dep	3	SENT_672	[p28l530t492r571b539],
8	207127	CD	NUMBER	207127	num	7	SENT_672	[p28l589t493r782b539],
9	Study	NNP	O	Study	nn	10	SENT_672	[p28l798t490r950b554],
10	Group	NNP	O	Group	dep	7	SENT_672	[p28l964t492r1141b552],
11	.	.	O	.	_	0	SENT_672	[p28l964t492r1141b552],

1	Antiviral	JJ	O	antiviral	amod	2	SENT_673	[p28l1155t490r1374b539],
2	Effect	NN	O	effect	_	0	SENT_673	[p28l1393t489r1552b547],
3	,	,	O	,	_	0	SENT_673	[p28l1393t489r1552b547],
4	Safety	NN	O	safety	conj_and	2	SENT_673	[p28l1567t489r1739b553],
5	,	,	O	,	_	0	SENT_673	[p28l1567t489r1739b553],
6	and	CC	O	and	_	0	SENT_673	[p28l1754t490r1851b539],
7	Pharmacokinetics	NNS	O	pharmacokinetic	conj_and	2	SENT_673	[p28l134t567r603b617],
8	of	IN	O	of	_	0	SENT_673	[p28l618t566r673b617],
9	Five	CD	NUMBER	five	prep_of	7	SENT_673	[p28l686t569r914b631],
10	.	.	O	.	_	0	SENT_673	[p28l686t569r914b631],

1	—	NN	O	—	_	0	SENT_674	[p28l686t569r914b631],
2	.	.	O	.	_	0	SENT_674	[p28l686t569r914b631],

1	Day	NN	DURATION	day	_	0	SENT_675	[p28l686t569r914b631],
2	Oral	NNP	O	Oral	nn	6	SENT_675	[p28l927t567r1032b617],
3	Administration	NNP	O	Administration	nn	6	SENT_675	[p28l1049t567r1444b617],
4	ofDe	NNP	O	ofDe	nn	6	SENT_675	[p28l1461t566r1896b624],
5	|	NN	O	|	nn	6	SENT_675	[p28l1461t566r1896b624],
6	eobuvir	NN	O	eobuvir	dep	1	SENT_675	[p28l1461t566r1896b624],
7	(	NN	O	(	nn	8	SENT_675	[p28l1461t566r1896b624],
8	B	NN	O	b	dep	6	SENT_675	[p28l1461t566r1896b624],
9	|	CD	NUMBER	|	number	10	SENT_675	[p28l1461t566r1896b624],
10	207127	CD	NUMBER	207127	num	11	SENT_675	[p28l1915t568r2140b624],
11	)	NN	O	)	dep	1	SENT_675	[p28l1915t568r2140b624],
12	,	,	O	,	_	0	SENT_675	[p28l1915t568r2140b624],
13	an	DT	O	a	det	19	SENT_675	[p28l131t660r192b695],
14	lnvestigational	JJ	O	lnvestigational	amod	19	SENT_675	[p28l211t645r599b708],
15	Hepatitis	NNP	MISC	Hepatitis	nn	19	SENT_675	[p28l618t647r852b707],
16	CVirus	NNP	MISC	CVirus	nn	19	SENT_675	[p28l867t647r1041b695],
17	RNA	NN	MISC	rna	nn	19	SENT_675	[p28l1059t647r1169b694],
18	Polymerase	NN	MISC	polymerase	nn	19	SENT_675	[p28l1186t645r1489b709],
19	Inhibitor	NN	MISC	inhibitor	appos	11	SENT_675	[p28l1506t645r1741b702],
20	,	,	O	,	_	0	SENT_675	[p28l1506t645r1741b702],
21	in	IN	O	in	_	0	SENT_675	[p28l1758t647r1801b694],
22	Patients	NNS	O	patient	prep_in	1	SENT_675	[p28l1820t647r2028b695],
23	with	IN	O	with	_	0	SENT_675	[p28l130t723r245b773],
24	Chronic	JJ	O	chronic	amod	27	SENT_675	[p28l262t723r467b773],
25	Hepatitis	NNP	O	Hepatitis	nn	27	SENT_675	[p28l484t725r717b785],
26	C.	NNP	PERSON	C.	nn	27	SENT_675	[p28l732t725r779b773],
27	Antimicrob	NNP	PERSON	Antimicrob	prep_with	22	SENT_675	[p28l790t723r1088b773],
28	.	.	O	.	_	0	SENT_675	[p28l790t723r1088b773],

1	Agents	NNS	O	agent	_	0	SENT_676	[p28l1100t725r1278b786],
2	Chemother	NNP	O	Chemother	dep	1	SENT_676	[p28l1291t723r1589b773],
3	.	.	O	.	_	0	SENT_676	[p28l1291t723r1589b773],

1	57	CD	NUMBER	57	_	0	SENT_677	[p28l1604t727r1685b780],
2	,	,	O	,	_	0	SENT_677	[p28l1604t727r1685b780],
3	4727-4735	CD	DURATION	4727-4735	number	4	SENT_677	[p28l1698t726r1990b773],
4	(	CD	NUMBER	(	appos	1	SENT_677	[p28l133t801r309b856],
5	2013	CD	DATE	2013	num	6	SENT_677	[p28l133t801r309b856],
6	)	NN	O	)	dep	4	SENT_677	[p28l133t801r309b856],
7	.	.	O	.	_	0	SENT_677	[p28l133t801r309b856],

1	Larrey	NNP	O	Larrey	_	0	SENT_678	[p28l132t880r300b942],
2	,	,	O	,	_	0	SENT_678	[p28l132t880r300b942],
3	D.	NNP	O	D.	nn	4	SENT_678	[p28l317t880r364b928],
4	etal	NNP	O	etal	appos	1	SENT_678	[p28l378t878r493b928],
5	.	.	O	.	_	0	SENT_678	[p28l378t878r493b928],

1	Rapid	JJ	O	rapid	amod	5	SENT_679	[p28l511t878r655b940],
2	and	CC	O	and	_	0	SENT_679	[p28l671t878r768b928],
3	strong	JJ	O	strong	conj_and	1	SENT_679	[p28l785t886r951b941],
4	antiviral	JJ	O	antiviral	amod	5	SENT_679	[p28l967t878r1174b928],
5	activity	NN	O	activity	nsubj	16	SENT_679	[p28l1191t880r1382b942],
6	of	IN	O	of	_	0	SENT_679	[p28l1395t877r1449b928],
7	the	DT	O	the	det	11	SENT_679	[p28l1457t878r1544b928],
8	non	JJ	O	non	amod	11	SENT_679	[p28l1560t878r1980b928],
9	—	NN	O	—	nn	11	SENT_679	[p28l1560t878r1980b928],
10	nuc	NN	O	nuc	nn	11	SENT_679	[p28l1560t878r1980b928],
11	|	NN	O	|	prep_of	5	SENT_679	[p28l1560t878r1980b928],
12	eosidic	JJ	O	eosidic	amod	16	SENT_679	[p28l1560t878r1980b928],
13	NS5B	NN	O	ns5b	nn	16	SENT_679	[p28l1997t880r2131b928],
14	polymerase	NN	O	polymerase	nn	16	SENT_679	[p28l133t956r437b1020],
15	inhibitor	NN	O	inhibitor	nn	16	SENT_679	[p28l453t956r677b1006],
16	BI	NN	O	bus	_	0	SENT_679	[p28l692t958r733b1005],
17	207127	CD	NUMBER	207127	dobj	16	SENT_679	[p28l751t959r942b1006],
18	in	IN	O	in	_	0	SENT_679	[p28l959t958r1001b1005],
19	combination	NN	O	combination	prep_in	17	SENT_679	[p28l1018t956r1352b1006],
20	with	IN	O	with	_	0	SENT_679	[p28l1367t956r1481b1006],
21	peginterferon	NN	O	peginterferon	nn	23	SENT_679	[p28l1500t955r1860b1019],
22	alfa	NN	O	alfa	nn	23	SENT_679	[p28l1877t955r1966b1006],
23	2a	NN	O	2a	prep_with	16	SENT_679	[p28l1983t959r2040b1006],
24	and	CC	O	and	_	0	SENT_679	[p28l2056t956r2152b1006],
25	ribavirin	NNP	O	ribavirin	conj_and	23	SENT_679	[p28l133t1034r404b1084],
26	.	.	O	.	_	0	SENT_679	[p28l133t1034r404b1084],

1	J.	NNP	PERSON	J.	nn	2	SENT_680	[p28l133t1034r404b1084],
2	Hepatol	NNP	PERSON	Hepatol	_	0	SENT_680	[p28l419t1034r631b1097],
3	.	.	O	.	_	0	SENT_680	[p28l419t1034r631b1097],

1	57	CD	NUMBER	57	_	0	SENT_681	[p28l646t1038r726b1091],
2	,	,	O	,	_	0	SENT_681	[p28l646t1038r726b1091],
3	39-46	CD	NUMBER	39-46	number	4	SENT_681	[p28l741t1037r899b1084],
4	(	CD	NUMBER	(	appos	1	SENT_681	[p28l916t1035r1090b1091],
5	2012	CD	DATE	2012	num	6	SENT_681	[p28l916t1035r1090b1091],
6	)	NN	O	)	dep	4	SENT_681	[p28l916t1035r1090b1091],
7	.	.	O	.	_	0	SENT_681	[p28l916t1035r1090b1091],

1	Zeuzem	NNP	O	Zeuzem	_	0	SENT_682	[p28l129t1114r353b1169],
2	,	,	O	,	_	0	SENT_682	[p28l129t1114r353b1169],
3	S.	NNP	O	S.	nn	4	SENT_682	[p28l368t1114r408b1162],
4	etal	NNP	O	etal	appos	1	SENT_682	[p28l422t1112r537b1162],
5	.	.	O	.	_	0	SENT_682	[p28l422t1112r537b1162],

1	Efﬁcacy	NN	O	efﬁcacy	_	0	SENT_683	[p28l554t1111r752b1176],
2	of	IN	O	of	_	0	SENT_683	[p28l765t1111r819b1162],
3	the	DT	O	the	det	6	SENT_683	[p28l828t1112r914b1162],
4	protease	NN	O	protease	nn	6	SENT_683	[p28l930t1120r1156b1174],
5	inhibitor	NN	O	inhibitor	nn	6	SENT_683	[p28l1172t1112r1396b1162],
6	BI	NN	O	bus	prep_of	1	SENT_683	[p28l1411t1114r1452b1161],
7	201	CD	NUMBER	201	number	8	SENT_683	[p28l1470t1115r1553b1162],
8	335	CD	NUMBER	335	dep	6	SENT_683	[p28l1568t1115r1675b1169],
9	,	,	O	,	_	0	SENT_683	[p28l1568t1115r1675b1169],
10	polymerase	NN	O	polymerase	nn	12	SENT_683	[p28l1691t1112r1995b1176],
11	inhibitor	NN	O	inhibitor	nn	12	SENT_683	[p28l133t1190r357b1240],
12	Bl	NN	O	bl	prep_of	1	SENT_683	[p28l372t1192r413b1239],
13	2071	CD	DATE	2071	number	14	SENT_683	[p28l430t1193r547b1240],
14	27	CD	DATE	27	dep	12	SENT_683	[p28l562t1193r636b1247],
15	,	,	O	,	_	0	SENT_683	[p28l562t1193r636b1247],
16	and	CC	O	and	_	0	SENT_683	[p28l650t1190r746b1240],
17	ribavirin	NNP	O	ribavirin	conj_and	6	SENT_683	[p28l765t1190r976b1240],
18	in	IN	O	in	_	0	SENT_683	[p28l994t1192r1037b1239],
19	patients	NNS	O	patient	prep_in	17	SENT_683	[p28l1055t1192r1265b1252],
20	with	IN	O	with	_	0	SENT_683	[p28l1279t1190r1392b1240],
21	chronic	JJ	O	chronic	amod	23	SENT_683	[p28l1409t1190r1603b1240],
22	HCV	NN	O	hcv	nn	23	SENT_683	[p28l1620t1192r1731b1240],
23	infection	NN	O	infection	prep_with	1	SENT_683	[p28l1745t1189r1987b1240],
24	.	.	O	.	_	0	SENT_683	[p28l1745t1189r1987b1240],

1	Gastroenterology	NN	O	gastroenterology	_	0	SENT_684	[p28l132t1268r576b1332],
2	141	CD	NUMBER	141	num	1	SENT_684	[p28l589t1272r702b1325],
3	,	,	O	,	_	0	SENT_684	[p28l589t1272r702b1325],
4	2047-55	CD	NUMBER	2047-55	appos	1	SENT_684	[p28l716t1271r954b1325],
5	;	:	O	;	_	0	SENT_684	[p28l716t1271r954b1325],
6	quiz	NN	O	quiz	nn	8	SENT_684	[p28l968t1270r1079b1330],
7	e14	NN	O	e14	nn	8	SENT_684	[p28l1092t1272r1186b1318],
8	(	NN	O	(	dep	1	SENT_684	[p28l1201t1269r1302b1325],
9	201	CD	NUMBER	201	number	10	SENT_684	[p28l1201t1269r1302b1325],
10	1	CD	NUMBER	1	num	11	SENT_684	[p28l1320t1269r1376b1325],
11	)	NN	O	)	dep	8	SENT_684	[p28l1320t1269r1376b1325],
12	.	.	O	.	_	0	SENT_684	[p28l1320t1269r1376b1325],

1	Bedard	NNP	PERSON	Bedard	_	0	SENT_685	[p28l132t1346r328b1404],
2	,	,	O	,	_	0	SENT_685	[p28l132t1346r328b1404],
3	J.	NNP	O	J.	nn	4	SENT_685	[p28l340t1348r374b1396],
4	etal	NNP	O	etal	appos	1	SENT_685	[p28l389t1346r504b1396],
5	.	.	O	.	_	0	SENT_685	[p28l389t1346r504b1396],

1	Identiﬁcation	NN	O	identiﬁcation	nn	5	SENT_686	[p28l520t1345r865b1396],
2	and	CC	O	and	_	0	SENT_686	[p28l881t1346r977b1396],
3	characterization	NN	O	characterization	conj_and	1	SENT_686	[p28l994t1346r1416b1396],
4	ofVCH	NN	O	ofvch	nn	5	SENT_686	[p28l1432t1345r1735b1403],
5	—	NN	O	—	_	0	SENT_686	[p28l1432t1345r1735b1403],
6	222	CD	NUMBER	222	dep	5	SENT_686	[p28l1432t1345r1735b1403],
7	,	,	O	,	_	0	SENT_686	[p28l1432t1345r1735b1403],
8	a	DT	O	a	det	20	SENT_686	[p28l1749t1361r1775b1396],
9	novel	JJ	O	novel	amod	17	SENT_686	[p28l1793t1346r1932b1396],
10	potent	JJ	O	potent	dep	13	SENT_686	[p28l1950t1354r2125b1408],
11	and	CC	O	and	_	0	SENT_686	[p28l131t1424r227b1474],
12	selective	JJ	O	selective	conj_and	13	SENT_686	[p28l244t1424r471b1474],
13	non	JJ	O	non	amod	17	SENT_686	[p28l488t1424r896b1474],
14	—	NN	O	—	nn	17	SENT_686	[p28l488t1424r896b1474],
15	nuc	NN	O	nuc	nn	17	SENT_686	[p28l488t1424r896b1474],
16	|	NN	O	|	nn	17	SENT_686	[p28l488t1424r896b1474],
17	eoside	NN	O	eoside	nn	20	SENT_686	[p28l488t1424r896b1474],
18	HCV	NN	O	hcv	nn	20	SENT_686	[p28l913t1426r1024b1474],
19	polymerase	NN	O	polymerase	nn	20	SENT_686	[p28l1038t1424r1343b1488],
20	inhibitor	NN	O	inhibitor	appos	5	SENT_686	[p28l1359t1424r1591b1474],
21	.	.	O	.	_	0	SENT_686	[p28l1359t1424r1591b1474],

1	Presented	VBN	O	present	_	0	SENT_687	[p28l1607t1424r1865b1474],
2	at	IN	O	at	_	0	SENT_687	[p28l1882t1432r1930b1474],
3	the	DT	O	the	det	5	SENT_687	[p28l1942t1424r2028b1474],
4	44th	JJ	ORDINAL	44th	amod	5	SENT_687	[p28l130t1502r247b1552],
5	Annual	JJ	SET	annual	prep_at	1	SENT_687	[p28l263t1502r448b1552],
6	Meeting	VBG	O	meet	partmod	5	SENT_687	[p28l466t1504r682b1565],
7	of	IN	O	of	_	0	SENT_687	[p28l698t1501r752b1552],
8	the	DT	O	the	det	12	SENT_687	[p28l761t1502r847b1552],
9	European	JJ	ORGANIZATION	european	amod	12	SENT_687	[p28l864t1504r1111b1564],
10	Association	NNP	ORGANIZATION	Association	nn	12	SENT_687	[p28l1127t1504r1426b1552],
11	forthe	NN	O	forthe	nn	12	SENT_687	[p28l1441t1501r1611b1552],
12	Study	NN	O	study	prep_of	6	SENT_687	[p28l1626t1502r1777b1566],
13	of	IN	O	of	_	0	SENT_687	[p28l1790t1501r1844b1552],
14	the	DT	O	the	det	15	SENT_687	[p28l1852t1502r1938b1552],
15	Liver	NN	O	liver	prep_of	12	SENT_687	[p28l1955t1504r2086b1559],
16	,	,	O	,	_	0	SENT_687	[p28l1955t1504r2086b1559],
17	Copenhagen	NNP	LOCATION	Copenhagen	appos	15	SENT_687	[p28l131t1580r485b1643],
18	,	,	O	,	_	0	SENT_687	[p28l131t1580r485b1643],
19	Denmark	NNP	LOCATION	Denmark	appos	15	SENT_687	[p28l502t1580r754b1637],
20	,	,	O	,	_	0	SENT_687	[p28l502t1580r754b1637],
21	2009	CD	DATE	2009	appos	15	SENT_687	[p28l769t1583r909b1630],
22	.	.	O	.	_	0	SENT_687	[p28l769t1583r909b1630],

1	Abstr	NNP	PERSON	Abstr	_	0	SENT_688	[p28l923t1580r1071b1630],
2	.	.	O	.	_	0	SENT_688	[p28l923t1580r1071b1630],

1	935	CD	NUMBER	935	_	0	SENT_689	[p28l1086t1583r1193b1630],
2	.	.	O	.	_	0	SENT_689	[p28l1086t1583r1193b1630],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_690	[p28l20t1720r139b1741],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_690	[p28l148t1720r373b1741],
3	&	CC	O	&	_	0	SENT_690	[p28l380t1720r600b1741],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_690	[p28l380t1720r600b1741],
5	|	CD	NUMBER	|	num	6	SENT_690	[p28l380t1720r600b1741],
6	CS	NNP	O	CS	conj_and	2	SENT_690	[p28l380t1720r600b1741],
7	|	NNP	O	|	nn	8	SENT_690	[p28l610t1718r612b1748],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_690	[p28l620t1720r728b1741],
9	95	CD	NUMBER	95	num	10	SENT_690	[p28l736t1720r763b1741],
10	NUMBER	NN	O	number	dep	12	SENT_690	[p28l773t1720r881b1741],
11	1	CD	NUMBER	1	num	12	SENT_690	[p28l891t1721r898b1741],
12	|	CD	NUMBER	|	dep	15	SENT_690	[p28l912t1718r914b1748],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_690	[p28l923t1720r1041b1741],
14	2014	CD	DATE	2014	num	15	SENT_690	[p28l1049t1720r1107b1741],
15	87	CD	DATE	87	_	0	SENT_690	[p28l2108t1720r2139b1741],

1	STATE	NN	O	state	_	0	SENT_691	[p28l21t1863r163b1900],

1	ART	NN	O	art	_	0	SENT_692	[p28l306t1863r399b1900],

1	Nelson	NNP	PERSON	Nelson	nsubj	22	SENT_693	[p28l130t2098r322b2155],
2	,	,	O	,	_	0	SENT_693	[p28l130t2098r322b2155],
3	D.R.	NNP	O	D.R.	nn	4	SENT_693	[p28l339t2100r433b2147],
4	et	NNP	O	et	dep	1	SENT_693	[p28l447t2105r496b2147],
5	aI.VX-222	NN	O	ai.vx-222	dep	4	SENT_693	[p28l505t2098r1035b2160],
6	/	:	O	/	punct	4	SENT_693	[p28l505t2098r1035b2160],
7	telaprevir	NN	O	telaprevir	dep	4	SENT_693	[p28l505t2098r1035b2160],
8	in	IN	O	in	_	0	SENT_693	[p28l1049t2100r1092b2147],
9	combination	NN	O	combination	prep_in	7	SENT_693	[p28l1109t2098r1443b2147],
10	with	IN	O	with	_	0	SENT_693	[p28l1458t2098r1571b2147],
11	peginterferona	NN	O	peginterferona	nn	13	SENT_693	[p28l1590t2097r2141b2161, p28l130t2179r188b2225],
12	|	CD	NUMBER	|	num	13	SENT_693	[p28l1590t2097r2141b2161, p28l130t2179r188b2225],
13	pha2a	NN	O	pha2a	prep_with	9	SENT_693	[p28l1590t2097r2141b2161, p28l130t2179r188b2225],
14	and	CC	O	and	_	0	SENT_693	[p28l203t2176r300b2225],
15	ribavirin	NNP	O	ribavirin	dep	4	SENT_693	[p28l318t2176r529b2225],
16	in	IN	O	in	_	0	SENT_693	[p28l547t2178r590b2225],
17	treatment-naive	JJ	O	treatment-naive	amod	21	SENT_693	[p28l606t2178r1031b2225],
18	genotype	NN	O	genotype	nn	21	SENT_693	[p28l1045t2183r1300b2239],
19	1c	NN	O	1c	nn	21	SENT_693	[p28l1318t2180r1372b2225],
20	HCV	NN	O	hcv	nn	21	SENT_693	[p28l1388t2177r1499b2225],
21	patients	NNS	O	patient	prep_in	15	SENT_693	[p28l1513t2178r1723b2238],
22	treated	VBN	O	treat	_	0	SENT_693	[p28l1737t2176r1925b2225],
23	for	IN	O	for	_	0	SENT_693	[p28l1939t2175r2012b2225],
24	12	CD	DURATION	12	num	25	SENT_693	[p28l2030t2179r2085b2225],
25	weeks	NNS	NUMBER	week	prep_for	22	SENT_693	[p28l128t2254r304b2303],
26	:	:	O	:	_	0	SENT_693	[p28l128t2254r304b2303],
27	Zenith	NNP	ORGANIZATION	Zenith	nn	28	SENT_693	[p28l318t2254r486b2303],
28	study	NN	O	study	dep	25	SENT_693	[p28l502t2254r656b2317],
29	.	.	O	.	_	0	SENT_693	[p28l502t2254r656b2317],

1	SVR	NNP	O	SVR	dep	2	SENT_694	[p28l671t2255r769b2303],
2	12	CD	NUMBER	12	amod	4	SENT_694	[p28l787t2257r844b2303],
3	interim	JJ	O	interim	amod	4	SENT_694	[p28l860t2256r1044b2303],
4	analyses	NNS	O	analysis	nsubj	5	SENT_694	[p28l1061t2254r1281b2317],
5	[	VBP	O	[	_	0	SENT_694	[p28l1298t2254r1484b2310],
6	abstr	NN	O	abstr	dobj	5	SENT_694	[p28l1298t2254r1484b2310],
7	.	.	O	.	_	0	SENT_694	[p28l1298t2254r1484b2310],
8	]	SYM	O	]	dep	5	SENT_694	[p28l1298t2254r1484b2310],

1	.	.	O	.	_	0	SENT_695	[p28l1298t2254r1484b2310],

1	Hepatology	NNP	O	Hepatology	_	0	SENT_696	[p28l1499t2254r1797b2317],
2	54	CD	NUMBER	54	num	1	SENT_696	[p28l1808t2258r1887b2311],
3	,	,	O	,	_	0	SENT_696	[p28l1808t2258r1887b2311],
4	1442	CD	DATE	1442	num	1	SENT_696	[p28l1906t2257r2028b2303],
5	(	NN	O	(	dep	1	SENT_696	[p28l131t2332r232b2387],
6	201	CD	NUMBER	201	number	7	SENT_696	[p28l131t2332r232b2387],
7	1	CD	NUMBER	1	num	8	SENT_696	[p28l250t2332r305b2387],
8	)	NN	O	)	dep	5	SENT_696	[p28l250t2332r305b2387],
9	.	.	O	.	_	0	SENT_696	[p28l250t2332r305b2387],

1	Lawitz	NNP	PERSON	Lawitz	_	0	SENT_697	[p28l130t2411r308b2466],
2	,	,	O	,	_	0	SENT_697	[p28l130t2411r308b2466],
3	E.	NNP	O	E.	nn	4	SENT_697	[p28l324t2411r362b2458],
4	etal	NN	O	etal	appos	1	SENT_697	[p28l376t2409r491b2458],
5	.	.	O	.	_	0	SENT_697	[p28l376t2409r491b2458],

1	Safety	NN	O	safety	nn	4	SENT_698	[p28l506t2408r667b2472],
2	and	CC	O	and	_	0	SENT_698	[p28l680t2409r776b2458],
3	antiviral	JJ	O	antiviral	conj_and	1	SENT_698	[p28l793t2409r1000b2458],
4	activity	NN	O	activity	_	0	SENT_698	[p28l1017t2411r1207b2472],
5	of	IN	O	of	_	0	SENT_698	[p28l1220t2408r1275b2458],
6	ANA598	NN	O	ana598	prep_of	4	SENT_698	[p28l1284t2411r1499b2458],
7	in	IN	O	in	_	0	SENT_698	[p28l1515t2411r1557b2458],
8	combination	NN	O	combination	prep_in	4	SENT_698	[p28l1574t2409r1908b2458],
9	with	IN	O	with	prep	4	SENT_698	[p28l1923t2409r2037b2458],
10	pegylated	VBN	O	pegylate	partmod	4	SENT_698	[p28l131t2487r391b2550],
11	interferon	NN	O	interferon	nn	12	SENT_698	[p28l410t2486r667b2536],
12	alpha-2a	NN	O	alpha-2a	dobj	10	SENT_698	[p28l684t2487r910b2549],
13	plus	CC	O	plus	prep	12	SENT_698	[p28l928t2487r1033b2549],
14	ribavirin	NNP	O	ribavirin	dep	13	SENT_698	[p28l1050t2487r1261b2536],
15	in	IN	O	in	_	0	SENT_698	[p28l1279t2489r1322b2536],
16	treatment-naive	JJ	O	treatment-naive	amod	20	SENT_698	[p28l1337t2489r1762b2536],
17	genotype-1	NN	O	genotype-1	nn	20	SENT_698	[p28l1777t2491r2075b2550],
18	chronic	JJ	O	chronic	amod	20	SENT_698	[p28l129t2565r324b2614],
19	HCV	NN	O	hcv	nn	20	SENT_698	[p28l340t2566r452b2614],
20	patients	NNS	O	patient	prep_in	10	SENT_698	[p28l466t2567r688b2627],
21	.	.	O	.	_	0	SENT_698	[p28l466t2567r688b2627],

1	Presented	VBN	O	present	_	0	SENT_699	[p28l705t2565r962b2614],
2	at	IN	O	at	_	0	SENT_699	[p28l979t2572r1027b2614],
3	the	DT	O	the	det	5	SENT_699	[p28l1040t2565r1126b2614],
4	45th	JJ	ORDINAL	45th	amod	5	SENT_699	[p28l1139t2565r1256b2614],
5	Annual	JJ	SET	annual	prep_at	1	SENT_699	[p28l1272t2565r1457b2614],
6	Meeting	VBG	O	meet	partmod	5	SENT_699	[p28l1475t2567r1690b2628],
7	of	IN	O	of	_	0	SENT_699	[p28l1707t2564r1762b2614],
8	the	DT	O	the	det	10	SENT_699	[p28l1770t2565r1856b2614],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_699	[p28l1872t2567r2120b2627],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_699	[p28l129t2645r428b2692],
11	for	IN	O	for	_	0	SENT_699	[p28l443t2642r515b2692],
12	the	DT	O	the	det	13	SENT_699	[p28l527t2643r613b2692],
13	Study	NN	O	study	prep_for	10	SENT_699	[p28l628t2643r778b2706],
14	of	IN	O	of	_	0	SENT_699	[p28l791t2642r846b2692],
15	the	DT	O	the	det	16	SENT_699	[p28l854t2643r940b2692],
16	Liver	NN	O	liver	prep_of	13	SENT_699	[p28l957t2645r1088b2700],
17	,	,	O	,	_	0	SENT_699	[p28l957t2645r1088b2700],
18	Vienna	NNP	LOCATION	Vienna	appos	16	SENT_699	[p28l1098t2645r1292b2700],
19	,	,	O	,	_	0	SENT_699	[p28l1098t2645r1292b2700],
20	Austria	NNP	LOCATION	Austria	appos	16	SENT_699	[p28l1306t2645r1502b2700],
21	,	,	O	,	_	0	SENT_699	[p28l1306t2645r1502b2700],
22	14-18	CD	DATE	14-18	appos	16	SENT_699	[p28l1521t2646r1675b2692],
23	April	NNP	DATE	April	tmod	6	SENT_699	[p28l1689t2643r1809b2705],
24	2010	CD	DATE	2010	num	23	SENT_699	[p28l1827t2643r2129b2692],
25	.	.	O	.	_	0	SENT_699	[p28l1827t2643r2129b2692],

1	Abstr	NNP	O	Abstr	_	0	SENT_700	[p28l1827t2643r2129b2692],
2	.	.	O	.	_	0	SENT_700	[p28l1827t2643r2129b2692],

1	LB13	NN	O	lb13	_	0	SENT_701	[p28l132t2722r269b2769],
2	.	.	O	.	_	0	SENT_701	[p28l132t2722r269b2769],

1	Hoffmann-La	NNP	PERSON	Hoffmann-La	nn	2	SENT_702	[p28l130t2797r472b2847],
2	Roche	NNP	PERSON	Roche	_	0	SENT_702	[p28l490t2798r661b2847],
3	.	.	O	.	_	0	SENT_702	[p28l490t2798r661b2847],

1	AN	DT	O	a	det	3	SENT_703	[p28l675t2800r750b2847],
2	NAPU	NNP	MISC	NAPU	nn	3	SENT_703	[p28l759t2800r907b2847],
3	RNA	NN	MISC	rna	_	0	SENT_703	[p28l916t2800r1038b2847],
4	:	:	O	:	_	0	SENT_703	[p28l916t2800r1038b2847],
5	A	DT	O	a	det	6	SENT_703	[p28l1051t2800r1088b2847],
6	study	NN	O	study	dep	3	SENT_703	[p28l1102t2798r1247b2861],
7	of	IN	O	of	_	0	SENT_703	[p28l1260t2797r1314b2847],
8	the	DT	O	the	det	9	SENT_703	[p28l1322t2798r1408b2847],
9	combination	NN	O	combination	prep_of	6	SENT_703	[p28l1422t2798r1756b2847],
10	of	IN	O	of	_	0	SENT_703	[p28l1772t2797r1827b2847],
11	RO5466731	NN	O	ro5466731	prep_of	9	SENT_703	[p28l1839t2799r2153b2855],
12	,	,	O	,	_	0	SENT_703	[p28l1839t2799r2153b2855],
13	RO51	NN	O	ro51	prep_of	9	SENT_703	[p28l132t2877r260b2925],
14	90591	CD	NUMBER	90591	num	13	SENT_703	[p28l274t2879r446b2933],
15	,	,	O	,	_	0	SENT_703	[p28l274t2879r446b2933],
16	ritonavir	NN	O	ritonavir	prep_of	9	SENT_703	[p28l463t2878r681b2925],
17	and	CC	O	and	_	0	SENT_703	[p28l694t2876r791b2925],
18	Copegus	NN	O	copegus	prep_of	9	SENT_703	[p28l807t2877r1039b2939],
19	(	CD	NUMBER	(	num	18	SENT_703	[p28l1055t2876r1303b2933],
20	ribavirin	NNP	O	ribavirin	dep	18	SENT_703	[p28l1055t2876r1303b2933],
21	)	CD	NUMBER	)	num	20	SENT_703	[p28l1055t2876r1303b2933],
22	with	IN	O	with	_	0	SENT_703	[p28l1318t2876r1431b2925],
23	or	CC	O	or	_	0	SENT_703	[p28l1448t2890r1501b2925],
24	without	IN	O	without	_	0	SENT_703	[p28l1513t2876r1721b2925],
25	RO5024048	NN	O	ro5024048	prep_without	20	SENT_703	[p28l1737t2877r2038b2925],
26	in	IN	O	in	_	0	SENT_703	[p28l131t2956r174b3003],
27	patients	NNS	O	patient	prep_in	25	SENT_703	[p28l192t2956r402b3016],
28	with	IN	O	with	_	0	SENT_703	[p28l416t2954r529b3003],
29	chronic	JJ	O	chronic	amod	31	SENT_703	[p28l545t2954r740b3003],
30	hepatitis	NN	O	hepatitis	nn	31	SENT_703	[p28l756t2954r981b3016],
31	C	NN	O	c	prep_with	27	SENT_703	[p28l995t2955r1029b3003],
32	who	WP	O	who	nsubj	35	SENT_703	[p28l1042t2954r1157b3003],
33	are	VBP	O	be	cop	35	SENT_703	[p28l1171t2968r1250b3003],
34	either	RB	O	either	advmod	35	SENT_703	[p28l1265t2954r1418b3003],
35	treatment-naive	JJ	O	treatment-naive	rcmod	6	SENT_703	[p28l1430t2956r1856b3003],
36	or	CC	O	or	_	0	SENT_703	[p28l1870t2968r1923b3003],
37	have	VBP	O	have	aux	39	SENT_703	[p28l1939t2954r2060b3003],
38	previously	RB	DATE	previously	advmod	39	SENT_703	[p28l131t3032r401b3095],
39	experienced	VBN	O	experience	conj_or	35	SENT_703	[p28l414t3032r737b3094],
40	a	DT	O	a	det	42	SENT_703	[p28l753t3047r779b3081],
41	null	JJ	O	null	amod	42	SENT_703	[p28l797t3032r889b3081],
42	response	NN	O	response	nsubj	52	SENT_703	[p28l908t3047r1143b3094],
43	to	TO	O	to	_	0	SENT_703	[p28l1156t3039r1209b3081],
44	interferon-based	JJ	O	interferon-based	amod	46	SENT_703	[p28l1225t3031r1663b3082],
45	treatment	NN	O	treatment	nn	46	SENT_703	[p28l1678t3039r1942b3081],
46	[	NN	O	[	prep_to	42	SENT_703	[p28l1959t3032r2151b3089],
47	clinical	JJ	O	clinical	amod	52	SENT_703	[p28l1959t3032r2151b3089],
48	tria	NN	O	trium	nn	52	SENT_703	[p28l128t3110r368b3173],
49	|	CD	NUMBER	|	num	52	SENT_703	[p28l128t3110r368b3173],
50	s.	NN	O	s.	nn	52	SENT_703	[p28l128t3110r368b3173],
51	gov	NN	O	gov	nn	52	SENT_703	[p28l128t3110r368b3173],
52	identiﬁer	NN	O	identiﬁer	xcomp	39	SENT_703	[p28l382t3109r618b3160],
53	NCT1628094	NN	O	nct1628094	nn	54	SENT_703	[p28l634t3111r1000b3167],
54	]	NN	O	]	dobj	35	SENT_703	[p28l634t3111r1000b3167],
55	.	.	O	.	_	0	SENT_703	[p28l634t3111r1000b3167],

1	US	NNP	ORGANIZATION	US	nn	3	SENT_704	[p28l1017t3112r1083b3160],
2	National	NNP	ORGANIZATION	National	nn	3	SENT_704	[p28l1100t3110r1316b3160],
3	Institutes	NNPS	ORGANIZATION	Institutes	_	0	SENT_704	[p28l1335t3112r1575b3160],
4	of	IN	ORGANIZATION	of	_	0	SENT_704	[p28l1589t3109r1644b3160],
5	Health	NNP	ORGANIZATION	Health	prep_of	3	SENT_704	[p28l1656t3110r1823b3160],
6	.	.	O	.	_	0	SENT_704	[p28l128t3188r753b3251],

1	Accessed	VBN	O	access	_	0	SENT_705	[p28l767t3188r1007b3238],
2	1	CD	DATE	1	num	3	SENT_705	[p28l1028t3192r1042b3237],
3	August	NNP	DATE	August	tmod	1	SENT_705	[p28l1066t3190r1254b3251],
4	201	CD	NUMBER	201	num	3	SENT_705	[p28l1268t3191r1352b3238],
5	3	CD	NUMBER	3	dep	3	SENT_705	[p28l1366t3191r1408b3238],
6	.	.	O	.	_	0	SENT_705	[p28l1366t3191r1408b3238],

1	Zeuzem	NNP	O	Zeuzem	_	0	SENT_706	[p28l127t3268r351b3323],
2	,	,	O	,	_	0	SENT_706	[p28l127t3268r351b3323],
3	S.	NNP	O	S.	nn	4	SENT_706	[p28l366t3267r406b3316],
4	etal	NNP	O	etal	appos	1	SENT_706	[p28l420t3266r535b3316],
5	.	.	O	.	_	0	SENT_706	[p28l420t3266r535b3316],

1	The	DT	O	the	det	3	SENT_707	[p28l544t3266r642b3316],
2	protease	NN	O	protease	nn	3	SENT_707	[p28l658t3273r884b3328],
3	inhibitor	NN	O	inhibitor	_	0	SENT_707	[p28l900t3266r1133b3323],
4	,	,	O	,	_	0	SENT_707	[p28l900t3266r1133b3323],
5	GS-9256	NN	O	gs-9256	conj_and	3	SENT_707	[p28l1147t3267r1379b3323],
6	,	,	O	,	_	0	SENT_707	[p28l1147t3267r1379b3323],
7	and	CC	O	and	_	0	SENT_707	[p28l1393t3266r1490b3316],
8	non-nucleoside	JJ	O	non-nucleoside	amod	10	SENT_707	[p28l1509t3266r1917b3316],
9	polymerase	NN	O	polymerase	nn	10	SENT_707	[p28l131t3344r435b3408],
10	inhibitor	NN	O	inhibitor	conj_and	3	SENT_707	[p28l451t3344r675b3393],
11	tegobuvir	NN	O	tegobuvir	nn	19	SENT_707	[p28l687t3344r947b3407],
12	alone	RB	O	alone	amod	19	SENT_707	[p28l960t3344r1116b3401],
13	,	,	O	,	_	0	SENT_707	[p28l960t3344r1116b3401],
14	with	IN	O	with	dep	12	SENT_707	[p28l1130t3344r1243b3393],
15	ribavirin	NNP	O	ribavirin	pobj	14	SENT_707	[p28l1262t3344r1488b3401],
16	,	,	O	,	_	0	SENT_707	[p28l1262t3344r1488b3401],
17	or	CC	O	or	_	0	SENT_707	[p28l1502t3359r1555b3393],
18	pegylated	VBN	O	pegylate	conj_or	12	SENT_707	[p28l1571t3344r1831b3408],
19	interferon	NN	O	interferon	dep	3	SENT_707	[p28l1849t3343r2106b3393],
20	plus	CC	O	plus	prep	19	SENT_707	[p28l131t3422r237b3484],
21	ribavirin	NNP	O	ribavirin	dep	20	SENT_707	[p28l253t3422r464b3471],
22	in	IN	O	in	_	0	SENT_707	[p28l483t3424r525b3471],
23	hepatitis	NNP	O	hepatitis	nn	25	SENT_707	[p28l544t3422r769b3484],
24	C.	NNP	ORGANIZATION	C.	nn	25	SENT_707	[p28l783t3423r829b3471],
25	Hepatology	NNP	ORGANIZATION	Hepatology	prep_in	21	SENT_707	[p28l844t3422r1142b3486],
26	55	CD	NUMBER	55	num	25	SENT_707	[p28l1153t3426r1233b3479],
27	,	,	O	,	_	0	SENT_707	[p28l1153t3426r1233b3479],
28	749-758	CD	NUMBER	749-758	number	29	SENT_707	[p28l1248t3425r1471b3471],
29	(	CD	NUMBER	(	appos	25	SENT_707	[p28l1488t3423r1662b3479],
30	2012	CD	DATE	2012	num	31	SENT_707	[p28l1488t3423r1662b3479],
31	)	NN	O	)	dep	29	SENT_707	[p28l1488t3423r1662b3479],
32	.	.	O	.	_	0	SENT_707	[p28l1488t3423r1662b3479],

1	Sulkowski	NNP	PERSON	Sulkowski	_	0	SENT_708	[p28l128t3500r401b3557],
2	,	,	O	,	_	0	SENT_708	[p28l128t3500r401b3557],
3	M.	NNP	O	M.	nn	4	SENT_708	[p28l416t3502r476b3550],
4	etal	NNP	O	etal	appos	1	SENT_708	[p28l490t3500r605b3550],
5	.	.	O	.	_	0	SENT_708	[p28l490t3500r605b3550],

1	High	JJ	O	high	amod	5	SENT_709	[p28l622t3500r742b3563],
2	sustained	JJ	O	sustained	amod	5	SENT_709	[p28l758t3500r1008b3550],
3	virologic	JJ	O	virologic	amod	5	SENT_709	[p28l1023t3500r1250b3563],
4	response	NN	O	response	nn	5	SENT_709	[p28l1266t3514r1501b3562],
5	rate	NN	O	rate	nsubj	14	SENT_709	[p28l1518t3507r1615b3550],
6	in	IN	O	in	_	0	SENT_709	[p28l1631t3502r1674b3549],
7	treatment-naive	JJ	O	treatment-naive	amod	10	SENT_709	[p28l1689t3502r2115b3550],
8	HCV	NN	O	hcv	nn	10	SENT_709	[p28l132t3580r243b3627],
9	genotype	NN	O	genotype	nn	10	SENT_709	[p28l255t3585r509b3642],
10	1a	NN	O	1a	prep_in	5	SENT_709	[p28l528t3582r581b3627],
11	and	CC	O	and	_	0	SENT_709	[p28l597t3578r694b3627],
12	1b	NN	O	1b	nn	13	SENT_709	[p28l715t3578r776b3627],
13	patients	NNS	O	patient	prep_in	5	SENT_709	[p28l792t3580r1002b3640],
14	treated	VBN	O	treat	_	0	SENT_709	[p28l1015t3578r1203b3628],
15	for	IN	O	for	_	0	SENT_709	[p28l1218t3577r1290b3627],
16	12	CD	DURATION	12	num	17	SENT_709	[p28l1308t3581r1364b3627],
17	weeks	NNS	NUMBER	week	prep_for	14	SENT_709	[p28l1378t3578r1541b3627],
18	with	IN	O	with	_	0	SENT_709	[p28l1554t3578r1668b3627],
19	an	DT	O	a	det	24	SENT_709	[p28l1684t3593r1744b3627],
20	interferon-free	JJ	O	interferon-free	amod	24	SENT_709	[p28l1763t3577r2145b3628],
21	all	DT	O	all	dep	20	SENT_709	[p28l129t3656r184b3706],
22	oral	JJ	O	oral	amod	24	SENT_709	[p28l200t3656r295b3706],
23	quad	NN	O	quad	nn	24	SENT_709	[p28l312t3656r444b3718],
24	regimen	NN	O	regimen	prep_with	17	SENT_709	[p28l463t3658r693b3719],
25	:	:	O	:	_	0	SENT_709	[p28l463t3658r693b3719],
26	interim	JJ	O	interim	amod	27	SENT_709	[p28l709t3658r893b3706],
27	results	NNS	O	result	dep	24	SENT_709	[p28l911t3656r1091b3706],
28	.	.	O	.	_	0	SENT_709	[p28l911t3656r1091b3706],

1	Presented	VBN	O	present	_	0	SENT_710	[p28l1108t3656r1366b3706],
2	at	IN	O	at	_	0	SENT_710	[p28l1382t3663r1430b3706],
3	the	DT	O	the	det	6	SENT_710	[p28l1443t3656r1529b3706],
4	47th	JJ	ORDINAL	47th	amod	6	SENT_710	[p28l1542t3656r1659b3706],
5	annual	JJ	SET	annual	amod	6	SENT_710	[p28l1676t3656r1852b3706],
6	meeting	NN	O	meeting	prep_at	1	SENT_710	[p28l1871t3658r2087b3719],
7	of	IN	O	of	_	0	SENT_710	[p28l129t3733r184b3783],
8	the	DT	O	the	det	10	SENT_710	[p28l192t3734r278b3783],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_710	[p28l295t3736r542b3796],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_710	[p28l558t3736r857b3784],
11	for	IN	O	for	_	0	SENT_710	[p28l872t3733r944b3783],
12	the	DT	O	the	det	13	SENT_710	[p28l956t3734r1042b3783],
13	Study	NN	O	study	prep_for	1	SENT_710	[p28l1057t3734r1208b3797],
14	of	IN	O	of	_	0	SENT_710	[p28l1221t3733r1275b3783],
15	the	DT	O	the	det	16	SENT_710	[p28l1284t3734r1369b3783],
16	Liver	NN	O	liver	prep_of	13	SENT_710	[p28l1386t3736r1517b3791],
17	,	,	O	,	_	0	SENT_710	[p28l1386t3736r1517b3791],
18	Barcelona	NNP	ORGANIZATION	Barcelona	appos	16	SENT_710	[p28l1534t3734r1803b3791],
19	,	,	O	,	_	0	SENT_710	[p28l1534t3734r1803b3791],
20	Spain	NNP	LOCATION	Spain	appos	16	SENT_710	[p28l1817t3735r1975b3796],
21	,	,	O	,	_	0	SENT_710	[p28l1817t3735r1975b3796],
22	18-22	CD	NUMBER	18-22	appos	16	SENT_710	[p28l1993t3737r2147b3783],

1	April	NNP	DATE	April	_	0	SENT_711	[p29l129t14r249b76],
2	2012	CD	DATE	2012	dep	1	SENT_711	[p29l266t14r568b64],
3	.	.	O	.	_	0	SENT_711	[p29l266t14r568b64],

1	Abstr	NNP	O	Abstr	_	0	SENT_712	[p29l266t14r568b64],
2	.	.	O	.	_	0	SENT_712	[p29l266t14r568b64],

1	1421	CD	DATE	1421	_	0	SENT_713	[p29l587t17r723b64],
2	.	.	O	.	_	0	SENT_713	[p29l587t17r723b64],

1	Gane	NNP	O	Gane	nn	3	SENT_714	[p29l128t94r276b149],
2	,	,	O	,	_	0	SENT_714	[p29l128t94r276b149],
3	E.J.	NNP	O	E.J.	dep	4	SENT_714	[p29l293t94r366b142],
4	etal	JJ	O	etal	_	0	SENT_714	[p29l381t92r496b142],
5	.	.	O	.	_	0	SENT_714	[p29l381t92r496b142],

1	Oral	JJ	O	oral	amod	3	SENT_715	[p29l510t92r614b142],
2	combination	NN	O	combination	nn	3	SENT_715	[p29l631t92r965b142],
3	therapy	NN	O	therapy	dep	12	SENT_715	[p29l980t92r1184b155],
4	with	IN	O	with	_	0	SENT_715	[p29l1196t92r1310b142],
5	a	DT	O	a	det	9	SENT_715	[p29l1326t107r1351b142],
6	nucleoside	JJ	O	nucleoside	amod	9	SENT_715	[p29l1369t92r1652b142],
7	polymerase	NN	O	polymerase	nn	9	SENT_715	[p29l1669t92r1973b155],
8	inhibitor	NN	O	inhibitor	nn	9	SENT_715	[p29l131t170r355b220],
9	(	NN	O	(	prep_with	3	SENT_715	[p29l369t171r513b227],
10	RG71	NN	O	rg71	dep	12	SENT_715	[p29l369t171r513b227],
11	28	CD	NUMBER	28	num	10	SENT_715	[p29l527t171r605b227],
12	)	NN	O	)	dep	18	SENT_715	[p29l527t171r605b227],
13	and	CC	O	and	_	0	SENT_715	[p29l621t170r717b220],
14	danoprevirfor	JJ	O	danoprevirfor	amod	17	SENT_715	[p29l734t169r1107b232],
15	chronic	JJ	O	chronic	amod	17	SENT_715	[p29l1120t170r1314b220],
16	hepatitis	NN	O	hepatitis	nn	17	SENT_715	[p29l1331t170r1555b232],
17	C	NN	O	c	conj_and	12	SENT_715	[p29l1570t172r1603b220],
18	genotype	NN	O	genotype	dep	20	SENT_715	[p29l1618t177r1872b233],
19	1	CD	NUMBER	1	num	18	SENT_715	[p29l1891t174r1905b219],
20	infection	NN	O	infection	dep	22	SENT_715	[p29l131t247r359b298],
21	(	CD	NUMBER	(	num	20	SENT_715	[p29l377t249r691b305],
22	INFORM-1	NN	O	inform-1	dep	25	SENT_715	[p29l377t249r691b305],
23	)	CD	NUMBER	)	num	22	SENT_715	[p29l377t249r691b305],
24	:	:	O	:	_	0	SENT_715	[p29l377t249r691b305],
25	a	DT	O	a	_	0	SENT_715	[p29l705t263r731b298],
26	randomised	VBN	O	randomise	partmod	25	SENT_715	[p29l749t248r1074b305],
27	,	,	O	,	_	0	SENT_715	[p29l749t248r1074b305],
28	double-blind	JJ	O	double-blind	amod	33	SENT_715	[p29l1089t248r1446b305],
29	,	,	O	,	_	0	SENT_715	[p29l1089t248r1446b305],
30	placebo-controlled	JJ	O	placebo-controlled	amod	33	SENT_715	[p29l1462t248r1976b310],
31	,	,	O	,	_	0	SENT_715	[p29l1462t248r1976b310],
32	doseescalation	JJ	O	doseescalation	amod	33	SENT_715	[p29l1990t248r2136b298, p29l129t325r391b374],
33	trial	NN	O	trial	dobj	26	SENT_715	[p29l406t325r519b374],
34	.	.	O	.	_	0	SENT_715	[p29l406t325r519b374],

1	Lancet	NNP	O	Lancet	_	0	SENT_716	[p29l533t327r703b374],
2	376	CD	NUMBER	376	num	1	SENT_716	[p29l714t328r829b381],
3	,	,	O	,	_	0	SENT_716	[p29l714t328r829b381],
4	1467-1475	CD	DATE	1467-1475	num	1	SENT_716	[p29l849t328r1132b374],
5	(	CD	NUMBER	(	num	7	SENT_716	[p29l1150t326r1324b381],
6	2010	CD	DATE	2010	num	7	SENT_716	[p29l1150t326r1324b381],
7	)	NN	O	)	dep	1	SENT_716	[p29l1150t326r1324b381],
8	.	.	O	.	_	0	SENT_716	[p29l1150t326r1324b381],

1	Zeuzem	NNP	O	Zeuzem	_	0	SENT_717	[p29l127t403r535b460],
2	,	,	O	,	_	0	SENT_717	[p29l127t403r535b460],
3	S.	NNP	O	S.	nn	4	SENT_717	[p29l127t403r535b460],
4	etaI	NNP	O	etaI	appos	1	SENT_717	[p29l127t403r535b460],
5	.	.	O	.	_	0	SENT_717	[p29l127t403r535b460],

1	Faldaprevir	NNP	O	Faldaprevir	nn	3	SENT_718	[p29l552t403r916b465],
2	(	NN	O	(	nn	3	SENT_718	[p29l552t403r916b465],
3	B	NN	O	b	_	0	SENT_718	[p29l552t403r916b465],
4	|	CD	NUMBER	|	num	6	SENT_718	[p29l552t403r916b465],
5	201335	CD	NUMBER	201335	num	6	SENT_718	[p29l934t404r1157b460],
6	)	NN	O	)	dep	3	SENT_718	[p29l934t404r1157b460],
7	,	,	O	,	_	0	SENT_718	[p29l934t404r1157b460],
8	Bl	NN	O	bl	dep	3	SENT_718	[p29l1174t405r1214b452],
9	207127	CD	NUMBER	207127	num	8	SENT_718	[p29l1232t406r1424b452],
10	and	CC	O	and	_	0	SENT_718	[p29l1438t403r1535b452],
11	ribavirin	NNP	O	ribavirin	dep	3	SENT_718	[p29l1553t403r1764b452],
12	oral	JJ	O	oral	amod	13	SENT_718	[p29l1781t403r1876b452],
13	therapy	NN	O	therapy	dep	3	SENT_718	[p29l1891t403r2096b466],
14	for	IN	O	for	_	0	SENT_718	[p29l128t480r200b530],
15	treatment-naive	JJ	O	treatment-naive	amod	17	SENT_718	[p29l212t483r637b531],
16	HCV	NN	O	hcv	nn	17	SENT_718	[p29l654t483r765b531],
17	genotype	NN	O	genotype	prep_for	13	SENT_718	[p29l778t488r1032b545],
18	1	CD	NUMBER	1	dep	3	SENT_718	[p29l1051t483r1381b531],
19	:	:	O	:	_	0	SENT_718	[p29l1051t483r1381b531],
20	SOUND-C1	NN	O	sound-c1	dep	18	SENT_718	[p29l1051t483r1381b531],
21	ﬁnal	JJ	O	ﬁnal	amod	24	SENT_718	[p29l1404t480r1514b530],
22	resu	NN	O	resu	nn	24	SENT_718	[p29l1533t481r1901b531],
23	|	NN	O	|	nn	24	SENT_718	[p29l1533t481r1901b531],
24	ts	NNS	O	t	dep	20	SENT_718	[p29l1533t481r1901b531],
25	.	.	O	.	_	0	SENT_718	[p29l1533t481r1901b531],

1	Antivir	NNP	O	Antivir	_	0	SENT_719	[p29l1533t481r1901b531],
2	.	.	O	.	_	0	SENT_719	[p29l1533t481r1901b531],

1	Ther	NNP	O	Ther	_	0	SENT_720	[p29l1918t481r2038b530],
2	.	.	O	.	_	0	SENT_720	[p29l1918t481r2038b530],

1	(	RB	O	(	amod	3	SENT_721	[p29l131t559r477b621],
2	2013	CD	DATE	2013	tmod	1	SENT_721	[p29l131t559r477b621],
3	)	NN	O	)	_	0	SENT_721	[p29l131t559r477b621],
4	;	:	O	;	_	0	SENT_721	[p29l131t559r477b621],
5	e-pub	NN	O	e-pub	dep	3	SENT_721	[p29l131t559r477b621],
6	ahead	RB	O	ahead	_	0	SENT_721	[p29l491t559r650b609],
7	of	IN	O	of	_	0	SENT_721	[p29l667t558r721b609],
8	print	NN	O	print	prep_ahead_of	5	SENT_721	[p29l733t561r856b621],
9	4	CD	DATE	4	num	8	SENT_721	[p29l869t563r900b608],
10	April	NNP	DATE	April	tmod	5	SENT_721	[p29l913t559r1033b621],
11	2013	CD	DATE	2013	num	10	SENT_721	[p29l1050t562r1190b609],
12	.	.	O	.	_	0	SENT_721	[p29l1050t562r1190b609],

1	Zeuzem	NNP	O	Zeuzem	_	0	SENT_722	[p29l129t851r352b906],
2	,	,	O	,	_	0	SENT_722	[p29l129t851r352b906],
3	S.	NNP	O	S.	nn	4	SENT_722	[p29l367t850r407b899],
4	etal	NNP	O	etal	appos	1	SENT_722	[p29l421t849r536b899],
5	.	.	O	.	_	0	SENT_722	[p29l421t849r536b899],

1	Faldaprevir	NNP	O	Faldaprevir	_	0	SENT_723	[p29l553t849r843b911],
2	and	CC	O	and	_	0	SENT_723	[p29l855t849r952b898],
3	deleobuvirfor	JJ	O	deleobuvirfor	amod	4	SENT_723	[p29l968t848r1337b899],
4	HCV	NN	O	hcv	conj_and	1	SENT_723	[p29l1352t851r1463b899],
5	genotype	NN	O	genotype	dep	1	SENT_723	[p29l1475t856r1729b913],
6	1	CD	NUMBER	1	num	7	SENT_723	[p29l1748t853r1763b898],
7	infection	NN	O	infection	dep	5	SENT_723	[p29l1788t848r2031b898],
8	.	.	O	.	_	0	SENT_723	[p29l1788t848r2031b898],

1	N.	NNP	O	N.	nn	2	SENT_724	[p29l2045t851r2093b898],
2	Engl	NNP	O	Engl	_	0	SENT_724	[p29l130t927r249b990],
3	.	.	O	.	_	0	SENT_724	[p29l130t927r249b990],

1	J.	NNP	O	J.	nn	2	SENT_725	[p29l259t929r294b977],
2	Med	NNP	O	Med	_	0	SENT_725	[p29l308t927r430b977],
3	.	.	O	.	_	0	SENT_725	[p29l308t927r430b977],

1	369	CD	NUMBER	369	_	0	SENT_726	[p29l445t930r560b984],
2	,	,	O	,	_	0	SENT_726	[p29l445t930r560b984],
3	630-639	CD	NUMBER	630-639	number	4	SENT_726	[p29l574t930r799b977],
4	(	CD	NUMBER	(	appos	1	SENT_726	[p29l815t928r989b984],
5	2013	CD	DATE	2013	num	6	SENT_726	[p29l815t928r989b984],
6	)	NN	O	)	dep	4	SENT_726	[p29l815t928r989b984],
7	.	.	O	.	_	0	SENT_726	[p29l815t928r989b984],

1	Poordad	NNP	O	Poordad	nn	3	SENT_727	[p29l132t1005r363b1062],
2	,	,	O	,	_	0	SENT_727	[p29l132t1005r363b1062],
3	F.	NNP	O	F.	_	0	SENT_727	[p29l380t1007r411b1054],
4	et	FW	O	et	nn	5	SENT_727	[p29l425t1013r474b1055],
5	al.	FW	O	al.	dep	3	SENT_727	[p29l483t1005r540b1054],
6	.	.	O	.	_	0	SENT_727	[p29l483t1005r540b1054],

1	Exploratory	JJ	O	exploratory	amod	2	SENT_728	[p29l557t1005r858b1069],
2	study	NN	O	study	_	0	SENT_728	[p29l871t1005r1016b1069],
3	of	IN	O	of	_	0	SENT_728	[p29l1029t1004r1083b1054],
4	oral	JJ	O	oral	amod	7	SENT_728	[p29l1092t1005r1187b1055],
5	combination	NN	O	combination	nn	7	SENT_728	[p29l1204t1005r1538b1055],
6	antiviral	JJ	O	antiviral	amod	7	SENT_728	[p29l1554t1005r1761b1055],
7	therapy	NN	O	therapy	prep_of	2	SENT_728	[p29l1776t1005r1980b1069],
8	for	IN	O	for	_	0	SENT_728	[p29l1991t1004r2064b1054],
9	hepatitis	NNP	O	hepatitis	nn	12	SENT_728	[p29l133t1083r357b1145],
10	C.	NNP	PERSON	C.	nn	12	SENT_728	[p29l372t1084r418b1133],
11	N.	NNP	PERSON	N.	nn	12	SENT_728	[p29l432t1085r480b1133],
12	Engl	NNP	PERSON	Engl	prep_for	2	SENT_728	[p29l495t1083r613b1146],
13	.	.	O	.	_	0	SENT_728	[p29l495t1083r613b1146],

1	J.	NNP	O	J.	nn	2	SENT_729	[p29l624t1085r658b1133],
2	Med	NNP	O	Med	_	0	SENT_729	[p29l672t1083r795b1133],
3	.	.	O	.	_	0	SENT_729	[p29l672t1083r795b1133],

1	368	CD	NUMBER	368	_	0	SENT_730	[p29l809t1086r925b1140],
2	,	,	O	,	_	0	SENT_730	[p29l809t1086r925b1140],
3	45-53	CD	NUMBER	45-53	number	4	SENT_730	[p29l937t1086r1096b1133],
4	(	CD	NUMBER	(	appos	1	SENT_730	[p29l1113t1084r1288b1140],
5	2013	CD	DATE	2013	num	6	SENT_730	[p29l1113t1084r1288b1140],
6	)	NN	O	)	dep	4	SENT_730	[p29l1113t1084r1288b1140],
7	.	.	O	.	_	0	SENT_730	[p29l1113t1084r1288b1140],

1	Knowdley	NNP	PERSON	Knowdley	_	0	SENT_731	[p29l132t1161r400b1224],
2	,	,	O	,	_	0	SENT_731	[p29l132t1161r400b1224],
3	K.V.	NNP	O	K.V.	nn	4	SENT_731	[p29l417t1163r504b1211],
4	etal	NN	O	etal	appos	1	SENT_731	[p29l518t1161r633b1211],
5	.	.	O	.	_	0	SENT_731	[p29l518t1161r633b1211],

1	Safety	NN	O	safety	_	0	SENT_732	[p29l648t1160r809b1224],
2	and	CC	O	and	_	0	SENT_732	[p29l821t1161r918b1211],
3	efﬁcacy	NN	O	efﬁcacy	conj_and	1	SENT_732	[p29l934t1160r1135b1224],
4	of	IN	O	of	_	0	SENT_732	[p29l1148t1160r1202b1211],
5	interferon-free	JJ	O	interferon-free	amod	6	SENT_732	[p29l1213t1160r1595b1211],
6	regimens	NNS	O	regimen	prep_of	1	SENT_732	[p29l1611t1163r1853b1224],
7	of	IN	O	of	_	0	SENT_732	[p29l1867t1160r1922b1211],
8	ABT	NNP	O	ABT	nn	10	SENT_732	[p29l130t1239r398b1294],
9	—	CD	NUMBER	—	num	10	SENT_732	[p29l130t1239r398b1294],
10	450/r	NN	O	450/r	prep_of	6	SENT_732	[p29l130t1239r398b1294],
11	,	,	O	,	_	0	SENT_732	[p29l130t1239r398b1294],
12	ABT	NNP	O	ABT	appos	6	SENT_732	[p29l411t1240r640b1294],
13	—	CD	NUMBER	—	number	14	SENT_732	[p29l411t1240r640b1294],
14	267	CD	NUMBER	267	dep	12	SENT_732	[p29l411t1240r640b1294],
15	,	,	O	,	_	0	SENT_732	[p29l411t1240r640b1294],
16	ABT	NNP	O	ABT	appos	6	SENT_732	[p29l654t1240r868b1287],
17	—	CD	NUMBER	—	number	18	SENT_732	[p29l654t1240r868b1287],
18	333	CD	NUMBER	333	dep	16	SENT_732	[p29l654t1240r868b1287],
19	+	CC	O	+	cc	18	SENT_732	[p29l884t1239r960b1289],
20	/	:	O	/	punct	1	SENT_732	[p29l884t1239r960b1289],
21	ribavirin	NNP	O	ribavirin	dep	1	SENT_732	[p29l976t1238r1186b1287],
22	in	IN	O	in	_	0	SENT_732	[p29l1205t1240r1247b1286],
23	patients	NNS	O	patient	prep_in	21	SENT_732	[p29l1266t1240r1475b1299],
24	with	IN	O	with	_	0	SENT_732	[p29l1489t1238r1602b1287],
25	chronic	JJ	O	chronic	amod	28	SENT_732	[p29l1619t1238r1813b1287],
26	HCV	NN	O	hcv	nn	28	SENT_732	[p29l1829t1239r1940b1287],
27	GT1	NN	O	gt1	nn	28	SENT_732	[p29l131t1317r222b1364],
28	infection	NN	O	infection	prep_with	23	SENT_732	[p29l248t1314r491b1365],
29	:	:	O	:	_	0	SENT_732	[p29l248t1314r491b1365],
30	results	NNS	O	result	dep	21	SENT_732	[p29l507t1315r675b1365],
31	from	IN	O	from	_	0	SENT_732	[p29l687t1314r810b1365],
32	the	DT	O	the	det	34	SENT_732	[p29l826t1315r911b1365],
33	aviator	NN	O	aviator	nn	34	SENT_732	[p29l925t1317r1105b1365],
34	study	NN	O	study	prep_from	30	SENT_732	[p29l1118t1315r1272b1379],
35	.	.	O	.	_	0	SENT_732	[p29l1118t1315r1272b1379],

1	Presented	VBN	O	present	_	0	SENT_733	[p29l1289t1315r1546b1365],
2	at	IN	O	at	_	0	SENT_733	[p29l1563t1323r1611b1365],
3	the	DT	O	the	det	5	SENT_733	[p29l1624t1315r1709b1365],
4	48th	JJ	ORDINAL	48th	amod	5	SENT_733	[p29l1722t1315r1839b1365],
5	Annual	JJ	SET	annual	prep_at	1	SENT_733	[p29l1855t1315r2040b1365],
6	Meeting	VBG	O	meet	partmod	5	SENT_733	[p29l132t1395r347b1456],
7	of	IN	O	of	_	0	SENT_733	[p29l363t1392r418b1443],
8	the	DT	O	the	det	10	SENT_733	[p29l426t1393r512b1443],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_733	[p29l529t1395r776b1455],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_733	[p29l792t1395r1090b1443],
11	for	IN	O	for	_	0	SENT_733	[p29l1105t1392r1177b1443],
12	the	DT	O	the	det	15	SENT_733	[p29l1189t1393r1275b1443],
13	Study	NNP	O	Study	nn	15	SENT_733	[p29l1290t1393r1441b1457],
14	ofthe	NN	O	ofthe	nn	15	SENT_733	[p29l1453t1392r1602b1443],
15	Liver	NN	O	liver	prep_for	10	SENT_733	[p29l1618t1395r1749b1450],
16	,	,	O	,	_	0	SENT_733	[p29l1618t1395r1749b1450],
17	Amsterdam	NNP	LOCATION	Amsterdam	appos	15	SENT_733	[p29l1763t1393r2083b1450],
18	,	,	O	,	_	0	SENT_733	[p29l1763t1393r2083b1450],
19	The	DT	LOCATION	the	det	20	SENT_733	[p29l128t1471r225b1521],
20	Netherlands	NNP	LOCATION	Netherlands	appos	15	SENT_733	[p29l242t1471r573b1528],
21	,	,	O	,	_	0	SENT_733	[p29l242t1471r573b1528],
22	24-28	CD	DATE	24-28	appos	15	SENT_733	[p29l588t1474r747b1521],
23	April	NNP	DATE	April	tmod	6	SENT_733	[p29l760t1471r880b1533],
24	2013	CD	DATE	2013	num	23	SENT_733	[p29l898t1474r1037b1521],
25	.	.	O	.	_	0	SENT_733	[p29l898t1474r1037b1521],

1	Gottwein	NNP	PERSON	Gottwein	_	0	SENT_734	[p29l129t1551r386b1606],
2	,	,	O	,	_	0	SENT_734	[p29l129t1551r386b1606],
3	J.M.	NNP	O	J.M.	nn	4	SENT_734	[p29l398t1551r497b1599],
4	etal	NN	O	etal	appos	1	SENT_734	[p29l510t1549r625b1599],
5	.	.	O	.	_	0	SENT_734	[p29l510t1549r625b1599],

1	Combination	NN	O	combination	nn	2	SENT_735	[p29l640t1549r981b1599],
2	treatment	NN	O	treatment	nsubj	12	SENT_735	[p29l997t1556r1260b1599],
3	with	IN	O	with	_	0	SENT_735	[p29l1273t1549r1386b1599],
4	hepatitis	NN	O	hepatitis	nn	7	SENT_735	[p29l1405t1549r1629b1611],
5	C	NN	O	c	nn	7	SENT_735	[p29l1644t1551r1677b1599],
6	virus	NN	O	virus	nn	7	SENT_735	[p29l1690t1551r1814b1599],
7	protease	NN	O	protease	prep_with	2	SENT_735	[p29l1831t1557r2056b1611],
8	and	CC	O	and	_	0	SENT_735	[p29l131t1627r227b1677],
9	NS5A	NN	O	ns5a	nn	10	SENT_735	[p29l245t1629r385b1677],
10	inhibitors	NNS	O	inhibitor	prep_with	2	SENT_735	[p29l401t1627r648b1677],
11	is	VBZ	O	be	cop	12	SENT_735	[p29l664t1629r698b1677],
12	effective	JJ	O	effective	_	0	SENT_735	[p29l713t1626r936b1677],
13	against	IN	O	against	_	0	SENT_735	[p29l950t1629r1141b1690],
14	recombinant	JJ	O	recombinant	amod	18	SENT_735	[p29l1156t1627r1493b1677],
15	genotype	NN	O	genotype	nn	18	SENT_735	[p29l1506t1635r1760b1691],
16	1a	NN	O	1a	nn	18	SENT_735	[p29l1779t1631r1847b1684],
17	,	,	O	,	_	0	SENT_735	[p29l1779t1631r1847b1684],
18	2a	NN	O	2a	prep_against	12	SENT_735	[p29l1862t1630r1934b1684],
19	,	,	O	,	_	0	SENT_735	[p29l1862t1630r1934b1684],
20	and	CC	O	and	_	0	SENT_735	[p29l1949t1627r2045b1677],
21	3a	NN	O	3a	nn	22	SENT_735	[p29l2062t1630r2119b1677],
22	viruses	NNS	O	virus	prep_against	12	SENT_735	[p29l129t1707r322b1755],
23	.	.	O	.	_	0	SENT_735	[p29l129t1707r322b1755],

1	Antimicrob	NNP	PERSON	Antimicrob	_	0	SENT_736	[p29l333t1705r627b1755],
2	.	.	O	.	_	0	SENT_736	[p29l333t1705r627b1755],

1	Agents	NNS	O	agent	_	0	SENT_737	[p29l638t1707r814b1768],
2	Chemother	NNP	O	Chemother	dep	1	SENT_737	[p29l828t1705r1122b1755],
3	.	.	O	.	_	0	SENT_737	[p29l828t1705r1122b1755],

1	57	CD	NUMBER	57	_	0	SENT_738	[p29l1136t1709r1216b1762],
2	,	,	O	,	_	0	SENT_738	[p29l1136t1709r1216b1762],
3	1291-1303	CD	DATE	1291-1303	number	4	SENT_738	[p29l1235t1708r1518b1755],
4	(	CD	NUMBER	(	appos	1	SENT_738	[p29l1536t1706r1710b1762],
5	2013	CD	DATE	2013	num	6	SENT_738	[p29l1536t1706r1710b1762],
6	)	NN	O	)	dep	4	SENT_738	[p29l1536t1706r1710b1762],
7	.	.	O	.	_	0	SENT_738	[p29l1536t1706r1710b1762],

1	Lok	NNP	O	Lok	_	0	SENT_739	[p29l131t1783r233b1840],
2	,	,	O	,	_	0	SENT_739	[p29l131t1783r233b1840],
3	A.S.	NNP	O	A.S.	nn	4	SENT_739	[p29l247t1785r340b1833],
4	etal	NN	O	etal	appos	1	SENT_739	[p29l354t1783r469b1833],
5	.	.	O	.	_	0	SENT_739	[p29l354t1783r469b1833],

1	Preliminary	JJ	O	preliminary	amod	2	SENT_740	[p29l486t1783r782b1847],
2	study	NN	O	study	_	0	SENT_740	[p29l795t1783r940b1847],
3	of	IN	O	of	_	0	SENT_740	[p29l953t1782r1007b1833],
4	two	CD	NUMBER	two	num	6	SENT_740	[p29l1015t1791r1116b1833],
5	antiviral	JJ	O	antiviral	amod	6	SENT_740	[p29l1130t1783r1337b1833],
6	agents	NNS	O	agent	prep_of	2	SENT_740	[p29l1354t1791r1529b1846],
7	for	IN	O	for	_	0	SENT_740	[p29l1542t1782r1615b1833],
8	hepatitis	NN	O	hepatitis	nn	10	SENT_740	[p29l1630t1783r1854b1846],
9	C	NN	O	c	nn	10	SENT_740	[p29l1869t1785r1902b1833],
10	genotype	NN	O	genotype	prep_for	2	SENT_740	[p29l131t1868r384b1925],
11	1	CD	NUMBER	1	dep	10	SENT_740	[p29l403t1865r418b1910],
12	.	.	O	.	_	0	SENT_740	[p29l432t1902r441b1911],

1	N.	NNP	O	N.	nn	2	SENT_741	[p29l455t1863r503b1911],
2	Engl	NNP	O	Engl	_	0	SENT_741	[p29l517t1861r636b1924],
3	.	.	O	.	_	0	SENT_741	[p29l517t1861r636b1924],

1	J.	NNP	O	J.	nn	2	SENT_742	[p29l646t1863r681b1911],
2	Med	NNP	O	Med	_	0	SENT_742	[p29l695t1861r818b1911],
3	.	.	O	.	_	0	SENT_742	[p29l695t1861r818b1911],

1	366	CD	NUMBER	366	_	0	SENT_743	[p29l832t1864r947b1918],
2	,	,	O	,	_	0	SENT_743	[p29l832t1864r947b1918],
3	216-224	CD	NUMBER	216-224	number	4	SENT_743	[p29l962t1864r1186b1911],
4	(	CD	NUMBER	(	appos	1	SENT_743	[p29l1202t1862r1376b1918],
5	2012	CD	DATE	2012	num	6	SENT_743	[p29l1202t1862r1376b1918],
6	)	NN	O	)	dep	4	SENT_743	[p29l1202t1862r1376b1918],
7	.	.	O	.	_	0	SENT_743	[p29l1202t1862r1376b1918],

1	Chayama	NNP	O	Chayama	_	0	SENT_744	[p29l129t1939r385b2003],
2	,	,	O	,	_	0	SENT_744	[p29l129t1939r385b2003],
3	K.	NNP	O	K.	nn	4	SENT_744	[p29l402t1941r444b1989],
4	etal	NN	O	etal	appos	1	SENT_744	[p29l458t1939r573b1989],
5	.	.	O	.	_	0	SENT_744	[p29l458t1939r573b1989],

1	Dual	JJ	O	dual	amod	4	SENT_745	[p29l589t1939r704b1989],
2	oral	JJ	O	oral	amod	4	SENT_745	[p29l720t1939r815b1989],
3	combination	NN	O	combination	nn	4	SENT_745	[p29l832t1939r1165b1989],
4	therapy	NN	O	therapy	nsubj	20	SENT_745	[p29l1180t1939r1384b2003],
5	with	IN	O	with	_	0	SENT_745	[p29l1396t1939r1509b1989],
6	the	DT	O	the	det	9	SENT_745	[p29l1524t1939r1610b1989],
7	NS5A	NN	O	ns5a	nn	9	SENT_745	[p29l1627t1941r1766b1989],
8	inhibitor	NN	O	inhibitor	nn	9	SENT_745	[p29l1781t1939r2005b1989],
9	BMS	NN	O	bm	prep_with	4	SENT_745	[p29l2020t1941r2151b1989],
10	—	CD	NUMBER	—	number	11	SENT_745	[p29l2020t1941r2151b1989],
11	790052	CD	NUMBER	790052	dep	9	SENT_745	[p29l132t2020r322b2067],
12	and	CC	O	and	_	0	SENT_745	[p29l337t2017r433b2067],
13	the	DT	O	the	det	17	SENT_745	[p29l448t2017r534b2067],
14	NS3	NN	O	ns3	nn	17	SENT_745	[p29l551t2019r649b2067],
15	protease	NN	O	protease	nn	17	SENT_745	[p29l667t2025r893b2079],
16	inhibitor	NN	O	inhibitor	nn	17	SENT_745	[p29l909t2017r1133b2067],
17	BMS	NN	O	bm	conj_and	9	SENT_745	[p29l1148t2019r1474b2067],
18	—	CD	NUMBER	—	number	19	SENT_745	[p29l1148t2019r1474b2067],
19	650032	CD	NUMBER	650032	dep	17	SENT_745	[p29l1148t2019r1474b2067],
20	achieved	VBN	O	achieve	_	0	SENT_745	[p29l1489t2017r1723b2067],
21	90	CD	PERCENT	90	number	22	SENT_745	[p29l1739t2020r1852b2067],
22	%	NN	PERCENT	%	amod	28	SENT_745	[p29l1739t2020r1852b2067],
23	sustained	JJ	O	sustained	amod	28	SENT_745	[p29l1866t2017r2115b2067],
24	virologic	JJ	O	virologic	amod	28	SENT_745	[p29l129t2095r356b2158],
25	respone	NN	O	respone	nn	28	SENT_745	[p29l372t2110r581b2158],
26	(	CD	NUMBER	(	num	28	SENT_745	[p29l598t2096r793b2152],
27	SVR12	NN	O	svr12	nn	28	SENT_745	[p29l598t2096r793b2152],
28	)	NN	O	)	dobj	20	SENT_745	[p29l598t2096r793b2152],
29	in	IN	O	in	_	0	SENT_745	[p29l811t2097r853b2144],
30	HCV	NNP	O	HCV	nn	31	SENT_745	[p29l873t2097r983b2145],
31	genotype	NN	O	genotype	prep_in	20	SENT_745	[p29l995t2103r1249b2159],
32	1	CD	NUMBER	1	num	31	SENT_745	[p29l1268t2099r1283b2144],
33	b	NN	O	b	prep	31	SENT_745	[p29l1299t2095r1329b2145],
34	infected	JJ	O	infected	amod	36	SENT_745	[p29l1345t2094r1555b2145],
35	null	JJ	O	null	amod	36	SENT_745	[p29l1573t2095r1666b2145],
36	responders	NNS	O	responder	dep	33	SENT_745	[p29l1684t2095r1988b2157],
37	.	.	O	.	_	0	SENT_745	[p29l1684t2095r1988b2157],

1	Presented	VBN	O	present	_	0	SENT_746	[p29l133t2173r390b2223],
2	at	IN	O	at	_	0	SENT_746	[p29l406t2181r455b2223],
3	the	DT	O	the	det	4	SENT_746	[p29l467t2173r553b2223],
4	Annual	JJ	SET	annual	prep_at	1	SENT_746	[p29l567t2173r752b2223],
5	Meeting	VBG	O	meet	dep	4	SENT_746	[p29l770t2175r985b2236],
6	of	IN	O	of	_	0	SENT_746	[p29l1001t2172r1056b2223],
7	the	DT	O	the	det	9	SENT_746	[p29l1064t2173r1150b2223],
8	American	NNP	O	American	nn	9	SENT_746	[p29l1164t2175r1413b2223],
9	Association	NNP	O	Association	prep_of	5	SENT_746	[p29l1429t2175r1727b2223],
10	for	IN	O	for	_	0	SENT_746	[p29l1742t2172r1814b2223],
11	the	DT	O	the	det	12	SENT_746	[p29l1826t2173r1912b2223],
12	Study	NN	O	study	prep_for	9	SENT_746	[p29l1927t2173r2077b2237],
13	of	IN	O	of	_	0	SENT_746	[p29l2090t2172r2144b2223],
14	Liver	NN	O	liver	nn	15	SENT_746	[p29l133t2252r255b2299],
15	Diseases	NNS	O	disease	prep_of	12	SENT_746	[p29l271t2252r504b2306],
16	,	,	O	,	_	0	SENT_746	[p29l271t2252r504b2306],
17	San	NNP	LOCATION	San	nn	18	SENT_746	[p29l519t2252r610b2299],
18	Francisco	NNP	LOCATION	Francisco	appos	15	SENT_746	[p29l629t2252r881b2307],
19	,	,	O	,	_	0	SENT_746	[p29l629t2252r881b2307],
20	California	NNP	LOCATION	California	appos	15	SENT_746	[p29l896t2249r1156b2307],
21	,	,	O	,	_	0	SENT_746	[p29l896t2249r1156b2307],
22	4-8	CD	NUMBER	4-8	appos	15	SENT_746	[p29l1169t2253r1264b2299],
23	November	NNP	DATE	November	tmod	5	SENT_746	[p29l1281t2250r1557b2299],
24	201	CD	NUMBER	201	num	23	SENT_746	[p29l1571t2253r1654b2299],
25	1	CD	NUMBER	1	num	4	SENT_746	[p29l1673t2250r1872b2299],
26	.	.	O	.	_	0	SENT_746	[p29l1673t2250r1872b2299],

1	Abstr	NNP	O	Abstr	_	0	SENT_747	[p29l1673t2250r1872b2299],
2	.	.	O	.	_	0	SENT_747	[p29l1673t2250r1872b2299],

1	LB	NN	O	lb	_	0	SENT_748	[p29l1889t2252r2013b2299],
2	—	CD	NUMBER	—	number	3	SENT_748	[p29l1889t2252r2013b2299],
3	4	CD	NUMBER	4	num	1	SENT_748	[p29l1889t2252r2013b2299],
4	.	.	O	.	_	0	SENT_748	[p29l1889t2252r2013b2299],

1	Everson	NNP	PERSON	Everson	_	0	SENT_749	[p29l131t2330r347b2385],
2	,	,	O	,	_	0	SENT_749	[p29l131t2330r347b2385],
3	G.T.	NNP	LOCATION	G.T.	nn	4	SENT_749	[p29l361t2330r453b2378],
4	etal	NN	O	etal	appos	1	SENT_749	[p29l467t2328r581b2378],
5	.	.	O	.	_	0	SENT_749	[p29l467t2328r581b2378],

1	Interim	JJ	O	interim	amod	2	SENT_750	[p29l599t2330r782b2378],
2	analysis	NN	O	analysis	dep	15	SENT_750	[p29l799t2328r1001b2392],
3	of	IN	O	of	_	0	SENT_750	[p29l1016t2327r1070b2378],
4	an	DT	O	a	det	8	SENT_750	[p29l1080t2343r1140b2378],
5	interferon	NN	O	interferon	nn	8	SENT_750	[p29l1158t2327r1416b2378],
6	(	CD	NUMBER	(	num	8	SENT_750	[p29l1434t2329r1550b2385],
7	IFN	NN	ORGANIZATION	ifn	nn	8	SENT_750	[p29l1434t2329r1550b2385],
8	)	NN	O	)	prep_of	2	SENT_750	[p29l1434t2329r1550b2385],
9	and	CC	O	and	_	0	SENT_750	[p29l1566t2328r1663b2378],
10	ribavirin	NNP	O	ribavirin	prep_of	2	SENT_750	[p29l1681t2328r1892b2378],
11	(	CD	NUMBER	(	num	10	SENT_750	[p29l1910t2329r2047b2385],
12	RBV	NN	O	rbv	dep	15	SENT_750	[p29l1910t2329r2047b2385],
13	)	CD	NUMBER	)	num	12	SENT_750	[p29l1910t2329r2047b2385],
14	free	JJ	O	free	amod	15	SENT_750	[p29l129t2405r229b2456],
15	regimen	NN	O	regimen	dep	30	SENT_750	[p29l245t2408r460b2469],
16	of	IN	O	of	_	0	SENT_750	[p29l477t2405r531b2456],
17	daclatasvir	NN	O	daclatasvir	nn	20	SENT_750	[p29l541t2406r822b2456],
18	(	CD	NUMBER	(	num	20	SENT_750	[p29l836t2407r999b2463],
19	DCV	NN	O	dcv	nn	20	SENT_750	[p29l836t2407r999b2463],
20	)	NN	O	)	prep_of	15	SENT_750	[p29l836t2407r999b2463],
21	,	,	O	,	_	0	SENT_750	[p29l836t2407r999b2463],
22	asunaprevir	NN	O	asunaprevir	prep_of	15	SENT_750	[p29l1013t2408r1322b2468],
23	(	CD	NUMBER	(	num	22	SENT_750	[p29l1337t2407r1489b2464],
24	ASV	NNP	ORGANIZATION	ASV	dep	22	SENT_750	[p29l1337t2407r1489b2464],
25	)	CD	NUMBER	)	num	24	SENT_750	[p29l1337t2407r1489b2464],
26	,	,	O	,	_	0	SENT_750	[p29l1337t2407r1489b2464],
27	and	CC	O	and	_	0	SENT_750	[p29l1504t2406r1600b2456],
28	BMS	NNP	O	BMS	conj_and	20	SENT_750	[p29l1619t2408r1944b2456],
29	—	CD	NUMBER	—	number	30	SENT_750	[p29l1619t2408r1944b2456],
30	791325	CD	NUMBER	791325	dep	35	SENT_750	[p29l1619t2408r1944b2456],
31	in	IN	O	in	_	0	SENT_750	[p29l1962t2408r2004b2455],
32	treatment	NN	O	treatment	prep_in	30	SENT_750	[p29l129t2487r566b2541],
33	—	CD	NUMBER	—	num	34	SENT_750	[p29l129t2487r566b2541],
34	na'I	NN	O	na'us	nsubj	35	SENT_750	[p29l129t2487r566b2541],
35	've	VBP	O	have	_	0	SENT_750	[p29l129t2487r566b2541],
36	,	,	O	,	_	0	SENT_750	[p29l129t2487r566b2541],
37	hepatitis	NNP	O	hepatitis	nn	38	SENT_750	[p29l583t2484r807b2547],
38	C	NNP	O	C	dep	40	SENT_750	[p29l822t2486r855b2534],
39	virus	NN	O	virus	nn	40	SENT_750	[p29l868t2486r992b2534],
40	genotype	NN	O	genotype	ccomp	35	SENT_750	[p29l1007t2492r1260b2548],
41	1	CD	NUMBER	1	num	43	SENT_750	[p29l1279t2488r1294b2533],
42	infected	JJ	O	infected	amod	43	SENT_750	[p29l1320t2483r1529b2534],
43	patients	NNS	O	patient	dep	40	SENT_750	[p29l1548t2486r1770b2547],
44	.	.	O	.	_	0	SENT_750	[p29l1548t2486r1770b2547],

1	Presented	VBN	O	present	_	0	SENT_751	[p29l1787t2484r2044b2534],
2	at	IN	O	at	_	0	SENT_751	[p29l130t2570r179b2612],
3	the	DT	O	the	det	5	SENT_751	[p29l191t2562r277b2612],
4	48th	JJ	ORDINAL	48th	amod	5	SENT_751	[p29l290t2562r407b2612],
5	Annual	JJ	SET	annual	prep_at	1	SENT_751	[p29l423t2562r607b2612],
6	Meeting	VBG	O	meet	partmod	5	SENT_751	[p29l626t2564r841b2625],
7	of	IN	O	of	_	0	SENT_751	[p29l857t2561r912b2612],
8	the	DT	O	the	det	10	SENT_751	[p29l920t2562r1006b2612],
9	European	NNP	ORGANIZATION	European	nn	10	SENT_751	[p29l1023t2564r1270b2624],
10	Association	NNP	ORGANIZATION	Association	prep_of	6	SENT_751	[p29l1286t2564r1584b2612],
11	for	IN	O	for	_	0	SENT_751	[p29l1599t2561r1672b2612],
12	the	DT	O	the	det	13	SENT_751	[p29l1683t2562r1769b2612],
13	Study	NN	O	study	prep_for	10	SENT_751	[p29l1784t2562r1934b2626],
14	of	IN	O	of	_	0	SENT_751	[p29l1947t2561r2002b2612],
15	the	DT	O	the	det	16	SENT_751	[p29l2010t2562r2096b2612],
16	Liver	NN	O	liver	prep_of	13	SENT_751	[p29l133t2642r263b2697],
17	,	,	O	,	_	0	SENT_751	[p29l133t2642r263b2697],
18	Amsterdam	NNP	LOCATION	Amsterdam	appos	16	SENT_751	[p29l278t2640r703b2697],
19	,	,	O	,	_	0	SENT_751	[p29l278t2640r703b2697],
20	The	DT	LOCATION	the	det	21	SENT_751	[p29l278t2640r703b2697],
21	Netherlands	NNP	LOCATION	Netherlands	appos	16	SENT_751	[p29l720t2640r1052b2697],
22	,	,	O	,	_	0	SENT_751	[p29l720t2640r1052b2697],
23	24-28	CD	DATE	24-28	appos	16	SENT_751	[p29l1066t2643r1225b2690],
24	April	NNP	DATE	April	tmod	6	SENT_751	[p29l1239t2640r1358b2702],
25	2013	CD	DATE	2013	num	24	SENT_751	[p29l1376t2640r1677b2690],
26	.	.	O	.	_	0	SENT_751	[p29l1376t2640r1677b2690],

1	Abstr	NNP	O	Abstr	_	0	SENT_752	[p29l1376t2640r1677b2690],
2	.	.	O	.	_	0	SENT_752	[p29l1376t2640r1677b2690],

1	1417	CD	DATE	1417	_	0	SENT_753	[p29l1697t2644r1832b2690],
2	.	.	O	.	_	0	SENT_753	[p29l1697t2644r1832b2690],

1	Jacobson	NNP	PERSON	Jacobson	_	0	SENT_754	[p29l127t2718r387b2775],
2	,	,	O	,	_	0	SENT_754	[p29l127t2718r387b2775],
3	|	CD	NUMBER	|	appos	1	SENT_754	[p29l404t2720r490b2768],
4	.	.	O	.	_	0	SENT_754	[p29l404t2720r490b2768],

1	M.	NNP	O	M.	nn	2	SENT_755	[p29l404t2720r490b2768],
2	etal.	NNP	O	etal.	_	0	SENT_755	[p29l504t2718r632b2775],
3	;	:	O	;	_	0	SENT_755	[p29l504t2718r632b2775],
4	POSITRON	NNP	O	POSITRON	nn	5	SENT_755	[p29l649t2720r917b2768],
5	Study	NNP	O	Study	dep	2	SENT_755	[p29l934t2718r1098b2782],
6	;	:	O	;	_	0	SENT_755	[p29l934t2718r1098b2782],
7	FUSION	NNP	O	FUSION	nn	8	SENT_755	[p29l1114t2720r1310b2768],
8	Study	NNP	O	Study	dep	5	SENT_755	[p29l1328t2718r1487b2782],
9	.	.	O	.	_	0	SENT_755	[p29l1328t2718r1487b2782],

1	Sofosbuvir	NNP	O	Sofosbuvir	nsubj	5	SENT_756	[p29l1502t2717r1781b2768],
2	for	IN	O	for	_	0	SENT_756	[p29l1793t2717r1865b2768],
3	hepatitis	NNP	O	hepatitis	nn	4	SENT_756	[p29l1880t2718r2105b2780],
4	C	NNP	O	C	prep_for	1	SENT_756	[p29l130t2798r164b2846],
5	genotype	NN	O	genotype	_	0	SENT_756	[p29l178t2804r432b2860],
6	2	CD	NUMBER	2	dobj	5	SENT_756	[p29l447t2799r474b2845],
7	or	CC	O	or	_	0	SENT_756	[p29l489t2811r543b2846],
8	3	CD	NUMBER	3	dobj	5	SENT_756	[p29l556t2799r583b2846],
9	in	IN	O	in	_	0	SENT_756	[p29l601t2798r643b2845],
10	patients	NNS	O	patient	prep_in	6	SENT_756	[p29l662t2798r871b2858],
11	without	IN	O	without	_	0	SENT_756	[p29l885t2796r1092b2846],
12	treatment	NN	O	treatment	nn	13	SENT_756	[p29l1105t2804r1368b2846],
13	options	NNS	O	option	prep_without	5	SENT_756	[p29l1382t2798r1593b2858],
14	.	.	O	.	_	0	SENT_756	[p29l1382t2798r1593b2858],

1	N.	NNP	O	N.	nn	2	SENT_757	[p29l1607t2798r1655b2846],
2	Engl	NNP	O	Engl	_	0	SENT_757	[p29l1670t2796r1788b2859],
3	.	.	O	.	_	0	SENT_757	[p29l1670t2796r1788b2859],

1	J.	NNP	O	J.	nn	2	SENT_758	[p29l1799t2798r1833b2846],
2	Med	NNP	O	Med	_	0	SENT_758	[p29l1847t2796r1970b2846],
3	.	.	O	.	_	0	SENT_758	[p29l1847t2796r1970b2846],

1	368	CD	NUMBER	368	_	0	SENT_759	[p29l1984t2799r2099b2853],
2	,	,	O	,	_	0	SENT_759	[p29l1984t2799r2099b2853],
3	1867-1877	CD	DATE	1867-1877	number	4	SENT_759	[p29l135t2876r419b2922],
4	(	CD	NUMBER	(	appos	1	SENT_759	[p29l436t2874r610b2930],
5	2013	CD	DATE	2013	num	6	SENT_759	[p29l436t2874r610b2930],
6	)	NN	O	)	dep	4	SENT_759	[p29l436t2874r610b2930],
7	.	.	O	.	_	0	SENT_759	[p29l436t2874r610b2930],

1	Gilead	NNP	ORGANIZATION	Gilead	nn	2	SENT_760	[p29l129t2951r292b3001],
2	Sciences	NNPS	ORGANIZATION	Sciences	_	0	SENT_760	[p29l309t2953r545b3001],
3	.	.	O	.	_	0	SENT_760	[p29l309t2953r545b3001],

1	Gilead	NNP	ORGANIZATION	Gilead	nn	4	SENT_761	[p29l559t2951r723b3001],
2	Reports	NNP	ORGANIZATION	Reports	nn	4	SENT_761	[p29l741t2953r941b3014],
3	Interim	NNP	ORGANIZATION	Interim	nn	4	SENT_761	[p29l958t2954r1142b3001],
4	Data	NNP	ORGANIZATION	Data	_	0	SENT_761	[p29l1161t2953r1278b3001],
5	From	IN	O	from	_	0	SENT_761	[p29l1297t2954r1426b3001],
6	Phase	NN	O	phase	prep_from	4	SENT_761	[p29l1445t2951r1595b3001],
7	2	CD	NUMBER	2	num	6	SENT_761	[p29l1610t2954r1638b3000],
8	LONESTAR	NNP	ORGANIZATION	LONESTAR	nn	9	SENT_761	[p29l1655t2953r1926b3001],
9	Study	NNP	O	Study	dep	4	SENT_761	[p29l1940t2951r2091b3015],
10	(	CD	NUMBER	(	num	12	SENT_761	[p29l1290t3108r1464b3165],
11	2013	CD	DATE	2013	num	12	SENT_761	[p29l1290t3108r1464b3165],
12	)	NN	O	)	dep	9	SENT_761	[p29l1290t3108r1464b3165],
13	.	.	O	.	_	0	SENT_761	[p29l1290t3108r1464b3165],

1	VOLUME	NN	O	volume	nn	3	SENT_762	[p29l543t3331r768b3373],
2	95	CD	NUMBER	95	num	3	SENT_762	[p29l785t3332r842b3373],
3	NUMBER	NN	O	number	_	0	SENT_762	[p29l863t3331r1087b3373],
4	1	CD	NUMBER	1	number	5	SENT_762	[p29l1109t3333r1122b3373],
5	|	CD	NUMBER	|	dep	3	SENT_762	[p29l1151t3327r1156b3388],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_762	[p29l1175t3331r1421b3373],
7	2014	CD	DATE	2014	num	6	SENT_762	[p29l1437t3332r1558b3373],
8	|	CD	NUMBER	|	num	9	SENT_762	[p29l1577t3327r1581b3388],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_762	[p29l1600t3331r2152b3384],

